

2018 ASCO[®] ANNUAL MEETING

DELIVERING DISCOVERIES: EXPANDING THE REACH OF PRECISION MEDICINE

Program

JUNE 1-5, 2018

McCORMICK PLACE | CHICAGO, ILLINOIS

am.asco.org | [#ASCO18](https://twitter.com/ASCO18)

Download the iPlanner mobile app
at am.asco.org/arc

54th Annual Meeting
June 1–5, 2018
Chicago, Illinois

ANNUAL MEETING PROGRAM

Copyright 2018 by the American Society of Clinical Oncology. All programs presented at the 2018 Annual Meeting constitute copyrighted presentations owned by the American Society of Clinical Oncology.

Copyright of the 2018 ASCO Annual Meeting Program is owned by the American Society of Clinical Oncology. ASCO reserves the rights to all recordings or reproductions or presentations at this Annual Meeting and all ASCO educational and scientific meetings.

CONTENTS

Scientific Sessions	4
Program Information	6
Continuing Education and Meeting Feedback	8
Maintenance of Certification	9
Planning Committees	10
Onsite Details	15
Featured Voices on Twitter	16
Policies	16
Awards	18
Ancillary Educational Events Directory	27
Program by Day	33

SCIENTIFIC SESSIONS

Breast Cancer—Local/Regional/Adjuvant

Oral Abstract Session	237
Poster Discussion Session	140
Poster Session	62

Breast Cancer—Metastatic

Oral Abstract Session.....	163
Clinical Science Symposium: Breast Cancer Immunotherapy: Can We Crack the Code?	333
Poster Discussion Session	101
Poster Session	70

Cancer Prevention, Hereditary Genetics, and Epidemiology

Oral Abstract Session	165
Clinical Science Symposium: Tumor Testing in Precision Oncology: From Heredity to Counseling to Implementation	236
Poster Discussion Session	148
Poster Session	107

Central Nervous System Tumors

Oral Abstract Session	42
Poster Discussion Session	149
Poster Session	112

**Developmental Therapeutics—Clinical Pharmacology and
Experimental Therapeutics**

Oral Abstract Session	44
Poster Discussion Session	330
Poster Session	242

Developmental Therapeutics—Immunotherapy

Oral Abstract Session	144
Poster Discussion Session	285
Poster Session	251

Gastrointestinal (Colorectal) Cancer

Oral Abstract Session	349
Poster Discussion Session	213
Poster Session	171

Gastrointestinal (Noncolorectal) Cancer

Oral Abstract Session	334
Poster Discussion Session	220
Poster Session	181

Genitourinary (Nonprostate) Cancer

Oral Abstract Session	166
Poster Discussion Session	101
Poster Session	80

Genitourinary (Prostate) Cancer

Oral Abstract Session	336
Poster Discussion Session	149
Poster Session	117

Gynecologic Cancer

Oral Abstract Session	351
Clinical Science Symposium: Engaging the Immune System in Ovarian Cancer	211
Poster Discussion Session	339
Poster Session	295

Head and Neck Cancer	
Oral Abstract Session	167
Clinical Science Symposium: Integrating Immunotherapy Into Standard of Care for Head and Cancer	51
Poster Discussion Session	150
Poster Session	126
Health Services Research, Clinical Informatics, and Quality of Care	
Oral Abstract Session	45
Poster Discussion Session	151
Poster Session	133
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant	
Oral Abstract Session	146
Clinical Science Symposium: Targeted Therapy in Leukemia	338
Poster Discussion Session	286
Poster Session	263
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	
Oral Abstract Session	211
Poster Discussion Session	290
Poster Session	269
Hematologic Malignancies—Plasma Cell Dyscrasia	
Oral Abstract Session	46
Poster Discussion Session	331
Poster Session	277
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers	
Oral Abstract Session	238
Poster Discussion Session	220
Poster Session	194
Lung Cancer—Non-Small Cell Metastatic	
Oral Abstract Session	337
Clinical Science Symposium: Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer: Caution Indicated!	50
Poster Discussion Session	213
Poster Session	200
Melanoma/Skin Cancers	
Oral Abstract Session	239
Poster Discussion Session	339
Poster Session	304
Patient and Survivor Care	
Oral Abstract Session	169
Clinical Science Symposium: Personalizing Care for Older Adults With Cancer: From Decision-Making to Care Delivery	295
Poster Discussion Session	340
Poster Session	313
Pediatric Oncology	
Pediatric Oncology I Oral Abstract Session	147
Pediatric Oncology II Oral Abstract Session	170
Poster Discussion Session	102
Poster Session	88

SCIENTIFIC SESSIONS continued

Professional Development

Clinical Science Symposium: Innovative Approaches to Oncology Education	217
Poster Session	262

Sarcoma

Oral Abstract Session	241
Poster Discussion Session	141
Poster Session	93

Tumor Biology

Oral Abstract Session	347
Clinical Science Symposium: Innovative Immune and Genomic Biomarkers for Solid Tumors	283
Poster Discussion Session	341
Poster Session	321

Multidisciplinary Sessions

Special Clinical Science Symposium: Tumor Genomics: Finding the Target, Hitting the Target	61
Special Clinical Science Symposium: Compelling Combinations: Raising the Bar With Immunotherapy	210
Special Clinical Science Symposium: The Arrival of Biosimilars	284
Highlights of the Day Session I	161
Highlights of the Day Session II	233
Highlights of the Day Session III	345
Molecular Oncology Tumor Board: Synchronous Primary Lung Cancers	288
Plenary Session Including the Science of Oncology Award	218

PROGRAM INFORMATION

The Annual Meeting Program features the program organized by day. Dates and times are subject to change. For the most up-to-date version of the program, consult the iPlanner (am.asco.org/arc).

Abstract Key

Abstract numbers may include the following prefixes:

LBA: Late-Breaking Abstract

TPS: Trials in Progress Abstract

Cross-Cutting Tracks

The topics of clinical trials, disparities, ethics, immunotherapy, and value are important for all oncology professionals and cut across disease- and topic-based tracks. These cross-cutting themes have been incorporated into sessions of every track throughout the meeting. For sessions that feature a cross-cutting track, search by track in the iPlanner.

Interact, *powered by SYNC*

New this year! Use Interact, *powered by SYNC*, to

- View speaker slides on your personal device in real time
- Take notes on slides during sessions
- Pose questions to session faculty

To access Interact:

1. Open the iPlanner app
2. Navigate to the session you are attending
3. Select the Interact icon from the session page
4. Once the presentation begins, you will see the presenter's slides on your device

You may also access Interact by going to interact.asco.org/Interact ID. You can find the Interact ID in the session listings in this Program.

To use Interact:

1. Tap the question mark icon to submit a question to faculty.
2. Tap the pencil icon to take notes (requires login with your name and email address). You will receive an email with a link to the slides and your notes after each session.
3. Pinch and zoom on your phone or tablet to get a better look at each slide.
4. Tap the circle arrow icon if your device is not keeping up with the main screen in the room.
5. Questions? Visit the Technology Assistance Desk in Concierge Services.

Session Types

Scientific Program

Plenary Session

The Plenary Session includes abstracts selected by the Scientific Program Committee as having practice-changing findings of the highest scientific merit.

Highlights of the Day Sessions

Highlights of the Day Sessions invite expert discussants to provide an overview of the previous day's Oral Abstract presentations, focusing on key findings and putting abstracts into clinical context.

Oral Abstract Sessions

Oral Abstract Sessions include didactic presentations of abstracts of the highest scientific merit, as determined by the Scientific Program Committee. Experts in the field serve as discussants and provide comprehensive themed discussions of the findings from the abstracts.

Clinical Science Symposia

Clinical Science Symposia provide a forum for science in oncology, combining didactic lectures on a specific topic with abstract presentations. Experts in the field serve as discussants placing studies in the appropriate context and critically discussing the applicability of the conclusions to clinical practice. Three special Clinical Science Symposia will be designated around specific pathways that cut across cancer types.

Poster Discussion Sessions

Select posters from the Poster Sessions will be discussed by expert discussants, with the abstract authors participating in a question and answer period as panel members. These sessions will be followed by networking with the discussants and authors.

Poster Sessions

Poster Sessions include selected abstracts of clinical research in poster format. Trials in Progress abstracts are presented within a track's Poster Session.

Educational Program

Education Sessions

Education Sessions are 75-minute sessions, offering multidisciplinary explorations of focused topics in clinical oncology.

Workshops

Workshops will offer interactive, didactic teaching to attendees on select topics. Attendees will participate in hands-on experiences, working in small groups to learn practical, take-home skills and tools to implement in their practices. Space is available on a first-come, first-served basis.

PROGRAM INFORMATION continued

Meet the Professor Sessions (Ticketed)

Meet the Professor Sessions provide open discussion between recognized experts and session attendees, with an opportunity for attendees to obtain answers to specific questions.

Clinical Problems in Oncology Sessions (Ticketed)

Clinical Problems in Oncology Sessions combine the use of case-based panel discussion with interactive audience-response technology.

Award Lectures

Presented throughout the Annual Meeting, Award Lectures recognize distinguished award recipients.

Opening Session

The Opening Session includes the Conquer Cancer Top Donor Recognition Awards, Presidential Address, Guest Speaker's Address, recognition of Fellows of the American Society of Clinical Oncology (FASCO), and the David A. Karnofsky Memorial Award and Lecture.

Annual Business Meeting (ASCO Members Only)

The ASCO Annual Business Meeting is for ASCO Members to hear updates on the state of the Society. Members are encouraged to preregister online to attend this event.

CONTINUING EDUCATION AND MEETING FEEDBACK

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

AMA Credit Designation Statement – Physicians

The American Society of Clinical Oncology designates this live activity for a maximum of 38.75 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit Designation Statement – Nurses

The maximum number of hours awarded for this CE activity is 38.75 contact hours.

ACPE Credit Designation Statement – Pharmacists

This activity has been approved for 38.75 contact hours (3.875 CEUs) under the ACPE universal activity number JA0000152-0000-18-004-L01-P.

Activity type: Knowledge.

The activity start date for continuing pharmacy credit eligibility is 06/01/18, with an expiration date of 06/05/2018.

AAPA/NCCPA Credit Designation Statement – PAs

PAs may claim a maximum of 38.75 Category 1 credits for completing this activity. NCCPA accepts *AMA PRA Category 1 Credit*[™] from organizations accredited by ACCME or a recognized state medical society.

Disclaimer and Unlabeled Usage Statement

The disclaimer and unlabeled usage statement can be found online at am.asco.org.

Meeting Feedback and Certificates

Certificate Options Available

Attendees can log in to the iPlanner (am.asco.org/arc) or CE Portal (ceportal.asco.org) to access any of the following certificates after claiming credit:

- Continuing Medical Education Certificate
- Continuing Nursing Education Certificate
- Continuing Pharmacy Education Certificate
- Certificate of Participation

Visit am.asco.org for more details, including eligibility.

Certificate of Attendance

Attendees can download a Certificate of Attendance from the Attendee Resource Center (am.asco.org/arc) if they need a record of their attendance at the Meeting but do not require documentation for continuing education purposes. Please note that this certificate does not award any continuing education credits.

Feedback and Credit Claim

Every participant is encouraged to submit a Meeting Feedback Form, provide session ratings, and access certificates for the Meeting through the iPlanner website or app, available for download via the Attendee Resource Center (am.asco.org/arc). Your feedback is utilized by leadership to enhance programs, develop new initiatives, gauge educational impact, and plan for future meetings.

Feedback and CE credit requests are due by July 9, 2018.

Access the following via the iPlanner mobile app or website:

- To provide feedback on a specific session:
 1. Select a session by searching by time or track
 2. Select "Rate This Session"
- To access certificates and claim credit:
 1. Select a session by searching by time or track
 2. Select "Claim Credit"
- To access the Meeting Feedback Form:
 1. Choose "Claim Credit/Give Feedback" from the iPlanner homepage

For questions or assistance, contact customerservice@asco.org.

Disclosure Information

As the continuing education provider for the 2018 Annual Meeting, ASCO is committed to balance, objectivity, and scientific rigor in the management of financial interactions with for-profit health-care companies that could create real or perceived conflicts of interest. Participants in the Meeting have disclosed their financial relationships in accordance with ASCO's Policy for Relationships with Companies; review the policy at asco.org/rwc.

ASCO offers a comprehensive disclosure management system, using one disclosure for all ASCO activities. Authors and participants disclose all interaction with companies. Disclosures are kept on file and can be confirmed or updated with each new activity. Disclosures are available online at am.asco.org.

Please email coi@asco.org with specific questions or concerns.

MAINTENANCE OF CERTIFICATION

MOC From the American Board of Internal Medicine

For physician attendees whose certification is through the American Board of Internal Medicine (ABIM), maintenance of certification (MOC) points are available for meeting attendance and engagement. Successful completion of this continuing medical education (CME) activity, which includes participation in the evaluation component, enables the participant to earn up

MAINTENANCE OF CERTIFICATION continued

to 38.75 MOC points in the ABIM's MOC program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to Accreditation Council for Continuing Medical Education for the purpose of granting ABIM MOC credit.

To receive ABIM MOC, participants must submit their Meeting Feedback Form, available via the iPlanner (website or app) or CE Portal (ceportal.asco.org), and claim their CME credits by July 9, 2018. Once both of these steps are complete, ASCO will transmit all information to ABIM on the participant's behalf.

ABIM MOC points will only be awarded if the Meeting Feedback Form is completed with detailed responses that demonstrate knowledge gained at the Meeting and how that knowledge may apply to practice. Visit am.asco.org for more details.

MOC From Other American Board of Medical Specialties Member Boards

MOC Approval Statement

*Through the American Board of Medical Specialties ("ABMS") ongoing commitment to increase access to practice relevant Maintenance of Certification ("MOC") Activities through the ABMS Continuing Certification Directory, 2018 ASCO Annual Meeting has met the requirements as an **MOC Part II CME Activity** (apply toward general CME requirement) and/or an **MOC Part II Self-Assessment Activity** for the following ABMS Member Boards:*

MOC Part II CME Activity

Radiology (ABR)

Note: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board's general CME requirement (only). Please refer directly to your Member Board's MOC Part II Lifelong Learning and Self-Assessment Program Requirements.

MOC From the American Board of Pediatrics

Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 14.5 MOC points in the American Board of Pediatrics' (ABP) MOC program. It is the CME activity provider's responsibility to submit participant completion information to the ACCME for the purpose of granting ABP MOC credit.

For questions or assistance, contact customerservice@asco.org

PLANNING COMMITTEES

2017-2018 ASCO Board of Directors

ASCO Officers

President

Bruce E. Johnson, MD, FASCO

Immediate Past President

Daniel F. Hayes, MD, FACP, FASCO

President-Elect

Monica M. Bertagnolli, MD, FACS, FASCO

Treasurer

Craig R. Nichols, MD, FACP, FASCO

Chief Executive Officer (ex-officio)

Clifford A. Hudis, MD, FACP, FASCO

Directors

Peter C. Adamson, MD

Charles D. Blanke, MD, FACP, FASCO

Linda D. Bosserman, MD, FACP, FASCO

Walter J. Curran, MD, FACP, FASCO

Stephen B. Edge, MD, FACS, FASCO

Arti Hurria, MD, FASCO

Maha Hussain, MD, FACP, FASCO

Reshma Jagsi, MD, DPhil

David Khayat, MD, PhD, FASCO

Michael P. Kosty, MD, FACP, FASCO

J. Chris Nunnink, MD, FASCO

Thomas G. Roberts Jr., MD, FASCO

Eric J. Small, MD, FASCO

Jaap Verweij, MD, PhD, FASCO

Jedd D. Wolchok, MD, PhD, FASCO

2018 Conquer Cancer Foundation Board of Directors

Chair

Thomas G. Roberts Jr., MD, FASCO

Chair Emeritus

W. Charles Penley, MD, FASCO

Treasurer

Sandra M. Swain, MD, FACP, FASCO

Secretary

Claire A. Huang

Chief Executive Officer (ex-officio)

Clifford A. Hudis, MD, FACP, FASCO

ASCO President (ex-officio)

Bruce E. Johnson, MD, FASCO

Executive Vice President and Chief

Philanthropic Officer (ex-officio)

Nancy R. Daly, MS, MPH

Directors

Howard A. Burris, MD, FACP, FASCO

Alexander Casdin

Susan L. Cohn, MD, FASCO

Lawrence H. Einhorn, MD, FASCO

Raj Mantena, RPH

Thomas A. Marsland, MD, FASCO

Robert J. Mayer, MD, FASCO

Gerald J. McDougall

Steven T. Rosen, MD, FACP, FASCO

Aaron A. Sasson

Margaret Tempero, MD, FASCO

Don Welsh

Cancer Communications Committee News Planning Subcommittee

Chair

John Heymach, MD, PhD

Chair-Elect

Sumanta Kumar Pal, MD

Immediate Past Chair

Harold J. Burstein, MD, PhD, FASCO

Nancy N. Baxter, MD

Warren Allen Chow, MD, FACP

William Dale, MD, PhD

Catherine S. Magid Diefenbach, MD

Robert Dreicer, MD, MS, MACP, FASCO

Andrew S. Epstein, MD

Timothy D. Gilligan, MD, MSc

David L. Graham, MD

Joshua Adam Jones, MD, MA

Carlos Rodriguez-Galindo, MD

Michael S. Sabel, MD, FACS

Mario Sznol, MD

Shannon Neville Westin, MD

Subcommittee Liaisons

Arti Hurria, MD, FASCO,

Board Liaison

Lidia Schapira, MD, FASCO,

Cancer.Net Liaison

Hugo Akabane, MD,

Professional Development Committee Liaison

Annual Meeting Education Committee

David R. Spigel, MD, *Chair*

Colin D. Weekes, MD, PhD, *Chair-Elect*

Michael A. Thompson, MD, PhD, FASCO,

Immediate Past Chair

Breast Cancer

Rebecca Alexandra Dent, MD—Track Leader

Stacy L. Moulder, MD, MS

Sara A. Hurvitz, MD

Judy Caroline Boughey, MD

Rinaa S. Punglia, MD, MPH

Tallal Younis, MBBCh, FRCP, FACP

Neelima Denduluri, MD

Alberto Jose Montero, MD, MBA

Cancer Prevention, Hereditary Genetics, and Epidemiology

Michael Mullane, MD—Track Leader

Bradley McGregor, MD

Margreet Ausems, MD, PhD

Surendra Srinivas Shastri, MD, MBBS

Jeff Boyd, PhD

Joanne Jeter, MD

Sailaja Kamaraju, MD

Prudence Lam, MD

Care Delivery and Practice Management

Moshe C. Chasky, MD, FACP—Track Leader

Edward R. Arrowsmith, MD, MPH

Suzanne Cole, MD, FACP

Lee Steven Schwartzberg, MD, FACP

Sue Sun Yom, MD, PhD

PLANNING COMMITTEES continued

Central Nervous System Tumors

Eric L. Chang, MD—Track Leader
Ingo Mellingerhoff, MD
Nicole A. Shonka, MD
Priscilla Brastianos, MD

Developmental Therapeutics and Translational Research

Julia A. Beaver, MD—Track Leader
Todd Michael Bauer, MD
Scott Gettinger, MD
Benjamin Besse, MD, PhD
Naoko Takebe, MD, PhD

Gastrointestinal (Colorectal) Cancer

Chi Lin, MD, PhD—Track Leader
Michael Overman, MD
Weijing Sun, MD, FACP
Sharlene Gill, MD, MPH, MBA
Arden Morris, MD

Gastrointestinal (Noncolorectal) Cancer

Federico Sanchez, MD—Track Leader
Ian Chau, MD
James Posey, MD
William Small, MD
Ramon De Mello, MD, PhD, FACP
Peter Enzinger, MD

Genitourinary (Nonprostate) Cancer

Ulka N. Vaishampayan, MD—Track Leader
Evan Y. Yu, MD
James Brugarolas, MD, PhD
Jeanny Aragon-Ching, MD, FACP

Genitourinary (Prostate) Cancer

Edward M. Schaeffer, MD, PhD—Track Leader
Himisha Beltran, MD
Chris Parker, BA, BM Bchir, MD, FRCR, FRCP
Alicia Morgans, MD, MPH

Geriatric Oncology

Stuart Lichtman, MD—Track Leader
Tanya Wildes, MD
Heidi Klepin, MD, MS
Gretchen Kimmick, MD

Global Health

Gilberto Lopes, MD, MBA—Track Leader
Julie Gralow, MD, FASCO
Yuko Kitagawa, MD, PhD, FACS
Alex Mutombo Baleka, MD

Gynecologic Cancer

Ronald J. Buckanovich, MD—Track Leader
Elise C. Kohn, MD
Linda Van Le, MD
Elizabeth Dickson, MD

Head and Neck Cancer

John A. Ridge, MD, PhD, FACS—Track Leader
Lori Wirth, MD
Joseph Kamel Salama, MD
Irina Veytsman, MD

Health Services Research, Clinical Informatics, and Quality of Care

Jeremy Warner, MD, MS—Track Leader
Ethan M. Basch, MD, FASCO
Katherine Virgo, PhD, FASCO
Ryan Nipp, MD
Michael Halpern, MD, PhD, MPH
Yousuf Zafar, MD, MHS

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft

Jorge E. Cortes, MD—Track Leader
Steven Devine, MD
Catriona HM Jamieson, MD, PhD
Elihu Estey, MD
Asad Bashey, MD, PhD

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Barbara Pro, MD—Track Leader
Matthew Alexander Lunning, DO
Nilanjan Ghosh, PhD, MBBS
Carla Casulo, MD
Ishmael Jaiyesimi, DO, MS, FACP

Hematologic Malignancies—Plasma Cell Dyscrasia

Irene M. Ghobrial, MD—Track Leader
Parameswaran Hari, MD
Joseph Mikhael, MD
Sagar Lonial, MD
Ravi Vij, MD

Lung Cancer

Shirish M. Gadgeel, MD—Track Leader
Aaron S. Mansfield, MD
Mark Kris, MD, FASCO
Puneeth Iyengar, MD, PhD
Anne Tsao, MD
Nathan A. Pennell, MD, PhD

Melanoma/Skin Cancers

Alexander Christopher Jonathan van Akkooi, MD, PhD—Track Leader
Eduardo Sotomayor, MD
Paolo Ascierto, MD
Ragini Kudchadkar, MD
Gregory Pennock, MD, FACP

Patient and Survivor Care

Patricia Robinson, MD—Track Leader
Louise Christie Walter, MD
Kevin Oeffinger, MD
Kathi Mooney, PhD, RN
Norah Henry, MD, PhD
Maryam Lustberg, MD

Pediatric Oncology

Sung Won Choi, MD, MS—Track Leader
Tara O. Henderson, MD, MPH
Paul David Harker-Murray, MD, PhD
Michael Ortiz, MD

Professional Development

Jane Meisel, MD—Track Leader
 Jill Gilbert, MD
 Thomas Openshaw, MD, MS
 Vyshak Alva Venur, MD
 Roberto Antonio Leon-Ferre, MD
 Brian Boulmay, MD

Sarcoma

Robin Lewis Jones, MD, MBBS,
 MRCP—Track Leader
 Mark Agulnik, MD
 Jonathan Trent II, MD, PhD
 Nicholas Paul Webber MD

Tumor Biology

Vamsidhar Velcheti, MD—Track Leader
 Ravi Salgia, MD, PhD
 Kwok-Kin Wong, MD, PhD
 Victoria Villaflor, MD

Liaisons

Eric J. Small, MD, FASCO—Board of Directors
 Fredrick Chite Asirwa, MD—International Affairs
 Committee
 Arif Kamal, MD, MBA, MHS, FAAHPM—Quality of
 Care
 Committee
 Karen Winkfield, MD, PhD—Health Disparities
 Committee
 Karen Lu, MD—Cancer Prevention Committee
 Deborah Mayer, PhD, AOCN, ANP-BC—Cancer
 Survivorship
 Committee
 R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA—
 Cancer
 Research Committee
 Debra Patt, MD, MPH, MBA—Clinical Practice Com-
 mittee
 Leonard Saltz, MD—Value Task Force
 Laura L. Tenner, MD—Ethics Committee
 Jeffrey J. Kirshner, MD—Clinical Practice Guidelines
 Committee

**Annual Meeting Scientific Program
 Committee**

Ann H. Partridge, MD, MPH, FASCO, *Chair*
 Suzanne George, MD, *Chair-Elect*
 David C. Smith, MD, *Immediate Past Chair*

Biostatistics

Mei-Yin Polley, PhD—Track Leader
 Rosemarie Mick, MSc
 Yu Shyr, PhD
 Kelley Kidwell, PhD
 Suzanne E. Dahlberg, PhD
 Susan Halabi, PhD, FASCO
 Karla Ballman, PhD

Breast Cancer—Metastatic

Ruth O'Regan, MD—Track Leader
 Angela DeMichele, MD
 Erika Hamilton, MD
 Beverly Moy, MD, FASCO
 Virginia Kaklamani, MD, DSc
 George Somlo, MD
 Sara Tolaney, MD, MPH

Breast Cancer—Local/Regional/Adjuvant

Elizabeth Mittendorf, MD, PhD—Track Leader
 Erica Mayer, MD, MPH
 Sherene Loi, MD, PhD
 Andrew Wahl, MD
 Jacqueline Sara Jeruss, MD, PhD
 Priyanka Sharma, MD
 Julia R. White, MD

**Cancer Prevention, Hereditary Genetics, and
 Epidemiology**

Veda Giri, MD—Track Leader
 John Goffin, MD
 Mark Robson, MD
 Kara Maxwell, MD, PhD
 Noelle LoConte, MD

Central Nervous System Tumors

David Reardon, MD—Track Leader
 Monica Malik, MD, DNB
 John De Groot, MD
 Amin Kassam, MD

**Developmental Therapeutics and Translational
 Research—Clinical Pharmacology and
 Experimental Therapeutics**

Christophe Le Tourneau, MD, PhD—Track Leader
 R. Donald Harvey, PharmD, FCCP, BCOP
 David Hyman, MD
 Laura Goff, MD
 William Figg, PharmD
 Geoffrey Shapiro, MD, PhD
 Ramesh Ramanathan, MD
 Kyriakos P. Papadopoulos, MD

**Developmental Therapeutics and Translational
 Research—Immunotherapy**

Sanjay Goel, MD—Track Leader
 James Gulley, MD, PhD, FACP
 Heather McArthur, MD, MPH
 Thomas Gajewski, MD, PhD
 Matthew Milowsky, MD
 Aparna Kalyan, MD
 Padmanee Sharma, MD, PhD

Gastrointestinal (Colorectal) Cancer

Wells A. Messersmith, MD, FACP—Track Leader
 Jordan Berlin, MD
 Hanna Sanoff, MD, MPH
 Jennifer Eads, MD
 Mark Kozloff, MD
 Fotios Loupakis, MD, PhD
 Heinz-Josef Lenz, MD

PLANNING COMMITTEES continued

Ritesh Rathore, MD
Larissa K. F. Temple, MD
Cathy Eng, MD, FACP
Jennifer Chan, MD

Gastrointestinal (Noncolorectal) Cancer

A. Craig Lockhart, MD—Track Leader
Keith Unger, MD
Daniel Chang, MD
Matthew Kulke, MD
E. Gabriela Chiorean, MD
Rebecca Thomas, MD
Rachna Shroff, MD
Zev Wainberg, MD
Colin Weekes, MD, PhD
Vaibhav Sahai, MBBS, MS
Sunil Sharma, MD, FACP

Genitourinary (Nonprostate) Cancer

Daniel George, MD—Track Leader
Karim Chamie, MD
Toni Choueiri, MD
Elizabeth R. Plimack, MD, MS
Petros Grivas, MD, PhD
Daniel E. Spratt, MD

Genitourinary (Prostate) Cancer

Ravi Madan, MD—Track Leader
Timur Mitin, MD, PhD
Tanya B. Dorff, MD
Felix Feng, MD
Anthony Joshua, MBBS, FRACP, PhD
Ganesh S. Palapattu, MD

Gynecologic Cancer

Deborah Armstrong, MD—Track Leader
Helen Mackay, MRCP, MD
Molly Brewer, MD
Linda Duska, MD, MPH
Patricia Eifel, MD
Karen McLean, MD, PhD

Head and Neck Cancer

Charu Aggarwal, MD, MPH—Track Leader
Faye Johnson, MD, PhD
K. William Harter, MD
Ezra Cohen, MD, FRCP, FASCO
Kerstin Stenson, MD
William M. Lydiatt, MD

Health Services Research, Clinical Informatics, and

Quality of Care

Ronald S. Go, MD—Track Leader
Rachel Freedman, MD, MPH
Erica Warner, MPH, ScD
Ronac Mamtani, MD
Ronald C. Chen, MD, MPH
Jack W. London, PhD
Tara Kaufmann, MD
Gabriel A. Brooks, MD, MPH

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Guillermo Garcia-Manero Jr., MD—Track Leader
Lori Maness, MD
Leslie Ellis, MD
Juliet Barker, MBBS
John Byrd, MD

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Susan O'Brien, MD—Track Leader
Leslie Andritsos, MD
Sonali Smith, MD
Matthew Davids, MD
Tycel Phillips, MD

Hematologic Malignancies—Plasma Cell Dyscrasia

David Vesole, MD, PhD, FACP—Track Leader
Noopur Raje, MD
Angela Dispenzieri, MD
Adam Cohen, MD
Brea Lipe, MD

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Robert Cameron, MD—Track Leader
Jamie Chافت, MD
Jay Lee, MD
Jared Weiss, MD
Leah Backhus, MD
Taofeek Owonikoko, MD, PhD, MS
Alexander Chi, MD

Lung Cancer—Non-Small Cell Metastatic

Melissa Johnson, MD—Track Leader
Scott Antonia, MD, PhD
Robert Doebele, MD, PhD
Benjamin Levy, MD
Ignatius Sai-Hong Ou, MD, PhD
Heather Wakelee, MD
Alice Shaw, MD, PhD
Gregory J. Riely, MD, PhD

Melanoma/Skin Cancers

Joshua Mammen, MD—Track Leader
Tara Gangadhar, MD
Douglas Johnson, MD
Janice Mehnert, MD

Patient and Survivor Care

Michelle Janelins, PhD, MPH—Track Leader
Christine Miasowski, PhD, MS, BSN
Shoshana Rosenberg, ScD
Martin Stockler, MBBS, MS, FRACP
James Hillard, MD
Thomas LeBlanc, MD, MA, MHS
Piyush Srivastava, MD
Sunil Verma, MD

Pediatric Oncology

Richard Aplenc, MD—Track Leader
Jacqueline Casillas, MD
Maryam Fouladi, MD
Scott Borinstein, MD, PhD

Sarcoma

Junecko Grilley-Olson, MD—Track Leader
Sam Yoon, MD
Rashmi Chugh, MD
Vicki Keedy, MD

Tumor Biology

Patrick C. Ma, MD, MSc—Track Leader
Ross Levine, MD
Kurt Schalper, MD, PhD
Eddy Yang, MD, PhD
Pamela Goodwin, MD
Michael Green, PhD
Wafik S. El-Deiry, MD, PhD, FACP

ONSITE DETAILS

ASCO Headquarters Office

Badge reprints and assistance available in N427a.

Emergency Response for Visitors

If an alarm sounds in McCormick Place:

- Horns and strobes will turn on
- Visitors will be directed over the public announcement system to exit through the closest “Emergency Exit”
- Doors marked as “Stairs” also serve as emergency exits

In the event of a power failure, all emergency systems will run on emergency power. Temporary safe areas are available in open parking lots, roadways, and grass areas adjacent to McCormick Place.

Faculty Registration and Speaker Ready Room

All faculty will check in at the Faculty Registration and Speaker Ready Room, located in the North Building, Room N426, to receive their badges and Meeting materials. Additionally, faculty and oral abstract presenters should report to N426 to review and submit their presentations at least 2 hours before their scheduled session.

Oncology Professionals Hall (OPH)

Located in the South Building, Level 3, Hall A, the OPH comprises Exhibits, Posters, the Industry Expert Theater, the Career Fair, a Food Court, and ASCO Bistro. Exhibits will highlight the most advanced treatments, products, and services in oncology and provide attendees the opportunity to meet with representatives from pharmaceutical companies, scientific publishers, and advocacy groups. Posters are located on the far-right side of the OPH and can be accessed from the Grand Concourse entrance or from the S101 lobby.

The Exhibitor Directory is available in Hall C Registration, Materials Pickup, and the Grand Concourse entrance to the OPH.

Exhibits are open Saturday through Monday, 9:00 AM – 5:00 PM. Posters are open Saturday – Monday, 8:00 AM – 5:00 PM. Poster Presenters can access their Posters an hour prior to their Poster Session.

Industry Expert Theater

The Industry Expert Theater is located in the back of OPH by the Food Court and will host hour-long presentations from industry leaders sharing the latest in oncology practices, products, services and technologies. Presentations are not certified for Continuing Education credit. The schedule will be available in the Exhibitor Directory and online at am.asco.org.

Services Available at McCormick Place

- **ASCO University Bookstore:** North Building, Concierge Services, and ASCO Central (Booth #7004)
- **Charge and Connect With Power Strips and Ethernet:** East Building, Lakeside Lounge
- **Charging Stations for Electronic Devices:** Located on round tables throughout McCormick Place
- **Chicago Concierge:** North Building, Concierge Services
- **CE and Technical Assistance Help Desk:** North Building, Concierge Services
- **First Aid Stations:** South Building, Level 2.5 near Business Center; East Building, Level 1 near Arie Crown Theater
- **Hotel Assistance Desk:** North Building, Concierge Services
- **International Assistance Desk:** North Building, Concierge Services
- **Internet Stations With Printers:** North Building, Level 2.5
- **Interact, Powered by SYNC and WIFI Help Desk:** North Building, Concierge Services
- **Member Services Desk:** North Building, Concierge Services, ASCO Central (Booth #7004); Hall C, Registration

ONSITE DETAILS continued

- **Networking Cafes With Power Outlets (Featuring ASCO TV):** North Building, Concierge Services South Building, S103 Lobby; East Building, Arie Crown Lobby; East Building, Lakeside Lounge
- **Nursing Lounge:** North Building, Room N227a
- **Poster/Meeting Video and Slides Station:** OPH
- **Prayer/Meditation Room:** East Building, Room E251

Shuttle Bus Service

Complimentary shuttle service is provided between McCormick Place and all official ASCO hotels. The complete shuttle schedule is available at am.asco.org/arc. Please be sure to check the ASCO Shuttle sign in your hotel for any changes. Service will be approximately every 20 minutes. McCormick Place is the transfer point for all routes.

Hours of Operation

Friday – Monday, 6:45 AM - 7:00 PM*
Tuesday, 6:45 AM - 1:30 PM*

* Last shuttle departs McCormick Place at this time.

If you have any questions regarding the shuttle or would like to make a reservation for a wheelchair-accessible ASCO Shuttle, please see the ASCO Shuttle supervisor at McCormick Place during shuttle hours or call Kushner & Associates at 312-808-2000.

FEATURED VOICES ON TWITTER

If you use Twitter, we invite you to use and follow the official meeting hashtag #ASCO18 and to follow ASCO's Featured Voices for observations and insight (see am.asco.org for the complete list of Featured Voices).

#ASCO18 Tweetup

All attendees who are active on social media, or would like to learn more about using social media, are invited to join us for casual conversation and drinks at the official #ASCO18 Tweetup on Saturday, June 2, at 5:30 PM in the McCormick Place Plate Room (South Building, Level 2.5 Plate Room Food Court). Signs will be posted and staff will be guiding attendees to the exact location.

POLICIES

For questions regarding these policies or attendee conduct, contact the ASCO Meetings Department at meetings@asco.org or visit ASCO Headquarters (Room N427a).

Special Assistance

ASCO, all official ASCO hotels, and McCormick Place comply with the Americans with Disabilities Act. If you require special assistance, please contact the 2018 ASCO Annual Customer Service Center at ascohousing@spargoinc.com or visit the Hotel Assistance Desk in the Grand Concourse Lobby onsite.

Age Requirement for Attendees

Because of the detailed nature of the programs and forums, no one under the age of 18 will be admitted to any official Meeting function unless permission to such individual is granted by ASCO. This includes, but is not limited to, all Meeting sessions, the Oncology Professionals Hall, and all ASCO-sponsored evening events.

Meeting Badge

For security reasons, the 2018 ASCO Annual Meeting badge will be required for admittance to all events. Please wear your badge so that it can be easily seen at all times. Lost badges should be reported to the Registration staff immediately. The following badge policies will be in effect throughout the Meeting:

- The 2018 ASCO Annual Meeting badge is the sole property of ASCO.
- The badge is nontransferable.
- False certification of individuals as paid Meeting attendees, misuse of badges, any method of assisting unauthorized persons to gain access to any Meeting event, or any inappropriate or unauthorized conduct will be just cause for repossessing badges of any individuals involved and expelling all parties involved from the Meeting without obligation on the part of ASCO for refund of any fees.

- All ASCO Meeting badges are encoded with basic information about you, including your name and mailing address. Exhibitors have the ability to scan your badge to obtain that information. Please note that by giving an exhibitor your badge to scan you are giving them consent to contact you.

Attendee Conduct

ASCO is committed to providing a friendly, safe, supportive, and harassment-free meeting environment, regardless of a person's race, color, ethnicity, national origin, citizenship status, age, religion, disability status, gender, gender identity, sexual orientation, genetic information, physical appearance, or other group identity. In addition, ASCO expects meeting attendees to communicate professionally and constructively, whether in person or virtually, and handle dissent or disagreement with courtesy and respect. Finally, individuals who are part of the 2018 ASCO Annual Meeting may not engage in any demonstrations or other behavior that ASCO deems to be potentially disruptive to the conduct of the Meeting.

Violation of this Attendee Conduct Policy is grounds for immediate removal from the Meeting (without a refund of any fees paid) and/or ineligibility for attendance at future ASCO symposia or meetings. Any person who is dismissed from the Meeting may request that ASCO reviews the matter, provided, however, that such dismissal will be effective immediately and will continue until and unless ASCO issues a contrary decision.

Cancellation Statement

ASCO reserves the right to cancel the 2018 ASCO Annual Meeting because of unforeseen circumstances. In the event of such cancellation, the full registration fee will be returned to each registrant.

Equal Opportunity Statement

The 2018 ASCO Annual Meeting is available without regard to race, color, sex, national origin, disability, age, or veteran status as provided by law and in accordance with ASCO's respect for personal dignity.

Authorization for Use of Image, Name, and Other Likeness

By attending the 2018 ASCO Annual Meeting or entering in the facility in which the 2018 ASCO Annual Meeting takes place, you agree that ASCO or authorized third parties may photograph or record your likeness, image, name, voice, and/or words, and may publish, display, reproduce, copy, and distribute your likeness, image, name, voice, and/or words for promotional, educational, or membership activities worldwide in all forms of media now known or later developed, including but not limited to advertising, training, websites, presentations, and marketing materials. You further acknowledge that ASCO or authorized third parties shall have the right, but not the obligation, to identify you in connection with such media by name and/or affiliation. No royalties will be payable in connection with this authorization or these uses.

Recording (Audio, Video, and Still Photography)

Copyright of the 2018 ASCO Annual Meeting program is owned by ASCO. ASCO reserves all rights associated with the Meeting, including (without limitation), the rights to all recordings or reproductions of presentations at this Meeting and all ASCO meetings and symposia.

Any photography, filming, taping, recording, or reproduction in any medium, including via the use of tripod-based equipment, of any of the programs and/or posters presented at the 2018 ASCO Annual Meeting without the express written consent of ASCO is strictly forbidden. Exception: Non-flash photography and audiotape recording using hand-held equipment, for strictly personal and noncommercial use, are permitted if not disruptive, as determined by ASCO.

No Soliciting in the Oncology Professionals Hall

The Oncology Professionals Hall gives 2018 ASCO Annual Meeting attendees the opportunity to meet with representatives from the health care industry about their products and services in a professional atmosphere that is consistent with the educational mission of ASCO. Meeting attendees are prohibited from soliciting business from other attendees or exhibitors in the Oncology Professionals Hall, unless the solicitation occurs within the specific exhibit space of the attendee.

No Smoking

Smoking is prohibited in all 2018 ASCO Annual Meeting facilities, including public areas and the Oncology Professionals Hall. This policy will be enforced.

AWARDS

ASCO 2018 SPECIAL AWARDS

David A. Karnofsky Memorial Award and Lecture

Presented during the Opening Session, Saturday, June 2, 9:30 AM, Hall B1
Ralph R. Weichselbaum, MD, University of Chicago Hospital

Science of Oncology Award and Lecture

Presented during the Plenary Session, Sunday, June 3, 1:00 PM, Hall B1
Douglas R. Lowy, MD, National Cancer Institute Center for Cancer Research

Allen S. Lichter Visionary Leader Award and Lecture

Presented on Saturday, June 2, 3:00 PM, S100a
Nancy E. Davidson, MD, FASCO, Fred Hutchinson Cancer Research Center

ASCO-American Cancer Society Award and Lecture

Presented on Monday, June 4, 9:45 AM, S102
Karen H. Lu, MD, The University of Texas MD Anderson Cancer Center

B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology

Presented on Monday, June 4, 3:00 PM, S404
Supriya Gupta Mohile, MD, MS, University of Rochester Medical Center

Gianni Bonadonna Breast Cancer Award and Lecture

Presented on Monday, June 4, at 4:45 PM, Hall D1
Gabriel N. Hortobagyi, MD, FACP, FASCO, The University of Texas MD Anderson Cancer Center

Pediatric Oncology Award and Lecture

Presented on Monday, June 4, 1:15 PM, S504
Gregory H. Reaman, MD, FASCO, U.S. Food and Drug Administration

Distinguished Achievement Award

Presented during the President's Dinner, Friday, June 1
John Mendelsohn, MD, The University of Texas MD Anderson Cancer Center

Excellence in Teaching Award

Presented during the President's Dinner, Friday, June 1
Gregory P. Kalemkerian, MD, University of Michigan

Humanitarian Award

Presented during the President's Dinner, Friday, June 1
Julie Gralow, MD, FASCO, Seattle Cancer Care Alliance

Partners in Progress Award

Presented on Monday, June 4, 1:15 PM, S504
Danielle Leach, MPH, St. Baldrick's Foundation

Public Service Award

Presented on Sunday, June 3, 11:30 AM, S100A
Gideon M. Blumenthal, MD, U.S. Food and Drug Administration

Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award

Presented during the Conquer Cancer Grants and Awards Ceremony and Reception
Lori J. Pierce, MD, FASCO, University of Michigan Health System

This award was generously provided by Hologic, Inc

International Women Who Conquer Cancer Mentorship Award

Presented during the Conquer Cancer Grants and Awards Ceremony and Reception
Rejin Kebudi, MD, Istanbul University

**Fellows of the American Society of
Clinical Oncology (FASCO)**

*Presented during the Opening Session,
Saturday, June 2, 9:30 AM, Hall B1*

Clement Adebamowo, MD, ScD
David J. Adelstein, MD, FACP
Alex A. Adjei, MD, PhD
Jaffer A. Ajani, MD
Kenneth C. Anderson, MD
Christopher G. Azzoli, MD
Jordan Berlin, MD
Smita Bhatia, MD, MPH
J. Sybil Biermann, MD
Michael R. Bishop, MD, FACP
A. William Blackstock, MD
Paul Celano, MD
Walter J. Curran, MD, FACR
Don S. Dizon, MD, FACP
Nagi S. El Saghir, MD, FACP
Laura Esserman, MD, MBA
Christopher Flowers, MD, MS
Giuseppe Giaccone, MD, PhD
Jill Gilbert, MD
Sharon H. Giordano, MD, MPH
Susan Halabi, PhD
Lyndsay Harris, MD
James Hayman, MD, MBA
Carolyn B. Hendricks, MD
Martee L. Hensley, MD
Roy S. Herbst, MD, PhD, FACP
Paul J. Hesketh, MD
Paulo Marcelo Hoff, MD, FACP, PhD
James N. Ingle, MD

Sundar Jagannath, MD
Mohammad Jahanzeb, MD
Hagop M. Kantarjian, MD
Beth Karlan, MD
James L. Khatcheressian, MD
Alok A. Khorana, MD
Hedy L. Kindler, MD
Andrew H. Ko, MD
Natasha B. Leighl, MD
Andrew Loblaw, MD
Jennifer Malin, MD, PhD
Bruce D. Minsky, MD
Beverly Moy, MD
Craig R. Nichols, MD, FACP
Kenneth Offit, MD, MPH
Mark S. Pascal, MD
Jyoti D. Patel, MD
Blase N. Polite, MD, MPA
Thomas G. Roberts Jr., MD
Howard I. Scher, MD
Gary K. Schwartz, MD
Manish A. Shah, MD
Lawrence N. Shulman, MD
Mary Lou Smith, JD, MBA
Philip J. Stella, MD
James A. Stewart, MD
John W. Sweetenham, MD, FRCP
Michael A. Thompson, MD, PhD
Anthony W. Tolcher, MD
Timothy J. Whelan, MD
Jedd D. Wolchok, MD, PhD
Marie Wood, MD
Antoinette J. Wozniak, MD

2018 Conquer Cancer Foundation of ASCO Merit Awards

Bradley Stuart Beller Endowed Merit Award

This special recognition is given to the fellow who submitted the overall highest-ranking abstract as determined by the Scientific Program Committee.

Andrea M. Gross, MD, National Institutes of Health

Brigid Leventhal Special Merit Award

In honor of Brigid Leventhal, a physician-pioneer in pediatric research, the Brigid Leventhal Merit Award is presented to the fellow who submitted the highest-ranking abstract in pediatrics as determined by the Scientific Program Committee's Pediatrics Track.

Fiorela Natali Hernandez Tejada, MD, The University of Texas MD Anderson Cancer Center

Pain and Symptom Management Special Merit Award

This special recognition is given to the fellow who submitted the highest-ranking abstract in pain and symptom management research as determined by the Scientific Program Committee.

Anita Roselyn Peoples, PhD, MPH, University of Rochester Medical Center

Allen S. Lichter, MD, Endowed Merit Award

This special recognition is given to the fellow who submitted the second-highest-ranking abstract as determined by the Scientific Program Committee.

Alicia Latham Schwark, MD, Memorial Sloan Kettering Cancer Center

AWARDS continued

James B. Nachman Endowed ASCO Junior Faculty Award in Pediatric Oncology

Established in memory of James B. Nachman, MD, Professor of Pediatrics at The University of Chicago and an internationally renowned pediatric cancer expert, this award is given to the junior faculty member who submitted the highest-ranking abstract in pediatric oncology as determined by the Scientific Program Committee.

John Shern, MD, National Cancer Institute at the National Institutes of Health

Newly Endowed Merit Awards

Dr. and Mrs. Douglas W. Blayney Endowed Merit Award

Mehdi Touat, MD, Dana-Farber Cancer Institute, Brigham and Women's Cancer Center, Harvard Medical School

Darla C. Ellis Endowed Women Who Conquer Cancer Merit Award

Nina Prabha Tamirisa, MD, MS, Duke University Medical Center

Loxo Oncology Endowed Merit Award

Natalie Vokes, MD, MPhil, Dana-Farber Cancer Institute

Kathleen I. Pritchard, MD, Endowed Merit Award

Romualdo Barroso-Sousa, MD, PhD, Dana-Farber Cancer Institute

Frances A. Shepherd, MD, Endowed Merit Award in Lung Cancer

Arpita Desai, MD, University of Chicago

Sherwin Family Endowed Merit Awards (3)

Rita Elias Assi, MD, The University of Texas MD Anderson Cancer Center

Katherine Clifton, MD, The University of Texas MD Anderson Cancer Center

Juliet Elizabeth Wolford, MD, University of California, Irvine

Drs. Rachna and Puneet Shroff Endowed Merit Award

Alberto Puccini, MD, USC Norris Comprehensive Cancer Center, Keck School of Medicine

Merit Award Recipients*

Merit Awards are given annually in recognition of outstanding abstracts submitted to the Annual Meeting. The Merit Award program was established to encourage more fellows and oncology trainees to attend the Annual Meeting and to further promote clinical research in young scientists.

Jithma P. Abeykoon, MD, Mayo Clinic, Rochester

Kathryn Cecilia Arbour, MD, Memorial Sloan Kettering Cancer Center

Francesca Battaglin, MD, USC Norris Comprehensive Cancer Center, Keck School of Medicine

Marc Oliva Bernal, MD, Princess Margaret Cancer Centre

Manali A. Bhave, MD, BA, Northwestern University

Prajwal Boddu, MD, The University of Texas MD Anderson Cancer Center

Joseph Nicholas Bodor, MD, PhD, Fox Chase Cancer Center

Dominick Bossé, MD, MSc, Dana-Farber Cancer Institute

Elena Ioana Braicu, MD, PhD, Charité Universitätsmedizin Berlin, European Competence Center for Ovarian Cancer, Charité Campus Virchow-Klinikum

Yanshuo Cao, MD, Princess Margaret Cancer Centre

Luisa Carbognin, MD, University of Verona

Alessia Castellino, MD, Mayo Clinic, Rochester

Fernando Caumont, MD, Virginia Mason Medical Center

Fumiko Ladd Chino, MD, BA, Duke University

Kevin Lee Min Chua, MBBS, National Cancer Centre Singapore

Julie Marie Collins, MD, MPH, National Cancer Institute

Vincenza Conteduca, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Colleen A. Cuthbert, PhD, University of Calgary

Ila Datar, PhD, Yale School of Medicine

Lisa Derosa, MD, Gustave Roussy Cancer Campus, Paris Saclay University

Michael Edward Devitt, MD, University of Virginia

Bhagirathbhai R. Dholaria, MBBS, Moffitt Cancer Center

Stephanie Dixon, MD, BS, St. Jude Children's Research Hospital

Soniya Dulal, MD, National Academy of Medical Sciences, Bir hospital

Gustavo Dos Santos Fernandes, MD, Memorial Sloan Kettering Cancer Center

Ahmad Ghorab, MD, MSc, The University of Texas MD Anderson Cancer Center

Ragisha Gopalakrishnan, MD, BS, Vanderbilt University Medical Center
 Kyle Greene, MD, University of Utah Huntsman Cancer Institute
 Shuchi Gulati, MD, FACP, University of Cincinnati Medical Center
 Pat Gulhati, MD, PhD, The University of Texas MD Anderson Cancer Center
 Anis Hamid, MBBS, Dana-Farber Cancer Institute
 Simon Heidegger, MD, Klinikum rechts der Isar, Technical University Munich
 Brian S. Henick, MD, Yale School of Medicine
 Raul Herrera, MD, The University of Texas MD Anderson Cancer Center
 Amy Houghtelin, MD, BS, Children's National Medical Center
 Boyu Hu, MD, The University of Texas MD Anderson Cancer Center
 Megan Jagosky, MD, Levine Cancer Institute
 Anuradha Jayaram, MBBS, MRCP, Institute of Cancer Research and The Royal Marsden NHS Trust Foundation
 Elizabeth Jimenez Aguilar, MD, Dana-Farber Cancer Institute
 Archit Joshi, MD, Cancer Institute (WIA)
 Jin Kang, MD, Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences
 Yada Kanjanapan, MBBS, Princess Margaret Cancer Centre, University Health Network
 Tyler Garrett Ketterl, MD, Fred Hutchinson Cancer Research Center
 Daniel Khalaf, MD, British Columbia Cancer Agency, Vancouver Centre
 Lillian Rose Klug, PhD, Portland VA Health Care System and OHSU Knight Cancer Institute
 Michael Lam, MBBS, The University of Texas MD Anderson Cancer Center
 Matteo Lambertini, MD, Institut Jules Bordet
 Nathalie LeVasseur, MD, British Columbia Cancer Agency
 Bryan Kincheon Li, MD, Hospital for Sick Children
 Wenhua Liang, MD, First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory, and National Clinical Research Center for Respiratory Disease
 Kristina Lindemann, MD, PhD, Institute of Clinical Medicine, University of Oslo
 Shiru Lucy Liu, MD, British Columbia Cancer Agency
 Stephen James Luen, MBChB, Peter MacCallum Cancer Centre
 Eoghan Ruadh Malone, MB BCh, BAO, BA, MSc, MRCPI, Princess Margaret Cancer Centre
 Shearwood McClelland III, MD, Oregon Health and Science University
 Kathan Mehta, MBBS, MPH, University of Pittsburgh
 Aaron Philip Mitchell, MD, The University of North Carolina at Chapel Hill
 Amr Mohamed, MD, Karmanos Cancer Institute
 Kevin Thomas Nead, MD, MPhil, University of Pennsylvania Perelman School of Medicine Hospital
 Tomohiro F. Nishijima, MD, New York University
 Mailha Nusrat, MD, The University of Texas MD Anderson Cancer Center
 Michael David Offin, MD, Memorial Sloan Kettering Cancer Center
 Thomas Ollila, MD, The Warren Alpert Medical School of Brown University
 Daniel Olson, MD, University of Chicago
 Seyed Saeed Pairawan, MD, The University of Texas MD Anderson Cancer Center
 Kaushal Parikh, MD, New York Medical College
 Wungki Park, MD, Mount Sinai St. Luke's and Roosevelt Hospitals
 Christine Megerdichian Parseghian, MD, The University of Texas MD Anderson Cancer Center
 Sandro Pasquali, MD, Fondazione IRCCS Istituto Nazionale dei Tumori
 Allan Andresson Lima Pereira, MD, PhD, The University of Texas MD Anderson Cancer Center
 Noam Falbel Ponde, MD, Centro Paulista de Oncologia
 Chethan Ramamurthy, BA, MD, Fox Chase Cancer Center
 Rahul Ravilla, MD, University of Arkansas
 Pasquale Rescigno, MD, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
 Nuria Romero-Laorden, MD, PhD, Hospital Universitario La Princesa
 Daniele Rossini, MD, Azienda Ospedaliera Universitaria Pisana, Istituto Toscano Tumori
 Joshua K. Sabari, MD, Memorial Sloan Kettering Cancer Center
 Andreas Nicholas Saltos, MD, H. Lee Moffitt Cancer Center & Research Institute
 Stephen Matthew Schleicher, MD, MBA, Memorial Sloan Kettering Cancer Center
 Shiraj Sen, MD, PhD, The University of Texas Southwestern Medical School
 Adam Sharp, MD, PhD, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
 Takehito Shukuya, MD, The Ohio State University
 Tharani Sivakumaran, MD, Peter MacCallum Cancer Centre
 Hadas Sorotsky, MD, Princess Margaret Cancer Centre
 Paolo Strati, MD, The University of Texas MD Anderson Cancer Center
 Stephanie Sullivan, MD, University of North Carolina at Chapel Hill
 Roger Sun, MD, PhD, Gustave Roussy Cancer Campus
 Mahesh Swaminathan, MBBS, The University of Texas MD Anderson Cancer Center
 Aaron C. Tan, MBBS, PhD, BSc, Royal North Shore Hospital
 Jessica Tao, MD, BS, Memorial Sloan Kettering Cancer Center
 Vatche Tchekmedyan, MD, Memorial Sloan Kettering Cancer Center
 Sibotian, MD, Winship Cancer Institute, Emory University
 Nadina Tinsley, MBBS, MRCP, Christie Hospital NHS Trust

AWARDS continued

Ryuma Tokunaga, MD, PhD, USC Norris Comprehensive Cancer Center, Keck School of Medicine
Veerisa Vimolchalao, MD, Chulalongkorn University
Panagiotis J. Vlachostergios, MD, PhD, Weill Cornell Medical College & New York-Presbyterian Hospital
Adrienne Gropper Waks, MD, Dana-Farber Cancer Institute
Seth Andrew Wander, MD, PhD, BS, Dana-Farber Cancer Institute
Jennifer Rui Wang, MD, ScM, The University of Texas MD Anderson Cancer Center
Yucai Wang, MD, PhD, Mayo Clinic, Rochester
Kunning Wang, PhD, The First Hospital Affiliated to college of Medicine, Xi'an Jiaotong University
Patrick Williams, MD, PhD, University of Texas MD Anderson Cancer Center
Xiaoliang Wu, MD, West Virginia University Cancer Institute
Fevzi Firat Yalniz, MD, The University of Texas MD Anderson Cancer Center
Divya Yerramilli, MD, MBBS, Harvard Radiation Oncology
Todd Yezefski, MD, MS, BA, University of Washington School of Medicine
Steven Yip, MD, British Columbia Cancer Agency, Vancouver Cancer Centre

Merit Awards were generously supported by AstraZeneca, Friends and Family of Dr. and Mrs. Ronald Beller, Dr. and Mrs. Douglas W. Blayney, Estate of Darla C. Ellis, Ipsen Biopharmaceuticals Inc., Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie Company, Michael Kelley, MD and Elise Hoffman, PharmD, Kidney Cancer Association, Lilly, Loxo Oncology, Merck & Co., Inc., Friends and Family of Dr. James B. Nachman, Novartis Oncology, Dr. Kathleen Pritchard Medicine Professional Corporation, Frances A. Shepherd, MD, FASCO, Drs. Rachna and Puneet Shroff, Stephen A. Sherwin, MD, Mr. Jackson G. Simpson, and Takeda Oncology.

2018 Advanced Clinical Research Award in Breast Cancer

Mariana Chavez MacGregor, MD, MSc, The University of Texas MD Anderson Cancer Center

This grant was generously supported by Breast Cancer Research Foundation®.

2018 Career Development Awards*

Ayal Aizer, MD, Dana-Farber Cancer Institute
Saud AIDubayan, MD, Dana-Farber Cancer Institute
Tina Cascone, MD, PhD, The University of Texas MD Anderson Cancer Center
Phedias Diamandis, MD, PhD, University Health Network
Marios Giannakis, MD, PhD, Dana-Farber Cancer Institute
Daniel Halperin, MD, The University of Texas MD Anderson Cancer Center
Tae Kon Kim, MD, PhD, Yale University
Benjamin Lok, MD, Princess Margaret Cancer Centre
Stephanie Markovina, MD, PhD, Washington University
Jonathan Marron, MD, PhD, Harvard Medical School
Otto Metzger, MD, Dana-Farber Cancer Institute
Ciara O'Sullivan, MB, BCh, BAO, Mayo Clinic
Nitya Raj, MD, Memorial Sloan Kettering Cancer Center
Daniel Shin, MD, University of California, Los Angeles
Roy Strowd III, MD, MEd, Wake Forest Baptist Medical Center

These grants were generously supported by AbbVie, Inc., Astellas, AstraZeneca, Breast Cancer Research Foundation®, Genentech BioOncology™, Lilly, and the Conquer Cancer Foundation of ASCO Mission Endowment.

2018 Gianni Bonadonna Breast Cancer Research Fellowship

Clinton Yam, MD, The University of Texas MD Anderson Cancer Center

This grant was generously supported by GlaxoSmithKline Oncology.

2018 International Development and Education Awards*

The Conquer Cancer Foundation's International Development and Education Award (IDEA) provides support for early-career oncologists in developing countries to attend the ASCO Annual Meeting and spend additional time at a cancer center in the United States or Canada. Eligible recipients also receive three years of complimentary ASCO membership, which includes a subscription to *Journal of Clinical Oncology*. The awards are designed to provide continuing medical education, assist in career development, and help establish strong relationships between recipients and leading ASCO Members who serve as scientific mentors.

Ryan Anthony Francisco Agas, MD, Benavides Cancer Institute, University of Santo Tomas Hospital (Philippines)
 Rereloluwa Nicodemus Babalola, MBChB, Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife (Nigeria)
 Jimmy Awisan Billod, MD, Baguio General Hospital and Medical Center (Philippines)
 Arunangshu Das, MBBS, FCPS, Square Hospitals Ltd. (Bangladesh)
 Jennifer Ivonne Dominguez, MD, MSc, Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran" (Mexico)
 Ivana Dusan Durutovic, MD, Clinical Center of Montenegro (Montenegro)
 Samir Fasih, MBBS, MD, MS, Shaukat Khanum Memorial Cancer Hospital and Research Centre (Pakistan)
 Aynur Oktamovna Kenjaeva, MD, Kazakh Institute Oncology and Radiology (Kazakhstan)
 Ishmael Kyei, MBBS, MD, Komfo Anokye Teaching Hospital (Ghana)
 Raul Alejandro Lopez, MD, Instituto Nacional de Cancerologia (Mexico)
 Vinicius Lorandi, MD, Hospital do Cancer Mãe de Deus (Brazil)
 Pesona Grace Lucksom, MBBS, MS, Sikkim Manipal Institute of Medical Sciences (India)
 Angela Awino McLigeyo, MBBS, University of Nairobi (Kenya)
 Patience Tatenda Musiwa-Mba, MBBS, MS, Parirenyatwa Group of Hospitals (Zimbabwe)
 Ram Vasudevan Nampootheri, MBBS, MD, Post Graduate Institute of Medical Education & Research (India)
 Sami Saleem Omar, MBBS, Rizgary Oncology Center (Iraq)
 Jitendra Pariyar, MD, Civil Service Hospital (Nepal)
 Andra Piciu, MD, PhD, "Prof. Dr. Ion Chiricuta" Institute of Oncology Cluj-Napoca (Romania)
 Raul Rogelio Trejo Rosales, MD, Hospital Oncologia, Centro Medico Nacional Siglo XXI (Mexico)
 Edom Seife Woldetsadik, MD, Black Lion Hospital, Addis Ababa University (Ethiopia)

These awards were generously supported by Fashion Targets Breast Cancer Fund and Takeda Oncology.

2018 International Development and Education Awards in Palliative Care*

Pauline Anne Peronilla Cauton, MD, St. Luke's Medical Center (Philippines)
 Anuja Damani, MBBS, MD, Tata Memorial Centre (India)
 Eunice Nkechi Omoyeni, MBBS, MPH, University College Hospital, Ibadan (Nigeria)
 Shristi Tiwari Sr. MBBS, MD, Nepal Cancer Hospital and Research Center (Nepal)

This award was generously provided by the Conquer Cancer Foundation of ASCO Mission Endowment.

2018 International Innovation Grants*

Sushma Bhatnagar, MD, All India Institute of Medical Sciences (AIIMS) (India)
 Laura Rodriguez Romo, MD, Centro Universitario Contra el Cáncer, Hospital Universitario "Dr. José Eleuterio González" U.A.N.L. (Mexico)
 Fidel Rubagumya, MBBS, Ocean Road Cancer Institute (Tanzania)

This award was generously provided by the American Society of Clinical Oncology.

2018 Long-term International Fellowship*

Dorothy C. Lombe, MD, Cancer Diseases Hospital (Zambia)/University of British Columbia

This award was generously provided by the Conquer Cancer Foundation of ASCO Mission Endowment.

2018 Medical Student Rotation for Underrepresented Populations*

Mustafa Basree, University of Pikeville Kentucky College of Osteopathic Medicine
 Anita Chanana, Stanford University
 Kirsten Concha-Moore, University of Arizona
 Kimberly Loo, Temple University School of Medicine
 Veronica Manzo, Stanford University
 Sylvester Moses, PhD, University of Arizona
 Kekoa Taparra, PhD, Mayo Clinic, Minnesota

These awards were generously provided by AbbVie, Inc., Eisai Inc., Gilead Sciences, Inc., GlaxoSmithKline Oncology, Janssen Oncology, and the Conquer Cancer Foundation of ASCO Mission Endowment.

AWARDS continued

2018 Resident Travel Award for Underrepresented Populations*

Maria Garcia-Jimenez, MD, MS, New York University
Joannie Ivory, MD, Saint Louis University
Carla Justiniano, MD, University of Rochester Medical Center
Patrick J. Moore, MD, East Carolina University
Jenny Ruiz, MD, Columbia University Medical Center
Cristian Serna-Tamayo, MD, University of Medicine and Dentistry of New Jersey

These awards were generously provided by Janssen Oncology and Pharmacyclics LLC, an AbbVie Company, and the Conquer Cancer Foundation of ASCO Mission Endowment.

2018 Young Investigator Awards*

Rajiv Agarwal, MD, Memorial Sloan Kettering Cancer Center
David Aggen, MD, PhD, Columbia University Medical Center
Kathryn Arbour, MD, Memorial Sloan Kettering Cancer Center
Marina Baretta, MD, Johns Hopkins University
Andrew Bruggeman, MD, University of California, San Diego
Zachary Buchwald, MD, PhD, Emory University
Jad Chahoud, MD, The University of Texas MD Anderson Cancer Center
Huizi Chen, MD, PhD, The Ohio State University
Eric Christenson, MD, Johns Hopkins University
Ana Christina Garrido-Castro, MD, Dana-Farber Cancer Institute
Jennifer Crombie, MD, Dana-Farber Cancer Institute
Anastasios Dimou, MD, University of Colorado Cancer Center
Adam Durbin, MD, PhD, Dana-Farber Cancer Institute
Hany Elmariah, MD, MS, Johns Hopkins University
Penny Fang, MD, MBA, The University of Texas MD Anderson Cancer Center
Timothy Ferng, MD, University of California, San Francisco
Carl Gay, MD, PhD, The University of Texas MD Anderson Cancer Center
Karthik Giridhar, MD, Mayo Clinic Minnesota
Colin Godwin, MD, MPhil, Fred Hutchinson Cancer Research Center
Pedram Heidari, MD, Massachusetts General Hospital
Wade Iams, MD, Northwestern University
Megan Insko, MD, PhD, Dana-Farber Cancer Institute
Russell Jenkins, MD, PhD, Dana-Farber Cancer Institute
Allison Kaeding, MD, Fred Hutchinson Cancer Research Center
Tyler Ketterl, MD, Fred Hutchinson Cancer Research Center
Niloufer Khan, MD, Memorial Sloan Kettering Cancer Center
Chul Kim, MD, MPH, Georgetown University
Paul Koller, MD, The University of Texas MD Anderson Cancer Center
Andrew Laccetti, MD, MS, The University of Texas MD Anderson Cancer Center
Lauren Levine, MD, MS, University of California, San Francisco
Ang Li, MD, University of Washington
Eben Lichtman, MD, The University of North Carolina, Chapel Hill
Jessica Lin, MD, Massachusetts General Hospital
David Liu, MD, MPH, MS, Dana-Farber Cancer Institute
Sydney Lu, MD, PhD, Memorial Sloan Kettering Cancer Center
Liam Macleod, MD, MPH, University of Pittsburgh
Abhishek Mangaonkar, MBBS, Mayo Clinic, Minnesota
Steven Maron, MD, The University of Chicago
Kamal Menghrajani, MD, Memorial Sloan Kettering Cancer Center
Douglas Micalizzi, MD, PhD, Massachusetts General Hospital
Brian Miller, MD, PhD, Dana-Farber Cancer Institute
Devarati Mitra, MD, PhD, Dana-Farber Cancer Institute
Ankur Nagaraja, MD, PhD, Dana-Farber Cancer Institute
Hong Ha Rosa Nguyen, MD, St. Jude's Children's Research Hospital
Maliha Nusrat, MD, The University of Texas MD Anderson Cancer Center
Daniel O'Neil, MD, MPH, Columbia University Medical Center
Eileen Parkes, MBBS, PhD, Queen's University Belfast
Ravi Patel, MD, PhD, University of Wisconsin
Zachary Reitman, MD, PhD, Dana-Farber Cancer Institute
Rachael Rowswell-Turner, MD, PhD, University of Rochester Medical Center
Shawn Sarkaria, MD, Columbia University Medical Center

Alison Schram, MD, Memorial Sloan Kettering Cancer Center
Eugene Shenderov, MD, DPhil, Johns Hopkins University
David Shulman, MD, Dana-Farber Cancer Institute
Adam Sperling, MD, PhD, Dana-Farber Cancer Institute
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center
Brian Sworder, MD, PhD, Stanford University
Jessica Tao, MD, Memorial Sloan Kettering Cancer Center
Diane Tseng, MD, PhD, Stanford University
Neil Vasan, MD, PhD, Memorial Sloan Kettering Cancer Center
Adrienne Waks, MD, Dana-Farber Cancer Institute
Audrey Wallace, MD, MSN, University of Alabama at Birmingham
Seth Wander, MD, PhD, Dana-Farber Cancer Institute
Adam Waxman, MD, University of Pennsylvania
Ruth White, MD, PhD, Columbia University Medical Center
Clinton Yam, MD, The University of Texas MD Anderson Cancer Center
Jessica Yang, MD, Columbia University Medical Center
Daniel Yokom, MD, Princess Margaret Cancer Center
Neeha Zaidi, MD, Johns Hopkins University

These grants were generously provided by AbbVie, Inc., American Society of Clinical Oncology, AMMF—The Cholangiocarcinoma Charity, ASCO/CCF Employees, Association of Northern California Oncologists, AstraZeneca, The Bili Project Foundation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals, Inc., Breast Cancer Research Foundation®, Bristol-Myers Squibb, The Cholangiocarcinoma Foundation, Eisai Inc., Estate of Darla C. Ellis, Florida Society of Clinical Oncology, Gateway for Cancer Research, Genentech BioOncology™, Generous Supporters of the Women Who Conquer Cancer, Genomic Health, Inc., Gilead Sciences, Inc., The Hayden Family Foundation, Helen L. Kay Charitable Trust, Incyte Corporation, Miodrag Kukrika, MD, Janssen Oncology and Pharmacyclics LLC, an AbbVie Company, Journal of Clinical Oncology, Kidney Cancer Association, The John and Elizabeth Leonard Family Foundation, Lilly, Lung Cancer Alliance, Merck & Co., Inc., Greg Parekh/ New Rhein Healthcare, LLC, Puma Biotechnology, Inc., Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc Young Investigator Award, The Norman & Ruth Rales Foundation, Sarcoma Foundation of America, Shawn C. Tomasello, The Sontag Foundation, Strike 3 Foundation, TargetCancer Foundation, TESARO, Texas Society of Clinical Oncology, Thomas G. Roberts Jr., MD, and Susan M. DaSilva, PhD, Twisted Pink Inc., Vaniam Group LLC, Women Leaders in Oncology, and The WWWW Foundation Inc. (QuadW) and The Sarcoma Fund of the QuadW Foundation of Communities Foundation of Texas.

Past Grant Recipients

Conquer Cancer congratulates the following grant recipients whose abstracts were selected for the 2018 Annual Meeting. Their abstracts include the results of the research funded by Conquer Cancer. Visit CONQUER.ORG for more information about the Conquer Cancer Grants and Awards Program.

Mark M. Awad, MD, PhD, Dana-Farber Cancer Institute (2017 Career Development Award), abstract 9069
Victoria Susana Blinder, MD, Memorial Sloan Kettering Cancer Center (2010 Career Development Award), abstract 6583
Roisin M. Connolly, MD, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine (2013 Career Development Award), abstract 511
Katherine D. Crew, MD, MS, Columbia University Medical Center (2007 Career Development Award), abstract 1550
Mrinal M. Gounder, MD, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College (2012 Career Development Award), abstract 11500
Siwen Hu-Lieskován, MD, PhD, Jonsson Comprehensive Cancer Center, University of California, Los Angeles (2015 Career Development Award), abstract 12013
Sean Matthew McBride, MD, MPH, Memorial Sloan Kettering Cancer Center (2015 Career Development Award), abstracts 6009 and TPS5100
Jennifer Leigh McQuade, MD, The University of Texas MD Anderson Cancer Center (2017 Career Development Award), abstract 9562

AWARDS continued

Paul K. Paik, MD, Memorial Sloan Kettering Cancer Center (2013 Career Development Award), abstract 9098

Michael A. Postow, MD, Memorial Sloan Kettering Cancer Center (2016 Career Development Award), abstract 9550

Quoc-Dien Trinh, MD, Brigham and Women's Hospital/Harvard Medical School (2016 Career Development Award), abstract 6546

Allan Andresson Lima Pereira, MD, PhD, The University of Texas MD Anderson Cancer Center (2016 Long-term International Fellowship), abstract 3533

Enrique Soto Perez De Celis, MD, City of Hope, 2016 Long-term International Fellowship, abstract 10009

Reva K. Basho, MD, Cedars-Sinai Medical Center (2016 Young Investigator Award), abstract 588

Connie Lee Batlevi, MD, PhD, Memorial Sloan Kettering Cancer Center (2016 Young Investigator Award), abstract 7520

Tina Cascone, MD, PhD, The University of Texas MD Anderson Cancer Center (2016 Young Investigator Award), abstract 8555

Michael Cecchini, MD, Yale University (2017 Young Investigator Award), abstract TPS4137

Catherine Callaghan Coombs, MD, University of North Carolina at Chapel Hill (2016 Young Investigator Award), abstract 12068

Catherine Handy, MD, MPH, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University (2017 Young Investigator Award), abstract 1502

Catherine Handy, MD, MPH, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University (2017 Young Investigator Award), abstract 5062

Brian S. Henick, MD, Yale School of Medicine (2017 Young Investigator Award), abstract 12002

Bob T. Li, MD, MPH, Memorial Sloan Kettering Cancer Center (2015 Young Investigator Award), abstract 2502

Jennifer Kimberly Lue, MD, Columbia University Medical Center (2017 Young Investigator Award), abstract 7546

Filipa Lynce, MD, Georgetown Lombardi Comprehensive Cancer Center (2013 Young Investigator Award), abstract 1038

Kara Noelle Maxwell, MD, PhD, University of Pennsylvania Perelman School of Medicine (2015 Young Investigator Award), abstract 1503

Aaron Philip Mitchell, MD, The University of North Carolina at Chapel Hill (2017 Young Investigator Award), abstract 6607

Pavlos Msaouel, MD, PhD, The University of Texas MD Anderson Cancer Center (2017 Young Investigator Award), abstract 4575

Philip Daniel Poorvu, MD, Dana-Farber Cancer Institute (2017 Young Investigator Award), abstract 533

Joshua Sasine, MD, UCLA David Geffen School of Medicine (2017 Young Investigator Award), abstract 8035

Stephen Matthew Schleicher, MD, MBA, Memorial Sloan Kettering Cancer Center (2017 Young Investigator Award), abstract 6543

Noam Avraham VanderWalde, MD, University of Tennessee Health Science Center/West Cancer Center (2014 Young Investigator Award), abstract 10037

Benjamin A. Weinberg, MD, Georgetown Lombardi Comprehensive Cancer Center (2016 Young Investigator Award), abstract TPS4150

* As of April 23, 2018.

ANCILLARY EVENTS DIRECTORY

Below is a list of educational events hosted by other CE-accredited providers taking place in Chicago during the 2018 ASCO Annual Meeting. For more information regarding these events, consult the contact information in the listings below.

The events listed in this directory are independent, accredited educational activities held adjunct to the ASCO Annual Meeting. These presentations are not sponsored, endorsed, or accredited by ASCO.

Title: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your Patients

Date and Time: Friday, June 1, 2018, 7:00 PM (Dinner and registration begin at 6:30 PM)

Location: Hilton Chicago, International Ballroom South

CME Provider and Supporter(s): This event is organized and accredited by Physicians' Education Resource and is supported by an educational grant provided by AstraZeneca.

Registration and Contact Information: To register for the event, visit <http://gotoper.com/go/ascoparp18>. For additional information, email info@gotoper.com or call 609-378-3701.

Event Summary: As the treatment landscape for patients with breast cancer continues to be shaped by the evolving role of PARP inhibition, it is essential for practitioners who treat these patients to remain up to date on the latest clinical evidence. This activity will provide expert guidance on the clinical implications of recent studies, and how to use the evidence to develop best practices. A case-based format will be used to explore several key concepts, including the rationale for application of PARP inhibition in the treatment of breast cancer, clinical applications of recent trial evidence, strategies that are being studied to help personalize treatment approaches, and mitigation and management of adverse events associated with PARP inhibitor use. This will be a dynamic, interactive educational forum, affording participants the chance to ask questions of leading experts in the treatment of patients with breast cancer.

Faculty

Mark E. Robson, MD - Chair

Clinical Genetics and Breast Medicine Services, Memorial Sloan Kettering Cancer Center

Susan Domchek, MD

Basser Center for BRCA, Perelman School of Medicine

Melinda L. Telli, MD

Stanford University Medical Center

Sara A. Hurvitz, MD

David Geffen School of Medicine at UCLA, Santa Monica—UCLA Outpatient Hematology/Oncology Practice

Title: Hedgehog Pathway Signaling Inhibitors in Cancer Treatment

Date and Time: Friday, June 1, 2018, 7:00 PM (Dinner and registration begin at 6:30 PM)

Location: Hilton Chicago, International North Ballroom

CME Provider and Supporter(s): This event is organized by ScioCME, accredited by Medical Education Resources, and is supported by an educational grant provided by Sun Pharmaceuticals

Registration and Contact Information: Pre-registration is not required. For additional information, visit www.sciocme.com or email lshepherd@sciocme.com.

Event Summary: The Hedgehog (Hh) signaling pathway plays a key role in regulating cell proliferation and differentiation, and maintaining stem cell activity. Research has linked aberrant activation of the Hh signaling pathway to a wide range of cancers, including skin, brain, blood, pancreatic, lung, prostate, and breast, prompting extensive research into therapeutic approaches targeting the Hh pathway. Currently, two FDA-approved Hh pathway inhibitors (HPIs) have shown effectiveness in treating skin cancer, and ongoing research is evaluating the efficacy of this class of targeted therapy both as single agents and in combination, in multiple cancer types. This symposium brings together leading experts with broad oncology research and practice experience to present the latest findings on Hh signaling mechanisms in the development and progression of various cancers. Faculty will present data from studies of approved and investigational HPIs in solid tumors and hematologic malignancies in which clinical activity has been seen, as well as emerging data from preclinical and early clinical studies. Future prospects for HPIs will be discussed, with focus particularly on evolving treatment strategies using HPIs in combination with other targeted agents and immune checkpoint inhibitors, which have shown promise in expanding the scope and therapeutic efficacy of these agents.

ANCILLARY EVENTS DIRECTORY continued

Faculty

Alex A. Adjei, MD, PhD, FACP
Mayo Clinic

Daniel V. Catenacci, MD
The University of Chicago Medical Center and Biological Sciences

Jorge E. Cortes, MD
The University of Texas MD Anderson Cancer Center

Amar J. Gajjar, MD
St Jude's Children's Research Hospital

Michael R. Migden, MD
The University of Texas MD Anderson Cancer Center

Title: Cases from the Community: Clinical Investigators Provide Their Perspectives on Emerging Research and Actual Patients with Non-Small Cell Lung Cancer

Date and Time: Friday, June 1, 2018, 6:30 PM (Dinner buffet will be provided)

Location: Hilton Chicago, Grand Ballroom

CME Provider and Supporter(s): This event is organized and accredited by Research to Practice and is supported by educational grants provided by AstraZeneca Pharmaceuticals, LP, Bristol-Myers Squibb Company, Genentech BioOncology, Merck, and Takeda Oncology.

Registration and Contact Information: To register for the event, visit www.ResearchToPractice.com/Meetings/NSCLC2018. For additional information, email meetings@researchtopractice.com or call +1-305-377-2828 or toll free (US only) 800-233-6153.

Event Summary: This CME symposium will focus on the discussion of patients with non-small cell lung cancer (NSCLC) being treated by practicing oncologists in the community setting. Five renowned investigators will serve as the faculty for the event, which will be divided into five topic modules each focused on a distinct area of NSCLC management. Each module will feature a faculty-led review of emerging research as well as case-based discussion designed to demonstrate the optimal application of the data presented to contemporary patient care. To cultivate an interactive experience and maintain audience interest, clinician attendees will use iPads to complete a pre-meeting survey related to the cases and topics selected for discussion. The results will be displayed throughout the event to foster additional debate and elucidate any knowledge and/or practice gaps among those in attendance. Attendees will also use the iPads to submit their own questions directly to the moderator or faculty.

Faculty

Matthew D. Hellmann, MD
Memorial Sloan Kettering Cancer Center

Corey J. Langer, MD
Perelman School of Medicine, University of Pennsylvania

Geoffrey R. Oxnard, MD
Dana-Farber Cancer Institute

Martin Reck, MD, PhD
LungenClinic Grosshansdorf

Alice Shaw, MD, PhD
Harvard Medical School

Neil Love, MD - Moderator
Research To Practice

Title: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of Immunotherapy

Date and Time: Saturday, June 2, 2018, 7:00 PM (Dinner and registration begin at 6:30 PM)

Location: Hilton Chicago, International South Ballroom

CME Provider and Supporter(s): This event is organized and accredited by Physicians' Education Resource, and is supported by educational grants provided by Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

Registration and Contact Information: To register for the event, visit <http://gotoper.com/go/ascoscc18>. For additional information, email info@gotoper.com or call 609-378-3701.

Event Summary: Cutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer. Unresectable cSCCs respond to any currently available treatment only about 30% of the time. This is a devastating skin cancer as there are limited beneficial treatment options. There is a clearly unmet clinical need for improved cytoreductive strategies that may mitigate deleterious surgical outcomes in this treatment setting. Increased education is needed to translate the results of research surrounding immunotherapeutic agents for the treatment of advanced or metastatic cSCC into clinical practice. It is imperative that clinicians from the multidisciplinary team understand how immunotherapy agents can potentially address currently unmet clinical needs in the field for patients who are not candidates for chemotherapeutic approaches or to mitigate the impact of potentially disfiguring surgeries. These agents have a different adverse event profile than traditional chemotherapeutic agents, and in some cases, durable efficacy. Immunotherapeutic agents are being assessed for their value in the setting of cSCC and have recently been granted a breakthrough therapy designation for the treatment of adults with metastatic cSCC and adults with locally advanced and unresectable cSCC. This interactive symposium will discuss the advances in care of patients with oncology immunotherapies in the treatment of cSCC, including the most recent data sets, multidisciplinary patient management, and adverse event considerations, while allowing maximum time for expert interaction and audience participation. This satellite symposium will focus on the role of personalized team-based care, and how new evidence can be practically applied to the bedside in the face of shifting treatment paradigms.

Faculty

Jason J. Luke, MD, FACP - Chair
The University of Chicago Medicine

Omid Hamid, MD
The Angeles Clinic and Research Institute, Cedars Sinai Medical Care Foundation

Chrysalyne Schmults, MD, MSCE
Harvard Medical School, Brigham and Women's Hospital

Title: Expert Insights: Addressing Critical Questions in the Evolving Management of Advanced Ovarian Cancer

Date and Time: Saturday, June 2, 2018, 7:00 PM (Dinner and registration begin at 6:30 PM)

Location: Hilton Chicago, International North Ballroom

This event is organized by Letters & Sciences, jointly accredited by Letters & Sciences and the University of North Texas Health Science Center, and is supported by an educational grant provided by AstraZeneca.

Registration and Contact Information: To register for the event, visit www.OvarianCaExpertInsights.com. For additional information, email Jamie Miller at jamiller@letsai.org or call 973-560-1234.

Event Summary: The use of PARP inhibitors has changed the landscape of ovarian cancer therapy. The rationale for the development of PARP inhibition was based on the concept of synthetic lethality, in which a cell can survive a deficiency of one gene/gene product, but may die if there is a deficiency in a combination of genes/gene products. In ovarian tumors with BRCA1/2 deficiency, inhibition of PARP imposes an intolerable burden of DNA damage repair deficiency and may induce cell death. However, the availability of PARP inhibition for the treatment of platinum-resistant advanced ovarian cancer, there is a need for increase in awareness and understanding of its mechanism of action and place in therapy as new therapies and data are emerging along the disease continuum from advanced disease into maintenance and upfront (initial) therapeutic settings. In this CME/CNE ancillary event, leading experts, clinicians, and researchers will bridge the identified educational/practice gaps that will help optimize the clinical role of PARP inhibition in the treatment of advanced metastatic ovarian cancer and as maintenance treatment by providing expert perspectives in the selection and sequencing strategies in patients with relapsed platinum-sensitive disease within the context of current options and ongoing/planned studies, as well as discuss strategies to minimize potential toxicities and improve long term tolerability, and highlight strategies and clinical trials for novel combinations of PARP inhibitors that will enhance efficacy in recurrent disease.

Faculty

Robert L. Coleman, MD, FACOG, FACS
MD Anderson Cancer Center

Ursula A. Matulonis, MD
Dana-Farber Cancer Institute

Kathleen N. Moore, MD
Stephenson Cancer Center

ANCILLARY EVENTS DIRECTORY continued

Gottfried E. Konecny, MD
University of California, Los Angeles

Angeles Alvarez Secord, MD
Duke University Medical Center

Title: Consensus Debates and Dilemmas: Sequencing Therapy in EGFR-mutated NSCLC

Date and Time: Saturday, June 2, 2018, 7:15 PM (Dinner and registration begin at 7:00 PM)

Location: Hilton Chicago, Continental Ballroom

CME Provider and Supporter(s): This event is organized and accredited by Medscape, LLC and is supported by an educational grant provided by AstraZeneca Pharmaceuticals LP.

Registration and Contact Information: To register for the event, visit <http://medscape.org/symposium/sequencing-registration>. For additional information, email Erin Rafferty at ERafferty@medscape.net.

Event Summary: Treatment selection in *EGFR*-mutated non-small cell lung cancer (NSCLC) is complicated, with choices among first-, second-, and third-generation therapy options. Emerging data are leading to an evolving treatment paradigm with novel treatment options, new considerations in diagnostic testing, and questions in regard to sequencing. Acquired resistance to tyrosine-kinase inhibitors (TKIs) inevitably develops, resulting in the need to test for mutations causing the resistance and select appropriate therapy based on the results. This symposium will use case studies as a framework for discussing evidence-based treatment selection and management strategies throughout the continuum of disease.

Faculty

Lecia V. Sequist, MD, MPH
Harvard Medical School, Massachusetts General Hospital

Suresh S. Ramalingam, MD
Winship Cancer Institute, Emory University School of Medicine

Rolf A. Stahel, MD
Cancer Center Zurich, University Hospital Zurich

Heather A. Wakelee, MD
Stanford University, Stanford Cancer Institute

Title: The CME Situation Room: How Will Biosimilars Impact Oncology Care?

Date and Time: Saturday, June 2, 2018, 7:00 PM (Dinner and Registration begin at 6:30 PM)

Location: Hilton Chicago, Waldorf, 3rd Floor

CME Provider and Supporter(s): This event is organized and accredited by Vindico Medical Education and is supported by educational grants provided by Pfizer, Inc., and Sandoz, Inc.

Registration and Contact Information: To register for the event, visit VindicoCME.com/060218B. For additional information call 888-960-0256 ext. 219 or 476.

Event Summary: Biosimilars are highly similar, yet not identical, biological products for an approved reference biologic compound, demonstrating no clinically meaningful differences in quality, safety, or efficacy to the originator product. With patents expiring for several approved biological therapies utilized in treatment algorithms for patients with cancer, biosimilars of these biological therapies have the potential to reduce health care costs and provide global treatment accessibility. As further biosimilars are approved, it is imperative that all members of the multidisciplinary care team understand the development and evaluation process for these drugs, as well as their interchangeability with the originator product, to foster appropriate incorporation into existing oncology treatment paradigms. In this live educational activity, expert faculty will review and discuss the development, approval guidelines, and safety profiles of biosimilars, as well as assess the potential impact on oncology-related expenditures. A rapid-fire panel discussion will review various perspectives concerning the clinical issues around the use of these products.

Faculty

Hope S. Rugo, MD - Chair
University of California San Francisco Comprehensive Cancer Center

Sanjiv S. Agarwala, MD
St. Luke's Cancer Center, Temple University

Edward Li, PharmD, BCOP
University of New England College of Pharmacy

Title: Debates, Dilemmas, and Consensus: Now Is the Time for Personalized Medicine in Pediatric Oncology

Date and Time: Saturday, June 2, 2018, 7:15 PM (Dinner and registration begin at 7:00 PM)

Location: Swissotel Chicago, Zurich Ballroom A-D

CME Provider and Supporter(s): This event is organized and accredited by Medscape, LLC and is supported by educational grants provided by Loxo Oncology and Bayer.

Registration and Contact Information: To register for the event, visit <http://www.medscape.org/symposium/pediatric-ntrk-registration>. For additional information, email Elizabeth Romanazzi at eromanazzi@webmd.net.

Event Summary: Many oncologists and other members of the care team who help manage patients with pediatric cancer lack awareness and knowledge of the need to personalize medicine by testing patients for oncogenic drivers (eg, NTRK fusions), and how to best use biomarker test results to guide selection of the most appropriate individual treatment regimen. These data include information on the diagnostic strategies for identifying cancer that harbors an NTRK fusion, the efficacy and unique side effect profile of TKR inhibitors, how to select the most appropriate regimen for patients with a TRK fusion in their cancer and incorporating emerging data into clinical practice. This interactive symposium will feature 3 expert faculty and is designed to provide much-needed comprehensive foundational education on personalizing medicine and oncogenic drivers in pediatric cancer, emerging research on management of cancers that contain NTRK fusions, and practical insights on the use of TRK inhibitors in patients with this type of cancer.

Faculty

Theodore W. Laetsch, MD
The University of Texas Southwestern Medical Center

Steven Dubois, MD
Dana-Farber Cancer Institute, Harvard Medical School

Douglas S. Hawkins, MD
Seattle Children's Hospital

Title: Unmasking the Potential of PARP Inhibition as a Therapeutic Target in mCRPC

Date and Time: Sunday, June 3, 2018, 7:15 PM (Dinner and registration begin at 7:00 PM)

Location: Chicago Hilton, Continental Ballroom

CME Provider and Supporter(s): This event is organized and accredited by Medscape, LLC and is supported by an educational grant provided by AstraZeneca Pharmaceuticals LP.

Registration and Contact Information: To register for the event, visit <https://www.medscape.org/symposium/parp-crpc-asco-registration>. For additional information, email Amy Cramer at acramer@medscape.net.

Event Summary: Clinical research that aims to improve outcomes for patients with mCRPC has yielded important advances in therapy. Recent years have seen a significant expansion of the therapeutic armamentarium for mCRPC – and recently, PARP inhibitors are showing promise. mCRPC has been shown to have genomic aberrations that interfere with DNA repair, some of which are sensitive to PARP inhibition. As a result, a number of PARP inhibitors are being investigated to improve outcomes for patients with mCRPC. As the treatment paradigm for mCRPC continues to evolve, physicians face critical knowledge gaps that pose a barrier to achieving optimal clinical outcomes. This symposium will feature 3 expert faculty who will discuss the science of PARP inhibition, genomic testing, and the latest trial data of PARP inhibitors in mCRPC.

Faculty

Johann de Bono, MD, PhD
Institute of Cancer Research

Emmanuel Stylianos Antonarakis, MD
Johns Hopkins Medicine

Himisha Beltran, MD
Weill Cornell Medicine

Title: Managing Patients With Advanced Soft Tissue Sarcomas: Contemporary and Future Approaches

Date and Time: Monday, June 4, 2018, 7:15 PM (Dinner and registration begin at 7:00 PM)

Location: Hilton Chicago, Continental Ballroom

CME Provider and Supporter(s): This event is organized and accredited by Medscape, LLC and is supported by educational grants provided by Loxo Oncology, Bayer, and Eisai.

Registration and Contact Information: To register for the event, visit <http://medscape.org/symposium/soft-tissue-sarcoma-registration>. For additional information, email Charlene Foroutan at cforoutan@medscape.net.

ANCILLARY EVENTS DIRECTORY continued

Event Summary: Faced with an evolving treatment paradigm and an expanding armamentarium, physicians are challenged to keep abreast of evidence-based recommendations for the differential diagnosis, multidisciplinary management, and individualized treatment of advanced STS. This interactive symposium will feature 3 expert faculty and is designed to provide education on differential diagnosis of STS subtypes, key clinical data on recently approved therapies for advanced STS, emerging data on agents under investigation for treatment of advanced STS, a multidisciplinary approach to formulate treatment plans for patients with STS, and tailoring treatment strategies for patients with advanced STS

Faculty

David Hyman, MD
Memorial Sloan Kettering Cancer Center

George D. Demetri, MD
Dana-Farber Cancer Institute, Harvard Medical School

Todd Bauer, MD
Sarah Cannon Research Institute

**American Society of Clinical Oncology
54th Annual Meeting**

Meeting Program

Abstract Key

LBA: Late-Breaking Abstract

TPS: Trials in Progress Abstract

Friday, June 1, 2018

1:00 PM - 2:15 PM Education Session

Changes in Head and Neck Cancer Staging: It's Personal

Location: S100bc

Interact ID: 10712

William M. Lydiatt, MD - Chair

Creighton University and Nebraska Methodist Hospital
Lip and Oral Cavity Cancer: Is Size All That Matters?

Brian O'Sullivan, MD

Princess Margaret Cancer Centre
HPV-Associated Oropharynx Cancer: New Staging for a New Disease

Snehal G. Patel, MD

Memorial Sloan Kettering Cancer Center
p16-Negative Cancer: Incorporating Extranodal Extension

Panel Question and Answer

1:00 PM - 2:15 PM Education Session

Is There a Role for Immunotherapy in Brain Cancer?

Location: S100a

Interact ID: 10739

Amy B. Heimberger, MD - Chair

The University of Texas MD Anderson Cancer Center
Antitumor Immune-Inducing Strategies for Glioblastoma

Michael Platten, MD

Mannheim University Hospital, German Cancer Research Center (DKFZ)
Vaccine Therapy for Glial Tumors

Gavin P. Dunn, MD, PhD

Washington University School of Medicine in St. Louis
Update on Checkpoint Inhibitors and Combinatorial Approach to Targeted Immunotherapies

John H. Sampson, MD, PhD

Duke University Medical Center
Chimeric Antigen Receptor (CAR) and Adoptive Cell Transfer

Panel Question and Answer

1:00 PM - 2:15 PM Education Session

Multidisciplinary Management of Bladder Cancer: A Case-Based Discussion

Location: Arie Crown Theater

Interact ID: 10721

Jeanny B. Aragon-Ching, MD, FACP - Chair

Inova Schar Cancer Institute
Challenges of Perioperative Systemic Therapy of Localized Urothelial Cancer

Gary D. Steinberg, MD

University of Chicago Pritzker School of Medicine
Nuances of Surgical Management of Localized/Locally Advanced Urothelial Cancer

Anthony L. Zietman, MD

Massachusetts General Hospital and Harvard Medical School
Bladder-Sparing Strategies in Bladder Cancer

Panel Question and Answer

1:00 PM - 2:15 PM Education Session

Point/Counterpoint: Next-Generation Sequencing—Is It Right for Every Patient?

Location: S102

Interact ID: 10699

Peter Paul Yu, MD, FASCO, FACP - Chair

Hartford HealthCare Cancer Institute
Moderator

Howard A. Burris, MD, FASCO

Sarah Cannon Research Institute
Most Patients Should Be Tested

Leonard B. Saltz, MD

Memorial Sloan Kettering Cancer Center

Counterpoint: We Need to Be Highly Selective in the Patients We Test

Panel Question and Answer

1:00 PM - 2:15 PM Education Session

Precision Medicine in Myeloma: Are We There Yet?

Location: E450

Interact ID: 10758

Herve Avet-Loiseau, MD, PhD

University Hospital

Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside

Craig Cole, MD - Chair

University of Michigan School of Medicine

Should High-Risk Patients Be Treated Differently?

Adam D. Cohen, MD

Abramson Cancer Center

CAR-T and Cellular Therapy in Myeloma

Panel Question and Answer

1:00 PM - 2:15 PM Education Session

Progress With a Price? The Pros and Cons of Extended Therapy

Location: Hall D1

Interact ID: 10804

Mariana Chavez-MacGregor, MD

The University of Texas MD Anderson Cancer Center

Clinical Aspects of Escalating or De-escalating Adjuvant Therapy in HER2+ Breast Cancer

Friday, June 1, 2018

William John Gradishar, MD, FASCO - Chair

Northwestern University

Pros and Cons of Extended Adjuvant Endocrine Therapy

Michael J. Hassett, MD, MPH

Dana-Farber Cancer Institute

Finances: The New Dose-Limiting Toxicity

Panel Question and Answer

1:00 PM - 2:15 PM Education Session

Rational Combinations With an Immuno-Oncology Backbone

Location: S406

Interact ID: 10715

Alexander M. Eggermont, MD, PhD, FASCO - Chair

Cancer Institut Gustave Roussy

Immunotherapy Combinations: Are Two of More Better Than One?

Jennifer Ann Wargo, MD, MMedSc

The University of Texas MD Anderson Cancer Center

Novel Checkpoint/Targeted Therapy Combinations

Marka R. Crittenden, MD, PhD

Earle A. Chiles Research Institute, Providence Cancer Center

Combining Immunotherapy With Radiation

Panel Question and Answer

1:00 PM - 2:15 PM Education Session

Supportive Care in Lung Cancer: Improving Value in the Era of Modern Therapies

Location: E451

Interact ID: 10783

Tracy A. Balboni, MD

Dana-Farber Cancer Institute

Evolving Role of Supportive Care in the Era of Novel Therapies and Prolonged Life Span

Ka-Kit Hui, MD, FACP

David Geffen School of Medicine at UCLA

East Meets West: Role of Complementary Treatments

Arif Kamal, MD, MBA, MHS, FAAHPM - Chair

Duke Cancer Institute

Value and Cost of Supportive Care

Panel Question and Answer

1:00 PM - 2:15 PM Education Session

The Contemporary Multidisciplinary Management of Metastatic Sarcoma

Location: S504

Interact ID: 10774

Nicholas Paul Webber, MD

Aurora Advanced Healthcare

Does the Surgeon Have a Role in the Treatment of Oligometastatic Disease?

David G. Kirsch, MD, PhD

Duke University Medical Center

The Role of Radiation and Interventional Radiology in Metastatic Disease

Juneko E. Grilley-Olson, MD - Chair

University of North Carolina at Chapel Hill

Is There an Optimal Treatment Sequence for Systemic Therapy in Metastatic Disease?

Panel Question and Answer

1:00 PM - 2:15 PM Education Session

The Informatics of Precision Cancer Medicine

Location: S404

Interact ID: 10702

James Lin Chen, MD - Chair

The Ohio State University

Health Information Technology Needs of Oncologists and Tumor Boards in the Era of Genomic Medicine

Subha Madhavan, PhD

Innovation Center for Biomedical Informatics, Georgetown University Medical Center

Enabling Genomic Interoperability Through Minimum Variant Level Data

Somasundaram Subramaniam, MD, MS

Swedish Cancer Institute

Precision Medicine in the Community Practice

Panel Question and Answer

1:00 PM - 2:15 PM Meet the Professor Session

On Either Side of the Knife: Novel Preoperative and Postoperative Systemic Therapies in Lung Cancer - Ticketed Session

Location: E253d

Interact ID: 10908

Patrick M. Forde, MD

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Enriqueta Felip, MD

Hospital Universitari de la Vall d'Hebron

Friday, June 1, 2018

1:00 PM - 2:15 PM Clinical Problems in Oncology Session

Clinical Challenges for Stem Cell Transplants: Selecting the Proper Patient, Timing, and Donor - Ticketed Session

Location: E253c

Interact ID: 10767

Lori S. Muffly, MD, MS

Stanford University Medical Center

The Impact of Age and Comorbidity in Selecting Patients, Donors, and Defining Outcomes for Stem Cell Transplant

Marcos J.G. De Lima, MD - Chair

Seidman Cancer Center, University Hospitals Cleveland Medical Center

Stem Cell Transplant With Less Than a Perfect Matched Donor

Celalettin Ustun, MD

University of Minnesota

Using Measurable Detectable Disease and Precision Medicine to Decide for or Against Stem Cell Transplant

Panel Question and Answer

1:00 PM - 3:15 PM Workshop

Talking With Patients About Risk and Uncertainty

Location: S405

Interact ID: 10926

Lesley Fallowfield, DBE, DPhil, FMedSci - Chair

SHORE-C

Workshop Moderator

Valerie A. Jenkins, DPhil - Chair

SHORE-C

Workshop Moderator

1:00 PM - 5:00 PM Workshop

Genomics for Oncologists 101: An Interactive Workshop

Location: S105ab

Interact ID: 10925

Richard L. Haspel, MD, PhD - Chair

Beth Israel Deaconess Medical Center and Harvard Medical School

Ramaswamy Govindan, MD - Chair

Washington University School of Medicine in St. Louis

Daniel Botelho Costa, MD, PhD

Beth Israel Deaconess Medical Center and Harvard Medical School

Utilization of Genomic Analysis in Oncology

Loren J. Joseph, MD

Beth Israel Deaconess Medical Center and Harvard Medical School

Molecular Pathologist's Perspective

Deepa Rangachari, MD

Beth Israel Deaconess Medical Center and Harvard Medical School
Utilization of Genomic Analysis in Oncology

Kate P. Shane-Carson, MS, LGC

The Ohio State University Comprehensive Cancer Center
Genetic Counselor's Perspective

1:00 PM - 5:00 PM Workshop

Grant Writing

Location: S103
Interact ID: 10693

Charles R. Thomas, MD, FASCO - Chair

Oregon Health and Science University
Choosing a Mentor and Obtaining Letters of Support

Norah Lynn Henry, MD, PhD

University of Utah
What to Do When Your First Grant Application Gets Rejected

Dawn L. Hershman, MD, FASCO

Columbia University Medical Center
Grant Writing Pearls

Karla V. Ballman, PhD

Weill Cornell Medicine
Working With a Biostatistician

Ming Lei, MD, PhD

National Cancer Institute at the National Institutes of Health
NCI Training and Career Development Grants

Dean Frohlich, PhD

Conquer Cancer Foundation of the American Society of Clinical Oncology
Conquer Cancer Foundation

2:45 PM - 4:00 PM Education Session

Global Health Perspective in Sarcomas and Other Rare Cancers

Location: S504
Interact ID: 10778

Antonio G. Nascimento, MD

A. C. Camargo Cancer Center
The Challenges of Diagnosing Sarcomas and Other Rare Cancers in Resource-Constrained Settings

Ashish Gulia, MD

Tata Memorial Centre
Treating Sarcomas and Other Rare Cancers in Resource-Constrained Settings

Gilberto Lopes, MD, MBA - Chair

Sylvester Comprehensive Cancer Center, University of Miami Health System
Access to New and Expensive Medications in Developing Countries

Panel Question and Answer

Friday, June 1, 2018

2:45 PM - 4:00 PM Education Session

My Patient Was Diagnosed With Nontargetable Advanced Non-Small Cell Lung Cancer: What Now?

Location: Hall D1
Interact ID: 10703

Nathan A. Pennell, MD, PhD

Cleveland Clinic
Assessment and Diagnostics of Newly Diagnosed Patients With Advanced Non-Small Cell Lung Cancer

Melissa Lynne Johnson, MD - Chair

Sarah Cannon Research Institute
Combination Chemotherapy Strategies in Frontline Therapy

Hossein Borghaei, DO, MS

Fox Chase Cancer Center
Novel Immunotherapy Combinations in the Initial Management of Non-Small Cell Lung Cancer

Panel Question and Answer

2:45 PM - 4:00 PM Education Session

Neuroendocrine Tumors: Do We Know What to Do?

Location: E451
Interact ID: 10732

Jonathan R. Strosberg, MD - Chair

H. Lee Moffitt Cancer Center & Research Institute
Role of Nuclear Medicine in Neuroendocrine Cancers

Nitya Prabhakar Raj, MD

Memorial Sloan Kettering Cancer Center
Upcoming Role of Directed Therapy in Neuroendocrine Tumors

Nicola Fazio, MD, PhD

European Institute of Oncology
When and How to Sequence Treatment in Neuroendocrine Tumors

Panel Question and Answer

2:45 PM - 4:00 PM Education Session

On the Shoulders of Giants: Breast Cancer—Where Precision Medicine Began

Location: S100a
Interact ID: 10781

Vyshak Alva Venur, MD

Fairview Hospital Cleveland Clinic Hospital
Welcome and Introduction

Jane Lowe Meisel, MD - Chair

Winship Cancer Institute
The Continuing Evolution of Targeted Therapy in Breast Cancer

Michael Gnant, MD

Medical University of Vienna

ER+ Breast Cancer: The Evolution of Endocrine Therapy

Lisa A. Carey, MD

University of North Carolina

HER2-Targeted Therapy: Changing the Story of Breast Cancer

Panel Question and Answer

2:45 PM - 4:00 PM Education Session

Personalized Care in the Management of Kidney Cancer

Location: Arie Crown Theater

Interact ID: 10722

Ulka N. Vaishampayan, MD - Chair

Karmanos Cancer Center

Personalized Approach to Systemic Therapy of Renal Cancer

Daniel Yick Chin Heng, MD, MPH

Tom Baker Cancer Centre, University of Calgary

Prognostic Biomarkers in the "Precise" Management of Kidney Cancer

James Brugarolas, MD, PhD

UT Southwestern Medical Center

Clinical Applications of the Biology of Renal Cancer

Panel Question and Answer

2:45 PM - 4:00 PM Education Session

Personalizing Postoperative Treatment for Head and Neck Cancer

Location: S100bc

Interact ID: 10713

Ellie Maghami, MD - Chair

City of Hope National Medical Center

Tumor-Related Factors Warranting Adjuvant Postoperative Therapy

Shlomo A. Koyfman, MD

Cleveland Clinic

Nodal Disease in HPV-Positive and HPV-Negative Cancer: Who Needs Postoperative Radiation?

Jared Weiss, MD

University of North Carolina Hospitals

Postoperative Chemoradiation: Which Patients, Which Agents?

Panel Question and Answer

Friday, June 1, 2018

2:45 PM - 4:00 PM Meet the Professor Session

Creating a Culture of Sustainable Quality Improvement in Your Practice - Ticketed Session

Location: E253d
Interact ID: 10686

Brian Hunis, MD, MBA
Memorial Cancer Institute

Arif Kamal, MD, MBA, MHS, FAAHPM
Duke Cancer Institute

2:45 PM - 4:00 PM Clinical Problems in Oncology Session

When Less Is More: Local-Regional Management of Breast Cancer - Ticketed Session

Location: E253c
Interact ID: 10775

Rinaa S. Punglia, MD
Dana-Farber Cancer Institute
DCIS: Is Active Surveillance Right for Some Patients?

Lee G. Wilke, MD - Chair
University of Wisconsin Hospitals and Clinics
Who Needs More Versus Less Surgery?

Chirag Shah, MD
Cleveland Clinic
Is Abbreviated Radiation a Reality?

Panel Question and Answer

2:45 PM - 5:45 PM Oral Abstract Session

Central Nervous System Tumors

Location: S102
Interact ID: 10832

Lakshmi Nayak, MD - Chair
Dana-Farber Cancer Institute

Vinay K. Puduvalli, MD - Chair
Ohio State University Comprehensive Cancer Center

2:45 PM Abstract 2000: GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma. *W. Wick, P. Dietrich, S. Kuttruff, N. Hilf, K. Frenzel, A. Admon, S. H. van der Burg, A. von Deimling, C. Gouttefangeas, J. R. Kroep, F. Martinez-Ricarte, H. Okada, C. H. Ottensmeier, B. Ponsati, H. S. Poulsen, S. Stevanovic, G. Tabatabai, H. Rammensee, U. Sahin, H. Singh*

- 2:57 PM Abstract 2001: A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).** *M. Platten*, D. Schilling, L. Bunse, A. Wick, T. Bunse, D. Riehl, I. Karapanagiotou-Schenkel, I. Harting, F. Sahm, A. Schmitt, J. P. Steinbach, A. Weyerbrock, J. Hense, M. Misch, D. Krex, S. Stevanovic, G. Tabatabai, A. von Deimling, M. Schmitt, W. Wick
- 3:09 PM Abstract 2002: Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma.** *I. K. Mellingshoff*, M. Penas-Prado, K. B. Peters, T. F. Cloughesy, H. A. Burris III, E. A. Maher, F. Janku, G. M. Cote, M. I. De La Fuente, J. Clarke, L. Steelman, K. Le, Y. Zhang, A. Sonderfan, D. Hummel, S. Schoenfeld, K. Yen, S. S. Pandya, P. Y. Wen
- 3:21 PM Howard Alan Fine, MD (Discussion of Abstract(s) 2000-2002)**
Weill Cornell Medical Center
Key Trials Update
- 3:33 PM Panel Question and Answer**
- 3:45 PM Abstract 2003: ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma.** *M. Touat*, A. M. Dubuc, D. M. Meredith, S. C. Gaffey, J. E. Geduldig, S. H. Ramkissoon, J. F. De Groot, E. Galanis, M. R. Welch, L. B. Nabors, I. Arrillaga, E. A. Chiocca, S. Santagata, D. Schiff, M. S. Ahluwalia, H. Colman, J. Drappatz, B. M. Alexander, P. Y. Wen, K. L. Ligon
- 3:57 PM Abstract 2004: Feasibility and benefit of molecularly-informed enrollment into early phase trials for patients with recurrent gliomas.** *C. Baldini*, N. Younan, E. Castanon Alvarez, S. N. Dumont, F. Bielle, J. Frenel, A. Di Stefano, A. Alentorn, R. Bahleda, A. Varga, G. Louvel, A. Hollebecque, K. Hoang-Xuan, J. Delattre, F. Dhermain, M. Sanson, J. Soria, A. Idbaih, C. Massard, M. Touat
- 4:09 PM Abstract 2005: Actionable targets involving FGF receptors in gliomas: Molecular specificities, spatial distribution, clinical outcome and radiological phenotype.** *A. Di Stefano*, A. Picca, E. Saragoussi, G. Berzero, A. Alentorn, M. Touat, F. Ducray, C. Villa, E. Trisolini, Y. Schmitt, A. Idbaih, K. Hoang-Xuan, J. Delattre, A. Lasorella, A. Iavarone, K. Mokhtari, J. Savatovsky, F. Bielle, M. Sanson
- 4:21 PM Joanna J. Phillips, MD, PhD (Discussion of Abstract(s) 2003-2005)**
University of California, San Francisco
Application of Precision Genomics for Clinical Trials
- 4:33 PM Panel Question and Answer**
- 4:45 PM Abstract 2006: Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients.** *D. A. Reardon*, L. Nayak, K. B. Peters, J. L. Clarke, J. T. Jordan, J. F. De Groot, P. L. Nghiemphu, T. J. Kaley, H. Colman, S. C. Gaffey, V. Caruso, M. Bednarek Debruyne, C. Bhavsar, A. M. Molinaro, T. Smith, M. Severgnini, P. Y. Wen
- 4:57 PM Abstract 2007: Phase II study of pembrolizumab in leptomeningeal carcinomatosis.** *P. K. Brastianos*, S. Prakadan, C. Alvarez-Breckenridge, E. Q. Lee, S. M. Tolaney, L. Nayak, N. U. Lin, A. Navia, I. Bihun, U. N. Chukwueke, K. S. Oh, M. White, E. R. Gerstner, D. P. Lawrence, J. V. Cohen, A. Giobbie-Hurder, D. P. Cahill, A. Shalek, S. L. Carter, R. J. Sullivan
- 5:09 PM Abstract 2008: Window-of-opportunity clinical trial of a PD-1 inhibitor in patients with recurrent glioblastoma.** *J. F. De Groot*, M. Penas-Prado, J. J. Mandel, B. J. O'Brien, S. S. Weathers, S. Zhou, K. Hunter, K. Alfaro-Munoz, G. N. Fuller, J. Huse, G. Rao, J. S. Weinberg, S. S. Prabhu, S. D. Ferguson, Y. Yuan, L. M. Vence, J. P. Allison, P. Sharma, A. B. Heimberger
- 5:21 PM Duane Anthony Mitchell, MD, PhD (Discussion of Abstract(s) 2006-2008)**
University of Florida Brain Tumor Immunotherapy Program, Preston A. Wells, Jr. Center for Brain Tumor Therapy
PD-1 Blockade in Neuro-oncology: Lessons and Challenges
- 5:33 PM Panel Question and Answer**

2:45 PM - 5:45 PM Oral Abstract Session

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Location: S406

Interact ID: 10833

Julia A. Beaver, MD - Chair

U.S. Food and Drug Administration

Christophe Le Tourneau, MD, PhD - Chair

Institut Curie

- 2:45 PM Abstract 2500: Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.** *F. Meric-Bernstam, M. Beeram, J. I. Mayordomo, D. L. Hanna, J. A. Ajani, M. A. Blum Murphy, R. K. Murthy, S. A. Piha-Paul, T. M. Bauer, J. C. Bendell, A. B. El-Khoueiry, H. Lenz, M. F. Press, N. Royer, D. F. Hausman, E. P. Hamilton*
- 2:57 PM Abstract 2501: Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.** *H. Iwata, K. Tamura, T. Doi, J. Tsurutani, S. Modi, H. Park, I. E. Krop, Y. Sagara, C. H. Redfern, R. K. Murthy, R. A. Redman, K. Shitara, Y. Fujisaki, M. Sugihara, L. Zhang, J. Shahidi, A. Yver, S. Takahashi*
- 3:09 PM Abstract 2502: A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers.** *B. T. Li, V. Makker, D. J. Buonocore, M. D. Offin, Z. T. Olah, E. Panora, R. Shen, A. L. Ho, R. Yaeger, G. Iyer, M. S. Ginsberg, G. Ulaner, D. B. Solit, D. M. Hyman, C. M. Rudin, M. F. Berger, J. Baselga, M. Scaltriti, M. E. Arcila, M. G. Kris*
- 3:21 PM Dennis J. Slamon, MD, PhD (Discussion of Abstract(s) 2500-2502)**
David Geffen School of Medicine at University of California, Los Angeles
Novel Strategies for HER2-Driven Tumors
- 3:33 PM Panel Question and Answer**
- 3:45 PM Abstract 2503: Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway.** *Y. Chae, C. Vaklavas, H. H. Cheng, F. Hong, L. Harris, E. P. Mitchell, J. A. Zwiebel, L. McShane, R. J. Gray, S. Li, S. P. Ivy, S. S. Ansher, S. R. Hamilton, P. M. Williams, J. V. Tricoli, C. L. Arteaga, B. A. Conley, P. J. O'Dwyer, A. P. Chen, K. Flaherty*
- 3:57 PM Abstract 2504: Biomarker-driven access to crizotinib in ALK, MET, or ROS1 positive (+) malignancies in adults and children: The French National AcSé Program.** *G. Vassal, N. Cozic, G. Ferretti, S. Taieb, R. Houot, L. Brugieres, T. Aparicio, J. Blay, I. Bieche, S. Lantuejoul, C. Mahier-Ait Oukhatar, N. Hoog Labouret, D. Moro-Sibilot*
- 4:09 PM Abstract 2505: First-in-human phase 1 study of the PARP/tankyrase inhibitor 2X-121 (E7449) as monotherapy in patients with advanced solid tumors and validation of a novel drug response predictor (DRP) mRNA biomarker.** *E. R. Plummer, D. Dua, N. Cresti, A. Suder, Y. Drew, P. Stephens, M. Foegh, S. Knudsen, S. McGonigle, B. Ink, D. Sarker*
- 4:21 PM David Michael Hyman, MD (Discussion of Abstract(s) 2503-2505)**
Memorial Sloan Kettering Cancer Center
Identifying Biomarkers of Response Independent of Histology
- 4:33 PM Panel Question and Answer**
- 4:45 PM Abstract 2506: First-in-human phase 1 study of TAK-931, an oral cell division cycle 7 (CDC7) inhibitor, in patients (pts) with advanced solid tumors.** *T. Shimizu, T. Doi, S. Kondo, H. Takahashi, N. Yamamoto, E. Sheldon-Waniga, X. Zhou, B. Bahamon, H. Li, Y. Kuboki*

- 4:57 PM **Abstract 2507: Phase I dose escalation study of the first-in-class selective PTEFb inhibitor BAY 1251152 in patients with advanced cancer: Novel target validation and early evidence of clinical activity.** *J. R. Diamond, V. Moreno, E. A. Lim, R. Cordoba, C. Cai, S. J. Ince, J. T. Lettieri, C. Merz, R. Valencia, V. Boni*
- 5:09 PM **Abstract 2508: A first-in-human phase 1 dose-escalation trial of the oral HIF-2a inhibitor PT2977 in patients with advanced solid tumors.** *K. P. Papadopoulos, E. Jonasch, N. J. Zojwalla, K. Wang, T. M. Bauer*
- 5:21 PM **Geoffrey Shapiro, MD, PhD (Discussion of Abstract(s) 2506-2508)**
Dana-Farber Cancer Institute
New Agents Targeting Replication, Transcription, and Hypoxia
- 5:33 PM *Panel Question and Answer*

2:45 PM - 5:45 PM Oral Abstract Session

Health Services Research, Clinical Informatics, and Quality of Care

Location: S404

Interact ID: 10841

Rachel A. Freedman, MD, MPH - Chair
Dana-Farber Cancer Institute

Ronald S. Go, MD - Chair
Mayo Clinic

- 2:45 PM **Abstract 6500: Randomized trial comparing a web-mediated follow-up via patient-reported outcomes (PRO) vs. routine surveillance in lung cancer patients: Final results.** *F. Denis, E. M. Basch, C. Lethrosne, N. Pourel, O. Molinier, Y. Pointreau, J. Domont, H. P. Bourgeois, H. Senellart, J. Bennouna, T. Urban, A. Septans, M. Balavoine, P. Solal-Celigny, A. C. Dueck, C. Letellier*
- 2:57 PM **Abstract 6501: Patient-reported outcomes, emoji, and activity measured on the Apple Watch in cancer patients.** *C. A. Thompson, K. J. Yost, A. Bartz, A. Kumar, K. J. Ruddy, D. L. Stan, J. H. Uhm, R. M. Warsame, T. E. Witzig, P. J. Novotny, J. Sloan*
- 3:09 PM **Abstract 6502: The effect of a lay health worker-led symptom assessment intervention for patients on patient-reported outcomes, healthcare use, and total costs.** *M. I. Patel, D. Ramirez, R. Agajanian, J. Bhattacharya, A. Milstein, K. Bundorf*
- 3:21 PM **Martin J. Taphoorn, MD (Discussion of Abstract(s) 6500-6502)**
Haaglanden Medical Center
The Power of PRO-Active Symptom Monitoring
- 3:33 PM *Panel Question and Answer*
- 3:45 PM **Abstract 6503: Frequency of post-treatment surveillance and survival in localized prostate cancer: AFT-30 a national study.** *R. C. Chen, Z. Mohammed, J. R. Schumacher, A. B. Francescatti, A. Cuddy, G. J. Chang, B. D. Kozower, C. C. Greenberg, A. McCarthy, S. B. Edge, D. P. Winchester, R. Basak*
- 3:57 PM **Abstract 6504: Lung cancer screening rates: Data from the lung cancer screening registry.** *D. Pham, S. Bhandari, M. Oechslis, C. M. Pinkston, G. H. Kloecker*
- 4:09 PM **Abstract 6505: Integrating tobacco treatment into cancer care: A first snapshot of RCT findings.** *E. R. Park, G. K. Perez, S. Regan, A. Muzikansky, N. Rigotti, D. E. Levy, J. S. Temel, M. E. Cooley, A. H. Partridge, W. F. Pirl, K. Irwin, E. R. Friedman, S. Borderud, K. Hyland, J. Rabin, K. Sprunck, D. Kwon, J. S. Ostroff*
- 4:21 PM **Cary Philip Gross, MD (Discussion of Abstract(s) 6503-6505)**
Yale School of Medicine
Cancer Screening and Follow-up Care: Too Little, Too Much, but Never Too Late

Friday, June 1, 2018

4:33 PM *Panel Question and Answer*

4:45 PM **Abstract 6506: Uptake of genetic testing and outcomes in a randomized study of remote genetic services as compared to usual care in community practices without genetic providers.** *A. R. Bradbury, L. J. Patrick-Miller, B. L. Egleston, C. Burke Sands, S. Abbas, C. Cacioppo, N. Reddy, E. McCarty Wood, S. M. Domchek*

4:57 PM **Abstract 6507: PRECISE: A clinical-grade automated molecular eligibility screening and just-in-time (JIT) physician decision support solution for molecularly-selected oncology trials.** *J. Tao, M. H. Eubank, E. Pamer, N. A. Cangemi, A. E. Drilon, J. J. Harding, A. M. Schram, L. M. Smyth, K. L. Jhaveri, B. T. Li, D. Chakravarty, A. Zehir, M. F. Berger, N. Schultz, A. Pinkhasik, S. B. Thomas, P. D. Stetson, S. M. Gardos, D. M. Hyman*

5:09 PM **Abstract 6508: A cloud-based virtual tumor board to facilitate treatment recommendations for patients with advanced cancers.** *S. Madhavan, E. M. Blais, V. M. Chung, A. E. Hendifar, S. Mikhail, M. A. Lowery, D. Sohal, P. R. Pohlmann, K. N. Moore, K. He, B. J. Monk, R. L. Coleman, T. J. Herzog, E. Petricoin III, D. C. Halverson, M. J. Pishvaian*

5:21 PM **Jeremy Warner, MD, MS (Discussion of Abstract(s) 6506-6508)**
Vanderbilt University Ingram Cancer Center
Genetics and Genomics in the Clouds and on the Ground

5:33 PM *Panel Question and Answer*

2:45 PM - 5:45 PM Oral Abstract Session

Hematologic Malignancies—Plasma Cell Dyscrasia

Location: E450

Interact ID: 10844

Angela Dispenzieri, MD - Chair
Mayo Clinic

Brea Lipe, MD - Chair
University of Rochester

2:45 PM **Abstract 8000: Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study A.R.R.O.W.** *M. Mateos, P. Moreau, J. R. Berenson, K. Weisel, A. Lazzaro, K. W. Song, M. A. Dimopoulos, M. Huang, A. Zahlten-Kumeli, A. K. Stewart*

2:57 PM **Abstract 8001: Pomalidomide (POM), bortezomib, and low-dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial.** *P. G. Richardson, A. O. Rocafiguera, M. Beksac, A. Liberati, M. Galli, F. Schjesvold, J. Lindsay, K. Weisel, D. White, T. Facon, J. San-Miguel, K. Sunami, P. O’Gorman, P. Sonneveld, X. Yu, T. Doerr, A. Bensmaine, M. H. Zaki, K. C. Anderson, M. A. Dimopoulos*

3:09 PM **Abstract 8002: Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001.** *A. Chari, J. Martinez-Lopez, M. Mateos, J. Blade, S. Lonial, L. Benboubker, A. O. Rocafiguera, B. Arnulf, J. San-Miguel, L. Pineiro, A. J. Jakubowiak, C. De Boer, J. Wang, J. M. Schechter, P. Moreau*

3:21 PM **David Samuel DiCapua Siegel, MD, PhD (Discussion of Abstract(s) 8000-8002)**
Hackensack University Medical Center
Optimizing Proteasome Inhibition in Relapsed/Refractory Myeloma

3:33 PM *Panel Question and Answer*

- 3:45 PM Abstract 8003: Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in Waldenström's macroglobulinemia.** *M. A. Dimopoulos, A. Tedeschi, J. Trotman, R. Garcia-Sanz, D. MacDonald, V. Leblond, B. Mahe, C. Herbaux, C. Tam, M. Palomba, J. Matous, C. Shustik, E. Kastritis, S. P. Treon, J. Li, Z. Salman, T. Graef, C. Buske*
- 3:57 PM Abstract 8004: Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.** *L. J. Costa, E. A. Stadtmauer, G. J. Morgan, G. P. Monohan, T. Kovacsovics, N. Burwick, A. J. Jakubowiak, M. Mobasher, K. Freise, J. A. Ross, J. C. Pesko, W. Munasinghe, J. Cordero, L. Morris, P. C. Maciag, O. Bueno, S. Kumar*
- 4:09 PM Abstract 8005: A phase 1 trial of ruxolitinib, lenalidomide, and methylprednisolone for relapsed/refractory multiple myeloma patients.** *J. R. Berenson, J. To, T. M. Spektor, C. Turner, R. A. Swift, B. M. Eades, G. Schwartz, S. Eshaghian, L. Stampleman, R. A. Moss, S. Lim, R. A. Vescio*
- 4:21 PM Craig C. Hofmeister, MD, MPH (Discussion of Abstract(s) 8003-8005)**
The Ohio State University
Something Borrowed, Something New...How to Repurpose Agents for Plasma Cells Dyscrasias
- 4:33 PM Panel Question and Answer**
- 4:45 PM Abstract 8006: Phase II study of ex vivo expanded cord blood natural killer cells for multiple myeloma.** *N. Shah, R. Mehta, L. Li, J. Mccarty, I. Kaur, R. Z. Orlowski, L. Cooper, D. A. Lee, K. Cao, S. Parmar, C. Hosing, S. Ahmed, Y. Nieto, Q. Bashir, K. K. Patel, C. Bollard, M. H. Qazilbash, R. E. Champlin, K. Rezvani, E. J. Shpall*
- 4:57 PM Abstract 8007: bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study.** *N. S. Raje, J. G. Berdeja, Y. Lin, N. C. Munshi, D. S. Siegel, M. Liedtke, S. Jagannath, D. Madduri, J. Rosenblatt, M. V. Maus, A. Turka, L. P. Lam, R. A. Morgan, T. Quigley, M. Massaro, K. Hege, F. Petrocca, J. Kochenderfer*
- 5:09 PM Abstract 8008: FDA analysis of pembrolizumab trials in multiple myeloma: Immune related adverse events (irAEs) and response.** *A. C. Krauss, F. Mulkey, Y. Shen, A. Rosenberg, B. Miller, T. Carioti, K. Scott, N. Gormley, M. R. Theoret, R. Sridhara, A. T. Farrell, R. Pazdur*
- 5:21 PM Parameswaran Hari, MD (Discussion of Abstract(s) 8006-8008)**
Medical College of Wisconsin
Promises and Perils of Immunotherapy in Myeloma
- 5:33 PM Panel Question and Answer**

3:45 PM - 6:00 PM Workshop

Developing a Survivorship Clinic

Location: S405
Interact ID: 10927

Kevin C. Oeffinger, MD - Chair
Duke University
ASCO Survivorship Compendium

Tara O. Henderson, MD, MPH
University of Chicago
ASCO Survivorship Compendium

Mark Allen O'Rourke, MD
Center for Integrative Oncology and Survivorship
ASCO Survivorship Compendium

Friday, June 1, 2018

Eva Grunfeld, MD, PhD - Chair

University of Toronto
The BETTER Approach

Donna Manca, MD

University of Alberta
The BETTER Approach

Aisha Lofters, MD, PhD

University of Toronto
The BETTER Approach

4:30 PM - 5:45 PM Education Session

Emerging Therapies in Upper Gastrointestinal Malignancies

Location: Arie Crown Theater
Interact ID: 10728

Kohei Shitara, MD

National Cancer Center Hospital East
Next-Generation Sequencing and Biomarkers for Gastric Cancer: What Is the Future?

Ramon Andrade De Mello, MD, PhD, FACP - Chair

Algarve Biomedical Centre, University of Algarve
What Will We Expect From Novel Therapies for Esophageal and Gastric Malignancies?

A. Craig Lockhart, MD

University of Miami Sylvester Comprehensive Cancer Center
Current and Future Aspects of Immunotherapy for Upper Gastrointestinal Tumors

Panel Question and Answer

4:30 PM - 5:45 PM Education Session

Incorporating Genomics Into the Care of Patients With Advanced Breast Cancer

Location: S100a
Interact ID: 10770

Lajos Pusztai, MD, PhD

Yale Cancer Center
Why Do We Care About Molecular Evolution in Breast Cancer?

Mark E. Burkard, MD, PhD

University of Wisconsin Carbone Cancer Center
How Does the Practicing Oncologist Make Sense of a Genomic Report?

Philippe L. Bedard, MD, FRCPC - Chair

Princess Margaret Cancer Centre
How Do Molecular Panels Help Me Make Clinical Decisions About My Patients?

Panel Question and Answer

4:30 PM - 5:45 PM Education Session

Perspectives in Oncology Utilization Management: Using Collaboration Rather Than Confrontation

Location: S504

Interact ID: 10684

Debra A. Patt, MD, MPH, MBA - Chair

McKesson Specialty Health/US Oncology Network

Understanding Utilization Management-Policy Background: Forms of Utilization Management From a Clinician Perspective

J. Russell Hoverman, MD, PhD

Texas Oncology

Interpreting Practice Reports on Utilization and Using the Reports to Improve Practice Efficiencies

Jennifer Malin, MD, PhD, FASCO

VA Greater Los Angeles Healthcare System

Understanding Utilization Management From the Payer Perspective

Panel Question and Answer

4:30 PM - 5:45 PM Education Session

Practical Methods for Integrating Genetic Testing Into Clinical Practice for Advanced Prostate Cancer

Location: E451

Interact ID: 10727

Heather H. Cheng, MD, PhD - Chair

University of Washington

Genomics Versus Genetics and Implications for Prostate Cancer Care

A. Oliver Sartor, MD

Tulane Medical School

How I Do It: Precision Medicine for Prostate Cancer in the Real World

Jacquelyn Powers, MS, LCGC

University of Pennsylvania Perelman School of Medicine

How I Do It: Practical Guidance on Genetic Counseling Without Genetic Counselor Support

Panel Question and Answer

4:30 PM - 5:45 PM Meet the Professor Session

Everything You Wanted (and Need) to Know About TKI Discontinuation in Chronic Myeloid Leukemia - Ticketed Session

Location: E253d

Interact ID: 10765

Delphine Rea, MD, PhD

Service des Maladies du Sang, Hôpital Saint-Louis

Jorge E. Cortes, MD

The University of Texas MD Anderson Cancer Center

Friday, June 1, 2018

4:30 PM - 5:45 PM Clinical Problems in Oncology Session

Genetic Evaluation and Management in Hereditary Prostate, Renal, and Endocrine Cancers - Ticketed Session

Location: E253c

Interact ID: 10792

Veda N. Giri, MD - Chair

Sidney Kimmel Cancer Center, Thomas Jefferson University

Case-Based Highlights of Hereditary Prostate Cancer

Brian M. Shuch, MD

Yale School of Medicine

Case-Based Discussion of Hereditary Genitourinary Cancer Syndromes

Katherine Nathanson, MD

University of Pennsylvania

Case-Based Review of Hereditary Endocrine Malignancies

Panel Question and Answer

4:30 PM - 6:00 PM Clinical Science Symposium

Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer: Caution Indicated!

Location: Hall D1

Interact ID: 10825

Caroline Elizabeth McCoach, MD, PhD - Chair

University of California, San Francisco

Antoinette J. Wozniak, MD, FASCO - Chair

Barbara Ann Karmanos Cancer Institute

4:30 PM Abstract 9008: Avelumab (anti-PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101. *A. T. Shaw, S. Lee, S. S. Ramalingam, T. M. Bauer, M. J. Boyer, E. Carcereny Costa, E. Felip, J. Han, T. Hida, B. G. Hughes, S. Kim, M. Nishio, T. Seto, P. Ezech, D. Chakrabarti, J. Wang, A. Chang, L. Fumagalli, B. J. Solomon*

4:42 PM Abstract 9009: Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNNSCLC). *D. Kim, S. M. Gadgeel, S. N. Gettinger, G. J. Riely, G. R. Oxnard, T. Mekhail, P. Schmid, A. Dowlati, R. S. Heist, A. J. Wozniak, G. Hernandez, I. Sarkar, E. Mitry, P. Foster, C. O'Hear, J. Spahn, S. I. Ou*

4:54 PM Leora Horn, MD (Discussion of Abstract(s) 9008-9009)

Vanderbilt University Medical Center

ALK Inhibitors and Immunotherapy: Path Forward?

5:06 PM Abstract 9010: Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget). *J. Mazieres, A. E. Drilon, L. Mhanna, J. Milia, A. Lusque, A. B. Cortot, L. Mezquita, A. Thai, S. Couraud, R. Veillon, C. Mascaux, R. Schouten, J. W. Neal, T. L. Ng, M. Frueh, N. Peled, V. Gounant, S. Papat, V. W. Zhu, O. Gautschi*

5:18 PM Abstract 9011: Response and durability of anti-PD-(L)1 therapy in never- or light-smokers with non-small cell lung cancer (NSCLC) and high PD-L1 expression. *J. F. Gainor, H. Rizvi, E. Jimenez Aguilar, M. Moordian, C. A. Lydon, D. Anderson, M. Tenet, J. L. Sauter, M. Mino-Kenudson, A. T. Shaw, M. M. Awad, M. D. Hellmann*

- 5:30 PM Benjamin Philip Levy, MD (Discussion of Abstract(s) 9010-9011)**
Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive
Cancer Center, Sibley Memorial Hospital
Immunotherapy in the Real World of Drivers
- 5:42 PM Panel Question and Answer**

4:30 PM - 6:00 PM Clinical Science Symposium

Integrating Immunotherapy Into Standard of Care for Head and Neck Cancer

Location: S100bc

Interact ID: 10742

Renata Ferrarotto, MD - Chair

The University of Texas MD Anderson Cancer Center

Thomas James Galloway, MD - Chair

Fox Chase Cancer Center

- 4:30 PM Abstract 6009: A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC).** *S. M. McBride, E. J. Sherman, C. Tsai, S. S. Baxi, J. Aghalar, J. Eng, W. I. Zhi, D. C. McFarland, L. S. Michel, D. Spielsinger, Z. Zhang, J. Flynn, L. Dunn, A. L. Ho, N. Riaz, D. G. Pfister, N. Y. Lee*
- 4:42 PM Marka R. Crittenden, MD, PhD (Discussion of Abstract(s) 6009)**
Earle A. Chiles Research Institute, Providence Cancer Center
Stepping Away From the "Ab-scopal": An Evaluation in Head and Neck Cancer
- 4:54 PM Abstract 6010: Safety evaluation of nivolumab (Nivo) concomitant with cetuximab-radiotherapy for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG 3504.**
R. L. Ferris, M. L. Gillison, J. Harris, A. D. Colevas, L. K. Mell, C. Kong, R. Jordan, K. Moore, M. T. Truong, C. Kirsch, D. A. Clump, J. Ohr, K. He, D. Blakaj, J. F. Deeken, M. Machtay, W. J. Curran Jr., Q. Le
- 5:06 PM Renata Ferrarotto, MD (Discussion of Abstract(s) 6010)**
The University of Texas MD Anderson Cancer Center
Immuno-radiotherapy: A New Approach?
- 5:18 PM Abstract 6011: Neoadjuvant anti-OX40 (MEDI6469) prior to surgery in head and neck squamous cell carcinoma.** *R. B. Bell, R. Duhon, R. S. Leidner, B. D. Curti, C. Ballesteros-Merino, B. Piening, B. Bernard, J. Pucilowska, C. B. Bifulco, B. A. Fox, T. Duhon, W. L. Redmond, Y. Koguchi, A. Cheng, A. A. Patel, G. Morris, R. Tamakawa, M. W. Schuster, W. J. Urba, A. D. Weinberg*
- 5:30 PM Panel Question and Answer**
- 5:48 PM John (Drew) A. Ridge, MD, PhD, FACS (Discussion of Abstract(s) 6011)**
Fox Chase Cancer Center
Beyond PD-1

Notes

Notes

Notes

Notes

Notes

8:00 AM - 8:45 AM Education Session

How to Navigate the Annual Meeting (Fellows and Junior Faculty Only)

Location: S501

Don S. Dizon, MD, FACP, FASCO

Lifespan Cancer Center

Technology Tools and Resources to Help You Navigate the Meeting

Travis John Osterman, DO, MS

Vanderbilt University School of Medicine

Optimizing Your Annual Meeting Experience As a Trainee

8:00 AM - 9:15 AM Education Session

Acute Myeloid Leukemia: The Good, the Bad, and the Ugly

Location: E451

Interact ID: 10795

Nicolas Boissel, MD, PhD

Hôpital Saint-Louis

The Good: Core-Binding Factor Acute Myeloid Leukemia—All Are Cured?

Jeffrey E. Lancet, MD

H. Lee Moffitt Cancer Center & Research Institute

The Bad: Secondary Leukemias—How Bad Are They?

John Sutton Welch, MD, PhD - Chair

Washington University

The Ugly: p53-Mutated Acute Myeloid Leukemia—Can It Be Solved?

Panel Question and Answer

8:00 AM - 9:15 AM Education Session

Bones in Myeloma: Imaging and Therapy

Location: E450

Interact ID: 10755

Elena Zamagni, MD, PhD

Bologna University School of Medicine

Is Skeletal Survey Dead in Myeloma? What Imaging to Use and When?

Ravi Vij, MD - Chair

Washington University School of Medicine in St. Louis

Practical Use of Imaging From MGUS to Myeloma

G. David Roodman, MD, PhD

Indiana University

Optimal Use of Bisphosphonates and Other Agents in Bone Disease in Multiple Myeloma

Panel Question and Answer

Saturday, June 2, 2018

8:00 AM - 9:15 AM Education Session

Germline Mutations: How to Recognize Variants and What to Do About Them

Location: S404

Interact ID: 10719

Bryan P. Schneider, MD - Chair

Indiana University School of Medicine

How to Recognize Germline Mutations Found During Somatic Tumor Testing

Charite Ricker, MS, CGC

University of Southern California Keck School of Medicine

Somatic Tumor Testing: Obtaining Consent With Germline Variants in Mind

Jeffrey N. Weitzel, MD

City of Hope

Finding a Germline Mutation During Tumor Testing: Implications for the Patient and the Family

Panel Question and Answer

8:00 AM - 9:15 AM Education Session

International Perspectives on Breast Cancer

Location: S100a

Interact ID: 10800

Gabriel N. Hortobagyi, MD, FACP, FASCO

The University of Texas MD Anderson Cancer Center

New and Important Changes in the TNM System

Eduardo L. Cazap, MD, PhD, FASCO

SLACOM

Breast Cancer in Latin America: A Map of the Disease in the Region With a Focus on Precision Medicine

Fatima Cardoso, MD - Chair

Champalimaud Clinical Centre, Champalimaud Foundation

Access to Targeted Agents

Carlos H. Barrios, MD

Latin American Cooperative Oncology Group

How to Improve Global Breast Cancer Research

Panel Question and Answer

8:00 AM - 9:15 AM Education Session

Liquid Biopsies: Current Uses and Future Directions

Location: S406

Interact ID: 10917

Maximilian Diehn, MD, PhD

Stanford Cancer Institute

Methods and Applications of cfDNA Analysis

Carlos Caldas, MD, FRCP, FRCPath, FMedSci
University of Cambridge
ctDNA for Monitoring and Managing Breast Cancer

David B. Solit, MD - Chair
Memorial Sloan Kettering Cancer Center
Role of ctDNA in the Treatment of Patients With Advanced Cancer

Panel Question and Answer

8:00 AM - 9:15 AM Education Session

Precision Medicine for Primary Central Nervous System Tumors: Are We There Yet?

Location: S100bc
Interact ID: 10740

Priscilla Kaliopi Brastianos, MD - Chair
Massachusetts General Hospital
How Can We Apply Precision Medicine to Craniopharyngioma and Meningioma?

Howard Colman, MD, PhD
Huntsman Cancer Institute
Opportunities for Investigating Novel Molecular Targets Including PARP/IDH/Fusions in Glioblastoma

Martin J. Van Den Bent, MD, PhD
Erasmus MC Cancer Centre
Individualized Treatments for Low-Grade Gliomas

Panel Question and Answer

8:00 AM - 9:15 AM Education Session

Progress Through Collaboration: ASCO and FDA's Efforts to Improve the Evidence Base for Treating Older Adults With Cancer

Location: S102
Interact ID: 10697

Arti Hurria, MD, FASCO
City of Hope National Medical Center
Addressing the Evidence Gap for Older Adults With Cancer: Progress and Challenges

Heidi D. Klepin, MD, MS
Comprehensive Cancer Center of Wake Forest Baptist Health
Strategies to Improve the Evidence Base: A Call to Action

Harpreet Singh, MD - Chair
U.S. Food and Drug Administration
Use of Real-World Evidence and Patient-Reported Outcomes in Regulatory Decision-Making: FDA Perspective

Panel Question and Answer

Saturday, June 2, 2018

8:00 AM - 9:15 AM Education Session

Tweets, Posts, and Snaps: Starting Down the Social Media Pathway

Location: S504

Interact ID: 10692

Matthew S. Katz, MD

Radiation Oncology Associates, PA

Risks Versus Benefits: Using Social Media Safely

Deanna J. Attai, MD

David Geffen School of Medicine at UCLA

Striking the Right Tone: Optimizing the Use of Social Media During Conferences

Merry Jennifer Markham, MD, FACP

University of Florida

When Your Patient 'Friends' You: Appropriate Communication With Patients and Families Online

Mina S. Sedrak, MD, MS - Chair

City of Hope

Leveraging Social Media to Advance Cancer Research: Challenges and Opportunities

Panel Question and Answer

8:00 AM - 9:15 AM Education Session

When You Hear Hoof Beats, Think of a Herd of Zebras! Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer

Location: Arie Crown Theater

Interact ID: 10784

Helena Alexandra Yu, MD

Memorial Sloan Kettering Cancer Center

Sequencing Agents in the Management of EGFR-Mutation-Positive Non-Small Cell Lung Cancer

Christine Marie Lovly, MD, PhD - Chair

Vanderbilt University Ingram Cancer Center

Management of ALK Non-Small Cell Lung Cancer Through First and Subsequent Lines of Therapy

David Planchard, MD, PhD

Gustave Roussy

Therapeutic Options for Patients With Other Genetically Defined Subgroups of Non-Small Cell Lung Cancer

Panel Question and Answer

8:00 AM - 9:15 AM Education Session

Where We Stand With Immunotherapy in Colorectal Cancer

Location: Hall D2

Interact ID: 10799

Michael J. Overman, MD - Chair

The University of Texas MD Anderson Cancer Center

Optimal Approach to Colorectal Cancer With Deficient Mismatch Repair (dMMR)

Michael Morse, MD

Duke University Medical Center

Challenges With Colorectal Cancer With Proficient Mismatch Repair (pMMR)

Marc S. Ernstoff, MD

Cleveland Clinic

Management of Immune-Checkpoint Toxicity

Panel Question and Answer

8:00 AM - 9:15 AM Clinical Problems in Oncology Session

Success Stories of Precision Medicine in Uncommon Head and Neck Tumors - Ticketed Session

Location: E253c

Interact ID: 10711

Manisha H. Shah, MD - Chair

The Ohio State University Comprehensive Cancer Center

Medullary Thyroid Cancer: Advances From Precision Medicine

Maria E. Cabanillas, MD

The University of Texas MD Anderson Cancer Center

Anaplastic Thyroid Cancer: Advances From Precision Medicine

Scott Andrew Laurie, MD

Ottawa Hospital Cancer Centre, University of Ottawa

Salivary Gland Cancers: Advances From Precision Medicine

Panel Question and Answer

8:00 AM - 9:30 AM Clinical Science Symposium

Tumor Genomics: Finding the Target, Hitting the Target

Location: Hall D1

Interact ID: 10827

Suzanne George, MD - Chair

Dana-Farber Cancer Institute/Harvard Medical School

- 8:00 AM Abstract 100: Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial.** *K. L. Jhaveri, V. Makker, X. V. Wang, A. P. Chen, K. Flaherty, B. A. Conley, P. J. O'Dwyer, P. M. Williams, S. R. Hamilton, L. Harris, L. McShane, L. Rubinstein, R. J. Gray, S. Li, E. P. Mitchell, D. Patton, J. Moscow, J. A. Zwiebel, C. L. Arteaga, S. Luoh*
- 8:12 AM Abstract 101: Results from molecular analysis for therapy choice (MATCH) arm 1: Taselisib for PIK3CA-mutated tumors.** *I. E. Krop, O. Jegede, J. E. Grilley-Olson, J. D. Lauring, S. R. Hamilton, J. A. Zwiebel, S. Li, L. Rubinstein, A. Doyle, D. R. Patton, E. P. Mitchell, C. L. Arteaga, B. A. Conley, D. Sims, L. Harris, A. P. Chen, K. Flaherty*
- 8:24 AM Fabrice Andre, MD, PhD (Discussion of Abstract(s) 100-101)**
Institut Gustave-Roussy, Université Paris Sud
MATCH and Mismatch

Saturday, June 2, 2018

- 8:36 AM Abstract 102: A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with *RET*-altered cancers.** *A. E. Drilon, V. Subbiah, G. R. Oxnard, T. M. Bauer, V. Velcheti, N. J. Lakhani, B. Besse, K. Park, J. D. Patel, M. E. Cabanillas, M. L. Johnson, K. L. Reckamp, V. Boni, H. H. Loong, M. Schlumberger, B. Solomon, S. Cruickshank, S. M. Rothenberg, M. H. Shah, L. J. Wirth*
- 8:48 AM Abstract 103: Impact of next-generation sequencing (NGS) on treatment selection in acute myeloid leukemia (AML).** *R. E. Assi, A. Alfonso Pierola, D. KC, Y. M. Abaza, A. Abou Zahr, K. Chamoun, G. Montalban-Bravo, K. Takahashi, E. Jabbour, T. M. Kadia, F. Ravandi, J. E. Cortes, C. D. Dinardo, N. G. Daver, G. Borthakur, N. Pemmaraju, M. Konopleva, A. Futreal, H. M. Kantarjian, G. Garcia-Manero*
- 9:00 AM Christine Marie Lovly, MD, PhD (Discussion of Abstract(s) 102-103)**
Vanderbilt University Ingram Cancer Center
Bullseye! Hitting the Target
- 9:12 AM Panel Question and Answer**

8:00 AM - 11:30 AM Poster Session

Breast Cancer—Local/Regional/Adjuvant

Location: Hall A

Abstracts on Boards 1-12 will be discussed during the Breast Cancer—Local/Regional/Adjuvant Poster Discussion Session.

Posters by Topic

Adjuvant Therapy: Boards 2, 5-9, 13-48

Local-Regional Therapy: Boards 4, 49-59

Neoadjuvant Therapy: Boards 1, 3, 10-12, 60-87

Trials in Progress: Boards 88a-92b

- Board 1 Abstract 509: HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.** *A. Prat, C. De Angelis, T. Pascual, C. Gutierrez, A. Lombart-Cussac, T. Wang, J. Cortes, B. N. Rexer, J. Veeraraghavan, A. Forero-Torres, A. C. Wolff, S. Morales, I. E. Krop, A. C. Pavlick, B. Bermejo, S. G. Hilsenbeck, M. Oliveira, R. Schiff, C. K. Osborne, M. F. Rimawi*
- Board 2 Abstract 510: Evaluation of trastuzumab without chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients: Randomized controlled trial (RESPECT).** *M. Sawaki, T. Saito, S. Baba, K. Kobayashi, H. Kawashima, M. Tsuneizumi, N. Sagawa, H. Bando, M. Takahashi, M. Yamaguchi, T. Takashima, T. Nakayama, M. Kashiwaba, T. Mizuno, Y. Yamamoto, N. Taira, H. Iwata, Y. Uemura, Y. Ohashi, H. Mukai*
- Board 3 Abstract 511: TBCRC026: Phase II clinical trial assessing the correlation of standardized uptake value (SUV) on positron emission tomography (PET) with pathological complete response (pCR) to pertuzumab and trastuzumab in patients with primary operable HER2-positive breast cancer.** *R. M. Connolly, J. P. Leal, L. Solnes, C. Huang, A. Carpenter, K. Gaffney, V. G. Abramson, L. A. Carey, M. C. Liu, M. F. Rimawi, J. M. Specht, A. M. Storniolo, V. Valero, C. Vaklavas, M. Camp, R. S. Miller, A. C. Wolff, A. Cimino-Mathews, R. L. Wahl, V. Stearns*
- Board 5 Abstract 513: Factors associated with lymphedema in patients/women with node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection on a prospective clinical trial.** *J. C. Boughey, K. V. Ballman, L. M. McCall, H. M. Kuerer, K. Hunt, J. M. Armer*

- Board 6** **Abstract 514: Phase II national clinical trial of prophylactic irradiation to the contralateral breast for BRCA mutation carriers treated for early breast cancer (EBC).** *E. Evron, M. A. Ben David, H. Goldberg, G. Fried, B. Kaufman, R. Catane, R. Pfeffer, D. Geffen, T. Karni, R. Abdah-Bortnyak, O. Rosengarten, D. Matceyevsky, M. J. Inbar, A. Kuten, B. W. Corn*
- Board 7** **Abstract 515: Persistence of circulating tumor cells in high risk early breast cancer patients five years after adjuvant chemotherapy and late recurrence: Results from the adjuvant SUCCESS A trial.** *W. Janni, B. K. Rack, P. A. Fasching, L. Haeberle, H. Tesch, R. Lorenz, F. Schochter, M. Tzschaschel, A. De Gregorio, T. N. Fehm, V. Müller, A. Schneeweiss, W. Lichtenegger, M. W. Beckmann, C. Scholz, K. Pantel, T. W. Friedl*
- Board 8** **Abstract 516: Genomic stratification with BCI of ER+ early breast cancer patients with limited long-term risk of breast cancer death.** *V. G. Kaklamani, G. M. Poage, T. Fornander, B. Nordenskjold, O. Stål, Y. Zhang, C. A. Schnabel*
- Board 9** **Abstract 517: Molecular alterations and late recurrence in postmenopausal women with hormone receptor-positive node-positive breast cancer (BC): Results from the "SOLE" trial.** *E. Guerini Rocco, K. P. Gray, E. Munzone, C. Fumagalli, M. Reforgiato, I. Leone, R. Kammler, G. Viale, P. Neven, E. Hitre, G. H. Jerusalem, E. Simoncini, A. Gombos, I. Deleu, A. Di Leo, A. Goldhirsch, M. Barberis, M. M. Regan, M. Colleoni*
- Board 10** **Abstract 518: Precision neoadjuvant therapy (P-NAT): A planned interim analysis of a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS).** *S. L. Moulder, K. R. Hess, R. P. Candelaria, G. M. Rauch, L. Santiago, B. Adrada, W. T. Yang, M. Z. Gilcrease, L. Huo, M. C. Stauder, B. Arun, R. M. Layman, R. K. Murthy, S. Damodaran, N. T. Ueno, A. M. Thompson, B. Lim, E. A. Mittendorf, J. K. Litton, W. F. Symmans*
- Board 11** **Abstract 519: Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrightNess, a randomized phase 3 study in early stage TNBC.** *M. L. Telli, O. Metzger, K. Timms, B. Evans, D. Vogel, H. Wei, J. T. Jones, R. J. Wenstrup, M. D. McKee, D. M. Sullivan, M. Fallstrom, D. Maag, P. J. Ansell, J. Sohn, S. Chen, N. Martinez, C. E. Geyer Jr., S. Loibl, M. Golshan*
- Board 12** **Abstract 520: Residual cancer burden (RCB) as prognostic in the I-SPY 2 TRIAL.** *W. F. Symmans, C. Yau, Y. Chen, B. Datnow, S. Wei, M. D. Feldman, J. Ritter, X. Duan, B. Chen, R. Tickman, H. Sattar, A. M. Magliocco, B. Kallakury, M. Troxell, S. Asare, M. C. Liu, A. DeMichele, D. Yee, D. A. Berry, L. Esserman*
- Board 13** **Abstract 521: Patient (pt)-reported function and symptoms in APHINITY: A randomized comparison of chemotherapy (C) + trastuzumab (H) + placebo (Pla) versus C + H + pertuzumab (P) as adjuvant therapy in pts with HER2-positive early breast cancer (EBC).** *J. Baselga, J. A. Petersen, E. Clark, C. Barton, E. Restuccia, M. J. Procter, A. Sonnenblick, D. Fumagalli, D. Parlier, A. Arahmani, G. Viale, L. L. Reaby, E. Frank, R. D. Gelber, M. J. Piccart-Gebhart, J. Bines, G. v. Minckwitz, S. M. Gasper*
- Board 14** **Abstract 522: Pooled analysis of two randomized phase III trials (PlanB/ SuccessC) comparing six cycles of docetaxel and cyclophosphamide to sequential anthracycline taxane chemotherapy in patients with intermediate and high risk HER2-negative early breast cancer (n=5,923).** *W. Janni, U. Nitz, B. K. Rack, O. Gluz, A. Schneeweiss, R. E. Kates, T. N. Fehm, H. H. Kreipe, S. Kummel, R. Wuerstein, A. D. Hartkopf, M. Clemens, T. Reimer, T. W. Friedl, L. Haeberle, P. A. Fasching, N. Harbeck*
- Board 15** **Abstract 523: A prospective study on the effect of endoxifen concentration and CYP2D6 phenotypes on clinical outcome in early stage breast cancer patients receiving adjuvant tamoxifen.** *A. B. Sanchez-Spitman, V. O. Dezentjé, J. J. Swen, D. Moes, E. Batman, C. H. Smorenburg, L. Jongen, M. Los, P. Neven, H. Gelderblom, H. Guchelaar*

Saturday, June 2, 2018

- Board 16 Abstract 524: Duration of extended adjuvant therapy with neratinib in early-stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial.** *M. Gnant, H. Iwata, A. E. Bashford, R. Separovic, A. Murias, E. Vicente, J. A. Means-Powell, I. A. Mayer, F. M. Senecal, R. Hui, R. H. De Boer, J. Chiu, A. Armstrong, A. Ruiz, R. Bryce, Y. Ye, A. Chan*
- Board 17 Abstract 525: Predicting expected absolute chemotherapy treatment benefit in women with early-stage breast cancer using a 12-gene expression assay.** *W. J. Gradishar, M. E. Robson, D. D. Flake II, L. S. Schwartzberg, P. Sharma, H. H. Soliman, A. M. Magliocco, K. Brown, S. Wehnelt, A. Gutin, R. Kronenwett, J. M. Lancaster*
- Board 19 Abstract 527: Tumor infiltrating lymphocytes to predict DFS from intense dose-dense (idd) EPC regimen: Results from the German Adjuvant Intergroup Node-positive study (GAIN-1).** *A. Noske, K. Weber, V. Moebus, S. Schmatloch, W. Weichert, C. Kohne, C. Solbach, B. Ingold Heppner, K. Steiger, V. Mueller, P. A. Fasching, T. Karn, M. van Mackelenbergh, F. Marne, W. D. Schmitt, C. Schem, E. Stickeler, C. Denkert, S. Loibl*
- Board 21 Abstract 529: Residual risk assessment with the Breast Cancer Index (BCI) for prediction of late distant recurrence (DR) in patients from the TransATAC study.** *J. Sestak, Y. Zhang, D. Sgroi, C. A. Schnabel, J. M. Cuzick, M. Dowsett*
- Board 22 Abstract 530: Overall survival in female Medicare beneficiaries with early stage breast cancer receiving bisphosphonates or denosumab.** *R. A. Herrera Pena, X. Lei, M. Chavez-MacGregor, H. Zhao, S. H. Giordano, M. E. Suarez-Almazor*
- Board 23 Abstract 531: Safety and tolerability of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer.** *T. Lyons, A. Gucaip, A. Arumov, S. Patil, M. Edelweiss, M. Gorsky, T. A. Troso-Sandoval, J. Bromberg, R. A. Sanford, N. M. Iyengar, S. Modi, R. Gupta, T. A. Traina*
- Board 24 Abstract 532: Adherence to hormonal therapy among commercially insured breast cancer patients.** *H. Zhao, X. Lei, M. Chavez-MacGregor, W. He, J. Niu, S. H. Giordano*
- Board 25 Abstract 533: Selection for Oncotype Dx testing among young women with early-stage ER+/HER2- breast cancer.** *P. D. Poorvu, S. I. Gelber, S. M. Rosenberg, K. J. Ruddy, R. Tamimi, J. M. Peppercorn, L. Schapira, V. F. Borges, S. E. Come, L. C. Collins, E. Warner, A. H. Partridge*
- Board 26 Abstract 534: Assessment and management of bone health in women treated with adjuvant anastrozole in the DATA study.** *I. Van Hellemond, C. H. Smorenburg, P. Peer, A. Swinkels, C. M. Seynaeve, M. Van Der Sangen, J. R. Kroep, H. de Graaf, A. H. Honkoop, F. Erdkamp, F. van den Berkmortel, M. De Boer, W. de Roos, S. C. Linn, A. Imholz, V. C. Tjan-Heijnen*
- Board 27 Abstract 535: Comprehensive transcriptomic profiling to identify breast cancer patients that may be spared adjuvant systemic therapy.** *M. Sjoström, S. L. Chang, N. Fishbane, E. Davicioni, L. Hartman, E. Holmberg, F. Y. Feng, C. W. Speers, L. J. Pierce, P. Malmström, M. Fernö, P. Karlsson*
- Board 28 Abstract 536: Breast cancer cell-free DNA (cfDNA) profiles reflect underlying tumor biology: The Circulating Cell-Free Genome Atlas (CCGA) study.** *M. C. Liu, T. Maddala, A. Aravanis, E. Hubbell, J. F. Beausang, D. Filippova, S. Gross, A. Jamshidi, K. Kurtzman, L. Shen, A. Valouev, O. Venn, N. Zhang, D. A. Smith, F. Couch, C. Curtis, R. T. Williams, E. A. Klein, A. Hartman, J. Baselga*
- Board 30 Abstract 538: Dose tailoring of breast cancer adjuvant chemotherapy aiming at avoiding both over and undertreatment: Results from the prospective PANTHER study.** *A. Matikas, T. Foukakis, V. Moebus, R. Greil, N. Bengtsson, G. G. Steger, M. Untch, H. Johansson, M. Hellstrom, P. Malmström, M. Gnant, S. Loibl, J. C. Bergh*

- Board 31 **Abstract 539: In silico evaluation of the 12-gene molecular score (EndoPredict) and the recurrence score (Oncotype DX) as predictors of response to neo-adjuvant chemotherapy in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer.** *H. H. Soliman, M. E. Robson, S. Wagner, D. D. Flake II, L. S. Schwartzberg, P. Sharma, A. M. Magliocco, R. Kronenwett, J. M. Lancaster, J. S. Lanchbury, A. Gutin, W. J. Gradishar*
- Board 32 **Abstract 540: Image-based risk score to predict recurrence of ER+ breast cancer in ECOG-ACRIN Cancer Research Group E2197.** *N. Verma, D. Harding, A. Mohammadi, L. J. Goldstein, H. L. Gilmore, M. D. Feldman, J. Tomaszewski, A. Basavanahally, M. Lloyd, P. Fu, S. Ganesan, N. E. Davidson, A. Madabhushi, J. Monaco*
- Board 33 **Abstract 541: Long-term benefit from tamoxifen therapy for patients with Luminal A and Luminal B breast cancer: Retrospective analysis of the STO-3 trial.** *L. Lindstrom, N. Yu, A. Iftimi, C. Yau, L. van 't Veer, B. Nordenskjöld, C. Benz, T. Fornander, O. Stål, K. Czene, L. Esserman*
- Board 34 **Abstract 542: Next-generation targeted sequencing (NGTS) investigating CDK4 as a prognostic driver in pure invasive lobular breast carcinoma (ILC): Preliminary results in early-stage patients (pts) stratified according to a validated clinico-pathological model.** *L. Carbognin, M. Simbolo, C. Vicentini, I. Sperduti, A. Calì, F. Schettini, M. Dieci, G. Griguolo, S. Pilotto, R. Nortilli, G. Pollini, G. Arpino, V. Guarneri, S. De Placido, P. Conte, E. Manfrin, M. Brunelli, A. Scarpa, G. Tortora, E. Bria*
- Board 35 **Abstract 543: Association of a low-expression SLC01B1 polymorphism with estrogen concentrations before and during aromatase inhibitor treatment for breast cancer.** *J. M. Dempsey, K. M. Kidwell, C. L. Gersch, Z. Desta, A. M. Storniolo, V. Stearns, T. C. Skaar, D. F. Hayes, N. L. Henry, J. M. Rae, D. L. Hertz*
- Board 36 **Abstract 544: Patient(Pt)-reported toxicities by chemotherapy regimen for early breast cancer (BC) (LCCC1334/1440).** *K. A. Nyrop, A. M. Deal, S. S. Shachar, E. M. Basch, B. B. Reeve, J. T. Lee, S. Choi, W. A. Wood, C. K. Anders, L. A. Carey, E. C. Dees, T. A. Jolly, K. E. Reeder-Hayes, G. G. Kimmick, M. S. Karuturi, R. E. Reinbolt, J. C. Specia, H. B. Muss*
- Board 37 **Abstract 545: Impact of high deductible insurance on out-of-pocket cost burden in breast cancer.** *C. Lu, F. Zhang, A. K. Wagner, L. Nekhlyudov, C. Earle, M. Callahan, R. LeCates, X. Xu, J. Wallace, S. Soumerai, D. Ross-Degnan, J. F. Wharam*
- Board 38 **Abstract 546: Patient(Pt)-reported toxicities during breast cancer (BC) chemotherapy (CRx): Associations with pre-treatment (Tx) measures of quality of life (QOL) and Tx discontinuation.** *K. A. Nyrop, A. M. Deal, S. S. Shachar, E. M. Basch, B. B. Reeve, J. T. Lee, S. Choi, W. A. Wood, C. K. Anders, L. A. Carey, E. C. Dees, T. A. Jolly, K. E. Reeder-Hayes, G. G. Kimmick, M. S. Karuturi, R. E. Reinbolt, J. C. Specia, H. B. Muss*
- Board 39 **Abstract 547: Treatment and outcomes in older women with DCIS: SEER-Medicare 2007-2013.** *M. C. Schroeder, C. Huang, K. M. Winkfield, A. Chiba, L. R. McNally, A. Thomas*
- Board 40 **Abstract 548: Urgent hypertension as a biomarker for bevacizumab in the curative setting.** *N. Kassem, F. Shen, G. Jiang, L. Gardner, S. Philips, A. M. O'Neill, K. D. Miller, T. Suter, D. A. Cameron, G. W. Sledge Jr., B. P. Schneider*
- Board 41 **Abstract 549: Timing of initiation of neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ hormone receptor (HR)-negative breast cancer: Exploratory analyses from the phase III ExteNET trial.** *B. Ejlersten, C. H. Barrios, E. Gokmen, N. Robert, N. Martinez, J. S. Link, S. Morales, M. Ruiz Borrego, M. Bhandari, Y. Rai, A. Luczak, T. Fujita, A. Wong, B. Yao, M. Martin*
- Board 42 **Abstract 550: Adjuvant tamoxifen adherence in men with early stage breast cancer.** *O. Oke, J. Niu, M. Chavez-MacGregor, H. Zhao, S. H. Giordano*
- Board 43 **Abstract 551: Predicting Oncotype DX scores using clinicopathologic features: A report from the National Cancer Database.** *C. Pesce, K. Kuchta, B. Erdogan, C. Wang, K. Yao, M. El-Tamer*

Saturday, June 2, 2018

- Board 44 Abstract 552: Estimation of historical control rate for a single arm de-escalation study: Application to the POSITIVE trial.** *Z. Sun, O. Pagani, A. H. Partridge, H. A. Azim Jr., F. Peccatori, M. Ruggeri, M. Colleoni, R. D. Gelber, M. M. Regan*
- Board 45 Abstract 553: Evaluation of the OncoMasTR prognostic signature in postmenopausal women with primary ER-positive breast cancer.** *I. Sestak, R. Buus, J. M. Cuzick, S. Barron, T. Loughman, B. Fender, C. Lopez Ruiz, P. Dynoodt, C. Wang, D. O'Leary, W. M. Gallagher, M. Dowsett*
- Board 46 Abstract 554: Balancing the risks versus benefits of trastuzumab: A call to action for oncologists, cardiologists, and cardio-oncologists.** *M. K. Rushton, I. Lima, C. Johnson, M. Tuna, S. Hawken, S. F. Dent*
- Board 47 Abstract 555: Comparison of outcomes for AJCC 8th Anatomic and Prognostic staging in contemporary triple negative breast cancer (TNBC) multisite registry.** *R. H. Shah, Y. Y. Wang, K. Finke, R. Yoder, A. O'Dea, L. E. Nye, S. Madhusudhana, M. S. Hoffmann, M. Elia, G. J. Crane, J. R. Klemp, Q. J. Khan, B. F. Kimler, P. Sharma*
- Board 48 Abstract 556: Role of cardiac reserve as a tool to unmask cardiotoxicity following anthracycline therapy and whether exercise training can attenuate cardiotoxicity.** *S. Fraser, E. Howden, S. Foulkes, A. Bigaran, K. Janssens, R. Beaudry, S. Selig, M. J. Haykowsky, Y. C. Antill, S. Loi, A. LaGerche*
- Board 49 Abstract 557: CA15-3/MUC1 in CCTG MA-32 (NCT01101438): A phase III RCT of the effect of metformin vs. placebo on invasive disease free and overall survival in early stage breast cancer (BC).** *R. J. Dowling, W. R. Parulekar, K. A. Gelmon, L. E. Shepherd, S. Virk, M. Ennis, F. Mao, J. A. Ligibel, D. L. Hershman, P. Rastogi, I. A. Mayer, T. J. Hobday, J. Lemieux, A. M. Thompson, M. Rabaglio-Poretti, T. J. Whelan, V. Stambolic, B. E. Chen, P. J. Goodwin*
- Board 51 Abstract 559: Association of clinical/pathological parameters with axillary involvement in early breast cancer in patients with limited sentinel node involvement (< 3 LK) after neoadjuvant chemotherapy (NACT).** *H. Kolberg, C. Liedtke, I. Bauerfeind, T. N. Fehm, B. Fleige, M. Hauschild, G. Helms, A. Lebeau, S. Schmatloch, P. Schrenk, L. Schwentner, A. Staebler, G. Von Minckwitz, S. Loibl, M. Untch, T. Kühn*
- Board 52 Abstract 560: Hypofractionated whole breast IMRT and brachytherapy boost after conservative surgery for breast cancer: Early results of a prospective non-randomised trial.** *I. Guix, I. Garcia, D. Alcaraz, S. Rubio Diez, A. Abad Esteve, J. Del Campo, J. Antoni, S. Gorostidi, M. Prats, L. Quinzanos, T. Guix, J. Tello, B. Guix*
- Board 53 Abstract 561: Results from a pilot of an innovative 4R Cancer Care Delivery Model in early breast cancer: Impact on timing and sequencing of guideline recommended care.** *C. B. Weldon, J. R. Trosman, C. B. Perez, S. Kulkarni, S. A. Khan, N. Hansen, V. Nelson, J. Stein, M. A. Simon, C. Spagnoli, J. Tepper, K. Pearson, W. J. Gradishar*
- Board 54 Abstract 562: Prospective phase II multicenter trial of ablation after breast lumpectomy added to treat (ABLATE) breast cancer without radiation.** *V. S. Klimberg, K. Gallagher, S. M. Feldman, J. Y. Lee, D. A. Ochoa, J. M. Mammen, R. S. Henry-Tillman, T. Frazier, M. McGinness, J. Barone, R. M. Barone, S. Korourian*
- Board 55 Abstract 563: At surgery for a core needle biopsy diagnosis of ductal carcinoma in situ with microinvasion: Is sentinel lymph node biopsy required?** *M. R. Flanagan, M. Stempel, E. Brogi, M. Morrow, H. S. Cody III*
- Board 57 Abstract 565: Comparison of breast conservative therapy to mastectomy in male breast cancer: A NCDB analysis.** *S. Bateni, A. J. Davidson, M. Arora, R. J. Bold, R. J. Canter, C. A. Sauder*
- Board 58 Abstract 566: Prediction of pathologic complete response by image-guided biopsy before surgery in breast cancer with complete clinical response to neoadjuvant chemotherapy: A prospective feasibility trial.** *H. Lee, S. Kim, K. Kim, J. Park, Y. Ju, E. Lee, H. Shin, H. Moon, D. Noh, I. Park, N. Cho, W. Han*

- Board 59 Abstract 567: Post neoadjuvant chemotherapy vacuum assisted biopsy in breast cancer: Can it determine pathologic complete response before surgery?** *M. Tasoulis, N. Roche, J. E. Rusby, R. Pope, S. Allen, K. Downey, A. Nerurkar, P. Osin, R. Wilson, F. MacNeill*
- Board 60 Abstract 568: Neo-/adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results on pathological complete response (pCR) for patients treated within the neoadjuvant setting.** *V. Moebus, S. Noeding, E. Ladda, P. Klare, M. Schmidt, A. Schneeweiss, W. Janni, F. Marmé, T. Reimer, S. Schmatloch, E. Stickeler, M. Untch, B. V. Sinn, V. Müller, P. A. Fasching, G. Von Minckwitz, J. Furlanetto, N. Burchardi, S. Loibl*
- Board 61 Abstract 569: Investigating denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-paclitaxel schedules: 2x2 factorial design (GeparX)—An iterim safety analysis.** *S. Kummel, P. Wimberger, G. Von Minckwitz, V. Nekljudova, C. Denkert, M. Just, C. Hanusch, O. J. Stoetzer, J. B. Huober, M. Hofmann, C. Jackisch, J. U. Blohmer, V. Vladimirova, A. Schneeweiss, M. Untch, S. Loibl*
- Board 62 Abstract 570: A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTT0 trial (BIG 1-06).** *E. Risi, C. Biagioni, M. Benelli, I. Migliaccio, A. McCartney, M. Bonechi, C. Guarducci, F. Hilbers, S. Di Cosimo, J. Baselga, D. Romagnoli, G. Boccalini, S. Vitale, A. Grilli, S. Biciato, C. Sotiriou, L. Biganzoli, A. Di Leo, L. Malorni*
- Board 63 Abstract 571: Prognostic implications of residual disease (RD) tumor-infiltrating lymphocytes (TIL) in triple negative breast cancer (TNBC) after neo-adjuvant chemotherapy (NAC).** *S. J. Luen, R. Salgado, M. Dieci, A. Vingiani, G. Curigliano, R. Hubbard, C. Castaneda Altamirano, J. Sanchez, T. D'Alfonso, E. Cheng, M. Castillo Garcia, S. Adams, F. Ahmed, D. L. Rimm, S. Demaria, W. F. Symmans, S. Michiels, S. Loi*
- Board 64 Abstract 572: Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial.** *N. Harbeck, U. Nitz, M. Christgen, R. E. Kates, M. W. Braun, S. Kummel, C. Schumacher, J. Potenberg, W. Malter, D. Augustin, B. Aktas, H. Forstbauer, J. Tio, A. Kleine-Tebbe, C. Liedtke, S. de Haas, R. Deurloo, R. Wuerstein, H. H. Kreipe, O. Gluz*
- Board 65 Abstract 573: Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: Survival results of WSG-ADAPT-TN phase II trial.** *O. Gluz, U. Nitz, C. Liedtke, M. Christgen, E. Grischke, H. Forstbauer, M. W. Braun, M. Warm, J. Hackmann, C. Uleer, B. Aktas, C. Schumacher, N. Bangemann, C. Lindner, S. Kummel, R. E. Kates, R. Wuerstein, H. H. Kreipe, N. Harbeck*
- Board 66 Abstract 574: Signatures of mutational processes and response to neoadjuvant chemotherapy in breast cancer: A genome-based investigation in the neoadjuvant GeparSepto trial.** *C. Denkert, M. Untch, S. C. Benz, K. Weber, J. Golovato, J. Budczies, V. Nekljudova, E. Stickeler, R. Parulkar, A. Schneeweiss, C. Jackisch, J. Sanborn, B. Conrad, H. Wiebringhaus, J. B. Huober, K. Rhiem, P. Soon-Shiong, P. A. Fasching, S. Rabizadeh, S. Loibl*
- Board 67 Abstract 575: Does the sequence of anthracycline and taxane matter? The NeoSAMBa trial.** *J. Bines, F. Kestelman, S. B. Siva, R. M. Sarmiento, I. A. Small, F. R. Rodrigues, P. S. Maroun, E. Millen, M. H. Bonamino*
- Board 68 Abstract 576: Breast Cancer Index (BCI) and prediction of pathological complete response (pCR) to neoadjuvant chemotherapy in estrogen receptor positive (ER+) breast cancer.** *L. Spring, Y. Zhang, K. Treuner, H. Park, M. Yuen, B. Moy, C. A. Schnabel, F. Andre, A. Bardia*
- Board 69 Abstract 577: Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTT0 trials.** *S. Chumsri, D. Serie, A. Mashadi-Hosseini, J. M. Kachergus, S. Warren, G. Colon-Otero, A. H. Partridge, L. A. Carey, F. Hilbers, V. Van Dooren, E. Holmes, S. Di Cosimo, O. Werner, J. B. Huober, J. Baselga, C. Sotiriou, E. A. Perez, A. C. Dueck, A. Moreno-Aspitia*

- Board 70 Abstract 578: Immune profiling of pre- and post-treatment breast cancer tissues from the S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamide.** X. Li, S. Warren, V. Pelekanou, V. Wali, A. Cesano, M. Liu, P. Danaher, N. Elliott, Z. A. Nahleh, D. F. Hayes, G. N. Hortobagyi, W. E. Barlow, C. Hatzis, L. Pusztai
- Board 71 Abstract 579: Integrative cluster classification to predict pathological complete response to neoadjuvant chemotherapy in early breast cancer.** E. Alba, O. M. Rueda, A. Lluch, J. Albanell, S. Chin, J. Chacon, L. Calvo, J. De La Haba, B. Bermejo, N. Ribelles, B. Cirauqui, M. Ramos Vazquez, M. Arcusa Lanza, E. M. Carrasco, J. Herranz, M. Chiesa, R. Caballero, A. Santonja Climent, F. Rojo, C. Caldas
- Board 72 Abstract 580: Intrinsic subtypes of HER2-positive breast cancer and their associations with pathologic complete response (pCR) and outcomes: Findings from NSABP B-41, a randomized neoadjuvant trial.** S. M. Swain, G. Tang, P. C. Lucas, A. Robidoux, D. Goerlitz, B. T. Harris, H. Bandos, C. E. Geyer Jr., P. Rastogi, E. P. Mamounas, N. Wolmark
- Board 73 Abstract 581: Care 001: Multicenter randomized open label phase II trial of neoadjuvant trastuzumabemtansine (T-DM1) in combination with lapatinib and nab-paclitaxel compared with paclitaxel, trastuzumab and pertuzumab in HER 2 neu over-expressed breast cancer patients (TEAL study).** T. A. Patel, J. Ensor Jr., S. Creamer, A. A. Rodriguez, P. A. Niravath, J. G. Darcourt, V. G. Kaklamani, J. L. Meisel, X. Li, J. G. Kuhn, R. R. Rosato, A. Belcheva, T. Boone, J. C. Chang
- Board 74 Abstract 582: Predicting neo-adjuvant chemotherapy response from pre-treatment breast MRI using machine learning and HER2 status.** N. Braman, K. Ravichandran, A. Janowczyk, J. Abraham, A. Madabhushi
- Board 75 Abstract 583: Efficacy analyses of central laboratory pCR results from the LILAC study comparing the biosimilar ABP 980 and trastuzumab.** H. Kolberg, Z. Tomasevic, G. Demetriou, Y. Fujiwara, M. Colleoni, H. Tesch, P. X. Santi, V. Hanes, N. Zhang
- Board 76 Abstract 584: Impact of residual nodal disease burden on sentinel node mapping and accuracy of intraoperative frozen section in node positive (cN1) breast cancer patients treated with neoadjuvant chemotherapy (NAC).** A. Laws, M. E. Hughes, J. Hu, W. T. Barry, L. S. Dominici, F. Nakhlis, T. Barbie, M. M. Duggan, A. Weiss, E. Rhei, K. Carter, K. Calvillo, S. Nimbkar, S. J. Schnitt, T. A. King
- Board 77 Abstract 585: Immune profiling of BRCA-mutated breast cancers.** J. M. Force, S. Abbott, G. Broadwater, I. Stashko, K. E. Westbrook, G. G. Kimmick, S. L. Sammons, T. Hyslop, H. Brauer, A. Mashadi-Hosseini, J. K. Plichta, E. S. Hwang, N. D. Kauff, K. J. Weinhold, S. Nair, E. Castellar, P. Marcom
- Board 78 Abstract 586: Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).** L. Pusztai, E. W. Hofstatter, G. G. Chung, N. R. Horowitz, D. R. Lannin, B. K. Killelea, A. B. Chagpar, M. DiGiovanna, C. Frederick, T. Burello, M. Harigopal
- Board 79 Abstract 587: The impact of chemotherapy sequence on survival in node-positive invasive lobular carcinoma.** N. P. Tamirisa, H. Vernia, S. M. Thomas, K. E. Westbrook, R. A. Greenup, J. K. Plichta, L. H. Rosenberger, T. Hyslop, E. S. Hwang, O. M. Fayanjy
- Board 80 Abstract 588: Incidence of PI3K pathway aberrations and their impact on response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) subtypes.** R. K. Basho, A. Trevarton, K. R. Hess, C. Fu, R. Lau, C. Lin, O. Lichtarge, W. T. Yang, W. F. Symmans, S. L. Moulder
- Board 81 Abstract 589: Ki67 to predict RCB0I after neoadjuvant chemotherapy and endocrine therapy in HER2- breast cancer patients from ABCSG 34.** C. F. Singer, M. Rudas, C. Fesl, G. G. Steger, G. Pfeiler, D. Egle, M. Balic, E. Petru, F. Fitzal, R. Greil, V. Bjelic-Radisic, R. Exner, Z. Bago-Horvath, M. Filipits, M. M. Tea, V. Wette, A. L. Petzer, C. Suppan, S. Frantal, M. Gnant

- Board 82 Abstract 590: Pathological complete response in basal subtype tumors to predict improved distant metastasis free survival in the NBRST trial.**
P. W. Whitworth, P. Baron, P. D. Beitsch, S. Untch, E. Yoder, T. Treece, M. W. Audeh
- Board 83 Abstract 591: Pharmacokinetics of CT-P6 and reference trastuzumab by clinical factors in patients with HER2 positive early-stage breast cancer (EBC).**
J. Stebbing, S. Yu, M. Kim, S. Park, S. Kim, H. Kim, N. Kim, F. J. Esteva
- Board 84 Abstract 592: Dynamic genomic instability modulation by neoadjuvant therapy in early breast cancer (GEICAM/2006-03_2006-14).**
E. Alba, O. M. Rueda, A. Lluch, J. Albanell, S. Chin, J. Chacon, L. Calvo, J. De La Haba, B. Bermejo, N. Ribelles, P. Sanchez Rovira, A. Plazaola, A. Barnadas, E. M. Carrasco, J. Herranz, M. Chiesa, R. Caballero, A. Santonja Climent, F. Rojo, C. Caldas
- Board 85 Abstract 593: Impact of metaplastic histology (MpBC) in triple-negative breast cancer (TNBC) patients (pts) receiving neoadjuvant systemic therapy (NAST).**
C. Yam, K. R. Hess, J. K. Litton, W. T. Yang, L. Santiago, R. P. Candelaria, E. A. Mittendorf, R. K. Murthy, S. Damodaran, T. Helgason, L. Huo, A. M. Thompson, M. Barton, M. L. Huang, E. M. Arribas, D. L. Lane, G. M. Rauch, B. E. Adrada, M. Z. Gilcrease, S. L. Moulder
- Board 86 Abstract 594: Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with HER2pos operable breast cancer treated with neo-adjuvant trastuzumab-containing chemotherapy.**
D. Kelly, R. Rahman, G. Gullo, D. W. Fennelly, J. M. Walshe, J. Crown
- Board 87 Abstract 595: Platinum-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC): A systematic review and meta-analysis of randomized controlled trials (RCTs).**
F. Poggio, M. Bruzzone, M. Ceppi, N. F. Ponde, G. La Valle, C. Sotiriou, L. Del Mastro, E. De Azambuja, M. Lambertini
- Board 88a Abstract TPS596: POSITIVE (IBCSG 48-14/BIG 8-13/A221405): Evaluating outcomes after interrupting endocrine therapy (ET) for women with endocrine responsive (ER+) early breast cancer (BC) who desire pregnancy.**
A. H. Partridge, O. Pagani, H. A. Azim Jr., F. Peccatori, M. Ruggeri, M. M. Regan, R. D. Gelber, Z. Sun
- Board 88b Abstract TPS597: ABC trial (A011502): Randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for breast cancer.**
W. Y. Chen, E. P. Winer, W. T. Barry, A. H. Partridge, L. A. Carey, M. Carvan, C. Matyka, K. Visvanathan, B. Symington, M. D. Holmes
- Board 89a Abstract TPS598: The Breast Cancer Weight Loss (BWEL) trial: Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early-stage breast cancer (Alliance A011401).**
J. A. Ligibel, W. T. Barry, C. M. Alfano, D. L. Hershman, M. L. Irwin, M. Neuhaus, C. A. Thomson, L. Delahanty, E. Frank, P. Spears, E. D. Paskett, J. O. Hopkins, V. Bernstein, V. Stearns, J. R. White, T. Wadden, P. J. Goodwin, L. A. Carey, A. Partridge, E. P. Winer
- Board 89b Abstract TPS599: Comparison of operative to monitoring and endocrine therapy for low-risk DCIS (COMET study).**
T. Lynch, E. S. Frank, D. E. Collyar, D. Basila, D. Pinto, A. Partridge, A. M. Thompson, E. S. Hwang
- Board 90a Abstract TPS600: POSNOC: Positive Sentinel Node—Adjuvant therapy alone versus adjuvant therapy plus clearance or axillary radiotherapy.**
A. Goyal, B. Mann, A. M. Thompson
- Board 90b Abstract TPS601: NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with positive axillary (PAX) nodes who are ypN0 after neoadjuvant chemotherapy (NC).**
E. P. Mamounas, H. Bandos, J. R. White, T. B. Julian, A. J. Khan, S. F. Shaitelman, M. A. Torres, F. Vicini, P. A. Ganz, S. A. McCloskey, S. Paik, N. Gupta, X. A. Li, D. J. DiCostanzo, W. J. Curran Jr., N. Wolmark

Saturday, June 2, 2018

- Board 91a Abstract TPS602: KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).** *P. Schmid, J. Cortes, J. C. Bergh, L. Pusztai, C. Denkert, S. Verma, H. L. McArthur, S. Kummel, Y. Ding, V. Karantza, T. Dang, R. A. Dent*
- Board 91b Abstract TPS603: NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.** *C. E. Geyer, S. Loibl, P. Rastogi, S. Seiler, J. P. Costantino, N. Vijayvergia, P. Cortazar, P. C. Lucas, C. Denkert, E. P. Mamounas, C. Jackisch, N. Wolmark*
- Board 92a Abstract TPS604: NRG Oncology BR005: Phase II trial assessing accuracy of tumor bed biopsies (Bx) in predicting pathologic response in patients (Pts) with clinical/radiological complete response (CR) after neoadjuvant chemotherapy (NCT) in order to explore the feasibility of breast-conserving treatment (BCT) without surgery.** *M. Basik, J. P. Costantino, J. F. De Los Santos, H. Umphrey, T. B. Julian, E. P. Mamounas, J. R. White, P. C. Lucas, J. L. Wagner, J. A. Tjoe, A. M. Thompson, N. Wolmark*
- Board 92b Abstract TPS605: PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients.** *J. Abraham, A. Vallier, W. Qian, A. Machin, L. Grybowicz, S. Thomas, C. Harvey, K. McAdam, L. Hughes-Davies, R. Roylance, E. Copson, E. Provenzano, K. Pinilla, E. McMurtry, M. Tischkowitz, H. M. Earl*

8:00 AM - 11:30 AM Poster Session

Breast Cancer—Metastatic

Location: Hall A

Abstracts on Boards 94-105 will be discussed during the Breast Cancer—Metastatic Poster Discussion Session.

Posters by Topic

HER2-Positive: Boards 94, 96, 106-120

Hormone Receptor-Positive: Boards 102-105, 121-149

Other/Nonsubtype Specific: Boards 95, 99-101, 150-173

Triple-Negative: Boards 97-98, 174-180

Trials in Progress: Boards 181a-190b

- Board 94 Abstract 1013: Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy.** *A. Urruticoechea, M. Rizwanullah, S. Im, A. Sánchez Ruiz, I. Lang, G. Tomasello, H. Douthwaite, T. Badovinac Crnjevic, S. Heeson, J. Eng-Wong, M. Munoz*
- Board 95 Abstract 1014: A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer.** *C. Saura, F. Thistlethwaite, U. Banerji, S. Lord, V. Moreno, I. MacPherson, V. Boni, C. D. Rolfo, E. G. de Vries, C. M. Van Herpen, S. Rottey, J. J. Geenen, F. Eskens, M. Gil Martin, E. Mommers, N. P. Koper, R. Mulder, P. G. Aftimos*
- Board 96 Abstract 1015: Clinical benefit of tucatinib after isolated brain progression: A retrospective pooled analysis of tucatinib phase 1b studies in HER2+ breast cancer.** *R. K. Murthy, E. P. Hamilton, C. Ferrario, N. Aucoin, C. I. Falkson, M. C. Chamberlain, T. Gray, V. F. Borges*

- Board 98 Abstract 1017: A phase II, single arm study assessing the efficacy of pembrolizumab (Pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC).** *H. L. McArthur, C. A. Barker, A. Gucalp, L. Lebron-Zapata, Y. H. Wen, C. Kallman, A. D'Agnolo, M. Rodine, B. Arnold, Z. Zhang, A. Y. Ho*
- Board 99 Abstract 1018: Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer.** *P. Sharma, V. G. Abramson, A. O'Dea, H. B. Pathak, Z. Y. Pessetto, Y. Y. Wang, K. Finke, M. S. Hoffmann, M. Elia, S. Lewis, J. Scott, J. De Jong, J. Urban, J. Heldstab, S. LaFaver, S. K. Williamson, G. Reed, B. F. Kimler, Q. J. Khan, A. K. Godwin*
- Board 100 Abstract 1019: The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of "indolent" stage IV disease (Stage IV_{indolent}).** *A. A. Davis, J. Pierga, L. Y. Dirix, S. Michiels, A. Rademaker, J. M. Reuben, T. N. Fehm, E. Munzone, M. Giuliano, J. Vidal-Martinez, D. Mavroudis, S. Grisanti, D. G. Generali, J. Garcia-Saenz, J. Stebbing, S. Dawson, P. Gazzaniga, F. Bidard, M. Cristofanilli*
- Board 101 Abstract 1020: Comparison of tissue genotyping (TG) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic breast cancer (MBC).** *N. Vidula, D. Juric, A. Niemierko, L. Spring, B. Moy, G. Malvarosa, M. Yuen, K. R. Habin, J. A. Shin, J. M. Peppercorn, S. J. Isakoff, L. W. Ellisen, A. Iafrate, A. Bardia*
- Board 102 Abstract 1021: Molecular alterations in the Ras-Raf-Erk (MAPK) pathway in metastatic hormone receptor positive (HR+)/HER2- breast cancer: Incidence and impact on clinical outcomes.** *A. Medford, A. Niemierko, B. Moy, L. Spring, G. Malvarosa, J. Younger, R. B. Lanman, R. J. Nagy, R. B. Corcoran, S. J. Isakoff, L. W. Ellisen, D. Juric, A. Bardia*
- Board 103 Abstract 1022: First-line ribociclib (RIB) + letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses.** *G. N. Hortobagyi, S. Paluch-Shimon, K. Petrakova, C. Villanueva, A. Chan, A. Nusch, Y. Yap, L. Hart, A. Favret, N. Marschner, G. S. Sonke, H. Oma Ohnstad, C. Arteaga, F. Su, W. He, M. K. Miller, S. M. Stemmer*
- Board 104 Abstract 1023: Treatment effect of palbociclib (PAL) plus endocrine therapy (ET) by prognostic and intrinsic subtype: A joint analysis of PALOMA2 and PALOMA3.** *R. S. Finn, M. Cristofanilli, J. Ettl, K. A. Gelmon, S. Verma, M. Colleoni, C. Giorgetti, E. R. Gauthier, Y. Liu, D. Lu, C. H. Bartlett, D. J. Slamon, N. C. Turner, H. S. Rugo*
- Board 105 Abstract 1024: Benefit of CDK 4/6 inhibition in less common breast cancer subsets: A U.S. Food and Drug Administration pooled analysis.** *J. J. Gao, J. Cheng, E. Bloomquist, R. Schroeder, L. Amiri-Kordestani, R. Sridhara, G. M. Blumenthal, R. Pazdur, J. A. Beaver, T. M. Prowell*
- Board 106 Abstract 1025: PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.** *T. Pascual, L. Pare, P. Galvan, M. A. Izquierdo, V. Rodrik-Outmezguine, B. Adamo, M. Vidal, J. Veeraraghavan, R. Schiff, C. K. Osborne, M. F. Rimawi, P. Nuciforo, A. Prat*
- Board 107 Abstract 1026: A phase II study of cabozantinib (cabo) alone or in combination with trastuzumab (T) in patients (pts) with breast cancer brain metastases (BCBM).** *J. P. Leone, J. Hu, W. T. Barry, D. G. Duda, E. R. Gerstner, R. K. Jain, S. Tan, E. S. Lawler, E. P. Winer, N. U. Lin, S. M. Toloney*

Saturday, June 2, 2018

- Board 108 **Abstract 1027: NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib (N) in women with metastatic HER2+ breast cancer (MBC).** *J. Abraham, S. Puhalla, W. M. Sikov, A. J. Montero, M. A. Salkeni, W. Razaq, J. H. Beumer, B. Kiesel, M. E. Buysse, L. M. Adamson, A. Srinivasan, K. L. Pogue-Geile, C. J. Allegra, S. A. Jacobs*
- Board 109 **Abstract 1028: An open-label, multicenter, phase Ib study to evaluate RC48-ADC in patients with HER2-positive metastatic breast cancer.** *B. Xu, J. Wang, Q. Zhang, Y. Liu, J. Feng, W. Wang, J. Fang*
- Board 110 **Abstract 1029: A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies (CCTG IND.229) [NCT02649686].** *S. K. Chia, P. L. Bedard, J. Hilton, E. Amir, K. A. Gelmon, R. A. Goodwin, D. Villa, M. Cabanero, H. Ritter, D. Tu, M. S. Tsao, L. Seymour*
- Board 111 **Abstract 1030: An open-label, dose-escalation phase I study to evaluate RC48-ADC, a novel antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.** *J. Wang, B. Xu, W. Wang, J. Fang*
- Board 112 **Abstract 1031: Serum PD-L1 and outcomes in CCTG MA.31 phase 3 trial of anti-HER2 therapy in first-line HER2+ metastatic breast cancer patients (trastuzumab arm only).** *K. Leitzel, S. M. Ali, L. E. Shepherd, W. R. Parulekar, L. Zhu, S. Virk, D. Nomikos, S. Aparicio, K. A. Gelmon, J. J. Drabick, L. Cream, E. Halstead, H. V. Polimera, A. Maddukuri, A. Ali, U. H. Patel, J. Poulouse, H. Spiegel, B. E. Chen, A. Lipton*
- Board 113 **Abstract 1032: Results from a phase I study of andeciximab in combination with paclitaxel in patients with previously untreated metastatic breast cancer.** *E. P. Hamilton, A. Bessudo, D. Bruetman, M. S. Gordon, R. Patel, A. H. Adewoye, J. Liu, A. Starodub, M. R. Patel*
- Board 114 **Abstract 1033: Safety and efficacy of pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC).** *D. B. Page, I. K. Kim, K. Sanchez, N. Moxon, S. L. Mellinger, A. K. Conlin, A. K. Acheson, K. S. Perlewitz, S. K. Lewis, K. A. Kemmer, Z. I. Mitri, R. K. Basho, E. Riffle, J. Ahn, J. Pucilowska, M. Martel, W. J. Urba, H. L. McArthur*
- Board 115 **Abstract 1034: Effect of breast tumor subtype and site of distant metastatic disease on prognostic outcome among patients with brain metastases and stage IV denovo breast cancer.** *S. S. Dawood, B. Sirohi, P. Mainwaring, R. A. Dent*
- Board 116 **Abstract 1035: Phase Ib study of trastuzumab emtansine (TDM1) in combination with lapatinib and nab-paclitaxel in metastatic HER2-neu overexpressed breast cancer patients: Stela results.** *T. A. Patel, J. Ensor Jr., A. A. Rodriguez, A. Belcheva, J. G. Darcourt, P. A. Niravath, J. G. Kuhn, V. G. Kaklamani, X. Li, T. Boone, J. C. Chang*
- Board 117 **Abstract 1036: A phase Ib trial of copanlisib and trastuzumab in pretreated recurrent or metastatic HER2-positive breast cancer "PantHER."** *N. M. Keegan, J. M. Walshe, S. Toomey, G. Gullo, M. J. Kennedy, K. N. Bulger, J. McCaffrey, C. M. Kelly, J. Crown, K. Egan, J. Kerr, A. Teiserskiene, A. Hernandez, I. Parker, R. McDermott, M. M. Keane, W. Grogan, O. S. Breathnach, P. G. Morris, B. Hennessy*
- Board 118 **Abstract 1037: Real-world (RW) characteristics, treatment (tx) patterns, and overall survival (OS) in US patients (pts) with metastatic breast cancer (mBC) and CNS metastases (CNS mets).** *A. Shewade, A. F. Hsieh, A. Mani, N. J. Al-Sakaff, T. Sanglier, M. D. Taylor, D. Heinzmann*
- Board 119 **Abstract 1038: SAFE-HEArT: A pilot study assessing the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function.** *F. Lynce, A. Barac, X. Geng, C. T. Dang, A. F. Yu, K. L. Smith, C. Gallagher, P. R. Pohlmann, R. Nunes, P. M. Herbolzheimer, R. D. Warren, M. B. Srichai, M. Hofmeyer, A. Cunningham, P. Timothee, F. M. Asch, A. N. Shajahan-Haq, M. T. Tan, C. Isaacs, S. M. Swain*
- Board 120 **Abstract 1039: Impact of HER2 mutation status on personalized molecular targeted therapy in advanced breast cancers.** *Z. Yi, F. Ma, Y. Guan, L. Chang, W. Wang, X. Guan, B. Liu, L. Li, C. Li, H. Qian, V. P. Reddy, B. Xu*

- Board 121 **Abstract 1040: Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009).** *A. Forero-Torres, H. Han, E. C. Dees, R. Wesolowski, A. Bardia, P. Kabos, R. M. Layman, J. M. Lu, K. A. Kern, R. Perea, K. J. Pierce, B. Houk, N. Pathan, H. S. Rugo*
- Board 122 **Abstract 1041: Maintenance of health-related quality of life in elderly patients treated with ribociclib + letrozole in MONALEESA-2.** *H. A. Burris, S. M. Tolaney, L. L. Hart, A. Favret, C. A. Alemany, G. H. Volas-Redd, M. Shtivelband, D. Chandiwana, D. D. Purkayastha, N. Caria, J. Baeck, G. N. Hortobagyi*
- Board 123 **Abstract 1042: Activity of tsetaxel, an oral taxane, given as a single-agent in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC) in a phase 2 study.** *A. D. Seidman, L. S. Schwartzberg, V. K. Gudena, P. Rubin, S. Kroll, J. P. O'Connell, K. Tang, J. O'Shaughnessy*
- Board 124 **Abstract 1043: Neutropenia and response to single agent palbociclib.** *N. P. McAndrew, M. A. Dickson, A. S. Clark, A. Troxel, C. Colameco, M. Gallagher, K. Gramlich, K. Zafman, D. J. Vaughn, G. K. Schwartz, P. J. O'Dwyer, A. DeMichele*
- Board 125 **Abstract 1044: Exhausted CD8+ cells (Tex) to predict response to PD-1 therapy in estrogen receptor (+) hormone therapy resistant breast cancer predictive of response to immune checkpoint inhibitors after epigenetic priming.** *P. N. Munster, M. Terranova Barberio, N. Pawlowska, M. Moasser, A. J. Chien, M. E. Melisko, H. S. Rugo, K. Abri, A. Harb, T. Deal, A. Daud, S. Thomas*
- Board 126 **Abstract 1045: EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician's choice (TPC) in OlympiAD.** *M. E. Robson, K. J. Ruddy, S. Im, E. Senkus-Konefka, B. Xu, S. M. Domchek, N. Masuda, W. Li, N. M. Tung, A. C. Armstrong, W. Bannister, C. D. Goessl, A. Degboe, R. Hettle, P. Conte*
- Board 127 **Abstract 1046: A randomized phase II trial evaluating CYP2D6 genotype-guided tamoxifen dosing in hormone receptor-positive metastatic breast cancer: TARGET-1.** *T. Takano, C. K. Imamura, K. Tamura, S. Saji, T. Yamanaka, K. Yonemori, M. Takahashi, J. Tsurutani, R. Nishimura, K. Sato, A. Kitani, N. T. Ueno, T. Mushiroda, M. Kubo, Y. Fujiwara, Y. Tanigawara*
- Board 128 **Abstract 1047: Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who received prior chemotherapy (CT): MONALEESA-7 subgroup analysis.** *S. A. Hurvitz, P. Wheatley-Price, D. Tripathy, Y. Lu, L. Chow, T. D. Bachelot, R. Hegg, S. K. Chia, D. A. Yardley, O. Kong, J. Alam, I. Diaz-Padilla, J. Baeck, A. Bardia*
- Board 129 **Abstract 1048: Impact of abemaciclib on the time to subsequent chemotherapy and the time to second disease progression across the MONARCH 2 and 3 studies.** *S. M. Tolaney, A. Di Leo, A. Lombart Cussac, M. N. Dickler, M. Campone, H. Iwata, M. Toi, P. A. Kaufman, V. A. Andre, S. Barriga, M. P. Goetz, G. W. Sledge Jr.*
- Board 130 **Abstract 1049: Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2- advanced breast cancer (ABC) who progressed on endocrine therapy.** *P. A. Kaufman, M. Toi, P. Neven, J. Sohn, G. L. Price, Y. Lin, M. Boye, L. Li, J. Gable, G. Cuyun Carter, G. W. Sledge Jr.*
- Board 131 **Abstract 1050: Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Final results from the run-in phase of a placebo-controlled randomized phase II.** *F. P. Duhoux, A. Jager, L. Y. Dirix, M. T. Huizing, G. H. Jerusalem, P. Vuylsteke, E. De Cuyper, D. Breiner, C. Mueller, C. Brignone, F. Triebel*

Saturday, June 2, 2018

- Board 132 **Abstract 1051: RIBECCA: A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole—Results of the first interim analysis.** *P. A. Fasching, A. Nusch, B. Heinrich, S. Brucker, T. Decker, C. M. Kurbacher, H. Tesch, P. Krabisch, C. Mundhenke, T. N. Fehm, W. Janni, D. Lueftner, A. Schneeweiss, M. H. Schuler, G. Guderian, C. Voges, J. Schubert, S. Kummel*
- Board 133 **Abstract 1052: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline *BRCA* mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases.** *N. M. Tung, S. Im, E. Senkus-Konefka, B. Xu, S. M. Domchek, N. Masuda, W. Li, A. C. Armstrong, P. F. Conte, W. Wu, C. D. Goessl, S. Runswick, M. E. Robson*
- Board 134 **Abstract 1053: The association of early toxicity and outcomes for patients treated with abemaciclib.** *H. S. Rugo, G. W. Sledge Jr., S. R. Johnston, M. P. Goetz, M. Martin, M. Toi, T. D. Forrester, M. Frenzel, J. Cox, S. Barriga, S. M. Tolaney*
- Board 135 **Abstract 1054: The tumor-immune microenvironment (TME) in HR+/HER2-metastatic breast cancer (mBC): Relationship to non-metastatic (met) tumors and prior treatment (tx) received.** *A. G. Waks, S. M. Tolaney, S. J. Schnitt, D. Dillon, E. Gjini, S. Abdelrahman, A. Marino-Enriquez, K. Helvie, L. Marini, O. Cohen, D. Kim, S. A. Wander, D. G. Stover, S. Rodig, I. E. Krop, E. P. Winer, N. U. Lin, N. Wagle*
- Board 136 **Abstract 1055: Plasma and tumor genomic correlates of response to BYL719 in *PI3KCA* mutated metastatic ER-positive breast cancer (ER+/HER2- BC).** *S. Dawson, L. Wein, M. Silva, S. J. Luen, C. VanGeelen, K. Moodie, P. Savas, C. Weng, A. Zivanovic Bujak, M. M. Yeung, S. Ftouni, K. Kuykhoven, R. J. Hicks, P. A. Francis, C. K. Lee, S. Loi*
- Board 137 **Abstract 1056: Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompleEment-1 trial.** *M. DeLaurentiis, P. Neven, G. H. Jerusalem, T. D. Bachelot, W. Jacot, S. F. Dent, M. Colleoni, A. Prat, M. Martin, A. E. Ring, P. H. Cottu, J. M. Lu, H. A. Azim, K. Zhou, J. Wu, J. Zarate, C. Zamagni*
- Board 138 **Abstract 1057: Mutation signature of patients with ER+ metastatic breast cancer who received endocrine therapy.** *F. Ma, Y. Zhang, Q. Ouyang, P. Dai, Z. Yi, W. Cao, Y. Zhou, C. Zhu, Y. Guan, L. Yang, X. Yi, X. Xia*
- Board 139 **Abstract 1058: Phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in metastatic breast cancer.** *K. Kalinsky, M. Onishi, J. Yu, M. S. Trivedi, M. K. Accordini, K. D. Crew, D. L. Hershman, M. A. Maurer, J. Silva*
- Board 140 **Abstract 1059: Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.** *S. M. Tolaney, P. Kabos, M. N. Dickler, L. Gianni, V. Jansen, Y. Lu, S. Young, H. S. Rugo*
- Board 141 **Abstract 1060: Hematologic adverse events following palbociclib (PAL) dose reduction in patients (pts) with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Pooled analysis from randomized phase 2 and 3 studies.** *S. Verma, S. Im, J. Ro, I. Bondarenko, N. Masuda, M. Colleoni, P. Schnell, E. Bananis, D. Lu, J. Ettl, M. Cristofanilli, H. S. Rugo, R. S. Finn*
- Board 142 **Abstract 1061: G1T38, an oral CDK4/6 inhibitor, dosed continuously in combination with fulvestrant for HR+ breast cancer: Preliminary phase 1b results.** *I. Bulat, M. Maglakelidze, C. Murias, G. P. Kurteva, R. Roylance, M. Gogiladze, A. Crijanovschi, A. McCullough, E. Shearin, J. Sorrentino, C. Sipes, Z. Yang, Y. Cai, R. K. Malik, A. P. Beelen*

- Board 143 Abstract 1062: Everolimus exposure and early metabolic response as predictors for treatment outcomes in breast cancer patients treated with everolimus and exemestane.** *A. Willemssen, L. de Geus-Oei, M. De Boer, J. Tol, Y. Kamm, P. C. De Jong, A. H. Vos, J. de Groot, S. F. Mulder, E. H. Aarntzen, W. R. Gerritsen, C. M. Van Herpen, N. P. Van Erp*
- Board 144 Abstract 1063: ¹⁸F-Fluoroestradiol (FES) and ¹⁸F-Fluorodeoxyglucose (FDG) PET imaging in lobular breast cancer.** *P. Manohar, L. Peterson, V. Wu, I. Jenkins, A. Novakova-Jiresova, J. M. Specht, J. Link, K. A. Krohn, P. Kinahan, D. A. Mankoff, H. M. Linden*
- Board 145 Abstract 1064: Outcome of everolimus based therapy in hormone receptor positive metastatic breast cancer patients after progression on palbociclib combination.** *A. Dhakal, R. A. Thomas, E. G. Levine, A. Brufsky, M. G. Hanna, A. Miller, T. Khoury, K. Takabe, A. P. Early, T. O'Connor, M. Opyrchal*
- Board 146 Abstract 1065: Phase II study of Ra-223 combined with hormonal therapy and denosumab for treatment of hormone receptor-positive breast cancer with bone-dominant metastasis.** *N. T. Ueno, R. K. Tahara, B. Saigal, T. Fujii, J. M. Reuben, H. Gao, A. Lucci, N. K. Ibrahim, S. Damodaran, Y. Shen, D. D. Liu, G. N. Hortobagyi, D. Tripathy, B. Lim, B. A. Chasen*
- Board 147 Abstract 1066: Sperm associated antigen 5 (SPAG5) as a predictor and monitor for response and distant relapse risk (DRR) to endocrine (ET) and chemo-therapies (CT) in oestrogen receptor positive (ER+) breast cancer (BC).** *T. M. Abdel-Fatah, G. Ball, A. M. Reid, P. Simpson, S. R. Lakhani, L. Pongor, B. Gyorffy, P. M. Moseley, A. R. Green, A. Pockley, C. Caldas, I. O. Ellis, S. Chan*
- Board 148 Abstract 1067: Healthcare medical costs among post-menopausal women with hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC) managed with systemic therapy following CDK 4/6 inhibitor (CDKi) in the real-world setting.** *N. Prinic, D. Tang, A. Bardia, D. Smith, W. M. Johnson, A. Aizer*
- Board 149 Abstract 1068: A phase I study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): safety, tolerability and pharmacokinetic (PK) analysis.** *R. Barroso-Sousa, H. Guo, W. T. Barry, A. R. Ferreira, R. Rees, E. P. Winer, N. Wagle, S. M. Tolaney*
- Board 150 Abstract 1069: EMBRACA: Efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation.** *H. S. Rugo, J. Ettl, N. E. Woodward, S. A. Hurvitz, A. Goncalves, K. Lee, L. Fehrenbacher, R. Yerushalmi, L. A. Mina, M. Martin, H. H. Roche, Y. Im, D. Markova, I. C. Tudor, W. Eiermann, J. L. Blum, A. L. Hannah, J. K. Litton*
- Board 151 Abstract 1070: Analysis of germline BRCA1/2 mutated (gBRCA^{mut}) hormone receptor-positive (HR+) and triple negative breast cancer (TNBC) treated with talazoparib (TALA).** *W. Eiermann, H. S. Rugo, S. Diab, J. Ettl, S. A. Hurvitz, A. Goncalves, K. Lee, L. Fehrenbacher, R. Yerushalmi, L. A. Mina, M. Martin, H. H. Roche, Y. Im, D. Markova, I. C. Tudor, J. L. Blum, A. L. Hannah, J. K. Litton*
- Board 152 Abstract 1071: Clinical evaluation of germline polymorphisms (SNPs) associated with disease response to capecitabine in metastatic breast cancer (MBC) (TBCRC 015).** *N. Choudhury, P. Evans, J. N. Ingle, I. A. Mayer, P. H. Morrow, A. M. Storniolo, A. Forero-Torres, C. H. Van Poznak, D. E. Merkel, E. C. Dees, G. F. Fleming, O. M. Hahn, P. C. Hoffman, O. I. Olopade, N. Cox, R. Nanda, P. H. O'Donnell*
- Board 153 Abstract 1072: Anti-tumor activity of PM1183 (lurbinectedin) in combination with capecitabine in metastatic breast cancer patients: Results from a phase I trial.** *A. Awada, P. G. Aftimos, E. Calvo, V. Boni, V. Moreno, B. Doger, X. Luepke, K. Zaragoza, M. Siguero, C. M. Kahatt, A. Soto-Matos, T. Sauri, J. Tabernero*

Saturday, June 2, 2018

- Board 154 **Abstract 1073: Concordance of genomic alterations (GA) in synchronous tumor biopsies (tBx) and circulating tumor (ct) DNA from metastatic breast cancer (MBC) patients (pts).** *M. Oliveira, M. Bellet, A. Suñol, F. Ruiz-Pace, P. Gomez, S. Escrivá, L. Garrigós, E. Zamora, M. Capelán, A. Azaro, M. Arumí, C. Ortiz, J. Matito, R. Fasani, F. M. Mancuso, M. Espinosa, P. Nuciforo, R. Dienstmann, A. Vivancos, C. Saura*
- Board 155 **Abstract 1074: Efficacy of olaparib monotherapy in patients (pts) with HER2-negative metastatic breast cancer (MBC) with germline BRCA mutation (gBRCAm) or lesional BRCA mutation (lBRCAm).** *E. Meisner, R. Rollins, J. Ensor Jr., A. Moran, A. Woodward, E. R. Ahn, C. A. Lynch, D. L. Citrin, D. Hansra, S. S. Aithal, M. Ninan, D. W. Nixon, S. Zook, S. M. Ali, M. Markman, R. H. Alvarez*
- Board 156 **Abstract 1075: Differences of TILs, hormone receptor, and HER2 status between primary and metastatic tumors.** *M. Ono, T. Osako, S. Taira, T. Shibayama, K. Kobayashi, T. Kobayashi, N. Gomi, T. Iwase, T. Ueno, Y. Ito, S. Ohno, F. Akiyama, S. Takahashi*
- Board 157 **Abstract 1076: Poly(ADP-Ribose) Polymerase Inhibitors (PARPi) for patients (pts) with locally advanced or metastatic breast cancer (BC): A meta-analysis.** *M. Tio, S. Patil, T. A. Traina, M. E. Robson, M. Khasraw*
- Board 158 **Abstract 1077: Multi-omic profiling of metastatic lesions to guide treatment selection: the Side Out 2 trial experience.** *M. Pierobon, N. J. Robert, D. W. Northfelt, M. Jahanzeb, B. Wong, K. Hodge, J. Aldrich, D. W. Craig, L. A. Liotta, J. D. Wulfkühle, R. I. Gallagher, D. Arguello, A. Conrad, A. C. Kemkes, D. M. Loesch, L. Vocila, B. Dunetz, J. D. Carpten, E. Petricoin III, S. P. Anthony*
- Board 159 **Abstract 1078: Efficacy of mirtazapine in preventing delayed nausea and vomiting induced by highly emetogenic chemotherapy: An open-label, randomized, multicenter phase III trial.** *J. Cao, B. Wang, Z. Wang, J. Zhang, L. Wang, E. Cao, Y. Zhao, Z. Feng, Q. Ouyang, S. Wang, X. Hu*
- Board 160 **Abstract 1079: Breast cancer stem cell autoantibodies to identify women with advanced breast cancer.** *S. E. Stanton, D. L. Cecil, M. M. O'Meara, J. S. Childs, M. L. Disis*
- Board 161 **Abstract 1080: Detection, dynamic monitoring, and resistance mechanism exploration of genomic alterations in circulating cell free tumor DNA (ctDNA) in Chinese metastatic breast cancer (mBC).** *H. Li, J. Yu, X. Liu, A. Wang, Z. Zhao, T. Cheung, W. Shi, Y. Zhang, P. Zhang, M. Tan, P. Du, W. Kong, Y. Liu, J. Zhang, Y. Yan, S. Jia*
- Board 162 **Abstract 1081: Racial disparity in breast cancer immune microenvironment.** *A. Elkhany, E. Katsuta, K. Takabe*
- Board 163 **Abstract 1082: Overall survival following locoregional surgery of the primary tumor in de novo stage IV breast cancer patients.** *H. Yao, Y. Yu, Y. Wang, T. Fu, J. Jiang, J. Zhao, Y. Chen, J. Tang, G. Ye, E. Song*
- Board 164 **Abstract 1083: Predictors of survival after loco-regional therapy (LRT) in stage 4 breast cancer (BC).** *A. Kommalapati, S. Tella, A. Ganti, P. Tandra*
- Board 165 **Abstract 1084: Analysis of circulating tumor cells (CTCs) in patients across multiple metastatic breast cancer (mBCa) cohorts identifies marked inter- and intra-patient heterogeneity in CTC size, shape, and overall morphology.** *G. Vansant, Y. Wang, B. Hom, A. Jendrisak, J. Schonhoft, R. P. Graf, P. Ontiveros, M. Kearney, M. A. Landers, R. Dittamore*
- Board 166 **Abstract 1085: Polymorphisms of MTHFR and TYMS to predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.** *S. Lin, B. Xu, J. Yue, X. Guan, X. Xia*
- Board 167 **Abstract 1086: Role of circulating miRNAs in detecting metastasis and having prognostic significance in metastatic breast cancer.** *S. Agelaki, C. Papadaki, I. Stoupis, L. Tsalikis, M. A. Papadaki, A. Monastiriotti, G. Markakis, D. Mavroudis*

- Board 168 **Abstract 1087: Androgen receptor expression in circulating tumor cells of metastatic breast cancer patients.** *J. E. de Kruijff, A. M. Sieuwerts, W. Onstenk, A. Jager, P. Hamberg, F. De Jongh, M. Smid, M. A. Timmermans, J. W. Martens, S. Sleijfer*
- Board 169 **Abstract 1088: Benefits and risks from maintenance therapy after first-line chemotherapy in patients with metastatic breast cancer.** *Y. Yu, Y. Wang, Q. Gao, Q. Ou, D. Lin, T. Fu, H. Yao*
- Board 170 **Abstract 1089: Phase II study of cabazitaxel as second-line treatment in patients with HER-2 negative metastatic breast cancer previously treated with taxanes.** *A. Koutras, F. Zagouri, G. Koliou, G. Lazaridis, D. Tryfonopoulos, A. Kotsakis, E. Res, N. K. Kentepozidis, E. Razis, A. Psyrris, G. Koumakis, H. Kalofonos, G. Fountzilas, M. A. Dimopoulos*
- Board 171 **Abstract 1090: Dynamic changes of interleukin 2 (IL-2) and circulating tumor cells (CTCs) in patients with advanced breast cancer (BCa) after systemic therapies.** *Q. Zhang, L. Gerratana, L. Flaum, A. N. Shah, B. Helfand, Y. Zhang, W. J. Gradishar, L. C. Platanius, M. Cristofanilli*
- Board 172 **Abstract 1091: Prognosis in young women under 40 with brain metastasis from breast cancer.** *A. Mustillo, J. M. Ayoub, L. Yelle, M. Florescu*
- Board 173 **Abstract 1092: What are the drivers of healthcare cost among patients with metastatic breast cancer (mBC)? Total cost of care analysis to inform value-based reimbursement.** *C. Burudpakdee, A. Seetasith, C. M. Reyes, S. Ogale, J. Munakata, L. K. Chu*
- Board 174 **Abstract 1093: Updated survival data and biomarker assessment of the CBCSG006 trial: A randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.** *J. Zhang, Y. Lin, X. Hu, W. Yang, X. Sun, B. Wang, Z. Wang, J. Luo, L. Wang, S. Zhang, J. Cao, Z. Tao, J. Wu, Z. Shao*
- Board 175 **Abstract 1094: Phase II (INSPIRE) trial of pembrolizumab (pembro) with serial immune and genomic profiling in patients (pts) with metastatic triple negative breast cancer (mTNBC).** *Z. W. Veitch, D. W. Cescon, S. Elston, S. Lien, C. Yang, B. X. Wang, H. K. Berman, M. O. Butler, E. Amir, C. Elser, S. Hakgor, A. Giesler, T. J. Pugh, P. S. Ohashi, L. L. Siu, P. L. Bedard*
- Board 176 **Abstract 1095: An open label, pilot study of veliparib (ABT-888) and lapatinib in patients with metastatic, triple negative (ER, PR, and HER-2 negative) breast cancer.** *E. M. Stringer-Reasor, E. S. Yang, J. E. May, V. Caterinicchia, Y. Li, A. Forero-Torres*
- Board 177 **Abstract 1096: Mechanisms of immune evasion in triple-negative breast cancer patients.** *J. I. Orozco, A. O. Manughian-Peter, M. P. Salomon, S. O'Day, D. S. Hoon, D. M. Marzese*
- Board 178 **Abstract 1097: Preliminary report of a phase 1b/2a trial, an oral inhibitor of phosphorylated P68 (P-p68) which mediates β -catenin nuclear translocation in advanced triple-negative breast cancer (TNBC).** *J. R. Diamond, P. Chalasani, E. Andreopoulou, W. L. Gluck, R. Nanda, C. Peterson, E. Benaim*
- Board 179 **Abstract 1098: An open label, single arm, prospective phase II study to evaluate the efficacy and safety of bevacizumab with gemcitabine and carboplatin as first-line treatment for metastatic triple negative breast cancer patients.** *S. Gupta, G. K. Babu, R. T. Chacko, D. Doval, C. Desai, N. Kilara, S. M. Nag, C. A. Shah, S. Deo, S. B. Koppikar, B. Swarup, A. A. Kukreja, V. Raina*
- Board 180 **Abstract 1099: Characterization of the inflammatory infiltrate and association with expression of PD-1, PDL1 and PDL2 and survival in triple-negative mammary carcinoma.** *M. C. Tavares, V. C. Lima Sr., V. P. Andrade, R. S. Riechelmann, M. Petaccia*
- Board 181a **Abstract TPS1100: A phase II study of atezolizumab (Atezo) combined with pertuzumab (P) and high-dose trastuzumab (H) for the treatment of central nervous system (CNS) metastases in patients with Her2-positive (HER2+) metastatic breast cancer (MBC).** *R. Barroso-Sousa, W. T. Barry, P. Kumthekar, H. Guo, K. M. Silvestri, I. E. Krop, E. P. Winer, S. M. Tolaney, N. U. Lin*

Saturday, June 2, 2018

- Board 181b Abstract TPS1101: SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab HR+ with or without letrozole in trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer.**
P. Villagra, A. Prat, M. Oliveira, L. De La Pena, X. Gonzalez, J. Cortes, S. Pernas Simon, J. Rios, J. Canes, E. Ciruelos
- Board 182a Abstract TPS1102: A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T-DM1.** *J. Baselga*, K. Tamura, T. Yamashita, S. Modi, E. Tokunaga, Y. Ito, H. Iwata, M. Charif, C. C. Lee, M. Sugihara, T. Jikoh, F. Andre
- Board 182b Abstract TPS1103: A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer.** *K. P. Casce*, P. Poulikakos, C. L. Shapiro, A. S. Bhardwaj, J. Fasano, H. Irie, P. Klein, A. Goel, K. Kalinsky, S. Adams, E. Andreopoulou, S. Jaffer, M. Ru, A. Tiersten
- Board 183a Abstract TPS1104: Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer.** *E. L. Mayer*, S. A. Wander, M. M. Regan, A. DeMichele, A. Forero-Torres, M. F. Rimawi, C. X. Ma, M. Cristofanilli, C. K. Anders, C. H. Bartlett, E. P. Winer, H. J. Burstein
- Board 183b Abstract TPS1105: PADA-1: A randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA *ESR1* mutation monitoring in ER-positive, HER2-negative metastatic breast cancer patients.** *F. Bidard*, R. Sabatier, F. Berger, B. Pistilli, F. Dalenc, T. De La Motte Rouge, J. Frenel, C. Dubot, S. Ladoire, J. Ferrero, L. Stefani, A. Lortholary, A. Hardy-Bessard, J. Grenier, S. Everhard, E. Jeannot, C. Proudhon, J. Lemonnier, S. Delaloge, T. D. Bachelot
- Board 184a Abstract TPS1106: Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC).**
J. O'Shaughnessy, M. J. Piccart-Gebhart, L. S. Schwartzberg, J. Cortes, N. Harbeck, S. Im, H. S. Rugo, M. Untch, D. A. Yardley, I. Bondarenko, S. Chan, V. Dieras, L. Gianni, M. D. Pegram, S. Kroll, J. P. O'Connell, J. L. Vacirca, T. Wei, K. Tang, A. D. Seidman
- Board 184b Abstract TPS1107: BYLieve: A phase II study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of *PIK3CA* mutant, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy.** *H. S. Rugo*, G. V. Bianchi, S. K. Chia, N. C. Turner, D. Juric, W. Jacot, M. Ruiz Borrego, L. I. Chap, U. A. Brown-Glaberman, C. C. Nienstedt, N. Sophos, A. Ridolfi, C. Lin, E. Ciruelos
- Board 185a Abstract TPS1108: Study TTC-352-101: Phase 1 study of TTC-352 in patients with metastatic breast cancer (BC) progressing on endocrine therapy.**
R. O'Regan, R. Hurley, J. C. Sachdev, D. A. Tonetti, G. R. Thatcher, R. P. Venuti, A. Z. Dudek
- Board 185b Abstract TPS1109: AIPAC (Active Immunotherapy PAclitaxel): A randomized, double blind, placebo controlled, multinational phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cancer.** *L. Dirix*, A. Jager, F. Marme, E. Brain, A. C. Armstrong, S. Nawrocki, F. Triebel
- Board 186a Abstract TPS1110: Phase II study of a combination therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer as a first-line treatment (WJOG9917B, NEWBEAT trial).** *Y. Ozaki*, K. Matsumoto, M. Takahashi, T. Mukohara, M. Futamura, N. Masuda, J. Tsurutani, K. Yoshimura, H. Minami, T. Takano

- Board 186b Abstract TPS1111: ATAIN: Phase 3 study of etirinotecan pegol (EP) vs. treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC).** *D. Tripathy, S. M. Tolaney, A. D. Seidman, C. K. Anders, N. K. Ibrahim, H. S. Rugo, C. Twelves, V. Diéras, V. Mueller, A. Hannah, M. A. Tagliaferri, J. Cortés*
- Board 187a Abstract TPS1112: An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity.** *A. Patsouris, O. Tredan, L. Campion, A. Goncalves, M. Arnedos, M. Sablin, P. Jézéquel, M. Jimenez, V. Pezzella, I. Bieche, C. Callens, A. Loehr, D. Nenciu, C. Vicier, F. Andre*
- Board 187b Abstract TPS1113: A randomized phase II study of pembrolizumab, an anti-PD (programmed cell death) 1 antibody, in combination with carboplatin compared to carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies.** *N. Vidula, A. Goga, J. Hwang, M. C. Liu, B. H. Park, R. Nanda, P. R. Pohlmann, A. M. Storniolo, A. Brufsky, V. G. Abramson, H. S. Rugo*
- Board 188a Abstract TPS1114: A phase II clinical trial to analyze olaparib response in patients with *BRCA1* and/or *BRCA2* promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study).** *J. De La Haba, A. Guerrero-Zotano, J. A. Perez-Fidalgo, S. Gonzalez Santiago, M. Muñoz, R. Andres, C. Cruz Zambrano, S. Moran Salama, S. Lopez-Tarruella, V. Quiroga Garcia, S. Servitja, M. Mele, S. Alonso Soler, B. Adamo, M. Escudero, N. Martin, S. Bezares, R. Caballero, M. Esteller, F. Rojo*
- Board 188b Abstract TPS1115: IMPassion132: A double-blind randomized phase 3 trial evaluating chemotherapy (CT) ± atezolizumab (atezo) for early progressing locally advanced/metastatic triple-negative breast cancer (mTNBC).** *R. Dent, F. Andre, A. Goncalves, S. Kummel, M. Martin, P. Schmid, F. Schuetz, S. M. Swain, V. Easton, E. Pollex, J. Cortés*
- Board 189a Abstract TPS1116: VIOLETTE: A randomized phase II study to assess DNA damage response inhibitors in combination with olaparib (Ola) vs Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer (TNBC) stratified by alterations in homologous recombination repair (HRR)-related genes.** *A. Tutt, C. Stephens, P. Frewer, A. Pierce, J. Rhee, K. So, L. Ottesen, E. Dean, S. J. Hollingsworth*
- Board 189b Abstract TPS1117: IPATunity130: A pivotal randomized phase III trial evaluating ipatasertib (IPAT) + paclitaxel (PAC) for *PIK3CA/AKT1/PTEN*-altered advanced triple-negative (TN) or hormone receptor-positive HER2-negative (HR+/HER2-) breast cancer (BC).** *R. Dent, S. Kim, M. Oliveira, S. J. Isakoff, C. H. Barrios, J. O'Shaughnessy, X. Lu, M. Wongchenko, D. Bradley, A. Mani, J. Baselga, N. C. Turner*
- Board 190a Abstract TPS1118: A randomized phase II trial of carboplatin with or without nivolumab in first- or second-line metastatic TNBC.** *A. Garrido-Castro, W. T. Barry, T. A. Traina, R. Wesolowski, N. M. Tung, T. Keenan, E. M. Van Allen, N. U. Lin, E. P. Winer, I. E. Krop, S. M. Tolaney*
- Board 190b Abstract TPS1119: A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC).** *R. Barroso-Sousa, H. Guo, W. T. Barry, G. Winship, B. Overmoyer, D. G. Duda, S. M. Tolaney*

8:00 AM - 11:30 AM Poster Session

Genitourinary (Nonprostate) Cancer

Location: Hall A

Abstracts on Boards 335-346 will be discussed during the Genitourinary (Nonprostate) Cancer Poster Discussion Session.

Posters by Topic

Bladder Cancer: Boards 338-339, 347-372

Germ Cell/Testicular: Boards 373-381

Kidney Cancer: Boards 335-336, 341-346, 382-411

Other GU Cancer: Board 340

Trials in Progress: Boards 412a-421b

- Board 335 Abstract 4509: Pegiloddecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC).**
N. M. Tannir, A. Naing, J. R. Infante, K. P. Papadopoulos, D. J. Wong, M. Korn, R. Aljumaily, K. A. Autio, S. Pant, T. M. Bauer, A. Drakaki, N. G. Daver, A. Hung, P. Van Vlasselaer, J. Leveque, M. Oft
- Board 336 Abstract 4510: A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma.** *U. N. Vaishampayan, D. F. McDermott, M. R. Matrana, S. Rha, A. J. Zurita, T. H. Ho, B. Keam, J. Lee, R. W. Joseph, S. Ali, W. M. Stadler, N. B. Haas, S. Sundararajan, S. Park, R. B. Mowat, J. Picus, A. Z. Dudek, Y. Zakharia, L. Gan, M. B. Atkins*
- Board 338 Abstract 4512: BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC).**
J. Taberero, J. J. Luke, A. M. Joshua, A. I. Varga, V. Moreno, J. Desai, B. Markman, C. A. Gomez-Roca, F. G. De Braud, S. P. Patel, M. S. Carlino, L. L. Siu, G. Curigliano, Z. Liu, Y. Ishii, P. Phillips, M. Wind-Rotolo, P. A. Basciano, A. Azrilevich, K. A. Gelmon
- Board 339 Abstract 4513: Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway.** *M. Joerger, P. A. Cassier, N. Penel, R. Cathomas, H. Richly, M. Schostak, A. Janitzky, M. Wermke, L. Nogova, D. W. Tai, C. Sayehli, C. Grüllich, E. Grande, A. Navarro, S. Park, H. Nogai, S. Bender, P. Ellinghaus, M. H. Schuler*
- Board 340 Abstract 4514: VinCaP: A phase II trial of vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the penis (CRUK/12/021).**
L. M. Pickering, H. Tovey, T. Elliott, S. M. Burnett, C. Cruickshank, A. Bahl, P. Kirkbride, A. Mitra, A. H. Thomson, N. Vasudev, B. Venugopal, R. Slade, L. Tregellas, B. Morgan, A. Hassall, E. Hall, S. Nicholson
- Board 341 Abstract 4515: Characterizing tumor immune microenvironment (TME) and outcomes for 409 patients (pts) treated on COMPARZ: Distinct clusters emphasize immune infiltration vs. angiogenesis.** *M. H. Voss, F. Kuo, A. Sanchez, I. Ostrovnya, Y. Cheng, P. Patel, M. Marker, A. Reising, T. A. Chan, R. J. Motzer, A. A. Hakimi*
- Board 342 Abstract 4516: Alterations in key clear cell renal cell carcinoma (RCC) genes to refine patient prognosis.** *D. Bossé, W. Xie, Y. Ged, A. W. Hahn, P. G. Bergerot, T. H. Ho, R. R. McKay, T. L. Rose, G. de Velasco, N. M. Tannir, P. Tamboli, L. J. Appleman, K. Rathmell, A. A. Hakimi, S. K. Pal, N. Agarwal, D. Y. Heng, S. Signoretti, M. H. Voss, T. K. Choueiri*
- Board 343 Abstract 4517: Prospective phase II multi-center study of individualized axitinib (Axi) titration for metastatic renal cell carcinoma (mRCC) after treatment with PD-1 / PD-L1 inhibitors.** *M. C. Ornstein, S. K. Pal, L. S. Wood, K. D. Allman, A. Martin, J. A. Garcia, T. D. Gilligan, D. Company, T. Olencki, K. Rathmell, B. I. Rini*

- Board 344 Abstract 4518: Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC).** *M. H. Voss, J. Buros Novik, M. D. Hellmann, M. Ball, A. A. Hakimi, D. Miao, C. Margolis, C. Horak, M. Wind-Rotolo, G. De Velasco, N. M. Tannir, P. Tamboli, L. J. Appleman, K. Rathmell, J. J. Hsieh, M. Allaf, T. K. Choueiri, E. VanAllen, A. Snyder, R. J. Motzer*
- Board 345 Abstract 4519: Gut microbiome composition to predict resistance in renal cell carcinoma (RCC) patients on nivolumab.** *L. Derosa, V. Iebba, L. Albiges, M. Fidelle, M. Bonaulet, E. Colomba, L. Zitvogel, B. Escudier, B. Routy*
- Board 346 Abstract 4520: A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy (CN), metastasectomy (MS) or post-treatment biopsy (Bx).** *J. Gao, J. A. Karam, N. M. Tannir, R. Slack, K. Ahrar, P. Rao, C. S. Ng, E. Jonasch, M. T. Campbell, S. F. Matin, A. J. Zurita, J. Wang, J. M. Blando, H. Zhao, L. M. Vence, S. Basu, H. Chen, J. P. Allison, C. G. Wood, P. Sharma*
- Board 347 Abstract 4521: Pembrolizumab (pembro) versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial.** *Y. Fradet, J. Bellmunt, R. De Wit, D. J. Vaughn, J. Lee, L. Fong, N. J. Vogelzang, M. A. Climent, D. P. Petrylak, T. K. Choueiri, A. Necchi, W. R. Gerritsen, H. Gurney, D. I. Quinn, S. Culine, C. N. Sternberg, K. Nam, T. L. Frenkl, R. F. Perini, D. F. Bajorin*
- Board 348 Abstract 4522: Conservative management following clinical complete response to neoadjuvant chemotherapy for muscle-invasive bladder cancer: Contemporary outcomes of a multi-institutional prospective cohort study.** *P. M. Mazza, G. W. Moran, G. Li, D. J. Robins, J. T. Matulay, H. W. Herr, C. B. Anderson, J. M. McKiernan*
- Board 349 Abstract 4523: Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210.** *A. V. Balar, R. Dreicer, Y. Loriot, J. L. Perez-Gracia, J. H. Hoffman-Censits, D. P. Petrylak, M. S. Van Der Heijden, B. Ding, X. Shen, J. E. Rosenberg*
- Board 350 Abstract 4524: Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).** *J. Vuky, A. V. Balar, D. E. Castellano, P. H. O'Donnell, P. Grivas, J. Bellmunt, T. Powles, D. F. Bajorin, N. M. Hahn, R. De Wit, M. Savage, L. Pang, T. L. Frenkl, S. M. Keefe, E. R. Plimack*
- Board 351 Abstract 4525: Upper tract urothelial carcinoma is non-basal and T-cell depleted.** *P. J. Vlachostergios, B. D. Robinson, B. Bhinder, R. Bareja, K. Park, P. Tavassoli, S. T. Tagawa, D. M. Nanus, J. Mosquera, D. Scherr, M. A. Rubin, O. Elemento, B. Faltas*
- Board 352 Abstract 4526: Ramucirumab (RAM) exposure-response (ER) relationship in RANGE, a randomized phase III trial of docetaxel (DOC) with or without RAM in advanced urothelial carcinoma (UC) patients (pts) who progressed on or after platinum therapy.** *R. De Wit, T. Powles, D. E. Castellano, A. Necchi, J. Lee, M. S. Van Der Heijden, N. Matsubara, A. Bamias, A. Flechon, C. N. Sternberg, A. Drakaki, E. Y. Yu, O. Hamid, A. Zimmermann, L. Gao, A. Long, R. A. Walgren, K. M. Bell-McGuinn, D. P. Petrylak*
- Board 353 Abstract 4527: Comprehensive genomic characterization of urothelial carcinomas.** *A. Nassar, R. Umeton, K. Lundgren, L. C. Harshman, E. M. Van Allen, T. K. Choueiri, G. Steele, J. Bellmunt, K. W. Mouw, G. Sonpavde, D. J. Kwiatkowski*
- Board 354 Abstract 4528: Clinical efficacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivolpi) in patients (pts) with chemotherapy-refractory metastatic urothelial carcinoma (mUC) either naïve (n) or refractory (r) to checkpoint inhibitor (CPI).** *R. Nadal, A. Mortazavi, M. N. Stein, S. K. Pal, D. K. Lee, H. L. Parnes, Y. Ning, L. M. Cordes, M. H. Bagheri, R. Thompson, C. Mayfield, S. M. Steinberg, P. Monk III, P. Lara Jr., R. Costello, P. K. Agarwal, D. Bottaro, W. L. Dahut, A. B. Apolo*

Saturday, June 2, 2018

- Board 355 **Abstract 4529: Atezolizumab (atezo) in special populations: Analyses from an expanded access program (EAP) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).** *J. H. Hoffman-Censits, S. K. Pal, H. Zheng, D. Tayama, J. Bellmunt*
- Board 356 **Abstract 4530: Optimization of PD-L1 algorithm for predicting overall survival (OS) in patients with urothelial cancer (UC) treated with durvalumab monotherapy.** *M. Zajac, J. Ye, P. Mukhopadhyay, X. Jin, Y. Ben, J. Antal, A. K. Gupta, M. Rebelatto, J. Williams, J. Walker*
- Board 357 **Abstract 4531: FGFR3 Driven Metastatic Urothelial Carcinoma of the Urinary Bladder (mUCB): A Comprehensive Genomic Profiling Study.** *J. S. Ross, L. M. Gay, E. K. Ferry, J. Jacob, O. Shapiro, J. H. Hoffman-Censits, S. Z. Millis, J. A. Elvin, J. Chung, J. Vergilio, J. Suh, S. H. Ramkissoon, E. A. Severson, S. Daniel, J. K. Killian, S. M. Ali, A. B. Schrock, V. A. Miller, G. Bratslavsky*
- Board 358 **Abstract 4532: Patient-reported outcomes (PROs) in patients with urothelial carcinoma (UC) treated with durvalumab (second-line or above) in phase 1/2 dose-escalation study 1108.** *P. H. O'Donnell, H. Arkenau, S. S. Sridhar, M. Ong, A. Drakaki, A. I. Spira, J. Zhang, M. S. Gordon, A. Degboe, A. K. Gupta, P. Mukhopadhyay, W. Huang, S. E. Abdullah, N. Angra, T. W. Friedlander*
- Board 359 **Abstract 4533: Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).** *T. Zhang, J. S. Staats, C. Chan, M. R. Harrison, P. H. O'Donnell, K. A. Batich, T. Chen, C. Krejsa, R. Izumi, D. J. George, K. J. Weinhold*
- Board 360 **Abstract 4534: FIERCE-21: Phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC).** *J. Bellmunt, J. Picus, M. Kohli, Y. E. Arriaga, M. I. Milowsky, G. Currie, S. Abella, S. K. Pal*
- Board 361 **Abstract 4535: Relapse-free survival (RFS) of clinical T2-4N0 urothelial bladder carcinoma (UBC) after radical cystectomy (RC), with or without perioperative chemotherapy (POC): Endpoints for clinical trial design.** *M. Bandini, A. Briganti, E. R. Plimack, G. Niegisch, E. Y. Yu, A. Bamias, N. Agarwal, S. S. Sridhar, C. N. Sternberg, U. N. Vaishampayan, C. Theodore, J. E. Rosenberg, J. Bellmunt, M. D. Galsky, F. Montorsi, A. Necchi*
- Board 362 **Abstract 4536: Prognostic value of genomic alterations of DNA repair genes in advanced bladder cancer (ABC).** *M. Yin, P. Grivas, S. M. Ali, J. Hsu, M. K. Vasekar, H. Enamekhoo, S. K. Pal, M. Joshi*
- Board 363 **Abstract 4537: A novel, robust multiplex urine-based immunoassay for bladder cancer detection.** *H. Furuya, Y. Dai, K. Hokutan, Y. Lotan, C. J. Rosser*
- Board 364 **Abstract 4538: Bladder cancer gene expression subtypes (60 gene signature) to define prognosis, differential immune response, and biomarker associations.** *G. M. Mayhew, Y. Shibata, J. Sun, C. M. Perou, D. N. Hayes, M. Lai-Goldman, H. Faruki*
- Board 365 **Abstract 4539: Model combining genomic and clinical factors to predict clinical benefit from PD1/PD-L1 inhibitors for advanced UC.** *A. Nassar, K. W. Mouw, C. Liu, K. Lundgren, E. M. Van Allen, L. C. Harshman, M. Pomerantz, M. A. Preston, X. X. Wei, B. A. McGregor, A. D. Choudhury, J. Bellmunt, T. K. Choueiri, D. J. Kwiatkowski, G. Sonpavde*
- Board 366 **Abstract 4540: Association of circulating tumor (ct)-DNA genomic alterations (GA) with outcomes in metastatic urothelial carcinoma (mUC).** *P. Grivas, G. R. Pond, R. J. Nagy, P. C. Barata, P. Mendiratta, D. Gopalakrishnan, A. Drakaki, S. Gupta, N. Agarwal, J. Wang, B. Faltas, U. N. Vaishampayan, G. Naik, B. A. McGregor, S. K. Pal, L. A. Kiedrowski, R. B. Lanman, G. Sonpavde*
- Board 367 **Abstract 4541: Combined checkpoint immunotherapy and cytotoxic chemotherapy: Further results from a phase Ib/II trial of pembrolizumab and docetaxel or gemcitabine in patients with advanced or metastatic urothelial cancer.** *M. Parikh, C. Pan, L. Beckett, Y. Li, D. Robles, C. DeVisser, P. Lara Jr.*

- Board 368 **Abstract 4542: A subgroup analysis of the East Asia population in RANGE: A randomized phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma (UC).** *N. Matsubara, D. P. Petrylak, H. Nishiyama, W. Su, J. Lee, J. Li, R. A. Walgren, O. Hamid, A. Zimmermann, K. M. Bell-McGuinn, L. Gao, G. Homma, I. Yana, T. Powles*
- Board 369 **Abstract 4543: Preliminary results from an ongoing phase 2a study of RX-3117, an oral nucleoside analogue to treat advanced urothelial cancer (aUC).** *J. Adashek, S. K. Pal, V. M. Chung, S. T. Tagawa, J. Picus, H. M. Babiker, S. Gupta, R. C. Wadlow, J. Poore, C. Peterson, E. Benaim*
- Board 370 **Abstract 4544: SPEAR-bladder (study informing treatment pathway decision in bladder cancer): First- through third-line time to treatment failure in the US.** *G. K. Doshi, A. Bhanegaonkar, M. Bharmal, H. Phatak, M. Boyd, K. M. Aguilar, M. Kearney*
- Board 371 **Abstract 4545: Efficacy of split schedule (SS) vs conventional schedule (CS) neoadjuvant cisplatin-based chemotherapy for muscle-invasive bladder cancer (MIBC).** *C. K. Osterman, D. S. Babu, D. M. Geynisman, B. Lewis, R. A. Somer, A. V. Balar, M. R. Zibelman, E. A. Guancial, G. Antinori, V. Narayan, T. J. Guzzo, E. R. Plimack, D. J. Vaughn, C. Fung, R. Mamtani*
- Board 372 **Abstract 4546: Correlation between gene expression and prognostic biomarkers in small cell bladder cancer (SCBC).** *V. S. Koshkin, A. Dhawan, M. Hu, J. Reynolds, P. Elson, J. McKenney, L. R. Saunders, K. Isse, S. Rashid, A. Balyimez, M. C. Ornstein, T. D. Gilligan, B. Lee, J. G. Scott, B. I. Rini, J. A. Garcia, P. Grivas, O. Y. Mian*
- Board 373 **Abstract 4547: Apache: An open label, randomized, phase 2 study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): Results at the end of first stage.** *D. Raggi, P. Giannatempo, L. Mariani, M. Colecchia, G. Calareso, R. Salvioni, S. M. Ali, J. S. Ross, J. Chung, A. Necchi*
- Board 374 **Abstract 4548: Use of 18F-FDG PET/CT to select candidates for active surveillance: Results of the SEMITEP trial of PET-directed strategy for stage 1 seminoma.** *Y. Lorient, S. Grimaldi, A. Flechon, H. Mahammed, E. Bompas, C. Chevreau, M. Gross Goupil, G. Gravis, S. Culine, T. Nguyen, S. Ladoire, P. Barthelemy, C. Helissey, B. Laguerre, E. SEVIN, J. Rigaud, S. Abadie Lacourtoisie, L. Geoffrois, L. Texier, K. Fizazi*
- Board 375 **Abstract 4549: Circulating miR-371a-3p for the detection of low volume viable germ cell tumor: Expanded pilot data, clinical implications and future study.** *L. Nappi, B. O Neil, S. Daneshmand, R. J. Hamilton, R. R. Leao, M. Thi, K. N. Chi, M. Gleave, B. J. Eigl, P. C. Black, A. I. So, D. Khalaf, C. K. Kollmannsberger, C. R. Nichols*
- Board 376 **Abstract 4550: Etoposide and cisplatin (EP) for metastatic good-risk germ cell tumors (GCTs): The Memorial Sloan-Kettering Cancer Center (MSKCC) experience in 944 patients (pts).** *S. Funt, D. J. McHugh, S. Tsai, D. O'Donnell, A. Knezevic, S. Patil, D. Silber, V. E. Reuter, J. Sheinfeld, B. S. Carver, M. Carousso, R. J. Motzer, D. F. Bajorin, G. J. Bosl, D. R. Feldman*
- Board 377 **Abstract 4551: Retroperitoneal cancer viability after postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in good risk germ cell tumors (GCTs).** *F. Taza, M. Chovanec, A. Snavelly, N. Adra, N. H. Hanna, C. Cary, T. A. Masterson, L. H. Einhorn, C. Albany*
- Board 378 **Abstract 4552: Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT).** *D. J. McHugh, S. Funt, D. Silber, A. Knezevic, S. Patil, D. O'Donnell, S. Tsai, V. E. Reuter, J. Sheinfeld, B. S. Carver, R. J. Motzer, D. F. Bajorin, G. J. Bosl, D. R. Feldman*
- Board 379 **Abstract 4553: The prognostic value of teratoma in the primary tumor and postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) specimens in patients with germ cell tumors (GCTs).** *F. Taza, M. Chovanec, A. Snavelly, N. Adra, N. H. Hanna, C. Cary, T. A. Masterson, L. H. Einhorn, C. Albany*

Saturday, June 2, 2018

- Board 380 **Abstract 4554: Psychological stress in long-term survivors of testicular cancer: A Danish nationwide cohort study.** *M. Kreiberg*, M. Bandak, J. Lauritsen, K. K. Andersen, J. W. Skøtt, C. Johansen, G. Daugaard
- Board 381 **Abstract 4555: Comprehensive genomic characterization of chemotherapy-resistant testicular germ cell tumors (TGCT).** *A. Necchi*, G. Bratslavsky, R. J. Corona, J. Chung, S. Z. Millis, L. M. Gay, J. A. Elvin, J. Vergilio, J. Suh, S. Ramkissoon, E. A. Severson, S. Daniel, J. K. Killian, S. M. Ali, A. B. Schrock, V. A. Miller, A. W. Welsh, J. S. Ross
- Board 382 **Abstract 4556: Quality-adjusted time without symptoms or toxicity (Q-TWiST): Analysis of cabozantinib (Cabo) vs sunitinib (Sun) in patients with advanced renal cell carcinoma (aRCC) of intermediate or poor risk (Alliance A031203).** *R. C. Chen*, M. Feuille, J. Meng, J. Lister, F. Marteau, M. J. Morris, D. J. George, T. K. Choueiri
- Board 383 **Abstract 4557: Interim data analysis of the ADAPT trial using the modified intent to treat (mITT) population re-evaluates Rocapuldence-T for clinical benefit over standard of care.** *R. A. Figlin*, C. G. Wood, A. H. Gamble, A. Plachco, M. S. Norris, J. M. Horvatinovich, I. Y. Tcherepanova, C. A. Nicolette, M. A. DeBenedette
- Board 384 **Abstract 4558: Phase Ib and phase II studies of pembrolizumab (P) with bevacizumab (B) for the treatment of metastatic renal cell carcinoma (RCC): BTRC-GU14-003.** *A. Z. Dudek*, L. C. Liu, A. S. Alva, M. Stein, S. Gupta, C. Albany, M. Joshi, Y. Zakharia, J. M. Lang, J. K. Schwarz, A. Al-Janadi
- Board 385 **Abstract 4559: Comprehensive molecular and immunohistochemical analysis of advanced renal cell carcinoma patients treated with mTOR inhibitors.** *J. García-Donas*, J. Roldan, N. Lainez, D. E. Castellano, E. E. González, M. A. Climent, J. Puente, J. Rodríguez-Moreno, T. Alonso Gordo, A. Gonzalez del Alba, J. A. Arranz, M. Santos, S. Hernando Polo, M. Domenech, L. Rodriguez, A. Herrador, M. Sáez, E. Gallardo Díaz, A. Gutierrez, C. Rodríguez-Antona
- Board 386 **Abstract 4560: Lenvatinib + pembrolizumab in patients with renal cell carcinoma: Updated results.** *C. Lee*, V. Makker, D. W. Rasco, M. H. Taylor, D. E. Stepan, R. C. Shumaker, E. V. Schmidt, M. Guo, C. E. Dutcus, R. J. Motzer
- Board 387 **Abstract 4561: Comparison of clinical outcomes with first-line pazopanib in clinical trial eligible and non-clinical trial eligible patients with renal cell carcinoma.** *E. Jonasch*, G. Procopio, R. E. Hawkins, A. Rodriguez Sanchez, S. Vazquez, N. Srihari, H. Kalofonos, A. Bamias, P. Bono, C. Babanrao Pisal, Y. Hirschberg, L. Dezzani, Q. I. Ahmad, M. Schmidinger
- Board 388 **Abstract 4562: Neutrophil-to-lymphocyte ratio as a potential prognostic factor of disease-free survival in high-risk renal cell carcinoma: Analysis of the S-TRAC trial.** *A. Patel*, A. Ravaud, R. J. Motzer, A. J. Pantuck, M. D. Staehler, B. Escudier, J. Martini, S. Krishnaswami, M. Casey, M. Lechuga, X. Lin, D. J. George
- Board 389 **Abstract 4563: A randomized phase II trial of pazopanib (PAZ) vs. temsirolimus (TEM) in patients (pts) with advanced clear-cell renal cell carcinoma (accRCC) with intermediate or poor-risk disease (the TemPa trial).** *A. J. Zurita*, J. A. Ross, C. E. Devine, A. Chandramohan, X. Wang, Z. D. Lim, J. Wang, P. G. Corn, P. Msaouel, N. M. Tannir
- Board 390 **Abstract 4564: Patterns of relapse and implications for post-nephrectomy surveillance for patients with high-risk non-clear cell renal cell carcinoma: Subgroup analysis of the phase 3 ECOG-ACRIN E2805 trial.** *V. Narayan*, M. Puligandla, P. Subramanian, R. Uzzo, R. S. DiPaola, N. B. Haas
- Board 391 **Abstract 4565: Disease-free survival in patients at highest risk of recurrent renal cell carcinoma in S-TRAC.** *A. Ravaud*, D. J. George, R. J. Motzer, A. J. Pantuck, M. D. Staehler, L. Serfass, S. Krishnaswami, M. Casey, L. L. DeAnnuntis, M. Lechuga, B. Escudier
- Board 392 **Abstract 4566: Replication stress response deficiency (RSRD) and response to immune therapy in clear cell renal cell carcinoma (ccRCC).** *P. G. Pilié*, D. J. McGrail, S. Lin, E. Jonasch

- Board 393 **Abstract 4567: A meta-analysis of randomized controlled trials for efficacy and safety of vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) adjuvant therapy in high-risk renal cell cancer (RCC).** *I. Fiaz, S. Malik, M. Husnain, Q. Sipra, W. Faridi, F. R. Gondal, H. Xie, S. Yadav, M. Kohli*
- Board 394 **Abstract 4568: Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).** *S. Pant, A. I. Spira, B. Cho, S. Goel, C. J. Hoimes, A. S. Alva, R. Balaraman, T. M. Bauer, P. A. Lowry, R. C. Ramaekers, R. D. Siegel, T. L. Werner, N. M. Tannir, D. Faltaos, D. Potvin, S. T. Neuteboom, J. Christensen, R. C. Chao, C. Kyriakopoulos*
- Board 395 **Abstract 4569: A FARETES study of the efficacy and safety of testosterone in metastatic renal cell carcinoma patients with fatigue.** *I. Tsimafeyeu, R. Zukov, P. Borisov, A. Bondarenko, K. Zakurdaeva, Y. Tishova*
- Board 396 **Abstract 4570: Patient-reported frustrations in renal cell carcinoma (RCC) care delivery: Results of a joint European Association of Urology (EAU)/ KCCure survey.** *C. D. Bergerot, D. Battle, P. G. Bergerot, D. J. George, H. J. Hammers, E. Jonasch, A. Bex, B. Ljungberg, N. Dizman, S. K. Pal, M. D. Staehler*
- Board 397 **Abstract 4571: Anxiety and patients: Perspectives on surveillance and adjuvant therapy in renal cell carcinoma.** *D. Battle, H. J. Hammers, E. Jonasch, I. Derweesh, D. J. George, A. Bex, B. Ljungberg, M. D. Staehler*
- Board 398 **Abstract 4572: Real world experience and biomarkers of nivolumab in dutch advanced renal-cell carcinoma patients.** *S. L. Verhaart, C. M. Van Herpen, S. Oosting, A. Van Der Veldt, S. Osanto, M. J. Aarts, D. Houtsma, F. P. Peters, G. Groenewegen, A. Bex, S. F. Mulder, L. M. Pronk, M. Tascilar, P. Hamberg, M. Los, G. Vreugdenhil, M. Polee, A. J. Ten Tije, J. B. Haanen, A. J. van den Eertwegh*
- Board 399 **Abstract 4573: Safety and activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma: A cytokine working group phase II study.** *L. J. Appleman, D. P. Normolle, T. F. Logan, P. Monk III, T. Olencki, D. F. McDermott, M. S. Ernstoff, J. K. Maranchie, R. A. Parikh, D. Friedland, H. Zeh III, X. Liang, L. H. Butterfield, M. T. Lotze*
- Board 400 **Abstract 4574: Prospective, multinational, observational study of real-world treatment outcomes with pazopanib in patients with advanced or metastatic renal cell carcinoma (PRINCIPAL Study).** *M. Schmidinger, G. Procopio, R. E. Hawkins, A. Rodriguez Sanchez, S. Vazquez, N. Srihari, H. Kalofonos, A. Bamias, P. Bono, C. Babanrao Pisal, Y. Hirschberg, L. Dezzani, Q. I. Ahmad, E. Jonasch*
- Board 401 **Abstract 4575: Comparative transcriptomic profiling of renal medullary carcinoma (RMC) to determine distinct signatures and pathways associated with response to chemotherapy.** *P. Msaouel, G. G. Malouf, X. Su, H. Yao, D. N. Tripathi, J. Gao, P. Rao, R. He, J. A. Karam, C. G. Wood, C. L. Walker, N. M. Tannir*
- Board 402 **Abstract 4576: Functional biomarkers of homologous repair (HR) deficiency to guide novel DNA damage response targeted therapy in clear cell renal cell carcinoma (ccRCC).** *P. G. Pilie, C. B. Peterson, Y. Peng, L. Zhou, T. A. Yap, G. Peng, E. Jonasch*
- Board 403 **Abstract 4577: Single-center analysis of 109 patients (pts) with metastatic chromophobe renal cell carcinoma (ChRCC): Differences in outcomes by histologic variant.** *Y. Ged, A. Knezevic, Y. Chen, A. Redzematovic, M. I. Carlo, C. Lee, D. R. Feldman, S. Patil, R. J. Motzer, M. H. Voss*
- Board 404 **Abstract 4578: Overall survival (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM.** *M. N. Fishman, J. I. Clark, A. S. Alva, B. D. Curti, N. Agarwal, R. J. Hauke, K. M. Mahoney, H. Moon, J. Treisman, S. Tykodi, G. A. Daniels, M. Morse, M. K. Wong, H. Kaufman, N. C. Gregory, J. P. Dutcher*

Saturday, June 2, 2018

- Board 405 Abstract 4579: Cabozantinib (Cabo) in advanced non-clear cell renal cell carcinoma (nccRCC): A retrospective multicenter analysis.** *N. Martinez Chanza, D. Bossé, M. A. Bilen, D. M. Geynisman, A. Balakrishnan, R. K. Jain, I. A. Bowman, Y. Zakharia, V. Narayan, B. Beuselinck, N. Agarwal, R. R. McKay, J. Hsu, S. Shah, A. Tripathi, E. T. Lam, T. L. Rose, B. A. Carneiro, N. J. Vogelzang, L. C. Harshman*
- Board 406 Abstract 4580: Pilot trial of ibrutinib plus nivolumab in patients with metastatic renal cell cancer (mRCC): results from a dose-finding cohort.** *P. Lara, M. Parikh, D. Robles, F. Lara, F. J. Meyers, C. Pan*
- Board 407 Abstract 4581: Active surveillance and deferred medical treatment (ASDT) in metastatic renal cell carcinoma (mRCC): Update of a single center experience and efficacy of medical treatment.** *P. Ivanyi, M. Tiemann, V. GrÅ¼nwald, H. Eggers, A. Ganser, C. Reuter*
- Board 408 Abstract 4582: Radiofrequency ablation of pathologically proven T1a renal tumors: 15 years follow up—A tertiary cancer center experience.** *M. E. Abdelsalam, S. H. Sabir, S. B. Kusin, S. F. Matin, C. G. Wood, J. A. Karam, K. Ahrar*
- Board 409 Abstract 4583: Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) and sarcomatoid dedifferentiation (sRCC) after treatment with immune checkpoint inhibitors (ICI): A single-institution retrospective study.** *J. A. Ross, B. Z. McCormick, J. Gao, P. Msaouel, M. T. Campbell, A. J. Zurita, A. Y. Shah, E. Jonasch, S. F. Matin, C. G. Wood, J. A. Karam, P. Sharma, N. M. Tannir*
- Board 410 Abstract 4584: Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL.** *M. Boegemann, J. Bedke, M. Schostak, M. Welslau, C. Hering-Schubert, T. Wolf, J. Schleicher, A. Petzold, C. Doehn, C. Gr¼lllich, V. GrÅ¼nwald, T. Steiner, R. Ehness, D. Klein, T. Medinger, P. Goebell*
- Board 411 Abstract 4585: Nivolumab (nivo) for patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC): A single-institution experience.** *J. Chahoud, M. T. Campbell, J. Gao, A. J. Zurita, A. Y. Shah, P. Msaouel, J. A. Ross, L. Xiao, E. Jonasch, P. Sharma, N. M. Tannir*
- Board 412a Abstract TPS4586: Pembrolizumab (pembro) plus epacadostat or placebo for locally advanced or metastatic urothelial carcinoma (UC) after failure of first-line platinum-containing chemotherapy: KEYNOTE-698/ECHO-303.** *T. Powles, J. Bellmunt, D. P. Petrylak, L. Fong, H. Nishiyama, C. N. Sternberg, M. Chen, L. Pang, M. Munteanu, Y. Zhao, D. C. Smith*
- Board 412b Abstract TPS4587: Phase 3, randomized, double-blind trial of pembrolizumab plus epacadostat or placebo for cisplatin-ineligible urothelial carcinoma (UC): KEYNOTE-672/ECHO-307.** *A. V. Balar, E. R. Plimack, P. Grivas, A. Necchi, M. De Santis, L. Pang, S. M. Keefe, K. O'Hayer, Y. Zhao, R. De Wit*
- Board 413a Abstract TPS4588: A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).** *M. D. Galsky, T. Powles, S. Li, D. Hennicken, G. Sonpavde*
- Board 413b Abstract TPS4589: IMvigor130: A randomized, phase III study evaluating first-line (1L) atezolizumab (atezo) as monotherapy and in combination with platinum-based chemotherapy (chemo) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).** *M. D. Galsky, E. Grande, I. D. Davis, M. De Santis, J. Arranz Arijia, E. Kikuchi, A. Mecke, A. Thastrom, A. Bamias*
- Board 414a Abstract TPS4590: EV-201 Study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy.** *J. E. Rosenberg, E. I. Heath, P. H. O'Donnell, N. M. Hahn, A. V. Balar, E. M. Gartner, A. Melhem-Bertrandt, D. P. Petrylak*

- Board 414b Abstract TPS4591: Phase II randomized study of first line avelumab with carboplatin-gemcitabine versus carboplatin-gemcitabine alone in patients with metastatic urothelial carcinoma ineligible for cisplatin-based therapy.** *A. Rodriguez Vida, B. Mellado, X. Garcia del Muro, A. Taus, R. Morales Barrera, P. Maroto, T. Bonfill, M. Domenech, A. Pinto, B. Perez Valderrama, M. A. Climent, J. Puente, J. L. Perez-Gracia, E. González-Billalabeitia, F. Vazquez, S. Galtes, B. Pons, S. Macia, D. E. Castellano, J. Bellmunt*
- Board 415a Abstract TPS4592: ATLAS: A phase 2, open-label study of rucaparib in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).** *P. Grivas, D. L. Nepert, K. Wride, D. Thomas, A. Loehr, A. Simmons, S. Chowdhury*
- Board 415b Abstract TPS4593: A phase I-II study to evaluate safety and efficacy of the combination of niraparib plus cabozantinib in patients with advanced kidney/urothelial carcinoma.** *D. E. Castellano, M. A. Climent, I. Duran, B. Mellado, J. Paramio, F. X. Real, J. Ramirez, J. L. Sanz, A. Font Pous*
- Board 416a Abstract TPS4594: SPIRE: A phase Ib/randomised IIa open label clinical trial combining guadecitabine (SGI-110) with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer.** *S. J. Crabb, S. Danson, J. Catto, C. McDowell, D. Dunkley, R. A. Huddart, G. Griffiths*
- Board 416b Abstract TPS4595: PECULIAR: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (PEM) and epacadostat (EPA), preceding radical cystectomy (Cy), for patients (pts) with muscle-invasive urothelial bladder cancer (MIUBC).** *A. Necchi, A. Briganti, M. Bianchi, D. Raggi, P. Giannatempo, R. Luciano, M. Coecchia, N. Fossati, G. Gandaglia, R. Colombo, A. Gallina, A. Salonia, R. Salvioni, S. M. Ali, J. S. Ross, J. Chung, F. Montorsi*
- Board 417a Abstract TPS4596: P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs).** *P. S. Grimison, N. J. Lawrence, M. R. Stockler, A. J. Martin, S. Yip, N. Wong, A. Yeung, M. Friedlander, D. Mazhar, F. Pashankar, D. I. Quinn, R. McDermott, R. Walker, M. Winstanley, F. J. Hanning, A. J. Weickhardt, A. G. Stevanovic, I. D. Davis, G. C. Toner*
- Board 417b Abstract TPS4597: PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).** *L. C. Harshman, M. Puligandla, N. B. Haas, C. G. Drake, D. F. McDermott, S. Signoretti, D. Cella, R. T. Gupta, L. I. Wagner, B. M. Shuch, P. Lara Jr., T. K. Choueiri, A. Kapoor, D. Y. Heng, M. Michaelson, M. A. Jewett, E. M. Van Allen, D. J. George, M. A. Carducci, M. Allaf*
- Board 418a Abstract TPS4598: A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).** *T. K. Choueiri, A. B. Apolo, T. Powles, B. Escudier, O. R. Aren, A. Shah, E. R. Kessler, J. J. Hsieh, J. Zhang, B. Simsek, C. Scheffold, R. J. Motzer*
- Board 418b Abstract TPS4599: KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.** *T. K. Choueiri, D. I. Quinn, T. Zhang, H. Gurney, G. K. Doshi, P. W. Cobb, F. Parnis, J. Lee, S. Park, A. Semenov, W. Chang, S. M. Wan, C. H. Poehlein, T. Powles*
- Board 419a Abstract TPS4600: Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study.** *X. X. Wei, R. R. McKay, K. P. Gray, W. M. Stadler, D. F. McDermott, B. A. McGregor, N. Agarwal, C. Kyriakopoulos, B. A. Carneiro, T. L. Rose, Y. Zakharia, D. A. Braun, K. J. Livak, C. J. Wu, E. M. Van Allen, S. Signoretti, J. M. Lang, F. S. Hodi, T. K. Choueiri, L. C. Harshman*
- Board 419b Abstract TPS4601: CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma.** *N. M. Tannir, R. J. Motzer, N. Agarwal, P. Liu, S. H. Whiting, B. O'Keeffe, X. Tran, G. P. Fiji, B. Escudier*

Saturday, June 2, 2018

- Board 420a Abstract TPS4602: NIVES study: A phase II trial of nivolumab (NIVO) plus stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC).** *C. Masini, C. Iotti, P. Ciammella, R. Gnani, A. Berselli, M. Vitale, U. De Giorgi, C. Mucciarini, S. Buti, G. Procopio, R. Iacovelli, G. V. Scagliotti, S. Bracarda, O. Caffo, F. Morelli, C. Bengala, F. Nole, S. Baier, S. Panni, C. Pinto*
- Board 420b Abstract TPS4603: CABOPRE: Phase II study of cabozantinib prior to cytoreductive nephrectomy (CN) in locally advanced and/or metastatic renal cell carcinoma (mRCC).** *G. de Velasco, B. González, T. Alonso, A. Pinto, J. Rodriguez-Moreno, J. M. Sepúlveda, J. Villa, N. Miranda, F. Guerrero, D. E. Castellano*
- Board 421a Abstract TPS4604: A phase 2, single-arm trial of neoadjuvant axitinib plus avelumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).** *A. Bex, J. V. Van Thienen, M. Schrier, K. Hendricksen, C. U. Blank, J. B. Haanen*
- Board 421b Abstract TPS4605: Vorolanib (CM082), everolimus, and the combination in patients with pretreated metastatic renal cell carcinoma (CONCEPT study): A randomized, phase 2/3, double-blind, multi-center trial.** *J. Guo, X. Sheng, D. Ye, Z. He, A. Zhou, X. Yao, Z. Wang, B. Shi, X. Tu, Y. Zhang, C. He, C. Fu, Z. Ji, B. Yang, B. Wu, S. Qin, Z. Hu, F. Zhou, F. Tan*

8:00 AM - 11:30 AM Poster Session

Pediatric Oncology

Location: Hall A

Abstracts on Boards 191-202 will be discussed during the Pediatric Oncology Poster Discussion Session.

Posters by Topic

Leukemia/Lymphoma: Boards 191, 199, 202-204

Pediatric Solid Tumors: Boards 192-198, 201, 205-232

Survivorship: Boards 233-246

Symptom Management/Supportive Care/Palliative Care: Boards 200, 247

Trials in Progress: Boards 248a-248b

- Board 191 Abstract 10518: Matched targeted therapy for pediatric patients with relapsed, refractory or high-risk leukemias: A report from the LEAP consortium.** *Y. Pikman, S. K. Tasian, M. Sulis, T. M. Blonquist, K. W. Maloney, J. L. McNeer, M. G. Pauly, N. N. Shukla, J. Tyner, P. D. Cole, M. J. Burke, N. Gossai, P. A. Brown, L. Gore, S. Hunger, T. M. Cooper, L. B. Silverman, M. H. Harris, M. L. Loh, K. Stegmaier*
- Board 192 Abstract 10519: Aqueous humor genomics predicts eye salvage in retinoblastoma.** *L. Xu, J. Berry, J. Hicks, P. Kuhn, R. Prabakar*
- Board 193 Abstract 10520: Parallel genomic and immune profiling of relapsed and metastatic osteosarcoma to reveal bases of low immunogenicity.** *J. A. Livingston, H. Beird, C. Wu, S. Cao, S. M. Advani, D. Ingram, W. Wang, A. J. Lazar, C. Leung, H. Y. Lin, A. Reuben, Y. Zheng, J. Roszik, S. Patel, R. S. Benjamin, R. G. Gorlick, V. O. Lewis, A. Futreal, N. C. Daw*
- Board 194 Abstract 10521: The influence of surgical excision on survival in high-risk neuroblastoma revisited after introduction of ch14.18/CHO immunotherapy in the HR-NBL1/SIOPEN trial.** *K. Holmes, U. Poetschger, S. Sarnacki, T. Monclair, G. Cecchetto, J. Gomez Chacon, J. Stenman, J. Joseph, R. Luksch, V. Castel, S. Ash, V. Papadakis, J. Malis, W. Balwierz, C. Owens, H. N. Lode, T. Boterberg, D. Valteau Couanet, A. D. Pearson, R. L. Ladenstein*

- Board 195 **Abstract 10522: A phase I NANT study of lenalidomide with ch14.18 and isotretinoin (RA) in patients with refractory/recurrent neuroblastoma (RR-NB).** *A. Marachelian, J. Villablanca, A. Duvalyan, S. Czarnnecki, S. G. Groshen, D. Tsao-Wei, R. Sposto, J. Malvar, J. Sun, K. C. Goldsmith, Y. P. Mosse, M. Granger, N. Seibel, J. Moscow, K. K. Matthay, M. Sheard, R. Seeger*
- Board 196 **Abstract 10523: ROR1-specific CAR for neuroblastoma using *sleeping beauty*-modified t cells.** *F. N. Hernandez Tejada, A. Najjar, A. D. Guerrero, L. G. Flores II, H. Singh*
- Board 197 **Abstract 10524: Survival and delayed effects of risk-stratified hepatoblastoma patients treated in the JPLT-2 trial.** *E. Hiyama, S. Kurihara, Y. Ueda, T. Hishiki, K. Ida, K. Watanabe, M. Yano, Y. Tanaka, K. Hoshino, K. Hiyama*
- Board 198 **Abstract 10525: KEYNOTE-051: An update on the phase 2 results of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1–positive advanced, relapsed or refractory solid tumor or lymphoma.** *B. Geoerger, H. Kang, M. Yalon-Oren, L. V. Marshall, C. Vezina, A. S. Pappo, T. W. Laetsch, A. Petrilli, M. Ebinger, J. Toporski, J. Glade-Bender, W. Nicholls, E. Fox, S. G. DuBois, M. Macy, S. L. Cohn, K. Pathiraja, S. J. Diede, S. Ebbinghaus, N. R. Pinto*
- Board 199 **Abstract 10526: The association between atopy and Hodgkin’s lymphoma in teenagers and young adults: A UK nationwide case control study.** *M. Rafiq, S. Thomas, C. Warren-Gash, A. Hayward*
- Board 200 **Abstract 10527: Intravenous fosaprepitant for the prevention of chemotherapy induced vomiting in children: A double blind placebo controlled, phase III randomized trial.** *A. Joshi, V. Radhakrishnan, J. Ramamoorthy, T. S. Ganesan, S. Rajaraman, P. Ganesan, M. Dhanushkodi, T. G. Sagar*
- Board 201 **Abstract 10528: The challenge of pediatric oncology: New business models to accelerate innovation.** *S. Das, R. F. Rousseau, P. C. Adamson, A. W. Lo*
- Board 202 **Abstract 10529: The social value of tisagenlecleucel, a CAR-T cell therapy, for the treatment of relapsed or refractory pediatric acute lymphoblastic leukemia in the United States: What are consequences of treatment delays?** *J. T. Snider, M. Brauer, K. Batt, P. Karaca-Mandic, J. Zhang, D. P. Goldman*
- Board 203 **Abstract 10530: Association of regulatory- and helper-T cells with inferior survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2.** *H. N. Lode, S. Troschke-Meurer, M. Marx, M. Zumpe, K. Ehlert, H. Loibner, R. L. Ladenstein, N. Siebert*
- Board 204 **Abstract 10531: Evaluation of pegaspargase (PEG-ASP) adverse events among adolescents and young adults (AYAs) and younger patients with lymphoid malignancies (LM) at the Children’s Hospital of Eastern Ontario (CHEO).** *N. Mathies, I. Laforest, K. Tang, G. Goulet, L. S. Abbott*
- Board 205 **Abstract 10532: Predictors of differential response to induction chemotherapy in high-risk neuroblastoma: A report from the Children’s Oncology Group (COG).** *N. R. Pinto, E. Hibbits, S. G. Kreissman, M. P. Granger, M. Irwin, R. Bagatell, W. B. London, E. G. Greengard, A. Naranjo, J. R. Park, S. G. DuBois*
- Board 206 **Abstract 10533: The addition of cycles of irinotecan/temozolomide (i/T) to cycles of vincristine, doxorubicin, cyclophosphamide (VDC) and cycles of ifosfamide, etoposide (IE) for the treatment of Ewing sarcoma (ES).** *P. A. Meyers, S. R. Ambati, E. K. Slotkin, F. Dela Cruz, L. H. Wexler*
- Board 207 **Abstract 10534: Rhabdomyosarcoma in the first year of life. outcome data from five trials and one registry of the Cooperative Weichteilsarkom Studiengruppe (CWS).** *M. Sparber-Sauer, S. Stegmaier, C. Vokuhl, I. Leuschner, G. Seitz, T. von Kalle, M. Scheer, M. W. Muentner, S. S. Bielack, B. Kazanowska, R. Ladenstein, F. Niggli, G. Ljungman, T. Klingebiel, J. Fuchs, S. Hettmer, E. Koscielniak*

Saturday, June 2, 2018

- Board 208 **Abstract 10535: Phase 1/2 intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia.** *C. van Tilburg, T. Milde, R. Witt, J. Ecker, A. Seitz, J. Schenk, M. Fruehwald, A. Pekrun, C. Rössig, R. Wieland, C. Floth, U. Kordes, B. Gruhn, T. Simon, C. Linderkamp, L. Taylor, J. Burhenne, S. Pfister, I. Karapanagiotou-Schenkel, O. Witt*
- Board 209 **Abstract 10536: Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors.** *A. V. Desai, G. M. Brodeur, J. Foster, S. L. Berg, E. M. Basu, S. Shusterman, A. J. Sabnis, M. Macy, J. Yoon, K. Gauvain, V. Esquibel, E. Chow Maneval, P. S. Multani, E. Fox*
- Board 210 **Abstract 10537: Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN).** *B. Geoerger, C. L. Moertel, J. Whitlock, G. B. McCowage, M. W. Kieran, A. Broniscer, D. R. Hargrave, P. Hingorani, L. B. Kilburn, S. Mueller, L. Tseng, N. Nebot, K. Dasgupta, M. W. Russo, E. Fox*
- Board 211 **Abstract 10538: G₂₂ as a circulating tumor biomarker (CTB) for neuroblastoma (NBL).** *F. M. Balis, C. Busch, A. V. Desai, E. Hibbits, A. Naranjo, R. Bagatell, M. Irwin, E. Fox*
- Board 212 **Abstract 10539: Immunotherapy with anti-GD2 antibody ch14.18/CHO±IL2 within the HR-NBL1/SIOPEN trial to improve outcome of high-risk neuroblastoma patients compared to historical controls.** *R. L. Ladenstein, U. Poetschger, D. Valteau Couanet, J. Gray, R. Luksch, V. Castel, S. Ash, G. Laureys, C. Owens, T. Trahair, G. C. Chan, E. Ruud, H. Schroeder, M. Beck Popovic, H. Loibner, G. Schreier, P. F. Ambros, S. Sarnacki, T. Boterberg, H. N. Lode*
- Board 213 **Abstract 10540: Cediranib phase II study in children with metastatic alveolar soft part sarcoma (ASPS).** *J. Glod, J. W. Cohen, B. C. Widemann, A. Goodwin, J. Derdak, E. Dombi, O. B. Kapustina, S. M. Steinberg, G. O'Sullivan, S. Kummar, A. P. Chen*
- Board 214 **Abstract 10541: Phase 1 study of olaratumab as monotherapy and in combination with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide in pediatric patients with relapsed or refractory solid tumors: Part A results.** *S. G. DuBois, B. Weigel, T. W. Laetsch, M. Macy, D. E. Levy, G. Mo, J. A. Wright, L. Mascarenhas*
- Board 215 **Abstract 10542: Phase I multicenter trial of CUDC-907 in children and young adults with relapsed/refractory solid tumors, CNS tumors, and lymphomas.** *D. S. Shulman, C. Carlowicz, C. Gustafson, K. T. Vo, E. Fox, J. A. Muscal, J. G. Supko, A. E. Place, S. N. Chi, S. Shusterman, G. Hanna, J. O'Brien, S. Ezrre, P. Kao, W. B. London, S. G. DuBois*
- Board 216 **Abstract 10543: First-in-child trial of celyvir (autologous mesenchymal stem cells carrying the oncolytic virus ICOVIR-5) in patients with relapsed and refractory pediatric solid tumors.** *M. Ramirez, D. Ruano, L. Moreno, Á. Lassaletta, F. Sirvent, M. Andión, C. Hernández, Á. González-Murillo, G. Melen, R. Alemany, J. García-Castro, L. Madero*
- Board 217 **Abstract 10544: Various checkpoint proteins, and tumor infiltrating lymphocytes in common pediatric solid tumors: Possibilities for novel immunotherapy.** *K. Mochizuki, S. Kawana, M. Muramatsu, H. Sano, S. Kobayashi, Y. Ohara, N. Takahashi, Y. Hashimoto, A. Kikuta*
- Board 218 **Abstract 10545: Visceral primary non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) in patients < 30 years of age: Findings of Children's Oncology Group (COG) study ARST0332.** *M. Kadappakam, J. Weng, S. L. Spunt, M. B. McCarville, L. Million, S. M. Hiniker, D. A. Barkauskas, D. S. Hawkins*
- Board 219 **Abstract 10546: Risk group accurately predicts outcome in primary extremity non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) in patients <30 years of age: Findings from Children's Oncology Group study ARST0332.** *S. F. Kreimer, D. Shen, S. L. Spunt, S. C. Kao, D. Parham, S. S. Donaldson, M. Ladra, M. J. Monument, D. A. Barkauskas, D. S. Hawkins, R. Randall*

- Board 220 **Abstract 10547: Nasopharyngeal carcinoma in children: Demographic, clinical, therapeutic characteristics and long term outcome of 97 patients.** *R. Kebudi, M. Altun, S. Bay Buyukkapu, O. Gorgun, R. Meral, I. Ayan, B. Zulfikar, F. Yaman Agaoglu, E. Darendeliler*
- Board 221 **Abstract 10548: Outcomes for young children with molecularly defined ependymoma treated on the multi-institutional SJYC07 clinical trial.** *S. Upadhyaya, G. W. Robinson, B. Orr, A. Onar-Thomas, C. A. Billups, G. T. Armstrong, Z. S. Sadighi, T. Hassall, D. C. Bowers, A. E. Bendel, J. R. Crawford, S. Partap, P. Klimo Jr., J. H. Harrel, C. L. Tinkle, D. J. Indelicato, F. A. Boop, T. E. Merchant, D. W. Ellison, A. J. Gajjar*
- Board 222 **Abstract 10549: Final results of the phase II, single arm trial of irinotecan and cisplatin in children with high-risk glial tumors.** *O. Cruz, J. Mora, M. Suñol, J. Vinent, E. Rodriguez, J. Muchart, C. Trampal, V. Caloretti, A. Guillen, C. de Torres*
- Board 223 **Abstract 10550: Risk prediction based on post induction bone marrow response and genomic profile: A new way to stratify stage M neuroblastoma patients?** *S. Fiedler, R. L. Ladenstein, U. Poetschger, R. Abbasi, A. Vicha, S. Ash, A. Garaventa, G. C. Chan, W. Balwierz, M. Ussowicz, D. Tweddle, G. Schleiermacher, G. Mann, A. Gabriel, M. Jeison, J. Kljanienco, M. Morini, D. Valteau Couanet, I. M. Ambros, P. F. Ambros*
- Board 224 **Abstract 10551: Pediatric preclinical testing consortium evaluation of the EZH2 inhibitor tazemetostat in orthotopic PDX models of pediatric brain tumors.** *X. Li, L. Qi, M. Kogiso, H. B. Lindsay, S. W. Erickson, Y. Guo, M. A. Smith, B. A. Teicher*
- Board 225 **Abstract 10552: Preclinical effect of selinexor (KPT-330), a selective inhibitor of nuclear export, in pediatric rhabdoid tumors.** *L. J. Marks, D. Diolaiti, P. S. Mundi, E. Gaviria, A. Rainey, F. Dela Cruz, A. Califano, A. Kung*
- Board 226 **Abstract 10553: Identification and validation of a 24-gene expression signature for subtype classification of medulloblastoma.** *Q. Xu, Q. WANG, J. Chen, C. Chen, Y. Sun, L. Chen, X. Du*
- Board 227 **Abstract 10554: Plasma cell-free DNA for noninvasive molecular profiling in high-risk stage 4 neuroblastoma.** *P. Kothari, J. Yang, M. F. Berger, N. N. Shukla, S. Modak, D. Tsui*
- Board 228 **Abstract 10555: Prospective study of ophthalmic artery chemosurgery (OAC) as alternative to enucleation in retinoblastoma.** *I. Aerts, R. Blanc, C. Saint Martin, A. Savignoni, N. Cassoux, L. Desjardins, F. P. Doz, C. Levy-gabriel, L. Lumbruso-Le Rouic*
- Board 229 **Abstract 10556: ADVL1513: Results of a phase 1 trial of entinostat, an oral histone deacetylase inhibitor, in pediatric patients with recurrent or refractory solid tumors.** *S. Malempati, B. H. Chang, J. M. Reid, X. Liu, C. G. Minard, C. Keller, E. Fox, B. Weigel*
- Board 230 **Abstract 10557: In vitro and xenograft anti-tumor activity, target modulation and drug synergy studies of PV-10 against refractory pediatric solid tumors.** *L. Swift, C. Zhang, T. M. Trippett, A. Narendran*
- Board 231 **Abstract 10558: NANT 2012-01: Phase 1 study of DFMO and celecoxib with cyclophosphamide and topotecan for relapsed or refractory high-risk neuroblastoma.** *A. Marachelian, M. D. Hogarty, A. Flynn, K. Liu, E. W. Gerner, E. Bruckheimer, A. Shamirian, C. Hasenauer, M. Norris, M. Haber, S. G. Groshen, D. S. Ziegler, K. K. Matthay*
- Board 232 **Abstract 10559: Gene expression analysis for improved subtyping of high-risk neuroblastoma.** *J. Pfeil, A. Thornton, A. Durbin, E. Kephart, H. Beale, L. Sanders, I. Bjork, O. Morozova, S. R. Salama, D. Haussler*
- Board 233 **Abstract 10560: Impact of survivorship care plans (SCPs) on adherence to surveillance for second malignant neoplasms (SMNs) and cardiac dysfunction in the Childhood Cancer Survivor Study (CCSS).** *A. P. Yan, Y. Chen, M. M. Hudson, T. M. Gibson, J. P. Neglia, K. C. Oeffinger, W. M. Leisenring, K. K. Ness, J. Ford, T. O. Henderson, L. L. Robison, G. T. Armstrong, Y. Yasui, P. C. Nathan*

Saturday, June 2, 2018

- Board 234 **Abstract 10561: Cardiac outcomes in childhood cancer survivors (CCS): A population-based study.** *A. Khanna, P. Pequeno, S. Gupta, P. Thavendiranathan, H. Abdel-Qadir, D. Lee, P. C. Nathan*
- Board 235 **Abstract 10562: The effect of medical social rehabilitation on quality of life in children with brain tumors: Interim results of observational prospective study.** *G. J. Tseitlin, A. G. Romyantsev, A. F. Karelin, M. J. Kokoreva, I. D. Borodina, T. P. Nikitina, A. V. Zinkovskaya, N. M. Porfir'eva, T. I. Ionova*
- Board 236 **Abstract 10563: Neurofibromatosis type 1 and risk of late outcomes after a primary tumor: A report from the Childhood Cancer Survivor Study.** *P. de Blank, N. Li, N. J. Ullrich, M. J. Fisher, S. Bhatia, Y. Yasui, C. A. Sklar, W. M. Leisenring, R. M. Howell, K. C. Oeffinger, K. K. Hardy, M. F. Okcu, T. M. Gibson, L. L. Robison, G. T. Armstrong, K. R. Krull*
- Board 237 **Abstract 10564: Radiation dose and volume to the pancreas and subsequent risk of diabetes mellitus: A report from the Childhood Cancer Survivor study.** *D. N. Friedman, P. Hilden, C. S. Moskowitz, R. M. Howell, R. Weathers, S. A. Smith, S. L. Wolden, E. S. Tonorezos, S. Mostoufi-Moab, E. J. Chow, L. Meacham, J. Whitton, W. Leisenring, L. L. Robison, G. T. Armstrong, K. C. Oeffinger, C. A. Sklar*
- Board 238 **Abstract 10565: Exercise intolerance among survivors of childhood cancer exposed to cardiotoxic therapy: Identification of survivors at increased risk through myocardial strain and ejection fraction.** *K. K. Ness, J. Plana Gomez, V. Joshi, R. V. Luepker, J. Durand, D. M. Green, R. Partin, MS, A. Santucci, D. K. Srivastava, M. M. Hudson, L. L. Robison, G. T. Armstrong*
- Board 239 **Abstract 10566: Long-term renal function after treatment for Wilms tumor. A report from the St. Jude Lifetime Cohort (SJLIFE) study.** *D. M. Green, M. Wang, M. J. Krasin, A. M. Davidoff, D. K. Srivastava, D. W. Jay, K. K. Ness, B. L. Shulkin, J. Q. Lancot, K. C. Shelton, R. C. Brennan, M. J. Ehrhardt, T. M. Gibson, B. A. Kurt, L. L. Robison, M. M. Hudson, S. L. Spunt*
- Board 240 **Abstract 10567: Racial/ethnic differences in neurocognitive, emotional and quality of life outcomes in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).** *S. Dixon, N. Li, Y. Yasui, S. Bhatia, J. N. Casillas, T. M. Gibson, W. Leisenring, K. K. Ness, J. Porter, L. L. Robison, M. M. Hudson, K. R. Krull, G. T. Armstrong*
- Board 241 **Abstract 10568: Chronic pain and disability in long-term survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).** *C. Karlson, N. M. Alberts, W. Liu, T. M. Brinkman, R. Annett, D. A. Mulrooney, F. Schulte, W. Leisenring, T. M. Gibson, R. M. Howell, D. Srivastava, K. C. Oeffinger, G. T. Armstrong, L. K. Zeltzer, K. R. Krull*
- Board 242 **Abstract 10569: Is physical activity and cardiorespiratory fitness reduced among childhood cancer survivors?** *D. Mizrahi, C. Wakefield, D. Simar, A. Maguire, G. Hubbard, J. Fardell, J. McBride, P. Field, R. J. Cohn*
- Board 243 **Abstract 10570: Neurologic morbidities, psychological distress, and functional independence in adult survivors of childhood cancer treated with CNS-directed therapies: A report from the Childhood Cancer Survivor Study.** *S. C. Vuotto, K. R. Krull, C. Li, M. F. Okcu, D. C. Bowers, N. J. Ullrich, D. Srivastava, R. M. Howell, T. M. Gibson, W. M. Leisenring, K. C. Oeffinger, L. L. Robison, G. T. Armstrong, T. M. Brinkman*
- Board 244 **Abstract 10571: Longitudinal assessment of patient-reported cumulative symptom burden as an indicator of chronic health conditions in adult survivors of childhood cancer: A joint report of the St. Jude Lifetime Cohort (SJLIFE) and the Childhood Cancer Survivor Study (CCSS).** *I. Huang, M. J. Ehrhardt, C. Li, D. A. Mulrooney, W. Chemaitilly, D. Srivastava, G. T. Armstrong, L. L. Robison, M. M. Hudson, K. R. Krull*
- Board 245 **Abstract 10572: The impact of CMV reactivation on HSCT outcomes in children with malignancies: A 13 years single center experience.** *F. Baccelli, A. Di Gangi, S. Bernasconi, G. Casazza, C. Favre, M. Menconi*

- Board 246 Abstract 10573: Comprehensive molecular characterization of pediatric treatment-induced glioblastoma: Germline DNA repair defects as a potential etiology.** *J. T. Lucas, J. DeSisto, G. Wu, A. Donson, S. Baker, M. A. Arnold, S. Bhatia, P. Flannery, R. Lemma, L. M. Hardie, L. M. Hoffman, K. Doris, A. Liu, N. K. Foreman, R. Vibhakar, S. Allen, T. E. Merchant, A. L. Green, B. Orr*
- Board 247 Abstract 10574: Retrospective study of age-adjusted growth patterns for height, weight and body mass index in pediatric acute leukemia and lymphoma.** *C. Phillips, H. Razzaghi, J. Huang, C. Bailey*
- Board 248a Abstract TPS10575: Open-label, dose-escalation, phase 1 study of venetoclax in combination with navitoclax and chemotherapy in patients with relapsed acute lymphoblastic leukemia.** *T. Alexander, S. L. Khaw, J. E. Rubnitz, S. I. Vear, N. J. Lacayo, M. Schmidt, B. Tong, L. Rosenwinkel, L. Bensman, M. Verdugo, S. Kim, E. Jabbour, W. Stock*
- Board 248b Abstract TPS10576: Phase 1 multicenter trial to assess the maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma.** *K. T. Vo, J. G. Michlitsch, A. T. Shah, J. Long-Boyle, M. Kim, C. Gustafson, A. Sweet-Cordero, K. K. Matthay, S. G. DuBois*

8:00 AM - 11:30 AM Poster Session

Sarcoma

Location: Hall A

Abstracts on Boards 254-265 will be discussed during the Sarcoma Poster Discussion Session.

Posters by Topic

Bone Tumors: Boards 264-273

Gastrointestinal Stromal Tumors (GIST): Boards 254-256, 275-284

Soft Tissue: Boards 257-263, 285-330

Trials in Progress: Boards 331a-333b

- Board 254 Abstract 11509: A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST).** *A. J. Wagner, W. D. Tap, A. F. Shields, A. Patnaik, R. Chugh, G. Tinoco, G. Michelson, O. Alcantar, M. Pelayo, C. Zhang, P. Severson, E. Martin, J. C. Trent II*
- Board 255 Abstract 11510: Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST).** *C. Serrano, A. Leal, J. Phallen, A. Marino-Enriquez, Y. Kuang, O. Triplett, J. A. Morgan, C. Barysaukas, A. J. Wagner, G. D. Demetri, V. E. Velculescu, C. Paweletz, J. A. Fletcher, S. George*
- Board 256 Abstract 11511: Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618.** *S. George, M. C. Heinrich, A. R. Abdul Razak, P. Chi, M. S. Gordon, K. N. Ganjoo, M. von Mehren, N. Somaiah, J. C. Trent II, Y. Su, R. Ruiz-Soto, O. Rosen, F. Janku*
- Board 257 Abstract 11512: Phase 2 results of selinexor in advanced de-differentiated (DDLs) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.** *M. M. Gounder, N. Somaiah, S. Attia, S. P. Chawla, V. M. Villalobos, B. Chmielowski, M. A. Burgess, G. K. Schwartz, R. F. Riedel, M. von Mehren, A. J. Wagner, E. Choy, S. Verma, B. Mudenda, M. Sadanowicz, J. J. Shah, L. Li, S. Shacham, M. G. Kauffman, A. R. Abdul Razak*

- Board 258 **Abstract 11513: Whole exome sequencing (WES) of metastatic leiomyosarcoma (LMS) and liposarcoma (LPS) and correlation of genomic aberrations with clinical outcomes in the phase III randomized trial of trabectedin (T) vs. dacarbazine (D).** *G. Kapoor, W. Li, D. Shen, R. E. Knoblauch, M. Gormley, G. C. Wang, D. S. Ricci, M. P. Smith, C. Motley, S. Malbrain, R. G. Maki, M. vonMehren, S. Patel, G. D. Demetri*
- Board 259 **Abstract 11514: A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma(WD/DD LPS), solid tumors (ST) and lymphomas (L).** *T. M. Bauer, M. M. Gounder, A. M. Weise, G. K. Schwartz, R. D. Carvajal, P. Kumar, O. Zernovak, A. Beck, J. Doyle, J. Mendell-Harary, J. P. Kochan, S. Chen, P. LoRusso, W. D. Tap, N. Somaiah, D. M. Hyman, F. Meric-Bernstam, D. S. Hong*
- Board 260 **Abstract 11515: IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) Sarcoma Groups phase I/II trial of sunitinib plus nivolumab in selected bone and soft tissue sarcoma subtypes—Results of the phase I part.** *J. Martin Broto, N. Hindi, A. Redondo, J. Martinez-Trufero, S. Stacchiotti, E. Palmerini, E. Alava, D. S. Moura, H. Perez Vega, I. Otero, P. Ledesma, E. Marchesi, J. A. Lopez-Martin*
- Board 261 **Abstract 11516: A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with metastatic sarcoma.** *C. M. Kelly, T. G. Bowler, R. R. Munhoz, P. Chi, M. A. Dickson, M. M. Gounder, M. Keohan, R. Dholakia, M. M. Condy, S. Singer, A. M. Crago, S. S. Yoon, C. E. Ariyan, S. Hwang, J. P. Erinjeri, C. R. Antonescu, L. Qin, W. D. Tap, S. P. D'Angelo*
- Board 262 **Abstract 11517: Compared descriptive analysis of immunologic landscape in soft tissue sarcoma and GIST.** *A. Dufresne, T. Lesluyes, M. Brahmi, C. Menetrier-Caux, C. Caux, J. Blay, F. Chibon*
- Board 263 **Abstract 11518: Prognostic stratification using the nomogram sarculator and its impact on study results in a randomized controlled trial (RCT) for localized soft tissue sarcomas (STS): A secondary analysis of the EORTC-STBSG 62931.** *S. Pasquali, S. Pizzamiglio, N. Touati, S. Litiere, S. Marreaud, B. Kasper, H. Gelderblom, S. Stacchiotti, P. Verderio, P. G. Casali, P. Woll, A. Gronchi*
- Board 264 **Abstract 11519: Efficacy and safety of lurbinectedin (PM1183) in Ewing sarcoma: Final results from a phase 2 study.** *V. Subbiah, K. K. Sankhala, R. Ratan, E. Sanz Garcia, V. Boni, T. Gil, V. M. Villalobos, S. P. Chawla, P. Lardelli, M. Siguero, C. M. Kahatt, A. Soto-Matos, S. Ferrari*
- Board 265 **Abstract 11520: Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: An open label phase 2 clinical trial.** *L. Xie, J. Xu, X. Sun, X. Tang, T. Yan, R. Yang, W. Guo*
- Board 266 **Abstract 11521: Neoadjuvant denosumab for the treatment of resectable giant cell tumor of bone: First results of Russian multicenter study.** *A. A. Fedenko, A. Tararykova*
- Board 267 **Abstract 11522: Genome and transcriptome profiling of relapsed and metastatic osteosarcoma.** *C. Wu, H. Beird, S. Cao, S. M. Advani, D. Ingram, W. Wang, A. J. Lazar, A. Reuben, Y. Zheng, J. Roszik, R. G. Gorlick, R. S. Benjamin, S. Patel, N. C. Daw, A. Futreal, V. O. Lewis*
- Board 268 **Abstract 11523: Rare bone sarcoma: A retrospective analysis of 149 adult patients from the French Sarcoma Group.** *P. Boudou-Rouquette, E. Martin, E. Kempf, N. Penel, A. Italiano, F. Duffaud, E. Bompas, N. Firmin, F. Bertucci, J. Kurtz, L. Chaigneau, N. Isambert, A. Thyss, J. Bay, C. Chevreau, J. Blay, S. Piperno-Neumann*
- Board 269 **Abstract 11524: Drug repurposing as a source of innovative therapies in osteosarcoma.** *G. Bouche, P. Pantziarka*
- Board 270 **Abstract 11525: Can DNA methylation patterns be used as predictive biomarkers for chemotherapy response in osteosarcoma?** *S. Mukherjee, M. A. Jeffries, A. Rivas, R. Malik, S. Ibrahim, K. Fung, J. White, W. H. Meyer, S. Vesely, D. A. Barkauskas, D. Hall, M. A. Cherry*

- Board 271 **Abstract 11526: Comprehensive genomic profiling of sarcomas in Chinese population.** *J. Lin, Q. Bi, H. Shen, Y. Jiang, Y. Liu, X. Mo, Y. Lei, Y. Xiao, S. Dong, Y. Yang, T. Yuan, F. Yang, M. Han, H. Dong, J. Wang, F. Li, Y. Ai*
- Board 272 **Abstract 11527: Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to \leq 25 years with relapsed/refractory osteosarcoma (OS).** *N. Gaspar, M. Casanova, F. Sirvent, R. Venkatramani, B. Morland, M. Gambart, E. Thebaud, S. J. Strauss, F. Locatelli, S. Gallego Melcon, A. Canete, S. S. Bielack, C. Rossig, I. Aerts, P. Marec-Berard, S. Kraljevic, S. Hayato, C. He, C. E. Dutcus, Q. Campbell-Hewson*
- Board 273 **Abstract 11528: A comparison of outcomes, presentation, and treatment in pediatric (Ped) versus adult patients (Pts) with Ewing sarcoma.** *E. B. Schwartz, L. Zhao, B. Siontis, L. H. Baker, R. Rao, E. R. Lawlor, S. Schuetze, R. Chugh*
- Board 275 **Abstract 11530: To compare the efficacy of sunitinib and imatinib following cytoreductive resection in GIST patients with progression on imatinib: A multi-center controlled study.** *X. Zhang, Y. Zhou, X. Wu, M. Nie, B. Zhang Sr., L. Sun, X. Liu, Z. Liu, Y. Kou, Y. Wang, Y. Zhang, J. Li, L. Shen*
- Board 276 **Abstract 11531: The prognostic value of blood neutrophil-to-lymphocyte ratio (NLR) factor in advanced gastrointestinal stromal tumors (GIST) treated with sunitinib after imatinib failure.** *P. Rutkowski, I. Lugowska, A. Klimczak, E. Bylina, B. Jagielska, P. Teterycz*
- Board 277 **Abstract 11532: Role of resection following focal progression with standard doses of imatinib in patients with advanced gastrointestinal stromal tumor: Results of propensity score analyses.** *H. Cho, M. Ryu, K. Kim, Y. Lee, J. Kim, M. Kim, S. Lee, Y. Park, C. Kim, B. Kim, M. Yoo, Y. Kang*
- Board 278 **Abstract 11533: A retrospective natural history study of patients (pts) with PDGFR α D842V mutant advanced gastrointestinal stromal tumor (GIST) previously treated with a tyrosine kinase inhibitor (TKI).** *M. von Mehren, M. C. Heinrich, H. Shi, P. McNamara, K. K. Mamlouk, A. Boral, S. George*
- Board 279 **Abstract 11534: Immune microenvironment profiling of gastrointestinal stromal tumors (GIST).** *M. A. Pantaleo, V. Indio, G. Tarantino, C. Agostinelli, M. Urbini, M. Nannini, M. Saponara, C. Castelli, S. Stacchiotti, L. Gatto, D. Santini, A. De Leo, A. Pession, A. Astolfi*
- Board 280 **Abstract 11535: LMTK3 to regulate the translation of oncogenic KIT in GIST regardless of imatinib sensitivity.** *L. R. Klug, A. Bannon, N. Javidi-Sharifi, A. Town, W. H. Fleming, J. VanSlyke, L. Musil, J. A. Fletcher, J. Tyner, M. C. Heinrich*
- Board 281 **Abstract 11536: Interrogating the sarcoma immune microenvironment (iME) using multiplex immunohistochemistry (miHC).** *A. Silverman, M. Ingham, R. D. Gartrell, D. K. Marks, H. R. Park, T. D. Hart, C. L. Esancy, Y. Lu, F. Remotti, H. E. Remotti, Y. M. Saenger, G. K. Schwartz*
- Board 282 **Abstract 11537: Phase II trial of continuous dosing of regorafenib in patients with metastatic or recurrent gastrointestinal stromal tumors (GISTs) after failure of imatinib and sunitinib.** *Y. Kang, J. Kim, C. Yoo, M. Beck, J. Ma, M. Ryu*
- Board 283 **Abstract 11538: Impact of proton pump inhibitors (PPIs) on sunitinib (SU) pharmacokinetics (PK) and activity in GIST patients (pts).** *O. Mir, R. Coriat, A. Paci, C. Honoré, M. Faron, S. N. Dumont, P. Terrier, J. Adam, A. Le Cesne*
- Board 284 **Abstract 11539: Utility of circulating tumor DNA (ctDNA) in the management of patients with gastrointestinal stromal tumor (GIST): Analysis of 152 patients.** *J. Arshad, A. Roberts, R. J. Nagy, B. A. Wilky, J. C. Trent II*
- Board 285 **Abstract 11540: Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE.** *P. Schöffski, A. Wozniak, B. Kasper, S. Aamdal, M. G. Leahy, P. Rutkowski, S. Bauer, H. Gelderblom, A. Italiano, L. H. Lindner, I. M. Hennig, S. J. Strauss, B. Zakotnik, A. Anthoney, B. Geoerger, J. Blay, P. Reichardt, W. T. van der Graaf, S. Marreaud, S. Stacchiotti*

Saturday, June 2, 2018

- Board 286 **Abstract 11541: Anti CXCR4 antibody combined with activated and expanded natural killer cells for sarcoma immunotherapy.** *M. Vela*
- Board 287 **Abstract 11542: Phase 1b/2 study of olaratumab plus gemcitabine and docetaxel for the treatment of advanced soft tissue sarcoma (STS) (ANNOUNCE 2): Phase 1b results.** *V. M. Villalobos, A. Redondo, B. A. Van Tine, G. K. Schwartz, M. A. Dickson, B. Chmielowski, P. Peterson, D. Cronier, J. A. Wright, S. Attia*
- Board 288 **Abstract 11543: CDKN2A deletion as a prognostic marker: A clinico-genomic analysis of sarcoma patients.** *N. Bui, J. Przybyl, L. Million, M. Van De Rijn, K. N. Ganjoo*
- Board 289 **Abstract 11544: Multi-institutional European phase I/II trial of trabectedin plus radiotherapy in metastatic soft tissue sarcoma (STS) patients. A Collaborative Spanish (GEIS), Italian (ISG) and French (FSG) Sarcoma Groups study.** *J. Martin Broto, A. Lopez-Pousa, N. Hindi, J. Cruz, J. Peinado, C. Morosi, J. Isern, M. Dolado, R. M. Alvarez Alvarez, A. Alvarez, G. Grignani, M. Gatti, P. Luna Fra, I. Alastuey, J. Blay, M. Sunyach, I. Rincon, A. Gronchi, J. Romero*
- Board 290 **Abstract 11545: Clinical and pathological analysis of eleven adult patients with inflammatory myofibroblastic tumor.** *X. Liu, X. Zhang, H. Wang, C. Wang, Y. Chen, J. WANG, Z. Luo*
- Board 291 **Abstract 11546: Efficacy and safety of apatinib in advanced soft tissue sarcoma: A multi-center, open-label phase II clinical trial.** *W. Yu, Z. Fan, J. Chen, H. Zhang, X. Zhang, G. Qu, Y. Chen, G. Huang, Y. Yao*
- Board 292 **Abstract 11547: A phase II trial of axitinib plus pembrolizumab for patients with advanced alveolar soft part sarcoma (ASPS) and other soft tissue sarcomas (STS).** *B. A. Wilky, M. M. Trucco, D. Kolonias, E. Wieder, T. Subhawong, A. Rosenberg, D. Kwon, W. Park, V. Florou, D. A. Kerr, E. Sfakianaki, J. R. Merchan, K. Komanduri, J. C. Trent II*
- Board 293 **Abstract 11548: Characteristics and clinical outcomes of French patients diagnosed with advanced soft tissue sarcoma (aSTS) in real-life setting: Data from the European sarcoma biological and clinical data banking (ESBCB).** *J. Blay, A. Le Cesne, F. Duffaud, N. Penel, S. Mathoulin-Pélissier, F. Ducimetiere, Y. D'yachkova, F. Chartier, H. Rassam, P. Cloitre*
- Board 294 **Abstract 11549: Genomic alterations in the homologous recombination pathway in soft-tissue sarcomas.** *N. D. Seligson, E. A. Kautto, E. N. Passen, C. W. Stets, A. Toland, J. L. Hays, J. L. Chen*
- Board 295 **Abstract 11550: A phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas.** *M. Agulnik, N. A. Mohindra, M. M. Milhem, S. Attia, S. I. Robinson, A. Rademaker, S. E. Abbinanti, R. Cehic, C. Humphreys, B. Prudner, S. H. Okuno, B. A. Van Tine*
- Board 296 **Abstract 11551: Targeted tumor profiling and actionable somatic variants in sarcoma.** *E. Ben Ami, M. L. Hemming, M. Nathenson, K. A. Thornton, P. Merriam, J. A. Morgan, C. P. Raut, S. George, A. J. Wagner, G. D. Demetri*
- Board 297 **Abstract 11552: Outcome of 91 clear cell sarcoma tumor patients: A retrospective study from the French Sarcoma Group (GSF-GETO).** *N. Firmin, P. Boudou-Rouquette, D. Duliege, L. Chaltiel, S. N. Dumont, M. Toulmonde, S. Salas, I. L. Ray-Coquard, T. Valentin, S. Piperno-Neumann, T. Ryckewaert, E. Bompas, N. Isambert Sr., J. Kurtz, C. Le Maignan, J. Egea, F. Bertucci, C. Perrin, F. Larousserie, C. Chevreau*
- Board 298 **Abstract 11553: Primary pulmonary sarcomas (PSRC): A comprehensive genomic profiling (CGP) study.** *S. Beaucaire-Danel, N. Girard, J. A. Elvin, J. Suh, J. Vergilio, S. H. Ramkissoon, E. A. Severson, S. Daniel, J. K. Killian, S. M. Ali, A. B. Schrock, J. Chung, R. J. Corona, V. A. Miller, L. M. Gay, J. S. Ross*
- Board 299 **Abstract 11554: Systemic therapy regimen outcomes in metastatic phyllodes tumors of the breast.** *A. M. Parkes, S. Patel, C. Leung, H. Y. Lin, A. P. Conley, N. Somaiah, D. M. Araujo, M. A. Zarzour, J. A. Ludwig, V. Ravi, R. S. Benjamin, R. Ratan*

- Board 300 Abstract 11555: Early metabolic response as predictor for treatment outcome of pazopanib in patients with metastatic soft tissue sarcomas (the PREDICT study).** *W. Van Der Graaf, M. Vlenterie, N. Steeghs, I. Desar, R. B. Verheijen, A. Koenen, W. Grootjans, L. de Geus-Oei, W. J. Oyen, N. P. Van Erp*
- Board 301 Abstract 11556: FAP-related desmoid tumours treated with low dose chemotherapy: Results from a multicentre retrospective analysis.** *B. Vincenzi, S. Provenzano, A. Brunello, G. Badalamenti, M. Nannini, T. Ibrahim, P. Hohenberger, S. Gasperoni, A. Napolitano, M. Silletta, M. Vitellaro, A. P. Dei Tos, D. Santini, G. Tonini, E. Palassini*
- Board 302 Abstract 11557: A multicenter phase II study of pazopanib in patients with unresectable or recurrent dermatofibrosarcoma protuberans (DFSP).** *J. Delyon, R. Porcher, M. Battistella, N. Meyer, H. Adamski, F. Bertucci, B. Guillot, T. Jouary, M. T. Leccia, S. Dalac, L. Mortier, L. Da Meda, E. Vicaut, F. Pedetour, S. Mourah, C. Lebbe*
- Board 303 Abstract 11558: Short, full-dose neoadjuvant chemotherapy in localized high-risk adult soft tissue sarcomas (STS): An exploratory subgroup analysis on responding patients in a randomized controlled trial comparing 3 neoadjuvant versus 3 neoadjuvant + 2 adjuvant cycles of full dose anthracycline and ifosfamide chemotherapy at a 10yr median FU.** *S. Stacchiotti, S. Pizzamiglio, A. Messina, C. Morosi, P. Collini, A. Lombart-Bosch, J. Martin Broto, A. Comandone, J. Cruz, G. Grignani, V. Quagliuolo, P. Picci, A. De Paoli, A. P. Dei Tos, P. Verderio, P. G. Casali, A. Gronchi*
- Board 304 Abstract 11559: Gemcitabine re-challenge in metastatic soft tissue sarcoma: A therapeutic option for selected patients.** *A. Sebio, G. Antoniou, K. Thway, A. Miah, S. Zaidi, C. Benson, W. T. van der Graaf, R. L. Jones*
- Board 305 Abstract 11560: First prospective observational study in diffuse-type tenosynovial giant cell tumors.** *M. Mastboom, E. Palmerini, S. Stacchiotti, E. Staals, B. Schreuder, S. Bauer, J. H. Healey, J. López Bastida, H. Gelderblom, A. Leithner, M. van de Sande*
- Board 306 Abstract 11561: Characterization of tumor microenvironment in extraskeletal myxoid chondrosarcoma (EMC).** *V. Indio, A. Astolfi, G. Tarantino, M. Urbini, C. Castelli, S. L. Renne, P. Collini, A. Gronchi, C. Colombo, A. Frezza, R. Maestro, A. P. Dei Tos, P. Picci, P. G. Casali, A. Pession, M. A. Pantaleo, S. Stacchiotti*
- Board 307 Abstract 11562: Phase 1b study of selinexor, a first in class selective inhibitor of nuclear export (SINE) compound, in combination with doxorubicin in patients (pts) with locally advanced or metastatic soft tissue sarcoma (STS).** *E. R. Malone, E. al-Ezzi, A. A. Gupta, P. Pedersen, D. Kolodziejczyk, R. Ellencherry, O. Zhu, A. R. Abdul Razak, J. H. Lewin*
- Board 308 Abstract 11563: Discovery and characterization of novel, recurrent, targetable ALK fusions in leiomyosarcoma.** *L. E. Davis, K. Nusser, J. Przybyl, M. Debiec-Rychter, J. Pittsenbarger, N. Hofmann, S. Varma, M. Davare*
- Board 309 Abstract 11564: Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years.** *C. Basse, A. Italiano, N. Penel, O. Mir, C. Chemin, M. Toulmonde, F. Duffaud, A. Le Cesne, C. Chevreau, C. Maynou, P. Anract, F. Gouin, M. Rios, N. Firmin, J. Kurtz, S. Piperno-Neumann, F. Bertucci, I. L. Ray-Coquard, F. Ducimetiere, J. Blay*
- Board 310 Abstract 11565: Identification of leiomyosarcoma circulating tumor DNA through ultra-low passage whole genome sequencing and correlation with tumor burden: A pilot experience.** *M. L. Hemming, K. S. Klega, K. E. Acker, A. Nag, A. Thorner, M. Nathenson, C. P. Raut, B. D. Crompton, S. George*
- Board 311 Abstract 11566: Impact of pathological stratification of advanced well differentiated/dedifferentiated (WD/DD) liposarcoma (LPS) on the response to trabectedin (T).** *R. Sanfilippo, E. Fumagalli, P. Collini, G. Fucà, S. L. Renne, M. Barisella, R. Bertulli, S. Provenzano, C. Morosi, A. Gronchi, A. P. Dei Tos, P. G. Casali*

Saturday, June 2, 2018

- Board 312 **Abstract 11567: Nodal involvement and survival in synovial, clear cell, angio, rhabdo, and epithelioid sarcoma.** *H. Wang, R. Miao, A. Jacobson, G. Boyd, S. Goldberg, D. Mitra, G. M. Cote, E. Choy, F. J. Hornicek, K. Raskin, T. F. DeLaney, Y. Chen*
- Board 313 **Abstract 11568: Survival impact of surgical management in reference centers for retroperitoneal sarcoma: A nationwide study of FSG-GETO and NETSARC.** *S. Bonvalot, E. Gaignard, E. Stoeckle, C. Honoré, P. Meeus, N. Penel, G. Ferron, N. Firmin, F. Duffaud, A. Di Marco, E. Bompas, M. Rios, F. Bertucci, N. Isambert Sr., A. Italiano, I. L. Ray-Coquard, A. Le Cesne, J. Coindre, F. Ducimetiere, J. Blay*
- Board 314 **Abstract 11569: Upfront isolated limb perfusion (ILP) in untreated patients with unresectable non-metastatic primary soft-tissue sarcomas (STS) of the limb: The Gustave Roussy experience.** *T. Assi, A. Cavalcanti, A. Le Cesne, M. Faron, J. Honart, A. Hadiji, O. Camuzard, T. Ibrahim, C. Le Pechoux, O. Mir, J. Adam, S. N. Dumont, P. Terrier, C. Honoré*
- Board 315 **Abstract 11570: Treatment of angiosarcoma with pazopanib and paclitaxel: Results of the phase II trial of the German Interdisciplinary Sarcoma Group (GISG-06 EVA) study.** *D. Pink, S. Bauer, T. Brodowicz, P. Reichardt, B. Kasper, S. Richter, P. Hohenberger*
- Board 316 **Abstract 11571: Inherited BRCA2 mutations and tumor hemi/homozygosity of metastatic soft tissue sarcoma in up to one-third of the 55 patients with shorter survival time.** *K. Takahashi, A. Mizumoto, J. Yashima, K. Kutsunai, H. Yamamoto, J. Sou, S. Toyooka, Y. Oyama, H. Nomori, H. Narahara, J. Yotsumoto, Y. Ono, M. Tonsho, S. Teraoka*
- Board 317 **Abstract 11572: Effect of JS001, a monoclonal antibody targeting programmed death-1 (PD-1), on responses and disease control in patients with advanced or refractory alveolar soft part sarcoma: Results from a phase 1 trial.** *S. Yang, J. Yang, X. Han, Y. Han, S. Jiang, J. Yao, Z. Zhang, S. Zhang, P. Liu, Y. Qin, H. Feng, S. Yao, Y. Sun, Y. Shi*
- Board 318 **Abstract 11573: Prognostic role of HMG proteins in a series of 301 advanced soft tissue sarcoma patients: A Spanish Group for Sarcoma Research Study (GEIS).** *N. Hindi, R. Ramos, J. Martinez-Trufero, R. M. Alvarez Alvarez, M. Cordeiro, L. Gonzalez de Sande, G. Marquina, J. M. Cano, J. Cruz, C. M. Valverde Morales, M. A. Vaz Salgado, J. Lavernia, A. Lopez-Pousa, R. Diaz Beveridge, I. Sevilla, A. Gutierrez, D. Marcilla, M. Taron, D. S. Moura, J. Martin Broto*
- Board 319 **Abstract 11574: Doxorubicin plus dacarbazine (DoDa), doxorubicin plus ifosfamide (DI) or doxorubicin alone (Do) as first line treatment for advanced leiomyosarcoma (LMS): A retrospective study from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).** *L. D'Ambrosio, N. Touati, J. Blay, G. Grignani, R. Flippot, A. M. Czarnecka, S. Piperno-Neumann, J. Martin Broto, R. Sanfilippo, D. Katz, F. Duffaud, B. Vincenzi, B. Kasper, D. P. Stark, F. Mazzeo, A. Tuchscherer, S. Litiere, W. Sents, H. Gelderblom, A. Gronchi*
- Board 320 **Abstract 11575: Subgroup analysis of elderly patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial.** *E. Younger, Z. Papai, B. A. Van Tine, S. Attia, K. V. Ballman, Y. Lu, D. K. Reinke, P. Schoffski, W. D. Tap, R. L. Jones*
- Board 321 **Abstract 11576: Genomic subtypes of angiosarcoma: A comprehensive genomic profiling (CGP) study.** *V. Ravi, S. E. Trabucco, M. M. Gounder, E. Sokol, U. Disel, G. M. Frampton, S. Z. Millis, A. B. Schrock, J. Chung, V. A. Miller, J. S. Ross, S. M. Ali*
- Board 322 **Abstract 11577: Identification of novel intra-genic deletions of CTNNB1 gene in WT desmoid-type fibromatosis.** *M. Urbini, A. Astolfi, P. Collini, V. Indio, A. Belfiore, N. Paielli, F. Perrone, G. Tarantino, E. Palassini, M. Fiore, A. Pession, S. Stacchiotti, M. A. Pantaleo, A. Gronchi, C. Colombo*
- Board 323 **Abstract 11578: Doxorubicin (D), gemcitabine (G), ifosfamide (I) and the EZH2 inhibitor EPZ-011989 in epithelioid sarcoma (ES): A comparison of different regimens in a patient-derived xenograft (PDX) model.** *N. Zaffaroni, A. Frezza, V. Zucco, A. Gronchi, C. Colombo, S. Pasquali, P. G. Casali, A. P. Dei Tos, P. Collini, M. A. Pantaleo, A. Astolfi, V. Indio, M. Tortoreto, S. Stacchiotti*

- Board 324 Abstract 11579: Frequency of genomic biomarkers of response to immunotherapy in sarcoma.** *S. E. Trabucco, S. M. Ali, E. Sokol, A. B. Schrock, L. A. Albacker, J. Chung, M. F. Xavier, U. Disel, V. A. Miller, J. S. Ross, G. M. Frampton, B. A. Wilky, V. Ravi, M. M. Gounder*
- Board 325 Abstract 11580: Management and outcome of patients with neo-adjuvant chemotherapy (CT) in locally advanced soft-tissue sarcoma (LASTS): The Gustave Roussy experience.** *S. N. Dumont, E. Cojocar, M. Faron, L. Haddag, J. Honart, N. Kiavue, F. Rimareix, A. Levy, C. Le Pechoux, A. Botticella, P. Terrier, J. Adam, O. Mir, A. Cavalcanti, C. Honoré, A. Le Cesne*
- Board 326 Abstract 11581: Genomic amplification of CDK4 in dedifferentiated liposarcomas as a predictive biomarker for microtubule disrupting agents.** *B. Demoret, A. Rogers, N. D. Seligson, E. A. Kautto, J. L. Hays, J. L. Chen*
- Board 327 Abstract 11582: Combination of CDK and Bcl-2 inhibitors in the treatment of soft-tissue sarcomas.** *X. Garcia del Muro, M. Fuentes-Guirado, R. López-Alemay, A. Pérez-Contreras, N. Mulet, S. Garcia-Monclús, O. M. Tirado, S. Rello-Varona*
- Board 328 Abstract 11583: Identification of histone deacetylase 2 (HDAC2) as a novel target for MDM2 directed therapies in dedifferentiated liposarcoma.** *C. W. Stets, B. Demoret, N. Grosenbacher, J. L. Hays, J. L. Chen*
- Board 329 Abstract 11584: Immune signature in sarcoma with prognostic and predictive implications.** *S. K. Raj, L. Miller, M. Winters, G. Russell, T. Pierre, P. Savage*
- Board 330 Abstract 11585: Lack of cardiac toxicity in patients treated with adoxorubicin with doxorubicin equivalent doses beyond 1000mg/m².** *K. K. Sankhala, R. L. Jones, V. S. Chua, K. Kim, S. Andrali, D. V. Quon, S. G. Wong, J. H. Lee, S. Rabizadeh, E. Sachdev, S. P. Chawla*
- Board 331a Abstract TPS11586: A phase I trial of pomalidomide in combination with liposomal doxorubicin in the treatment of advanced or refractory Kaposi sarcoma in individuals with or without HIV.** *R. Ramaswami, K. A. Lurain, P. H. Goncalves, A. Widell, M. Lindsley, W. D. Figg, C. J. Peer, S. M. Steinberg, V. Khetani, P. L. Choyke, J. R. Fontana, D. Whitby, T. S. Uldrick, R. Yarchoan*
- Board 331b Abstract TPS11587: PEMBROSARC combination of MK3475 and metronomic cyclophosphamide (mCP) in patients (pts) with advanced sarcomas a multicentre phase II trial with 3 new combination strategies.** *M. Toulmonde, T. Grellety, J. Blay, A. Le Cesne, N. Penel, S. Piperno-Neumann, F. Bertucci, C. Chevreau, E. Bompas, S. Cousin, S. Sellan-Albert, M. Pulido, C. A. Bellera, B. Lortal, S. Mathoulin-Pélissier, A. Italiano*
- Board 332a Abstract TPS11588: SU2C-SARC032: A phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma.** *Y. M. Mowery, K. V. Ballman, R. F. Riedel, B. E. Brigman, S. Attia, C. F. Meyer, S. Schuetze, M. A. Burgess, B. Chmielowski, M. A. Dickson, L. P. Hartner, M. M. Milhem, G. Tinoco, B. A. Van Tine, A. J. Wagner, D. K. Reinke, D. G. Kirsch*
- Board 332b Abstract TPS11589: Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa).** *A. J. Wagner, R. F. Riedel, B. A. Van Tine, R. Chugh, K. N. Ganjoo, L. D. Cranmer, S. Pollack, K. K. Sankhala, E. M. Gordon, V. Ravi, J. L. Hornick, D. J. Kwiatkowski, B. Grigorian, N. Desai, M. A. Dickson*
- Board 333a Abstract TPS11590: TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.** *V. Ravi, A. S. Brohl, S. P. Chawla, S. Attia, R. F. Riedel, D. A. Liebner, K. A. Thornton, A. Basu Mallick, C. R. Mehta, L. Liu, D. Alvarez, C. P. Theuer, S. I. Robinson, N. Penel, S. Stacchiotti, W. D. Tap, R. L. Jones, R. G. Maki*
- Board 333b Abstract TPS11591: Phase 1/2 study of safety/efficacy using trabectedin, ipilimumab and nivolumab triple therapy as first line treatment of advanced soft tissue sarcoma.** *E. M. Gordon, V. S. Chua-Alcala, K. Kim, S. Andrali, M. Del Rosario, W. W. Tseng, S. Pollack, S. P. Chawla*

Saturday, June 2, 2018

9:30 AM - 12:00 PM Opening Session

Opening Session With Fellows of the American Society of Clinical Oncology, Guest Speaker's Address, Presidential Address, and David A. Karnofsky Memorial Award and Lecture

Location: Hall B1

Interact ID: 10805

Thomas G. Roberts, MD, FASCO

Farallon Capital Management LLC

Conquer Cancer Welcome and Top Donor Recognition Awards

Clifford A. Hudis, MD, FACP, FASCO

American Society of Clinical Oncology

Introduction of Bruce E. Johnson, MD, FASCO

Bruce E. Johnson, MD, FASCO

Dana-Farber Cancer Institute

President's Address

Norman E. Sharpless, MD

National Cancer Institute at the National Institutes of Health

NCI Director's Remarks

Scott Gottlieb, MD

U.S. Food and Drug Administration

FDA Commissioner's Remarks

Daniel F. Hayes, MD, FACP, FASCO

University of Michigan Comprehensive Cancer Center

Presentation of the Fellows of the American Society of Clinical Oncology

Daniel F. Hayes, MD, FACP, FASCO

University of Michigan Comprehensive Cancer Center

Presentation of the 2018 David A. Karnofsky Memorial Award

Ralph R. Weichselbaum, MD

University of Chicago Pritzker School of Medicine

Oligometastasis From Conception to Treatment

12:00 PM - 1:00 PM Education Session

ASCO Voices

Location: Arie Crown Theater

David R. Spigel, MD - Chair

Sarah Cannon Research Institute, Tennessee Oncology

Trevor John Bayliss, MD

Berkshire Health Services

Heroes, Mentors, and Hope

Edmond Ang, MBBCh, MRCP

Palmerston North Hospital

Chemoboy

Nina Shah, MD

University of California, San Francisco

Did You Ever Know That You're My Hero? An Unexpected Gift From Our Career in Oncology

Rachna T. Shroff, MD

University of Arizona

Did You Ever Know That You're My Hero? An Unexpected Gift From Our Career in Oncology

Monica Morrow, MD, FASCO

Memorial Sloan Kettering Cancer Center

Surgery Is Never Elegant When Women Are In the Operating Room

Patrick J. Loehrer, MD, FASCO

Indiana University Melvin and Bren Simon Cancer Center

The Call

1:15 PM - 2:30 PM Poster Discussion Session

Breast Cancer—Metastatic

Location: Hall D1

Interact ID: 10857

Arlene Chan, MD, FRACP - Chair

Breast Cancer Research Centre - WA & Curtin University

Roisin M. Connolly, MD - Chair

Johns Hopkins Kimmel Comprehensive Cancer Center

1:15 PM Sara M. Tolaney, MD, MPH (Discussion of Abstract(s) 1013-1015)

Dana-Farber Cancer Institute

New Frontiers in HER2-Positive Breast Cancer

1:27 PM Panel Question and Answer

1:33 PM Kari Braun Wisinski, MD (Discussion of Abstract(s) 1017-1018)

University of Wisconsin Carbone Cancer Center

Novel Approaches for HER2-Negative Metastatic Breast Cancer

1:45 PM Panel Question and Answer

1:51 PM Minetta C. Liu, MD (Discussion of Abstract(s) 1019-1021)

Mayo Clinic

Applications of Liquid Biopsies in Metastatic Breast Cancer

2:03 PM Panel Question and Answer

2:09 PM Erika Paige Hamilton, MD (Discussion of Abstract(s) 1022-1024)

Sarah Cannon Research Institute

The Elusive Hunt for CDK Inhibitor Biomarkers

2:21 PM Panel Question and Answer

Posters discussed in this session are on display in the Breast Cancer—Metastatic Poster Session. See page 70 for poster information.

1:15 PM - 2:30 PM Poster Discussion Session

Genitourinary (Nonprostate) Cancer

Location: Hall D2

Interact ID: 10865

Alexandra Drakaki, MD, PhD - Chair

University of California Los Angeles

Kent William Mouw, MD, PhD - Chair

Dana-Farber Cancer Institute

Saturday, June 2, 2018

- 1:15 PM Laurence Albiges, MD, PhD (Discussion of Abstract(s) 4509-4510)**
Gustave Roussy, Université Paris-Saclay
Novel Combinations for Advanced Renal Cell Carcinoma
- 1:27 PM Panel Question and Answer**
- 1:33 PM Petros Grivas, MD, PhD (Discussion of Abstract(s) 4512-4514)**
University of Washington
Novel Therapeutic Strategies for Advanced Bladder and Penile Cancer
- 1:45 PM Panel Question and Answer**
- 1:51 PM Eric Jonasch, MD (Discussion of Abstract(s) 4515-4517)**
The University of Texas MD Anderson Cancer Center
Enrichment and Optimization of Anti-VEGF Targeted Strategies in Metastatic Renal Cell Carcinoma
- 2:03 PM Panel Question and Answer**
- 2:09 PM Brian M. Shuch, MD (Discussion of Abstract(s) 4518-4520)**
Yale School of Medicine
Biomarker Development and Applications in Advanced Renal Cell Carcinoma
- 2:21 PM Panel Question and Answer**

Posters discussed in this session are on display in the Genitourinary (Nonprostate) Cancer Poster Session. See page 80 for poster information.

1:15 PM - 2:30 PM Poster Discussion Session

Pediatric Oncology

Location: S504

Interact ID: 10877

Steven G. DuBois, MD - Chair

Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorders Center

E. Anders Kolb, MD - Chair

Alfred I. duPont Hospital for Children

- 1:15 PM Katherine A. Janeway, MD (Discussion of Abstract(s) 10518-10520)**
Dana-Farber Cancer Institute
Refining the Genomic Landscape of Pediatric Cancers
- 1:27 PM Panel Question and Answer**
- 1:33 PM Navin R. Pinto, MD (Discussion of Abstract(s) 10521-10524)**
Seattle Children's Hospital
Therapeutic Advances in Embryonal Tumors
- 1:45 PM Panel Question and Answer**
- 1:51 PM Sharon M. Castellino, MD, MSc (Discussion of Abstract(s) 10525-10526)**
Children's Healthcare of Atlanta
Immune Modulation in Pediatric Lymphoma
- 2:03 PM Panel Question and Answer**
- 2:09 PM Robin Elizabeth Norris, MD, MPH, MS (Discussion of Abstract(s) 10527-10529)**
Rainbow Babies and Children's Hospital
The Challenges of Optimizing Pediatric Cancer Care in the Current Economic Climate
- 2:21 PM Panel Question and Answer**

Posters discussed in this session are on display in the Pediatric Oncology Poster Session. See page 88 for poster information.

1:15 PM - 2:30 PM Education Session

ASCO Town Hall: Utilization Management in Oncology

Location: S102

Interact ID: 10928

John Vernon Cox, DO, FASCO - Chair

University of Texas Southwestern Medical Center

Introduction and Panel Moderator

Barbara L. McAneny, MD, MACP, FASCO

New Mexico Oncology Hematology Consultants, Ltd, and President-Elect, American Medical Association

Vision of AMA: Focus on Administrative Burden

Robin Zon, MD, FACP, FASCO

Michiana Hematology Oncology, PC

Pathways and MACRA: ASCO's Proposal

Melissa S. Dillmon, MD

Harbin Clinic LLC

Issues From the States: Pharmacy Benefit Managers

Blase N. Polite, MD, MPA, FASCO

University of Chicago

What to Expect From Washington, DC, in 2018-2019

Panel Question and Answer

1:15 PM - 2:30 PM Education Session

ASCO/Radiological Society of North America (RSNA) Joint Session: Assessing Response and Progression With Targeted Therapy and Immunotherapy

Location: S100a

Interact ID: 10810

Bruce E. Johnson, MD, FASCO - Chair

Dana-Farber Cancer Institute

Bruce George Haffty, MD - Chair

Rutgers Cancer Institute of New Jersey

David A. Mankoff, MD, PhD

University of Pennsylvania

Molecular Imaging and Targeted Therapy

Umar Mahmood, MD, PhD

Massachusetts General Hospital

Monitoring Response to Immunotherapy

Jedd D. Wolchok, MD, PhD, FASCO

Memorial Sloan Kettering Cancer Center

Immune-Related Response and RECIST in Radiographic Imaging

Panel Question and Answer

Saturday, June 2, 2018

1:15 PM - 2:30 PM Education Session

Covering Cancer: Perspectives From the Media

Location: Arie Crown Theater

Interact ID: 10915

Richard L. Schilsky, MD, FACP, FASCO, FSCT - Chair

American Society of Clinical Oncology

Introduction and Panel Moderator

Marilynn Marchione

Associated Press

Panel Participant

Liz Szabo

Kaiser Health News

Panel Participant

Matthew Herper

Forbes

Panel Participant

Sharon Begley

STAT

Panel Participant

Anne Thompson

NBC News

Panel Participant

Panel Question and Answer

1:15 PM - 2:30 PM Education Session

Global Access to Essential Cancer Medicine

Location: S404

Interact ID: 10682

Fredrick Chite Asirwa, MD - Chair

AMPATH

Lessons From the Field: Access to Essential Medicines at Ampath-Kenya

Avram Denburg, MD, FRCPC

Hospital for Sick Children

Access to Essential Medicines for Children With Cancer: Challenges and the Pursuit of Innovative Solutions

George F. Tidmarsh, MD, PhD

Citizens Oncology Foundation

The Role of Industry in Improving Access to Cancer Medicines in Low- to Middle-Income Countries

Rifat Atun, MBBS

Harvard School of Public Health

Global Access to Cancer Medicines: The Role of International Health Institutions

Panel Question and Answer

1:15 PM - 2:30 PM Education Session

Immunotherapy Biomarkers: Beyond PD-L1

Location: Hall B1
Interact ID: 10716

Charles G. Drake, MD, PhD - Chair

Columbia University Herbert Irving Comprehensive Cancer Center
PD-L1: Prognostic and Predictive State of the Science

Timothy An-thy Chan, MD, PhD

Memorial Sloan Kettering Cancer Center
Immunotherapy Biomarkers: Tumor Mutational Burden

Kurt A. Schalper, MD, PhD

Yale School of Medicine
Future Directions in Immunotherapy Biomarkers

Panel Question and Answer

1:15 PM - 2:30 PM Education Session

Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice

Location: S100bc
Interact ID: 10910

Sandro Santagata, MD, PhD

Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School
New Paradigm of Central Nervous System Tumor Classification

Gelareh Zadeh, MD, PhD

Princess Margaret Cancer Centre, University Health Network
Tissue Acquisition Before, During, and After Treatment: Incorporating New WHO Classification Into Practice

Evanthia Galanis, MD - Chair

Mayo Clinic
Integrating Tumor Genomics Including WHO Guidelines Into Novel Clinical Trial Designs

Panel Question and Answer

1:15 PM - 2:30 PM Education Session

Practical Considerations for Antibodies in Myeloma

Location: E450
Interact ID: 10757

Jacob Laubach, MD - Chair

Dana-Farber Cancer Institute
Debate: Should Everyone Receive Monoclonal Antibodies in First Relapse? Yes

Joseph Mikhael, MD - Chair

Mayo Clinic
Debate: Should Everyone Receive Monoclonal Antibodies at First Relapse? No

Saturday, June 2, 2018

Niels Van De Donk, MD, PhD

VU University Medical Center

What Do You Do When Monoclonal Antibodies Fail?

Faith Davies, MD, MRCP, MRCPATH, FRCPath

Myeloma Institute, University of Arkansas for Medical Sciences

Future Monoclonal Antibodies: BCMA and Beyond

Panel Question and Answer

1:15 PM - 2:30 PM Education Session

Practice-Changing Developments in Stage III Melanoma: Surgery, Adjuvant Targeted Therapy, and Immunotherapy

Location: S406

Interact ID: 10750

Alexander Christopher Jonathan Van Akkooi, MD, PhD

Netherlands Cancer Institute

Extent of Surgery for Stage III Melanoma: How Much Is Appropriate?

Ragini Reiney Kudchadkar, MD - Chair

Winship Cancer Institute

Adjuvant Targeted Therapy: First Choice?

Olivier Michielin, MD, PhD

University Hospital Lausanne

Adjuvant Immunotherapy: First Choice!

Panel Question and Answer

1:15 PM - 2:30 PM Meet the Professor Session

Treatment of Early-Relapse Follicular Lymphoma - Ticketed Session

Location: E253d

Interact ID: 10803

Julie Vose, MD, MBA, FASCO

University of Nebraska Medical Center

Jonathan W. Friedberg, MD

University of Rochester Medical Center

1:15 PM - 2:30 PM Clinical Problems in Oncology Session

Malignant Mesothelioma: Therapies to Get Really Excited About - Ticketed Session

Location: E253c

Interact ID: 10797

Anne S. Tsao, MD - Chair

The University of Texas MD Anderson Cancer Center

Frontline Therapy With Antiangiogenic Agents in the Management of Mesothelioma

Raffit Hassan, MD

Thoracic and Gastrointestinal Oncology Branch, National Cancer Institute
Immunotherapy and Other Mesothelin-Targeted Agents for the Treatment of Malignant Mesothelioma

Joseph S. Friedberg, MD

University of Maryland School of Medicine
Does Surgery and Other Local Therapies Have a Role in the Management of Mesothelioma?

Panel Question and Answer

1:15 PM - 4:45 PM Poster Session

Cancer Prevention, Hereditary Genetics, and Epidemiology

Location: Hall A

Abstracts on Boards 83-94 will be discussed during the Cancer Prevention, Hereditary Genetics, and Epidemiology Poster Discussion Session.

Posters by Topic

Cancer Genetics: Boards 84-88, 94-119
Cancer Prevention: Boards 89-90, 93, 120-133
Epidemiology: Boards 91-92, 134-147
Genetic Testing: Boards 83, 148-163
Prevention of Secondary Malignancies: Board 164
Trials in Progress: Boards 165a-165b

- Board 83** **Abstract 1512: Implementing universal genetic counseling (GC) and multigene germline testing (MGT) for pancreatic cancer (PC) patients (pts).** *M. B. Yurgelun, A. B. Chittenden, C. I. Ukaegbu, T. G. Dhingra, S. Gaonkar, J. Sotelo, D. A. Rubinson, N. J. McCleary, T. E. Clancy, T. A. Abrams, J. M. Cleary, A. P. Madigan, L. K. Brais, K. Perez, B. M. Wolpin, S. Syngal*
- Board 84** **Abstract 1513: Long-term (7-year) outcomes of universal mismatch repair screening (uMMR) of 1156 colorectal (CRC) and endometrial cancers (EC) in an academic setting.** *M. J. Hall, Y. Chertock, M. Savage, J. Sicilia, M. B. Daly*
- Board 85** **Abstract 1514: Identification and referral of women at risk for BRCA mutations.** *C. Bellcross, A. Hermstad, C. L. Tallo, C. Leonard, I. Pencea, C. L. Stanislaw, W. Kohlmann*
- Board 86** **Abstract 1515: Inherited defects in checkpoint kinase 2 (CHEK2) to confer increased susceptibility to testicular germ cell tumors.** *S. H. Aldubayan, L. T. Pyle, J. T. Loud, M. H. Greene, C. Sweeney, K. Nathanson, E. M. Van Allen, D. R. Stewart, D. Lessel*
- Board 87** **Abstract 1516: DNA damage repair (DDR) germline mutations in patients (Pts) with urothelial carcinoma (UC).** *M. I. Carlo, J. Vijai, D. Mandelker, Y. Kemel, A. M. Regazzi, L. Zhang, Z. K. Stadler, M. F. Walsh, K. A. Cadoo, D. B. Solit, J. Coleman, A. A. Hakimi, S. Funt, G. Iyer, J. E. Rosenberg, M. E. Robson, K. Offit, D. F. Bajorin*
- Board 88** **Abstract 1517: Clinical factors associated with urinary tract cancers (UTCs) among Lynch syndrome (LS) patients (Pts).** *J. W. Wischhusen, C. I. Ukaegbu, T. G. Dhingra, H. Uno, F. Kastrinos, S. Syngal, M. B. Yurgelun*
- Board 89** **Abstract 1518: Adapted physical activity and recommendations for second cancers prevention for adolescents and young adults with cancer.** *J. Carretier, A. Lion, B. Fervers, O. Febvey-Combes, H. J. Boyle, P. Marec-Berard*
- Board 90** **Abstract 1519: Nutrition assessment among men undergoing genetic counseling for inherited prostate cancer: A teachable moment.** *V. N. Giri, M. Bruneau Jr., E. Obeid, C. Smaltz, B. Milliron*

Saturday, June 2, 2018

- Board 91 Abstract 1520: Risk of second primary HPV-associated cancers after index HPV-associated cancers.** *R. Suk, P. Mahale, K. Sonawane, A. G. Sikora, J. Chhatwal, K. M. Schmeler, K. Sigel, S. B. Cantor, E. Chiao, A. A. Deshmukh*
- Board 92 Abstract 1521: Dietary inflammatory index and breast cancer risk by menopausal status and histological subtype.** *A. Castello, N. Shivappa, A. Ruiz, A. Casas, A. Lluch Hernandez, J. M. Baena-Cañada, S. Antolin, P. Sánchez Rovira, M. Ramos Vazquez, J. Garcia-Saenz, A. Anton, M. Munoz, A. de Juan, C. Jara-Sanchez, J. Vioque, B. Perez-Gomez, J. R. Hébert, V. Lope, M. Martin, M. Pollan*
- Board 93 Abstract 1522: Value of EGD for gastric cancer surveillance in patients with hereditary non-polyposis colorectal cancer (HNPCC) or Lynch syndrome (LS).** *S. Ladigan, D. B. Vangala, J. Kuhlkamp, C. Pox, C. Engel, R. Hueneburg, C. Perne, J. Nattermann, V. Steinke-Lange, N. Rahner, H. K. Schackert, M. Kloor, C. Strassburg, M. Morak, E. Holinski-Feder, R. Büttner, S. Aretz, M. Loeffler, W. H. Schmiegel, K. Schulmann*
- Board 94 Abstract 1523: “What if I keep my breasts?” Extended follow-up of unaffected BRCA mutation carriers diagnosed with breast cancer (BC) in the Toronto magnetic resonance imaging (MRI) screening study.** *E. Warner, S. Zhu, K. Hill, P. Causer, R. A. Jong, M. Yaffe, E. Ramsay, S. Narod, D. B. Plewes*
- Board 95 Abstract 1524: Expanding BRCA1/2 testing criteria to include other confirmed breast and ovarian cancer susceptibility genes.** *F. Couch, H. Shimelis, J. S. Dolinsky, E. Polley, C. Horton, A. Yussuf, L. Hoang, J. Lilyquist, V. Speare, C. Hu, S. Hart, H. LaDuca*
- Board 97 Abstract 1526: Towards personalised risk assessment and clinical management: A worldwide study of age-, sex-, geographic region-, gene- and cancer-specific risks for Lynch syndrome.** *A. K. Win, J. C. Reece, G. Lee, R. W. Haile, G. Möslein, F. A. Macrae, M. A. Jenkins*
- Board 98 Abstract 1527: Evaluation of whole body MRI for early detection of cancer in TP53 mutation carriers: Final results of the LIFSCREEN study.** *O. Caron, K. Eleni, S. Foulon, P. Benusiglio, V. Bonadona, L. Faivre, C. M. Maugard, C. Dugast, E. Barouk-Simonet, C. Delnatte, Y. Bignon, F. Eisinger, N. Chabbert-Buffet, V. Feillel, P. Pujol, K. Malekzadeh, C. Balleyguier, L. Fasse, T. Frébourg, L. Brugieres*
- Board 100 Abstract 1529: Differences between screen-detected and interval breast cancers among BRCA mutation carriers.** *M. L. Pilewskie, E. C. Zabor, M. Stempel, O. Petruolo, D. Mangino, M. E. Robson, M. S. Jochelson*
- Board 101 Abstract 1530: Effect of breastfeeding on the risk of breast cancer in Li-Fraumeni syndrome.** *P. Khincha, A. F. Best, J. T. Loud, S. A. Savage, M. Achatz*
- Board 102 Abstract 1531: Interest in and outcomes with web-based education for return of genetic research results for inherited susceptibility to breast cancer.** *A. R. Bradbury, J. B. Gaieski, B. L. Egleston, L. J. Patrick-Miller, W. Chung, O. I. Olopade, K. N. Maxwell, S. Walser, D. Fetzer, J. Brower, A. C. Brandt, D. Clark, L. DiGiovanni, J. M. Long, J. Powers, D. Mckenna, J. Stopfer, C. M. Weipert, K. Nathanson, S. M. Domchek*
- Board 103 Abstract 1532: Development of HOPE-Genomics: An IT platform for patient-directed cancer genome sequencing education and return of results.** *I. Solomon, J. Shen, A. Albayrak, G. Alterovitz, E. Cerami, C. Del Vecchio Fitz, R. A. Freedman, L. Lopez, L. M. Sholl, E. VanAllen, S. A. McGraw, S. W. Gray*
- Board 104 Abstract 1533: Genomic profiling of tumors from patients with germline BRCA mutations.** *A. Laenkhholm, I. H. Soenderstrup, M. Jensen, J. Eriksen, M. Thomassen, A. Gerdes, M. Rossing, H. Brauer, A. Mashadi-Hossein, S. Ferree, B. Ejlersen*
- Board 106 Abstract 1535: Risk of pediatric malignancy in families known to carry BRCA1/2 mutations.** *K. T. Nead, N. Mitra, W. Zhou, R. C. Gillette, D. Clark, J. E. Ebrahimzadeh, J. M. Long, D. Mckenna, J. Powers, K. N. Maxwell, P. D. Shah, A. R. Bradbury, K. Nathanson, S. M. Domchek*
- Board 107 Abstract 1536: Feasibility of perioperative multi-gene panel testing (MGPT) in cancer patients eligible for hereditary genetic evaluation (GE): The PROTECT pilot.** *M. J. Hall, E. A. Handorf, A. Forman, Y. Chertock, E. Obeid, M. B. Daly*

- Board 108 **Abstract 1537: Importance of genetic counseling referrals for high-risk women with endometrial cancer despite intact mismatch repair immunohistochemistry.** *J. Lee, A. L. Brodsky, D. Gerber, J. Fehniger, S. Asgari, A. Cantor, J. Martineau, J. A. Smith, O. M. Ginsburg, B. Pothuri*
- Board 109 **Abstract 1538: Investigation of discordant sibling pairs from hereditary breast cancer (HBC) families.** *K. Landry, D. Seward, J. Dragon, W. McKinnon, L. S. Colello, J. Sweasy, S. Wallace, M. Cuke, M. Wood*
- Board 110 **Abstract 1539: Genetic testing and clinical management practices for variants in non-*BRCA1/2* breast (and/or ovarian) cancer susceptibility genes: An international survey by the Enigma Clinical Working Group.** *S. Nielsen, A. De Nicolo, D. Eccles, I. L. Romero, S. M. Domchek, A. Monteiro, D. Goldgar, A. Spurdle, E. Gomez Garcia*
- Board 111 **Abstract 1540: Non-*BRCA* hereditary gene mutations and breast cancer phenotype: An ISC-RAM Consortia study.** *B. Arun, F. R. Schnabel, J. Chun, A. L. Heeke, J. A. Smith, D. F. Roses, E. Kurz, K. Landry, A. Gutierrez Barrera, M. Wood, C. Isaacs*
- Board 112 **Abstract 1541: Integrative clinical genomics of early-onset breast cancer.** *L. Li, Z. Yi, C. Li, X. Guan, B. Xu, F. Ma*
- Board 113 **Abstract 1542: Beyond *BRCA1* and *BRCA2*: Implementation of a multigene panel for the upfront testing of germline mutations in ovarian cancer.** *M. Mira, I. C. Miguel, S. Fragoso, A. Luís, A. Clara, S. Bento, A. G. Opinião, P. Machado, S. Santos, P. Rodrigues, J. Parreira, A. Francisca, F. H. Vaz*
- Board 114 **Abstract 1543: Prospective Registry of Multiplex Testing (PROMPT): Feasible and sustainable.** *H. Symecko, J. Brower, C. Drogan, T. Harstad, E. E. Salo-Mullen, N. Pradhan, J. Hamilton, J. Balmaña, M. F. Walsh, F. Couch, J. E. Garber, K. Offit, S. M. Domchek, M. E. Robson*
- Board 115 **Abstract 1544: Treatment failure: Why patients with *BRCA* mutations are declining risk-reducing surgery.** *O. R. Khouri, D. Gerber, J. Lee, J. Fehniger, L. R. Boyd, B. Pothuri*
- Board 116 **Abstract 1545: Identification and characterization of germline pathogenic variants using matched tumor-normal next-generation sequencing in 7363 pan-cancer patients in China.** *Y. Yi, F. Ma, M. F. Sharpnack, J. Zhao, Y. Guan, P. Dai, J. Huan, L. Liu, Q. Ouyang, Y. Zhou, R. Chen, L. Yang, X. Yi, D. P. Carbone, X. Xia, J. Yang, K. He*
- Board 117 **Abstract 1546: Population health and cancer testing pilot protocol (PHACT).** *M. S. Dhawan, J. Budge, K. Inokuchi, N. Lovick, J. Mak, A. Zhou, W. Stedden, P. Morris, K. Williams, P. N. Munster*
- Board 118 **Abstract 1547: Evaluating empowerment in genetic counseling using patient reported outcomes.** *S. Lee, J. Yuen, J. Lim, E. Courtney, S. Li, H. Soh, Y. Chen, M. McAllister, E. Fenwick, J. Y. Ngeow*
- Board 119 **Abstract 1548: The effect of Genetic Cancer Risk Assessment (GCRA) on the uptake of risk-reducing surgeries (RRS) in Hispanic women with breast cancer (BC).** *Y. Chavari Guerra, K. Yang, J. Abugattas, S. Brown, A. Campbell Fontaine, A. Cock-Rada, M. Cruz Correa, A. Daneri-Navarro, A. Del Toro-Valero, P. R. Duncan, I. K. Komenaka, A. Mora Alferez, C. Ricker, Y. Rodriguez, G. W. Unzeitig, C. Villarreal-Garza, B. Nehoray, R. Mejia, S. Sand, J. N. Weitzel*
- Board 120 **Abstract 1549: Influence of vitamin D (Vit D) on mammographic density (MD) and insulin like growth factor 1 (IGF1): Results of CALGB (Alliance) 70806.** *M. Wood, D. K. Seisler, M. Hsieh, D. Kontos, A. B. Ambaye, H. T. Le-Petross, S. Jung, H. Liu, P. J. Zekan, L. Cardinal, J. Charlamb, L. X. Wang, G. W. Unzeitig, J. E. Garber, J. R. Marshall*
- Board 121 **Abstract 1550: Randomized double-blind placebo-controlled biomarker modulation study of vitamin d in premenopausal women at high risk for breast cancer (SWOG S0812).** *K. D. Crew, G. L. Anderson, D. L. Hershman, M. Terry, P. Tehranifar, D. L. Lew, M. Yee, E. A. Brown, S. S. Kairouz, N. Kuwajerwala, T. B. Bevers, J. E. Doster, C. Zarwan, L. Kruper, L. M. Minasian, L. G. Ford, B. Arun, M. Neuhaus, P. Brown*

Saturday, June 2, 2018

- Board 122 **Abstract 1551: Case-only analyses for identifying genotypes that modify the effect of finasteride in the Prostate Cancer Prevention Trial (PCPT): SWOG S9217.** *J. Dai, M. L. LeBlanc, P. J. Goodman, M. S. Lucia, I. M. Thompson Jr., T. Catherine*
- Board 123 **Abstract 1552: Chest x-ray (CXR) screening to improve outcomes in lung cancer: Reanalysis of the lung cancer component of the Prostate-Lung-Colorectal-Ovary (PLCO) randomized controlled trial.** *J. P. Flores, A. Moreno-Koehler, M. Finkelman, J. Caro, G. M. Strauss*
- Board 124 **Abstract 1553: Long-term effectiveness and immunogenicity of quadrivalent HPV vaccine in young men: 10-year end-of study analysis.** *S. Goldstone, A. Giuliano, J. Palefsky, A. Luxembourg*
- Board 125 **Abstract 1554: Breast Cancer Risk Perception and Adherence to U.S. Cancer Prevention Guidelines.** *J. Eckroate, A. B. Chagpar, E. W. Hofstatter*
- Board 126 **Abstract 1555: Clinical characteristics and EGD surveillance in Lynch-syndrome patients with small bowel/duodenal carcinomas.** *D. B. Vangala, C. Pox, S. Ladigan, C. Engel, R. Hueneburg, C. Perne, V. Steinke-Lange, N. Rahner, H. K. Schackert, M. Kloor, S. Holzapfel, J. Kuhlkamp, C. Strassburg, M. Morak, E. Holinski-Feder, R. Büttner, S. Aretz, M. Loeffler, W. H. Schmiegel, K. Schulmann*
- Board 127 **Abstract 1556: Effects of U.S. Preventive Services Task Force (USPSTF) guidelines on cervical cancer screening, incidence, and mortality.** *A. Melamed, J. A. Rauh-Hain, G. Fink, K. James, L. Rice, D. Schrag, M. G. del Carmen, A. A. Wright*
- Board 128 **Abstract 1557: Profile of cancer-screening resistant individuals (EDIFICE 6).** *T. De La Motte Rouge, J. F. Morere, S. Couraud, M. Roupert, C. Touboul, C. Lhomel, L. Greillier, F. Eisinger, J. Viguier*
- Board 129 **Abstract 1558: A health system experience with an electronic medical record based application to increase lung cancer screening.** *B. Weckbaugh, T. West, M. Rosado-de-Christenson, T. J. Pluard, J. A. Spertus, J. Subramanian*
- Board 130 **Abstract 1559: Attributable failure and costs associated with continued smoking by cancer patients.** *G. W. Warren, E. Garrett-Mayer, K. M. Cummings*
- Board 131 **Abstract 1560: Overweight and breast cancer risk in the International Breast Cancer Intervention studies I and II.** *S. G. Smith, I. Sestak, M. A. Morris, A. Howell, J. F. Forbes, J. M. Cuzick*
- Board 132 **Abstract 1561: Smoking cessation after a cancer diagnosis and survival in cancer patients.** *G. W. Warren, A. Alberg*
- Board 133 **Abstract 1562: Community based lung cancer screening program: Evaluation of the initial lung cancer screening CT scan.** *T. Mishra, A. Hakimian, M. Vercillo, A. Joob*
- Board 134 **Abstract 1563: Herpes zoster vaccine and varicella zoster virus infection among cancer patients having chemotherapy.** *L. Y. Law, D. M. Carpenter, L. M. Grigor, B. P. Nair*
- Board 135 **Abstract 1564: Occupational exposure to pesticides and prognosis of diffuse large b cell lymphoma: A cohort study.** *S. Lamure, C. Carles, Q. Aquereburu, P. Quittet, E. Tchernonog, F. Paul, E. Jourdan, A. Waultier, C. Defez, L. Sanhes, S. Burcheri, D. Donadio, C. Exbrayat, A. Saad, J. Labourey, I. Baldi, G. Cartron, P. Fabbro-Peray*
- Board 136 **Abstract 1565: Risk of second malignancies in breast cancer patients who received chemotherapy: A SEER analysis.** *S. Nutalapati, S. R. Jain*
- Board 137 **Abstract 1566: Impact of prophylactic bilateral salpingo-oophorectomy on bone health in BRCA mutation carriers: A prospective cohort study.** *E. Hall, J. Kotsopoulos, A. Finch, I. Thompson, B. Rosen, J. Murphy, S. Narod, A. Cheung*
- Board 138 **Abstract 1567: Comparing the prevalence of non-AIDS defining cancers by HIV status in the Ohio Medicaid population.** *S. M. Koroukian, S. Navale, N. K. Schiltz, G. Cooper, L. Li*

- Board 139 **Abstract 1568: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 2006 to 2016: A systematic analysis for the Global Burden of Disease study.** *C. Fitzmaurice*
- Board 140 **Abstract 1569: Milk intake and mammographic density in premenopausal women.** *Y. Han, X. Zong, D. E. Eapen, Y. Li, G. A. Colditz, A. Toriola*
- Board 141 **Abstract 1570: Association between pesticides use and incidence of diffuse large B cell lymphoma (DLBCL).** *A. Altahan, M. G. Martin*
- Board 144 **Abstract 1573: The role of adiposity in the association between type 2 diabetes and the risk of breast cancer.** *M. Bota, P. Autier, P. Boyle*
- Board 145 **Abstract 1574: Nasopharyngeal cancer in Alaska Native people: A cancer health disparity.** *M. J. Olnes, E. Pihl, M. Minder, J. C. Parrish, P. Holck, J. Tiesinga, B. Stillwater, G. Zimpelman, S. Nash, H. Martinson*
- Board 146 **Abstract 1575: Prevalence of HIV infection among cancer patients in a Haitian hospital.** *J. Bernard, L. C. Pierre, K. Moise, V. DeGennaro Jr.*
- Board 147 **Abstract 1576: Non-AIDS defining malignancies among HIV-infected patients in a tertiary referral center in Hong Kong.** *D. Mak, E. K. Hui, L. Chan, W. Lam, M. Lee, S. Lau*
- Board 148 **Abstract 1577: Prevalence of germline genetic alterations in colorectal cancer patients.** *A. Cercek, Y. Kemel, D. Mandelker, C. Stewart, A. G. Arnold, M. Sheehan, R. Yaeger, N. H. Segal, A. M. Varghese, L. B. Saltz, L. A. Diaz Jr., J. Shia, D. M. Hyman, M. F. Berger, D. B. Solit, L. Zhang, K. Offit, M. E. Robson, Z. K. Stadler*
- Board 149 **Abstract 1578: Genetic testing and results in population-based breast cancer patients and ovarian cancer patients.** *A. W. Kurian, K. C. Ward, N. Howlander, D. Deapen, A. S. Hamilton, A. Mariotto, D. Miller, S. J. Katz, L. Penberthy*
- Board 150 **Abstract 1579: Impact of pre-surgical germline multigene panel testing on choice of surgery for breast cancer.** *E. Zarcaro, L. W. Ellisen, K. M. Shannon, E. Blouch, S. J. Isakoff*
- Board 151 **Abstract 1580: Mosaic TP53 pathogenic variants on multi-gene hereditary cancer panel testing: Clinical characteristics and follow-up testing.** *S. A. Jackson, M. Roberts, J. L. Mester, M. L. Marshall, K. J. Vogel Postula, A. R. Stettner, K. J. Arvai, R. T. Klein, A. F. Wagner, K. S. Hruska*
- Board 152 **Abstract 1581: Promoting breast cancer screening after multiplex genetic panel testing (MGPT) and genetic counseling.** *G. Idos, A. W. Kurian, C. Ricker, D. Sturgeon, J. Culver, K. Kingham, R. Koff, N. M. Chun, C. Rowe-Teeter, J. Kidd, B. Evans, K. Brown, M. Mills, C. Ma, C. Hong, K. J. McDonnell, U. Ladabaum, J. M. Ford, S. B. Gruber*
- Board 153 **Abstract 1582: Promoting colorectal cancer (CRC) screening after multiplex genetic testing and genetic counseling.** *G. Idos, A. W. Kurian, C. Ricker, D. Sturgeon, J. Culver, K. Kingham, R. Koff, N. M. Chun, C. Rowe-Teeter, J. Kidd, B. Evans, K. Brown, M. Mills, C. Ma, C. Hong, K. McDonnell, U. Ladabaum, J. M. Ford, S. B. Gruber*
- Board 154 **Abstract 1583: Examining patients' medical and psychosocial experiences following detection of a CDH1 variant with multiplex genetic testing.** *J. Hamilton, J. M. Long, A. C. Brandt, J. Brower, H. Symecko, E. E. Salo-Mullen, S. Christian, F. Couch, J. E. Garber, K. Offit, M. E. Robson, S. M. Domchek*
- Board 155 **Abstract 1584: Impact of germline BRCA identification on subsequent breast cancer stage and therapy: Implications for routine screening.** *T. Hadar, P. Mor, G. Amit, S. Lieberman, E. Tahover, O. Rosengarten, M. Carmon, O. Olsha, R. Abu Dalo, R. Michaelson-Cohen, E. Golomb, R. Rabinovitch, E. Levy-Lahad*
- Board 156 **Abstract 1585: Implementing genetic risk assessment in a community free clinic.** *L. Marsh, D. Kamara, B. Rimel*
- Board 157 **Abstract 1586: The incidence of germline cancer susceptibility mutations in primary CNS neoplasm patients.** *K. Lord, C. Boman, G. Patel, S. Thatikonda, M. D. Groves*

Saturday, June 2, 2018

- Board 158 **Abstract 1587: Value of germline multi-gene panel next generation sequencing (NGS) in identification of hereditary cancer syndromes (HCS) in colorectal cancer population (CRC).** *J. Gu, C. Ricker, A. Barzi*
- Board 159 **Abstract 1588: Multiplex germline testing in selected melanomas presenting to oncology clinic.** *P. Funchain, B. Heald, J. Song, E. Nizialek, J. Marquard, M. J. McNamara, A. A. Tarhini, B. Gastman, J. Arbesman*
- Board 160 **Abstract 1589: Incidence of pathogenic variants in individuals with a personal or family history of pancreatic cancer.** *P. M. Kasi, S. K. Macklin, S. L. Hines*
- Board 161 **Abstract 1590: Implementation of strategies to increase genetic counseling referral rates for ovarian cancer patients.** *K. J. Milliron, V. Prince, L. Hipp, S. Uppal, M. Brackmann, R. Reynolds, S. Merajver, K. McLean*
- Board 162 **Abstract 1591: Referral patterns and attrition rate for germline testing in pancreatic cancer (PC) patients.** *E. J. Walker, J. C. Carnevale, C. Pedley, A. Blanco, S. Chan, E. A. Collisson, A. H. Ko*
- Board 163 **Abstract 1592: The impact of genetic counseling on patients' knowledge about tumor genomic profiling.** *R. D. Pentz, B. McDaniels, C. Bellcross, W. L. Shaib, J. M. Switchenko, M. D. Dixon*
- Board 164 **Abstract 1593: Incidence and risk of second primary malignancy after an index potentially-human papillomavirus-associated cancer.** *E. Adjei Boakye, P. Buchanan, L. J. Hinyard, N. Osazuwa-Peters, M. C. Simpson, M. Schootman, J. F. Piccirillo*
- Board 165a **Abstract TPS1594: Evaluating intermittent dosing of aspirin for colorectal cancer prevention.** *K. M. Alber, H. Murff, R. Ness, D. Seidner, X. Zhu, M. Shrubsole, M. Tull, K. A. Benante, A. J. Segura, K. Kalinichenko, L. Hou, B. Jovanovic, G. Della'Zanna, E. Richmond, S. A. Khan, Q. Dai*
- Board 165b **Abstract TPS1595: A phase IIB pre-surgical trial of oral tamoxifen (TAM) versus transdermal 4-hydroxytamoxifen (4-OHT) in women with DCIS of the breast.** *K. A. Benante, Y. Xu, M. Tull, A. J. Segura, K. M. Alber, K. Kalinichenko, L. Hou, B. Jovanovic, M. Perloff, B. M. Heckman-Stoddard, E. P. Dimond, S. A. Khan*

1:15 PM - 4:45 PM Poster Session

Central Nervous System Tumors

Location: Hall A

Abstracts on Boards 167-178 will be discussed during the Central Nervous System Tumors Poster Discussion Session.

Posters by Topic

Brain Metastases: Boards 167-169, 220-228

Central Nervous System Tumors: Boards 170-219

Trials in Progress: Boards 229a-230b

- Board 167 **Abstract 2009: Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.** *S. B. Goldberg, S. N. Gettinger, A. Mahajan, R. S. Herbst, A. C. Chiang, R. Lilenbaum, L. Jilaveanu, E. Rowen, H. Gerrish, A. Komlo, W. Wei, V. Chiang, H. M. Kluger*
- Board 168 **Abstract 2010: Risk of CNS adverse events (CNS-AEs) for patients with non-small cell lung cancer (NSCLC) and melanoma brain metastases (BM) treated with CNS radiation (CNS-RT) and immune checkpoint inhibitors (CPIs).** *M. E. Devitt, R. S. Abraham, J. Hines, B. J. Horton, C. E. Fadol, J. M. Larner, J. Sheehan, R. D. Hall, R. D. Gentzler*
- Board 169 **Abstract 2011: Risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: Results from a national cohort.** *B. Iorgulescu, M. Harary, C. Zogg, K. L. Ligon, D. A. Reardon, F. S. Hodi, A. A. Aizer, T. Smith*

- Board 170 **Abstract 2012: A large, multicenter, retrospective study to identify a cutoff of MGMT methylation status by quantitative pyrosequencing approach in patients (PTS) with glioblastoma (GBM).** *G. Lombardi, L. Bellu, V. Villani, S. Rizzato, M. Russo, M. Carosi, E. De Carlo, L. Biasini, M. Gardiman, P. Fiduccia, A. Pambuku, A. Della Puppa, M. Skrap, F. Servadei, D. D'Avella, C. M. Carapella, M. Caccese, R. Bertorelle, A. Pace, V. Zagonel*
- Board 171 **Abstract 2013: Differential elevation of TERT activity and sensitivity to temozolomide by type of TERT mutation in MGMT promoter-methylated glioblastoma.** *M. Weller, A. Papachristodoulou, B. Hentschel, D. Gramatzki, J. Felsberg, M. Loeffler, G. Schackert, M. Westphal, J. Tonn, M. Silginer, A. von Deimling, T. Pietsch, G. Reifenberger, P. Roth*
- Board 172 **Abstract 2014: The natural course of hypermutator gliomas.** *C. Kamiya-Matsuoka, N. R. Metrus, K. R. Shaw, M. Penas-Prado, S. S. Weathers, M. E. Loghin, K. Alfaro-Munoz, Y. Yuan, B. J. O'Brien, R. A. Harrison, W. A. Yung, F. Meric-Bernstam, J. F. De Groot*
- Board 173 **Abstract 2015: Phase 1b/2 study of pexidartinib (PEX) in combination with radiation therapy (XRT) and temozolomide (TMZ) in newly diagnosed glioblastoma.** *H. Colman, J. J. Raizer, T. Walbert, S. R. Plotkin, M. C. Chamberlain, E. T. Wong, V. K. Puduvalli, D. A. Reardon, F. M. Iwamoto, M. M. Mrugala, B. Johnson, K. Sonty, D. A. Karlin, M. Pelayo, M. Hutchinson, H. Hsu*
- Board 174 **Abstract 2016: Safety and preliminary efficacy data from a phase I study of an implantable low intensity pulsed ultrasound (LIPU) device for disrupting the blood-brain barrier (BBB) in patients treated by chemotherapy for recurrent glioblastoma (GBM).** *A. Idubaihi, M. Canney, C. Desseaux, A. Vignot, B. Law-Ye, D. Leclercq, L. Belin, A. Bissery, Y. De Ricke, M. Sanson, K. Hoang-Xuan, C. Dehais, C. Houillier, F. Laigle-Donadey, J. Delattre, A. Carpenter*
- Board 175 **Abstract 2017: VX001 phase I study in patients with progressive glioblastoma: Final results.** *W. Wick, A. Wick, F. Sahm, D. Riehl, A. von Deimling, M. Bendszus, P. Kickingereder, P. Beckhove, F. H. Schmitz-Winnenthal, C. Jungk, S. Wieckowski, L. Podola, C. Herold-Mende, A. Unterberg, M. Platten*
- Board 176 **Abstract 2018: Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2.** *A. J. Chalmers, S. Short, C. Watts, C. Herbert, A. Morris, J. Stobo, G. Cruickshank, L. Dunn, S. Erridge, L. Godfrey, S. Jefferies, J. S. Lopez, C. McBain, M. Pittman, S. Dillon, A. James, S. A. Nowicki, A. Williamson, C. Kelly, S. E. Halford*
- Board 177 **Abstract 2019: CXCR4 blockade at the end of irradiation to improve local control of glioblastoma (GBM).** *R. P. Thomas, S. Nagpal, M. Iv, S. G. Soltys, S. Bertrand, J. S. Pelpola, J. Yang, R. L. Ball, M. Brown, L. D. Recht*
- Board 178 **Abstract 2020: Effect of dexamethasone in glioblastoma (GBM) patients on systemic and intratumoral T cell responses induced by personalized neoantigen-targeting vaccine.** *D. A. Reardon, D. S. Neuberg, D. B. Keskin, I. Tirosh, A. Anandappa, N. D. Mathewson, J. Sun, S. A. Shukla, E. Gjini, S. Li, A. Giobbie-Hurder, K. Wucherpfennig, M. Suva, E. Fritsch, S. Rodig, K. L. Ligon, K. J. Livak, N. Hacohen, C. J. Wu, P. A. Ott*
- Board 179 **Abstract 2021: Long-term stroke risk of single-fraction photon-based stereotactic radiosurgery for meningioma.** *S. McClelland, J. N. Ciporen, T. Mitin, J. J. Jaboin*
- Board 180 **Abstract 2022: A unique MRI-based radiomic signature predicts hypermutated glioma genotype.** *I. Hassan, A. Kotrotsou, C. Kamiya-Matsuoka, K. Alfaro-Munoz, N. Elshafeey, N. A. El Shafei, P. Zinn, J. F. De Groot, R. R. Colen*
- Board 181 **Abstract 2023: Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux-M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).** *M. J. Van Den Bent, P. French, M. Eoli, J. M. Sepúlveda, A. E. Walenkamp, J. Frenel, E. Franceschi, P. M. Clement, M. Weller, I. de Heer, J. Looman, J. Dey, S. Krause, H. Xiong, P. J. Ansell, S. Nuyens, M. Spruyt, J. Brilhante, T. Gorlia, V. Golfopoulos*

Saturday, June 2, 2018

- Board 183 **Abstract 2025: Depression and survival of glioma patients: A systematic review and meta-analysis.** *N. Lamba, C. Shi, L. Zheng, D. Cote, Q. Regestein, C. Liu, S. Routh, T. Smith, R. Mekary, M. Broekman*
- Board 184 **Abstract 2026: Association between treatment facility volume and mortality in patients with glioblastoma (GBM): A large national analysis.** *S. Aulakh, M. DeDeo, J. Free, K. Berdeguez, S. Rosenfeld, A. Quinones-Hinojosa, A. A. Chanan-Khan, S. Ailawadhi*
- Board 185 **Abstract 2027: Angiotensinogen gene silencing to predict bevacizumab response in recurrent glioblastoma patients.** *T. Urup, L. Gillberg, S. R. Michaelsen, I. J. Christensen, H. Broholm, U. N. Lassen, K. Grønnebæk, H. S. Poulsen*
- Board 186 **Abstract 2028: Genomic landscape of pineoblastoma.** *B. K. Li, A. Vasiljevic, B. Ho, A. Jouvet, E. I. Hwang, J. R. Hansford, A. Laquerriere, M. Delisle, S. Gururangan, J. R. Fangusaro, F. Forest, N. Sumihito, H. Toledano, M. Fouladi, G. Gauchotte, D. S. Ziegler, E. Bouffet, R. G. Grundy, C. Dufour, A. A. Huang*
- Board 187 **Abstract 2029: Contrast enhancement as a prognostic factor in IDH1/2 mutant glioma.** *B. Suchorska, U. Schüller, A. Biczok, F. Kreth, M. Lenski, N. L. Albert, A. Giese, B. Ertl-Wagner, M. Ingrisch, J. Tonn*
- Board 188 **Abstract 2030: Meningioma: Association of mean and “hot spot” MIB1 with grade.** *C. Dardis, L. S. Ashby, S. Coons*
- Board 189 **Abstract 2031: Interrogating machine learning classifiers and dimensionality reduction techniques for radiomic prediction of glioma tumor grade.** *K. Wahid, A. Kotrotsou, S. Abrol, A. Hassan, N. Elshafeey, R. R. Colen*
- Board 190 **Abstract 2032: Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.** *E. Q. Lee, A. Muzikansky, D. A. Reardon, J. Dietrich, L. Nayak, D. G. Duda, U. N. Chukwueke, R. Beroukhim, L. M. Doherty, C. Kane, D. C. LaFrankie, B. Fontana, J. Stefanik, S. Ruland, V. Caruso, J. Bruno, S. C. Gaffey, P. Y. Wen*
- Board 191 **Abstract 2033: Effect of therapeutic pressure on stability of EGFR amplification in glioblastoma.** *M. S. Ahluwalia, C. R. Dimino, M. M. Mansukhani, V. Murty, P. Canoll, Y. Narita, Y. Muragaki, H. K. Gan, R. T. Merrell, M. J. Van Den Bent, Z. Zha, L. Roberts-Rapp, F. Jiang, M. Guseva, E. E. Bain, C. J. Ocampo, P. J. Ansell, A. B. Lassman*
- Board 192 **Abstract 2034: NKG2D chimeric antigen receptor-t cells to target GBM.** *H. Dai, D. Yang, B. Sun, L. Shi, P. Zhang, X. Zhao*
- Board 193 **Abstract 2035: A phase I/II clinical trial of autologous CMV-specific cytotoxic t cells (CMV-TC) for glioblastoma: Dose escalation results.** *M. Penas-Prado, K. Rezvani, S. S. Weathers, S. Zhou, C. Kamiya-Matsuoka, B. J. O'Brien, M. E. Lohin, R. A. Harrison, B. L. Pei, S. Ictech, K. Hunter, W. A. Yung, J. F. De Groot, E. J. Shpall, A. B. Heimberger*
- Board 194 **Abstract 2036: Phase I study of afatinib and radiotherapy (RT) with or without temozolomide (TMZ) in newly diagnosed glioblastoma (GB).** *F. Saran, L. Welsh, A. James, C. McBain, R. Gattamaneni, S. Jefferies, F. Harris, A. Cseh, K. Pemberton, J. Schaible, S. Bender, M. Brada*
- Board 195 **Abstract 2037: Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with recurrent glioblastoma.** *L. Nayak, T. Smith, S. C. Gaffey, K. B. Peters, J. L. Clarke, J. T. Jordan, J. F. De Groot, P. L. Nghiemphu, T. J. Kaley, H. Colman, T. Armstrong, M. J. Taphoorn, V. Caruso, M. Bednarek Debruyne, C. Bhavsar, A. M. Molinaro, M. Severgnini, P. Y. Wen, D. A. Reardon*
- Board 196 **Abstract 2038: How far have we really come? Trends in survival and mortality for gliomas between 1973 to 2014 from SEER.** *S. R. Sheikh, T. Radivoyevitch, M. A. Vogelbaum*

- Board 197 Abstract 2039: Comprehensive genomic profiling of brain tumors to provide targeted therapy options and diagnostic certainty for oligodendrogliomas.**
L. A. Albacker, D. Pavlick, J. S. Ross, G. J. Lesser, R. J. Corona, H. Colman, M. D. Groves, S. H. Hsu, A. S. Chi, V. A. Miller, G. M. Frampton, S. Ramkissoon
- Board 198 Abstract 2040: Concordance between RTOG and EORTC risk factors in low grade gliomas: Who will remain standing in the ring at bell's sound?**
E. Franceschi, A. Mura, A. Paccapelo, S. Bartolini, S. Minichillo, A. Lanese, R. Agati, D. Balestrini, M. Currà, C. Scafati, M. Visani, M. Di Battista, L. Lombardo, G. Genestreti, A. A. Brandes
- Board 199 Abstract 2041: Phase II trial of SurVaxM combined with standard therapy in patients with newly diagnosed glioblastoma.** *M. S. Ahluwalia, D. A. Reardon, A. P. Abad, W. T. Curry, E. T. Wong, A. Belal, J. Qiu, K. Mogensen, C. Schilero, D. Casucci, L. Mechtler, E. J. Uhlmann, M. J. Ciesielski, R. Fenstermaker*
- Board 200 Abstract 2042: Secondary prophylaxis with romiplostim for temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma.** *E. Le Rhun, P. Devos, C. Houillier, S. Cartalat-Carel, O. L. Chinot, A. Di Stefano, M. Dib, N. Reyns, F. Dubois, M. Weller*
- Board 201 Abstract 2043: Association of anticonvulsant prophylaxis in patients with primary and metastatic brain tumors and 1-year overall survival: A systematic review and meta-analysis.** *T. J. Brown, C. M. Zoccoli, A. Ali, L. J. Kim, M. J. Glantz*
- Board 202 Abstract 2044: Phase I factorial study of temozolomide plus memantine, mefloquine, and metformin as post-radiation adjuvant therapy for newly diagnosed glioblastoma.** *S. Maraka, M. D. Groves, A. G. Mammoser, I. Melguizo-Gavilanes, C. A. Conrad, I. Tremont-Lukats, M. E. Loghin, B. J. O'Brien, V. K. Puduvali, E. P. Sulman, K. R. Hess, K. D. Aldape, M. R. Gilbert, J. F. De Groot, W. A. Yung, M. Penas-Prado*
- Board 203 Abstract 2045: A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study).**
M. Khasraw, K. L. McDonald, M. Rosenthal, Z. Lwin, D. M. Ashley, H. Wheeler, E. Barnes, E. Koh, M. C. Foote, M. Buckland, L. Fisher, R. Leonard, M. Hall, S. Yip, J. Simes
- Board 204 Abstract 2046: Hypofractionated stereotactic radiotherapy and anti-PDL1 durvalumab combination in recurrent glioblastoma: Results of the phase I part of the phase I/II STERIMGLI trial.** *D. Pouessel, A. Mervoyer, D. Larrieu-Ciron, B. Cabarrou, J. Attal, M. Robert, J. Frenel, P. Olivier, M. Poulblanc, M. Mounier, E. Moyal*
- Board 205 Abstract 2047: Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS).** *G. Lombardi, G. De Salvo, R. Ruda, E. Franceschi, M. Eoli, M. Faedi, A. Pace, I. Lolli, S. Rizzato, D. Germano, F. Pasqualetti, M. Farina, G. Magni, L. Bellu, A. Pambuku, E. Bergo, S. Indraccolo, M. Gardiman, R. Soffiatti, V. Zagonel*
- Board 206 Abstract 2048: Plasma cell-free DNA (cfDNA) concentration and radiographic tumor burden in patients with glioblastoma (GBM).** *S. J. Bagley, J. Mays, S. A. Nabavizadeh, S. S. Yee, S. S. Levy, A. S. Desai, E. L. Carpenter*
- Board 207 Abstract 2049: Preoperative and non-invasive prediction of chromosome arm 1p/19q codeletion in oligodendroglial tumors using MRI-based radiomics.**
J. Wei, D. Gu, J. Tian
- Board 208 Abstract 2050: IDH-wild type low grade gliomas: An AINO (Italian Association of Neuro-Oncology) retrospective study.** *R. Ruda, F. Bruno, A. Silvani, T. Ius, L. Bello, G. Minniti, A. Pace, G. Lombardi, R. Soffiatti*
- Board 209 Abstract 2051: Non-invasive determination of the O⁶-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status in glioblastoma (GBM) using magnetic resonance imaging (MRI).** *S. Rathore, S. Bakas, M. P. Nasrallah, S. J. Bagley, H. Akbari, S. Ha, E. C. Mamourian, C. D. Watt, C. Davatzikos*

Saturday, June 2, 2018

- Board 210 Abstract 2052: Improved prognostic accuracy of alternative MGMT methylation status cutpoint: A single institution experience.** *J. Easaw, R. Gloria, E. Batuyong, E. Kornaga, A. Almuqate, W. Sayeed, D. Itani*
- Board 211 Abstract 2053: NRG BN002: Phase I study of checkpoint inhibitors anti-CTLA-4, anti-PD-1, the combination in patients with newly diagnosed glioblastoma.** *A. E. Sloan, M. R. Gilbert, P. Zhang, K. D. Aldape, J. Wu, L. R. Rogers, P. Y. Wen, I. J. Barani, F. M. Iwamoto, R. R. Raval, A. D. Voloschin, J. F. De Groot, M. Won, M. P. Mehta*
- Board 212 Abstract 2054: GEINO 1402: A phase Ib dose-escalation study followed by an extension phase to evaluate safety and efficacy of crizotinib in combination with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed glioblastoma (GB): Results of the dose-escalation phase.** *M. Martinez Garcia, M. J. Gil Gil, E. Pineda Losada, G. Velasco, F. Alameda, A. Taus, J. Capellades, A. Márquez-Martín, B. Sarmiento, C. Mesia Barroso, J. Bruna Escuer, E. Verger, A. Hernandez-Lain, M. Guzman, J. M. Sepúlveda*
- Board 213 Abstract 2055: Correlation of immune infiltration of cytotoxic T cells and activated microglia in glioblastoma (GBM) post anti-PD1 therapy with response.** *A. Silverman, R. D. Gartrell, J. Zhao, S. Batool, T. D. Hart, S. Hasan, J. H. Garvin, G. Zanazzi, F. M. Iwamoto, R. Rabadan, P. Canoll, Y. M. Saenger*
- Board 214 Abstract 2056: Preliminary report of a multicenter, phase 2 study of bevacizumab in children and adults with neurofibromatosis 2 and progressive vestibular schwannomas: An NF Clinical Trials Consortium study.** *S. R. Plotkin, J. H. Tonsgard, N. J. Ullrich, J. C. Allen, T. L. Rosser, J. L. Campian, D. W. Clapp, M. J. Fisher, G. R. Cutter, B. R. Korf, R. Packer, C. Thomas, M. A. Karajannis, J. O. Blakeley*
- Board 215 Abstract 2057: Prospective analysis of cancer stem cell drug response assay for glioblastoma patients.** *T. Ranjan, C. M. Howard, J. Valluri, A. Yu, K. Aziz, D. Jho, T. D. Julien, J. Leonardo, A. Alberico, A. Cortese, K. L. Denning, P. Claudio*
- Board 216 Abstract 2058: Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival.** *D. M. Peereboom, L. B. Nabors, P. Kumthekar, M. A. Badruddoja, K. L. Fink, F. S. Lieberman, S. Phuphanich, E. M. Dunbar, T. Walbert, D. Schiff, D. D. Tran, L. S. Ashby, N. A. Butowski, F. M. Iwamoto, R. Lindsay, J. Bullington, M. Schulder, J. Sherman, T. Goswami, D. A. Reardon*
- Board 217 Abstract 2059: Integrated clinical experience with ONC201 in H3 K27M glioma.** *A. S. Chi, S. L. Gardner, I. Arrillaga, P. Y. Wen, T. Batchelor, M. D. Hall, Y. Odia, W. T. Zaky, S. Khatua, N. A. Shonka, Z. Khatib, R. Tarapore, L. Schalop, J. E. Allen, W. Oster, M. P. Mehta*
- Board 218 Abstract 2060: Community socioeconomic status to identify higher-risk patients with malignant glioma.** *A. S. Bower, C. Yelton, C. Cramer, M. H. Soike, E. McTyre, R. Wicks, R. Merrill, S. Azagba, S. B. Tatter, A. W. Laxton, G. J. Lesser, M. D. Chan, R. E. Stroud*
- Board 219 Abstract 2061: Dianhydrogalactitol in bevacizumab-refractory GBM: Further analysis of a phase 1-2 trial.** *K. C. Shih, M. R. Patel, N. A. Butowski, G. S. Falchook, S. H. Kizilbash, S. F. Jones, J. A. Bacha, D. Brown, R. S. Schwartz, S. Kanekal, J. C. Constant, H. A. Burris III*
- Board 220 Abstract 2062: Neurological death in patients with EGFR-mutant non-small cell lung cancer.** *M. Ramotar, S. Barnes, M. Doherty, D. B. Shultz*
- Board 221 Abstract 2063: Impact of prior systemic therapy on lymphocytic infiltration in surgically resected breast cancer brain metastases.** *A. Bacotti, R. Wang, A. M. Deal, G. Prince, M. J. McKee, S. J. Moschos, E. Brogi, A. Morikawa, C. K. Anders, A. D. Seidman*
- Board 222 Abstract 2064: Outcomes of lung cancer patients with leptomeningeal metastases in the targeted therapy era.** *K. S. Nevel, N. DiStefano, X. Lin, A. Cowan, A. Skakodub, S. Ogilvie, E. Pentsova, A. A. Boire*

- Board 223 Abstract 2065: Impact of apolipoprotein E (APOE) genotype on neurocognitive function (NCF) in patients with brain metastasis (BM): An analysis of NRG Oncology's RTOG 0614.** *J. S. Wefel, S. Deshmukh, P. D. Brown, D. R. Grosshans, E. P. Sulman, J. H. Cerhan, M. P. Mehta, D. Khuntia, W. Shi, M. V. Mishra, J. H. Suh, N. N. Laack, Y. Chen, A. Curtis, J. Laba, R. B. Mowat, A. Thakrar, S. L. Pugh, D. W. Bruner*
- Board 224 Abstract 2066: Incidence of treatment effect and characteristic MRI findings in immunotherapy-treated melanoma patients with brain metastases receiving stereotactic radiosurgery.** *J. L. Sovich, A. Srinivasan, M. M. Kim, J. Heth, L. A. Fecher, C. D. Lao*
- Board 225 Abstract 2067: Mutational complexity increases in lung adenocarcinoma (LADC) with the development of brain metastasis (BM).** *M. K. Stein, M. G. Martin, J. Xiu, S. Mittal, S. Phuphanich, A. P. Provenzano, S. Michelhaugh, A. J. Brenner, D. S. Subramaniam, A. L. Sumrall, A. B. Heimberger, S. Kesari, W. M. Korn, M. K. Pandey*
- Board 226 Abstract 2068: Discovery of a predictive protein biomarker for leptomeningeal disease after craniotomy and radiation.** *M. H. Soike, J. Ruiz, E. McTyre, S. O'Neill, S. Qasem, C. M. Furdul, J. Lee, T. Lycan Jr., C. Rodman, K. Watabe, S. B. Tatter, A. W. Laxton, M. D. Chan, J. Su*
- Board 227 Abstract 2069: MRI texture features and outcomes to immune checkpoint inhibitors in melanoma brain metastases.** *A. Bhatia, M. Birger, H. Veeraraghavan, H. Um, A. S. McKenney, M. Cugliari, A. Bialczak, R. Malani, Z. Zhang, T. Yang, R. J. Young, A. N. Shoushtari*
- Board 228 Abstract 2070: Timing, presentation, and patterns of failure of leptomeningeal disease after surgical resection and radiosurgery for brain metastases: A multi-institutional analysis.** *R. S. Prabhu, S. G. Soltys, B. E. Turner, S. Marcrom, J. B. Fiveash, P. M. Foreman, R. H. Press, K. R. Patel, W. J. Curran Jr., W. Breen, P. D. Brown, K. Jethwa, I. S. Grills, J. Arden, L. M. Foster, M. A. Manning, J. D. Stern, A. L. Asher, S. Burri*
- Board 229a Abstract TPS2071: A randomized, multicenter phase 2 study of DSP-7888 dosing emulsion in combination with bevacizumab (Bev) versus Bev alone in patients with recurrent or progressive glioblastoma.** *J. F. De Groot, T. F. Cloughesy, M. W. Pitz, Y. Narita, T. Nonomura*
- Board 230a Abstract TPS2073: A phase II, open label, single arm study of nivolumab for recurrent or progressive IDH mutant gliomas with prior exposure to alkylating agents.** *L. Donovan, D. Cieremans, L. Nayak, Y. Odia, F. M. Iwamoto*
- Board 230b Abstract TPS2074: Phase I/II study of laser interstitial thermotherapy (LITT) combined with checkpoint inhibitor for recurrent glioblastoma (rGBM).** *A. E. Sloan, L. R. Rogers, M. Machtay*

1:15 PM - 4:45 PM Poster Session

Genitourinary (Prostate) Cancer

Location: Hall A

Abstracts on Boards 236-247 will be discussed during the Genitourinary (Prostate) Cancer Poster Discussion Session.

Posters by Topic

Advanced Disease: Boards 236-237, 239-244, 246-284

Biomarkers/Epidemiology/Outcomes: Boards 285-305

Local-Regional: Boards 238, 306-311

Other: Boards 245, 312

Trials in Progress: Boards 313a-320b

Saturday, June 2, 2018

- Board 236 Abstract LBA5009: Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).** *D. J. George, E. I. Heath, A. O. Sartor, G. Sonpavde, W. R. Berry, P. Healy, C. Winters, C. Riggan, M. Anand, J. Kephart, M. I. Milowsky, M. T. Fleming, K. C. Balaji, T. Zhang, R. L. Bitting, M. R. Harrison, M. A. McNamara, J. A. Freedman, S. Halabi, A. J. Armstrong, D. Bruner*
- Board 237 Abstract 5010: Health-related quality of life (HRQoL) deterioration and pain progression in men with non-metastatic castration-resistant prostate cancer (M0 CRPC): Results from the PROSPER study.** *G. Attard, F. Saad, B. F. Tombal, M. Hussain, C. N. Sternberg, D. Phung, S. Naidoo, K. Modelska, A. Reisman, C. Ivanescu, D. F. Penson*
- Board 238 Abstract 5011: Self-management in prostate cancer survivors: A randomized controlled trial.** *T. A. Skolarus, T. Metreger, H. Kim, R. L. Grubb III, J. R. Gingrich, H. Zhu, S. Hwang, J. D. Piette, S. T. Hawley*
- Board 239 Abstract 5012: Phenotypic and genomic characterization of CTCs as a biomarker for prediction of Veliparib therapy benefit in mCRPC.** *R. Dittamore, Y. Wang, S. Daignault-Newton, W. M. Stadler, A. Jendrisak, F. Y. Feng, A. E. Dago, J. Lee, R. P. Graf, M. A. Landers, A. Chinnaiyan, M. Hussain*
- Board 240 Abstract 5013: Genomic profiling of primary prostate tumors from patients who develop metastatic castration-resistant prostate cancer (mCRPC).** *J. Mateo, S. Carreira, G. Seed, R. Chandler, D. Dolling, I. Figueiredo, S. Miranda, D. Nava Rodrigues, C. Bertan, D. Bianchini, C. Ralph, R. J. Jones, U. B. McGovern, M. A. Varughese, O. Parikh, S. Jain, T. Elliott, N. Porta, E. Hall, J. S. De Bono*
- Board 241 Abstract 5014: The complete genomic landscape of metastatic prostate cancer pinpoints clinically targetable subgroups.** *L. F. van Dessel, J. van Riet, M. Smits, M. S. Van Der Heijden, P. Hamberg, E. E. Voest, J. M. Zuetenhorst, N. Steeghs, P. Witteveen, J. W. Martens, M. P. Hendriks, A. M. Bergman, R. De Wit, S. Sleijfer, E. P. Cuppen, H. J. van de Werken, N. Mehra, M. P. Lolkema*
- Board 242 Abstract 5015: Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCRPC): Results for 2nd-line therapy.** *D. Khalaf, M. Annala, D. L. Finch, C. D. Oja, J. Vergidis, M. Zulfiqar, K. Sunderland, K. Beja, G. R. Vandekerkhove, M. Gleave, A. W. Wyatt, K. N. Chi*
- Board 243 Abstract 5016: Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP+D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP).** *K. A. Autio, E. S. Antonarakis, T. M. Mayer, U. N. Vaishampayan, D. H. Shevrin, M. R. Harrison, S. T. Tagawa, M. I. Milowsky, J. N. Graff, T. M. Beer, A. V. Balar, M. Stein, E. I. Heath, A. J. Armstrong, C. J. Paller, L. T. Nordquist, E. S. Dayan, K. Tse, G. Heller, H. I. Scher*
- Board 244 Abstract 5017: Prostate radiotherapy in newly-diagnosed metastatic hormone-sensitive prostate cancer: A single-institution experience.** *S. C. Morgan, O. Holmes, J. Craig, S. Grimes, L. Eapen, S. Malone*
- Board 245 Abstract 5018: Timing of androgen deprivation therapy for prostate cancer patients after radiation: Planned combined analysis of two randomized phase 3 trials.** *A. Loblaw, J. Bassett, C. D'Este, G. R. Pond, P. Cheung, J. L. Millar, M. Frydenberg, M. T. King, H. Lukka, S. Malone, R. L. Milne, T. Pickles, R. Smith, M. R. Stockler, S. Turner, K. H. Tai, H. Woo, G. M. Duchesne*
- Board 246 Abstract 5019: KEYNOTE-046: ADXS-PSA plus pembrolizumab (pembro) in metastatic castration-resistant prostate cancer (mCRPC).** *M. N. Stein, L. Fong, R. F. Tutrone, A. E. Mega, M. Lobo, Q. Hong, N. B. Haas*
- Board 247 Abstract 5020: Microsatellite instability in prostate cancer and response to immune checkpoint blockade.** *W. Abida, M. L. Cheng, J. Armenia, S. Middha, K. A. Autio, D. E. Rathkopf, M. J. Morris, D. C. Danila, S. F. Slovin, E. Carbone, M. Hullings, J. F. Hechtman, V. E. Reuter, M. F. Berger, P. W. Kantoff, C. L. Sawyers, N. Schultz, D. B. Solit, A. Gopalan, H. I. Scher*

- Board 248 Abstract 5021: Immunotherapy utilizing the combined use of NK and ADCC mediating agents with PARP inhibition.** *K. Fenerty, M. R. Padget, J. Schlom, J. W. Hodge*
- Board 249 Abstract 5022: Radium-223 re-treatment in an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases: 2-year follow-up.** *A. O. Sartor, D. Heinrich, N. Mariados, M. J. Méndez-Vidal, D. Keizman, C. Thellenberg Karlsson, A. Pe'er, G. Procopio, S. J. Frank, K. Pulkkanen, E. Rosenbaum, S. Severi, J. Trigo Perez, L. Trandafir, V. J. Wagner, R. Li, L. T. Nordquist*
- Board 250 Abstract 5023: Longer term preplanned efficacy and safety analysis of abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial.** *K. Fizazi, S. Feyerabend, N. Matsubara, M. Ozguroglu, L. E. Fein, A. Rodríguez Antolín, B. Y. Alekseev, G. Sulur, A. Protheroe, P. De Porre, S. Li, Y. C. Park, S. Mundle, N. Tran, K. N. Chi*
- Board 251 Abstract 5024: Disease response and fracture assessment by whole body diffusion-weighted MRI (WB-DWMRI) in metastatic castration resistant prostate cancer (mCRPC).** *C. C. Parker, R. Alonzi, N. Tunariu, D. Koh, J. Staffurth, A. Tree, M. D. Blackledge, S. Chua, G. J. Cook, Y. Du, A. R. Padhani, A. Robinson, J. S. De Bono, P. Flohr, B. Johnson, J. Finch, P. Chatfield, S. Perry, D. Dolling, E. Hall*
- Board 252 Abstract 5025: Cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC): Real-life use, effectiveness, safety, and quality of life (QoL) in the FUJI cohort.** *S. Oudard, K. Fizazi, F. Joly, F. Tubach, M. Rouyer, S. Lamarque, E. Guiard, A. Balestra, C. Lacueille, J. Jové, C. Droz-Perroteau, A. Fourrier-Réglat, N. Moore*
- Board 253 Abstract 5026: Survival outcomes from a cumulative analysis from worldwide observational studies on sequential use of new agents (NAs) in metastatic castration-resistant prostate cancer (mCRPC) (CASTOR study).** *O. Caffo, M. Wissing, D. Bianchini, A. M. Bergman, F. B. Thomsen, S. Schmid, E. Y. Yu, E. Bournakis, A. Sella, U. Basso, U. De Giorgi, M. Tucci, H. Gelderblom, L. Galli, I. Sperduti, S. Oudard*
- Board 254 Abstract 5027: Relationship between sipuleucel-T (sip-T) cytolytic T lymphocyte (CTL) activity and overall survival (OS) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).** *C. G. Drake, E. S. Antonarakis, D. P. Petrylak, D. I. Quinn, A. S. Kibel, N. N. Chang, E. Dearstyne, D. Campogan, H. Haynes, T. Vu, N. A. Sheikh, E. J. Small*
- Board 255 Abstract 5028: Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): Detailed analyses from the phase 3 LATITUDE trial.** *K. N. Chi, N. Tran, S. Feyerabend, N. Matsubara, M. Ozguroglu, L. E. Fein, A. Rodríguez Antolín, B. Y. Alekseev, G. Sulur, A. Protheroe, P. De Porre, S. Li, Y. C. Park, S. Mundle, K. Fizazi*
- Board 256 Abstract 5029: Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223.** *A. J. Armstrong, S. Gupta, P. Healy, G. Kemeny, L. B. Leith, M. Zalutsky, C. Spritzer, C. Davies, C. Rothwell, K. Ware, J. Somarelli, K. Wood, T. Ribar, D. Gerber, M. Anand, S. Halabi, S. Gregory, D. J. George*
- Board 257 Abstract 5030: Genomic characterization of ductal adenocarcinoma of the prostate.** *M. T. Schweizer, E. S. Antonarakis, T. A. Bismar, L. Guedes, H. H. Cheng, M. S. Tretiakova, F. Vakar-Lopez, MD, N. Klemfuss, E. Q. Konnick, E. A. Mostaghel, A. C. Hsieh, P. S. Nelson, E. Y. Yu, R. B. Montgomery, L. D. True, J. I. Epstein, T. L. Lotan, C. Pritchard*

Saturday, June 2, 2018

- Board 258 **Abstract 5031: Combination of niclosamide to target androgen receptor variant 7 (AR-V7) and abiraterone to target androgen synthesis for the treatment of castration-resistant prostate cancer (CRPC): Initial results from a phase Ib/II trial.** *C. Pan, P. Lara Jr., C. P. Evans, M. Parikh, M. Dall'era, C. Liu, D. Robles, A. Gao*
- Board 259 **Abstract 5032: Association of metastasis-free survival (MFS) and overall survival (OS) in nonmetastatic castration-resistant prostate cancer (nmCRPC).** *M. R. Smith, M. Mehra, S. Nair, J. Lawson, E. J. Small*
- Board 260 **Abstract 5033: Relationship of time to metastasis (TTM) and site of metastases in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Results from the phase 3 SPARTAN trial.** *M. R. Smith, F. Saad, D. E. Rathkopf, B. A. Hadaschik, S. Chowdhury, M. K. Yu, A. Lopez-Gitlitz, O. B. Rooney, M. Darif, E. J. Small*
- Board 261 **Abstract 5034: Predicting disease progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): An analysis from the phase 3 SPARTAN trial.** *E. J. Small, F. Saad, D. E. Rathkopf, B. A. Hadaschik, S. Chowdhury, M. K. Yu, A. Lopez-Gitlitz, O. B. Rooney, Y. Shu, M. Darif, M. R. Smith*
- Board 262 **Abstract 5035: Testing the impact of adjuvant radiotherapy (aRT) after radical prostatectomy (RP) on overall mortality (OM) in prostate cancer patients with pathologically node positive disease: A nationwide analysis.** *F. Abdollah, A. Sood, D. Dalela, J. Keeley, Q. Trinh, S. R. Alane, C. Rogers, J. O. Peabody, M. Menon*
- Board 263 **Abstract 5036: Correlates of response to anti-PD-1 immune checkpoint blockade (ICB) in mismatch repair proficient (MMRp) and deficient (MMRd) patients (pts) with metastatic castration resistant prostate cancer (mCRPC).** *M. Smits, H. Westdorp, M. A. Gorris, T. van Ee, T. Duijveman-de Boer, K. Verrijp, J. C. Jones, I. M. van Oort, M. Sedelaar, A. Van Der Heijden, A. Witjes, A. Eijkelenboom, M. Ligtenberg, K. Grunberg, J. C. Textor, J. A. Schalken, J. L. Gulley, W. R. Gerritsen, J. De Vries, N. Mehra*
- Board 265 **Abstract 5038: A transcriptome analysis of castration resistant prostate cancer metastases in a prospective cohort study reveals high expression of AKT pathway genes predictive of long term response to abiraterone acetate/prednisone.** *M. Kohli, S. Dehm, V. Bhargava, M. Gormley, J. P. Sinnwell, W. Tan, D. W. Hillman, Y. Li, R. E. Jimenez, R. M. Weinshilboum, K. R. Kalari, L. Wang, H. Sicotte*
- Board 266 **Abstract 5039: DNA repair mutations and treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) as hallmarks of distinct subgroups of metastatic castration resistant prostate cancer (mCRPC): Data from the West Coast Prostate Cancer Dream Team.** *R. R. Aggarwal, P. Lloyd, J. Huang, T. M. Beer, L. Zhang, G. V. Thomas, L. D. True, J. J. Alumkal, V. Friedl, A. Weinstein, R. E. Reiter, M. Rettig, P. Lara Jr., M. Gleave, A. Foye, D. Playdle, F. Y. Feng, K. N. Chi, J. Stuart, E. J. Small*
- Board 267 **Abstract 5040: Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase II trial.** *S. K. Sandhu, J. A. Violet, J. Ferdinandus, S. Thang, A. Irvani, C. Guo, G. Kong, A. Ravi Kumar, T. J. Akhurst, A. Beaulieu, D. G. Murphy, J. Mooi, B. Tran, G. C. Toner, S. Williams, R. J. Hicks, M. Hofman*
- Board 268 **Abstract 5041: Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry.** *A. O. Sartor, C. S. Higano, M. R. Cooperberg, N. J. Vogelzang, S. R. Dakhil, C. M. Pieczonka, J. Vacirca, R. S. Conception, R. F. Tutrone, L. T. Nordquist, C. A. Olsson, D. F. Penson, I. Schnadig, J. L. Bailen, B. Mehlhaff, N. N. Chang, N. A. Sheikh, B. Brown, A. J. Armstrong*
- Board 269 **Abstract 5042: Cancer-related morbidity at the end of life in men with prostate cancer.** *D. Yerramilli, E. Walsh, E. Turner, G. Young, R. D. Nipp, J. Donovan, F. Hamdy, N. David, R. Martin, J. S. Temel, A. L. Zietman*

- Board 270 **Abstract 5043: Association between health-related quality of life (HRQoL) and clinical outcomes in non-metastatic castration-resistant prostate cancer (M0 CRPC): Results from the PROSPER study.** *G. Attard, F. Saad, B. F. Tombal, M. Hussain, C. N. Sternberg, D. Phung, S. Naidoo, K. Modelska, A. Reisman, C. Ivanescu, D. F. Penson*
- Board 271 **Abstract 5044: Transcriptional and post-transcriptional regulation of ribonucleotide reductase (RRM2) control its oncogenic role in prostate cancer progression.** *Y. Z. Mazzu, J. Armenia, G. Chakraborty, Y. Yoshikawa, T. A. Gerke, M. O. Atiq, K. H. Stopsack, K. Komura, G. M. Lee, L. A. Mucci, P. W. Kantoff*
- Board 272 **Abstract 5045: c15-160: Enzalutamide (ENZA) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1b Prostate Cancer Clinical Trials Consortium study.** *D. E. Rathkopf, K. A. Autio, E. S. Antonarakis, H. H. Cheng, G. Arauz, A. Slack, M. Hullings, H. I. Scher, F. Y. Feng, K. E. Knudsen*
- Board 273 **Abstract 5046: Patterns of PSA versus clinically progressive disease in the E3805 CHARTED trial.** *A. H. Bryce, Y. Chen, G. Liu, M. A. Carducci, D. F. Jarrard, J. A. Garcia, R. Dreicer, M. Hussain, M. A. Eisenberger, M. Kohli, N. M. Hahn, E. R. Plimack, N. J. Vogelzang, J. Picus, R. S. DiPaola, L. C. Harshman, C. Sweeney*
- Board 274 **Abstract 5047: Pembrolizumab (Pembro) plus enzalutamide (Enz) in metastatic castration resistant prostate cancer (mCRPC): Extended follow up.** *J. N. Graff, J. J. Alumkal, R. F. Thompson, A. Moran, G. V. Thomas, M. A. Wood, C. G. Drake, R. Slotke, T. M. Beer*
- Board 275 **Abstract 5048: Association of genomic alterations (GAs) in circulating tumor DNA (ctDNA) with progression on abiraterone acetate (AA) or enzalutamide (enza) in advanced prostate cancer.** *A. W. Hahn, E. Ledet, D. D. Stenehjem, R. Nussenzweig, M. Braithwaite, B. L. Maughan, M. B. Lilly, A. O. Sartor, N. Agarwal*
- Board 276 **Abstract 5049: Bone targeted therapy and skeletal related events in the era of modern therapies for castration resistant prostate cancer with bone metastases.** *L. Zhang, K. P. Gray, G. Shaw, C. Evan, E. Francini, C. Sweeney*
- Board 277 **Abstract 5050: Phase II safety and tolerability study of Radium-223 (R223) in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CTrial-IE (ICORG) 13-21.** *R. S. McDermott, J. P. Greene, O. Deignan, J. McCaffrey, I. Parker, A. Bowes, A. Teiserskiene, J. Feeney, P. G. Thirion, S. P. Finn, P. J. Kelly*
- Board 278 **Abstract 5051: Efficacy and tolerability of first-line abiraterone + prednisone (ABI) versus enzalutamide (ENZ) for metastatic castration-resistant prostate cancer (mCRPC) in men \geq 80 years: A retrospective cohort study.** *D. Khalaf, K. Zou, W. J. Struss, B. J. Eigl, C. K. Kollmannsberger, D. L. Finch, K. Noonan, J. Vergidis, M. Zulfiqar, K. N. Chi*
- Board 279 **Abstract 5052: Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in advanced prostate cancer (aPC) over treatment and time.** *D. D. Stenehjem, A. W. Hahn, R. Nussenzweig, E. Carroll, D. M. Gill, E. B. Bailey, J. A. Batten, B. L. Maughan, N. Agarwal*
- Board 280 **Abstract 5053: Unique patterns of the selection and change in circulating tumor cell (CTC) phenotypes and genotypes by drug class in metastatic castration-resistant prostate cancer (mCRPC).** *H. I. Scher, J. Schonhoff, R. P. Graf, A. E. Dago, J. Lee, R. Sutton, N. A. Schreiber, M. Hullings, A. Jendrisak, Y. Wang, M. A. Landers, R. Dittamore*
- Board 281 **Abstract 5054: Clonal concordance and genomic heterogeneity in single CTC copy number alterations vs. paired IMPACT metastatic tissue sequencing from mCRPC patient samples.** *H. I. Scher, A. E. Dago, J. Lee, R. Sutton, R. P. Graf, N. A. Schreiber, M. Hullings, Y. Wang, M. A. Landers, D. B. Solit, M. F. Berger, N. Schultz, R. Dittamore*
- Board 282 **Abstract 5055: Clinical outcomes with cumulative tumor suppressor gene (TSG) alterations in castration sensitive (CSPC) and resistant (CRPC) prostate cancer.** *A. Hamid, K. P. Gray, G. Shaw, L. E. MacConaill, C. Evan, B. D. Bernard, M. Loda, A. D. Choudhury, C. Sweeney*

Saturday, June 2, 2018

- Board 283 **Abstract 5056: Clinical outcomes following androgen receptor axis therapies (ARAT) among men with prostate cancer (PCa) having major cardiovascular diseases (CVDs) or extreme polypharmacy (EPP): A population based study.** G. L. Lu-Yao, G. Nightingale, N. Nikita, S. A. Patel, K. Gandhi, B. Leiby, S. Hegarty, A. M. Barsevick, N. Padron, T. Rebbeck, A. E. Chapman, L. G. Gomella, W. K. Kelly
- Board 284 **Abstract 5057: Safety data from a phase II randomized trial of radium-223 dichloride (Ra-223) plus enzalutamide (Enza) vs. Enza alone in men with metastatic castration refractory prostate cancer (mCRPC).** B. L. Maughan, J. M. Hoffman, K. Morton, B. Koppula, J. A. Batten, J. Thorley, J. Hawks, K. Boucher, N. Agarwal
- Board 285 **Abstract 5058: Six-month patient-reported outcome (PRO) results from AQUARIUS, a prospective, observational, multicenter phase 4 study in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone acetate + prednisone (AAP) or enzalutamide (ENZ).** A. Thiery Vuillemin, M. Poulsen, L. Dourthe, R. Trepiakas, E. Lagneau, E. P. Pintus, D. Beal-Ardisson, A. J. Birtle, G. Ploussard, H. Besson, M. Lukac, P. Robinson, A. H. Reid
- Board 286 **Abstract 5059: Expression of immune checkpoints (ICs) on circulating tumor cells (CTCs) in men with metastatic prostate cancer (mPC).** T. Zhang, R. G. Austin, S. E. Park, D. Runyambo, R. Boominathan, C. Rao, E. Bronson, M. Anand, P. Healy, D. J. George, M. A. McNamara, A. J. Armstrong
- Board 287 **Abstract 5060: The association of BRCA1 and BRCA2 mutations on prostate cancer risk, frequency, and mortality: Systematic review and meta-analysis.** M. Oh, R. Aljadeed, N. M. Al Khushaym, A. Althagafi, S. Fallatah, H. M. Babiker, A. McBride, I. Abraham
- Board 288 **Abstract 5061: Differences in genomic signatures and opportunities for targeted and immunotherapy treatment between castrate-resistant TMPRSS2:ERG fusion-positive and -negative refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC).** L. Kotula, G. Bratslavsky, H. A. Fisher, T. Byler, R. J. Corona, J. Jacob, A. Basnet, J. Chung, J. A. Elvin, J. Vergilio, J. Suh, S. H. Ramkissoon, S. Daniel, E. A. Severson, A. B. Schrock, S. M. Ali, V. A. Miller, L. M. Gay, J. S. Ross
- Board 289 **Abstract 5062: Prevalence of homologous recombination deficiency (HRD) mutations in localized prostate cancer according to Gleason grade: Implications for neoadjuvant clinical trial design.** C. Handy, A. S. Baras, T. L. Lotan, E. S. Antonarakis
- Board 290 **Abstract 5063: Early changes in PSA and association with outcomes in mCRPC patients.** P. Rescigno, D. Dolling, M. Rediti, V. Conteduca, M. Ong, H. Li, A. G. Omlin, S. Schmid, O. Caffo, A. Zivi, C. J. Pezaro, C. Morley, N. Romero-Laorden, M. Saez, N. Mehra, S. Sideris, S. K. Sandhu, C. N. Sternberg, U. De Giorgi, J. S. De Bono
- Board 291 **Abstract 5064: Molecular and clinical implications of CHD1 loss and SPOP mutations in advanced prostate cancer.** P. Rescigno, G. Boysen, D. Nava Rodrigues, G. Seed, D. Dolling, R. Riisnaes, M. Crespo, D. Bianchini, S. Sumanasuriya, I. Figueiredo, R. Christova, V. Gil, J. Goodall, A. Sharp, M. A. Rubin, W. Yuan, C. Barbieri, J. Mateo, S. Carreira, J. S. De Bono
- Board 292 **Abstract 5065: Analysis of genomic alterations in matched circulating tumor cell DNA (CTC DNA) and plasma tumor DNA (ctDNA) in men with metastatic castration resistant prostate cancer (mCRPC).** S. Gupta, D. H. Hovelson, S. A. Tomlins, G. Kemeny, C. Liu, D. J. George, C. Rothwell, M. Anand, D. M. Nanus, P. Giannakakou, S. Gregory, A. J. Armstrong
- Board 293 **Abstract 5066: Prostate cancer (PCa) incidence and severity in hypogonadal men treated with testosterone compared to untreated controls: Experience from 6,500 patient-years from a controlled registry study.** A. Haider, K. S. Haider

- Board 294 Abstract 5067: Clinical qualification of plasma androgen receptor (pAR) status and outcome on abiraterone acetate (AA) plus prednisone or dexamethasone (+P/D) in a phase II multi-institutional study in metastatic castration resistant prostate cancer (mCRPC).** *A. Jayaram, A. Wingate, M. T. Sharabiani, D. Wetterskog, F. Calabro, L. Barwell, W. Arlt, A. S. Merseburger, S. Feyerabend, A. Berruti, F. Lefresne, D. Shen, M. Gormley, G. Kapoor, W. Li, R. J. Jones, C. N. Sternberg, B. F. Tombal, G. Attard*
- Board 295 Abstract 5068: Association of high CD8+ tumor infiltrating lymphocytes at prostatectomy with improved survival of prostate cancer patients.** *Y. Yang, K. Attwood, C. Versaggi, A. Omilian, W. Bshara, B. Xu, E. Kauffman, J. Mohler, K. Guru, Q. Li, S. George, P. Basse, C. Morrison, A. Papanicolau-Sengos, P. Kalinski, G. S. Chatta*
- Board 296 Abstract 5069: Treatment outcomes for patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) pts and DNA damage repair gene mutations.** *S. Yip, A. Angeles, A. Beigi, E. W. Warner, D. Khalaf, K. Sunderland, G. R. Vandekerkhove, M. Annala, K. A. Schrader, A. W. Wyatt, K. N. Chi*
- Board 297 Abstract 5070: Tumor-infiltrating lymphocytes in biallelic-CDK12 mutated prostate cancer.** *M. Barrero, M. Rediti, M. Crespo, D. Dolling, P. Rescigno, C. Messina, R. Chandler, D. Bianchini, A. Petremolo, R. Riisnaes, A. Ferreira, D. Nava Rodrigues, C. Bertan, A. Sharp, S. Sumanasuriya, A. Paschalis, N. Tunariu, J. Mateo, S. Carreira, J. S. De Bono*
- Board 298 Abstract 5071: Impact of treatment sequence on the outcomes of metastatic castration resistant prostate cancer patients (mCRPC) with germline BRCA2 mutations: A subanalysis of the PROREPAIR-B study.** *N. Romero-Laorden, E. Castro, A. Medina, D. Lorente, E. González-Billalabeitia, M. J. Méndez-Vidal, A. Gonzalez del Alba, R. Lozano, P. Borrega, E. Fernandez Parra, M. Sáez, I. Garcia Carbonero, A. Rodriguez Vida, R. Morales Barrera, A. del Pozo, C. Pritchard, P. Lapunzina, J. Piulats Rodriguez, J. Puente, D. Olmos*
- Board 299 Abstract 5072: Association of changes in the B-cell receptor (BCR) repertoire with overall survival after sipuleucel-T (sip-T) treatment for prostate cancer.** *L. Zhang, H. Kandadi, A. Paciorek, N. N. Chang, N. A. Sheikh, L. Fong*
- Board 300 Abstract 5073: A pre-specified statistical model based on four kallikrein markers in blood to predict advanced pathology on radical prostatectomy.** *T. Steuber, A. Haese, A. Tin, D. D. Sjoberg, D. Pehrke, H. Huland, M. Graefen, T. Schlomm, A. J. Vickers, H. Lilja, G. Sauter*
- Board 301 Abstract 5074: Plasma androgen receptor (pAR) status and activity of taxanes in metastatic castration resistant prostate cancer (mCRPC).** *V. Conteduca, A. Jayaram, N. Romero-Laorden, D. Wetterskog, S. Salvi, G. Gurioli, E. Scarpi, E. Castro, M. Marin, C. Lolli, G. Schepisi, A. Wingate, A. Medina, G. Fornarini, U. Basso, B. Mellado, E. Gonzalez-Billalabeitia, D. Olmos, G. Attard, U. De Giorgi*
- Board 302 Abstract 5075: Exploration of the cGAS-STING pathway in prostate cancer.** *E. Reilly, A. McCavigan, S. M. Walker, N. McCabe, E. Parkes, D. P. Harkin, R. D. Kennedy, L. A. Knight*
- Board 303 Abstract 5076: Germline variant alleles in rs12422149 of *SLCO2B1* and response to abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC).** *A. W. Hahn, D. M. Gill, P. Hale, A. Poole, R. Nussenzweig, S. Wilson, J. M. Farnham, R. A. Stephenson, B. L. Maughan, L. Cannon-Albright, N. Agarwal*
- Board 304 Abstract 5077: Long-term patterns in race-specific, distant metastasis-free survival following radiation treatment for prostate cancer.** *J. Cullen, C. A. Smith, H. Kuo, I. L. Rosner, Y. Chen, L. Hurwitz, S. Stroup, T. C. Brand, J. Sterbis, C. Porter, K. R. Rice, W. Skinner, A. V. D'Amico, G. L. Lu-Yao*
- Board 305 Abstract 5078: Evaluation of an immunotherapeutic DNA-vaccine in biochemically relapsed prostate cancer.** *N. D. Shore, E. I. Heath, L. T. Nordquist, H. H. Cheng, K. Bhatt, M. Morrow, T. McMullan, K. Kraynyak, J. Lee, B. Sacchetta, L. Liu, S. Rosencranz, S. T. Tagawa, R. A. Parikh, R. F. Tutrone, J. A. Garcia, Y. E. Whang, W. K. Kelly, I. Csiki, M. L. Bagarazzi*

Saturday, June 2, 2018

- Board 306 Abstract 5079: Ten year treatment outcomes of radical prostatectomy vs external beam radiation therapy vs brachytherapy for 1,503 patients with intermediate risk prostate cancer.** *B. W. Goy, R. J. Burchette, M. S. Soper, T. C. Chang, H. A. Cosmatos*
- Board 307 Abstract 5080: Long-term androgen deprivation, with or without radiotherapy, in locally-advanced prostate cancer: Updated results from a phase III randomized trial.** *P. Sargos*
- Board 308 Abstract 5081: A pharmacodynamic biomarker study of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (CANCAP02).** *S. Pacey, N. Shah, B. Davies, O. Bratt, A. Warren, R. D. Baird, V. Gnanapragasam, S. Ingle, S. Stearn, A. Machin, W. Qian, W. Zhao, E. Harrington, E. M. Oelmann, M. Hategan, S. S. Kumar, J. Garcia Corbacho*
- Board 309 Abstract 5082: Neoadjuvant androgen deprivation therapy and enzalutamide: Imaging and pathological responses.** *D. J. VanderWeele, B. Turkbey, F. Karzai, S. Harmon, A. G. Sowalsky, H. Ye, S. Wilkinson, G. Chun, S. A. Gold, P. A. Pinto, P. L. Choyke, W. L. Dahut*
- Board 310 Abstract 5083: Effect of rilimogene galvacirepvec/rilimogene glafolivec on intra/peritumoral immune infiltrate in patients with localized prostate cancer undergoing radical prostatectomy.** *J. L. Gulley, H. Abdul Sater, J. Marte, R. N. Donahue, B. Walter Rodriguez, C. R. Heery, M. Stern, D. Thompson, L. M. Cordes, G. Chun, F. Karzai, M. Bilusic, J. Schlom, W. L. Dahut, R. A. Madan, P. A. Pinto*
- Board 311 Abstract 5084: Combination of a therapeutic cancer vaccine and immune checkpoint inhibitors in prostate cancer.** *R. A. Madan, M. Bilusic, J. Strauss, F. Karzai, L. M. Cordes, P. M. Arlen, M. R. Theoret, M. Rauckhorst, C. Pritchard, H. Abdul Sater, A. Couvillon, A. Hankin, M. Williams, W. L. Dahut, J. Schlom, J. L. Gulley*
- Board 312 Abstract 5085: The influence of decision aids on prostate cancer screening preferences: A randomized survey study.** *K. Tsai, A. B. Weiner, S. Kundu, M. Keeter, D. Victorson, E. M. Schaeffer, W. Catalona*
- Board 313a Abstract TPS5086: Investigation of metformin (MET) in patients with castration resistant prostate cancer (CRPC) in combination with enzalutamide (ENZ) vs. ENZ alone: A randomized, open label, phase 2 trial. SAKK 08/14—IMPROVE.** *C. A. Rothermundt, R. Cathomas, A. Xyrafas, M. Schneider, C. Biaggi Rudolf, E. Roggero, N. Fischer, S. Rothschild, A. Patrikidou, W. B. Mingrone, T. Hermanns, T. Wehrhahn, A. Erdmann, B. Mueller, P. O. Bohanes, K. Ribbi, S. Gillessen*
- Board 313b Abstract TPS5087: A phase 2 trial of darolutamide maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with AR targeting agents and non-progressive on a subsequent taxane (SAKK 08/16).** *R. Cathomas, S. Hayoz, A. C. Fuhrer, C. Biaggi Rudolf, A. Pedrazzini, G. Procopio, S. Gillessen*
- Board 314a Abstract TPS5088: A phase I study of ¹⁷⁷Lu-DKFZ PSMA 617 combined with the radiosensitizer idronoxil in men with metastatic castrate-resistant prostate cancer (mCRPC) (LuPin trial).** *M. Crumbaker, A. M. Joshua, R. Epstein, L. Emmett*
- Board 314b Abstract TPS5089: Phase Ib study of avelumab plus carboplatin in patients with metastatic castration resistant prostate cancer progressing after one line of chemotherapy and one novel androgen receptor axis inhibitor.** *A. Rodriguez Vida, A. Taus, B. Pons, L. Cano, S. Galtes, S. Macia, J. Albanell, J. Bellmunt*
- Board 315a Abstract TPS5090: A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: An Alliance Foundation trial (AFT-19).** *R. R. Aggarwal, S. E. Eggener, R. C. Chen, G. Heller, A. Patnaik, H. Xiao, D. Weckstein, J. Mohler, M. Watson, M. Taplin, L. A. Skoog-Sluman, M. Pereji, E. Aikins-Afful, C. J. Ryan, M. J. Morris*

- Board 315b Abstract TPS5091: Talapro-2: A 2-part, placebo-controlled phase 3 study of talazoparib (TALA) with background enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage repair deficiencies.** *N. Agarwal, A. Azad, A. Fay, J. Carles, N. D. Shore, L. T. Nordquist, L. I. Karsh, C. Dunshhee, S. Ponnathapura Nandakumar, B. Sullivan, A. Czibere, F. Wang, K. Fizazi*
- Board 316a Abstract TPS5092: A prospective phase 2/3 multicenter study of ¹⁸F-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY).** *M. J. Morris, P. Carroll, S. Probst, F. Pouliot, L. Saperstein, B. A. Siegel, A. S. Alva, M. A. Preston, A. Patnaik, M. A. Gorin, J. C. Durack, M. Nichols, T. Lin, T. Strack, V. A. DiPippo, J. D. Jensen, S. Mahmood, V. Wong, K. J. Pienta*
- Board 316b Abstract TPS5093: ODENZA: A study of patient preference between ODM-201 (darolutamide) and enzalutamide in men with metastatic castrate-resistant prostate cancer (mCRPC).** *G. Martineau, S. Foulon, J. Eymard, Y. Lorient, G. Baciarello, J. F. Berdah, C. Helissey, P. Lavaud, F. Joly, N. Zaghdoud, A. Hue, K. Fizazi*
- Board 317a Abstract TPS5094: A phase II trial of enzalutamide, docetaxel and androgen deprivation therapy (ENZADA) in patients with metastatic castrate sensitive prostate cancer (mCSPC).** *E. F. Burgess, C. Grigg, P. E. Clark, D. Boselli, J. T. Symanowski, D. Raghavan*
- Board 317b Abstract TPS5095: Phase II trial of rucaparib (Without ADT) in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations (TRIUMPH).** *M. C. Markowski, H. Wang, R. Sullivan, M. Haffner, A. M. De Marzo, T. L. Lotan, E. S. Antonarakis*
- Board 318a Abstract TPS5096: CRLX101 plus olaparib in patients with metastatic castration-resistant prostate cancer.** *G. Chen, F. Karzai, R. A. Madan, L. M. Cordes, M. Bilusic, H. Owens, A. Hankin, M. Williams, A. Couvillon, J. L. Gulley, W. L. Dahut, A. Thomas*
- Board 318b Abstract TPS5097: c15-148: Phase I/II trial of concurrent chemohormonal therapy using enzalutamide and cabazitaxel in patients with metastatic castration resistant prostate cancer (mCRPC).** *J. N. Graff, T. M. Beer, J. J. Alumkal, D. Kreitner, D. Petreaca, G. V. Thomas, H. H. Cheng*
- Board 319a Abstract TPS5098: The GENTleMEN study: Genetic testing for men with metastatic prostate cancer in Washington state and beyond.** *H. H. Cheng, D. Bowen, N. Klemfuss, C. M. Sievers, S. H. Kang, A. Zhou, C. Pritchard, P. Nelson, R. B. Montgomery*
- Board 319b Abstract TPS5099: Phase II neoadjuvant and immunologic study of B7-H3 targeting with enoblituzumab in localized intermediate- and high-risk prostate cancer.** *E. Shenderov, A. Demarzo, K. Boudadi, M. Allaf, H. Wang, C. Chapman, C. Pavlovich, T. Bivalacqua, T. S. O'Neal, R. Harb, R. Abdallah, C. G. Drake, D. M. Pardoll, E. S. Antonarakis*
- Board 320a Abstract TPS5100: Apalutamide + abiraterone + leuprolide with stereotactic, ultra-hypofractionated radiation (AASUR) in very high risk prostate cancer (PCa).** *S. M. McBride, M. J. Zelefsky, D. E. Spratt, M. Kollmeier, S. F. Slovin, J. Aghalar, J. W. Hearn, R. B. Den, C. Deville, K. Borofsky, H. Xiao, W. Abida, H. I. Scher, D. E. Rathkopf*
- Board 320b Abstract TPS5101: A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and cardiovascular disease (CVD) receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist).** *S. F. Slovin, C. Melloni, S. Mansor-Lefebvre, A. Neijber, M. Roe*

Head and Neck Cancer

Location: Hall A

Abstracts on Boards 1-12 will be discussed during the Head and Neck Cancer Poster Discussion Session.

Posters by Topic

Advanced Disease: Boards 1-5, 10, 13-29

Biomarkers/Epidemiology/Outcomes: Boards 7-8, 30-52

Local-Regional: Boards 6, 53-67

Other (Salivary, Thyroid): Boards 9, 11-12, 68-77

Trials in Progress: Boards 78a-82b

- Board 1** **Abstract 6013: Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs standard of care (SOC) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in KEYNOTE-040.** *E. E. Cohen, D. Soulieres, C. Le Tourneau, J. Dinis, L. F. Licitra, M. Ahn, A. Soria, J. H. Machiels, N. Mach, R. Mehra, B. Burtness, M. C. Ellison, J. D. Cheng, D. R. Chirovsky, R. F. Swaby, K. J. Harrington*
- Board 2** **Abstract 6014: Association of immune-related adverse events (irAEs) with improved response, progression-free survival, and overall survival for patients with metastatic head and neck cancer receiving anti-PD-1 therapy.** *C. C. Foster, S. Kochanny, A. Khattri, R. Acharya, A. Dekker, Y. C. Tan, E. Klema, R. J. Brisson, V. Saloura, A. T. Pearson, E. E. Vokes, R. S. Leidner, H. M. Mehanna, T. Y. Seiwert*
- Board 3** **Abstract 6015: Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck.** *K. Saleh, A. Daste, N. Martin, E. Pons-Tostivint, A. Auperin, R. G. Herrera-Gómez, N. Baste, F. Bidault, J. Guigay, C. Le Tourneau, E. Saada, C. Even*
- Board 4** **Abstract 6016: A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck.** *M. H. Taylor, D. W. Rasco, M. S. Brose, N. J. Vogelzang, S. L. Richey, A. L. Cohn, D. A. Richards, D. E. Stepan, C. E. Dutcus, M. Guo, R. C. Shumaker, E. V. Schmidt, L. J. Wirth*
- Board 5** **Abstract 6017: Phase II multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma.** *T. M. Wise-Draper, M. O. Old, F. P. Worden, P. E. O'Brien, E. E. Cohen, N. Dunlap, M. L. Mierzwa, K. Casper, S. Palackdharry, B. Hinrichs, A. Molinolo, V. Takiar, J. Mark, A. Tang, M. K. Riaz, J. C. Morris, N. Hashemi Sadraei, C. Xie, M. L. Gillison*
- Board 6** **Abstract 6018: A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 "PembroRad" trial.** *X. Sun, C. Sire, Y. Tao, L. Martin, M. Alfonsi, J. Prevost, M. Rives, C. Lafond, J. Tourani Sr., J. Biau, L. Geoffrois, A. Coutte, X. Liem, E. Vauleon, F. Drouet, J. Ramee, G. Waksi, L. Sinigaglia, A. Auperin, J. Bourhis*
- Board 7** **Abstract 6019: Discovery of a reliable and robust methylome classifier of HPV driven head and neck cancer with favorable response to chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).** *B. Tawk, J. Debus, C. Schwager, A. Linge, U. Ganswindt, I. Tinhofer, V. Budach, M. Stuschke, P. Balermipas, F. Rödel, A. Grosu, D. Zips, S. E. Combs, M. Krause, W. Weichert, M. Baumann, C. Belka, G. Dyckhoff, C. Herold-Mende, A. Abdollahi*

- Board 8** **Abstract 6020: High-accuracy HPV testing versus p16 IHC using multiple clinically relevant outcomes: The University of Chicago Experience.** *S. Kochanny, C. C. Foster, A. Khattri, R. J. Brisson, A. Dekker, E. Klema, R. Acharya, J. Segal, M. W. Lingen, N. Cipriani, A. T. Pearson, V. Saloura, E. E. Vokes, T. Y. Seiwert*
- Board 9** **Abstract 6021: A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209.** *M. Schlumberger, K. Newbold, B. Hasan, S. Marreaud, S. Assele, L. F. Licitra, P. Schoffski, S. Leboulleux, L. Locati, Y. Godbert, V. Rohmer, B. Jarzab, S. Domenico, O. E. Bechter, S. Zanetta, J. Capdevila, E. Kapiteijn, L. Bastholt*
- Board 10** **Abstract 6022: A phase II study of lenvatinib in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.** *V. Tchekmedyian, E. J. Sherman, L. Dunn, C. Tran, N. Katabi, A. Ni, S. Haque, D. G. Pfister, A. L. Ho*
- Board 11** **Abstract 6023: Facilitating rapid precision oncology in anaplastic thyroid cancer: Clinical implications of next generation sequencing (NGS) mutation testing and impact on survival.** *J. R. Wang, G. J. Cote, M. Zafereo, P. C. Iyer, R. Dadu, N. L. Busaidy, N. D. Gross, E. M. Sturgis, R. Ferrarotto, C. Lu, G. B. Gunn, J. Myers, S. Y. Lai, M. D. Williams, M. E. Cabanillas*
- Board 12** **Abstract 6024: Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with anaplastic thyroid cancer.** *L. J. Wirth, E. Eigendorff, J. Capdevila, L. G. Paz-Ares, C. Lin, M. H. Taylor, R. Ramlau, M. Butler, J. Delord, Z. Horvath, H. Gelderblom, P. A. Ascierto, A. Fasolo, D. Führer, H. Wu, G. Bostel, S. Cameron, J. E. Faris, A. I. Varga*
- Board 13** **Abstract 6025: Phase I/II trial of pembrolizumab(P) and vorinostat(V) in recurrent metastatic head and neck squamous cell carcinoma (HN) and salivary gland cancer (SGC).** *C. P. Rodriguez, V. Wu, J. M. Voutsinas, J. P. Fromm, V. G. Pillarisetty, S. Lee, R. Santana-Davila, B. H. Goulart, C. S. Baik, L. Q. Chow, K. D. Eaton, R. G. Martins*
- Board 14** **Abstract 6026: Phase II trial of apatinib in patients with recurrent and/or metastatic adenoid cystic carcinoma of the head and neck: Updated analysis.** *G. Zhu, L. Zhang, R. Li, S. Dou, W. Yang, C. Zhang*
- Board 16** **Abstract 6028: Nivolumab (nivo) vs investigator's choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age.** *N. F. Saba, G. R. Blumenschein Jr., J. Guigay, L. F. Licitra, J. Fayette, K. J. Harrington, N. Kiyota, M. L. Gillison, R. L. Ferris, V. Jayaprakash, M. J. Lynch, L. Li, P. Brossart*
- Board 17** **Abstract 6029: Comparison between lobaplatin and cisplatin plus 5-fluorouracil combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized phase III clinical trial.** *K. Liu, W. Xia, W. Qiu, Y. Yu, G. Liu, H. Liang, W. Li, S. Lv, L. Ke, H. Mo, G. Ling, M. Chen, K. Cao, C. Zhao, C. Qian, X. Lv, X. Yanqun, X. Guo, X. Huang*
- Board 18** **Abstract 6030: Anti-VEGF treatment to modulate tumor microenvironment (TME) prior to chemotherapy in EBV-positive nasopharyngeal carcinoma (NPC).** *W. Chong, C. Tan, C. Lim, W. Loh, K. Loh, Y. Lim, S. Chong, L. Wang, S. Tan, G. Chan, Y. Huang, S. Lee, B. C. Goh*
- Board 19** **Abstract 6031: A phase I/II trial adding poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel (Carbo-Tax) in patients with head and neck squamous cell carcinoma (HNSCC) Alliance A091101.** *M. J. Jelinek, N. R. Foster, A. J. Zoroufy, J. A. De Souza, G. K. Schwartz, P. N. Munster, T. Y. Seiwert, E. E. Vokes*
- Board 20** **Abstract 6032: Randomised phase II study with cetuximab in combination with 5-FU and cisplatin or carboplatin versus cetuximab in combination with paclitaxel and carboplatin for treatment of patients with relapsed or metastatic squamous cell carcinoma of the head and neck (CETMET trial).** *S. Friesland, G. Tsakonas, C. Kristensen, M. Herlestam Calero Moren, H. Haugen, K. Soderstrom, L. Specht*

Saturday, June 2, 2018

- Board 22 **Abstract 6034: Hyperfractionated reirradiation with cetuximab for recurrent head and neck cancer: The GORTEC 2008-01 multicentric phase II study.** *M. Saint-Ghislain, Y. Tao, M. Alfonsi, P. Boisselier, M. Garcia-Ramirez, C. Tuchsais, P. Maingon, C. Sire, A. Hasbini, M. Saliou, C. Lafond, H. Qiu, S. Guihard, P. Garaud, m. Calais, J. Thariat, L. Martin, J. Bourhis*
- Board 23 **Abstract 6035: Saline alone vs saline plus mannitol hydration for the prevention of acute cisplatin nephrotoxicity: A randomized trial.** *B. Beeler, W. P. Delacruz, F. L. Flynt, S. Terrazzino, N. Hullinger, J. Aden, T. Byrd, M. M. King, D. A. Nelson*
- Board 24 **Abstract 6036: Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with Pembrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232).** *K. J. Harrington, A. H. Kong, N. Mach, T. Rordorf, J. Corral Jaime, V. Espeli, S. Treichel, B. Gumuscu, J. J. Kim, J. A. Chesney*
- Board 25 **Abstract 6037: An open-label, non-randomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of the interim safety analysis.** *A. G. Sacco, K. Messer, A. Natsuhara, R. Chen, D. J. Wong, F. P. Worden, D. Adkins, E. Pittman, J. Zhang, G. A. Daniels, K. A. Gold, M. Espiritu, B. Sutton, E. E. Cohen*
- Board 26 **Abstract 6038: Association of a baseline neutrophil-to-lymphocyte ratio (NLR) with progression-free and overall survival in head and neck cancer patients receiving anti-PD-1 therapy.** *C. C. Foster, S. Kochanny, A. Khattri, R. Acharya, A. Dekker, Y. C. Tan, E. Klema, R. J. Brisson, V. Saloura, A. T. Pearson, E. E. Vokes, R. S. Leidner, H. M. Mehanna, T. Y. Seiwert*
- Board 27 **Abstract 6039: RM-1929 photo-immunotherapy in patients with recurrent head and neck cancer: Results of a multicenter phase 2a open-label clinical trial.** *A. M. Gillenwater, D. Cognetti, J. M. Johnson, J. Curry, S. T. Kochuparambil, D. McDonald, M. J. Fidler, K. Stenson, N. Vasan, M. Razaq, J. Campana, F. Mott*
- Board 28 **Abstract 6040: COTI-2, a potent orally available small molecule targeting mutant p53, with promising efficacy as monotherapy and combination treatment in preclinical tumor models.** *R. T. Ho, K. Y. Salim, A. Lindemann, A. A. Patel, H. Takahashi, L. Wang, M. Zhao, S. J. Frank, J. Myers, A. A. Osman, C. Lynam, A. D. Silva*
- Board 29 **Abstract 6041: CAPTN: A nomogram for predicting survival and guiding therapy for patients with de novo metastatic head and neck squamous cell carcinoma.** *J. R. Robbins, M. Stadler, M. Shukla, S. Firat, B. Massey, B. Campbell, C. J. Schultz, S. J. Wong*
- Board 30 **Abstract 6042: Absolute lymphocyte count (ALC) during and after chemoradiation (CRT) for squamous cell carcinoma of the head and neck (SCCHN): Effect of the regimen and potential therapeutic implications.** *M. Uglane, S. Shah, A. Shaikh, N. Campbell, M. Bhayani, E. E. Vokes, R. Nanda, V. T. Raghavan, B. Brockstein*
- Board 31 **Abstract 6043: The use of exosome and immune profiling to analyze a phase 2 study on the addition of patritumab or placebo to cetuximab and a platinum agent for recurrent / metastatic head and neck cancer (R/M HNSCC) patients.** *T. Ng, F. Flores-Borja, G. Alfano, P. Barber, G. Weitsman, F. Wong, J. Vicencio, M. Galazi, J. Doyle, J. Greenberg, M. D. Forster, A. Coolen*
- Board 32 **Abstract 6044: Cisplatin dose intensity (CDDP-D) in human papillomavirus-positive (HPV+) localized oropharyngeal carcinoma (OPC) treated with chemoradiotherapy (CRT).** *M. Oliva Bernal, S. Huang, W. Xu, J. Su, A. R. Hansen, A. J. Hope, R. W. Jang, A. Bayley, E. X. Chen, M. E. Giuliani, J. Ringash, S. V. Bratman, J. Cho, J. Waldron, I. Weinreb, D. B. Chepeha, J. Kim, B. O'Sullivan, L. L. Siu, A. Spreafico*

- Board 33 Abstract 6045: Randomized phase 2 trial of patritumab (P) or placebo (PBO) + cetuximab (C) + cisplatin (CIS) or carboplatin (CAR) for recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).** *K. J. Harrington, M. D. Forster, C. Le Tourneau, J. Ariza, S. Chen, J. Greenberg, K. Hirotani, E. Remenar*
- Board 34 Abstract 6046: Incidence of ototoxicity in head and neck cancer (HNSCC) patients (pts) receiving concomitant chemo-radiation (CRT) with weekly or triweekly cisplatin (Cis).** *J. Das, A. Custer, D. Blakaj, M. O. Old, S. Zhao, A. D. Bhatt, S. Y. Kang, A. Agrawal, E. Ozer, J. Wobb, R. Rupert Jr., D. L. Mitchell, G. Brock, C. F. Verschraegen, J. W. Rocco, M. R. Bonomi*
- Board 35 Abstract 6047: Interference between mutational load, immune signatures and outcome in patients with head and neck cancer treated with definitive chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).** *I. Tinhofer, T. Eder, A. Hess, V. Fleischer, P. Balcermpas, C. Rödel, A. Linge, M. Krause, M. Baumann, M. Stuschke, D. Zips, H. S. Schafer, A. Grosu, A. Abdollahi, J. Debus, C. Belka, S. Pigorsch, G. Multhoff, S. Combs, V. Budach*
- Board 36 Abstract 6048: Cisplatin-induced ototoxicity in head and neck squamous cell carcinoma (HNSCC) patients treated with chemoradiation: The role of WFS1 and ABCC2 heritable variants.** *M. Mahler, Y. Zhang, K. Hueniken, M. Brown, Z. Chen, M. Mirshams, J. Wang, L. L. Siu, A. Spreafico, D. A. Breadner, W. A. Teft, R. B. Kim, E. Winquist, C. Falls, F. Liu, D. P. Goldstein, S. V. Bratman, W. Xu, A. Hope, G. Liu*
- Board 37 Abstract 6049: Development and validation of a combined metabolic and immune prognostic classifier for head and neck cancer.** *H. M. Mehanna, J. Brooks, A. Menezes, M. Ibrahim, N. Lal, L. Archer, S. von Zeidler, R. Bao, A. Khattri, H. Valentine, R. Spruce, N. Batis, J. Bryant, A. D. Beggs, D. Tennant, C. West, G. W. Middleton, J. Cazier, B. Willcox, T. Y. Seiwert*
- Board 38 Abstract 6050: A study to evaluate immunological response to PD-1 inhibition in squamous cell carcinoma of the head and neck (SCCHN) using novel PET imaging with [18F]F-AraG.** *A. D. Colevas, N. Bedi, S. Chang, U. Y. Nieves, S. Chatterjee, G. A. Davidzon, S. Srinivas, Q. Le, A. Gambhir, J. B. Sunwoo*
- Board 39 Abstract 6051: Cardiovascular disease risks among head and neck cancer survivors in a large, population-based cohort study.** *M. Wei, M. Hashibe, S. Abdelaziz, J. Hunt, L. Buchmann, K. G. Rowe, J. Synder, Y. Wan, V. Deshmukh, M. Newman, A. M. Fraser, K. Herget, M. Monroe*
- Board 40 Abstract 6052: ICR gene signature to identify differential immune landscapes in anatomic subsites of head and neck squamous cell carcinomas and implications in personalized medicine.** *S. I. Pai, D. Clayburgh, M. Patel, R. B. Bell, B. Yueh, D. Lin, K. Halliwell, T. Turan, J. Samayoa, B. Cairns, J. Park, R. S. Leidner, L. J. Wirth, N. F. Saba, D. M. Shin, N. Fujioka, F. Marincola, D. E. Afar, D. Chao*
- Board 41 Abstract 6053: Comprehensive proteomic and genomic profiling to identify therapeutic targets in adenoid cystic carcinoma.** *S. P. Thyparambil, Y. Kim, A. Chambers, D. Yan, S. SELLAPPAN, C. Gong, A. Sedgewick, Y. Newton, J. Sanborn, C. J. Vaske, S. C. Benz, F. Cecchi, H. Kang, T. A. Hembrough*
- Board 42 Abstract 6054: Molecular prediction of lymph node metastases using immunohistochemical analysis of primary oral tongue squamous cell carcinomas.** *F. Amen, M. Eden, A. Marker, B. Barrett, P. Wilson, A. Sandison, S. DiParma, M. Petkar, K. J. Harrington, C. Nutting, C. Kerawala, P. Clarke, H. Mirghani, E. Shamil, K. Thway, K. Naresh, G. W. Stamp, P. Rhys-Evans*
- Board 43 Abstract 6055: Prognostic role of pretreatment plasma EBV DNA on stage III nasopharyngeal carcinoma staged by AJCC/UICC 8th edition TNM staging classification.** *V. Lee, D. L. Kwong, T. Leung, C. Choi, B. O'Sullivan, V. Lai, C. Tong, K. Lam, A. S. Chan, P. P. Ho, W. W. Chan, D. K. Leung, S. Chan, K. Tsang, P. Khong, M. Luk, A. W. Lee*

Saturday, June 2, 2018

- Board 44 Abstract 6056: Tracking tumor-specific mutations in plasma, saliva and para-carcinoma tissues from patients with head and neck squamous cell carcinomas.** *P. Wu, Y. Tang, Y. Gong, X. Tao, Y. Guan, L. Yang, X. Xia, X. Yi, C. Xie*
- Board 45 Abstract 6057: Association of low serum albumin concentration with reduced overall survival for patients with metastatic head and neck cancer receiving anti-programmed death receptor-1 therapy.** *S. Kochanny, C. C. Foster, A. Khattri, R. Acharya, A. Dekker, Y. Tan, E. Klema, R. J. Brisson, V. Saloura, A. T. Pearson, E. E. Vokes, R. S. Leidner, H. M. Mehanna, T. Y. Seiwert*
- Board 46 Abstract 6058: Impacts of plasma EBV DNA load during different time-points of induction chemotherapy plus radiotherapy for nasopharyngeal carcinoma.** *J. Lin, W. Wang, Y. Liu*
- Board 47 Abstract 6059: Gene expression signature after one dose of neoadjuvant pembrolizumab associated with tumor response in head and neck squamous cell carcinoma (HNSCC).** *E. Kim, S. Palackdharry, B. Yaniv, J. Mark, A. Tang, K. Wilson, Y. Patil, E. Janssen, L. Conforti, V. Takiar, B. Hinrichs, T. M. Wise-Draper*
- Board 48 Abstract 6060: Second primary thyroid cancer following index head and neck cancer.** *K. M. Polednik, M. C. Simpson, E. Adjei Boakye, K. A. Mohammed, N. Osazuwa-Peters*
- Board 49 Abstract 6061: Immune profiling of head and neck squamous cell carcinoma (HNSCC) by a multiplex immunofluorescence (mIF) panel using multispectral microscopy.** *J. De La Iglesia, L. Martin, T. Van Veen, F. Song, N. Gimbrone, R. S. Ranaweera, J. Masannat, J. Parameswaran, B. Wenig, J. Hernandez-Prera, L. B. Harrison, J. J. Caudell, A. Giuliano, R. Slebos, C. H. Chung*
- Board 50 Abstract 6062: Number of nodal metastases associated with overall survival in HPV-negative head and neck cancer.** *D. Farquhar, T. Hackman, M. Masood, M. C. Weissler, A. F. Olshan, J. Weiss, S. Sheth*
- Board 51 Abstract 6063: Using mobile and sensor technology to identify early dehydration risk in head and neck cancer patients undergoing radiation treatment: Impact on symptoms.** *S. K. Peterson, A. S. Garden, E. H. Shinn, S. Shete, S. L. Martch, M. Camero, G. Baum, E. Farcas, K. Lin, F. Raab, V. Nandigam, Y. Yan, R. Ferrarotto, J. Godino, K. Patrick, B. M. Beadle*
- Board 52 Abstract 6064: Minimally-invasive dual testing for active HPV E6,E7 and PD-L1 expression in HNSCC.** *H. Mirghani, Y. Carrasco, A. Chargin, B. K. Patterson*
- Board 53 Abstract 6065: A double-blind, randomized pilot study of NS-21 in the prevention of radiation dermatitis for patients with head and neck cancer.** *C. Hsieh, H. Chou, P. Shueng, C. Hsu, D. Kuo, L. Liao, W. Lo, L. Wang, C. Hsiao*
- Board 54 Abstract 6066: Safety and effectiveness of transoral surgery for superficial head and neck cancer: The National Registration Survey of superficial head and neck cancer in Japan.** *C. Katada, S. Fujii, T. Yokoyama, Y. Sakamoto, M. Ichinoe, T. Okamoto, A. Watanabe, D. Kikuchi, S. Yoshinaga, T. Tsuchida, Y. Shimizu, T. Oyama, T. Kamijo, N. Hanaoka, Y. Kawahara, A. Shiotani, A. Ochiai, T. Kato, M. Muto, R. Hayashi*
- Board 55 Abstract 6067: Neck dissection rate in node positive human papillomavirus associated oropharyngeal carcinoma following chemoradiotherapy.** *S. Porceddu, H. Liu, A. Bernard, L. Tam, R. Milne, M. C. Foote, M. L. McGrath, B. Cartmill, E. Brown, B. H. Burmeister, B. Panizza*
- Board 56 Abstract 6068: A randomised, double-blind, placebo-controlled phase IIa trial of AMG319 given orally as neoadjuvant therapy in patients with human papillomavirus (HPV) positive and negative head and neck squamous cell carcinoma (HNSCC).** *C. H. Ottensmeier, T. Jones, J. J. Sacco, J. A. McCaul, P. Brennan, C. Paterson, A. G. Schache, R. Shaw, R. P. Singh, J. H. Davies, L. Chudley, D. Jeffrey, G. Thomas, P. Loadman, N. A. Dobbs, L. Essame, G. Acton, S. Katugampola, B. Vanhaesebroeck, E. King*

- Board 57 Abstract 6069: Preliminary toxicity data from the combination of pembrolizumab and definitive-dose radiotherapy for locally advanced head and neck cancer with contraindication to cisplatin therapy.** *J. Weiss, J. R. Bauman, A. M. Deal, S. Sheth, B. S. Chera, C. Shen, C. Hilliard, T. Y. Seiwert, R. Mehra, J. E. Grilley-Olson*
- Board 58 Abstract 6070: Impact of patient symptoms and caregiver tasks on psychological distress in caregivers for head and neck cancer (HNC).** *E. Castellanos, M. S. Dietrich, N. L. Wells, S. M. Bond, K. L. Schumacher, B. A. Murphy*
- Board 59 Abstract 6071: A phase I study of the PI3K inhibitor buplarlisib (B) with concurrent chemoradiotherapy (CRT) in patients with high risk locally advanced squamous cell cancer of the head and neck (LASCCHN).** *J. H. Lorch, R. B. Tishler, N. G. Chau, G. J. Hanna, G. Rabinowitz, J. D. Schoenfeld, D. N. Margalit, A. M. O'Neill, D. Annino, L. A. Goguen, R. Uppaluri, E. J. Harris, A. Kacew, J. Huang, L. Ma, P. Mchugh, R. I. Haddad*
- Board 60 Abstract 6072: The prognostic impact of level I lymph node involvement in oropharyngeal squamous cell carcinoma.** *R. Xiao, M. C. Ward, K. Yang, D. J. Adelstein, S. A. Koyfman, B. Prendes, B. Burkey*
- Board 61 Abstract 6073: Cisplatin (CIS) versus cetuximab (CET) with definitive concurrent radiotherapy (RT) for head and neck squamous cell carcinoma (HNSCC): An analysis of veteran's health data.** *J. Bauml, R. R. Vinnakota, Y. A. Park, S. E. Bates, A. T. Fojo, C. Aggarwal, J. DiStefano, C. Knepley, E. M. Genden, S. A. Limaye, C. A. Ciunci, J. P. Wisnivesky, N. Damjanov, C. J. Langer, R. B. Cohen, K. Sigel*
- Board 62 Abstract 6074: A phase I dose-finding study of metformin in combination with concurrent cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma.** *S. Gulati, B. Yaniv, S. Palackdharry, V. Takiar, M. L. Mierzwa, M. K. Riaz, J. C. Morris, C. Xie, J. Gutkind, P. B. Desai, N. Hashemi Sadraei, T. M. Wise-Draper*
- Board 63 Abstract 6075: Suboptimal regimens in sequential treatment (ST) with ICT (induction chemotherapy) followed by CCRT (concomitant chemotherapy) in "real life" patients with locally advanced pharyngo-laryngeal squamous-cell carcinoma (LAPLSCC) and prognosis.** *C. Orte, I. Pajares Bernad, E. Ortega Izquierdo, E. Vicente Gonzalez, B. Bonaga Serrano, R. Terre Falcon, L. Roque Taveras, J. Martinez-Trufero*
- Board 64 Abstract 6076: Avelumab-cetuximab-radiotherapy (RT) versus standards of care (SoC) in locally advanced squamous cell carcinoma of the head and neck (SCCHN): Safety phase of the randomized trial GORTEC 2017-01 (REACH).** *Y. Tao, A. Auperin, X. Sun, C. Sire, L. Martin, A. Coutte, J. Miroir, C. Lafond, N. Colin-Bataillou, A. Maillard, L. Gibel, C. Michel, J. Guigay, J. Bourhis*
- Board 65 Abstract 6077: Long-term outcomes for re-irradiation of recurrent head-and-neck cancers: Report of acute and long-term toxicity.** *N. Aghdam, I. Paydar, A. Bush, A. W. Gramza, B. J. Davidson, J. F. Deeken, K. Harter*
- Board 66 Abstract 6078: Regional lymph node metastases oncogenic mutations compared to primary tumors in HPV+ oropharynx patients.** *J. F. Deeken, D. Thach, P. Lee, G. K. Bajaj, M. Ahmad, R. K. Iyer*
- Board 67 Abstract 6079: Post-treatment evaluation of head and neck cancer patients in the era of advanced imaging and value-based care.** *T. Hirsch, M. Stadler, B. Campbell, S. Firat, B. Massey, C. J. Schultz, M. Shukla, S. J. Wong, J. R. Robbins*
- Board 68 Abstract 6080: Prevention of surgical site infection after oral cancer surgery by topical tetracycline: Results of a multicenter randomized control trial.** *M. Funahara, S. Yanamoto, M. Ueda, T. Suzuki, Y. Ota, F. Nishimaki, H. Kurita, N. Yamakawa, T. Kirita, M. Okura, Y. Mekaru, K. Arakaki, M. Umeda*
- Board 69 Abstract 6081: Second interim analysis of RIFTOS MKI, a global non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).** *M. S. Brose, F. Pitoia, J. W. Smit, C. Lin, M. M. Fellous, I. Bayh, I. Sugitani, M. Schlumberger*

Saturday, June 2, 2018

- Board 70 **Abstract 6082: An open-label, randomized phase III trial of gemcitabine and carboplatin (GC) followed by Epstein-Barr virus-specific autologous cytotoxic T lymphocytes (EBV-CTLs) versus GC as front-line therapy for patients (pts) with advanced nasopharyngeal carcinoma (NPC).** *H. Toh, J. Menezes*
- Board 71 **Abstract 6083: Integrative whole-genome analysis of salivary duct carcinoma.** *S. Park, Y. Kim, S. Song, M. Lee, T. Swatloski, H. Kim, Y. Ko, H. Jeong, K. Park*
- Board 72 **Abstract 6084: Novel approach for unresectable salivary duct carcinoma: Targeting HER2 and androgen receptor.** *D. Kawakita, Y. Tada, C. Fushimi, H. Takahashi, T. Masubuchi, K. Miura, S. Kano, K. Tsukahara, H. Ozawa, K. Okami, Y. Sato, A. Shimizu, Y. Imanishi, T. Hanazawa, M. Ando, H. Hirai, T. Nagao*
- Board 73 **Abstract 6085: A novel prognostic risk classification model for NUT midline carcinoma: a largest cohort analysis from the NMC registry.** *N. G. Chau, C. Ma, K. Danga, H. Al-Sayegh, M. Sridharan, V. Nardi, R. Barrette, C. Lathan, S. G. DuBois, R. I. Haddad, G. Shapiro, S. E. Sallan, A. Dhar, J. J. Nelson, C. A. French*
- Board 74 **Abstract 6086: Phase II study on lenvatinib (LEN) in recurrent and/or metastatic (R/M) adenoid cystic carcinomas (ACC) of the salivary glands (SG) of the upper aerodigestive tract (NCT02860936).** *L. Locati, D. Galbiati, G. Calareso, S. Alfieri, R. Granata, P. Bossi, C. Bergamini, C. Resteghini, S. Cavalieri, F. Platini, P. Quattrone, M. Mancinelli, A. Zucchella, L. Mariani, G. Fedele, L. F. Licitra*
- Board 75 **Abstract 6087: Combination of dabrafenib (DAB) and lapatinib (LAP) for the treatment of BRAF-mutant thyroid cancer.** *E. J. Sherman, A. L. Ho, J. A. Fagin, S. Haque, C. Robinson, R. A. Ghossein, H. X. Chen, D. G. Pfister*
- Board 76 **Abstract 6088: A phase II trial of cabozantinib (CABO) for the treatment of radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC) in the first-line setting.** *M. S. Brose, S. Shenoy, N. Bhat, A. K. Harlacker, R. K. Yurtal, Z. A. Posey, D. M. Torrente, C. Grande, C. M. Squillante, A. Troxel, M. Yarchoan*
- Board 77 **Abstract 6089: Comprehensive genomic profiling of anaplastic thyroid carcinoma.** *D. W. Bowles, J. S. Ross, L. M. Gay, V. Agrawal, S. M. Ali, S. A. Khan*
- Board 78a **Abstract TPS6090: A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669.** *E. E. Cohen, D. Rischin, D. G. Pfister, J. B. Vermorken, Y. Zhao, H. Gowda, J. Y. Ge, F. Jin, K. J. Harrington*
- Board 78b **Abstract TPS6091: A phase 2, multicenter, open-label study to evaluate the efficacy and safety of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC).** *J. E. Bauman, N. F. Saba, D. Adkins, Y. Wang, Y. He, E. Paradise, R. B. Cohen*
- Board 79a **Abstract TPS6092: ECHO-310: A phase 3, randomized trial of epacadostat + nivolumab + chemo vs EXTREME as first-line treatment of recurrent/metastatic SCCHN.** *E. E. Cohen, R. Mehra, A. Psyrris, J. E. Bauman, R. Schaub, L. Zhou, L. Li, V. Jayaprakash, J. Guigay*
- Board 79b **Abstract TPS6093: A phase 1b/2a, multi-center, open-label study to evaluate the safety and efficacy of combination treatment with MEDI0457 (INO-3112) and durvalumab (MEDI4736) in patients with recurrent/metastatic human papilloma virus-associated head and neck squamous cell cancer.** *C. Aggarwal, B. Halmos, M. Porosnicu, N. F. Saba, A. Sukari, S. J. Grethlein, R. Mehra, D. Adkins, M. J. Fidler, R. Kumar, J. Yang, S. E. Abdullah, M. Haigentz Jr.*
- Board 80a **Abstract TPS6094: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study.** *J. H. Machiels, L. F. Licitra, Y. Tao, C. Yen, D. Rischin, J. Waldron, B. Burtneess, V. Gregoire, S. S. Agarwala, J. Yorlino, J. Delord, S. Aksoy, S. Ikeda, R. Hong, J. Y. Ge, H. M. Brown, B. Bidadi, L. L. Siu*

- Board 80b Abstract TPS6095: EORTC 1559-HNCG: A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)—"UPSTREAM".** *R. Galot, L. F. Licitra, C. Le Tourneau, J. Guigay, I. Tinhofer, A. H. Kong, C. A. Caballero, C. Fortpied, A. Govaerts, D. Staelens, T. Raveloarivahy, J. Laes, J. R. Canon, S. Henry, E. Saada-Bouزيد, J. H. Machiels*
- Board 81a Abstract TPS6096: A phase 2, multicenter study to evaluate the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-145) for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC).** *R. S. Leidner, A. Sukari, C. H. Chung, J. Ohr, M. Haigentz Jr., E. E. Cohen, R. J. Brown, S. Suzuki, I. Gorbachevsky, M. Fardis, R. L. Ferris*
- Board 81b Abstract TPS6097: PATHOS: A phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer.** *M. Evans, S. Knott, C. Hurt, J. Patterson, M. Robinson, K. A. Hutcheson, L. Nixon, M. Beasley, J. Lee, W. Wade, N. Palaniappan, C. Simon, N. Powell, W. Greenhalf, T. Jones*
- Board 82a Abstract TPS6098: BEST OF: A phase III study assessing the best of radiotherapy (Intensity Modulated RadioTherapy, IMRT) compared to the best of surgery (Trans-Oral Surgery, TOS) in patients with T1-T2, N0 oropharyngeal squamous cell carcinoma (OPSCC).** *C. Simon, C. A. Caballero, C. Fortpied, M. Evans, P. Koivunen, J. Stelmes, M. Urbanowicz, J. Bourhis, F. Zimmermann, J. P. Klussmann, A. Dietz, G. Spriano, C. R. Leemans, S. Singer, I. Tinhofer, J. Patterson, S. Quaglioni, K. Hunter, V. Gregoire*
- Board 82b Abstract TPS6099: Hope for salivary gland cancer (SGC): EORTC HNCG/ UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) inpatients with recurrent and/or metastatic androgen receptor (AR) expressing SGC (NCT01969578).** *L. Locati, C. A. Caballero, C. Fortpied, F. Perrone, P. Quattrone, K. Harrington, V. Gregoire, L. F. Licitra*

1:15 PM - 4:45 PM Poster Session

Health Services Research, Clinical Informatics, and Quality of Care

Location: Hall A

Abstracts on Boards 335-346 will be discussed during the Health Services Research, Clinical Informatics, and Quality of Care Poster Discussion Session.

Posters by Topic

Care Delivery/Models of Care: Boards 347-374

Clinical Informatics: Boards 335, 375-382

Disparities/Access to Care: Boards 341, 383-395

Outcomes: Boards 343, 345, 396-411

Quality of Care/Quality Improvement: Boards 346, 412-427

Telemedicine: Boards 344, 425-429

Value/Cost of Care: Boards 337-340, 342, 430-445

Trials in Progress: Boards 446a-446b

- Board 335 Abstract 6509: Clinical trajectory modeling to predict hospitalization or death after palliative chemotherapy.** *K. L. Kehl, H. Elmarakeby, E. M. Van Allen, D. Schrag*
- Board 337 Abstract 6511: End of life spending among cancer patients in an ACO vs. non-ACO.** *M. Lam, J. Figueroa, K. Reimold, E. J. Orav, A. Jha*
- Board 338 Abstract 6512: Are National Comprehensive Cancer Network (NCCN) Evidence Blocks (EB) Affordability Ratings (AR) representative of real-world costs? An evaluation of advanced non small cell lung cancer (aNSCLC).** *S. D. Ramsey, P. Lin, Y. Yim, W. B. Wong, N. Wu, D. Sheinson, J. T. Cohen*

Saturday, June 2, 2018

- Board 339 **Abstract 6513: Cost-effectiveness of multi-gene panel sequencing (MGPS) for advanced non-small cell lung cancer (aNSCLC) patients.** *L. M. Steuten, B. H. Goulart, N. J. Meropol, D. Pritchard, S. D. Ramsey*
- Board 340 **Abstract 6514: Cost-effectiveness analysis of abiraterone acetate (AA) versus docetaxel (D) for the management of metastatic hormone naïve prostate cancer (mHNPC).** *C. Ramamurthy, A. F. Correa, E. A. Handorf, D. M. Geynisman*
- Board 341 **Abstract 6515: Potential life-years lost: The impact of the cancer drug regulatory process in Canada.** *J. Gotfrit, J. Shin, R. Mallick, D. J. Stewart, P. Wheatley-Price*
- Board 342 **Abstract 6516: Trends of new cancer drug approvals from the perspective of a publicly funded healthcare system: Analyses of the pan-Canadian Oncology Drug Review (pCODR) recommendations.** *S. Niraula*
- Board 343 **Abstract 6517: FDA acceptance of surrogate endpoints in later lines of therapy.** *E. Y. Chen, S. K. Joshi, V. Prasad*
- Board 344 **Abstract 6518: Internet- and mobile-based lifestyle intervention for prostate cancer patients on androgen deprivation therapy: Prospective, multicenter, randomized trial.** *Y. Park, J. Lee, I. Cheong, J. Hwang, S. Seo, K. Lee, J. Yoo, S. Chung, Y. Ko, Y. Lee, S. Lee*
- Board 345 **Abstract 6519: Objective metrics of patient activity: Use of wearable trackers and patient reported outcomes in predicting unexpected healthcare events in cancer patients undergoing highly emetogenic chemotherapy.** *A. S. Martin, R. W. Boles, L. Nocera, A. Kolatkar, M. May, Z. Hasnain, N. T. Ueno, S. Yennu, A. Alexander, A. Mejia, M. Li, F. A. Cozzens Phillips, P. K. Newton, J. Broderick, C. Shahabi, P. Kuhn, J. J. Nieva*
- Board 346 **Abstract 6520: Opioid use in long term cancer survivors.** *L. C. Barbera, R. Sutradhar, D. Howell, D. Dudgeon, H. Seow, M. O'Brien, C. Atzema, A. Husain, C. Earle, J. Sussman, E. Corn, C. DeAngelis*
- Board 347 **Abstract 6521: Implementation of breast cancer pathway for genetic counseling and testing in multi-state health system.** *S. L. Graff, D. Kurbegov, D. Moorman*
- Board 348 **Abstract 6522: Trends and disparities in place of death for cancer patients in the United States, 1999-2015.** *F. L. Chino, A. Kamal, T. W. LeBlanc, Y. Zafar, G. Suneja, J. P. Chino*
- Board 349 **Abstract 6523: Methodologic challenges of defining oncology provider networks from administrative claims data.** *K. B. Stitzenberg, S. Shai, W. H. Weir, P. Mucha, T. Kuo, A. Meyer, J. G. Trogdon*
- Board 350 **Abstract 6524: Trends related to program participation, implementation, best practices, challenges and resource requests among oncology care model (OCM) participants.** *D. Gutkin, E. Zhao, K. Phillips, K. Cavaliere, H. Braun, B. Powell*
- Board 351 **Abstract 6525: Value-based healthcare delivery models in oncology: A systematic review.** *E. Aviki, S. M. Schleicher, S. Mullangi, K. Matsoukas, D. Korenstein*
- Board 352 **Abstract 6526: Treatment patterns among patients diagnosed with stage IV cancers who died within one month of diagnosis.** *H. M. Sineshaw, R. A. Freedman, K. Ng, R. U. Osarogiagbon, K. J. Ruddy, A. Jemal*
- Board 353 **Abstract 6527: Results from a pilot of an innovative 4R Cancer Care Delivery Model: Impact on patient self-management.** *J. R. Trosman, C. B. Weldon, C. B. Perez, S. Kulkarni, S. A. Khan, N. Hansen, V. Nelson, J. Stein, M. A. Simon, C. Spagnoli, J. Tepper, K. Pearson, W. J. Gradishar*
- Board 354 **Abstract 6528: Defining survivorship and surveillance with evidence.** *R. Dood, Y. Zhou, S. D. Armbruster, S. Tworoger, R. L. Coleman, A. Sood, K. A. Baggerly*

- Board 355 Abstract 6529: Use of next-generation sequencing tests to guide cancer treatment: Results from a survey of U.S. oncologists.** *A. N. Freedman, C. N. Klabunde, K. Wiant, L. Enewold, S. W. Gray, K. K. Filipinski, N. L. Keating, D. Leonard, T. G. Lively, T. S. McNeel, L. M. Minasian, A. L. Potosky, D. Rivera, R. L. Schilsky, D. Schrag, N. I. Simonds, H. M. Sineshaw, G. Willis, J. de Moor*
- Board 356 Abstract 6530: Patient predictive factors for clinical trial participation.** *A. R. Mallen, B. M. Boac, S. Todd, S. E. Robertson, A. Gandhi, M. Kuznicki, B. Cao, A. M. Magliocco, R. M. Wenham, B. Fridley, H. Chon*
- Board 357 Abstract 6531: Factors associated with follow-up physician visits among women with early stage breast cancer.** *F. Quyyumi, M. K. Accordino, D. Buono, A. Neugut, G. Hillyer, J. D. Wright, D. L. Hershman*
- Board 358 Abstract 6532: Early discharge after induction chemotherapy for acute myeloid leukemia: Safety outcomes and hospital readmissions.** *N. V. Baclig, S. A. Buckley, A. B. Halpern, P. C. Hendrie, M. M. Percival, P. S. Becker, E. Estey, R. B. Walter*
- Board 359 Abstract 6533: Financial toxicity in patients with colorectal cancer and neuroendocrine tumors.** *L. Apostolidis, K. Mehlis, J. Witte, B. Surmann, M. Kudlich, G. Walthier, W. Greiner, E. C. Winkler*
- Board 360 Abstract 6534: Burdensome end-of-life (EOL) transitions among frail older adults with advanced cancer.** *D. E. Lage, Y. Lee, S. L. Mitchell, J. S. Temel, S. Berry, A. El-Jawahri*
- Board 361 Abstract 6535: Patient-reported satisfaction with multidisciplinary (MD) v serial care (SC) for lung cancer.** *K. D. Ward, W. Chen, M. Smeltzer, M. B. Meadows, N. R. Faris, C. Berryman, B. M. Jackson, F. Rugless, M. Ray, R. U. Osarogiabon*
- Board 362 Abstract 6536: Outcomes of embedded palliative care outpatients consults on timing of palliative care access, symptoms, and end-of-life quality indicators among advanced non-small cell lung cancer patients.** *S. Yennu, B. L. Prado, Z. Lu, S. Naqvi, J. L. Williams, T. Lim, E. Bruera*
- Board 363 Abstract 6537: Diffusion of innovation in oncology: A case study of immuno-oncology (IO) adoption for advanced non-small lung cancer (aNSCLC) patients across practices in the US.** *C. S. Bennette, A. Z. Torres, M. Tucker, S. Khozin, A. P. Abernethy, N. R. Brown, N. J. Meropol*
- Board 364 Abstract 6538: A multidisciplinary toxicity team for cancer immunotherapy-related adverse events.** *J. Naidoo, L. Cappelli, E. J. Lipson, P. M. Forde, W. H. Sharfman, J. Zhang, J. Mammen, K. Moseley, K. Suresh, S. Mehta, I. Sander, J. Probasco, A. Parian, R. Rouf, M. Berkenstock, P. Brothers, J. Riemer, L. A. Emens, C. O. Bingham, J. R. Brahmer*
- Board 365 Abstract 6539: Reportable actionability versus pragmatic actionability: Implementing precision medicine at three large health systems.** *M. A. Thompson, A. Zaman, A. M. Winzeler, J. Kern, A. Ghosh, J. Godden, J. L. Weese, M. Singh, B. L. Eisenberg, M. J. Demeure, N. Z. Haque, S. C. Hoover, S. N. Kalkanis*
- Board 366 Abstract 6540: Patient comorbid conditions and cancer clinical trial participation.** *J. M. Unger, D. L. Hershman, M. Fleury, R. Vaidya*
- Board 367 Abstract 6541: Cancer pain in the emergency department: A multicenter study of the Comprehensive Oncologic Emergencies Research Network.** *C. J. Coyne, R. A. Shatsky, D. D. Durham, A. Klotz, A. Bastani, C. Baugh, C. Grudzen, D. Henning, D. Adler, J. Wilson, J. F. Rico, D. Pallin, S. J. Yeung, S. Bernstein, J. Caterino, T. Madsen, R. Ryan, D. Kyriacou, A. Venkat, C. C. Reyes-Gibby*
- Board 368 Abstract 6542: Practice transformation: Early impact of OCM on hospital admissions.** *M. Mendenhall, K. M. Dyehouse, A. S. Guinigundo, T. Meyer-Smith, B. Bourbeau, D. M. Waterhouse*
- Board 369 Abstract 6543: Cancer survival in the context of growing hospital participation in Medicare ACOs.** *S. M. Schleicher, J. A. Lavery, B. E. Barrow, D. M. Rubin, M. H. Radzyner, E. Duck, P. Bach*

Saturday, June 2, 2018

- Board 370 **Abstract 6544: 24-hour cancer clinic: An approach to same-day care.** *J. T. Kapke, R. Narra, T. Curtis, D. Atkinson, J. D. Rizzo, L. C. Michaelis*
- Board 371 **Abstract 6545: ECHO palliative care in africa (ECHO-PACA): Improving access to quality palliative care.** *S. Yennu, C. E. Amos Jr, J. Weru, E. B. Deedei Addo, J. A. Arthur, O. Soyannwo, R. C. Chidebe, E. Bruera, S. Reddy*
- Board 372 **Abstract 6546: Do accountable care organizations impact prostate cancer screening?** *Q. Trinh, A. P. Cole, A. Krasnova, A. Ramaswamy, D. F. Friedlander, J. Sammon, J. S. Weissman, S. A. Fletcher, A. S. Kibel, M. Sun*
- Board 373 **Abstract 6547: Implementation of individualized care plans in high risk oncology patients: A team based model to decrease unnecessary utilization.** *G. C. Kunapareddy, B. Switzer, P. Pinnamaneni, J. Hooley, L. Varella, C. Poole, H. Tackitt, C. Best, C. Hallman, A. Torres, R. Lagman, A. J. Montero*
- Board 374 **Abstract 6548: Risk stratification and predictive value of the HOSPITAL score for oncology patient readmissions.** *A. Neerukonda, B. N. Polite, M. Connolly*
- Board 375 **Abstract 6549: Clinician perspectives on electronic health records, communication, and patient safety across diverse medical oncology practices.** *M. R. Patel, C. R. Friese, K. Mendelsohn-Victor, A. J. Fauer, B. Ghosh, A. Ramakrishnan, L. Bedard, J. J. Griggs, M. Manojlovich*
- Board 376 **Abstract 6550: Impact of a cognitive computing clinical trial matching system in an ambulatory oncology practice.** *T. C. Haddad, J. Helgeson, K. Pomerleau, M. Makey, P. Lombardo, S. Coverdill, A. Urman, M. Rammage, M. P. Goetz, N. LaRusso*
- Board 377 **Abstract 6551: Statistical significance of bevacizumab trials when considering the portfolio of all studies.** *D. L. Tao, N. D. Gay, V. Prasad*
- Board 378 **Abstract 6552: Analysis of use of a molecular reporting and treatment decision support tool in more than 1300 cancer cases.** *G. A. Bien-Willner, C. Hülsewig, D. B. Jackson, S. Kaduthanam, S. Brock, M. A. Stein, S. Hettich, M. Weber, M. Loehr*
- Board 379 **Abstract 6553: Association of baseline body mass index (BMI) with overall survival (OS) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) treated with nivolumab (N) and pembrolizumab (P).** *J. Zhi, S. Khozin, D. Kuk, A. Z. Torres, R. Sorg, S. E. Lee, R. A. Miksad, R. Pazdur, A. P. Abernethy*
- Board 380 **Abstract 6554: Trial prospector update: A point of care automated clinical trials matching application.** *D. L. Bajor, N. Sharma, M. S. Patel, G. Zhang, P. Mergler, S. Tao, S. Sigdel, S. Fulton, J. Surdam, N. J. Meropol*
- Board 381 **Abstract 6555: Artificial intelligence methods to predict chemotherapy-induced neutropenia in breast cancer patients.** *P. A. DeWan, O. Inbar, C. S. Spina, K. Rudeen, C. Lagor, M. S. Walker, E. J. Stepanski, J. O. Nwankwo, B. Hyde*
- Board 382 **Abstract 6556: Factors impacting progression-free survival (PFS) as a predictor of overall survival (OS).** *D. J. Stewart, D. Bossé, J. F. Hilton, G. D. Goss, M. Fung-Kee-Fung, D. J. Jonker*
- Board 383 **Abstract 6557: The influence of socioeconomic status, tumor characteristics and patterns of breast cancer care on breast cancer specific survival among elderly women.** *A. L. Kong, A. B. Nattinger, E. L. McGinley, M. Nattinger, L. E. Pezzin*
- Board 384 **Abstract 6558: Feasibility of a self-funded model to provide breast cancer services to uninsured women in New York City.** *J. Zaballero, E. Aviki, K. Abderholden, S. M. Schleicher, J. A. Smith*
- Board 385 **Abstract 6559: Cigarette price, smoking behaviors, and lung cancer mortality in Indiana.** *R. Nguyen, N. H. Hanna*
- Board 386 **Abstract 6560: Impact of high-deductible insurance on breast cancer care among lower-income women.** *J. F. Wharam, F. Zhang, C. Lu, A. K. Wagner, L. Nekhlyudov, C. Earle, S. Stephen, D. Ross-Degnan*
- Board 387 **Abstract 6561: Increasing access to NGS tests for women and racial minorities to lift barriers to molecular driven clinical trial enrollment.** *J. Cotta, B. Gordon, J. C. Trent II*

- Board 388 Abstract 6562: Financial toxicity associated with conflict-induced cross-border travel for cancer care: Experience of Iraqi patients in Lebanon.** *D. Mukherji, M. Skelton, R. Alameddine, O. Saifi, M. Salim Hammoud, M. Daher, M. Charafeddine, W. Faraj, S. N. Temraz, A. Shamseddine, L. Y. Mula-Hussain, M. Saleem, K. F. Namiq, O. Dewachi, G. Abu Sitta*
- Board 389 Abstract 6563: Assessing the impact of early Medicaid expansion on insurance, stage at diagnosis, and survival among young adults ineligible for dependent coverage.** *J. Barnes, K. J. Johnson*
- Board 390 Abstract 6564: Superior survival in adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) treated in pediatric vs. adult centers is only partially attributable to inadequate adoption of pediatric protocols: A population-based IMPACT Cohort study.** *S. Gupta, J. D. Pole, C. Lau, C. Nagamuthu, R. Sutradhar, N. N. Baxter, P. C. Nathan*
- Board 391 Abstract 6565: Changes in access to care and financial hardship associated with Affordable Care Act (ACA) implementation for cancer survivors aged 19-64 years.** *A. J. Davidoff, X. Han, X. Hu, Z. Zheng, K. S. Virgo*
- Board 392 Abstract 6566: Addressing financial concerns of cancer clinical trial participants: Longitudinal outcomes of an equity intervention.** *R. D. Nipp, H. Lee, E. Gorton, M. Lichtenstein, E. R. Park, B. A. Chabner, B. Moy*
- Board 393 Abstract 6567: Impact of hospital safety-net burden on oncology patterns of care and outcomes.** *R. Sarkar, Z. D. Guss, C. Lopez, M. Brandel, J. D. Murphy*
- Board 394 Abstract 6568: Overall survival based on oncologist density in the United States: Do we need to redefine underserved areas for oncologic care?** *K. Mehta, S. Siddappa Malleshappa, S. Patel, T. Mehta, S. Giri, L. J. Appleman, V. A. Passero, R. A. Parikh*
- Board 395 Abstract 6569: Geographic distribution and survival outcomes for rural cancer patients treated in clinical trials.** *J. M. Unger, A. Moseley, B. Symington, M. Chavez-MacGregor, S. D. Ramsey, D. L. Hershman*
- Board 396 Abstract 6570: Investigating hospice utilization for oncology patients using a claims database.** *M. C. Horvath, R. Wurtz, B. A. Virnig, N. Engel-Nitz, L. S. Lal, C. Elliott, S. DaCosta Byfield*
- Board 397 Abstract 6571: Hospital utilization and disposition among patients with malignant bowel obstruction: A population-based comparison of surgical to medical management.** *S. Bateni, R. J. Bold, S. L. Stewart, F. J. Meyers, R. J. Canter*
- Board 398 Abstract 6572: Effect of blinding on completion rate of patient-reported outcome measures in FDA cancer trial submissions, 2007-2017.** *J. Roydhouse, B. King-Kallimanis, L. J. Howie, H. Singh, P. G. Kluetz*
- Board 399 Abstract 6573: Prevalence of quality of life (QoL) outcomes and association with survival in cancer clinical trials.** *B. Gyawali, T. Hwang*
- Board 400 Abstract 6574: Validity of using cancer registry data for comparative effectiveness research.** *Z. D. Guss, P. Sheridan, R. Sarkar, B. S. Rose, R. Xu, J. D. Murphy*
- Board 401 Abstract 6576: Predicting acute care use following initiation of systemic therapy for solid tumors.** *R. C. Grant, R. Moineddin, Z. Yao, M. L. Powis, R. Croxford, E. Grunfeld, V. Kukreti, M. K. Krzyzanowska*
- Board 402 Abstract 6577: Racial, age, and sex disparities in chronic lymphocytic leukemia (CLL) patients treated with novel therapies.** *M. Thompson, C. Nabhan, B. D. Cheson, J. N. Allan, P. M. Barr, A. P. Skarbnik, R. Jacobs, C. S. Ujjani, R. R. Furman, S. J. Schuster, N. N. Shah, J. M. Pagel, B. T. Hill, D. M. Brander, M. Shadman, C. Zent, N. Lamanna, H. H. Tuncer, F. Lansigan, A. R. Mato*
- Board 403 Abstract 6578: Real-world data (RWD) on tumor response (rwTR) in advanced non-small cell lung cancer (aNSCLC) patients receiving cancer immunotherapy and targeted therapies.** *M. Lu, N. Sadetsky, P. Lambert, S. Whipple, M. D. Taylor, T. Riehl, G. J. Riely*

Saturday, June 2, 2018

- Board 404 **Abstract 6579: State breast density inform mandate laws and utilization of adjunctive screening tests and cancer detection following screening mammography.** *C. P. Gross, J. R. Hoag, X. Xu, I. Richman, J. Aminawung, P. R. Soulos, S. Busch*
- Board 405 **Abstract 6580: Toward understanding toxicity over time (ToxT) in myeloma cooperative group trials: Feasibility of a novel longitudinal adverse event analysis in ECOG-ACRIN E1A06.** *S. J. Jacobus, P. J. Novotny, A. K. Stewart, R. M. Warsame, N. S. Callander, R. Fonseca, M. V. Midathada, A. A. Singh, T. E. O'Brien, D. MacFarlene, D. L. Grinblatt, A. A. Chanan-Khan, S. Rajkumar, A. C. Dueck, G. Thanarajasingam*
- Board 406 **Abstract 6581: Assessing the difference in efficacy and effectiveness of cancer systemic treatment (tx): A comparison of clinical trial (CT) overall survival (OS) and toxicity data with population-based, real world (RW) OS data.** *C. Phillips, H. Guo, D. Schwartz, W. Isaranuwatjai, J. M. Beca, W. Dai, J. Arias, S. Gavura, K. K. Chan*
- Board 407 **Abstract 6582: Enrollment in high-deductible health plans and access to care, out-of-pocket spending, and hospital emergency department use among cancer survivors.** *Z. Zheng, A. Jemal, M. P. Banegas, X. Han*
- Board 408 **Abstract 6583: Work status after treatment for breast cancer: A controlled, prospective, longitudinal study of an ethnically diverse cohort.** *V. S. Blinder, S. Patil, C. E. Eberle, G. Jung, L. J. Kampel, C. Hwang, T. Bao, M. E. Robson, M. Malik, F. Gany*
- Board 409 **Abstract 6584: Trends in chronic opioid therapy among cancer survivors.** *T. Salz, J. A. Lavery, A. N. Lipitz Snyderman, D. Boudreau, N. Moryl, E. F. Gillespie, D. Korenstein*
- Board 410 **Abstract 6585: Prediction of venous thromboembolism (VTE) in multiple myeloma (MM): Myeloma clot score (MCS).** *K. M. Santillippo, T. Wang, S. Luo, K. R. Carson, T. S. Thomas, B. Gage*
- Board 411 **Abstract 6586: A novel approach to mine the Veterans Administration Informatics and Computing Infrastructure (VINCI) allows one to assess the efficacy of cancer therapies: Abiraterone and enzalutamide in Veterans with metastatic prostate cancer (PC).** *H. Leuva, K. Sigel, J. Wilkerson, Y. Park, G. McWilliams, C. B. Anderson, T. Hsu, P. Rescigno, J. S. De Bono, D. H. Aggen, C. G. Drake, E. Langhoff, S. E. Bates, A. T. Fojo*
- Board 412 **Abstract 6587: Cancer patient-reported knowledge and preferences for liquid biopsies and blood biomarkers at a comprehensive cancer centre.** *M. Lee, S. X. Jiang, Y. Gao, K. Hueniken, L. Lu, L. Eng, A. McCartney, T. Obuobi, N. Kuehne, B. Id Said, M. Liang, H. Sorotsky, M. Brown, W. Xu, G. Liu*
- Board 413 **Abstract 6588: Safety and tolerability of cancer drugs studied in phase 3 randomized controlled trials (RCTs) over the last decade.** *D. Ribnikar, H. Goldvaser, A. Ocana, A. J. Templeton, B. Seruga, E. Amir*
- Board 414 **Abstract 6589: Classifying lung cancer stage from health care claims with a clinical algorithm or a machine-learning approach.** *G. A. Brooks, N. L. Keating, S. L. Bergquist, M. B. Landrum, S. Rose*
- Board 415 **Abstract 6590: Development of a dashboard for end-of-life care at an academic hospital.** *K. B. Adelson, N. J. Meropol, J. Hamrick, T. Haydell, J. Martineau, J. Kraut, K. M. Severino, R. Lilienbaum*
- Board 416 **Abstract 6591: Adherence to oral anticancer medications after implementation of an ambulatory adherence program at a large urban academic hospital.** *M. A. Curry, T. Redelico, C. Terrell, I. G. Chineke, J. A. LaFollette, W. Bell, D. Flood, P. Mishra, S. Power, L. Bernal-Mizrachi*
- Board 417 **Abstract 6592: The impact of the ASCO Choosing Wisely campaign for breast and prostate cancer on physician behavior.** *D. L. Rodin, P. Kakani, M. Rosenthal, A. Sinaiko*

- Board 418 **Abstract 6593: Use of hypofractionated radiotherapy for early stage breast cancer after implementation of evidence-based clinical guidelines.** *S. Gautam, R. P. Zimmerman, D. J. Debono, J. Barron, G. Sylwestrzak*
- Board 419 **Abstract 6594: CYP2C19-guided voriconazole prophylaxis in neutropenic AML patients.** *J. K. Hicks, K. Shahbazian, R. E. Quilitz, R. S. Komrokji, T. E. Kubal, J. Lancet, Y. Pasikhova, D. Qin, W. So, A. P. Velez, H. L. McLeod, J. N. Greene*
- Board 420 **Abstract 6595: Does training oncologists to have goals of care discussions affect healthcare utilization among patients with advanced cancer?** *N. A. Bickell, K. B. Adelson, J. P. Gonsky, J. J. Lin, R. Franco, N. Egorova, C. B. Smith*
- Board 421 **Abstract 6596: Improving documentation of pain and constipation management within the cancer center of a large public healthcare network.** *G. Dutcher, D. Flood, M. A. Curry, A. Washington, P. Mishra, C. Streetman, J. A. LaFollette, W. Bell, S. Smith, M. C. Senchery, S. Power, L. Bernal-Mizrachi*
- Board 422 **Abstract 6597: Does training oncologists to have goals of care discussions increase and improve the quality of GoC discussions with advanced cancer patients?** *N. A. Bickell, K. B. Adelson, J. P. Gonsky, J. J. Lin, S. Pintova, R. Franco, N. Egorova, C. B. Smith*
- Board 423 **Abstract 6598: Use of QT interval prolonging drugs (QT drugs) and electrocardiogram (ECG) monitoring in patients (pts) receiving first-line anti-cancer systemic therapy (tx): A population-based analysis.** *R. C. Pezo, A. T. Yan, C. Earle, K. K. Chan*
- Board 424 **Abstract 6599: Implementation of dietary education within a multidisciplinary team approach to improve treatment accuracy and efficiency in prostate cancer external beam radiation therapy.** *T. L. Evans, J. Restrepo, A. V. Cheuk, S. Li, N. Bektic-Marrero, G. A. Dawson*
- Board 425 **Abstract 6600: Prevalence of HIV, hepatitis b virus (HBV), and hepatitis c virus (HCV) among newly diagnosed cancer patients treated in academic and community oncology practices: SWOG S1204.** *S. D. Ramsey, J. M. Unger, L. H. Baker, R. F. Little, R. Loomba, J. Hwang, R. Chugh, M. A. Konerman, K. B. Arnold, D. L. Hershman*
- Board 426 **Abstract 6601: Identifying and interpreting actionable molecular alterations from next-generation sequencing results in the community: A Sarah Cannon molecular cancer conference.** *H. H. Dilks, A. McKenzie, S. F. Jones, D. B. Daniel, E. Arrowsmith, M. A. Stipanov, B. M. Anz, D. Johnson, A. Tran, B. R. Nadeau, S. L. Krueger, B. R. Daniel, D. W. Holland, K. Tucker, M. Correll, D. R. Spigel, H. A. Burris III*
- Board 427 **Abstract 6602: A nationwide analysis of palliative care service utilization in hospitalized metastatic cancer patients.** *K. Parikh, S. Yandrapalli, A. Kumar, M. Frankenthaler, D. Liu*
- Board 428 **Abstract 6603: TelePsychiatry for cancer patients undergoing active treatment.** *C. Otto, K. Cotter, J. Harris, W. Breitbart*
- Board 429 **Abstract 6604: Utilization of telemedicine at two high-volume cancer care organizations.** *R. Williams, M. Aspden, P. D. Stetson, C. Otto*
- Board 430 **Abstract 6605: The effect of supervised, individualized exercise on cost savings during cancer treatment.** *K. Y. Wonders, M. M. Safa, E. J. Vannorsdall, A. R. Calvo*
- Board 431 **Abstract 6606: A proportional comparison of cancer burden and patient advocacy organization (PAO) funding by histology demonstrates many underfunded histologies.** *S. D. Kamath, S. M. Kircher, A. B. Benson III*
- Board 432 **Abstract 6607: Duration of physician-industry relationships and prescribing changes in oncology.** *A. P. Mitchell, A. Winn, J. L. Lund, S. Dusetzina*
- Board 433 **Abstract 6608: What role does the patient perspective play in determining access to innovative therapies?** *C. F. Jones, J. F. Soto Barrientos, G. Spentzouris, C. Hunter-Lavin*

Saturday, June 2, 2018

- Board 434 **Abstract 6609: Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III/IV Hodgkin lymphoma.** *S. F. Huntington, G. R. Von Keudell, A. J. Davidoff, C. P. Gross, S. A. Prasad*
- Board 435 **Abstract 6610: Cost-effectiveness of chimeric antigen receptor t-cell therapy in pediatric relapsed/refractory acute lymphoblastic leukemia.** *R. Sarkar, N. J. Gloude, J. D. Murphy*
- Board 436 **Abstract 6611: Trajectories of medical care cost by service type for recurrent and de novo advanced cancer patients.** *M. P. Banegas, M. J. Hassett, E. Keast, N. M. Carroll, M. C. O’Keeffe-Rosetti, P. A. Fishman, A. M. Cronin, H. Uno, M. C. Hornbrook, D. P. Ritzwoller*
- Board 437 **Abstract 6612: The potential cost-effectiveness of first-line immunotherapy + chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC).** *J. A. Roth, T. Nguyen, B. H. Goulart*
- Board 438 **Abstract 6613: The financial impact of hypofractionated radiation for prostate cancer.** *A. Moore, I. Stav, R. B. Den, M. Sarfaty, V. Neiman, E. Rosenbaum, D. A. Goldstein*
- Board 439 **Abstract 6614: A value framework analysis of the Canadian Cancer Trials Group.** *J. Del Paggio, A. M. Fundytus, W. M. Hopman, J. L. Pater, B. E. Chen, M. D. Brundage, A. E. Hay, C. M. Booth*
- Board 440 **Abstract 6615: Network metanalysis and cost-effectiveness of abiraterone, docetaxel or placebo plus androgen deprivation therapy (ADT) for hormone-sensitive advanced prostate cancer.** *P. N. Aguiar, P. Tan, S. Simko, C. N. Barreto, B. G. Aguiar, A. Del Giglio, G. Lopes*
- Board 441 **Abstract 6616: Utilization of imaging during staging and surveillance of localized colon cancer in a large insured population.** *U. Durani, D. Asante, T. R. Halfdanarson, H. Heien, L. R. Sangaralingham, R. S. Go*
- Board 442 **Abstract 6617: Immunotherapy (IO) versus non-IO for oncology drugs: Comparing survival benefits (SB) using restricted mean survival time.** *A. P. Rahmadian, S. Delos Santos, S. Parshad, L. Everest, M. C. Cheung, K. K. Chan*
- Board 443 **Abstract 6618: Trends of hospitalizations with invasive fungal infections in patients with acute leukemia and hematopoietic stem cell from 2005-2014 in the United States.** *S. Kamboj, H. Elias, V. Kumar*
- Board 444 **Abstract 6619: Gastrointestinal (GI) cancer (CA) drugs approved by the US Food and Drug Administration (FDA): Clinical value and cost considerations.** *D. M. Jiang, R. W. Jang, K. K. Chan, G. Liu, E. Amir, E. Elimova*
- Board 445 **Abstract 6620: Can oral chemotherapy parity laws reduce patients’ out-of-pocket (OOP) costs?** *A. P. Sitlinger, R. Sachdev, P. A. Ubel, C. Wong, T. W. LeBlanc, T. Zhang, D. Anderson, Y. Zafar*
- Board 446a **Abstract TPS6621: A randomized, controlled trial to assess a multi-level intervention to improve adherence to oral cancer medications.** *R. Potdar, S. Karki, C. M. Dourado, K. Mohiuddin, D. Djibo, J. C. Leighton, J. G. Ford*
- Board 446b **Abstract TPS6622: Ambulatory cancer care electronic symptom self-reporting (ACCESS) for surgical patients: A randomized controlled trial.** *C. Stabile, L. K. Temple, B. A. Simon, P. D. Stetson, D. Stein, A. J. Vickers, A. Pusic*

3:00 PM - 4:15 PM Poster Discussion Session

Breast Cancer—Local/Regional/Adjuvant

Location: Hall D1
Interact ID: 10858

Jacqueline Sara Jeruss, MD, PhD - Chair
University of Michigan

Andrew O. Wahl, MD - Chair

University of Nebraska Medical Center

- 3:00 PM Shanu Modi, MD (Discussion of Abstract(s) 509-511)**
Memorial Sloan Kettering Cancer Center
Less Is More: A Targeted Difference
- 3:12 PM** *Panel Question and Answer*
- 3:18 PM Julia R. White, MD (Discussion of Abstract(s) 513-514)**
NRG Oncology, and The Ohio State University Comprehensive Cancer Center
Out of the Box: Local/Regional Therapy
- 3:30 PM** *Panel Question and Answer*
- 3:36 PM Erica L. Mayer, MD, MPH (Discussion of Abstract(s) 515-517)**
Dana-Farber Cancer Institute
Cracking the Code: Predicting Late Risk in Hormone-Receptor-Positive Disease
- 3:48 PM** *Panel Question and Answer*
- 3:54 PM Priyanka Sharma, MD (Discussion of Abstract(s) 518-520)**
University of Kansas Medical Center
Advances in Precision Medicine in Triple-Negative Breast Cancer
- 4:06 PM** *Panel Question and Answer*

Posters discussed in this session are on display in the Breast Cancer—Local/Regional/Adjuvant Poster Session. See page 62 for poster information.

3:00 PM - 4:15 PM Poster Discussion Session

Sarcoma

Location: S404

Interact ID: 10878

Elizabeth J. Davis, MD - Chair

Vanderbilt University

Nadia Hindi, MD - Chair

Fondazione IRCCS Istituto Nazionale dei Tumori

- 3:00 PM Sebastian Bauer, MD (Discussion of Abstract(s) 11509-11511)**
West German Cancer Center, University Hospital Essen
GIST: Moving Beyond Imatinib, Sunitinib, and Regorafenib
- 3:12 PM** *Panel Question and Answer*
- 3:18 PM Mark Andrew Dickson, MD (Discussion of Abstract(s) 11512-11514)**
Memorial Sloan Kettering Cancer Center
Targeting Therapies in L-Type Sarcomas
- 3:30 PM** *Panel Question and Answer*
- 3:36 PM Neeta Somaiah, MD (Discussion of Abstract(s) 11515-11517)**
The University of Texas MD Anderson Cancer Center
Immuno-oncology in Sarcoma: Are We Any Closer?
- 3:48 PM** *Panel Question and Answer*
- 3:54 PM Scott H. Okuno, MD (Discussion of Abstract(s) 11518-11520)**
Mayo Clinic
Refining Adjuvant Therapy in Soft Tissue Sarcomas and New Treatments in Bone Sarcomas
- 4:06 PM** *Panel Question and Answer*

Posters discussed in this session are on display in the Sarcoma Poster Session. See page 93 for poster information.

Saturday, June 2, 2018

3:00 PM - 4:15 PM Award Lecture

Allen S. Lichter Visionary Leader Award and Lecture

Location: S100a

Interact ID: 10809

Daniel F. Hayes, MD, FACP, FASCO

University of Michigan Comprehensive Cancer Center

Presentation of the 2018 Allen S. Lichter Visionary Leader Award

Nancy E. Davidson, MD, FASCO

University of Pittsburgh Cancer Institute

Serendipity and Purpose

3:00 PM - 4:15 PM Education Session

Biden Cancer Initiative Colloquium

Location: S406

Interact ID: 11188

Panel Discussion

3:00 PM - 4:15 PM Education Session

Emerging Personalized Strategies in Systemic Therapy for the Treatment of Melanoma

Location: E451

Interact ID: 10751

Paolo Antonio Ascierto, MD - Chair

National Tumour Institute Fondazione G. Pascale

Novel Combinations of Therapy in Melanoma

Keith Flaherty, MD

Massachusetts General Hospital

Novel Targets for Therapy in Melanoma

Stephanie L. Goff, MD

National Cancer Institute at the National Institutes of Health

Is There a Role for Adoptive Cell Therapy in the Treatment of Melanoma?

Panel Question and Answer

3:00 PM - 4:15 PM Education Session

Pain Management in the Era of the Opioid Crisis

Location: S100bc

Interact ID: 10919

George F. Koob, PhD

National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health

Mechanisms of Opioid Addiction

Eduardo Bruera, MD - Chair

The University of Texas MD Anderson Cancer Center

Screening and Diagnosis of Chemical Coping and Aberrant Opioid Use Among Patients With Cancer-Related Pain

Egidio Del Fabbro, MD

Virginia Commonwealth University Massey Cancer Center

The Management of Cancer-Related Pain and Aberrant Opioid Use in Patients

Panel Question and Answer

3:00 PM - 4:15 PM Education Session

Patient-Reported Outcomes: Expanding From Plenary to Everyday Practice

Location: S102

Interact ID: 10701

Ethan M. Basch, MD, FASCO - Chair

The University of North Carolina at Chapel Hill

PROs: From Evidence to Implementation

Carolyn Kerrigan, MD, MHCDS

Geisel School of Medicine, Dartmouth College

Can Your Practice Afford PROs? Acquisition and Maintenance Considerations

Lisa Catherine Barbera, MD

Odette Cancer Centre, Sunnybrook Health Sciences Centre

PROs by Mandate: Lessons Learned From Province-wide Implementation

Galina Velikova, PhD

Leeds Institute of Cancer and Pathology/St James's Institute of Oncology

Integrating PROs with Electronic Patient Records

Panel Question and Answer

3:00 PM - 4:15 PM Education Session

Precision Medicine Versus Population Medicine in Colorectal Cancer

Location: Hall D2

Interact ID: 10706

Michael J. Hall, MD, MS

Fox Chase Cancer Center

Precision Prevention and Screening: General Population Versus Individuals With High Risk

Weijing Sun, MD, FACP - Chair

University of Kansas Medical Center

Application of Recent Adjuvant Data (3 Versus 6 Months of FOLFOX) to Individual Patient Care.

Arden M. Morris, MD

University of Michigan

Surveillance: Evidence Based?

Panel Question and Answer

Saturday, June 2, 2018

3:00 PM - 4:15 PM Meet the Professor Session

International Translation of Quality Oncology Care Measures and Standards - Ticketed Session

Location: E253d

Interact ID: 10689

Mohammad Jahanzeb, MD, FASCO

University of Miami Sylvester Comprehensive Cancer Center

Evangelia Razis, MD, PhD

Hellenic Cooperative Oncology Group (HeCOG)

3:00 PM - 4:15 PM Clinical Problems in Oncology Session

Moving Beyond Whole Brain and Large Field Spine Radiation for Central Nervous System Metastases: Is Less More? - Ticketed Session

Location: E253c

Interact ID: 10741

Helen Alice Shih, MD, MS - Chair

Massachusetts General Hospital

Is There Still a Role for Whole Brain Radiation Therapy?

Yoshiya Yamada, MD

Memorial Sloan Kettering Cancer Center

Does Stereotactic Body Radiation Therapy for Spinal Metastases Lead to Better Preservation of Neuro Function and QOL?

Matthias Preusser, MD

Medical University of Vienna, Comprehensive Cancer Center

Potential Value and Limitations of EGFR, ALK/ROS1, and Other Targeted Therapies for CNS Metastases

Panel Question and Answer

3:00 PM - 6:00 PM Oral Abstract Session

Developmental Therapeutics—Immunotherapy

Location: Hall B1

Interact ID: 10834

Sanjay Goel, MD - Chair

Montefiore Medical Center/Albert Einstein College of Medicine

Matthew I. Milowsky, MD - Chair

UNC School of Medicine

3:00 PM Abstract 3000: ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers. T. A. Yap, H. A. Burris III, S. Kummar, G. S. Falchook, R. K. Pachynski, P. LoRusso, S. S. Tykodi, G. T. Gibney, J. F. Gainor, O. E. Rahma, T. Y. Seiwert, F. Meric-Bernstam, M. A. Blum Murphy, J. K. Litton, E. M. Hooper, H. A. Hirsch, C. Harvey, M. Clancy, T. McClure, M. K. Callahan

- 3:12 PM Abstract 3001: Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results.** *R. E. Sanborn, M. J. Pishvaian, M. K. Callahan, A. M. Weise, B. I. Sikic, O. E. Rahma, D. C. Cho, N. A. Rizvi, R. L. Bitting, A. Starodub, A. Jimeno, M. J. Yellin, T. Rawls, L. Vitale, A. Halim, H. Zhang, T. Keler*
- 3:24 PM Abstract 3002: A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.** *B. I. Sikic, N. J. Lakhani, A. Patnaik, S. Shah, S. R. Chandana, D. W. Rasco, A. D. Colevas, T. J. O'Rourke, K. P. Papadopoulos, G. A. Fisher Jr., M. Chao, B. Agoram, J. Y. Chen, J. Huang, M. Axt, R. Majeti, I. L. Weissman, C. H. Takimoto, M. D. Pegram, S. K. Padda*
- 3:36 PM Aparna Kalyan, MD (Discussion of Abstract(s) 3000-3002)**
Northwestern Medicine Developmental Therapeutics Institute
Novel Targets for Immune Checkpoint Therapy
- 3:48 PM Panel Question and Answer**
- 4:00 PM Abstract 3003: Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large b cell lymphoma.** *F. L. Locke, A. Ghobadi, C. A. Jacobson, E. D. Jacobsen, D. B. Miklos, L. J. Lekakis, I. Braunschweig, O. O. Oluwole, Y. Lin, T. Siddiqi, A. Deol, P. M. Reagan, U. Farooq, A. Bot, Y. Jiang, J. M. Rossi, A. Xue, W. Y. Go, S. S. Neelapu*
- 4:12 PM Abstract 3004: Treatment of metastatic human papillomavirus-associated epithelial cancers with adoptive transfer of tumor-infiltrating t-cells.**
S. Stevanovic, S. R. Helman, J. R. Wunderlich, M. M. Langhan, S. L. Doran, M. M. Kwong, R. P. Somerville, C. A. Klebanoff, U. Kammula, R. M. Sherry, J. C. Yang, S. A. Rosenberg, C. S. Hinrichs
- 4:24 PM Abstract 3005: Pilot study of NY-ESO-1⁺ t cells in advanced myxoid/round cell liposarcoma.** *S. P. D'Angelo, M. Druta, D. A. Liebner, S. Schuetze, N. Somaiah, B. A. Van Tine, W. D. Tap, T. Pulham, K. Chagin, E. Norry, R. G. Amado*
- 4:36 PM Jason J. Luke, MD, FACP (Discussion of Abstract(s) 3003-3005)**
University of Chicago Comprehensive Cancer Center
Evolution of Cellular Therapies in Cancer
- 4:48 PM Panel Question and Answer**
- 5:00 PM Abstract 3006: NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.**
A. Diab, M. E. Hurwitz, D. C. Cho, V. Papadimitrakopoulou, B. D. Curti, S. S. Tykodi, I. Puzanov, N. K. Ibrahim, S. M. Tolaney, D. Tripathy, J. Gao, A. O. Siefker-Radtke, W. Clemens, M. A. Tagliaferri, S. N. Gettinger, H. M. Kluger, J. M. Larkin, G. Grignani, M. Sznol, N. M. Tannir
- 5:12 PM Abstract 3007: Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF- β , in patients with HPV associated cancers.**
J. Strauss, M. E. Gatti-Mays, J. Redman, R. A. Madan, E. Lamping, M. Manu, A. Burmeister, J. L. Marte, L. M. Cordes, L. Ojalvo, C. Helwig, J. Schlom, J. L. Gulley
- 5:24 PM Abstract 3008: ALT-803, an IL-15 superagonist, in combination with nivolumab in metastatic non-small cell lung cancer: Ongoing experience and biomarker development from a non-randomized, open-label, phase Ib/II trial.**
J. M. Wrangle, V. Velcheti, M. Patel, E. Garrett-Mayer, E. G. Hill, M. Farhad, K. R. Anderton, J. Rytlewski, M. D. Robinson, C. Krieg, W. L. Redmond, P. R. Rhode, A. Rock, H. C. Wong, M. P. Rubinstein
- 5:36 PM Heather L. McArthur, MD, MPH (Discussion of Abstract(s) 3006-3008)**
Cedars-Sinai Medical Center
Novel Cytokine-Based Combination Strategies
- 5:48 PM Panel Question and Answer**

3:00 PM - 6:00 PM Oral Abstract Session

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft

Location: E450

Interact ID: 10842

Ehab L. Atallah, MD - Chair

Medical College of Wisconsin

Veronika Bachanova, MD - Chair

University of Minnesota

- 3:00 PM Abstract 7000: Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study.** *D. A. Pollyea, C. D. Dinardo, S. de Botton, E. Stein, G. J. Roboz, A. S. Mims, R. T. Swords, J. K. Altman, R. Collins, G. N. Mannis, G. L. Uy, W. B. Donnellan, A. Pigneux, A. T. Fathi, H. Liu, B. Wu, E. C. Attar, M. S. Tallman, R. M. Stone, H. M. Kantarjian*
- 3:12 PM Abstract 7001: Early intervention in transfusion independent (TI) patients (Pts) with lower-risk myelodysplastic syndromes (MDS) treated with attenuated doses of hypomethylating agents (HMAs) is associated with high response rates and long duration of response.** *M. Swaminathan, E. Jabbour, F. Ravandi, T. M. Kadia, G. Borthakur, N. J. Short, S. Pierce, J. Waukau, D. Miller, J. E. Cortes, Y. Alvarado, H. M. Kantarjian, G. Garcia-Manero*
- 3:24 PM Eunice S. Wang, MD (Discussion of Abstract(s) 7000-7001)**
Roswell Park Comprehensive Cancer Center
Advancing Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes
- 3:36 PM Panel Question and Answer**
- 3:48 PM Abstract 7002: Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up.** *J. E. Cortes, M. J. Mauro, M. W. Deininger, C. Chuah, D. Kim, V. Kota, J. H. Lipton, P. H. Rousselot, D. Milojkovic, P. D. Le Coutre, V. Garcia Gutierrez, R. J. Crescenzo, E. Leip, F. An, N. Bouxin, A. Hochhaus, T. H. Brümmendorf, C. Gambacorti-Passerini*
- 4:00 PM Abstract 7003: Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results.** *F. Mahon, C. Boquimpani, N. Takahashi, N. Benyamini, N. D. Clementino, V. Shuvaev, A. Merchant, J. H. Lipton, A. G. Turkina, R. De Paz Arias, B. Moiraghi, F. E. Nicolini, J. Dengler, T. Sacha, D. Kim, R. Fellague-Chebra, S. Acharya, S. Chaturvedi, C. Bouard, T. P. Hughes*
- 4:12 PM Abstract 7004: Moxetumomab pasudotox in heavily pretreated patients with relapsed/refractory hairy cell leukemia: Results of a pivotal international study.** *R. J. Kreitman, C. Dearden, P. L. Zinzani, J. Delgado, T. Robak, P. D. Le Coutre, B. T. Gjertsen, X. Troussard, G. Saglio, G. J. Roboz, L. Karlin, D. E. Gladstone, K. Balic, N. Standifer, P. He, S. Marshall, W. H. Wilson, I. Pastan, N. Yao, F. J. Giles*
- 4:24 PM Javier Pinilla-Ibarz, MD (Discussion of Abstract(s) 7002-7004)**
H. Lee Moffitt Cancer Center and Research Institute
Advancing Treatment of Chronic Myeloid Leukemia and Hairy Cell Leukemia
- 4:36 PM Panel Question and Answer**
- 4:48 PM Abstract 7005: Factors impacting disease-free survival in adult B cell B-ALL patients achieving MRD-negative CR after CD19 CAR-T cells.** *K. A. Hay, J. Gauthier, A. V. Hirayama, D. Li, A. Sheih, V. Wu, J. M. Voutsinas, S. Cherian, X. Chen, B. S. Pender, R. M. Hawkins, A. Vakil, R. N. Steinmetz, T. Phi, S. R. Riddell, D. G. Maloney, C. J. Turtle*

- 5:00 PM Abstract 7006: Outcomes of patients (pts) treated with prior blinatumomab (Blin) in ZUMA-3: A study of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) t cell therapy, in adult pts with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).** *B. D. Shah, O. O. Oluwole, M. R. Baer, M. R. Bishop, H. E. Holmes, G. J. Schiller, W. B. Donnellan, K. M. Carr-O'Dwyer, A. Mardiros, J. M. Rossi, T. Shen, A. Xue, R. K. Jain, R. Vezan, W. G. Wierda*
- 5:12 PM Abstract 7007: Tumor gene signature associated with neurotoxicity in R/R B-ALL patients treated with JCAR015, a CD19-directed CART cell product.** *N. E. Olson, S. P. Ragan, S. Ponko, N. S. Trede, H. M. Stern, C. L. Sutherland*
- 5:24 PM Abstract 7008: Initial results of two phase I trials delivering mblL-21 ex vivo expanded haploidentical NK cells after fludarabine/cytarabine for patients with relapsed/refractory myeloid leukemias.** *S. O. Ciurea, L. Silla, K. Cao, K. Rezvani, E. J. Shpall, D. Soebbing, R. E. Champlin, D. A. Lee*
- 5:36 PM Sarah A. Cooley, MD (Discussion of Abstract(s) 7005-7008)**
University of Minnesota
Cellular Therapy in Leukemia
- 5:48 PM Panel Question and Answer**

3:00 PM - 6:00 PM Oral Abstract Session

Pediatric Oncology I

Location: S504

Interact ID: 10849

Maryam Fouladi, MD - Chair

Cincinnati Children's Hospital Medical Center

To Be Determined - Chair

- 3:00 PM Abstract 10500: COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy.** *K. P. Dunsmore, S. Winter, M. Devidas, B. L. Wood, N. Esiashvili, N. Eisenberg, N. Briegel, R. J. Hayashi, J. M. Gastier-Foster, A. J. Carroll, N. A. Heerema, B. Asselin, K. R. Rabin, P. Zweidler-McKay, E. A. Raetz, M. L. Loh, N. J. Winick, W. L. Carroll, S. Hunger*
- 3:12 PM Abstract 10501: Effect of dexrazoxane on left ventricular function and treatment outcomes in patients with acute myeloid leukemia: A Children's Oncology Group report.** *K. D. Getz, L. Sung, K. Leger, T. A. Alonzo, R. B. Gerbing, T. M. Cooper, E. Kolb, A. S. Gams, B. Ky, R. Aplenc*
- 3:24 PM Abstract 10502: Improved survival among children and adolescent and young adults with acute lymphoblastic leukemia (ALL) treated at specialized cancer centers in California.** *E. M. Alvarez, M. H. Malogolowkin, Q. Li, L. S. Muffly, T. Wun, T. Keegan*
- 3:36 PM Ajay Vora, MD (Discussion of Abstract(s) 10500-10502)**
Great Ormand Street Hospital
Improving Outcomes in Children, Adolescents, and Young Adults with Acute Leukemia
- 3:48 PM Panel Question and Answer**
- 4:00 PM Abstract 10503: SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).** *A. M. Gross, P. Wolters, A. Baldwin, E. Dombi, M. J. Fisher, B. D. Weiss, A. Kim, J. O. Blakeley, P. Whitcomb, M. Holmblad, S. Martin, M. Roderick, S. M. Paul, J. Therrien, K. Heisey, A. Doyle, M. A. Smith, J. Glod, S. M. Steinberg, B. C. Widemann*
- 4:12 PM Abstract 10504: Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)-associated plexiform neurofibroma: A phase I/IIa study.** *G. B. McCowage, S. Mueller, C. A. Pratilas, D. R. Hargrave, C. L. Moertel, J. Whitlock, E. Fox, P. Hingorani, M. W. Russo, K. Dasgupta, L. Tseng, B. Mookerjee, B. Georger*

Saturday, June 2, 2018

- 4:24 PM Abstract 10505: Dabrafenib in pediatric patients with *BRAFV600*–positive high-grade glioma (HGG).** *D. R. Hargrave*, L. Moreno, A. Broniscer, E. Bouffet, I. Aerts, N. Andre, W. V. Shen, A. Bertozzi-Salamon, K. J. Cohen, I. J. Dunkel, M. W. Kieran, A. Lissat, M. W. Russo, K. Dasgupta, L. Tseng, B. Mookerjee, B. Geoerger
- 4:36 PM Abstract 10506: Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with *BRAFV600*–mutant relapsed refractory low-grade glioma.** *M. W. Kieran*, E. Bouffet, A. Broniscer, K. J. Cohen, B. Geoerger, J. R. Hansford, P. Hingorani, I. Aerts, N. Andre, A. Bertozzi-Salamon, I. J. Dunkel, T. R. Hummel, S. Leary, L. Moreno, M. W. Russo, L. Tseng, K. Dasgupta, N. Nebot, J. Whitlock, D. R. Hargrave
- 4:48 PM Jason R. Fangusaro, MD (Discussion of Abstract(s) 10503-10506)**
Ann and Robert H. Lurie Children’s Hospital of Chicago
Targeting BRAF and MEK in Neural Tumors
- 5:00 PM Panel Question and Answer**
- 5:12 PM Abstract 10507: The randomised induction for high-risk neuroblastoma comparing COJEC and N5-MSKCC regimens: Early results from the HR-NBL1.5/SIOPEN trial.** *A. Garaventa*, U. Poetschger, D. Valteau-Couanet, V. Castel, M. Elliott, S. Ash, G. C. Chan, G. Laureys, M. Beck Popovic, K. Vetterranta, W. Balwierz, H. Schroeder, C. Owens, M. Cesen, V. Papadakis, T. Trahair, R. Luksch, G. Schleiermacher, P. F. Ambros, R. L. Ladenstein
- 5:24 PM Abstract 10508: Phase II trial of irinotecan/temozolomide/dinutuximab/ granulocyte macrophage colony stimulating factor (I/T/DIN/GMCSF) in children with relapsed/refractory neuroblastoma (NBL): A report from the Children’s Oncology Group (COG).** *R. Mody*, A. Naranjo, A. L. Yu, E. Hibbitts, W. B. London, B. L. Shulkin, M. T. Parisi, S. Servaes, M. B. Dicciani, P. M. Sondel, J. Glade-Bender, H. Katzenstein, J. Maris, J. R. Park, R. Bagatell
- 5:36 PM To be determined (Discussion of Abstract(s) 10507-10508)**
Advances in Pediatric Neuroblastoma Therapy
- 5:48 PM Panel Question and Answer**

4:45 PM - 6:00 PM Poster Discussion Session

Cancer Prevention, Hereditary Genetics, and Epidemiology

Location: S404

Interact ID: 10859

John R. Goffin, MD - Chair

Juravinski Cancer Centre

Kara Noelle Maxwell, MD, PhD - Chair

University of Pennsylvania Perelman School of Medicine

- 4:45 PM Sara Pirzadeh-Miller, MS, CGC (Discussion of Abstract(s) 1512-1514)**
University of Texas Southwestern Medical Center
Implementation of System-wide Approaches to Identification of Patients for Germline Genetic Testing
- 4:57 PM Panel Question and Answer**
- 5:03 PM Scott A. Tomlins, MD, PhD (Discussion of Abstract(s) 1515-1517)**
University of Michigan
Addressing Genetic Predisposition to Genitourinary Cancers: A Gap in Practice
- 5:15 PM Panel Question and Answer**
- 5:21 PM Amy Leader, PhD (Discussion of Abstract(s) 1518-1521)**
Thomas Jefferson University
Systems-Based Interventions to Address Secondary Cancer Prevention
- 5:33 PM Panel Question and Answer**

5:39 PM Elias Obeid, MD, MPH (Discussion of Abstract(s) 1522-1523)
Fox Chase Cancer Center
Hereditary Cancer Screening Modalities: The New and the Old

5:51 PM Panel Question and Answer

Posters discussed in this session are on display in the Cancer Prevention, Hereditary Genetics, and Epidemiology Poster Session. See page 107 for poster information.

4:45 PM - 6:00 PM Poster Discussion Session

Central Nervous System Tumors

Location: E451

Interact ID: 10860

Alba Ariela Brandes, MD - Chair
AUSL-IRCCS Institute of Neurological Sciences

Monica Malik, MD, DNB - Chair
Nizam's Institute of Medical Sciences

4:45 PM Hussein Abdul-Hassan Tawbi, MD, PhD (Discussion of Abstract(s) 2009-2011)
The University of Texas MD Anderson Cancer Center
Current Insights Into Checkpoint Therapy for Central Nervous System Metastases

4:57 PM Panel Question and Answer

5:03 PM To Be Determined (Discussion of Abstract(s) 2012-2014)
Evolving Biomarkers for Outcome: Strengths and Pitfalls

5:15 PM Panel Question and Answer

5:21 PM Stephen Joseph Bagley, MD (Discussion of Abstract(s) 2015-2017)
Abramson Cancer Center
Thinking Out of the Box: Novel Therapeutic Approaches

5:33 PM Panel Question and Answer

5:39 PM Isabel Arrillaga, MD, PhD (Discussion of Abstract(s) 2018-2020)
Massachusetts General Hospital
What's on the Horizon for Newly Diagnosed Glioblastoma

5:51 PM Panel Question and Answer

Posters discussed in this session are on display in the Central Nervous System Tumors Poster Session. See page 112 for poster information.

4:45 PM - 6:00 PM Poster Discussion Session

Genitourinary (Prostate) Cancer

Location: S406

Interact ID: 10866

Mitchell E. Gross, MD, PhD - Chair
University of Southern California

Srikala S. Sridhar, MD, FRCPC - Chair
Princess Margaret Cancer Centre, University Health Network

4:45 PM Alicia K. Morgans, MD, MPH (Discussion of Abstract(s) LBA5009-5011)
Vanderbilt University Medical Center
Optimizing Patient-Centered Care and Follow-up in Prostate Cancer

4:57 PM Panel Question and Answer

Saturday, June 2, 2018

- 5:03 PM Simpa Samuel Salami, MD, MPH (Discussion of Abstract(s) 5012-5015)**
University of Michigan
Molecular Dissection of Prostate Cancer
- 5:15 PM Panel Question and Answer**
- 5:21 PM Timur Mitin, MD, PhD (Discussion of Abstract(s) 5016-5018)**
Oregon Health and Science University
Rethinking Localized and Systemic Treatments Across the Spectrum of Prostate Cancer
- 5:33 PM Panel Question and Answer**
- 5:39 PM Winald R. Gerritsen, MD, PhD (Discussion of Abstract(s) 5019-5020)**
Radboud University Medical Center
Working to Define a Role for Immunotherapy in Prostate Cancer
- 5:51 PM Panel Question and Answer**

Posters discussed in this session are on display in the Genitourinary (Prostate) Cancer Poster Session. See page 117 for poster information.

4:45 PM - 6:00 PM Poster Discussion Session

Head and Neck Cancer

Location: S100a
Interact ID: 10868

Cristina P. Rodriguez, MD - Chair
University of Washington

Assuntina Gesualda Sacco, MD - Chair
University of California San Diego Moores Cancer Center

- 4:45 PM William Nassib William, MD (Discussion of Abstract(s) 6013-6016)**
The University of Texas MD Anderson Cancer Center
Probing the Depths of Immunotherapy: More Than Survival
- 4:57 PM Panel Question and Answer**
- 5:03 PM Athanassios Argiris, MD (Discussion of Abstract(s) 6017-6018, 6021)**
Hygeia Hospital
New Drug, New Setting
- 5:15 PM Panel Question and Answer**
- 5:21 PM Amanda Psyrris, MD (Discussion of Abstract(s) 6019-6020)**
University General Hospital Attikon, National and Kapodistrian University of Athens
Transcending p16
- 5:33 PM Panel Question and Answer**
- 5:39 PM Laura Locati, MD (Discussion of Abstract(s) 6022-6024)**
Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori
Tough Problems in Rare Tumors
- 5:51 PM Panel Question and Answer**

Posters discussed in this session are on display in the Head and Neck Cancer Poster Session. See page 126 for poster information.

4:45 PM - 6:00 PM Poster Discussion Session

Health Services Research, Clinical Informatics, and Quality of Care

Location: S102

Interact ID: 10869

Ronald C. Chen, MD, MPH - Chair

University of North Carolina at Chapel Hill

Ronac Mamtani, MD - Chair

University of Pennsylvania

4:45 PM Gabriel A. Brooks, MD, MPH (Discussion of Abstract(s) 6509-6511)

Dartmouth-Hitchcock Medical Center

Getting More at the End of Life

4:57 PM Panel Question and Answer

5:03 PM Daniel A. Goldstein, MD (Discussion of Abstract(s) 6512-6514)

Davidoff Cancer Center

Are We Getting Closer to Cost-Effective Care?

5:15 PM Panel Question and Answer

5:21 PM Sunil Verma, MD (Discussion of Abstract(s) 6515-6517)

Tom Baker Cancer Centre, University of Calgary

Is There a Drug Approval Problem?

5:33 PM Panel Question and Answer

5:39 PM Kathryn Jean Ruddy, MD, MPH (Discussion of Abstract(s) 6518-6520)

Mayo Clinic

Surviving Cancer: Moving, Grooving, and Not Overusing

5:51 PM Panel Question and Answer

Posters discussed in this session are on display in the Health Services Research, Clinical Informatics, and Quality of Care Poster Session. See page 133 for poster information.

4:45 PM - 6:00 PM Education Session

ASCO Book Club: *Black Man in a White Coat* by Damon Tweedy, MD

Location: S100bc

Interact ID: 10929

Teresa Gilewski, MD - Chair

Memorial Sloan Kettering Cancer Center

Damon Tweedy, MD - Author of *Black Man in a White Coat*

Duke University School of Medicine

4:45 PM - 6:00 PM Education Session

Incorporating Current Adjuvant/Neoadjuvant Clinical Trial Data Into Everyday Practice in Breast Cancer

Location: Hall D1

Interact ID: 10776

Kathy Miller, MD

Indiana University Melvin and Bren Simon Cancer Center

Using the Neoadjuvant Approach in Developing Novel Therapies in ER+ Breast Cancer

Saturday, June 2, 2018

Ruth O'Regan, MD - Chair

University of Wisconsin Carbone Cancer Center

Evolving Approaches in Systemic Therapy for Triple-Negative Breast Cancer in Neoadjuvant and Adjuvant Settings

Neelima Denduluri, MD

US Oncology

Tailored Therapy for Early-Stage HER2+ Breast Cancer

Panel Question and Answer

4:45 PM - 6:00 PM Education Session

Pancreatic Cancer: Present and Future

Location: Hall D2

Interact ID: 10731

Federico Augusto Sanchez, MD - Chair

Aurora Healthcare

Pancreas Cancer: Current State of Therapy Use of Guidelines and Pathways

Douglas B. Evans, MD

Medical College of Wisconsin

What Makes a Pancreas Cancer Resectable?

Eileen Mary O'Reilly, MD

Memorial Sloan Kettering Cancer Center

Beyond Frontline Therapy

Andrew Aguirre, MD, PhD

Dana-Farber Cancer Institute

Molecular Subtype and Directed Therapy in Pancreas Cancer

Panel Question and Answer

4:45 PM - 6:00 PM Education Session

Precision Medicine in Non-Small Cell Lung Cancer: Current Standards in Pathology and Biomarker Interpretation

Location: Arie Crown Theater

Interact ID: 10704

Dara Aisner, MD, PhD

University of Colorado School of Medicine

Role of Pathologic Features in the Management of Lung Cancer

Geoffrey R. Oxnard, MD - Chair

Dana-Farber Cancer Institute

Biopsies (Blood, Urine, Tumor): When to Do Them and What Do They Mean?

Noah Brown, MD

University of Michigan Health System

Next-Generation Sequence Reports: Making Sense Out of the Noise

Panel Question and Answer

4:45 PM - 6:00 PM Meet the Professor Session

The Challenges of Managing Sarcoma in the AYA and Geriatric Populations - Ticketed Session

Location: E253d
Interact ID: 10771

Mark Agulnik, MD
Northwestern University Feinberg School of Medicine

Lara Emily Davis, MD
Oregon Health & Science University

4:45 PM - 6:00 PM Clinical Problems in Oncology Session

Sequencing for Stage IV Melanoma: When Do We Use What? - Ticketed Session

Location: E253c
Interact ID: 10752

Christian U. Blank, MD, PhD
Netherlands Cancer Institute
Systemic Treatment of Stage IV Melanoma: Sequencing of Therapies, Biomarkers, and the Cancer Immunogram

Bryan Burmeister, MD
Princess Alexandra Hospital/University of Queensland
When and How to Use Radiotherapy in Stage IV Melanoma

Joshua Matthew Varghise Mammen, MD - Chair
University of Kansas
What Role Is There for Surgery in Stage IV Melanoma?

Panel Question and Answer

Notes

Notes

Notes

Notes

Notes

Notes

Notes

7:30 AM - 9:15 AM Highlights of the Day Session

Highlights of the Day Session I

Location: Hall D1

Interact ID: 10814

David R. Spigel, MD - Chair

Sarah Cannon Research Institute, Tennessee Oncology

7:30 AM Joon H. Uhm, MD

Mayo Clinic

Central Nervous System Tumors

7:45 AM Christophe Le Tourneau, MD, PhD

Institut Curie

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

8:00 AM Patrick Hwu, MD

The University of Texas MD Anderson Cancer Center

Developmental Therapeutics—Immunotherapy

8:15 AM Ethan M. Basch, MD, FASCO

The University of North Carolina at Chapel Hill

Health Services Research, Clinical Informatics, and Quality of Care

8:30 AM Guillermo Garcia-Manero, MD

The University of Texas MD Anderson Cancer Center

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

8:45 AM Amrita Y. Krishnan, MD

City of Hope

Hematologic Malignancies—Plasma Cell Dyscrasia

7:30 AM - 9:30 AM Education Session

Training Program Directors' Breakfast (Training Program Directors and Associate Training Program Directors Only)

Location: S103

Interact ID: 10921

7:30 AM Breakfast and Networking

7:45 AM Julia Lee Close, MD - Chair

University of Florida

Welcome and Introductions

7:55 AM Frank P. Worden, MD

University of Michigan Comprehensive Cancer Center

Review of Programs and Resources for Program Directors

8:10 AM Frances A. Collichio, MD

University of North Carolina School of Medicine

Milestones 2.0 and Harmonized Milestones

8:25 AM Roberto Antonio Leon-Ferre, MD

Mayo Clinic

Trainee Council Updates and Sharing

Surbhi Sidana, MD

Mayo Clinic

Trainee Council Updates and Sharing

Sunday, June 3, 2018

Evelyn Mary Brosnan, MD, MBA
Dartmouth Hitchcock Medical Center
Trainee Council Updates and Sharing

8:45 AM Julia Lee Close, MD, and Adaeze Nwosu-Iheme, MD
University of Florida
Implementation of a Bias Curriculum

9:10 AM Frank P. Worden, MD
University of Michigan Comprehensive Cancer Center
Open Discussion: What Keeps You Up at Night?

8:00 AM - 9:15 AM Education Session

Beyond Chemotherapy: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin Lymphoma

Location: E450
Interact ID: 10707

Catherine Bollard, MD, MBChB
Children's National Medical Center
The Landscape of Anti-CD-19 CAR-T Cells in the Management of Non-Hodgkin Lymphoma

Leo I. Gordon, MD - Chair
Northwestern University
Cell Therapy in Lymphoma: Practical Applications and New Targets

Loretta J. Nastoupil, MD
The University of Texas MD Anderson Cancer Center
Checkpoint Inhibitors in Lymphoma: When and How

Panel Question and Answer

8:00 AM - 9:15 AM Education Session

Overcoming Unique Obstacles to Implementing Precision Medicine Trials in the Community Setting

Location: S100bc
Interact ID: 10691

Edward S. Kim, MD - Chair
Levine Cancer Institute, Atrium Health
Identify Strategies and Best Practices for Precision Medicine Trials

Michael A. Thompson, MD, PhD, FASCO
Aurora Advanced Healthcare
Challenges Conducting Precision Medicine Trials in the Community

Lora Jane Black, RN, MPH, OCN, CCRP
Sanford Research
Technologies and Resources for Implementing Precision Medicine Trials in Community-Based Settings

Panel Question and Answer

8:00 AM - 9:15 AM Education Session

Thinking Beyond RECIST

Location: S100a
Interact ID: 10787

Mizuki Nishino, MD, MPH

Dana-Farber Cancer Institute
Is It Time to Move Beyond RECIST Criteria for Tumor Response Evaluation?

Prateek Prasanna, PhD

Case Western Reserve University
Novel Quantitative Tumor Imaging: Techniques and Clinical Applications

Lawrence Howard Schwartz, MD - Chair

Columbia University Medical Center
Incorporating Novel Imaging Techniques and Novel Imaging Study End Points in Clinical Trials: Opportunities and Challenges

Panel Question and Answer

8:00 AM - 9:15 AM Meet the Professor Session

Adjuvant/Neoadjuvant Treatment in Melanoma: Where Surgery Meets Medical Oncology - Ticketed Session

Location: E253c
Interact ID: 10749

Amod Sarnaik, MD

Moffitt Cancer Center

Georgina V. Long, MD, PhD, FRACP

Melanoma Institute Australia, The University of Sydney

8:00 AM - 9:15 AM Meet the Professor Session

How Do I Treat Hepatocellular Carcinoma? - Ticketed Session

Location: E253d
Interact ID: 10730

Anthony B. El-Khoueiry, MD

University of Southern California Norris Comprehensive Cancer Center

Graziano Oldani, MD

HepatoPancreato-Biliary Centre, Geneva University Hospitals

8:00 AM - 11:00 AM Oral Abstract Session

Breast Cancer—Metastatic

Location: Hall D2
Interact ID: 10829

Beverly Moy, MD, FASCO - Chair

Massachusetts General Hospital Cancer Center

Sunday, June 3, 2018

Ruth O'Regan, MD - Chair

University of Wisconsin Carbone Cancer Center

- 8:00 AM Abstract 1000: Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3.** *D. J. Slamon, P. Neven, S. K. Chia, S. Im, P. A. Fasching, M. DeLaurentiis, K. Petrakova, G. V. Bianchi, F. J. Esteva, M. Martin, X. Pivot, G. Vidam, Y. Wang, C. K. Rodriguez Lorenc, M. K. Miller, T. Taran, G. H. Jerusalem*
- 8:12 AM Abstract 1001: Genetic landscape of resistance to CDK4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant.** *N. C. Turner, B. O'Leary, R. Cutts, Y. Liu, S. Hrebien, X. Huang, M. Beaney, K. Fenwick, F. Andre, S. Loibl, S. Loi, I. Garcia-Murillas, C. H. Bartlett, M. Cristofanilli*
- 8:24 AM Abstract 1002: Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer.** *P. Neven, H. S. Rugo, S. M. Tolaney, H. Iwata, M. Toi, M. P. Goetz, P. A. Kaufman, S. Barriga, Y. Lin, G. W. Sledge Jr.*
- 8:36 AM Angela DeMichele, MD, MSCE (Discussion of Abstract(s) 1000-1002)**
Penn Medicine Abramson Cancer Center
Present and Future of CDK Inhibitors
- 8:48 AM Panel Question and Answer**
- 9:00 AM Abstract 1003: Phase III multicenter, randomized study of utidalone plus capecitabine versus capecitabine alone for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer.** *B. Xu, P. Zhang, T. Sun, Q. Zhang, Z. Jiang, Z. Yuan, X. Wang, S. Cui, Y. Teng, X. Hu, J. Yang, H. Pan, Z. Tong, H. Li, Q. Yao, Y. Wang*
- 9:12 AM Abstract 1004: Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC).** *A. Bardia, J. R. Diamond, L. T. Vahdat, S. M. Tolaney, J. O'Shaughnessy, R. L. Moroosse, I. A. Mayer, V. G. Abramson, D. Juric, R. M. Sharkey, S. A. Washkowitz, W. A. Wegener, D. M. Goldenberg, K. Kalinsky*
- 9:24 AM Virginia G. Kaklamani, MD (Discussion of Abstract(s) 1003-1004)**
University of Texas Health Science Center
HER2-Negative Metastatic Breast Cancer: Chemotherapy With a Twist
- 9:36 AM Panel Question and Answer**
- 9:48 AM Abstract 1005: Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study.** *G. H. Jerusalem, E. Kovalenko, D. A. Yardley, R. H. De Boer, S. A. Hurvitz, B. Ejlersen, S. Blau, M. Ozguroglu, L. Landherr, M. Ewertz, T. Taran, J. Fan, F. Noel-Baron, A. Louveau, H. A. Burris III*
- 10:00 AM Abstract LBA1006: Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.** *J. Baselga, S. F. Dent, J. Cortés, Y. Im, V. Diéras, N. Harbeck, I. E. Krop, S. Verma, T. R. Wilson, H. Jin, L. Wang, F. Schimmoller, J. Y. Hsu, J. He, M. DeLaurentiis, P. Drullinsky, W. Jacot*
- 10:12 AM Abstract 1007: AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.** *P. Schmid, J. Abraham, S. Chan, D. Wheatley, M. Brunt, G. Nemsadze, R. Baird, Y. Park, P. Hall, T. Perren, R. C. Stein, M. László, J. Ferrero, M. Phillips, J. Conibear, S. Sarker, A. Prendergast, H. Cartwright, K. Mousa, N. C. Turner*

- 10:24 AM Abstract 1008: Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC).** *R. Dent, S. Im, M. Espie, S. Blau, A. R. Tan, S. J. Isakoff, M. Oliveira, C. Saura, M. Wongchenko, A. V. Kapp, W. Y. Chan, S. M. Singel, D. J. Maslyar, J. Baselga, S. Kim*
- 10:36 AM Cynthia X. Ma, MD, PhD (Discussion of Abstract(s) 1005-1008)**
Washington University School of Medicine in St. Louis
The PI3K-AKT-mTOR Pathway: Are We Making Headway?
- 10:48 AM Panel Question and Answer**

8:00 AM - 11:00 AM Oral Abstract Session

Cancer Prevention, Hereditary Genetics, and Epidemiology

Location: S404

Interact ID: 10831

Veda N. Giri, MD - Chair

Sidney Kimmel Cancer Center, Thomas Jefferson University

Noelle K. LoConte, MD - Chair

University of Wisconsin Carbone Cancer Center

- 8:00 AM Abstract 1500: Low-fat dietary pattern and all cancer mortality in the Women's Health Initiative (WHI) randomized trial.** *R. T. Chlebowski, G. L. Anderson, J. E. Manson, R. L. Prentice, A. K. Aragaki, S. Linda, S. A. Beresford, L. H. Kuller, K. Johnson, D. Lane, J. Luo, T. E. Rohan, L. Jiao, A. Barac, C. Womack, M. Coday, M. Datta, C. A. Thomson*
- 8:12 AM Abstract 1501: Pre- and post-treatment body weight and prognosis in a multiethnic cohort of breast cancer patients.** *L. Shang, N. T. Jaskowiak, D. Hedeker, O. I. Olopade, D. Huo*
- 8:24 AM Abstract 1502: Cardiorespiratory fitness and incident lung and colon cancer: FIT-Cancer Cohort.** *C. Handy, M. H. Al-Mallah, Z. Dardari, C. A. Brawner, L. E. Lamerato, S. Keteyian, J. K. Ehrman, K. Visvanathan, M. J. Blaha*
- 8:36 AM Jennifer A. Ligibel, MD (Discussion of Abstract(s) 1500-1502)**
Dana-Farber Cancer Institute
The Role of Diet and Fitness in Optimizing Cancer Prevention and Outcomes
- 8:48 AM Panel Question and Answer**
- 9:00 AM Abstract 1503: Inherited mutations in breast cancer patients with and without multiple primary cancers.** *K. N. Maxwell, J. Vijai, J. Lilyquist, T. P. Slaviv Jr., A. Kulkarni, O. Vaccaro, B. Wubbenhorst, S. L. Neuhausen, S. Hart, V. Ravichandran, T. Thomas, C. Hu, K. A. Schrader, A. DeMichele, K. Offit, J. N. Weitzel, F. Couch, S. M. Domchek, K. Nathanson*
- 9:12 AM Abstract 1504: Frequency of actionable cancer predisposing germline mutations in patients with lung cancers.** *S. Mukherjee, M. G. Zauderer, V. Ravichandran, Y. Kemel, D. Mandelker, N. Pradhan, A. Zehir, S. M. Lipkin, P. Srinivasan, C. Bandlamudi, B. S. Taylor, D. R. Jones, L. Zhang, M. F. Berger, D. B. Solit, M. E. Robson, Z. K. Stadler, J. Vijai, K. Offit*
- 9:24 AM Abstract 1505: Pathogenic somatic mutation (SM) of mismatch repair (MMR) genes and associations with microsatellite instability (MSI), tumor mutational burden (TMB) and SM in other DNA repair pathways in 24,223 tumor genomic profiles.** *J. N. Bodor, E. A. Handorf, R. Feldman, M. J. Hall*
- 9:36 AM Mark E. Burkard, MD, PhD (Discussion of Abstract(s) 1503-1505)**
University of Wisconsin Carbone Cancer Center
Patient Evaluation in an Expanding Genetic World: Multiple Genes, Multiple Cancers, Multiple Molecular Signatures

Sunday, June 3, 2018

9:48 AM *Panel Question and Answer*

10:00 AM **Abstract 1506: A breast cancer risk model as a predictor of interval cancer rate and tumor characteristics.** *N. Dreher, I. Acerbi, E. K. Hadeler, Y. Shieh, M. E. Melisko, L. Esserman, L. van 't Veer, Athena Investigators and Advocates*

10:12 AM **Abstract 1507: Validation of a combined residual risk score for healthy unaffected women presenting to breast cancer (BC) screening centers.** *K. Dalton, E. Hughes, W. Hedegard, C. A. Adami, A. Sibley, M. Piz, J. Holman, A. Gutin, J. S. Lanchbury, D. F. Grear*

10:24 AM **Abstract 1508: Polygenic risk score for breast cancer in high-risk women.** *M. Black, S. Li, H. LaDuca, J. Chen, R. Hoiness, S. Gutierrez, H. Lu, J. S. Dolinsky, J. Xu, C. Vachon, F. Couch, B. Tippin Davis*

10:36 AM **Antonis Antoniou, PhD (Discussion of Abstract(s) 1506-1508)**
University of Cambridge
Controversies in Cancer Risk Modeling: Breast Density and Polygenic Risk Scores

10:48 AM *Panel Question and Answer*

8:00 AM - 11:00 AM Oral Abstract Session

Genitourinary (Nonprostate) Cancer

Location: Arie Crown Theater

Interact ID: 10837

Amishi Yogesh Shah, MD - Chair

University of Texas MD Anderson Cancer Center

Matthew R. Zibelman, MD - Chair

Fox Chase Cancer Center

8:00 AM **Abstract 4500: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results from cohort A of KEYNOTE-427.** *D. F. McDermott, J. Lee, C. Szczylik, F. Donskov, J. Malik, B. Y. Alekseev, J. M. Larkin, V. B. Matveev, R. A. Gafanov, P. Tomczak, S. S. Tykodi, P. F. Geertsen, P. J. Wiechno, S. Shin, F. Pouliot, T. Alonso Gordo, W. Li, R. F. Perini, C. Schloss, M. B. Atkins*

8:12 AM **Abstract 4502: A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of sorafenib (So) in patients (pts) with metastatic renal cell carcinoma (mRCC) after a radical resection of the metastases: RESORT trial.** *G. Procopio, F. Cognetti, R. Miceli, M. Milella, A. Mosca, V. E. Chiuri, A. Bearz, F. Morelli, C. Ortega, F. Atzori, M. Donini, R. Ratta, A. Martinetti, R. Montone, F. G. De Braud, V. Cappelletti, E. Verzoni*

8:24 AM **Abstract 4511: Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).** *B. Escudier, R. J. Motzer, B. I. Rini, T. Powles, D. F. McDermott, C. Suarez, S. Bracarda, W. M. Stadler, F. Donskov, H. Gurney, S. Oudard, M. Uemura, E. T. Lam, C. Grüllich, B. Ding, T. Khaznadar, C. Quach, E. Piau, C. Schiff, and M. B. Atkins*

8:36 AM **Toni K. Choueiri, MD (Discussion of Abstract(s) 4500, 4502, 4511)**
Dana-Farber Cancer Institute
Optimizing Systemic Therapy in Advanced Renal Cell Carcinoma

8:48 AM *Panel Question and Answer*

9:00 AM **Abstract 4503: First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).** *A. O. Siefker-Radtke, A. Necchi, S. Park, J. Garcia-Donas, R. A. Huddart, E. F. Burgess, M. T. Fleming, A. Rezazadeh, B. Mellado, S. Varlamov, M. Joshi, I. Duran, S. T. Tagawa, A. OHagan, A. N. Avadhani, B. Zhong, P. De Porre, Y. Loriot*

- 9:12 AM Abstract 4504: Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC).** *J. E. Rosenberg, S. S. Sridhar, J. Zhang, D. C. Smith, J. D. Ruether, T. W. Flaig, J. C. Baranda, J. M. Lang, E. R. Plimack, R. S. Sangha, E. I. Heath, J. R. Merchan, D. I. Quinn, S. Srinivas, M. I. Milowsky, C. Wu, E. M. Gartner, A. Melhem-Bertrandt, D. P. Petrylak*
- 9:24 AM Abstract 4505: Cctg BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993).** *S. S. Sridhar, N. Blais, B. Tran, M. N. Reaume, S. A. North, M. R. Stockler, K. N. Chi, N. E. Fleshner, G. Liu, J. W. Robinson, S. Mukherjee, Y. Rahim, E. Winqvist, C. M. Booth, N. T. Nguyen, E. K. Beardsley, N. S. Alimohamed, G. T. McDonald, K. Ding, W. R. Parulekar*
- 9:36 AM Andrea B. Apolo, MD (Discussion of Abstract(s) 4503-4505)**
Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
Nonimmunotherapy Strategies in Advanced Bladder Cancer
- 9:48 AM Panel Question and Answer**
- 10:00 AM Abstract 4506: A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).** *T. Powles, A. Rodriguez-Vida, I. Duran, S. J. Crabb, M. S. Van Der Heijden, A. Font Pous, G. Gravis, U. Anido Herranz, A. Protheroe, A. Ravaud, D. Maillet, M. Mendez-Vidal, C. Suarez, A. Lorch, C. N. Sternberg, M. D. Linch, S. Sarker, A. Prendergast, K. Mousa, D. E. Castellano*
- 10:12 AM Abstract 4507: Preoperative pembrolizumab (pembro) before radical cystectomy (RC) for muscle-invasive urothelial bladder carcinoma (MIUC): Interim clinical and biomarker findings from the phase 2 PURE-01 study.** *A. Necchi, A. Briganti, M. Bianchi, D. Raggi, P. Giannatempo, R. Luciano, M. Colecchia, S. Massa, M. Bandini, N. Fossati, G. Gandaglia, R. Colombo, A. Gallina, A. Salonia, R. Salvioni, S. M. Ali, J. S. Ross, J. Chung, F. Montorsi*
- 10:24 AM Abstract 4508: Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).** *D. R. Feldman, J. Hu, S. Srinivas, W. M. Stadler, B. A. Costello, L. J. Appleman, M. I. Milowsky, S. Patil, M. Bromberg, P. Nolan, T. B. Dorff, V. E. Reuter, H. Al-Ahmadie, S. Funt, D. F. Bajorin, G. J. Bosl, D. I. Quinn, R. J. Motzer*
- 10:36 AM Matt D. Galsky, MD (Discussion of Abstract(s) 4506-4508)**
Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute
Neoadjuvant Immunotherapy in Localized Bladder Cancer: Frontline Management of High-Risk Germ Cell Cancer
- 10:48 AM Panel Question and Answer**

8:00 AM - 11:00 AM Oral Abstract Session

Head and Neck Cancer

Location: E451

Interact ID: 10840

Charu Aggarwal, MD, MPH - Chair

Abramson Cancer Center

Jessica Ruth Bauman, MD - Chair

Fox Chase Cancer Center

Sunday, June 3, 2018

- 8:00 AM Abstract 6000: Results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck.** *V. M. Patil, V. Noronha, A. Joshi, J. Agarwal, S. G. Laskar, A. Budrukkar, V. Murthy, S. Kannan, A. Bhattacharjee, P. Chaturvedi, P. S. Pai, D. Chaukar, A. D'cruz, A. Manjrekar, V. Mathrudev, K. Prakash Nawale, A. Bhelekar, S. D. Banavali, K. Prabhash*
- 8:12 AM Abstract 6001: Definitive cetuximab-based (CRT-CX) vs. non-cetuximab based chemoradiation (CRT) in older patients with squamous cell carcinoma of the head and neck (HNSCC): Analysis of the SEER-Medicare linked database.** *D. P. Zandberg, K. J. Cullen, V. Varki, I. Suzuki, S. Bentzen, O. G. Golubeva*
- 8:24 AM Abstract LBA6002: Are women with head and neck cancer undertreated?** *A. Park, A. Albaster, H. Shen, L. K. Mell, J. A. Katzell*
- 8:36 AM Faye M. Johnson, MD, PhD (Discussion of Abstract(s) 6000-LBA6002)**
The University of Texas MD Anderson Cancer Center
Redefining Perceptions in Locally Advanced Disease
- 8:48 AM Panel Question and Answer**
- 9:00 AM Abstract 6003: Treatment deintensification to surgery only for stage I human papillomavirus-associated oropharyngeal cancer.** *J. D. Cramer, R. L. Ferris, U. Duvvuri*
- 9:12 AM Abstract 6004: Phase II study: Induction chemotherapy and transoral surgery as definitive treatment (Tx) for locally advanced oropharyngeal squamous cell carcinoma (OPSCC): A novel approach.** *R. S. Siegel, H. Rafei, A. Joshi, R. Taheri, N. Fousheé, N. Sadeghi*
- 9:24 AM Abstract 6005: Survival outcomes by HPV status in non-oropharyngeal head and neck cancers: A propensity score matched analysis of population level data.** *S. Tian, J. M. Switchenko, J. Jhaveri, R. J. Cassidy III, M. J. Ferris, R. H. Press, N. T. Pfister, M. Patel, N. F. Saba, M. W. McDonald, K. A. Higgins, D. S. Yu, W. J. Curran Jr., T. W. Gillespie, J. J. Beitler*
- 9:36 AM Sharon Spencer, MD (Discussion of Abstract(s) 6003-6005)**
University of Alabama at Birmingham
HPV: Will Less Be More?
- 9:48 AM Panel Question and Answer**
- 10:00 AM Abstract 6006: Results of a randomized, placebo (PBO) controlled, double-blind P2b trial of GC4419 (avisopasem manganese) to reduce duration, incidence and severity and delay onset of severe radiation-related oral mucositis (SOM) in patients (pts) with locally advanced squamous cell cancer of the oral cavity (OC) or oropharynx (OP).** *C. M. Anderson, C. M. Lee, D. Saunders, A. Curtis, N. Dunlap, C. S. Nangia, A. S. Lee, J. Holmlund, J. M. Brill, S. T. Sonis, J. M. Buatti*
- 10:12 AM Abstract 6007: Phase II trial of high-dose melatonin oral gel for the prevention and treatment of oral mucositis in H&N cancer patients undergoing chemoradiation (MUCOMEL).** *A. Lozano, J. Marruecos, J. Rubió-Casadevall, N. Farre, A. Lopez-Pousa, J. Giralt, I. Planas, B. Cirauqui, M. Lanzuela, R. Morera, A. Escribano, J. Gomez-Millan, M. D. Toledo, G. V. Masedo, L. Cascallar, P. Grima, V. Valenti, C. Tarrago, R. Bosser, R. Mesia Sr.*
- 10:24 AM Abstract 6008: Multicenter phase II trial of palbociclib, a selective cyclin dependent kinase (CDK) 4/6 inhibitor, and cetuximab in platinum-resistant HPV unrelated (-) recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC).** *D. Adkins, P. J. Oppelt, J. C. Ley, K. Trinkaus, P. C. Neupane, A. G. Sacco, K. A. Palka, F. P. Worden, J. E. Grilley-Olson, R. J. Maggiore, C. E. Steuer, N. F. Saba*
- 10:36 AM Stuart J. Wong, MD (Discussion of Abstract(s) 6006-6008)**
Medical College of Wisconsin
Potpourri of Stuff That Matters (Really)
- 10:48 AM Panel Question and Answer**

8:00 AM - 11:00 AM Oral Abstract Session

Patient and Survivor Care

Location: S102

Interact ID: 10848

Piyush Srivastava, MD - Chair

Kaiser Permanente

Martin R. Stockler, MBBS, MS, FRACP - Chair

NHMRC Clinical Trials Centre, The University of Sydney

- 8:00 AM Abstract 10000: Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).** *S. Shen, J. M. Unger, K. D. Crew, C. Till, H. Greenlee, J. Gralow, S. R. Dakhil, L. M. Minasian, J. L. Wade III, M. J. Fisch, N. L. Henry, D. L. Hershman*
- 8:12 AM Abstract 10001: The effect of acupuncture versus cognitive behavior therapy on insomnia in cancer survivors: A randomized clinical trial.** *J. J. Mao, S. Xie, K. Duhamel, T. Bao, P. W. Kantoff, Q. S. Li, F. Barg, S. Song, P. Gehrman, S. N. Garland*
- 8:24 AM Gabriel Lopez, MD (Discussion of Abstract(s) 10000-10001)**
The University of Texas MD Anderson Cancer Center
Integrating Integrative Medicine Into Supportive Care: Are We Ready?
- 8:36 AM Panel Question and Answer**
- 8:48 AM Abstract LBA10003: Improving communication with older patients with cancer using geriatric assessment (GA): A University of Rochester NCI Community Oncology Research Program (NCORP) cluster randomized controlled trial (CRCT).** *S. G. Mohile, R. M. Epstein, A. Hurria, C. E. Heckler, P. Duberstein, B. E. Canin, N. Gilmore, M. Wells, H. Xu, E. Culakova, L. M. Lowenstein, M. A. Flannery, A. Magnuson, K. Loh, K. M. Mustian, J. O. Hopkins, J. Liu, N. Melnyk, G. R. Morrow, W. Dale*
- 9:00 AM Abstract 10004: Symptom burden in hospitalized patients with curable and incurable cancers.** *R. Newcomb, R. D. Nipp, A. T. Chan, E. P. Hochberg, V. A. Jackson, B. J. Cashavelly, R. L. Wong, J. Greer, D. P. Ryan, J. S. Temel, A. El-Jawahri*
- 9:12 AM Abstract 10005: Randomized trial of a symptom monitoring intervention for hospitalized patients with cancer.** *C. Fuh, M. Ruddy, B. Temel, S. D'arpino, B. J. Cashavelly, E. P. Hochberg, V. Jackson, J. Greer, D. P. Ryan, A. El-Jawahri, J. S. Temel, R. D. Nipp*
- 9:24 AM Ethan M. Basch, MD, FASCO (Discussion of Abstract(s) LBA10003-10005)**
The University of North Carolina at Chapel Hill
Patient-Reported Assessments: Tell Us How You Really Feel
- 9:36 AM Panel Question and Answer**
- 9:48 AM Abstract 10006: Does timing of palliative care consults impact end-of-life health services utilization in pancreatic cancer patients?** *N. Bhulani, A. Gao, A. Gupta, C. Ahn, M. E. Paulk, S. Houck, J. J. Li, C. M. Guenther, S. M. Kazmi, M. S. Beg*
- 10:00 AM Abstract 10007: Patient (Pt) and oncologist (MD) discordance in goals of care in end of life (EOL) decision making.** *S. L. Douglas, B. J. Daly, N. J. Meropol, A. R. Lipson*
- 10:12 AM Abstract 10008: Understanding factors contributing to geographic variations in end-of-life expenditures.** *N. L. Keating, H. Huskamp, E. Kouri, D. Schrag, M. C. Hornbrook, D. A. Haggstrom, M. B. Landrum*
- 10:24 AM Shelly S. Lo, MD (Discussion of Abstract(s) 10006-10008)**
Loyola University Medical Center
The Sooner the Better: Palliative Care and End-of-Life Discussions
- 10:36 AM Panel Question and Answer**

8:00 AM - 11:00 AM Oral Abstract Session

Pediatric Oncology II

Location: S504

Interact ID: 10850

Jacqueline Casillas, MD - Chair

University of California, Los Angeles

Sogol Mostoufi-Moab, MD, MSCE - Chair

The Children's Hospital of Philadelphia

- 8:00 AM Abstract 10509: Subsequent malignant neoplasms (SMNs) among non-irradiated survivors of childhood cancer treated with chemotherapy in the Childhood Cancer Survivor Study.** *L. M. Turcotte, Q. Liu, Y. Yasui, T. O. Henderson, T. M. Gibson, W. Leisenring, M. A. Arnold, R. M. Howell, D. M. Green, G. T. Armstrong, L. L. Robison, J. P. Neglia*
- 8:12 AM Abstract 10510: Risk-adapted therapy for pediatric Hodgkin lymphoma (HL) results in lower risk of late effects: A report from the Childhood Cancer Survivor Study (CCSS).** *K. C. Oeffinger, K. Stratton, M. M. Hudson, W. Leisenring, R. M. Howell, S. L. Wolden, L. S. Constine, L. Diller, T. O. Henderson, C. A. Sklar, P. C. Nathan, S. M. Castellino, D. Barnea, S. A. Smith, G. T. Armstrong, L. L. Robison*
- 8:24 AM Abstract 10511: Mortality following breast cancer in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.** *C. S. Moskowitz, J. F. Chou, J. P. Neglia, R. M. Howell, L. Diller, A. Partridge, W. M. Leisenring, G. T. Armstrong, L. L. Robison, K. C. Oeffinger, T. O. Henderson*
- 8:36 AM Patricia A. Ganz, MD, FASCO (Discussion of Abstract(s) 10509-10511)**
University of California, Los Angeles
Defining the Risks of Secondary Malignancies in Childhood Cancer Survivors
- 8:48 AM Panel Question and Answer**
- 9:00 AM Abstract 10512: Association of exercise with late mortality in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor study.** *J. Scott, N. Li, Q. Liu, Y. Yasui, W. Leisenring, P. C. Nathan, T. M. Gibson, S. Armenian, T. Nilsen, K. C. Oeffinger, K. K. Ness, S. Adams, L. L. Robison, G. T. Armstrong, L. Jones*
- 9:12 AM Abstract 10513: Impact of exercise on psychological burden in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).** *E. S. Tonorezos, J. Ford, L. Wang, K. K. Ness, Y. Yasui, W. M. Leisenring, C. A. Sklar, L. L. Robison, K. C. Oeffinger, P. C. Nathan, G. T. Armstrong, K. R. Krull, L. Jones*
- 9:24 AM Abstract 10514: Patient-level predictors of lack of healthcare provider recommendation for human papillomavirus (HPV) vaccination as reported by childhood cancer survivors and their families.** *J. M. York, J. L. Klosky, Y. Chen, J. A. Connelly, K. Wasilewski-Masker, A. Giuliano, L. L. Robison, F. L. Wong, M. M. Hudson, S. Bhatia, W. Landier*
- 9:36 AM Leontien Kremer, MD, PhD (Discussion of Abstract(s) 10512-10514)**
Emma Children's Hospital and Academic Medical Center
Cancer Prevention Strategies in Childhood Cancer Survivors
- 9:48 AM Panel Question and Answer**
- 10:00 AM Abstract 10515: Targeted resequencing of pediatric rhabdomyosarcoma: report from the Children's Oncology Group, the Children's Cancer and Leukaemia Group, The Institute of Cancer Research UK, and the National Cancer Institute.** *J. F. Shern, R. Patidar, Y. Song, A. Walton, J. S. Wei, X. Wen, E. R. Rudzinski, D. A. Barkauskas, D. Hall, C. M. Linardic, M. Jenney, J. Chisholm, R. Brown, A. Kelsey, J. Selfe, S. Gatz, S. Skapek, D. S. Hawkins, J. Shipley, J. Khan*

- 10:12 AM Abstract 10516: A prospective study of pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN0321.** *J. I. Geller, N. G. Cost, Y. Chi, E. J. Perlman, Y. Kim, M. Cajaiba, E. A. Mullen, R. D. Glick, G. Khanna, N. C. Daw, P. F. Ehrlich, C. V. Fernandez, J. Dome*
- 10:24 AM Abstract 10517: Hope and benefit-finding among adolescents and young adults with cancer: Results from the PRISM randomized controlled trial.** *A. R. Rosenberg, M. Bradford, K. S. Barton, N. Etsekson, E. McCauley, J. Curtis, J. Wolfe, K. S. Baker, J. P. Yi-Frazier*
- 10:36 AM Todd Michael Cooper, DO (Discussion of Abstract(s) 10515-10517)**
Seattle Children's Cancer and Blood Disorders Center, University of Washington
Innovative Trials in Pediatric Cancer
- 10:48 AM Panel Question and Answer**

8:00 AM - 11:30 AM Poster Session

Gastrointestinal (Colorectal) Cancer

Location: Hall A

Abstracts on Boards 1-11 will be discussed during the Gastrointestinal (Colorectal) Cancer Poster Discussion Session.

Posters by Topic

Advanced Disease: Boards 1-7, 10, 13-57

Anal Cancer: Boards 58-60

Biomarkers/Epidemiology/Outcomes: Boards 8-9, 61-90

Local-Regional: Boards 11, 91-103

Other: Boards 104-107

Trials in Progress: Boards 108a-112b

- Board 1 Abstract 3508: Per protocol analysis and final OS update of the FIRE-3 (AIO KRK-0306) study comparing FOLFIRI plus cetuximab vs. FOLFIRI plus bevacizumab.** *S. Stintzing, L. Miller-Phillips, L. Fischer von Weikersthal, T. Decker, A. Kiani, U. Vehling-Kaiser, S. Al-Batran, C. A. Lerchenmuller, C. Kahl, G. Seipelt, F. Kullmann, M. H. Moehler, W. Scheithauer, S. Held, D. P. Modest, A. Jung, T. Kirchner, V. Heinemann*
- Board 2 Abstract 3509: mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO- KRK0109).** *M. Geissler, J. Riera-Knorrenschild, A. Tannapfel, J. Greeve, A. Florschütz, S. Wessendorf, T. Seufferlein, S. Kanzler, S. Held, V. Heinemann, A. C. Reinacher-Schick, U. M. Martens*
- Board 3 Abstract 3510: REVERSE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan—Biomarker analysis.** *Y. Tsuji, K. Shitara, T. Yamanaka, T. Denda, K. Shinozaki, Y. Komatsu, Y. Kobayashi, J. Furuse, H. Okuda, M. Asayama, K. Akiyoshi, Y. Kagawa, T. Kato, E. Oki, T. Ando, Y. Hagiwara, Y. Ohashi, T. Yoshino*
- Board 4 Abstract 3511: Anti-EGFR resistant clones decay exponentially after progression: Implications for anti-EGFR rechallenge.** *C. M. Parseghian, J. M. Loree, V. K. Morris II, A. A. Pereira, E. Vilar Sanchez, B. K. Kee, K. P. Raghav, A. Dasari, J. Wu, V. M. Raymond, K. Banks, A. Talasz, R. B. Lanman, M. J. Overman, S. Kopetz*
- Board 6 Abstract 3513: Distinct impacts of KRAS, NRAS and BRAF mutations on survival of patients with metastatic colorectal cancer.** *Y. Wang, J. M. Loree, C. Yu, M. Tschautscher, A. M. Briggler, M. J. Overman, R. Broaddus, F. Meric-Bernstam, J. C. Jones, J. Balcom, B. Kipp, S. Kopetz, A. Grothey*

- Board 7 **Abstract 3514: KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer.** *D. T. Le, P. Kavan, T. Kim, M. E. Burge, E. Van Cutsem, H. Hara, P. M. Boland, J. Van Laethem, R. Geva, H. Taniguchi, T. S. Crocenzi, M. Sharma, C. E. Atreya, L. A. Diaz Jr., L. W. Liang, P. Marinello, T. Dai, B. H. O'Neil*
- Board 8 **Abstract 3515: Tumour-infiltrating CD8⁺ lymphocytes as a prognostic marker in colorectal cancer: A retrospective, pooled analysis of the QUASAR2 and VICTOR trials.** *M. Glaire, E. Domingo, G. Nicholson, M. Novelli, K. Lawson, D. Oukrif, W. Kidal, H. E. Danielsen, R. Kerr, D. J. Kerr, I. Tomlinson, D. N. Church*
- Board 9 **Abstract 3516: Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC).** *J. Tie, J. Cohen, Y. Wang, M. Lee, R. Wong, S. Kosmider, S. Ananda, J. Cho, I. Faragher, J. J. McKendrick, C. Corfield, B. Lee, K. M. Field, I. Jones, L. Li, C. Tomasetti, N. Papadopoulos, K. W. Kinzler, B. Vogelstein, P. Gibbs*
- Board 10 **Abstract 3517: Validation of neoadjuvant rectal cancer (NAR) score as a surrogate endpoint for overall survival in real-life practice settings.** *Y. You, T. J. George Jr., Y. Chiang, C. Eng, P. Das, G. J. Chang, A. Dasari, A. Cuddy, Y. Yang, G. Yothers*
- Board 11 **Abstract 3518: RIA: Randomized phase II study comparing induction (I) mFOLFOX6 with or without aflibercept followed by chemoradiation (CRT) and total mesorectal excision (TME) in high risk-rectal cancer. GEMCAD 14-02 trial.** *C. Fernandez-Martos, C. Pericay, F. Losa, R. Garcia-Carbonero, L. Layos, N. Rodriguez Salas, M. Martin, V. Alonso, R. Vera, J. Gallego, J. Capdevila, A. Salud, M. Nogue, J. Maurel, I. Guasch, C. Montagut Viladot, C. López-López, M. Cañas, I. Macias Declara, X. García-Albéniz*
- Board 13 **Abstract 3520: Genomic landscape, clinical characteristics and outcomes of early onset (EO) compared with average onset (AO) colorectal cancer (CRC).** *G. D. Fernandes, W. K. Chatila, R. Yaeger, R. B. Mendelsohn, Z. K. Stadler, N. H. Segal, A. M. Varghese, D. R. Lagunes, L. A. Diaz Jr., J. Shia, E. Vakiani, J. F. Hechtman, N. Schultz, M. F. Berger, D. M. Hyman, D. B. Solit, L. B. Saltz, J. Garcia-Aguilar, A. Cercek*
- Board 14 **Abstract 3521: Final overall survival (OS) analysis of first-line (1L) FOLFOX-4 ± cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial.** *S. Qin, W. Guo, J. Xu, Q. Li, Y. Cheng, T. S. Liu, J. Chen, W. Chen, J. Li*
- Board 15 **Abstract 3522: Effect of matched therapy in metastatic colorectal cancer on progression free survival in the phase I setting.** *M. Lam, A. A. Pereira, J. M. Loree, S. M. Advani, M. J. Overman, A. Johnson, V. Holla, Y. Khotskaya, N. S. Sanchez, F. Meric-Bernstam, S. Kopetz, S. Pant*
- Board 16 **Abstract 3523: APOLLON: A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC).** *Y. Kuboki, T. Yoshino, T. Kato, Y. Kagawa, M. Gamoh, H. Yasui, K. Yamazaki, Y. Komatsu, H. Satake, M. Goto, H. Tanioka, E. Oki, M. Kotaka, A. Makiyama, T. Denda, J. Soeda, K. Shibuya, M. Iwata, K. Oba, K. Yamaguchi*
- Board 17 **Abstract 3524: Optimizing treatment strategy for advanced rectal cancer in the West and Japan: International multicenter cohort study.** *A. Ouchi, N. Ikoma, Y. You, K. Komori, D. Shida, B. K. Bednarski, T. Kinoshita, S. Tsukamoto, M. A. Rodriguez-Bigas, T. Oshiro, J. M. Skibber, H. Ochiai, Y. Shimizu, Y. Kanemitsu, G. J. Chang*
- Board 18 **Abstract 3525: Change in CEA as an early predictor of progression to first-line systemic therapy in metastatic colorectal cancer.** *P. Gulhati, J. Yin, L. Pederson, H. Schmoll, P. M. Hoff, J. Douillard, J. R. Hecht, C. Tournigand, N. Tebbut, B. Chibaudel, A. De Gramont, Q. Shi, M. J. Overman*
- Board 19 **Abstract 3526: A validation study of stratification by the 55-gene classifier for assessing recurrence risk in stage II colon cancer: The 55 STAR study (UMIN23879).** *S. Yamaguchi, K. Hase, E. Shinto, E. Oki, M. Shimokawa, M. Ishiguro, M. Morita, T. Kusumoto, N. Tomita, Y. Hashiguchi, M. Tanaka, S. Ohnuma, S. Tada, T. Matsushima*

- Board 20 Abstract 3527: Effect of PET-CT on disease recurrence and its management in patients with potentially resectable colorectal cancer liver metastases. The long-term results of a randomized controlled trial (PET-CT Imaging prior to liver resection for colorectal adenocarcinoma metastases).** *P. E. Serrano Aybar, C. Gu, M. Husien, D. Jalink, G. Martel, M. E. Tsang, J. I. Hallet, S. Gallinger, A. Ritter, V. McAlister, N. Sela, H. Solomon, K. Beyfuss, C. Li, E. Lee, C. Moulton, M. N. Levine*
- Board 21 Abstract 3528: A randomized phase II study of perioperative chemotherapy plus bevacizumab versus postoperative chemotherapy plus bevacizumab inpatients with upfront resectable hepatic colorectal metastases (APPROACH).** *Y. Chun, S. Kim, K. Lee, S. Cho, T. Kim, J. Baek, Y. Park, S. Hong, J. Kim, S. Beom, M. Jung, S. Shin, J. Ahn*
- Board 22 Abstract 3529: Impact of the type and modalities of preoperative chemotherapy on the outcome of liver resection for colorectal liver metastases: A LiverMetSurvey study.** *Y. Goto, P. F. Innominato, M. A. Allard, C. Castro Benitez, O. Ciaccio, G. Pittau, E. Vibert, A. Sa Cunha, D. Cherqui, D. Castaing, K. Okuda, Y. Akagi, H. Tanaka, R. Adam*
- Board 23 Abstract 3530: Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.** *E. Shinozaki, A. Kawazoe, Y. Kuboki, Y. Komatsu, T. Nishina, H. Hara, S. Yuki, K. Shitara, H. Bando, D. Kotani, K. Takahashi, Y. Mikamoto, H. Hasegawa, N. Hirano, S. Nomura, Y. Togashi, H. Nishikawa, A. Sato, A. Ohtsu, T. Yoshino*
- Board 24 Abstract 3531: Results of a randomized phase 3 study evaluating the potential benefit of a second-look surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-NTC01226394).** *D. Goere, O. Glehen, F. Quenet, M. Ducreux, J. Guilloit, M. Texier, E. Benhamou, D. Elias*
- Board 25 Abstract 3532: High levels of cell-free DNA (cfDNA) at baseline (BL) and increase of at least one mutation at day 14 (D14) as independent prognostic biomarkers for patients (pts) with advanced colorectal cancer (aCRC) under regorafenib.** *P. Kehagias, C. Vandeputte, L. Ameye, H. El Housni Sr., A. Deleporte, K. P. Geboes, T. Delaunoit Sr., M. Peeters, G. Demolin, L. A. D'Hondt, J. Janssens, J. Carrasco, S. Holbrechts, J. Goeminne, P. Vergauwe, J. Van Laethem, G. Ghanem, M. Paesmans, P. Flamen, A. Hendlisz*
- Board 26 Abstract 3533: Circulating tumor DNA (ctDNA) as an early marker to monitor clinical benefit of regorafenib and TAS-102 in patients with metastatic colorectal cancer (mCRC).** *A. A. Pereira, M. Lam, P. Kanikarla Marie, K. P. Raghav, V. K. Morris II, H. Brown, J. Windham, D. Y. Duose, M. J. Overman, E. Vilar Sanchez, I. I. Wistuba, P. Kipp, F. Janku, S. Sinha, S. Kopetz*
- Board 27 Abstract 3534: Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab + first-line FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.** *T. J. Price, L. Shen, B. Ma, R. Esser, W. Chen, P. Gibbs, R. S. Lim, A. Cheng*
- Board 28 Abstract 3535: Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial.** *M. Ychou, M. Rivoire, S. Thezenas, R. Guimbaud, F. Ghiringhelli, A. Mercier Blas, L. Mineur, E. Francois, F. Khemissa, M. Chauvenet, Y. Bécouarn, P. Houyau, T. Aparicio, M. Galais, F. Audemar, E. Assenat, A. Adenis, C. Jouffroy-Zeller, R. Adam, O. Bouche*
- Board 29 Abstract 3536: Safety analysis of a phase III randomized trial comparing FOLFOX + Bevacizumab vs FOLFOXIRI + Bevacizumab as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 circulating tumor cells (CTCs) (VISNÚ-1 TTD TRIAL).** *A. Gomez, J. Viteez, S. Gil, A. Salud Salvia, B. G. Suárez, P. García Alfonso, E. Martínez de Castro, G. A. Quintero Aldana, J. J. Reina, E. González Flores, M. S. Fernández, M. Rodríguez Garrote, M. Flor Oncala, M. Safont, A. La Casta Munoa, R. Lopez, G. Monica, B. García-Paredes, E. Diaz-Rubio, E. Aranda*

Sunday, June 3, 2018

- Board 30 **Abstract 3537: Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (mCRC).** *R. Xu, J. Li, Y. Bai, Y. Deng, L. Yang, H. Zhong, Z. Chen, H. Pan, W. Guo, Y. Shu, Y. Yuan, J. Xu, L. Shen, N. Wang, X. Wang, H. Chi, J. Peng, Y. Hua, W. Su, S. Qin*
- Board 31 **Abstract 3538: Outcomes of oxaliplatin-based (Ox) chemotherapy (CT) on R0 resection of colonic liver metastases (CLM).** *N. A. Bosma, M. Thiesen, W. Y. Cheung, D. J. Renouf, C. Speers, D. Tilley, E. Dixon, C. Ball, P. A. Tang, R. M. Lee-Ying*
- Board 33 **Abstract 3540: First-in-human dose escalation of monalizumab plus durvalumab, with expansion in patients with metastatic microsatellite-stable colorectal cancer.** *N. H. Segal, J. Naidoo, G. Curigliano, S. Patel, S. Sahebjam, K. P. Papadopoulos, M. S. Gordon, D. Wang, A. Gómez Rueda, X. Song, X. Li, S. Marshall, S. E. Abdullah, J. R. Diamond*
- Board 34 **Abstract 3541: Effect of time to resection of colorectal liver metastases on recurrence risk.** *E. Y. Chen, S. C. Mayo, K. G. Billingsley, G. M. Vaccaro, M. Kearney, C. D. Lopez*
- Board 35 **Abstract 3542: Bevacizumab (B) + bi-weekly capecitabine (C) and oxaliplatin (O) (XELOX2) or FOLFOX4 in first-line treatment of metastatic colorectal cancer (mCRC): Final results of a multicenter randomized phase II trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM protocol 2802).** *E. Maiello, G. Di Maggio, S. S. Cordio, S. Cinieri, F. Giuliani Sr., S. Pisconti, A. Rinaldi, A. Febraro, T. P. Latiano, M. Aieta, D. Rizzi, M. Di Maio, G. Colucci, R. Bordonaro*
- Board 36 **Abstract 3543: Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer.** *V. Gorbunova, T. Beck, R. Hofheinz, P. Garcia-Alfonso, M. Nechaeva, A. Cubillo Gracian, L. Mangel, E. Elez, D. A. Deming, R. K. Ramanathan, A. Torres, D. M. Sullivan, P. B. Komarnitsky, J. Berlin*
- Board 37 **Abstract 3544: Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in the randomized phase III FRESCO trial.** *Y. Bai, S. Qin, J. Li, Y. Deng, L. Yang, R. Xu, H. Zhong, Z. Chen, H. Pan, W. Guo, Y. Shu, C. Peng, Y. Chen, H. Li, N. Wang, X. Guo, W. Wang, S. Fan, J. Xu, L. Shen*
- Board 38 **Abstract 3545: Correlation of measurements of tumor heterogeneity based on next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) with clinical outcomes in STEAM, a prospective, randomized, multicenter study in metastatic colorectal cancer (mCRC).** *S. Yaung, N. Tikoo, A. Nicholas, N. Sommer, J. C. Bendell, H. Hurwitz, R. Price, J. F. Palma, J. J. Lee, F. Casey*
- Board 39 **Abstract 3546: A phase I expansion study of trifluridine and tipiracil (FTD/TPI) in combination with irinotecan (IRI) and bevacizumab (BEV) in patients with metastatic colorectal cancer (mCRC).** *A. M. Varghese, D. B. Cardin, J. Hersch, A. B. Benson III, H. S. Hochster, R. E. Winkler, F. Benedetti, K. Hamada, J. Berlin, L. B. Saltz*
- Board 40 **Abstract 3547: A meta-analysis exploring the role of PET and PET-CT in the management of potentially resectable colorectal cancer liver metastasis.** *J. Daza Vargas, N. Solis, S. Parpia, S. Gallinger, C. Moulton, P. E. Serrano Aybar*
- Board 41 **Abstract 3548: FOLFIRINOX plus cetuximab (CET) or bevacizumab (BEV) in patients (pts) with initially unresectable colorectal liver metastases (CRLM) with BRAF mutated (mut) tumors: A subgroup analysis of the UNICANCER PRODIGE 14-ACCORD 21 (METHEP2) trial.** *E. Lopez-Crapez, A. Adenis, S. Thezenas, E. Assenat, E. Francois, R. Guimbaud, M. Chauvenet, F. Khemissa, F. Audemar, E. Suc, M. Rivoire, F. Ghiringhelli, A. Mercier-Blas, L. Mineur, Y. Becouarn, P. Houyau, T. Stanbury, C. Jouffroy-Zeller, O. Bouche, M. Ychou*

- Board 42 **Abstract 3549: Proteomic profiling of phosphatidylinositol 3-kinase (PI3K) altered metastatic colorectal cancer (mCRC) after protein kinase B (Akt) inhibition: Insulin like growth factor 1 receptor (IGF1R) mediates adaptive resistance.** *M. Nusrat, J. Oh, Z. Jiang, A. Dasari, D. R. Fogelman, B. K. Kee, D. Menter, K. P. Raghav, V. K. Morris II, J. Wu, F. Meric-Bernstam, J. Morris, M. J. Overman, S. Kopetz*
- Board 43 **Abstract 3550: Folate gene prediction of treatment response to 5-FU and leucovorin in advanced colorectal cancer.** *B. Gustavsson, E. Odin, P. Saksena, H. Wedel, A. Edsjo, G. U. Carlsson, H. A. Taffin, E. Bexé Lindskog, K. M. Ganlov, A. Vedin, Y. Wettergren*
- Board 44 **Abstract 3551: Real-world data on overall survival (OS) impact of anti-EGFR sequence in patients (pts) with microsatellite stable (MSS) all-RAS and BRAF^{V600E} wild-type metastatic (met) colorectal cancer (CRC).** *E. Elez, G. Argiles, R. Comas, A. Garcia, N. Mulet, A. Noguerido, J. Capdevila, I. Matos, G. Martini, J. Grau Bejar, G. Villacampa, P. Nuciforo, J. Hernandez-Losa, S. Landolfi, A. Vivancos, T. M. Mercade, J. Tabernero, R. Dienstmann*
- Board 45 **Abstract 3552: A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer.** *P. M. Boland, M. Fakhri, D. Lim, K. Attwood, W. Tan, M. Mastro, R. Bies, C. Fountzilas, R. V. Iyer, W. Ma*
- Board 46 **Abstract 3553: Association between genotypes, clinical scores and survival outcome in metastatic colorectal cancer.** *M. Reinaldo, Ö. Reig, F. Esposito, V. Sanchez, P. Rodriguez, S. Albiol, M. Cuatrecasas, E. Hernández, M. Vila-Cadasesús, P. Jares, L. Pedrosa, E. Pineda Losada, J. Camps, A. Prat, J. Maurel*
- Board 47 **Abstract 3554: What is the prognostic impact of BRAF mutation in patients undergoing resection of colorectal liver metastases? Results of nationwide intergroup (ACHBT, FRENCH, AGEO) cohort of 249 patients.** *J. Bachet, N. Moreno-Lopez, L. Viganò, U. Marchese, M. Gelli, L. Raoux, S. Truant, C. Laurent, A. Herrero, B. Le Roy, S. Deguelle Lardiere, G. Passot, V. Hautefeuille, C. De La Fouchardiere, P. Artru, T. Ameto, A. Brouquet, A. Sa Cunha, S. Benoist*
- Board 48 **Abstract 3555: A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood.** *J. Jia, D. Niedzwiecki, H. E. Uronis, M. Morse, Y. Zafar, S. D. Hsu, E. Bolch, R. J. Nagy, R. B. Lanman, A. Talasz, S. Haley, A. B. Nixon, J. H. Strickler*
- Board 49 **Abstract 3556: Apatinib as a salvage treatment for refractory metastatic colorectal cancer.** *X. Chen, P. Li, J. Sun, B. Wang, P. Lin, X. Cai, X. Han, Y. Gu*
- Board 50 **Abstract 3557: ENCORE 601: A phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer.** *N. S. Azad, K. Shirai, A. J. McRee, M. Opyrchal, D. B. Johnson, P. Ordentlich, S. Brouwer, S. Sankoh, E. V. Schmidt, M. L. Meyers, M. L. Johnson*
- Board 51 **Abstract 3558: EORTC-ESSO 1409 GITCG: A prospective colorectal liver metastasis database with an integrated quality assurance program (CLIMB).** *C. A. Caballero, L. C. Alvarez, H. Nilsson, T. Ruers, P. Senellart, M. Rivoire, S. Stattner, F. Primavesi, R. Troisi, T. Gruenberger, J. Heil, A. Schnitzbauer, N. N. Rahbari, R. Swijnenburg, H. Z. Malik, M. Protic, A. Neven, M. E. Mauer, G. J. Poston, S. Evrard*
- Board 52 **Abstract 3559: Surgical quality and the impact of liver resection on outcome in the New EPOC study.** *S. A. Pugh, J. A. Bridgewater, D. Cunningham, T. Maughan, T. Maishman, M. Radford, A. Whitehead, J. Mellor, G. Griffith, J. N. Primrose*
- Board 53 **Abstract 3560: Screening and stepped care targeting psychological distress in patients with metastatic colorectal cancer: The TES cluster randomized trial.** *C. Schuurhuizen, A. Braamse, A. Beekman, P. Cuijpers, M. Van Der Linden, A. Hoogendoorn, I. R. Konings, H. M. Verheul, J. Dekker*

- Board 54 Abstract 3561: Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-RRK-0216).** *A. Stein, M. Binder, S. Al-Batran, A. Hinke, L. Waberer, E. Goekkurt, T. Meyer, D. Statovci, R. Deppenbusch, J. Riera-Knorrenschild, S. Lorenzen, T. J. Ettrich, S. Doerfel, C. Bokemeyer, S. Hegewisch-Becker*
- Board 55 Abstract 3562: Update survival analysis from a multicenter, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC).** *A. Avallone, G. Nasti, G. Rosati, C. Carlomagno, L. Silvestro, A. Cassata, C. Romano, V. Granata, A. De Stefano, S. Tafuto, F. Bianco, V. Vicario, D. Bilancia, S. Lastoria, A. Petrillo, F. Izzo, C. Gallo, P. Delrio, A. Budillon, M. Piccirillo*
- Board 56 Abstract 3563: Comparison of mismatch repair status between primary and matched metastatic sites in patients with colorectal cancer.** *W. He, W. Hu, C. Jiang, X. Xia, L. Xia*
- Board 57 Abstract 3564: Health related quality of life in elderly or frail patients with advanced colorectal cancer treated with dose reduced capecitabine.** *D. A. Breadner, M. D. Vincent, D. J. Jonker, M. Cripps, P. Klimo, J. J. Biagi, W. Lam, A. O'Connell, F. Whiston, L. Stitt, S. Welch*
- Board 58 Abstract 3565: Prognostic impact of residual HPV ctDNA detection after chemoradiotherapy for anal canal carcinoma.** *L. Cabel, E. Jeannot, I. Bieche, S. Vacher, C. Callens, A. Bernard, A. Morel, A. Lièvre, J. Otz, M. Minsat, L. Bazire, J. Pierga, B. Buecher, P. Mariani, F. Bidard, W. Cacheux*
- Board 59 Abstract 3566: Phase II study of panitumumab, 5-fluorouracil, mitomycin-c and radiotherapy treatment in patients with non-metastatic squamous cell carcinoma of the anal canal: safety and efficacy results (VITAL study)—GEMCAD 09-02.** *J. Feliu, R. Garcia-Carbonero, J. Capdevila, I. Guasch, V. Alonso, C. López-López, P. Garcia Alfonso, C. Castañón Lopez, I. Sevilla, J. Maurel*
- Board 60 Abstract 3567: FOLFCIS regimen for treatment of cancer of the anal canal.** *S. Mondaca, W. K. Chatila, J. F. Hechtman, D. Bates, A. Cercek, N. H. Segal, Z. K. Stadler, A. M. Varghese, M. F. Berger, M. Capanu, J. Shia, N. Schultz, L. B. Saltz, R. Yaeger*
- Board 61 Abstract 3568: Association of postoperative carcinoembryonic antigen (CEA) levels with survival in stage III colon cancer (CC): Post hoc analysis of the MOSAIC and PETACC-8 studies.** *E. Auclin, J. Taieb, C. Lepage, T. Aparicio, R. Faroux, E. Mini, G. Folprecht, R. Salazar, M. Banzi, C. Louvet, J. Van Laethem, J. Tabernero, T. Hickish, A. De Gramont, T. Andre, D. Vernerey*
- Board 62 Abstract 3569: SATB2 loss and the immune milieu of colorectal cancer (CRC).** *D. O'Connor, D. J. Brennan, K. Naicker, S. Das, B. Moran, R. Klingler, F. Ponten, S. M. Hewitt, K. Jirstrom, A. T. Byrne, J. O'Sullivan, W. M. Gallagher*
- Board 63 Abstract 3570: Causal modeling of CALGB 80405 (Alliance) to identify network drivers of metastatic colorectal cancer (CRC).** *R. K. Das, L. Furchtgott, J. A. Meyerhardt, A. B. Nixon, F. Innocenti, D. Cunha, K. Rich, H. Lenz, D. Niedzwiecki, E. M. O'Reilly, F. Ou, J. Latourelle, D. Wuest, B. Hayete, I. Khalil, A. P. Venook*
- Board 64 Abstract 3571: Night shift work duration and risk of colorectal cancer according to IRS1 and IRS2 expression.** *Y. Shi, L. Liu, R. Nishihara, T. Hamada, M. Song, D. Nevo, K. Kosumi, M. Gu, K. Wu, M. Giannakis, Y. Ma, J. Nowak, A. T. Chan, C. S. Fuchs, J. A. Meyerhardt, E. Giovannucci, G. Dai, E. S. Schernhammer, S. Ogino, X. Zhang*
- Board 65 Abstract 3572: Impact of MLH1, PMS2, MSH2, and MSH6 alterations on tumor mutation burden (TMB) and PD-L1 expression in 1,057 microsatellite instability-high (MSI-H) tumors.** *M. E. Salem, A. Grothey, E. S. Kim, J. Xiu, R. M. Goldberg, W. M. Korn, A. F. Shields, A. Seeber, J. J. Hwang, P. A. Philip, H. Lenz, D. Raghavan, J. Marshall*

- Board 66 Abstract 3573: Association between density of tumor infiltrating lymphocytes and disease-free survival (DFS) in patients with resected stage I-III colorectal cancer in the FACS randomized trial.** *S. A. Pugh, K. Moutasim, N. M. Jenkins, B. Shinkins, G. Thomas, D. Mant, J. N. Primrose*
- Board 67 Abstract 3574: MSI-high and MSI-stable colorectal carcinomas (CRC): A comprehensive genomic profiling (CGP) study.** *S. M. Ali, L. M. Gay, J. A. Elvin, J. Vergilio, S. H. Ramkissoon, J. Suh, E. A. Severson, S. Daniel, J. K. Killian, A. B. Schrock, J. Chung, G. M. Frampton, D. Fabrizio, L. A. Albacker, V. A. Miller, R. J. Corona, J. S. Ross*
- Board 68 Abstract 3575: Genetic variation in TET3 and survival in metastatic colorectal cancer (mCRC) from FIRE-3, TRIBE, and MAVERICC clinical trials.** *S. B. Gruber, S. Schmit, M. Melas, C. Qu, V. Heinemann, S. Stintzing, A. Falcone, F. Loupakis, C. Mancao, S. Cao, C. Cremolini, D. V. Conti, W. Zhang, H. Lenz*
- Board 69 Abstract 3576: Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.** *F. Battaglin, S. Cao, J. Millstein, A. Puccini, R. Tokunaga, M. Naseem, S. Soni, M. McSkane, M. D. Berger, A. Barzi, W. Zhang, V. Zagonel, C. Cremolini, S. Stintzing, F. Loupakis, A. Falcone, V. Heinemann, H. Lenz*
- Board 70 Abstract 3577: Molecular analyses of left- and right-sided tumors in adolescents and young adults (AYA) with colorectal cancer (CRC).** *M. Jagosky, R. M. Goldberg, D. Raghavan, A. Puccini, A. F. Shields, D. Arguello, W. M. Korn, A. Seeber, J. J. Hwang, P. A. Philip, J. Marshall, E. S. Kim, H. Lenz, M. E. Salem*
- Board 71 Abstract 3578: Results from a phase I study of andeciximab in combination with FOLFIRI and bevacizumab in patients with second line metastatic colorectal cancer.** *Z. A. Wainberg, J. C. Bendell, H. Lenz, A. D. Baron, J. Berlin, A. Bessudo, D. Bruetman, K. Y. Chung, H. Park, M. R. Patel, A. H. Adewoye, J. Liu, R. Patel, M. A. Shah*
- Board 72 Abstract LBA3579: Comparison of chemotherapy use, cost, and survival in patients with metastatic colorectal cancer in Western Washington and British Columbia.** *T. Yezefski, D. Le, L. Chen, J. Snider, C. Speers, S. Gill, H. F. Kennecke, V. Shankaran*
- Board 73 Abstract 3580: Prognostic value of tumour infiltrating lymphocytes in stage II colon cancer. A nationwide population-based study.** *A. C. Eriksen, F. B. Sørensen, J. Lindebjerg, H. Hager, R. d. Christensen, S. Kjaer-Frifeldt, T. Hansen*
- Board 74 Abstract 3581: Early response metrics for predicting trial outcomes: A report from volumetric CT for precision analysis of clinical trials (Vol-PACT).** *P. Hilden, M. Gonen, D. E. Connors, Y. Tang, B. Zhao, H. Yang, S. Karovic, J. Flynn, S. Adam, A. T. Fojo, G. Kelloff, M. L. Maitland, G. R. Oxnard, L. H. Schwartz, C. S. Moskowitz*
- Board 75 Abstract 3582: Genome-wide association with survival in stage II-III colon cancer clinical trials (NCCTG N0147, Alliance for Clinical Trials in Oncology; NSABP C-08, NRG Oncology).** *K. Penney, B. L. Banbury, Q. Shi, C. J. Allegra, S. R. Alberts, U. Peters, G. Yothers, F. A. Sinicrope, W. Sun, S. Nair, T. A. Harrison, R. M. Goldberg, P. C. Lucas, L. H. Colangelo, J. N. Atkins, P. A. Newcomb, A. T. Chan*
- Board 76 Abstract 3583: Validation of tumor infiltrating lymphocytes (TIL) and tumor budding as predictors of prognosis in patients with stage III colon cancers treated in a FOLFOX-based adjuvant trial: NCCTG N0147 (Alliance).** *F. A. Sinicrope, Q. Shi, H. Lee, N. R. Foster, S. R. Alberts, T. C. Smyrk*
- Board 77 Abstract 3584: Prognostic value of CD73 expression in resected colorectal cancer liver metastasis.** *N. Messaoudi, D. Henault, D. Stephen, I. Cousineau, P. St-Hilaire, F. Vandenbroucke-Menu, M. Dagenais, R. Letourneau, M. Plasse, A. Roy, R. W. Lapointe, B. Nguyen, D. Trudel, E. Arslanian, G. Soucy, A. Mes-Masson, J. Stagg, S. Turcotte*

Sunday, June 3, 2018

- Board 78 **Abstract 3585: The impact of skeletal muscle and adipose tissue on long-term survival in patients with resectable colorectal cancer.** *M. B. Sawyer, J. Hopkins, R. Reif, D. Bigam, V. E. Baracos, D. Eurich*
- Board 79 **Abstract 3586: Prognostic immune scoring of colorectal cancer liver metastasis with MHC class-I expression combined to T cell quantification.** *D. Henault, D. Stephen, P. St-Hilaire, N. Messaoudi, F. Vandenbroucke-Menu, M. Plasse, R. Letourneau, A. Roy, M. Dagenais, R. W. Lapointe, B. Nguyen, G. Soucy, A. Mes-Masson, S. Turcotte*
- Board 80 **Abstract 3587: Prognostic significance of number versus location of positive mesenteric nodes in node positive colon cancer.** *K. Kataoka, E. Debrie, M. Shiozawa, E. Goetghebeur, W. P. Ceelen*
- Board 81 **Abstract 3588: Prognostic evaluation of a new class of liquid biopsy biomarkers in patients with metastatic colorectal cancer: Using the tumor microenvironment as a source of protein biomarkers.** *S. N. Kehlet, A. Høye, M. K. Boisen, J. S. Johansen, M. A. Karsdal, N. Willumsen, J. Erler*
- Board 82 **Abstract 3589: Adjuvant chemotherapy and survival outcomes in diabetic patients with colon cancer: A population-based analysis.** *S. L. Liu, S. Gill, W. Y. Cheung*
- Board 83 **Abstract 3590: Clinico-pathological and molecular characterisation of *BRAF* mutant metastatic colorectal cancer (mCRC): Are all mutations created equal?** *M. Schirripa, P. Biason, F. Cortiula, M. Pino, F. Urbano, C. Antoniotti, S. Corallo, F. Gelsomino, A. Orlandi, G. Munari, U. Malapelle, M. Rugge, C. Mescoli, L. Reggiani Bonetti, G. Lanza, A. P. Dei Tos, G. De Maglio, V. Zagonel, F. Loupakis, M. Fassan*
- Board 84 **Abstract 3591: Somatic DNA mutations, tumor mutational burden (TMB), and MSI Status: Association with efficacy in patients (pts) with metastatic colorectal cancer (mCRC) of FIRE-3 (AIO KRK-0306).** *V. Heinemann, N. Kraemer, H. Buchner, L. Fischer von Weikersthal, T. Decker, A. Kiani, U. Vehlning-Kaiser, S. Al-Batran, T. Heintges, C. A. Lerchenmuller, C. Kahl, F. Kullmann, M. H. Moehler, W. Scheithauer, S. Held, D. P. Modest, J. Neumann, A. Jung, T. Kirchner, S. Stintzing*
- Board 85 **Abstract 3592: Distinct somatic alterations in right- versus left-sided colorectal cancers.** *R. Imperial, Z. Ahmed, O. M. Toor, A. Khaliq, N. Melton, P. Case, J. Case, L. S. Cummings, K. F. Kennedy, S. Hassan, S. Q. Ye, R. M. Mohammad, A. Hussain, T. J. Pluard, J. Subramanian, A. Masood*
- Board 86 **Abstract 3593: Differences in the characteristics of younger and older MSI-H colorectal cancer (CRC) as determined by universal reflex testing.** *A. J. Franke, W. P. Skelton IV, M. Gaffar, F. Lutfi, S. Welniak, M. Feely, J. S. Starr, H. D. Parekh, A. Iqbal, S. Tan, C. J. Allegra, T. J. George Jr.*
- Board 87 **Abstract 3594: International harmonization of diagnostic criteria for *HER2*-amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method.** *S. Fujii, A. M. Magliocco, E. Valtorta, J. Kim, W. Okamoto, K. Sawada, Y. Nakamura, V. Torri, S. Kopetz, W. Park, K. Tsuchihara, T. Kim, K. P. Raghav, S. Siena, T. Yoshino*
- Board 88 **Abstract 3595: The characteristics of *ARID1A* mutations in colorectal cancer.** *A. Mehrvarz Sarshekeh, J. M. Loree, G. C. Manyam, A. A. Pereira, K. P. Raghav, M. Lam, J. S. Davis, A. Dasari, V. K. Morris II, D. Menter, C. Eng, R. Broaddus, M. Routbort, R. Luthra, D. M. Maru, M. J. Overman, F. Meric-Bernstam, S. Kopetz*
- Board 89 **Abstract 3596: A prospective cohort study in colorectal cancer assessing the relationship between post-surgery detection of methylated *BCAT1* or *IKZF1* ctDNA and risk for residual disease and survival.** *D. Murray, G. P. Young, S. K. Pedersen, P. Rabbitt, S. E. Byrne, K. J. Cornthwaite, A. Roy, C. Karapetis, E. L. Symonds*
- Board 90 **Abstract 3597: Prognostic impact of *BRAF* V600E mutation in patients with non-metastatic colorectal cancer with microsatellite instability: A systematic review and meta-analysis.** *S. Manthradi, W. Sun, A. Saeed*

- Board 91 **Abstract 3598: CD3⁺ and CD8⁺ tumor-infiltrating lymphocyte (TIL) densities to prognostically stratify DNA mismatch repair-deficient (dMMR) colon cancer patients (pts): NCCTG N0147 (Alliance).** *H. H. Yoon, Q. Shi, E. N. Heying, A. Muranyi, F. Ough, A. Djalilvand, J. Clements, R. Bowermaster, W. Liu, M. Barnes, S. R. Alberts, K. Shanmugam, F. A. Sinicrope*
- Board 92 **Abstract 3599: Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration.** *A. F. Shields, F. Ou, J. Paul, A. F. Sobrero, T. Yoshino, J. Taieb, I. Souglakos, Q. Shi, R. Kerr, R. Labianca, T. Yamanaka, D. Vernerey, I. Boukovinas, T. Kato, V. Torri, S. Kakolyris, T. Andre, A. Grothey, J. A. Meyerhardt, T. Iveson*
- Board 93 **Abstract 3600: Total neoadjuvant treatment versus chemoradiotherapy in locally advanced rectal cancer: A propensity score analysis from two prospective phase II clinical trials.** *J. Zhang, H. Hu, Y. Cai, D. Chen, J. Xiao, J. Ling, Y. Deng*
- Board 94 **Abstract 3601: Association of adverse events (AEs) with outcomes in early stage colon cancer (CC): An analysis of 10,695 CC patients from the ACCENT database.** *W. Y. Cheung, T. Andre, A. Grothey, R. Kerr, J. Dixon, D. G. Haller, A. De Gramont, S. R. Alberts, C. Twelves, M. J. O'Connell, L. B. Saltz, S. Lonardi, T. Yoshino, G. Yothers, R. M. Goldberg, Q. Shi*
- Board 95 **Abstract 3602: Patients' preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile?** *P. L. Blinman, A. J. Martin, M. Jefford, D. Goldstein, D. Boadle, M. F. Morris, N. C. Tebbutt, C. Aiken, J. Paul, E. Segelov, A. M. Haydon, T. Iveson, M. R. Stockler*
- Board 96 **Abstract 3603: Association of sex and adverse events (AEs) of adjuvant chemotherapy (ACT) in early stage colon cancer (CC): A pooled analysis of 28,636 patients (pts) in the ACCENT database.** *A. D. Wagner, A. Grothey, T. Andre, J. Dixon, N. Wolmark, D. G. Haller, C. J. Allegra, E. VanCutsem, T. J. George Jr., A. De Gramont, S. R. Alberts, C. Twelves, M. O'Connell, L. B. Saltz, C. D. Blanke, G. Francini, R. Kerr, R. M. Goldberg, G. Yothers, Q. Shi*
- Board 97 **Abstract 3604: Impact of adjuvant chemotherapy in higher risk stage II colon cancer with a deficient mismatch repair (dMMR)/ microsatellite instability-high (MSI-H) profile.** *A. Mohamed, R. Jiang, P. A. Philip, M. Diab, M. Behera, C. Wu, B. F. El-Rayes, M. Akce*
- Board 98 **Abstract 3605: Fish oil supplementation and inflammatory response during neoadjuvant chemoradiation for rectal cancer: Results from a prospective, randomized, controlled trial.** *J. D. Silva, M. M. Silva, C. L. Mello, M. D. Begnami, M. G. Silva, S. Aguiar Junior*
- Board 99 **Abstract 3606: Who should undergo lateral pelvic node dissection after neoadjuvant chemoradiation for rectal cancer?** *S. Malakorn, T. Sammour, B. K. Bednarski, Y. You, J. M. Skibber, M. A. Rodriguez-Bigas, G. J. Chang*
- Board 100 **Abstract 3607: Mesorectal excision with or without lateral lymph node dissection for clinical stage II, III lower rectal cancer: Long-term follow-up data of Japan Clinical Oncology Group study JCOG0212.** *M. Ota, S. Fujita, J. Mizusawa, Y. Kanemitsu, M. Ito, A. Shiomi, M. Ohue, S. Fujii, S. Saito, M. Shiozawa, T. Yamaguchi, H. Bando, K. Katsumata, S. Okamura, Y. Akagi, N. Takiguchi, S. Yamaguchi, H. Ike, T. Akasu, Y. Moriya*
- Board 101 **Abstract 3608: Predicting treatment outcome of rectal cancer patients underwent neoadjuvant chemoradiotherapy by ctDNA: The potential use of ctDNA monitoring as organ-sparing approach.** *L. Yang, Y. Wang, L. Shen, J. Wan, W. Deng, J. Zhu, Z. Zhang*
- Board 102 **Abstract 3609: Reasons for urban-rural differences in colon cancer outcomes: A population-based analysis.** *N. A. Bosma, D. Tilley, W. Y. Cheung*
- Board 103 **Abstract 3610: Prognostic impact of CDX2 in stage II colon cancer: Results from two nationwide cohorts.** *T. Hansen, S. Kjaer-Frifeldt, A. C. Eriksen, J. Lindebjerg, L. Jensen, F. B. Soerensen, A. K. Jakobsen*

Sunday, June 3, 2018

- Board 104 **Abstract 3611: Molecular characterization of appendiceal cancer and comparison with right-sided (R-CRC) and left-sided colorectal cancer (L-CRC).** *R. Tokunaga, J. Xiu, C. Johnston, R. M. Goldberg, P. A. Philip, A. Seeber, A. Puccini, M. Naseem, F. Battaglin, M. D. Berger, S. Soni, M. McSkane, A. Barzi, W. Zhang, J. J. Hwang, A. F. Shields, J. Marshall, W. M. Korn, H. Lenz*
- Board 105 **Abstract 3612: HER2 positive rates are enriched amongst colorectal cancer brain metastases: A study amongst 1,920 consecutive patients.** *R. Tan, C. W. Chua, S. Koo, S. Choo, E. Tan, S. Y. Ong, M. C. Ng, D. W. Tai, D. C. Macalinao, C. Thng, J. Khoo, K. Lim, T. Lim, A. S. Lim, I. B. Tan*
- Board 106 **Abstract 3613: Age-related real-world outcomes for patients (pts) with metastatic colorectal cancer (mCRC).** *M. Curtis, N. C. Nussbaum, H. J. Hamrick, C. S. Bennette, N. J. Meropol, R. A. Miksad*
- Board 107 **Abstract 3614: Effects of proton pump inhibitors (PPIs) on FOLFOX and XELOX regimens in colorectal cancer (CRC).** *G. Wong, V. Ha, M. P. Chu, D. Dersch-Mills, S. Ghosh, C. Chambers, M. B. Sawyer*
- Board 108a **Abstract TPS3615: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer.** *J. J. Lee, G. Yothers, S. A. Jacobs, H. K. Sanoff, D. J. Cohen, K. A. Guthrie, N. L. Henry, P. A. Ganz, S. Kopetz, P. C. Lucas, C. J. Allegra, C. D. Blanke, N. Wolmark, H. S. Hochster, T. J. George Jr., M. J. Overman*
- Board 108b **Abstract TPS3616: Novel PET/CT imaging biomarkers of CB-839 in combination with panitumumab and irinotecan in patients with metastatic and refractory RAS wildtype (WT) colorectal cancer: A phase I/II study.** *S. Das, D. B. Cardin, L. W. Goff, J. Berlin, M. Schulte, H. C. Manning, R. J. Coffey, J. Whisenant, R. Krumsick, K. K. Ciombor*
- Board 109a **Abstract TPS3617: NuTide 302: A phase IB study to assess the safety, pharmacokinetics and clinical activity of NUC-3373 in combination with standard agents used in colorectal cancer treatment.** *S. P. Blagden, T. Evans, E. A. Ghazaly, C. Gnanaranjan, A. De Gramont, J. Tabernero, J. Berlin*
- Board 109b **Abstract TPS3618: First-line treatment with panitumumab plus FOLFIRI in elderly patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer and good performance status: OPALO trial.** *J. Feliu, A. Salud, E. Pineda Losada, V. Alonso, A. Cubillo, G. Soler, A. Carmona, A. Ruiz Casado, B. Martinez-Amores, M. Guillot Morales, C. Llorca, C. Castañon Lopez, G. Soler Gonzalez, P. Escudero, I. Macias Declara, J. Aparicio*
- Board 110a **Abstract TPS3619: ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bev.** *Z. A. Wainberg, L. Wang, H. Yue, M. Motwani, S. Kasichayanula, M. E. Blaney, L. Naumovski, J. H. Strickler*
- Board 110b **Abstract TPS3620: A randomized phase II study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: S1613.** *K. P. Raghav, S. L. McDonough, B. R. Tan Jr., C. S. Denlinger, A. M. Magliocco, N. W. Choong, N. Sommer, F. A. Scappaticci, D. Campos, K. A. Guthrie, S. Kopetz, M. Fakih, H. S. Hochster*
- Board 111a **Abstract TPS3621: Physical activity program in patients with metastatic colorectal cancer who receive palliative first-line chemotherapy: A randomized controlled phase III trial—(ACTIVE-2 SAKK 41/14).** *V. Hess, R. C. Winterhalder, K. Ribi, B. Handschin, S. Pederiva, J. Luthi, M. Kueng, D. Helbling, P. Moosmann, P. O. Bohanes, B. C. Pestalozzi, E. Rickenbacher, C. Biaggi Rudolf, C. Berset, S. Rondeau, D. Horber, J. Thaler*

- Board 111b Abstract TPS3622: PRODIGE 52-UCGI 29-CCTG/CO.27 (IROCAS): A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4 and/or N2) colon cancer (a UNICANCER GI-PRODIGE trial).** *J. Bennouna, T. Andre, L. Miglianico, L. Campion, L. Mineur, Y. Lam, S. Hiret, P. Artru, O. Bouche, F. Borde, A. Aleba, L. Rajpar, C. Rebischung, Y. Toucheffeu, P. Kavan, S. Gill, T. Asmis, C. Jouffroy-Zeller, J. Emile, J. Taieb*
- Board 112a Abstract TPS3623: Phase I trial of TAS-102 and concurrent radiation therapy for patients with locally recurrent, unresectable or metastatic, rectal cancer.** *J. M. Hubbard, A. D. Leal, C. L. Hallemeier, D. H. Ahn, N. Mishra, N. R. Foster, T. S. Bekaii-Saab, A. Grothey*
- Board 112b Abstract TPS3624: NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemotherapy (NAC) in stage II-IV rectal cancer.** *T. J. George, G. Yothers, J. J. Lee, S. A. Jacobs, M. Deutsch, C. J. Allegra, N. Wolmark*

8:00 AM - 11:30 AM Poster Session

Gastrointestinal (Noncolorectal) Cancer

Location: Hall A

Abstracts on Boards 198-209 will be discussed during the Gastrointestinal (Noncolorectal) Cancer Poster Discussion Session.

Posters by Topic

Esophageal or Gastric Cancer: Boards 198-202, 210-262

Hepatobiliary Cancer: Boards 203, 206-209, 263-282

Neuroendocrine/Carcinoid: Boards 283-294

Other GI Cancer: Board 295

Pancreatic Cancer: Boards 204-205, 296-319

Trials in Progress: Boards 320a-333b

- Board 198 Abstract 4009: Phase III study comparing triplet chemotherapy with S-1 and cisplatin plus docetaxel versus doublet chemotherapy with S-1 and cisplatin for advanced gastric cancer (JCOG1013).** *Y. Yamada, N. Boku, J. Mizusawa, S. Iwasa, S. Kadowaki, N. Nakayama, M. Azuma, T. Sakamoto, K. Shitara, T. Okuno, K. Chin, A. Nozaki, M. Nakamura, H. Hara, H. Katayama, H. Fukuda, T. Yoshikawa, T. Sano, M. Sasako, M. Terashima*
- Board 199 Abstract 4010: The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.** *M. A. Shah, K. Shitara, F. Lordick, Y. Bang, N. C. Tebbutt, J. Metges, K. Muro, L. Shen, S. Tjulandin, J. L. Hays, R. Xu, M. Fontaine, E. Brooks, B. Xu, W. Li, C. Li, L. Borodyansky, E. Van Cutsem*
- Board 200 Abstract 4011: A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT).** *A. Makiyama, K. Sagara, J. Kawada, T. Kashiwada, A. Hosokawa, Y. Horie, H. Satake, Y. Yamamoto, H. Tanioka, K. Shinozaki, K. Nishikawa, K. Uchino, Y. Sukawa, T. Yamanaka, K. Yamazaki, S. Hironaka, N. Boku, I. Hyodo, T. Esaki, K. Muro*
- Board 201 Abstract 4012: Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.** *K. A. Goodman, N. Hall, T. S. Bekaii-Saab, F. Ou, E. Twohy, M. O. Meyers, D. J. Boffa, K. Mitchell, K. Perry, W. L. Frankel, A. P. Venook, E. M. O'Reilly, D. H. Ilson*
- Board 202 Abstract 4013: A multi-center, randomized, prospective study evaluating the optimal radiation dose of definitive concurrent chemoradiation for inoperable esophageal squamous cell carcinoma.** *Y. Xu, W. Zhu, X. Zheng, W. Wang, J. Li, R. Huang, H. He, J. Chen, L. Liu, Z. Sun, X. Yang, M. Zeng, J. Pu, W. Hu, Y. Bao, Z. Liu, J. Ma, M. Chen*

- Board 203 **Abstract 4014: Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG1113, FUGA-BT).** *M. Ueno, C. Morizane, T. Okusaka, J. Mizusawa, H. Katayama, M. Ikeda, M. Ozaka, K. Sugimori, A. Fukutomi, H. Hara, N. Mizuno, H. Yanagimoto, K. Sano, K. Tobimatsu, K. Yane, S. Nakamori, N. Sata, S. Yukisawa, H. Ishii, J. Furuse*
- Board 204 **Abstract 4015: Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer.** *N. Bahary, A. Wang-Gillam, S. Haraldsdottir, B. G. Somer, J. S. Lee, M. A. O'Rourke, A. Nayak-Kapoor, G. L. Beatty, M. Liu, D. Delman, G. R. Rossi, E. P. Kennedy, N. N. Vahanian, C. J. Link, I. Garrido-Laguna*
- Board 205 **Abstract 4016: Effect of anti-CTGF human recombinant monoclonal antibody pamrevlumab on resectability and resection rate when combined with gemcitabine/nab-paclitaxel in phase 1/2 clinical study for the treatment of locally advanced pancreatic cancer patients.** *V. J. Picozzi, M. J. Pishvaian, K. Mody, J. M. Winter, J. A. Glaspy, T. Larson, M. R. Matrana, K. Saikali, M. Carney, S. Porter, P. Yu, E. Kouchakji, E. Carrier*
- Board 206 **Abstract 4017: Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.** *M. Kudo, K. Ueshima, T. Torimura, N. Tanabe, M. Ikeda, H. Aikata, N. Izumi, T. Yamasaki, S. Nojiri, K. Hino, H. Tsumura, N. Isoda, K. Yasui, T. Kuzuya, T. Okusaka, J. Furuse, N. Kokudo, K. Okita, K. Yoshimura, Y. Arai*
- Board 207 **Abstract 4018: Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis.** *M. Peck-Radosavljevic, M. Kudo, J. Raoul, H. Lee, T. Decaens, J. Heo, S. Lin, H. Shan, Y. Yang, I. Bayh, K. Nakajima, A. Cheng*
- Board 208 **Abstract 4019: Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.** *G. K. Abou-Alfa, T. Meyer, A. Cheng, A. El-Khoueiry, L. Rimassa, B. Ryoo, I. Cicin, P. Merle, Y. Chen, J. Park, J. Blanc, L. Bolondi, H. Klumpfen, S. L. Chan, V. Dadduzio, C. Hessel, A. E. Borgman-Hagey, G. Schwab, R. K. Kelley*
- Board 209 **Abstract 4020: Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update.** *A. X. Zhu, R. S. Finn, J. Edeline, S. Cattan, S. Ogasawara, D. H. Palmer, C. Verslype, V. Zagonel, L. Fartoux, A. Vogel, D. Sarker, G. Verset, S. L. Chan, J. J. Knox, B. Daniele, S. Ebbinghaus, J. Ma, A. B. Siegel, A. Cheng, M. Kudo*
- Board 210 **Abstract 4021: Two novel registry-based prediction models for overall survival in patients with metastatic esophageal or gastric cancer.** *H. van den Boorn, A. Abu-Hanna, E. ter Veer, J. van Kleef, F. Lordick, M. Stahl, J. A. Ajani, R. Guimbaud, S. Park, S. J. Dutton, Y. Bang, N. Haj Mohammad, M. A. Sprangers, R. H. Verhoeven, A. H. Zwinderman, M. G. van Oijen, H. W. Van Laarhoven*
- Board 211 **Abstract 4022: Oxaliplatin plus capecitabine (XELOX) in the perioperative treatment of locally advanced gastric adenocarcinoma in combination with D2 gastrectomy (NEO-CLASSIC).** *T. Liu, Y. Yu, Y. Fang, Z. Shen, M. Yan, H. Cao, Y. Liu, X. Wang, Y. Cui, Y. Wang, F. Liu, W. Chen, W. Li, Y. Sun*
- Board 212 **Abstract 4023: Final analysis of single-arm confirmatory study of diagnostic endoscopic resection (ER) plus selective chemoradiotherapy (CRT) for stage I esophageal squamous cell carcinoma (ESCC): JCOG0508.** *K. Minashi, K. Nihei, G. Ogawa, K. Takizawa, T. Yano, Y. Amanuma, T. Tsuchida, H. Ono, T. Iizuka, S. Shichijyo, I. Oda, Y. Morita, M. Tajika, J. Fujiwara, Y. Yamamoto, C. Katada, S. Hori, H. Doyama, H. Fukuda, M. Muto*
- Board 213 **Abstract 4024: Updated report of a randomized phase III trial comparing 4 and 8 courses of S-1 adjuvant chemotherapy for p-stage II gastric cancer: JCOG1104 (OPAS-1).** *M. Terashima, T. Yoshikawa, J. Mizusawa, S. Nunobe, Y. Nishida, M. Kaji, N. Fukushima, S. Hato, Y. Choda, H. Yabusaki, K. Yoshida, K. Misawa, A. Takeno, M. Tsuda, Y. Kawachi, H. Katayama, H. Fukuda, N. Boku, T. Sano, M. Sasako*

- Board 214 Abstract 4025: PD-L1 and IDO1 expression and clinical outcome in 305 patients with surgically resected esophageal cancer.** *Y. Baba, T. Ishimoto, Y. Hiyoshi, M. Iwatsuki, Y. Miyamoto, N. Yoshida, H. Baba*
- Board 215 Abstract 4026: Survival outcomes in gastric and gastroesophageal junction adenocarcinoma treated with peri-operative chemotherapy with or without pre-operative radiotherapy.** *S. Tian, R. Jiang, N. A. Madden, M. J. Ferris, Z. Buchwald, K. M. Xu, K. Cardona, S. Maithel, M. W. McDonald, J. Y. Lin, W. J. Curran Jr., M. Behera, B. F. El-Rayes, P. R. Patel*
- Board 216 Abstract 4027: Racial disparities in surgical management and survival in hispanic patients with potentially resectable esophageal cancer.** *D. Gupta, Y. Liu, R. Jiang, F. Fernandez, S. Force, A. Pickens, C. E. Steuer, M. W. McDonald, K. A. Higgins, J. J. Beitler, S. S. Ramalingam, D. M. Shin, T. K. Owonikoko, N. F. Saba*
- Board 217 Abstract 4028: Single-arm confirmatory trial of laparoscopy assisted total or proximal gastrectomy with nodal dissection for clinical stage I gastric cancer: Japan Clinical Oncology Group study JCOG1401.** *H. Katai, J. Mizusawa, H. Katayama, C. Kunisaki, S. Sakuramoto, N. Inaki, T. Kinoshita, Y. Iwasaki, K. Misawa, N. Takiguchi, M. Kaji, H. Okitsu, T. Yoshikawa, M. Terashima*
- Board 218 Abstract 4029: Biomarker study for trastuzumab continuation beyond progression in a randomized phase II trial of weekly paclitaxel±trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum (WJOG7112G).** *Y. Sukawa, A. Makiyama, T. Esaki, G. Hirano, M. Komoda, T. Kashiwada, J. Kawada, A. Hosokawa, T. Tsuda, A. Tsuji, T. Moriwaki, H. Tanioka, K. Yonesaka, K. Nishio, K. Noshio, K. Yamazaki, S. Hironaka, N. Boku, I. Hyodo, K. Muro*
- Board 219 Abstract 4030: Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).** *D. V. Catenacci, H. Park, H. E. Uronis, Y. Kang, J. Lacy, P. C. Enzinger, S. Park, K. Lee, M. C. Ng, P. J. Gold, J. Yen, A. Franovic, R. J. Kelly, A. Wynter-Horton, D. Li, J. Muth, J. E. Baughman, S. Hong, J. K. Davidson-Moncada, Y. Bang*
- Board 220 Abstract 4031: Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.** *R. J. Kelly, J. Lee, Y. Bang, K. Almhanna, M. A. Blum Murphy, D. V. Catenacci, H. C. Chung, Z. A. Wainberg, M. Gibson, K. Lee, J. C. Bendell, C. S. Denlinger, P. Z. Brohawn, P. He, J. McDevitt, J. Englert, G. Y. Ku*
- Board 221 Abstract 4032: Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers.** *A. Hollebecque, Z. A. Wainberg, J. A. Ajani, J. Marshall, D. Cunningham, S. I. Ou, J. Lutzky, R. Jamal, G. Curigliano, M. Gutierrez, J. J. Nemunaitis, R. E. Sanborn, D. P. Zandberg, F. Xiao, N. Angra, S. E. Abdullah, N. H. Segal*
- Board 222 Abstract 4033: A phase II study of perioperative intraperitoneal paclitaxel plus S-1/paclitaxel for curatively resectable gastric cancer with serosal invasion: The GAPS study.** *S. Ito, M. Imano, Y. Uenosono, T. Arigami, H. Yabusaki, Y. Hirono, S. Ueda, T. Matsumura, R. Fukushima, A. Takeno, K. Kishi, Y. Chiba, S. Chiba, H. Imamoto, Y. Ito, A. Matsuki, H. Ishigami, H. Yamaguchi, J. Kitayama, H. Furukawa*
- Board 223 Abstract 4034: Lymph node ratio as a clinical determinant for selecting adjuvant chemotherapy regimen in curative D2 resected gastric cancer.** *J. Hwang, M. Ki, H. Shim, W. Bae, S. Cho, I. Chung*
- Board 224 Abstract 4035: Oxaliplatin, 5FU and nab-paclitaxel as neoadjuvant regimen in patients with resectable oesogastric adenocarcinoma: A GERCOR phase 2 study (FOXAGAST).** *S. S. Watson, C. De La Fouchardiere, S. C. Kim, R. Cohen, J. Bachet, C. Tournigand, J. Ferraz, M. Lefevre, D. Colin, M. Svrcek, A. Meurisse, C. Louvet*

- Board 225 **Abstract 4036: Randomized, double-blind, phase 2 study of S-1 plus oxaliplatin (SOX) with or without ramucirumab (RAM) as first-line therapy followed by paclitaxel plus RAM as second-line therapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma (AGC).** *K. Muro, T. Yoshikawa, K. Shitara, D. Oh, Y. Kang, H. Chung, T. Kudo, K. Chin, S. Kadowaki, Y. Hamamoto, S. Hironaka, K. Yoshida, C. Yen, Y. Omuro, L. Bai, K. Maeda, A. Ozeki, R. Yoshikawa, Y. Kitagawa*
- Board 226 **Abstract 4037: Psychiatric comorbidities among esophageal cancer survivors in South Korea: A nationwide population-based, longitudinal study.** *J. Heo, O. Noh, M. Chun, Y. Oh, O. Cho*
- Board 227 **Abstract 4038: Multicenter observational study on re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab.** *T. Kashiwada, H. Saeki, Y. Uenosono, A. Makiyama, M. Iwatsuki, Y. Narita, H. Satake, Y. Matsuda, H. Sonoda, E. Oki, Y. Maehara*
- Board 228 **Abstract 4039: Development of non-hematological adverse events in apatinib-treated gastric cancer and their association with clinical outcome: Results from a phase IV study.** *Y. Ba, J. Li, S. Qin, L. Wen, W. Deng, G. Zhang, T. Jia, H. Zhong, J. Yang, X. Lin, Y. Bai, Y. He, Z. Xie, T. Yi, X. Wu, F. Ye, L. Liu, Y. Huang, M. Wang, J. Wang*
- Board 229 **Abstract 4040: Role of neoadjuvant chemotherapy or chemoradiotherapy in esophageal carcinoma.** *H. Yao, Y. Yu, Q. Ou, Y. Wang, Q. Gao, T. Fu, D. Lin, S. Wu*
- Board 230 **Abstract 4041: Laparoscopy-assisted versus open D2 distal gastrectomy for advanced gastric cancer: Five year overall survival and morbidity results from a randomized phase II multicenter clinical trial (COACT 1001).** *Y. Kim, B. Nam, Y. Lee, Y. Park, S. Lee, O. Jeong, J. Lee, K. Yoon, S. Jeong, O. Kwon, T. Kim, W. Yu, M. Han, S. Kim, K. Ryu*
- Board 231 **Abstract 4042: International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1).** *M. Terashima, K. Yoshida, S. Y. Rha, J. Bae, G. Li, H. Katai, M. Watanabe, Y. Seto, H. Yang, J. Ji, H. Baba, Y. Kitagawa, S. Morita, M. Nishiyama*
- Board 232 **Abstract 4043: Association between *Helicobacter pylori* infection and outcome in advanced gastric cancer patients treated with S-1 adjuvant chemotherapy.** *S. Nishizuka, G. Tamura, M. Nakatochi, T. Iwaya, V. A. Espina, L. A. Liotta, K. Koeda*
- Board 233 **Abstract 4044: Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis.** *K. Shitara, M. A. Shah, M. Di Bartolomeo, S. Lonardi, S. Al-Batran, E. Van Cutsem, D. H. Ilson, I. Chau, M. Alsina, J. Lacy, D. Takahari, N. Sugimoto, J. C. Bendell, Z. A. Wainberg, M. Tehfe, D. R. Ferry, R. Wei, R. A. Walgren, M. Das, C. S. Fuchs*
- Board 234 **Abstract 4045: Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, single-arm study.** *F. Wang, T. S. Liu, X. Yuan, K. Gu, Y. Yuan, Y. Deng, J. Xu, Y. Bai, Y. Wang, W. Liao, H. Zhang, F. Bi, B. Wang, Z. Zhuang, H. Luo, R. Xu*
- Board 235 **Abstract 4046: Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer: Japan Clinical Oncology Group study (JCOG0501).** *Y. Iwasaki, M. Terashima, J. Mizusawa, H. Katayama, K. Nakamura, H. Katai, T. Yoshikawa, Y. Ito, M. Kaji, Y. Kimura, M. Hirao, M. Yamada, A. Kurita, M. Takagi, M. Gotoh, A. Takagane, H. Yabusaki, N. Hirabayashi, T. Sano, M. Sasako*
- Board 236 **Abstract 4047: Preliminary result of phase 1/2 study of ramucirumab plus nivolumab in patients with previously treated advanced gastric adenocarcinoma (NivoRam study).** *D. Takahari, H. Shoji, H. Hara, T. Esaki, N. Machida, K. Nagashima, K. Aoki, K. Honda, T. Miyamoto, N. Boku, K. Kato*

- Board 237 Abstract 4048: Differential response to adjuvant chemotherapy based on Lauren subtype affects clinical outcome of gastric cancer: A cohort study and meta-analysis.** *K. WANG, E. Li, R. Busuttill, J. Kong, S. T. Pattison, J. J. Sung, J. Yu, E. M. El-Omar, J. A. Simpson, A. Boussioutas*
- Board 238 Abstract 4049: Pembrolizumab for patients with previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase 2 KEYNOTE-180 study.** *M. A. Shah, T. Kojima, P. C. Enzinger, D. Hochhauser, J. Raimbourg, A. Hollebecque, F. Lordick, S. Kim, M. Tajika, H. Kim, A. C. Lockhart, H. Arkenau, F. El Hajbi, M. Gupta, P. Pfeiffer, Q. Liu, J. Lunceford, S. Kang, P. Bhagia, K. Kato*
- Board 239 Abstract 4050: The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced gastric cancer (GC).** *S. Yuki, K. Shitara, S. Kadowaki, K. Minashi, A. Takeno, H. Hara, T. Kajiwara, Y. Sunakawa, S. Iwasa, Y. Yamamoto, F. Nagashima, R. Nakanishi, T. Esaki, T. Yoshikawa, S. Nomura, T. Kuwata, S. Fujii, W. Okamoto, A. Ohtsu, T. Yoshino*
- Board 240 Abstract 4051: A single-arm confirmatory study of definitive chemoradiotherapy (dCRT) including salvage treatment in patients (pts) with clinical (c) stage II/III esophageal carcinoma (EC) (JCOG0909).** *Y. Ito, H. TAKEUCHI, G. Ogawa, K. Kato, M. Onozawa, K. Minashi, T. Yano, K. Nakamura, T. Tsushima, H. Hara, T. Okuno, S. Hironaka, I. Nozaki, T. Ura, K. Chin, T. Kojima, S. Seki, K. Sakanaka, H. Fukuda, Y. Kitagawa*
- Board 241 Abstract 4052: Comparison of clinical outcome and safety after minimally invasive esophagectomy: Ivor Lewis versus McKeown—A real-world multicenter observational study from China.** *Y. Liu, Y. Li, X. Fu, L. Liu, L. Xu, X. Li, J. Hu, H. Zhao, X. Zhang, D. Liu, H. Yang, T. Zhang*
- Board 242 Abstract 4053: Final results of a phase 3 study of comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in chemoradiotherapy for locally advanced esophageal carcinoma (ESO-Shanghai 1).** *Y. Chen, J. Ye, Z. Zhu, W. Zhao, L. Li, M. Fan, C. Wu, H. Tang, G. Xu, Q. Lin, J. Li, Y. Xia, Y. Li, J. Zhou, K. Zhao*
- Board 243 Abstract 4054: The activity of crizotinib in chemo-refractory MET-amplified esogastric adenocarcinomas: Results from the AcS6-crizotinib program.** *T. Aparicio, N. Cozic, C. De La Fouchardiere, E. Meriaux, J. Plaza, L. Mineur, R. Guimbaud, E. Samalin, F. Mary, T. Lecomte, C. A. Gomez-Roca, P. Haineaux, A. Grattet, J. Selves, Y. Menu, N. Colignon, C. Mahier-Ait Oukhatar, F. Legrand, G. Vassal*
- Board 244 Abstract 4055: PET scan-directed chemoradiation (CRT) for esophageal squamous cell carcinoma (ESCC): No benefit for salvage chemo in PET non-responders (PETnr).** *M. Greally, J. F. Chou, D. Molena, V. W. Rusch, M. S. Bains, B. J. Park, A. J. Wu, D. P. Kelsen, Y. Y. Janjigian, D. H. Ilson, G. Y. Ku*
- Board 245 Abstract 4056: Tumor mutation burden (TMB) and immune-related adverse events (irAEs) compared to antibiotic (abx) use to predict for response to immune checkpoint inhibitors in esophagogastric cancer (EGC).** *M. Greally, W. K. Chatila, M. Margolis, J. F. Hechtman, Y. Tuvy, R. Kundra, M. Ladanyi, D. P. Kelsen, D. H. Ilson, M. F. Berger, L. H. Tang, D. B. Solit, N. Schultz, Y. Y. Janjigian, G. Y. Ku*
- Board 246 Abstract 4057: Feasibility study of trastuzumab (T) and pertuzumab (P) added to neoadjuvant chemoradiotherapy (nCRT) in resectable HER2+ esophageal adenocarcinoma (EAC) patients (pts): The TRAP study.** *S. Schokker, R. J. Molenaar, S. L. Meijer, R. A. Mathot, S. Van Der Woude, S. K. Krishnadhath, G. Creemers, G. A. Nieuwenhuijzen, M. Van Der Sangen, L. V. Beerepoot, J. Heisterkamp, M. Los, M. Slingerland, A. Cats, G. Hospers, M. F. Bijlsma, C. J. Punt, M. I. van Berge Henegouwen, M. C. Hulshof, H. W. Van Laarhoven*
- Board 247 Abstract 4058: Laparoscopic versus open surgery for advanced gastric cancer.** *G. Li, J. Yu, C. Huang, Y. Sun, X. Su, H. Cao, J. Hu, K. Wang, J. Suo, K. Tao, X. He, H. Wei, M. Ying, W. Hu, X. Du, Y. Hu, Z. Li, H. Liu, P. Chen, J. Ji*

Sunday, June 3, 2018

- Board 248 **Abstract 4059: Capecitabine plus oxaliplatin versus capecitabine plus oxaliplatin with concurrent radiotherapy in the treatment of gastric cancer after D2 gastrectomy.** *C. Xie, X. Jin, D. Chen*
- Board 249 **Abstract 4060: Quality of life in the CRITICS study, a multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer.** *R. Van Amelsfoort, I. Walraven, E. P. Jansen, A. Cats, N. C. van Grieken, N. K. Aaronson, H. Boot, P. A. Lind, E. Meershoek – Klein Kranenbarg, M. Nordsmark, H. Putter, A. K. Trip, J. W. van Sandick, K. Sikorska, H. van Tinteren, C. J. Van De Velde, M. Verheij*
- Board 250 **Abstract 4061: Selumetinib plus docetaxel as second-line chemotherapy in KRAS mutant, KRAS amplified or MEK signatred gastric cancer patients: First arm of the umbrella trial in GC though the molecular screening, VIKTORY trial.** *J. Lee, S. Kim, I. Kozarewa, H. Kim, K. Kim, P. G. Mortimer, S. J. Hollingsworth, M. Park, S. Park, E. Harrington, W. Kang*
- Board 252 **Abstract 4063: Co-existing alterations in cell-cycle pathway genes and impact on benefit from trastuzumab in advanced esophagogastric cancers (EGC): Analysis of 527 Her2-amplified cases.** *J. Chao, S. J. Klempler, S. B. Maron, M. Bailey, S. Kim, J. He, D. Lipson, S. M. Ali, V. A. Miller, J. S. Ross, R. Madison, J. Lee, D. V. Catenacci, A. B. Schrock*
- Board 253 **Abstract 4064: Diversity of first-line palliative systemic treatments for esophagogastric cancer patients with synchronous metastases: A real world evidence study.** *W. P. Dijksterhuis, M. G. van Oijen, R. H. Verhoeven, H. W. Van Laarhoven*
- Board 254 **Abstract 4065: Investigation of PD-L1 expression and response to pembrolizumab (pembro) in gastric cancer (GC) and cervical cancer (CC) using combined positive score (CPS) and tumor proportion score (TPS).** *K. Kulangara, L. Guerrero, A. Posch, S. Boyer, D. A. Hanks, J. Carnahan, J. Wang, J. Lunceford, M. Savage, M. J. Marton, S. K. Pruitt, J. W. Juco, K. Emancipator*
- Board 255 **Abstract 4066: Comparison of bimodality versus trimodality therapy for esophageal or gastroesophageal junction (GEJ) cancer: Experience from the Princess Margaret Cancer Centre.** *A. Natori, H. Sim, B. A. Chan, P. Sun, S. Moignard, D. Yokom, C. H. Lim, D. M. Jiang, L. X. Ma, E. X. Chen, G. Liu, J. J. Knox, G. E. Darling, J. C. Yeung, R. Wong, S. Hafezi-Bakhtiari, J. Conner, P. Rogalla, R. W. Jang, E. Elimova*
- Board 256 **Abstract 4067: Phase III study of intraperitoneal/intravenous adjuvant chemotherapy compared intravenous adjuvant chemotherapy in patients with stage III gastric cancer.** *Y. Yang, J. Du, J. Wei, W. Guan, G. Chen, M. Wang, L. Yu, H. Qian, B. Liu*
- Board 257 **Abstract 4068: Frequency of overexpression of HER3 and prognostic consequences in European patients with early gastric cancer.** *N. Martinez Lago, I. Abdulkader Nallib, M. Vieito, J. Carrera, S. Candamio Folgar, Y. Vidal Insua, F. Vazquez Rivera, J. Antunez Lopez, R. López López, M. Padin Iruegas*
- Board 258 **Abstract 4069: Circulating tumor DNA dynamics in resectable gastric cancer.** *A. Leal, N. C. van Grieken, J. Phallen, D. N. Palsgrove, V. Adleff, F. Warmerdam, D. L. Van der Peet, H. M. Verheul, D. Van Spronsen, J. M. Van Riel, M. Geenen, J. E. Portielje, H. W. Van Laarhoven, E. P. Jansen, K. Sikorska, E. Meershoek – Klein Kranenbarg, C. J. Van De Velde, M. Verheij, A. Cats, V. E. Velculescu*
- Board 259 **Abstract 4070: Induction chemoradiotherapy for esophageal cancer: Comparing CROSS regimen with cisplatin/5-FU.** *A. Geller, A. Muniappan, H. Zheng, H. A. Gaissert, C. D. Wright, D. J. Mathisen, M. Lanuti*
- Board 260 **Abstract 4071: Translating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: Prevalence and outcome data** **Translating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: prevalence and outcome data.** *I. Gardeazabal, C. Hierro, C. Viaplana, P. Nuciforo, A. Vivancos, T. M. Mercade, E. Garralda, M. E. Semidey, J. Grau Bejar, R. Dienstmann, S. Landolfi, M. Alsina*

- Board 262 Abstract 4073: Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy reasonable treatment for gastric signet-ring cell adenocarcinoma and linitis plastica with peritoneal metastasis? CYTO-CHIP study—Ancillary results.** *P. Bonnot, G. Piessen, F. Mercier, M. Pocard, B. Meunier, J. Bereder, K. Abboud, F. Marchal, F. Quenet, D. Goere, C. Arvieux, S. Msika, D. Pezet, N. Pirro, R. Wernert, P. RAT, J. Lefevre, T. Courvoisier, M. Rivoire, O. Glehen*
- Board 263 Abstract 4074: Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).** *S. Stein, M. J. Pishvaian, M. S. Lee, K. Lee, S. Hernandez, A. Kwan, B. Liu, W. Grossman, K. Iizuka, B. Ryoo*
- Board 264 Abstract 4075: Anti-programmed death-1 antibody SHR-1210 (S) combined with apatinib (A) for advanced hepatocellular carcinoma (HCC), gastric cancer (GC) or esophagogastric junction (EGJ) cancer refractory to standard therapy: A phase 1 trial.** *J. Xu, Y. Zhang, R. Jia, Y. Wang, R. Liu, G. Zhang, C. Zhao, J. Zou, Q. Wang*
- Board 265 Abstract 4076: A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).** *M. Ikeda, M. W. Sung, M. Kudo, M. Kobayashi, A. D. Baron, R. S. Finn, S. Kaneko, A. X. Zhu, T. Kubota, S. Kraljevic, K. Ishikawa, A. B. Siegel, H. Kumada, T. Okusaka*
- Board 266 Abstract 4077: A multicenter, single arm phase II trial of a small molecule immune-modulator icaritin: Safety, overall survival, immune dynamics, and PD-L1 expression in advanced hepatocellular carcinoma.** *Y. Sun, Q. Li, J. Xu, J. Liang, Y. Cheng, S. Li, L. Zheng, B. Ye, K. Meng, S. Qin*
- Board 267 Abstract 4078: Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma.** *C. Yoo, J. Kang, K. Kim, H. Lim, J. Kim, M. Lee, T. Kim, B. Ryoo*
- Board 268 Abstract 4079: Phase Ib study of binimetinib (MEK162) in combination with capecitabine in gemcitabine-pretreated advanced biliary tract cancer.** *J. Kim, K. Lee, K. Suh, J. Bang, Y. Bang, D. Oh*
- Board 269 Abstract 4080: Phase II trial of sorafenib plus doxorubicin (SD) in patients (Pts) with advanced hepatocellular carcinoma (HCC) after progression of disease (PD) on sorafenib (S).** *I. H. El Dika, M. Capanu, J. F. Chou, J. J. Harding, A. D. Hrabovsky, R. K. Do, J. Shia, J. Germino, E. M. O'Reilly, G. K. Abou-Alfa*
- Board 270 Abstract 4081: A phase II study of ramucirumab for advanced, pre-treated biliary cancers.** *J. Mizrahi, M. M. Javle, L. Xiao, G. R. Varadhachary, K. P. Raghav, R. A. Wolff, R. T. Shroff*
- Board 271 Abstract 4082: Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.** *R. D. Kim, A. S. Pokleповic, A. B. Nixon, D. W. Kim, H. P. Soares, J. Kim, J. Zhou, F. Tariq, N. Burgess, H. K. Sanoff*
- Board 272 Abstract 4083: Phase 1B study of enzalutamide (ENZA) with or without sorafenib (SORA) in patients (pts) with advanced hepatocellular carcinoma (HCC).** *J. J. Harding, R. K. Kelley, B. R. Tan Jr., E. Iobst, C. Boussayoud, K. E. Muenkel, R. K. Do, J. F. Chou, M. Capanu, C. Ruiz, M. Rodriguez Lee, J. Wilton, R. V. Iyer, G. K. Abou-Alfa*
- Board 273 Abstract 4084: Selumetinib (Sel) and cisplatin/gemcitabine (CisGem) for advanced biliary tract cancer (BTC): A randomized trial.** *M. Doherty, V. C. Tam, M. G. McNamara, D. W. Hedley, N. C. Dhani, E. X. Chen, R. W. Jang, P. A. Tang, H. Sim, G. M. O'Kane, S. DeLuca, L. Wang, K. Brooks, J. J. Knox*
- Board 274 Abstract 4085: ADI-PEG 20 and FOLFOX6: A phase 1 study in pts (pts) with advanced hepatocellular carcinoma (HCC).** *J. J. Harding, R. K. Do, E. Hollywood, K. Uhlitskykh, E. Valentino, P. J. Wan, C. R. Hamilton, J. Frick, X. Feng, A. Johnston, J. S. Bomalaski, C. Li, E. M. O'Reilly, G. K. Abou-Alfa*
- Board 275 Abstract 4086: Phase II study of pembrolizumab in advanced, unresectable hepatocellular carcinoma.** *L. G. Feun, Y. Li, M. Wangpaichitr, P. D. Jones, S. P. Richman, B. Madrazo, D. Kwon, P. Martin, P. J. Hosein, N. Savaraj*

Sunday, June 3, 2018

- Board 276 **Abstract 4087: Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker analyses.** *R. K. Kelley, E. Mitchell, S. Behr, J. Hwang, B. Keenan, S. E. Umetsu, J. D. Gordan, A. H. Ko, P. Cinar, C. E. Atreya, K. Van Loon, T. Weber, Z. Ngo, Z. E. Quandt, C. Liu, A. P. Venook, L. Fong*
- Board 277 **Abstract 4088: Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).** *R. K. Kelley, B. Ryoo, P. Merle, J. Park, L. Bolondi, S. L. Chan, H. Lim, A. D. Baron, F. Parnis, J. Knox, S. Cattan, T. C. Yau, J. Loughheed, S. Milwee, A. El-Khoueiry, A. Cheng, T. Meyer, G. K. Abou-Alfa*
- Board 278 **Abstract 4089: Real-time circulating tumor DNA profiling of advanced cholangiocarcinoma (CCA).** *K. Mody, M. J. Borad, T. S. Bekaii-Saab, J. Yang, R. K. Ramanathan, D. H. Ahn, A. Mahipal, A. Roberts, R. J. Nagy, P. M. Kasi*
- Board 279 **Abstract 4090: Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).** *L. Rimassa, I. Cicin, J. Blanc, H. Klumpen, V. Zagonel, A. Tran, S. C. Kim, Z. Lin, V. C. Tam, S. Hazra, M. Mangeshkar, A. El-Khoueiry, A. Cheng, T. Meyer, R. K. Kelley, G. K. Abou-Alfa*
- Board 280 **Abstract 4091: Impact of cholangiocarcinoma (CC) molecular heterogeneity on outcome during first-line chemotherapy and access to targeted therapies in early clinical trials (CT).** *H. Verdaguer, I. Brana, C. Hierro, A. Azaro, E. Elez, E. Garralda, B. Laquente, J. Grau Bejar, F. Ruiz-Pace, C. Viaplana, S. Aguilar, R. Dienstmann, T. M. Mercade*
- Board 281 **Abstract 4092: A bi-institutional phase II study of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (Dex) combined with systemic gemcitabine and oxaliplatin (GemOx) for unresectable intrahepatic cholangiocarcinoma (ICC).** *A. Cercek, N. E. Kemeny, T. Boerner, B. R. Tan Jr., J. F. Chou, M. Gonen, T. M. Boucher, H. Hauser, R. K. Do, M. A. Lowery, P. Kingham, M. I. D'Angelica, J. A. Drebin, P. J. Allen, N. Vachharajani, M. M. Doyle, R. Fields, W. G. Hawkins, W. C. Chapman, W. R. Jarnagin*
- Board 282 **Abstract 4093: Understanding quality of life in hepatocellular carcinoma patients.** *S. Hudgens, R. Copher, L. Floden, G. Meier*
- Board 283 **Abstract 4094: Additional value of tumour growth rate (TGR) in patients (pts) diagnosed with well-differentiated neuroendocrine tumours (NETs) achieving RECIST-defined stable disease (SD): Subgroup analysis of the GREPONET study.** *A. Lamarca, J. Crona, M. Ronot, M. Opalinska, C. Lopez Lopez, D. Pezzutti, L. Carvalho, R. Franca, P. Najran, L. de Mestier, H. Vidal Trueba, N. Schaefer, A. Sundin, F. Costa, M. Pavel, C. Dromain*
- Board 284 **Abstract 4095: Assessing prognosis of neuroendocrine neoplasms: Results of a collaborative multinational effort including over 10,000 European patients—The ENETS registry.** *I. Borbath, D. Bikmukhametov, S. Maasberg, R. Garcia-Carbonero, P. Jiméñez-Fonseca, A. Castañó, A. Kollar, E. Sedlackova, J. Barkmanova, B. Kos-Kudla, D. Handkiewicz-Junak, G. Kaltsas, A. Koumariannou, M. Falconi, K. E. Oberg, B. Wiedenmann, H. Franz, R. Lohmann, U. Pape, C. Verslype*
- Board 285 **Abstract 4096: A phase I/II study of the combination of temozolomide (TM) and pazopanib (PZ) in advanced pancreatic neuroendocrine tumors (PNETs) (NCT01465659).** *M. A. Bhave, S. M. Kircher, A. Kalyan, J. Berlin, M. F. Mulcahy, S. J. Cohen, C. S. Denlinger, E. G. Chiorean, V. Sahai, M. Zalupski, A. Rademaker, A. B. Benson III, H. Nimeiri*
- Board 286 **Abstract 4097: First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Phase 1 results.** *M. L. Johnson, T. Meyer, D. M. Halperin, A. T. Fojo, N. Cook, L. S. Blaszkowsky, B. L. Schlechter, J. C. Yao, Y. Jemai, K. Kriksciukaite, M. Jones, N. Ezema, L. Mei, L. Alland, M. H. Kulke*

- Board 287 Abstract 4098: Comprehensive genomic profiling of 724 gastroenteropancreatic neuroendocrine tumors (GEP-NETs).** *A. Puccini, K. Poorman, M. E. Salem, R. M. Goldberg, A. F. Shields, J. Xiu, W. M. Korn, A. Seeber, M. D. Berger, R. Tokunaga, M. Naseem, F. Battaglin, A. Barzi, S. Iqbal, W. Zhang, S. Soni, J. J. Hwang, P. A. Philip, J. Marshall, H. Lenz*
- Board 288 Abstract 4099: First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.** *J. R. Strosberg, E. M. Wolin, B. A. Chasen, M. H. Kulke, D. L. Bushnell Jr., M. E. Caplin, R. P. Baum, T. J. Hobday, A. E. Hendifar, M. Lopera Sierra, K. E. Oberg, P. B. Ruszniewski, E. Krenning*
- Board 289 Abstract 4100: The role of Ki-67 in determining optimal chemotherapy in high grade neuroendocrine tumors.** *K. Thomas, B. Voros, D. C. Patel, R. Thiagarajan, E. Woltering, R. A. Ramirez*
- Board 290 Abstract 4101: Peptide receptor radionuclide therapy (PRRT) transcriptomic signature in blood for prediction of ¹⁷⁷Lu-octreotate efficacy.** *L. Bodei, M. S. Kidd, A. Singh, W. A. van der Zwan, S. Severi, I. Drozdov, J. B. Cwikla, R. P. Baum, D. J. Kwkkeboom, G. Paganelli, E. Krenning, I. M. Modlin*
- Board 291 Abstract 4102: Clinical outcomes in patients with baseline renal dysfunction in the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.** *J. R. Strosberg, E. M. Wolin, B. A. Chasen, M. H. Kulke, D. L. Bushnell Jr., M. E. Caplin, R. P. Baum, T. J. Hobday, A. E. Hendifar, L. Ravasi, K. E. Oberg, P. B. Ruszniewski, E. Krenning*
- Board 292 Abstract 4103: Optimal cut points for Ki-67 proliferative index in predicting survival in high grade neuroendocrine tumors.** *R. A. Ramirez, B. Voros, K. Thomas, D. C. Patel, R. Thiagarajan, E. Woltering*
- Board 293 Abstract 4104: Pembrolizumab (P) monotherapy in patients with previously treated metastatic high grade neuroendocrine neoplasms (HG-NENs).** *N. Vijayvergia, A. Dasari, E. A. Ross, E. Dotan, D. M. Halperin, I. A. Astsaturov, M. J. Hall, N. M. Ross, D. McClean, C. S. Denlinger, S. J. Cohen, P. F. Engstrom*
- Board 294 Abstract 4105: Multicenter phase 2 study of nintedanib in patients (pts) with advanced progressing carcinoid tumors.** *R. V. Iyer, B. Konda, D. H. Owen, K. Attwood, S. Sarker, S. Suffren, J. Wilton, R. Bies, D. Casucci, D. L. Reidy, M. H. Shah*
- Board 295 Abstract 4106: Clinicopathological, genomic and immunological features of hyperprogressive disease during PD-1 blockade in gastric cancer patients.** *Y. Togashi, T. Kamada, A. Sasaki, Y. Nakamura, S. Fukuoka, Y. Tada, A. Kawazoe, K. Shitara, H. Nishikawa*
- Board 296 Abstract 4107: Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX).** *J. Taieb, Y. Rinaldi, A. Pointet, E. Barbier, F. Khemissa, A. Grate, L. Miglianico, H. Laharie-Mineur, K. Bouhier-Leporrier, F. Ghiringhelli, A. Thiriot Bidault, P. Texereau, R. Coriat, E. Terrebonne, M. Gouttebel, D. Malka, C. Lepage, J. Bachelot*
- Board 297 Abstract 4108: Targeting advanced pancreatic cancer with activated t cells armed with anti-CD3 x anti-EGFR bispecific antibody.** *L. G. Lum, M. Choi, T. M. Le, A. Thakur, A. Deol, K. K. Ballen, L. Volodin, T. L. Kindwall-Keller, Q. Liu, G. Dyson, A. F. Shields*
- Board 298 Abstract 4109: Sequential treatment with Nab-paclitaxel plus Gemcitabine and Folfirinox in metastatic pancreatic adenocarcinoma: GABRINOX phase II results.** *E. Assenat, C. De La Fouchardiere, C. Mollevi, E. Samalin, F. Portales, F. Desseigne, C. Carencio, M. Dupuy, E. Lopez-Martinez, C. Fiess, T. Mazard, M. Ychou*

- Board 299 **Abstract 4110: Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) + nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC).** *T. S. Bekaii-Saab, A. Starodub, B. F. El-Rayes, S. Shahda, B. H. O'Neil, A. M. Noonan, W. L. Shaib, W. T. Hanna, S. Mikhail, A. S. Neki, Y. Chang, X. Dai, W. Li, E. Brooks, C. Oh, L. Borodyansky, C. Li*
- Board 300 **Abstract 4111: A phase 1/2, open-label dose-escalation study of liposomal irinotecan (nal-IRI) plus 5- fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer (mPAC).** *A. P. Dean, Z. A. Wainberg, R. K. Ramanathan, P. M. Boland, K. Mody, B. Zhang, B. Belanger, F. A. de Jong, S. Braun*
- Board 301 **Abstract 4112: A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG Z5041 trial (Alliance).** *A. C. Wei, F. Ou, Q. Shi, E. M. O'Reilly, J. A. Meyerhardt, R. A. Wolff, H. L. Kindler, D. B. Evans, V. Deshpande, J. Misdraji, E. P. Tamm, D. Sahani, M. J. Moore, E. Newman, N. B. Merchant, J. Berlin, L. W. Goff, P. W. Pisters, M. C. Posner*
- Board 303 **Abstract 4114: Comprehensive molecular profiling of paired patient samples of primary and metastatic (met) pancreatic ductal adenocarcinoma (PDAC).** *N. Trivedi, R. Feldman, H. Wang, N. R. Karki, J. Marshall, B. A. Weinberg*
- Board 304 **Abstract 4115: Geographic and ethnic heterogeneity in the BRCA1/2 pre-screening population for the randomized phase III POLO study of olaparib maintenance in metastatic pancreatic cancer (mPC).** *T. Golan, H. L. Kindler, J. Park, M. Reni, T. M. Mercade, P. Hammel, E. Van Cutsem, D. Arnold, D. Hochhauser, G. Y. Locker, M. J. Hall*
- Board 305 **Abstract 4116: Potentially curative combination of TGF- β 1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study.** *J. E. Murphy, J. Y. Wo, D. P. Ryan, W. Jiang, B. Y. Yeap, G. D. Duda, J. N. Allen, L. S. Blaszczkowski, C. Ferrone, A. R. Parikh, R. D. Nipp, A. X. Zhu, L. Goyal, K. D. Lillemoe, T. F. DeLaney, R. K. Jain, J. W. Clark, Y. Boucher, C. Fernandez-del Castillo, T. S. Hong*
- Board 306 **Abstract 4117: Nab-paclitaxel plus S-1 followed by S-1 maintenance therapy as a first-line strategy for advanced pancreatic adenocarcinoma.** *Y. Shi, H. Yan, J. Li, Y. Lv, Q. Han, Z. Wang, G. Dai*
- Board 307 **Abstract 4118: Prospective trial of preoperative FOLFIRINOX in patients with resectable pancreatic ductal adenocarcinoma (PDAC): Report of early endpoints.** *S. Shahda, M. G. House, N. J. Zyromski, A. Sehdev, H. M. Cramer, J. Flynn, F. Akisik, E. P. Ceppa, C. M. Schmidt, A. Nakeeb, J. Lin, S. M. Perkins, H. Burney, B. H. O'Neil*
- Board 308 **Abstract 4119: Overall survival of PEGylated pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).** *J. R. Hecht, A. Naing, G. S. Falchook, M. R. Patel, J. R. Infante, R. Aljumaily, D. J. Wong, K. A. Autio, Z. A. Wainberg, M. M. Javle, J. C. Bendell, S. Pant, A. Hung, P. Van Vlasselaer, J. Leveque, M. Oft, K. P. Papadopoulos*
- Board 309 **Abstract 4120: Prognosis of resectable pancreatic cancer based on systemic therapy sequence and regimen: An NCDB analysis.** *A. Deng, C. Wang, S. J. Cohen, J. M. Winter, A. Basu Mallick*
- Board 310 **Abstract 4121: A phase II trial of neoadjuvant gemcitabine/nab-paclitaxel and SBRT for potentially resectable pancreas cancer: An evaluation of acute toxicity.** *M. Palta, B. G. Czito, E. Duffy, M. Malicki, D. Niedzwiecki, J. L. Abbruzzese, H. E. Uronis, G. C. Blobe, D. G. Blazer III, C. Willett*
- Board 311 **Abstract 4122: Quantitative multiplex immune fluorescence to reveal the impact of chemoradiation therapy on modulation of the immune micro-environment of pancreatic ductal adenocarcinoma.** *T. Enzler, R. D. Gartrell, L. Fazlollahi, H. E. Remotti, T. D. Hart, D. K. Marks, A. Raufi, Y. Lu, S. Perni, P. Kim, C. Monsalve, S. E. Bates, Y. M. Saenger, D. P. Horowitz*

- Board 312 Abstract 4123: Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc).** *M. J. Overman, P. LoRusso, J. H. Strickler, S. P. Patel, S. J. Clarke, A. M. Noonan, T. Prasanna, M. A. Amin, J. J. Nemunaitis, J. Desai, K. J. O'Byrne, T. J. George Jr., J. Englert, D. She, Z. A. Cooper, Y. Wu, A. Khan, R. Kumar, J. C. Bendell*
- Board 313 Abstract 4124: Final results from a phase II study of 5-fluorouracil, oxaliplatin, and dasatinib (FOLFOX-D) in previously untreated metastatic pancreatic adenocarcinoma.** *T. J. George, J. S. Starr, H. D. Parekh, A. M. Ivey, S. P. McGorray, Y. Wang, L. H. Dang, K. C. Daily, C. J. Allegra, D. L. DeRemer, S. J. Hughes, M. A. McEwan, I. Barnes, J. L. Cioffi, J. G. Trevino*
- Board 314 Abstract 4125: Adjuvant treatment for resected sub-centimeter T1 pancreatic cancer.** *W. L. Shaib, A. S. Naranyan, J. M. Switchenko, M. Akce, J. Sarmiento, S. Maithel, D. A. Kooby, P. R. Patel, K. Cardona, O. B. Alese, B. F. El-Rayes*
- Board 315 Abstract 4126: Precision medicine for pancreatic cancer patients: preliminary results from the know your tumor program.** *E. Petricoin, D. C. Halverson, L. Rahib, A. E. Hendifar, S. Mikhail, V. M. Chung, V. J. Picozzi, D. Sohal, L. M. Matrisian, J. R. Brody, S. Madhavan, M. J. Pishvaian*
- Board 316 Abstract 4127: Chemotherapy and radiotherapy application for pancreatic cancer in Europe and USA: An international population-based study.** *L. Huang, L. Jansen, Y. Balavarca, L. van der Geest, V. Lemmens, L. Van Eycken, H. De Schutter, T. B. Johannesen, M. Primic-Zakelj, V. Zadnik, M. Mägi, D. Pulte, P. Schrotz-King, H. Brenner*
- Board 317 Abstract 4128: DNA repair deficiency, genomic instability and immune profiling in a phase 1 study of locally advanced pancreatic cancer patients treated with veliparib, gemcitabine and radiotherapy.** *R. Tuli, N. N. Nissen, S. Lo, M. Bryant, A. Osipov, A. Rogatko, M. Tighiourt, Z. Liu, N. Deng, A. E. Hendifar, S. L. Shiao*
- Board 318 Abstract 4129: High prevalence of hereditary cancer syndromes and outcomes in adults with early-onset pancreatic cancer.** *M. Montiel, S. A. Bannon, J. B. Goldstein, M. E. Mork, P. R. Quesada, W. Dong, L. Feng, E. Borrás, G. A. Maitra, G. R. Varadhachary, M. H. Katz, A. Futreal, D. R. Fogelman, E. Vilar-Sanchez, F. McAllister*
- Board 319 Abstract 4130: Outcome driven persona-typing for precision oncology: Beyond a genomics centered view of individualized therapy.** *E. Petricoin, S. Madhavan*
- Board 320a Abstract TPS4131: An investigator initiated multicenter phase I/II study of paclitaxel, ramucirumab with nivolumab as the second-line treatment in patients with metastatic gastric cancer.** *T. Nishina, S. Hironaka, S. Kadowaki, T. Yamanaka, T. E. Nakajima*
- Board 320b Abstract TPS4132: FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: the RAMIRIS Study.** *S. Lorenzen, P. C. Thuss-Patience, C. Pauligk, E. Goekkurt, T. J. Ettrich, F. Lordick, P. Reichardt, M. Stahl, H. Kopp, S. Hegewisch-Becker, A. Reichart, H. Alguel, D. Bichev, A. Kestler, U. Hacker, N. S. Ziegenhagen, C. Mueller, B. Hermes, S. Al-Batran*
- Board 321a Abstract TPS4133: A randomized phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.** *K. Yamaguchi, Y. Bang, D. Sakai, H. Yasui, Y. Kawaguchi, M. Sugihara, K. Saito, R. Dalal, K. Shitara*
- Board 321b Abstract TPS4134: MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer.** *D. Oh, S. Al-Batran, H. C. Chung, A. Hollebecque, S. Iqbal, K. Kim, J. Lacy, G. A. Manji, E. M. O'Reilly, O. E. Rahma, H. H. Yoon, A. Kwan, X. He, H. Barak, P. Z. Sayyed, X. Zhang, J. Wang, E. Cha, T. S. Bekaii-Saab*

Sunday, June 3, 2018

- Board 322a **Abstract TPS4135: FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in.** *D. V. Catenacci, P. C. Enzinger, A. A. Tesfaye, M. A. Tejani, J. Powers, C. Zhang, N. Marina, C. Eng, E. Cheung, A. J. Scott, P. D. Eisenberg*
- Board 322b **Abstract TPS4136: KEYNOTE-585: Phase 3 study of chemotherapy (chemo) + pembrolizumab (pembro) vs chemo + placebo as neoadjuvant/adjunct treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer.** *Y. Bang, E. Van Cutsem, C. S. Fuchs, A. Ohtsu, J. Tabernero, D. H. Ilson, W. Hyung, V. E. Strong, T. O. Goetze, T. Yoshikawa, L. H. Tang, P. M. Hwang, K. Shitara*
- Board 323a **Abstract TPS4137: NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.** *M. Cecchini, P. LoRusso, Y. Shyr, S. P. Ivy, J. Sklar, K. Dooley, J. Lacy*
- Board 323b **Abstract TPS4138: An intergroup phase III trial of ramucirumab plus irinotecan in third or more line beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial).** *D. Sakai, N. Boku, Y. Koderu, Y. Komatsu, M. Fujii, S. Iwasa, E. Oki, W. Koizumi, M. Gamoh, K. Muro, T. Shimokawa, T. Satoh*
- Board 324a **Abstract TPS4139: Iconic: Peri-operative immuno-chemotherapy in operable oesophageal and gastric cancer.** *S. Mansukhani, M. Davidson, A. Gillbanks, C. Peckitt, A. Musallam, R. Begum, D. Morganstein, A. Wotherspoon, A. M. Riddell, J. M. Kinross, J. Marchesi, K. von Loga, W. H. Allum, S. Rao, D. J. Watkins, I. Chau, D. Cunningham, N. Starling, A. Chaudry, M. Gerlinger*
- Board 324b **Abstract TPS4140: Induction nivolumab or nivolumab/ipilimumab prior to concurrent chemoradiation plus nivolumab in patients with operable stage II/III esophageal/gastroesophageal junction cancer.** *R. J. Kelly, R. K. Hales, R. J. Battafarano, S. C. Yang, E. J. Shin, C. Hu, V. Anagnostou, V. E. Velculescu, J. L. Feliciano, E. Thompson, K. N. Smith, C. Sears, D. M. Pardoll, V. Rowe, H. Rodavia, A. I. Amjad, P. Guerrieri, B. A. Jobe, A. H. Zaidi*
- Board 325a **Abstract TPS4141: IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma.** *R. S. Finn, M. Ducreux, S. Qin, P. Galle, A. X. Zhu, M. Ikeda, T. Kim, D. Xu, W. Verret, J. Liu, W. Grossman, A. Cheng*
- Board 325b **Abstract TPS4142: A multi-center randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first line therapy for patients with advanced unresectable biliary tract cancer.** *V. Sahai, K. A. Griffith, M. S. Beg, M. Zalupski*
- Board 326a **Abstract TPS4143: TREETOPP: A phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs).** *M. M. Javle, D. Oh, M. Ikeda, S. Qin, W. Yong, Y. Chao, N. McIntyre, C. Hsieh, L. Chow, A. Chang, M. McHale, B. Lindmark*
- Board 326b **Abstract TPS4144: A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.** *G. K. Abou-Alfa, S. L. Chan, J. Furuse, P. R. Galle, R. K. Kelley, S. Qin, J. Armstrong, A. Darilay, G. Vlahovic, A. Negro, B. Sangro*
- Board 327a **Abstract TPS4145: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin (LV) or gemcitabine plus cisplatin in advanced cholangiocarcinoma: The AIO-NIFE-trial, an open label, randomized, multicenter phase II trial.** *T. J. Ettrich, A. W. Berger, T. Seufferlein, L. Perkhofer*

- Board 327b Abstract TPS4146: A multicenter pilot study of nivolumab (NIVO) with drug eluting bead transarterial chemoembolization (deb-TACE) in patients (pts) with liver limited hepatocellular carcinoma (HCC).** *J. J. Harding, J. P. Erinjeri, B. R. Tan Jr., K. A. Reiss, K. Mody, D. Khalil, H. Yarmohammadi, G. Nadolski, J. D. Giardina, M. Capanu, R. K. Do, M. Bradley, C. Boussayoud, E. Valentino, T. Merghoub, W. R. Jarnagin, M. C. Soulen, K. T. Brown, G. K. Abou-Alfa*
- Board 328a Abstract TPS4147: Pembrolizumab-based therapy in previously treated high grade extrapulmonary neuroendocrine carcinomas.** *C. Hooker, J. A. Chan, R. R. Aggarwal, P. Cinar, T. Hope, K. Kolli, L. Zhang, S. Calabrese, J. A. Grabowsky, J. Zhang, L. Fong, N. P. Raj, E. K. Bergsland*
- Board 328b Abstract TPS4148: A phase I/II study of fosbretabulin in combination with everolimus in neuroendocrine tumors that have progressed after at least one prior regimen for metastatic disease.** *A. Chauhan, S. Arnold, S. A. Slone, H. Flynn, H. Weiss, L. B. Anthony*
- Board 329b Abstract TPS4150: A phase I/II study of ribociclib plus everolimus in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) refractory to chemotherapy.** *B. A. Weinberg, H. Wang, A. K. Witkiewicz, J. Marshall, E. S. Knudsen, M. J. Pishvaian*
- Board 330a Abstract TPS4151: Eutinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma.** *M. Baretti, J. N. Durham, R. Walker, A. Mitcheltree, B. Christmas, L. Cope, E. M. Jaffee, N. S. Azad*
- Board 330b Abstract TPS4152: Phase 1b study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer.** *K. Perez, D. A. Rubinson, J. M. Cleary, J. A. Meyerhardt, A. K. Patel, T. A. Abrams, O. E. Rahma, S. Raghavan, A. Aguirre, M. N. Needle, K. Das, J. Pitarresi, B. Bakir, A. K. Rustgi, B. M. Wolpin*
- Board 331a Abstract TPS4153: SWOG S1505: A randomized phase II study of perioperative mFOLFIRINOX vs. gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma.** *D. Sohal, S. L. McDonough, S. A. Ahmad, N. Gandhi, M. S. Beg, A. Wang-Gillam, K. Guthrie, A. M. Lowy, P. A. Philip, H. S. Hochster*
- Board 331b Abstract TPS4154: A SU2C catalyst randomized phase II trial of pembrolizumab with or without paricalcitol in patients with stage IV pancreatic cancer who have been placed in best possible response.** *V. M. Chung, E. H. Borazanci, G. S. Jameson, R. Evans, M. Downes, M. L. Truitt, H. Patel, A. M. Lowy, D. Roe, K. Ansaldo, M. T. Barrett, R. L. Korn, L. Caldwell, G. Slethaug, R. Hultsch, H. Han, D. Engelthaler, T. Pearson, E. Lenkiewics, D. D. Von Hoff*
- Board 332a Abstract TPS4155: A phase I/II study of trifluridine/tipiracil (TAS-102) in combination with nanoliposomal irinotecan (NAL-IRI) in advanced GI cancers.** *O. B. Alese, W. L. Shaib, M. Akce, C. Wu, B. F. El-Rayes*
- Board 332b Abstract TPS4156: SM-88 in advanced cancers of the pancreas (SMACP).** *M. S. Noel, A. J. Ocean, G. H. Sokol, S. Hoffman, G. Del Priore*
- Board 333a Abstract TPS4157: A phase II trial of cabozantinib and erlotinib for patients with EGFR and c-MET co-expressing metastatic pancreatic adenocarcinoma.** *O. B. Gbolahan, A. Sehdev, S. Shahda, S. Perkins, M. Korc, P. J. Loehrer Sr., B. H. O'Neil*
- Board 333b Abstract TPS4158: PRIMUS-001: An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation (ISRCTN75002153) – Part of Precision-Panc.** *J. S. Graham, J. W. Valle, T. Evans, D. B. Grose, J. Paul, J. Stobo, S. Cooke, J. Dixon-Hughes, H. Weir, S. Mohan, A. Biankin, D. K. Chang*

8:00 AM - 11:30 AM Poster Session

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Location: Hall A

Abstracts on Boards 114-125 will be discussed during the Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Poster Discussion Session.

Posters by Topic

Adjuvant Therapy: Boards 114-115, 126-132

Local-Regional Non-Small Cell Lung Cancer: Boards 116-119, 133-164

Mesothelioma: Boards 120-122, 166-175

Small Cell Lung Cancer: Boards 123-124, 176-183

Thymic Malignancies: Boards 125, 184-185

Trials in Progress: Boards 186a-190b

- Board 114 Abstract 8508: Final overall survival for CSLC 0501: Phase 3 study of adjuvant versus neoadjuvant chemotherapy with docetaxel combined carboplatin for resectable stage I B-IIIA non-small cell lung cancer.** *X. Yang, W. Zhong, X. Ben, G. Qiao, Q. Wang, C. Wang, H. Luo, Z. Wang, H. Yan, S. Liu, Y. Wu*
- Board 115 Abstract 8509: Comparative efficacy and safety of Pemetrexed or paclitaxel plus thoracic radiation therapy (TRT) in elderly patients with nonsquamous locally advanced NSCLC.** *G. Bai, Y. Bao, R. Mao, C. Zheng, L. Xiao, M. Eli, H. Zhang, H. Zhao*
- Board 116 Abstract 8510: Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial.** *S. Peters, D. De Ruyscher, U. Dafni, E. Felip, M. Guckenberger, J. F. Vansteenkiste, R. M. Huber, E. Nadal-Alforja, A. Irigoyen, A. Becker, A. Piguat, M. Kassapian, A. Gasca-Ruchti, A. Martinez Marti, N. Andratschke, M. Lambrecht, C. Belka, H. Roschitzki-Voser, R. A. Stahel*
- Board 117 Abstract 8511: Long-term survival comparison of stereotactic radiotherapy versus surgery for elderly patients with clinical stage T1-T2 non-small cell lung cancer.** *F. S. Kong, C. He, Y. Zang, S. K. Althouse, L. Tim, K. Kesler*
- Board 118 Abstract 8512: A phase II trial of stereotactic body radiation therapy for operable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group (JCOG0403)—Long term follow-up results.** *Y. Nagata, M. Hiraoka, T. Shibata, H. Onishi, M. Kokubo, K. Karasawa, Y. Shioyama, R. Onimaru, E. Kunieda, S. Ishikura*
- Board 119 Abstract 8513: Effect of radiation dose escalation on outcomes in patients with N2 stage IIIA NSCLC undergoing induction therapy prior to surgical resection.** *G. A. Durm, S. Perkins, S. I. Jalal, F. (. Kong, T. J. Birdas*
- Board 120 Abstract 8514: SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemo-naïve patients with malignant pleural mesothelioma.** *A. S. Tsao, J. Miao, I. I. Wistuba, N. J. Vogelzang, J. Heymach, F. V. Fossella, C. Lu, M. R. Velasco, B. Box-Noriega, J. G. Hueftle, S. M. Gadgeel, M. W. Redman, D. R. Gandara, K. Kelly*
- Board 121 Abstract 8515: Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.** *M. G. Zauderer, P. Szlosarek, S. Le Moulec, S. Popat, P. Taylor, D. Planchard, A. Scherpereel, T. Jahan, M. Koczywas, M. Forster, R. B. Cameron, T. Peikert, C. Campbell, I. Sapir, A. McDonald, C. Oei, A. Clawson, M. Roche, D. A. Fennell*
- Board 122 Abstract 8516: The TCGA malignant pleural mesothelioma (MPM) project: VISTA expression and delineation of a novel clinical-molecular subtype of MPM.** *M. Ladanyi, B. W. Robinson, P. J. Campbell*

- Board 123 Abstract 8517: Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC).** *D. C. Cho, A. Mahipal, A. Dowlati, W. A. Chow, N. H. Segal, K. Y. Chung, B. J. Schneider, J. J. Nemunaitis, A. R. Abdul Razak, F. Y. Tsai, A. S. Balmanoukian, L. Bazhenova, F. Xiao, N. Angra, S. E. Abdullah, J. J. Luke*
- Board 124 Abstract 8518: Safety and antitumor activity of durvalumab monotherapy in patients with pretreated extensive disease small-cell lung cancer (ED-SCLC).** *J. W. Goldman, A. Dowlati, S. J. Antonia, J. J. Nemunaitis, M. O. Butler, N. H. Segal, P. A. Smith, J. Weiss, D. P. Zandberg, F. Xiao, N. Angra, S. E. Abdullah, S. M. Gadgeel*
- Board 125 Abstract 8519: Efficacy of milciclib (PHA-848125AC), a pan-cyclin d-dependent kinase inhibitor, in two phase II studies with thymic carcinoma (TC) and B3 thymoma (B3T) patients.** *B. Besse, M. C. Garassino, A. Rajan, S. Novello, J. Mazieres, G. J. Weiss, D. M. Kocs, J. M. Barnett, C. Davite, P. Crivori, G. Giaccone*
- Board 126 Abstract 8520: The comparison of tumor mutational burden (TMB) in patients of early and late stage lung adenocarcinoma in China.** *K. Zhang, S. Fei, J. Lu, Q. Yang, J. Yang, Y. Zeng, Y. Liu, G. Xiong, X. Jiao, Y. Tao, Z. Yuan, W. Gao, Z. Wei, D. Liu, T. Xu, S. Cai, F. Li, R. Cao, L. Liu*
- Board 127 Abstract 8521: Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG.** *M. Provencio-Pulla, E. Nadal-Alforja, M. Cobo, A. Insa, M. Costa Rivas, M. Majem, D. Rodriguez-Abreu, G. Lopez-Vivanco, M. Domine, E. Del Barco Morillo, B. Massuti, R. G. Campelo, A. Martinez Marti, R. Bernabé, F. Franco, M. Jove, R. Arrabal, P. Martin, J. Casal, V. Calvo*
- Board 128 Abstract 8522: Post-operative radiation therapy (PORT) in resected non-small cell lung cancer (NSCLC): An updated population based analysis.** *S. Shamp, T. Biswas*
- Board 129 Abstract 8523: The population-based impact of adjuvant chemotherapy (CTX) on outcomes in AJCC6 stage IB non-small cell lung cancer (NSCLC).** *R. K. Arora, A. W. Gibson, D. G. Bebb, W. Y. Cheung*
- Board 130 Abstract 8524: Evaluation of different treatment strategies between right-sided and left-sided pneumonectomy for stage I-IIIa non-small cell lung cancer patients.** *Z. Wang, B. Jia, Q. Zheng, Y. Wang, X. Qi*
- Board 131 Abstract 8525: Population-based study predicting the probability of death resulting from non-small cell lung cancer (NSCLC) and other causes among NSCLC patients with surgery.** *B. Jia, Z. Wang, Q. Zheng, Y. Wang, X. Qi*
- Board 132 Abstract 8526: Effects of comprehensive genomic testing in a large non-small cell cancer NSCLC cohort: Racial and survival impacts.** *F. Ardeshir-Larijani, A. Alahmadi, P. Fu, G. Wildey, M. Lipka, A. Dowlati*
- Board 133 Abstract 8527: Definitive local therapy for oligo-recurrence in patients with completely resected non-small cell lung cancer.** *H. Matsuguma, R. Nakahara, I. Wakamatsu, T. Sugiyama, Y. Nakamura, T. Kasai, Y. Kamiyama, N. Hoshi, K. Inoue, S. Katano, K. Yokoi*
- Board 134 Abstract 8528: A deep-learning radiomics model for predicting survival in early-stage non-small cell lung cancer.** *T. L. Chaunzwa, D. C. Christiani, M. Lanuti, A. Shafer, N. Diao, R. H. Mak, H. Aerts*
- Board 136 Abstract 8530: Carboplatin (CBDCA), S-1 and concurrent thoracic radiotherapy (TRT) for elderly patients with locally advanced non-small cell lung cancer (NSCLC): A phase II study.** *S. Niho, S. Umemura, Y. Hosomi, H. Okamoto, K. Nihei, H. Tanaka, T. Hida, K. Goto, T. Akimoto, Y. Ohe*
- Board 137 Abstract 8531: Multimodal treatment in operable stage III non-small cell lung cancer using the new TNM staging classification version 8: Long term results of a pooled analysis of three SAKK trials.** *M. Frueh, D. C. Betticher, R. Stupp, A. Xyrafas, S. Peters, H. Ris, A. Ochsenein, R. A. Schmid, R. A. Stahel, W. Weder, M. Guckenberger, S. Rothschild, D. Lardinois, N. Mach, M. T. Mark, O. Gautschi, S. Thierstein, C. Biaggi Rudolf, M. Pless*

Sunday, June 3, 2018

- Board 138 **Abstract 8532: Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer (NSCLC).** *C. A. Shu, C. Grigg, C. Chiuzan, R. F. Garofano, V. Patel, S. Hernandez, T. Negri, A. G. Sacher, S. Smith-Marrone, M. Stoopler, J. F. Gainor, M. M. Awad, F. D'Ovidio, J. R. Sonett, M. Bacchetta, A. Saqi, N. A. Rizvi*
- Board 139 **Abstract 8533: The effect of prior smoking history on the molecular profile of EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC).** *H. Sorotsky, M. Moskovitz, J. Weiss, M. Pintilie, N. B. Leighl, P. A. Bradbury, G. Liu, A. Kia, M. Cabanero, T. J. Pugh, D. Torti, M. S. Tsao, J. Torchia, F. A. Shepherd*
- Board 140 **Abstract 8534: Comparative evaluation of effectiveness of neoadjuvant chemoimmunotherapy (nPCIT) for non-small cell lung cancer (NSCLC).** *Y. Lazutin, S. P. Pylytsin, I. N. Turkin, L. Y. Vladimirova, T. G. Ayrapetova, A. V. Chubaryan, I. A. Leyman, P. A. Anistratov, O. N. Stateshny, A. S. Shogenov, M. A. Gappoeva, M. Afaunov, S. G. Beleckiy, R. Isaeva*
- Board 141 **Abstract 8535: NanoPac inhalation treatment of NSCLC in a nude rat orthotopic lung cancer model.** *G. Dizerega, W. Johnston, J. Verco, M. J. Balteazor, R. Wolff, P. Kuehl*
- Board 142 **Abstract 8536: Concurrent chemotherapy and radiation versus chemotherapy alone for N3 stage IIIb NSCLC in elderly patients.** *A. Qin, E. Lusk, S. Daignault-Newton, B. J. Schneider*
- Board 143 **Abstract 8537: NORA trial (GCEP 15/02): First efficacy results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (MOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC).** *D. Isla, M. Majem, M. Guirado, B. Massuti, R. De Las Penas, A. Ortega Granados, M. Domine, R. Marse Fabregat, M. Sala Gonzalez, A. Paredes, T. Moran, S. Vazquez Estévez, J. Coves, J. Gonzalez Larriba, M. Sánchez, D. Vicente, N. Farre, L. Fernandez Fornos, F. Valcarcel, M. Provencio-Pulla*
- Board 144 **Abstract 8538: Insurance disparity in cause-specific mortalities: A SEER study on early stage, non-elderly NSCLC cancer survivors.** *C. Jiang, Q. Wang, W. Yang, L. Deng, Z. Xiao, Y. Liu, G. A. Sara*
- Board 145 **Abstract 8539: Progression-free survival (PFS) and cardiac-toxicity-adjusted-PFS (CTA-PFS) as predictors of overall survival (OS) in locally advanced non-small cell lung cancers (LA-NSCLC) treated with concurrent chemoradiation (CCRT): A secondary analysis of NRG Oncology RTOG 0617.** *C. Hu, M. Machtay, J. J. Dignam, R. Paulus, J. D. Bradley*
- Board 146 **Abstract 8540: Routine use of a modest next generation sequencing panel provides additional clinically useful data beyond single gene testing in non-small cell lung cancer and is fit for purpose as a clinical assay: Collated data from a single molecular diagnostic laboratory.** *D. A. Moore, K. Balbi, H. Arkenau, P. Bennett*
- Board 147 **Abstract 8541: Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3).** *V. W. Rusch, J. E. Chaft, B. Johnson, I. I. Wistuba, M. G. Kris, J. M. Lee, P. A. Bunn Jr., D. J. Kwiatkowski, K. L. Reckamp, D. J. Finley, E. B. Haura, S. N. Waqar, R. C. Doebele, E. B. Garon, J. Blasberg, A. Nicholas, K. Schulze, S. Phan, M. Gandhi, D. P. Carbone*
- Board 148 **Abstract 8542: Association between certain NSCLC driver mutations and sensitivity markers for chemotherapy or PD-(L)1 inhibition: A large-sample analysis.** *W. Liang, Y. Zhao, H. Liang, H. Yang, Z. Wang, W. Chen, C. Xu, X. Yang, J. He*
- Board 149 **Abstract 8543: Association between hospital volume, treatment patterns, and overall survival (OS) of patients with stage 3A non-small cell lung cancer (NSCLC).** *S. Tella, A. Kommalapati, A. Ganti*
- Board 150 **Abstract 8544: The ASCENT trial: A phase II study of neoadjuvant afatinib, chemoradiation and surgery for stage III EGFR mutation-positive NSCLC.** *L. V. Sequist, H. Willers, M. Lanuti, A. Muzikansky, A. B. Chen, P. A. Janne, N. C. Choi, M. Mino-Kenudson, S. Swanson, C. D. Wright, Z. Piotrowska, G. R. Oxnard, R. H. Mak*

- Board 151 Abstract 8545: Using deep-learning radiomics to predict lung cancer histology.** *T. L. Chaunzwa, D. C. Christiani, M. Lanuti, A. Shafer, N. Diao, R. H. Mak, H. Aerts*
- Board 153 Abstract 8547: Clinical relevance of intratumoural immune cell composition in non-small cell lung cancer.** *X. Li, J. Zhang, J. Su, J. Yang, W. Zhong, X. Zhang, Y. Wu, J. Hou*
- Board 154 Abstract 8548: Evaluating PD-L1 status and its correlation with clinical features in surgically resected lung adenocarcinoma patients: Comparison of tissue microarrays and whole tissue section.** *H. Huang, Y. Yeh, T. Chou, Y. Wu, C. Chiang, C. Shen, C. Chiu*
- Board 155 Abstract 8549: Impact of somatic mutations on recurrence free survival (RFS) and overall survival (OS) for resected non-small cell lung cancer (NSCLC): results from the Japan Molecular Epidemiology for lung cancer study (JME).** *A. Tamiya, Y. Koh, A. Kubo, M. Ando, S. Isa, H. Saka, N. Yoshimoto, M. Serizawa, S. Takeo, H. Adachi, T. Tagawa, O. Kawashima, M. Yamashita, K. Kataoka, Y. Ichinose, Y. Takeuchi, K. Watanabe, A. Matsumura, T. Kawaguchi*
- Board 156 Abstract 8550: Circulating tumor DNA (ctDNA) as a marker of minimal residual disease (MRD) in localized non-small cell lung carcinoma (NSCLC).** *N. I. Simon, A. A. Davis, N. A. Mohindra, V. M. Villafior, Y. Chae*
- Board 157 Abstract 8551: Microwave ablation plus recombinant human endostatin (endostar) versus microwave ablation alone in inoperable stage I non small cell lung cancer.** *M. Meng, G. Huang, X. Ye, X. Yang, W. Li, X. Han, J. Wang, Z. Wei, Y. Ni*
- Board 158 Abstract 8552: Long-term results of a phase I/II trial of nelfinavir with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.** *R. Rengan, R. Mick, D. Pryma, L. L. Lin, J. P. Christodouleas, J. P. Plastaras, C. B. Simone II, A. K. Gupta, T. L. Evans, J. Stevenson, C. J. Langer, J. Kucharczuk, J. S. Friedberg, S. Lam, D. Patsch, S. M. Hahn, A. Maity*
- Board 159 Abstract 8553: Significance of aromatase-estrogen receptor axis in EGFR status of lung adenocarcinoma.** *K. Tanaka, S. Rokudai, K. Shimizu, S. Nakazawa, K. Obayashi, K. Kaira, T. Oyama, K. Shirabe, A. Mogi, M. Nishiyama, H. Kuwano*
- Board 160 Abstract 8554: Long-term outcomes after sublobar resection for clinical stage IA lung adenocarcinoma meeting node-negative criteria defined by HRCT and FDG-PET/CT.** *Y. Tsutani, H. Nakayama, T. Tasaki, H. Hanaki, H. Ito, Y. Miyata, M. Okada*
- Board 161 Abstract 8555: A phase I study of neoadjuvant cisplatin (C), docetaxel (D) and nintedanib (N) for resectable non-small cell lung cancer (NSCLC).** *T. Cascone, B. Sepesi, H. Y. Lin, N. Kalhor, J. Zhang, F. V. Fossella, A. S. Tsao, V. K. Lam, C. Lu, F. Mott, G. R. Simon, M. Antonoff, R. J. Mehran, D. C. Rice, A. A. Vaporciyan, M. Godoy, J. Lee, S. Swisher, W. N. William Jr., J. Heymach*
- Board 162 Abstract 8556: A comparative safety analysis for durvalumab in patients with locally advanced, unresectable NSCLC: PACIFIC versus pooled durvalumab monotherapy studies.** *S. J. Antonia, M. D. Hellmann, P. A. Dennis, G. Melillo, S. E. Abdullah, A. Lloyd, N. A. Rizvi*
- Board 163 Abstract 8557: Geriatric assessment to predict toxicity in elderly patients with unresectable locally advanced non-small-cell lung cancer treated with concurrent chemoradiotherapy.** *E. Nadal, J. C. Ruffinelli, R. Palmero, A. Navarro, M. Plana, C. Mesia Barroso, M. Arnaiz, I. Brao, M. Arellano, S. Padrones, J. Borràs, F. Cardenal, J. Saldana, M. Rebollo*
- Board 164 Abstract 8558: Long-term survival after salvage SBRT for recurrent or secondary non-small cell lung cancer after prior surgery or radiation therapy.** *C. He, Y. Liu, A. Cerra-Franco, K. Shiue, R. Liu, M. P. Langer, K. M. Rieger, D. Ceppas, T. J. Birdas, K. Kesler, R. C. Zellars, L. Tim, F. S. Kong*
- Board 166 Abstract 8560: Long-term survival following trimodality therapy vs. medical management of malignant pleural mesothelioma.** *F. Larose, Y. Lacasse, S. Martel, L. Lang-Lazdunski*

Sunday, June 3, 2018

- Board 167 **Abstract 8561: Uncommon ALK fusion partners in advanced ALK-positive non-small-cell lung cancer.** *J. Kang, X. Zhang, H. Chen, Q. Zhou, H. Tu, W. Li, Y. Wu, J. Yang*
- Board 168 **Abstract 8562: PBRM1 genomic alterations in mesothelioma: Potential predictor of immunotherapy efficacy.** *J. S. Ross, L. M. Gay, E. Sokol, J. A. Elvin, J. Vergilio, J. Suh, S. H. Ramkissoon, S. Daniel, E. A. Severson, J. K. Killian, S. M. Ali, A. B. Schrock, J. Chung, G. M. Frampton, L. A. Albacker, R. J. Corona, M. D. Mix, A. Shapiro, G. Bratslavsky, V. A. Miller*
- Board 169 **Abstract 8563: Phase 1b study of avelumab in advanced previously treated mesothelioma: long-term follow-up from JAVELIN Solid Tumor.** *R. Hassan, A. Thomas, J. J. Nemunaitis, M. R. Patel, J. Bennouna, F. Chen, J. Delord, A. Dowlati, S. T. Kochuparambil, M. H. Taylor, J. D. Powderly II, U. N. Vaishampayan, C. F. Verschraegen, H. J. Grote, A. von Heydebreck, K. M. Chin, J. L. Gulley*
- Board 170 **Abstract 8564: Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma.** *V. Panou, M. Gadiraju, A. Wolin, C. M. Weipert, E. Skarda, A. N. Husain, J. D. Patel, B. Rose, V. Nelakuditi, A. K. Johnson, M. Helgeson, D. Fischer, N. Sulai, K. Turaga, D. Huo, J. Segal, S. Kadri, Z. Li, H. L. Kindler, J. E. Churpek*
- Board 171 **Abstract 8565: Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM).** *A. Desai, T. Karrison, B. Rose, E. Pemberton, B. Hill, C. M. Straus, Y. C. Tan, T. Y. Seiwert, H. L. Kindler*
- Board 172 **Abstract 8566: Tumor burden (TB) and treatment exposure (TE) in patients (pts) with malignant pleural mesothelioma (MPM) receiving nintedanib (N)/placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in phase II of the LUME-Meso study.** *S. Popat, F. Grosso, N. Steele, A. K. Nowak, S. Novello, L. Greillier, M. Reck, T. John, P. Taylor, N. B. Leighl, G. L. Ceresoli, J. B. Sørensen, N. Pavlakis, D. Planchard, B. G. Hughes, J. Mazieres, M. A. Socinski, H. Buchner, J. Barrueco, G. V. Scagliotti*
- Board 173 **Abstract 8567: Long-term survival outcomes of a placebo-controlled phase 3 trial with NGR-hTNF in combination with best investigator choice in relapsed malignant pleural mesothelioma (MPM).** *V. Gregorc, C. Lazzari, A. Bulotta, M. Viganò, D. Ghio, F. Fontana, G. Salini, A. Lambiase*
- Board 174 **Abstract 8568: Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM).** *N. Pavlakis, F. Grosso, N. L. Steele, A. K. Nowak, S. Popat, L. Greillier, M. Reck, T. John, P. Taylor, N. B. Leighl, G. L. Ceresoli, J. B. Sørensen, D. Planchard, B. G. Hughes, J. Mazieres, M. A. Socinski, U. von Wangenheim, J. Barrueco, G. V. Scagliotti*
- Board 175 **Abstract 8569: A real-world experience of nivolumab in advanced malignant mesothelioma (MM).** *H. Hamad, S. Shāfi, V. Lenge De Rosen, J. Zhang*
- Board 176 **Abstract 8570: Efficacy and safety of lurbinectedin (PM1183) in small cell lung cancer (SCLC): Results from a phase 2 study.** *J. Trigo Perez, A. Leary, B. Besse, D. E. Castellano, S. Ponce Aix, J. ARRONDEAU, V. Moreno, B. Doger, R. Lopez, A. Awada, C. Jungels, M. D. Forster, V. Boni, P. Lardelli, M. Siguero, C. M. Kahatt, A. Soto-Matos, R. S. Kristeleit*
- Board 177 **Abstract 8571: Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC).** *A. F. Farago, B. J. Drapkin, A. Charles, B. Y. Yeap, R. S. Heist, C. G. Azzoli, D. M. Jackman, J. Marcoux II, D. A. Barbie, D. T. Myers, S. Phat, J. Zhong, J. B. Grinnell, L. V. Sequist, M. Mino-Kenudson, S. Maheswaran, D. A. Haber, A. N. Hata, N. J. Dyson, A. T. Shaw*
- Board 178 **Abstract 8572: Large-scale nationwide genomic screening system for small cell lung cancer in Japan (LC-SCRUM-Japan).** *Y. Ogawa, S. Umemura, H. Murakami, M. Shingoji, N. Kobayashi, T. Shimokawaji, H. Daga, T. Seto, N. Okamoto, H. Aono, Y. Fujiwara, S. Hara, N. Kanaji, S. Matsumoto, H. Udagawa, K. Yoh, K. Goto*

- Board 179 Abstract 8573: Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC).** *N. Marcoux, S. N. Gettinger, G. M. O’Kane, K. C. Arbour, J. W. Neal, H. Husain, T. L. Evans, J. R. Brahmer, A. Muzikansky, P. Bonomi, S. A. Del Prete, A. Wurtz, A. F. Farago, D. Dias-Santagata, M. Mino-Kenudson, H. A. Yu, H. A. Wakelee, F. A. Shepherd, Z. Piotrowska, L. V. Sequist*
- Board 180 Abstract 8574: Identifying treatment options for SCLC patients with multiplexed clinical proteomic testing.** *E. An, S. Hong, H. An, S. P. Thyparambil, S. SELLAPPAN, D. Yan, Y. Tian, F. Cecchi, T. A. Hembrough, T. Kim*
- Board 181 Abstract 8575: A phase II study of pembrolizumab and paclitaxel in refractory extensive disease small cell lung cancer.** *Y. Kim, B. Keam, C. Ock, S. Song, M. Kim, S. Kim, K. Kim, J. Kim, T. Kim, D. Kim, J. Lee, D. Heo*
- Board 182 Abstract 8576: Genomic evolutions in the progression from lung preneoplasia to adenocarcinoma.** *X. Hu, J. Fujimoto, R. Chen, C. Chow, W. Sun, X. Song, X. Mao, P. Scheet, H. Kadara, C. Behrens, C. Wu, J. Lee, M. Antonoff, A. A. Vaporciyan, S. Swisher, J. Zhang, J. Heymach, I. I. Wistuba, A. Futreal*
- Board 183 Abstract 8577: Early assessment of therapy response in small cell lung cancer via longitudinal ctDNA analysis.** *J. F. Palma, C. Woestmann, S. McNamara, B. Hinzmann, S. Fröhler, H. Adams, M. Feldkamp, S. Siemann, M. Lange, A. Blüher, S. Yaung, L. Xi, N. Tikoo, A. Balasubramanyam, C. Ju, A. Pati, B. Wehn, T. Muley, X. M. Ma, F. Herth*
- Board 184 Abstract 8578: Association of the high expressions of SOX2 and IGF-1R signaling molecules in thymic epithelial tumors with shorter overall survival.** *G. Lee, J. Kang, I. Woo, H. An, H. Lee*
- Board 185 Abstract 8579: A phase II study of regorafenib in patients with thymic epithelial tumours previously treated with chemotherapy.** *M. Perrino, S. Bozzarelli, P. A. Zucali, T. M. De Pas, M. Simonelli, F. De Vincenzo, F. Conforti, P. Persico, C. Miggiano, N. Cordua, A. Cioffi, S. Sala, F. Mrakic Sposta, L. Giordano, A. Santoro*
- Board 186a Abstract TPS8580: Phase II randomized clinical trial comparing immunotherapy plus stereotactic ablative radiotherapy (I-SABR) versus SABR alone for stage I, selected stage IIa or isolated lung parenchymal recurrent non-small cell lung cancer: I-SABR.** *J. Y. Chang, L. Feng, S. H. Lin, J. W. Welsh, M. Antonoff, D. R. Gomez, J. Heymach*
- Board 186b Abstract TPS8581: EA5142 adjuvant nivolumab in resected lung cancers (ANVIL).** *J. E. Chait, S. E. Dahlberg, O. V. Khullar, M. J. Edelman, C. B. Simone II, J. Heymach, C. M. Rudin, S. S. Ramalingam*
- Board 187a Abstract TPS8582: Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.** *N. R. Evans, S. Cowan, C. Solomides, D. C. Hooper, L. Harshyne, G. L. Lu-Yao, H. Yang, L. Phan, D. Poller, B. Leiby, M. Werner-Wasik, B. Lu, J. M. Johnson, R. S. Axelrod, A. Argiris, R. Zinner*
- Board 187b Abstract TPS8583: Randomized, double-blind phase 3 study evaluating neoadjuvant platinum-based chemotherapy with perioperative pembrolizumab or placebo in resectable stage IIB or IIIA NSCLC: KEYNOTE-671.** *N. No Lastname, J. Yang, G. L. Ferraro, S. M. Keller*
- Board 188a Abstract TPS8584: SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.** *S. Rothschild, A. Zippelius, S. Savic, M. Gonzalez, W. Weder, A. Xyrafas, C. Rusterholz, M. Pless*
- Board 188b Abstract TPS8585: Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC.** *H. J. Ross, D. E. Kozono, J. J. Urbanic, T. M. Williams, C. Dufrane, I. Bara, M. Gandhi, K. Schulze, J. M. Brockman, X. F. Wang, E. E. Vokes, T. Stinchcombe*

Sunday, June 3, 2018

- Board 189a **Abstract TPS8586: CONFIRM: A phase III randomized trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma.** *D. A. Fennell, E. V. Kirkpatrick, K. Cozens, S. Danson, G. G. Hanna, J. F. Lester, J. Lord, M. Nye, E. H. Ottensmeier, P. W. Szlosarek, N. L. Steele, D. T. Barnes, K. D. Vadher, T. Maishman, S. J. Hill, G. Griffiths*
- Board 189b **Abstract TPS8587: ATLANTIS: Global, randomized phase III study of lurbinectedin (L) with doxorubicin (DOX) vs. CAV or topotecan (T) in small-cell lung cancer after platinum therapy.** *A. F. Farago, L. G. Paz-Ares, T. Ciuleanu, A. Fülöp, A. Navarro, L. Bonanno, J. A. Lopez-Vilariño, R. Nuñez, C. M. Kahatt, G. Kos, A. Soto-Matos*
- Board 190a **Abstract TPS8588: A two-part, open-label, randomized, phase 2/3 study of dinutuximab and irinotecan versus irinotecan for second-line treatment of subjects with relapsed or refractory small cell lung cancer.** *M. J. Edelman, O. Juan, A. Navarro, G. Golden, E. Borg, A. V. Saunders*
- Board 190b **Abstract TPS8589: Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and ¹⁷⁷Lu-DOTA⁰-Tyr³-Octreotate for patients with extensive-stage small cell lung cancer.** *C. Kim, D. S. Subramaniam, S. V. Liu, G. Giaccone*

8:00 AM - 11:30 AM Poster Session

Lung Cancer—Non-Small Cell Metastatic

Location: Hall A

Abstracts on Boards 335-346 will be discussed during the Lung Cancer—Non-Small Cell Metastatic Poster Discussion Session.

Posters by Topic

Metastatic Non-Small Cell Lung Cancer: Boards 335-426

Trials in Progress: Boards 427a-433b

- Board 335 **Abstract 9012: Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A randomized phase 2 study (GOAL, Spanish Lung Cancer Group).** *R. G. Campelo, O. Arrieta Rodriguez, B. Massuti, D. Rodriguez-Abreu, A. Ortega Granados, M. Majem, D. Vicente, P. Lianes, J. Bosch-Barrera, A. Insa, M. Domine, N. Reguart, M. Guirado, M. Sala, S. Vazquez-Estevez, R. Bernabe Caro, A. Drozdowskyj, A. Verdu, N. Karachaliou, R. Rosell*
- Board 336 **Abstract 9013: Combination of metformin plus TKI vs. TKI alone in EGFR(+) LUNG adenocarcinoma: A randomized phase II study.** *O. Arrieta Rodriguez, F. B. Barron, M. Salinas Padilla, L. A. Ramirez-Tirado, D. Flores-Estrada, G. Cruz-Rico, M. Arguelles Jiménez, A. Cardona Zorrilla*
- Board 337 **Abstract 9014: A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor (TKI) naïve patients with advanced NSCLC.** *A. E. Lisberg, A. L. Cummings, J. W. Goldman, K. Bornazyan, N. D. Reese, T. Wang, P. Coluzzi, B. A. Ledezma, M. A. Mendenhall, B. Jones, J. Madrigal, J. M. Carroll, J. Gukasyan, T. Williams, L. Sauer, C. L. Wells, A. R. Hardy, P. J. Linares, C. R. Adame, E. B. Garon*
- Board 338 **Abstract 9015: First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non-small cell lung cancer (NSCLC).** *R. C. Doebele, G. J. Riely, A. I. Spira, L. Horn, Z. Piotrowska, D. B. Costa, J. W. Neal, S. Zhang, W. Reichmann, D. Kerstein, S. Li, P. A. Janne*
- Board 339 **Abstract 9016: Tepotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14-skipping mutations: Phase II trial.** *E. Felip, L. Horn, J. D. Patel, H. Sakai, J. Scheele, R. Bruns, P. K. Paik*

- Board 340 Abstract 9017: Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF- β and PD-L1.** *L. G. Paz-Ares, T. Kim, D. Vicente Baz, E. Felip, D. Lee, K. Lee, C. Lin, M. A. Di Nicola, R. M. Alvarez Alvarez, I. Dussault, C. Helwig, L. Ojalvo, J. L. Gulley, B. Cho*
- Board 341 Abstract 9018: Responses and durability in NSCLC treated with pegilodecakin and anti-PD-1.** *E. B. Garon, J. G. Schneider, D. J. Wong, R. Aljumaily, W. M. Korn, J. R. Infante, M. R. Patel, K. A. Autio, K. P. Papadopoulos, A. Naing, N. Y. Gabrail, P. N. Munster, J. W. Goldman, A. Hung, P. Van Vlasselaer, J. Leveque, M. Oft, D. R. Spigel*
- Board 342 Abstract 9019: First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP.** *V. Papadimitrakopoulou, M. W. Redman, D. R. Gandara, F. R. Hirsch, P. C. Mack, C. J. Langer, M. J. Edelman, C. Aggarwal, M. A. Socinski, S. N. Gettinger, S. N. Waqar, K. Griffin, N. B. Leighl, T. K. Owonikoko, J. D. Bradley, S. S. Ramalingam, T. Stinchcombe, C. D. Blanke, K. Kelly, R. S. Herbst*
- Board 343 Abstract 9020: Nivolumab (Nivo) + ipilimumab (Ipi) vs platinum-doublet chemotherapy (Chemo) as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC): Safety analysis and patient-reported outcomes (PROs) from CheckMate 227.** *M. Reck, M. D. Hellmann, L. G. Paz-Ares, S. S. Ramalingam, J. R. Brahmer, K. J. O'Byrne, P. Bhagavatheeswaran, F. E. Nathan, H. Borghaei*
- Board 344 Abstract 9021: Health-related quality of life (HRQoL) in the KEYNOTE-189 study of pembrolizumab (pembro) or placebo (pbo) + pemetrexed (pem) + platinum (pl) for metastatic NSCLC.** *M. C. Garassino, D. Rodriguez-Abreu, S. M. Gadgeel, E. E. González, E. Felip, F. De Angelis, M. Domine, M. J. Hochmair, S. F. Powell, S. Y. Cheng, H. Bischoff, N. Peled, M. Reck, R. Hui, E. B. Garon, M. J. Boyer, J. Yang, T. A. Burke, M. Pietanza, L. Gandhi*
- Board 345 Abstract 9022: Clinical and molecular features predicting long-term response (LTR) to anti-PD-(L)1 based therapy in patients with NSCLC.** *H. Rizvi, A. J. Plodkowski, M. Tenet, D. Halpenny, N. Long, J. L. Sauter, F. Sanchez-Vega, W. K. Chatila, N. Schultz, M. Ladanyi, K. C. Arbour, J. E. Chaft, M. D. Hellmann*
- Board 346 Abstract 9023: Randomized phase II study of pembrolizumab after stereotactic body radiotherapy (SBRT) versus pembrolizumab alone in patients with advanced non-small cell lung cancer: The PEMBRO-RT study.** *W. Theelen, H. Peulen, F. Lalezari, J. de Vries, J. De Langen, J. Aerts, K. Monkhorst, P. Baas*
- Board 347 Abstract 9024: Quality of life analysis of Pemetrexed versus Erlotinib maintenance in EGFR mutation negative advanced non small cell lung cancer.** *V. Agarwala, V. M. Patil, V. Noronha, A. Joshi, A. Chougale, V. Trivedi, R. Kumar, S. More, S. Goud, A. Janu, A. Mahajan, K. Prabhsh*
- Board 348 Abstract 9025: A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.** *J. W. Goldman, J. Mazieres, F. Barlesi, M. Koczywas, K. H. Dragnev, T. Göksel, A. B. Cortot, N. Girard, C. Wesseler, H. Bischoff, E. Nadal, K. Park, S. Lu, A. Taus, M. Cobo, K. Hurt, A. Chiang, A. Hossain, W. J. John, L. G. Paz-Ares*
- Board 349 Abstract 9026: 24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC.** *R. D. Gentzler, C. J. Langer, H. Borghaei, S. M. Gadgeel, V. Papadimitrakopoulou, A. Patnaik, S. F. Powell, R. G. Martins, J. Stevenson, S. I. Jalal, A. W. Panwalkar, J. C. Yang, M. A. Gubens, L. V. Sequist, M. M. Awad, J. Fiore, S. Saraf, S. M. Keller, L. Gandhi*
- Board 350 Abstract 9027: Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial.** *F. A. Shepherd, V. Papadimitrakopoulou, T. Mok, Y. Wu, J. Han, M. Ahn, S. S. Ramalingam, T. John, M. Sebastian, W. Theelen, G. Laus, B. Collins, A. Markovets, K. S. Thress, G. R. Oxnard*

Sunday, June 3, 2018

- Board 351 **Abstract 9028: Association of STK11/LKB1 mutations with primary resistance to PD-1/PD-L1 axis blockade in PD-L1 positive non-squamous NSCLC.**
F. Skoulidis, B. W. Carter, J. Zhang, I. I. Wistuba, V. Papadimitrakopoulou, J. Heymach
- Board 352 **Abstract 9029: Meta-analysis exploring the effect of oncogenic driver mutations on outcome of metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICI) or docetaxel (doc).**
A. Agyeman, J. J. Vallejo, A. Myers, G. M. Blumenthal
- Board 353 **Abstract 9030: 4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.**
E. Felip, M. D. Hellmann, R. Hui, E. Carcereny, N. B. Leighl, M. Ahn, J. P. Eder, A. S. Balmanoukian, C. Aggarwal, L. Horn, A. Patnaik, M. A. Gubens, S. S. Ramalingam, E. Jensen, D. A. Kush, E. B. Garon
- Board 354 **Abstract 9031: Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model.**
N. A. Pennell, A. Mutebi, Z. Zhou, M. Ricculli, W. Tang, H. Wang, A. Guerin, T. Arnhart, K. W. Culver, G. A. Otterson
- Board 355 **Abstract 9032: Lorlatinib in patients (Pts) with previously treated ALK⁺ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety.**
B. Besse, B. J. Solomon, E. Felip, T. M. Bauer, S. I. Ou, R. A. Soo, R. Chiari, S. M. Gadgeel, G. J. Riely, E. Tan, H. Hayashi, J. Mazieres, H. C. Thurm, J. Martini, A. Abbattista, G. Peltz, J. S. Clancy, A. T. Shaw
- Board 356 **Abstract 9033: YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results.**
B. Cho, J. Han, S. Kim, K. Lee, D. Kim, Y. Lee, G. Lee, J. Lee, E. Cho, J. Kim, S. Lee, Y. Min, S. W. Shin, H. Kim, M. Hong, J. Ahn, S. Choi, M. Ahn
- Board 357 **Abstract 9034: RET-rearranged lung cancers: Immunophenotype and response to immunotherapy.**
J. K. Sabari, M. D. Offin, S. L. Wu, A. Ni, D. Halpenny, J. Montecalvo, D. Liu, T. K. Pak, K. C. Arbour, W. V. Lai, M. D. Hellmann, G. J. Riely, M. G. Kris, C. M. Rudin, N. Rekhtman, B. T. Li, J. D. Land, A. E. Drilon
- Board 358 **Abstract 9035: Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer.**
V. Subbiah, T. Cascone, K. R. Hess, I. M. Subbiah, S. Nelson, N. Morikawa, M. B. Nilsson, T. Bhatt, S. Ali, W. N. William Jr., V. M. Raymond, R. B. Lanman, D. P. Carbone, R. Salgia, T. K. Owonikoko, G. R. Simon, F. Meric-Bernstam, R. C. Doebele, J. Heymach
- Board 359 **Abstract 9036: Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy.**
L. Gandhi, P. A. Janne, M. Opyrchal, S. S. Ramalingam, I. I. Rybkin, N. Hafez, L. E. Raez, D. Gabrilovich, F. Wang, P. Ordentlich, S. Brouwer, S. Sankoh, E. V. Schmidt, M. L. Meyers, M. D. Hellmann
- Board 360 **Abstract 9037: Comparison of outcomes with PD-L1 tumor proportion score (TPS) of 50-74% vs 75-100% in patients with non-small cell lung cancer (NSCLC) treated with first-line PD-1 inhibitors.**
E. Jimenez Aguilar, H. Rizvi, S. Kravets, C. A. Lydon, A. E. Adeni, S. Subegdjo, M. D. Hellmann, M. M. Awad
- Board 361 **Abstract 9038: Gemcitabine-cisplatin (GC) + necitumumab (N) versus GC as first-line treatment for stage IV squamous cell lung cancer (SqCLC): An open-label randomized multicenter phase Ib-II trial in Japan.**
H. Yoshioka, S. Watanabe, H. Sakai, K. Hotta, M. Takenoyama, K. Yamada, S. Sugawara, Y. Takiguchi, Y. Hosomi, K. Tomii, S. Niho, N. Yamamoto, M. Nishio, Y. Ohe, A. Kamada, K. Suzukawa, Y. Omori, S. Enatsu, K. Nakagawa, T. Tamura
- Board 363 **Abstract 9040: Characterization of 1,233 NSCLCs with non-del19/L858R EGFR mutations (EGFR^m) using comprehensive genomic profiling (CGP).**
S. I. Ou, S. M. Ali, J. Bogart, S. L. Graziano, M. D. Mix, J. S. Ross, V. A. Miller, A. B. Schrock

- Board 364 Abstract 9041: Safety and activity of durvalumab + tremelimumab in immunotherapy (IMT)-pretreated advanced NSCLC patients.** *E. B. Garon, A. I. Spira, S. B. Goldberg, J. E. Chaft, V. Papadimitrakopoulou, S. J. Antonia, J. R. Brahmer, D. R. Camidge, J. D. Powderly II, A. J. Wozniak, E. Felip, G. Gao, J. M. Englert, M. M. Awad*
- Board 365 Abstract 9042: Tumor mutation burden and efficacy of targeted therapy in patients with *EGFR* mutant lung cancers.** *M. D. Offin, H. Rizvi, M. Tenet, A. Ni, F. Sanchez Vega, M. G. Kris, C. M. Rudin, G. J. Riely, H. A. Yu, M. D. Hellmann*
- Board 366 Abstract 9043: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC.** *D. R. Camidge, S. Peters, T. Mok, S. M. Gadgeel, P. K. Cheema, N. Pavlakis, F. De Marinis, D. L. Stroyakovskiy, B. Cho, L. Zhang, D. Moro-Sibilot, A. H. Zeaiter, E. Mitry, B. Balas, B. Müller, A. Shaw*
- Board 367 Abstract 9044: Exome analysis to reveal genomic markers associated with better efficacy of nivolumab in lung cancer patients.** *C. Richard, J. Fumet, S. Chevrier, V. Derangere, F. Ledys, A. Lagrange, L. Favier, B. P. Coudert, L. Arnould, C. Truntzer, R. Boidot, F. Ghiringhelli*
- Board 368 Abstract 9045: BRAF-mutant non-small cell lung cancer (NSCLC): Patient (pt) characteristics and outcomes by class of mutation.** *I. Dagogo-Jack, P. Martinez, B. Y. Yeap, C. Ambrogio, C. A. Lydon, T. Nguyen, A. Iafrate, J. K. Lennerz, B. E. Johnson, A. T. Shaw, M. M. Awad*
- Board 369 Abstract 9046: Phase I/II study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).** *A. N. Saltos, T. Tanvetyanon, C. C. Williams, E. B. Haura, B. C. Creelan, S. J. Antonia, N. Tchekmedyan, K. Goas, T. Mamplata, R. Thapa, D. Chen, A. A. Beg, J. E. Gray*
- Board 370 Abstract 9047: Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC).** *M. Reck, T. Karagiannis, T. Wehler, M. Shtivelband, J. Gonzalez-Larriba, J. Rothenstein, M. Frueh, Y. Deng, A. Lopez-Chavez, A. Sandler, M. A. Socinski*
- Board 371 Abstract 9048: Detection and clearance of *RET* variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292.** *G. R. Oxnard, A. E. Drilon, M. H. Shah, L. J. Wirth, T. M. Bauer, V. Velcheti, N. J. Lakhani, B. Besse, K. Park, J. D. Patel, M. E. Cabanillas, E. J. Sherman, K. Gordon, S. Smith, M. Nguyen, E. Zhu, S. M. Rothenberg, K. Ebata, B. B. Tuch, V. Subbiah*
- Board 372 Abstract 9049: Prognostic relevance of tumor sequencing in metastatic lung adenocarcinomas.** *R. Shen, A. Martin, A. Ni, M. D. Hellmann, E. Jordan, A. Arora, R. Ptashkin, A. Zehir, M. G. Kris, K. C. Arbour, C. M. Rudin, M. F. Berger, D. B. Solit, V. E. Seshan, M. E. Arcila, M. Ladanyi, G. J. Riely*
- Board 373 Abstract 9050: An open-label, multicenter, phase II single arm trial of osimertinib in non-small cell lung cancer patients with uncommon *EGFR* mutation (KCSG-LU15-09).** *M. Ahn, J. Cho, J. Sun, S. Lee, J. Ahn, K. Park, E. Kang, Y. Choi, K. Kim, H. An, H. Lee*
- Board 374 Abstract 9051: Dendritic-cell vaccine (DCVAC) with first line chemotherapy in patients with stage IV NSCLC primary analysis of phase 2, open-label, randomized, multicenter trial.** *L. Havel, M. Zemanova, M. Pesek, V. Kolek, R. Spisek, J. Bartunkova, L. Pecen, I. Krasnopolskaya, M. Cernovská*
- Board 375 Abstract 9052: Association of *EGFR* and *HER-2* exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer.** *M. V. Negrao, A. Reuben, J. P. Robichaux, X. Le, M. B. Nilsson, C. Wu, J. Zhang, L. C. Landry, E. Roarty, W. Rinsurongkawong, S. Swisher, G. R. Simon, A. Futreal, B. S. Glisson, J. Heymach*
- Board 376 Abstract 9053: Efficacy and safety results of ramucirumab in combination with osimertinib in advanced T790M-positive *EGFR*-mutant NSCLC.** *D. Planchard, H. A. Yu, J. C. Yang, K. Lee, P. Garrido Lopez, K. Park, J. Kim, D. Lee, S. He, B. H. Chao, L. G. Paz-Ares*

Sunday, June 3, 2018

- Board 377 **Abstract 9054: Survival disparities among African American (AA) patients (pts) with EGFR-mutated non-small cell lung cancer (NSCLC).** *H. Cheng, H. D. Hosgood, Q. Ye, J. N. Sharma, C. Su, B. Halmos, R. Perez-Soler*
- Board 378 **Abstract 9055: Prevalence and prognosis of DNA repair deficiency in squamous cell carcinoma (SCC) patients enrolled on the S1400 LungMAP study.** *T. K. Owonikoko, M. W. Redman, L. A. Byers, K. Griffin, F. R. Hirsch, P. C. Mack, D. R. Gandara, J. D. Bradley, T. Stinchcombe, K. Kelly, S. S. Ramalingam, R. S. Herbst, V. Papadimitrakopoulou*
- Board 379 **Abstract 9056: Differential outcomes in patients with uncommon EGFR exon 19 mutations.** *T. Stewart, A. Truini, M. DeVeaux, D. Zelterman, Z. Walther, A. Wurtz, S. N. Gettinger, K. A. Politi, S. B. Goldberg*
- Board 380 **Abstract 9057: Correlation between nivolumab exposure and treatment outcome in NSCLC.** *S. L. Koolen, E. A. Basak, D. Hurkmans, M. W. Schreurs, S. Bins, E. O. De Hoop, A. J. Wijkhuis, I. Den Besten, S. Sleijfer, R. Debets, A. Van Der Veldt, J. Aerts, R. H. Mathijssen*
- Board 381 **Abstract 9058: Durvalumab in \geq 3rd-line advanced NSCLC: Updated results from the phase 2 ATLANTIC study.** *M. C. Garassino, B. Cho, J. Kim, J. Mazieres, J. E. Gray, P. Wheatley-Price, K. Park, R. A. Soo, Y. Huang, C. Wadsworth, P. A. Dennis, N. A. Rizvi*
- Board 382 **Abstract 9059: A randomized phase 2 study of abemaciclib versus docetaxel in patients with stage IV squamous non-small cell lung cancer (sqNSCLC) previously treated with platinum-based chemotherapy.** *G. V. Scagliotti, I. Bondarenko, T. Ciuleanu, M. Bryl, A. Fülöp, D. Vicente, H. Bischoff, K. Hurt, Y. Lu, S. Estrem, S. R. Wijayawardana, A. Chiang, R. Govindan*
- Board 383 **Abstract 9060: PD-L1 expression, tumor mutation burden and response to immune checkpoint blockade in patients with HER2-mutant lung cancers.** *W. V. Lai, D. L. Feldman, D. J. Buonocore, E. B. Brzostowski, H. Rizvi, A. J. Plodkowski, A. Ni, J. K. Sabari, M. D. Offin, M. G. Kris, A. E. Drilon, M. E. Arcila, M. D. Hellmann, B. T. Li*
- Board 384 **Abstract 9061: Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status.** *R. M. Huber, D. Kim, M. Ahn, C. J. Langer, M. Tiseo, H. West, H. J. Groen, K. L. Reckamp, M. J. Hochmair, N. B. Leighl, K. Holmskov Hansen, S. N. Gettinger, L. G. Paz-Ares, E. S. Kim, E. F. Smit, S. Kim, W. Reichmann, D. Kerstein, D. R. Camidge*
- Board 385 **Abstract 9062: Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.** *D. R. Camidge, G. A. Otterson, J. W. Clark, S. I. Ou, J. Weiss, S. Ades, U. Conte, Y. Tang, S. C. Wang, D. Murphy, K. D. Wilner, L. C. Villaruz*
- Board 386 **Abstract 9063: A multicenter phase II study of low-dose erlotinib in frail patients with EGFR mutation-positive, non-small cell lung cancer: Thoracic oncology research group (TORG) trial 1425.** *K. Yamada, S. Miyamoto, K. Azuma, H. Ishii, A. Bessho, N. Fukamatsu, H. Kunitoh, M. Ishii, H. Tanaka, H. Aono, Y. Nakahara, K. Kusaka, Y. Hosomi, N. Kikuchi, Y. Mori, H. Itani, T. Kasai, M. Ichiki, N. Seki, H. Okamoto*
- Board 387 **Abstract 9064: Time to treatment discontinuation (TTD) as a pragmatic endpoint in metastatic non-small cell lung cancer (mNSCLC): A pooled analysis of 8 trials.** *Y. Gong, K. L. Kehl, G. R. Oxnard, S. Khozin, P. S. Mishra-Kalyani, G. M. Blumenthal*
- Board 388 **Abstract 9065: Predictive value of CD73 expression in EGFR-mutation positive non-small-cell lung cancer patients received immune checkpoint inhibitors.** *H. Ishii, K. Azuma, T. Kinoshita, N. Matsuo, Y. Naito, T. Tokito, K. Yamada, T. Hoshino*
- Board 389 **Abstract 9066: Impact of central nervous system (CNS) involvement in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with immune checkpoint inhibitors (ICI).** *L. Hendriks, C. Henon, L. Mezquita, E. Auclin, R. Ferrara, C. Audigier-Valette, C. Le Pechoux, A. Botticella, S. Ammari, A. Gazzah, C. Caramella, J. Adam, D. Planchard, A. C. Dingemans, B. Besse*

- Board 390 **Abstract 9067: Immune-related adverse events and nivolumab outcomes in non-small cell lung cancer patients: A multi-institutional, retrospective cohort study.** *R. J. Moor, K. E. Roberts, R. Mason, B. Gunawan, S. Feng, J. Hong, M. Von Itzstein, B. G. Hughes, Z. Lwin, V. K. Jain, K. J. Bigby, M. W. Azer, J. Sanmugarajah, K. J. O'Byrne*
- Board 391 **Abstract 9068: Next generation sequencing (NGS) based mutation profiling and heterogeneity of resistance mechanisms to AZD9291.** *J. Zhao, R. Chen, G. Lin, X. Ai, W. Sheng, Y. Ji, Z. Fan, L. Miao, L. Zhu, Q. Zhao, R. Guo, X. Yi, X. Xia*
- Board 392 **Abstract 9069: Mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKIs) in MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC).** *M. M. Awad, M. Bahcall, L. M. Sholl, F. H. Wilson, C. Paweletz, M. Capelletti, G. C. Leonardi, M. Watanabe, H. Baba, E. S. Chambers, A. J. Redig, M. Nishino, P. A. VanderLaan, D. B. Costa, Y. Imamura, P. A. Janne*
- Board 393 **Abstract 9070: Immuno-oncology biomarker study in a large cohort of LC-SCRUM-Japan: Assessment of PD-L1 expression and tumor mutation burden in non-small cell lung cancer patients treated with immune checkpoint inhibitors.** *K. Yoh, S. Matsumoto, K. Nishino, N. Furuya, S. Miyamoto, S. Oizumi, S. Hashimoto, S. Sugawara, M. Kodani, N. Okamoto, S. Hara, Y. Hayashi, N. Motoi, G. Ishii, K. Goto*
- Board 394 **Abstract 9071: Refining the sensitivity of plasma cell-free DNA (cfDNA) genotyping by controlling for plasma tumor content.** *C. Meador, Y. Hu, J. C. Yang, T. Mok, G. Laus, T. Hovey, K. S. Thress, G. R. Oxnard*
- Board 395 **Abstract 9072: Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).** *S. I. Ou, L. Gandhi, S. M. Gadgeel, F. Barlesi, J. C. Yang, L. De Petris, D. Kim, R. Govindan, A. C. Dingemans, L. Crino, L. Herve, S. Papat, J. Ahn, E. Dansin, A. H. Zeaiter, B. Müller, H. Johansdottir, B. Balas, P. N. Morcos, A. Shaw*
- Board 396 **Abstract 9073: Comparative effectiveness of carboplatin-pemetrexed (Carbo-Pem) with vs. without bevacizumab (Bev) in patients with advanced non-squamous (Sq) non-small cell lung cancer (NSCLC).** *S. J. Bagley, N. Mitra, N. J. Meropol, B. Holzman, R. B. Cohen, C. J. Langer, A. Vachani*
- Board 397 **Abstract 9074: Therapeutic and prognostic impact of genetic alterations identified in nationwide genome screening for squamous cell lung cancer (LC-SCRUM-Japan).** *T. Sakamoto, S. Matsumoto, E. Sugiyama, K. Yoh, N. Kobayashi, T. Yokoyama, M. Shingoji, T. Kato, H. Aono, S. Hara, S. Sugawara, A. Sekine, K. Goto*
- Board 398 **Abstract 9075: Hyperprogression after immunotherapy: Clinical implication and genomic alterations in advanced non-small cell lung cancer patients (NSCLC).** *Y. Kim, C. Kim, H. Kim, J. Sun, J. Ahn, M. Ahn, S. Lee, H. Lee, K. Park*
- Board 399 **Abstract 9076: Rare targetable drivers (RTD) in NSCLC: PD-L1 expression, tumor mutation burden (TMB), microsatellite instability (MSI) and outcomes with immune check-point inhibitors (ICPi).** *E. Dudnik, E. Bshara, A. Grubstein, L. Fridel, T. Shochat, L. C. Roisman, M. Ilouze, A. B. Rozenblum, S. Geva, A. Zer, O. Rotem, A. Allen, N. Peled*
- Board 400 **Abstract 9077: Identification of osimertinib resistance mechanisms in Chinese NSCLC patients: Analysis from AURA17 trial.** *M. Hu, Y. Wu, X. Zhu, Y. Sun, X. Lu, J. Wang, M. Wang, Y. Cheng, Y. Chen, Y. Zhao, Y. Shi, Y. Lu, M. Shi, H. Zhang, X. Huang, Z. Ding, G. Chen, C. Zhou*
- Board 401 **Abstract 9078: Early prediction of outcomes to PD1 inhibitors in non-small cell lung cancer (NSCLC) using next generation sequencing (NGS) of plasma circulating tumor DNA (ctDNA).** *N. Guibert, G. Jones, J. F. Beeler, V. Plagnol, M. Delaunay, A. Casanova, G. Favre, A. Pradines, J. Mazieres*
- Board 402 **Abstract 9079: Dissecting the prognostic role of common EGFR-mutations of metastatic NSCLC in TKI era: A systematic review and subgroup meta-analysis.** *F. Kuan, L. Kuo, W. Yang, C. Shi, M. Chen, J. W. Chang, C. Yang, K. Lee*

Sunday, June 3, 2018

- Board 403 **Abstract 9080: Subgroup analysis of histology in ALTER0303: Anlotinib hydrochloride as 3rd line and further line treatment in refractory advanced NSCLC patients (pts).** *Y. Cheng, B. Han, K. Li, Q. Wang, L. Zhang, J. Shi, Z. Wang, J. He, Y. Shi, W. Chen, X. Wang, Y. Luo, K. Nan, F. Jin, B. Li*
- Board 404 **Abstract 9081: Frequency of brain metastases and outcomes in patients with HER2-, KRAS-, and EGFR-mutant lung cancers.** *M. G. Kris, M. D. Offin, D. L. Feldman, A. Ni, W. V. Lai, K. C. Arbour, M. Daras, E. Pentsova, L. M. DeAngelis, K. Beal, R. J. Young, E. Jordan, M. E. Arcila, D. R. Jones, J. M. Isbell, G. J. Riely, A. E. Drilon, H. A. Yu, B. T. Li*
- Board 405 **Abstract 9082: Can duration of response be used as a surrogate endpoint for overall survival in advanced non-small cell lung cancer?** *B. M. Pfeiffer, M. Kulakova, M. Hashim, B. Heeg*
- Board 406 **Abstract 9083: Concurrent genomic alterations in lung adenocarcinoma with a MET exon 14 skipping mutation.** *J. Rotow, W. Wu, C. M. Blakely, R. B. Lanman, V. M. Raymond, F. J. Kaye, P. Gui, J. Fraser, A. Wolff, E. A. Collisson, C. E. McCoach, T. G. Bivona*
- Board 407 **Abstract 9084: Immune-related adverse events to predict survival in patients with advanced non-small cell lung cancer treated with nivolumab: A multicenter analysis.** *B. Ricciuti, A. De Giglio, M. Brambilla, M. Bassanelli, G. Metro, V. Ludovini, S. Baglivo, R. Chiari*
- Board 408 **Abstract 9085: Contribution of nationwide genome screening in Japan (LC-SCRUM-Japan) to the development of precision medicine for non-small cell lung cancer.** *T. Seto, S. Matsumoto, K. Yoh, Y. Fujiwara, T. Yokoyama, K. Nishino, T. Kato, S. Sugawara, M. Shingoji, M. Kodani, K. Ohashi, K. Tsuchihara, K. Goto*
- Board 409 **Abstract 9086: Early determination of benefit or futility in treating NSCLC using the LCSS 3-Item Global Index (3-IGI).** *R. J. Gralla, P. J. Hollen, R. D. Hall, R. D. Gentzler, H. Cheng, B. Halmos, J. Crawford, M. Lesser*
- Board 410 **Abstract 9087: Landscape of EGFR-dependent and independent mechanisms of osimertinib resistance in EGFR-mutant NSCLC patients.** *X. Le, S. Puri, M. V. Negrao, M. B. Nilsson, J. P. Robichaux, T. A. Boyle, J. K. Hicks, E. Roarty, W. Rinsurongkawong, B. S. Glisson, J. Zhang, V. Papadimitrakopoulou, J. E. Gray, J. Heymach*
- Board 411 **Abstract 9088: Demographic composition of lung cancer trials: FDA analysis.** *L. A. Fashoyin-Aje, L. L. Fernandes, R. Sridhara, P. Keegan, R. Pazdur*
- Board 412 **Abstract 9089: Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC.** *A. Chiappori, C. C. Williams, B. C. Creelan, T. Tanvetyanon, J. E. Gray, E. B. Haura, R. Thapa, D. Chen, A. A. Beg, T. A. Boyle, J. Bendiske, E. Morris, A. Tao, F. K. Hurtado, L. Manenti, J. Castro, S. J. Antonia*
- Board 413 **Abstract 9090: Avelumab (anti-PD-L1) in patients with platinum-treated advanced NSCLC: 2.5-year follow-up from the JAVELIN Solid Tumor trial.** *A. Rajan, J. L. Gulley, D. R. Spigel, N. Iannotti, J. C. Chandler, D. J. Wong, J. W. Leach, W. J. Edenfield, D. Wang, C. H. Redfern, H. Grote, A. von Heydebreck, M. M. Ruisi, N. Munshi, K. Kelly*
- Board 414 **Abstract 9091: Association of pre-existing thyroid autoimmunity with the development of thyroid dysfunction induced by nivolumab.** *S. Kimbara, Y. Fujiwara, S. Iwama, K. Ohashi, A. Kuchiba, H. Arima, N. Yamazaki, S. Kitano, N. Yamamoto, Y. Ohe*
- Board 415 **Abstract 9092: Genetic aberrations related to increased risks of brain metastasis in non-small cell lung cancer (GASTO-1036).** *D. Li, T. Qin, Q. Ou, X. Hou, K. Wang, X. Chen, S. Ma, H. Bao, X. Wu, X. Wang, Y. Shao, Y. Mou, L. Chen*
- Board 416 **Abstract 9093: Long-term efficacy and outcomes with sequential crizotinib followed by alectinib in ALK+ NSCLC.** *J. J. Lin, B. Y. Yeap, L. A. Ferris, S. Yoda, I. Dagogo-Jack, J. K. Lennerz, J. F. Gainor, A. T. Shaw*

- Board 417 **Abstract 9094: Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC).** *D. Kim, D. S. Tan, S. Ponce Aix, L. V. Sequist, E. F. Smit, T. Hida, J. C. Yang, E. Felip, T. Seto, C. Grohé, J. Wolf, J. Ko, M. Diallo, P. Pultar, M. Giovannini, S. Kim*
- Board 418 **Abstract 9095: An amplicon-based liquid biopsy for detecting ALK and ROS1 fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients.** *L. Mezquita, C. Jovelet, L. Lacroix, D. Planchard, G. Recondo, E. Pailler, E. Auclin, V. Plagnol, K. Howarth, C. D. Morris, E. Green, E. Rouleau, C. Nicotra, C. Caramella, J. Adam, N. Auger, F. Farace, L. Friboulet, B. Besse*
- Board 419 **Abstract 9096: Real-world treatment patterns and survival of BRAF V600-mutated metastatic non-small cell lung cancer patients.** *L. Horn, J. Bauml, P. M. Forde, K. L. Davis, N. J. Myall, M. Sasane, A. Dalal, K. W. Culver, A. J. Wozniak, C. S. Baik, A. Mutebi, P. Zhang, H. A. Wakelee, B. E. Johnson*
- Board 420 **Abstract 9097: Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.** *J. Mazieres, F. Barlesi, I. Rouquette, B. Besse, I. Monnet, C. Audigier-Valette, A. Toffart, P. Renault, S. Moreau Fraboulet, S. Hiret, B. Mennequier, D. Debieuvre, V. Westeel, P. Masson, A. Madroszyk, E. Amour, F. Morin, G. Zalczman, D. Moro-Sibilot, P. J. Souquet*
- Board 421 **Abstract 9098: Targeting NFE2L2 mutations in advanced squamous cell lung cancers with the TORC1/2 inhibitor TAK228.** *P. K. Paik, B. Qeriqi, L. S. Ahn, M. S. Ginsberg, N. Tandon, D. McFarland, L. A. Doyle, E. de Stanchina, C. M. Rudin*
- Board 422 **Abstract 9099: Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma.** *A. M. Campbell, R. S. Herbst, S. N. Gettinger, S. B. Goldberg, H. M. Kluger, A. C. Chiang, R. Lilienbaum, K. A. Schalper, R. T. Sowell, S. M. Kaech, R. H. Decker*
- Board 423 **Abstract 9100: EGFR reporting in stage IV adenocarcinoma of the lung: Demographic predictors of EGFR testing and survival.** *S. Shaheen, L. Ji, H. Mirshahidi, S. Otoukesh, G. Nagaraj, S. Mirshahidi, J. W. Morgan*
- Board 424 **Abstract 9101: Clinical utility of plasma-based digital next-generation sequencing (NGS) in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.** *J. Zugazagoitia, I. Ramos Garcia, J. Trigo Perez, M. Palka, A. Gómez Rueda, E. Jantus-Lewintre, C. Camps, D. Isla, S. Ponce Aix, R. G. Campelo, M. Provencio-Pulla, R. Bernabe Caro, O. Juan Vidal, E. Felip, J. De Castro, J. Sanchez Torres, I. Faull, R. B. Lanman, P. Garrido Lopez, L. G. Paz-Ares*
- Board 425 **Abstract 9102: Association of CDKN2A gene alteration with high expression of PD-L1.** *Y. Zhang, J. A. Marin-Acevedo, A. G. Azzouqa, R. Manochakian, Y. Lou*
- Board 426 **Abstract 9103: The effect of thoracic radiation on overall survival and their association with systemic immune therapy in stage IV NSCLC: Findings from the National Cancer Database.** *F. S. Kong, W. Wang, G. Durm, J. Wan, J. Jin, W. Pi, C. Hu, M. P. Langer, T. Lautenschlaeger, S. Paczesny, T. J. Birdas, N. H. Hanna*
- Board 427a **Abstract TPS9104: ECHO-306/KEYNOTE-715: A phase 3 study of first-line epacadostat plus pembrolizumab with or without platinum-based chemotherapy vs pembrolizumab plus platinum-based chemotherapy plus placebo for metastatic non-small cell lung cancer (mNSCLC).** *R. Hui, M. Munteanu, Y. Zhao, Y. Luo, A. Samkari, M. C. Garassino*
- Board 427b **Abstract TPS9105: MORPHEUS: A phase Ib/II multi-trial platform evaluating the safety and efficacy of cancer immunotherapy (CIT)-based combinations in patients (pts) with non-small cell lung cancer (NSCLC).** *M. L. Johnson, B. J. Solomon, M. M. Awad, B. Cho, J. F. Gainor, S. B. Goldberg, B. Keam, D. Lee, C. Huang, H. Helms, H. Barak, M. Fasso, C. Bleul, E. Cha, N. A. Rizvi*

Sunday, June 3, 2018

- Board 428a **Abstract TPS9106: A phase 2 study of poziotinib in patients with EGFR or HER2 exon 20 mutation-positive non-small cell lung cancer.** *Z. Yang, N. Tchekmedyan, D. T. Chu, G. Reddy, G. Bhat, M. A. Socinski*
- Board 428b **Abstract TPS9107: Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC).** *L. Gandhi, K. Aufiero Ramirez, P. Schwarzenberger, T. Ricciardi, M. J. Macri, A. Ryan, R. R. Venhaus*
- Board 429a **Abstract TPS9108: A trial of CV301 in combination with anti-PD-1 therapy versus anti-PD-1 therapy in subjects with non-small cell lung cancer.** *A. Rajan, J. Strauss, A. Orpia, M. E. Gatti-Mays, E. Wagner, C. R. Heery, C. Pico, J. L. Gulley*
- Board 429b **Abstract TPS9109: ECHO-305/KEYNOTE-654: A phase 3, randomized, double-blind study of first-line epacadostat plus pembrolizumab vs pembrolizumab plus placebo for metastatic non-small cell lung cancer (mNSCLC) with high PD-L1 levels.** *M. M. Awad, M. Munteanu, Y. Zhao, L. Xu, A. Samkari, L. G. Paz-Ares*
- Board 430a **Abstract TPS9110: Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC.** *P. A. Janne, H. A. Yu, M. L. Johnson, M. Vigliotti, N. Shipitofsky, F. M. Guevara, S. Chen, C. Yu*
- Board 430b **Abstract TPS9111: A phase 1b trial of RORγ agonist LYC-55716 in combination with pembrolizumab to evaluate safety, efficacy, and immune biomarker profiles in patients with metastatic non-small cell lung cancer.** *D. R. Camidge, S. M. Gadgeel, G. A. Weems, H. Wilkins, M. L. Johnson*
- Board 431a **Abstract TPS9112: Phase I/II study of nivolumab and ipilimumab combined with nintedanib in advanced NSCLC.** *S. Puri, S. Niyongere, M. S. Chatwal, T. A. Boyle, D. Chen, D. Noyes, S. J. Antonia, J. E. Gray*
- Board 431b **Abstract TPS9113: Phase I/II trial of dasatinib and osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer.** *C. Kim, S. V. Liu, D. S. Subramaniam, G. Giaccone*
- Board 432a **Abstract TPS9114: Trial in progress: Multicenter observational study to evaluate the relationship between gut bacterial flora and their therapeutic or adverse effects in advanced non-small cell lung cancer patients treated with nivolumab.** *T. Yokoi, R. Itotani, M. Niki, H. Yoshioka, K. Hirano, S. Yamamoto, H. Ishikawa, T. Kijima, M. Hirabayashi, M. Fukui*
- Board 432b **Abstract TPS9115: eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients.** *L. Horn, Y. Wu, M. Reck, H. A. Wakelee, C. Liang, F. Tan, K. Harrow, V. Oertel, G. Dukart, T. Mok*
- Board 433a **Abstract TPS9116: A multicenter, randomized, double-blind, placebo-controlled phase III study of apatinib or placebo plus gefitinib as first-line treatment in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC).** *H. Zhao, Z. Zhang, F. Luo, Y. Ma, W. Fang, Y. Yang, Y. Zhang, Y. Huang, L. Zhang*
- Board 433b **Abstract TPS9117: Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung.** *B. P. Levy, L. G. Paz-Ares, J. Bennouna, E. Felip, D. Rodríguez Abreu, D. Isla, F. Barlesi, O. Molinier, J. Madelaine, C. Audigier-Valette, S. Kim, M. Ozguroglu, M. Erman, F. B. Badin, T. Mekhail, R. J. Scheff, J. W. Riess*

9:45 AM - 11:00 AM Education Session

A New Era in the Management of Melanoma Brain Metastases

Location: S100bc
Interact ID: 10753

Grant A. McArthur, MBBS, PhD, FRACP

Peter MacCallum Cancer Centre and University of Melbourne

Biology of Melanoma Brain Metastases: Incidence, Prognosis, Surveillance, and More

Caroline Robert, MD, PhD

Gustave Roussy Institute

Different Combinations of Systemic Therapy for Melanoma Brain Metastases

Hussein Abdul-Hassan Tawbi, MD, PhD - Chair

The University of Texas MD Anderson Cancer Center

What to Do First in Case of Melanoma Brain Metastases and Simultaneous Extracerebral Disease

Panel Question and Answer

9:45 AM - 11:00 AM Education Session

ASCO/European Cancer Organization (ECCO) Joint Session: Access and Innovation With Multiplex Genomic Testing

Location: S100a

Interact ID: 10807

Philip Poortmans, MD, PhD - Chair

Institut Curie

Bruce E. Johnson, MD, FASCO - Chair

Dana-Farber Cancer Institute

Kojo Elenitoba-Johnson, MD

Perelman School of Medicine at the University of Pennsylvania

Utilization of Multiplex Testing in the United States

Matti S. Aapro, MD

Cancer Center, Clinique de Genolier

Utilization of Multiplex Testing in Europe

David R. Spigel, MD

Sarah Cannon Research Institute, Tennessee Oncology

Reimbursement and Payment of Multiplex Testing in the United States

Jan Geissler, MBA

Leukemia Patient Advocates Foundation

European Patient Perspective

Panel Question and Answer

9:45 AM - 11:00 AM Meet the Professor Session

Biology and Therapeutic Promise of Exploiting IDH Mutations in Gliomas - Ticketed Session

Location: E253c

Interact ID: 10911

Daniel P. Cahill, MD, PhD

Massachusetts General Hospital

Ranjit Bindra, MD

Yale University

Sunday, June 3, 2018

9:45 AM - 11:00 AM Meet the Professor Session

How to Bring Geriatric Assessment Into Your Practice - Ticketed Session

Location: E253d

Interact ID: 10790

Shabbir M.H. Alibhai, MD

University Health Network

9:45 AM - 11:15 AM Clinical Science Symposium

Compelling Combinations: Raising the Bar With Immunotherapy

Location: Hall D1

Interact ID: 10826

David C. Smith, MD - Chair

University of Michigan

9:45 AM Solange Peters, MD, PhD

Centre Hospitalier Universitaire Vaudois - CHUV

Setting the Stage: Where Are We Now With Immunotherapy?

9:57 AM Abstract 104: Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). *S. Loibl, M. Untch, N. Burchardi, J. B. Huober, J. U. Blohmer, E. Grischke, J. Furlanetto, H. Tesch, C. Hanusch, M. Rezai, C. Jackisch, W. D. Schmitt, G. Von Minckwitz, J. Thomalla, S. Kummel, B. Rautenberg, P. A. Fasching, K. Rhiem, C. Denkert, A. Schneeweiss*

10:09 AM Abstract 105: Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). *L. G. Paz-Ares, A. Luft, A. Tafreshi, M. Gumus, J. Mazieres, B. Hermes, F. Cay Senler, A. Fülöp, J. Rodriguez-Cid, S. Sugawara, Y. Cheng, S. Novello, B. Halmos, Y. Shentu, D. Kowalski*

10:21 AM Abstract 106: TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.

P. A. Konstantinopoulos, S. E. Waggoner, G. A. Vidal, M. M. Mita, G. F. Fleming, R. W. Holloway, L. Van Le, J. C. Sachdev, E. Chapman-Davis, G. Colon-Otero, R. T. Penson, U. A. Matulonis, Y. B. Kim, K. N. Moore, E. M. Swisher, B. J. Dezube, J. Y. Wang, N. Buerstatte, S. Arora, P. N. Munster

10:33 AM Abstract 108: Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.

G. V. Long, R. Dummer, O. Hamid, T. Gajewski, C. Caglevic, S. Dalle, A. Arance, M. S. Carlino, J. Grob, T. Kim, L. V. Demidov, C. R. Jacobs, C. Robert, J. M. Larkin, J. Anderson, J. E. Maleski, M. M. Jones, S. J. Diede, T. C. Mitchell

10:45 AM Charles G. Drake, MD, PhD (Discussion of Abstract(s) 104-108)

Columbia University Herbert Irving Comprehensive Cancer Center
Putting It Together: Have Combinations Come of Age?

10:57 AM Panel Question and Answer

9:45 AM - 11:15 AM Clinical Science Symposium

Engaging the Immune System in Ovarian Cancer

Location: S406

Interact ID: 10746

Marcus O. Butler, MD - Chair

Princess Margaret Cancer Centre, University Health Network

Kunle Odunsi, MD - Chair

Roswell Park Comprehensive Cancer Center

9:45 AM Abstract 5509: Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Interim analysis of a phase 2, open-label, randomized, multicenter trial. *L. Rob, P. Mallmann, P. Knapp, B. Melichar, J. Klat, L. Minar, Z. Novotny, J. Bartunkova, R. Spisek, L. Pecen, H. Hassan, D. Cibula*

9:57 AM Abstract 5510: Clinical data from the DeCidE¹ trial: Assessing the first combination of DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with stage IIc-IV recurrent epithelial ovarian cancer. *O. Dorigo, J. L. Tanyi, J. Strauss, A. M. Oza, T. Pejovic, P. Ghatage, J. A. Villella, S. Fiset, L. D. MacDonald, L. Leopold, G. N. Rosu*

10:09 AM Leisha A. Emens, MD, PhD (Discussion of Abstract(s) 5509-5510)
Johns Hopkins Kimmel Comprehensive Cancer Center and Bloomberg-Kimmel Institute for Cancer Immunotherapy
Vaccines: Beyond Prevention

10:21 AM Abstract 5511: Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study. *U. A. Matulonis, R. Shapira-Frommer, A. Santin, A. S. Lisyanskaya, S. Pignata, I. Vergote, F. Raspagliesi, G. S. Sonke, M. Birrer, D. M. Provencher, J. Sehouli, N. Colombo, A. González-Martín, A. Oaknin, P. B. Ottevanger, V. Rudaitis, K. Katchar, Z. Wang, J. Ruman, J. A. Ledermann*

10:33 AM Abstract 5512: Association of high tumor mutation (TMB) with DNA damage repair (DDR) alterations and better prognosis in ovarian cancer. *W. Tian, B. Shan, Y. Zhang, Y. Ren, S. Liang, J. Zhao, X. Zhao, D. Peng, S. Cai, H. Wang*

10:45 AM Janos Laszlo Tanyi, MD, PhD (Discussion of Abstract(s) 5511-5512)
University of Pennsylvania
Immune Therapy in Ovarian Cancer: The Continuing Search for Biomarkers

10:57 AM Panel Question and Answer

9:45 AM - 12:45 PM Oral Abstract Session

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Location: E450

Interact ID: 10843

Christopher Flowers, MD, MS - Chair

Emory University, Winship Cancer Institute

Barbara Pro, MD - Chair

Northwestern University Feinberg School of Medicine

Sunday, June 3, 2018

- 9:45 AM Abstract 7500: RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R²) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma.**
N. H. Fowler, F. Morschhauser, P. Feugier, R. Bouabdallah, H. Tilly, M. Palomba, C. Fruchart, E. N. Libby, O. Casasnovas, M. Gomes Da Silva, D. Pranger, P. Zachee, A. Martin Garcia-Sancho, A. Lopez-Guillermo, J. Larouche, K. Ando, D. Liu, J. Wang, L. Xerri, G. A. Salles
- 9:57 AM Abstract 7501: Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM).**
R. Owen, H. McCarthy, S. Rule, S. D'Sa, S. K. Thomas, F. Forconi, T. C. Anderson, M. J. Kersten, P. L. Zinzani, S. Iyengar, J. Kothari, M. Minnema, E. Kastiris, R. Izumi, J. G. Slatter, D. Mittag, H. Wei, D. Chen, P. Patel, R. R. Furman
- 10:09 AM Abstract 7502: Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL).**
W. G. Wierda, T. Siddiqi, I. Flinn, X. C. Badoux, T. J. Kipps, J. N. Allan, A. Tedeschi, J. M. Pagel, B. J. Kuss, E. González Barca, P. Ghia, K. Eckert, C. Zhou, J. Ninomoto, J. P. Dean, D. F. James, C. Tam
- 10:21 AM Bruce D. Cheson, MD, FASCO (Discussion of Abstract(s) 7500-7502)**
Georgetown University Hospital, Lombardi Comprehensive Cancer Center
Toward a Chemotherapy-Free Future in Lymphoid Malignancies
- 10:33 AM Panel Question and Answer**
- 10:45 AM Abstract 7503: Randomized phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced staged Hodgkin lymphoma: Final analysis of the AHL2011 LYSA study.**
O. Casasnovas, P. Brice, R. Bouabdallah, G. A. Salles, A. Stamatoulas, J. Dupuis, O. Reman, T. Gastinne, B. Joly, K. Bouabdallah, E. Nicolas-Virelizier, P. Feugier, F. Morschhauser, R. Delarue, A. Berriolo-Riedinger, V. Edeline, A. Traverse-Glehen, M. Andre, N. Mounier, M. Meignan
- 10:57 AM Abstract 7504: Activity and tolerability of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results.**
R. H. Advani, I. Flinn, L. Popplewell, A. Forero-Torres, N. L. Bartlett, N. Ghosh, J. P. Kline, T. Tran, J. Lynn, J. Y. Chen, B. Agoram, J. Huang, C. H. Takimoto, M. Chao, S. M. Smith
- 11:09 AM Abstract 7505: Updated safety & long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.**
J. S. Abramson, L. I. Gordon, M. Palomba, M. A. Lunning, J. E. Arnason, A. Forero-Torres, M. Wang, D. G. Maloney, A. Sehgal, C. Andreadis, E. Purev, S. R. Solomon, N. Ghosh, T. M. Albertson, B. Xie, J. Garcia, T. Siddiqi
- 11:21 AM Caron Alyce Jacobson, MD (Discussion of Abstract(s) 7503-7505)**
Dana-Farber Cancer Institute
CART and Other Vehicles for Immunotherapy
- 11:33 AM Panel Question and Answer**
- 11:45 AM Abstract 7507: Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.**
L. H. Sehn, M. Kamdar, A. F. Herrera, A. McMillan, C. Flowers, W. Kim, T. Kim, M. Özcan, J. Demeter, M. Hertzberg, M. Trněný, G. A. Salles, A. Davies, J. H. Hirata, J. Cheng, G. Ku, M. J. Matasar
- 11:57 AM Abstract 7508: High, durable minimal residual disease negativity (MRD-) with venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study.**
P. Hillmen, A. P. Kater, J. F. Seymour, A. W. Langerak, B. Eichhorst, C. Owen, S. E. Assouline, A. Janssens, P. Marlton, X. C. Badoux, R. Mous, B. Chyla, R. Humerickhouse, M. Boyer, K. Humphrey, Y. Jiang, E. Punnoose, J. Wang, Q. J. Wu, M. Mobasher
- 12:09 PM Alison J. Moskowitz, MD (Discussion of Abstract(s) 7507-7508)**
Memorial Sloan Kettering Cancer Center
Tailoring Therapy in Lymphoid Malignancies
- 12:21 PM Panel Question and Answer**

11:30 AM - 12:45 PM Poster Discussion Session

Gastrointestinal (Colorectal) Cancer

Location: Hall D2

Interact ID: 10863

Chi Lin, MD, PhD - Chair

University of Nebraska Medical Center

Mark Kozloff, MD - Chair

Ingalls Memorial Hospital

11:30 AM Alberto F. Sobrero, MD (Discussion of Abstract(s) 3508-3511)

IRCCS A.O.U. San Martino IST

My Take: Timing of EGFR-Directed Therapy

11:42 AM Panel Question and Answer

11:48 AM Ryan Bruce Corcoran, MD, PhD (Discussion of Abstract(s) 3512-3513)

Massachusetts General Hospital

Molecular Subsets: Prognosis and Prediction

12:00 PM Panel Question and Answer

12:06 PM Neil Howard Segal, MD, PhD (Discussion of Abstract(s) 3514-3515)

Memorial Sloan Kettering Cancer Center

Immune Therapy: Why Don't We Have the KEY for VICTORY?

12:18 PM Panel Question and Answer

12:24 PM Dustin A. Deming, MD (Discussion of Abstract(s) 3516-3518)

University of Wisconsin Carbone Cancer Center

Biomarkers and New Approaches in Anorectal Cancer

12:36 PM Panel Question and Answer

Posters discussed in this session are on display in the Gastrointestinal (Colorectal) Cancer Poster Session. See page 171 for poster information.

11:30 AM - 12:45 PM Poster Discussion Session

Lung Cancer—Non-Small Cell Metastatic

Location: Arie Crown Theater

Interact ID: 10874

Joshua Bauml, MD - Chair

University of Pennsylvania

Heather A. Wakelee, MD - Chair

Stanford Cancer Institute

11:30 AM Stephen V. Liu, MD (Discussion of Abstract(s) 9012-9014)

Georgetown University Medical Center

Novel Approaches for EGFR-Mutant Non-Small Cell Lung Cancer

11:42 AM Panel Question and Answer

11:48 AM D. Ross Camidge, MD, PhD (Discussion of Abstract(s) 9015-9019)

University of Colorado-Denver

Old Targets Revisited, New Drug Discovery

12:00 PM Panel Question and Answer

12:09 PM Jhanelle Elaine Gray, MD (Discussion of Abstract(s) 9020-9021)

H. Lee Moffitt Cancer Center & Research Institute

What Immunotherapy Means to Patients

Sunday, June 3, 2018

12:21 PM *Panel Question and Answer*

12:27 PM **Sarah B. Goldberg, MD (Discussion of Abstract(s) 9022-9023)**
Yale Cancer Center
Optimizing the Use of Immunotherapy

12:39 PM *Panel Question and Answer*

Posters discussed in this session are on display in the Lung Cancer—Non-Small Cell Metastatic Poster Session. See page 200 for poster information.

11:30 AM - 12:45 PM Education Session

Controversies in Adjuvant/Neoadjuvant Chemotherapy in Localized Soft Tissue Sarcoma

Location: E451

Interact ID: 10768

Jonathan C. Trent, MD, PhD

Sylvester Comprehensive Cancer Center

Neoadjuvant/Adjuvant Chemotherapy Should Be Considered Standard in High-Risk Extremity Soft Tissue Sarcoma

Axel Le Cesne, MD

Gustave Roussy Cancer Campus

Neoadjuvant/Adjuvant Chemotherapy Should Be Considered Experimental in High-Risk Extremity Soft Tissue Sarcoma

Elizabeth H. Baldini, MD, MPH - Chair

Dana-Farber Cancer Institute and Brigham and Women's Hospital

Is There a Role for Neoadjuvant Chemo-Radiation in High-Risk Extremity Soft Tissue Sarcoma?

Panel Question and Answer

11:30 AM - 12:45 PM Education Session

Filling the Gap: Creating an Outpatient Palliative Care Program in Your Institution

Location: S504

Interact ID: 10794

Esme Finlay, MD

University of New Mexico Cancer Research and Treatment Center

How to Obtain Buy-in From Stakeholders to Support Outpatient Palliative Care

Michael Rabow, MD

University of California, San Francisco

Understanding the Finances of Outpatient Palliative Care Programs

Mary K. Buss, MD, MPH - Chair

Beth Israel Deaconess Medical Center

Peering Behind the Curtain: Examples of Successful Palliative Care Practices and Why They Work

Panel Question and Answer

11:30 AM - 12:45 PM Education Session

How Can Genetics Personalize Cancer Survivorship?

Location: S102

Interact ID: 10754

Lindsay M. Morton, PhD - Chair

National Cancer Institute at the National Institutes of Health

Germline Genomics and the Risk of Developing Treatment-Related Subsequent Neoplasms

Sarah L. Kerns, PhD, MPH

University of Rochester Medical Center

Using Genetic Information for Risk Prediction of Radiotherapy Toxicity

M. Eileen Dolan, PhD

University of Chicago

Role of Genomics in Precision Management of Chemotherapy-Induced Ototoxicity and Neuropathy

Panel Question and Answer

11:30 AM - 12:45 PM Education Session

Lynch Syndrome 360

Location: S404

Interact ID: 10906

Heather Hampel, MS

The Ohio State University Comprehensive Cancer Center

Identification of Lynch Syndrome: From Universal Testing to Tumor Sequencing in Colorectal and Endometrial Cancer

Luis A. Diaz, MD

Memorial Sloan Kettering Cancer Center

The Treatment of Lynch Syndrome-Associated Advanced Malignancy

Matthew B. Yurgelun, MD - Chair

Dana-Farber Cancer Institute

Lynch Syndrome: Update on Comprehensive Screening and Risk Reduction

Panel Question and Answer

11:30 AM - 12:45 PM Education Session

Management of Biochemically Recurrent Prostate Cancer: Which Imaging, Which Treatment, and When?

Location: S406

Interact ID: 10726

Michael J. Morris, MD

Memorial Sloan Kettering Cancer Center

Lifting the Veil on Micrometastatic Disease: Emerging Imaging Strategies in Biochemical Recurrence

Sunday, June 3, 2018

Daniel Eidelberg Spratt, MD

University of Michigan

Precision Risk Stratification and Treatment in Biochemical-Recurrent Prostate Cancer

Alicia K. Morgans, MD, MPH - Chair

Vanderbilt University Medical Center

Biochemical Recurrence: Judicious Clinical Management of an Evolving Disease State

Panel Question and Answer

11:30 AM - 12:45 PM Education Session

Moving From Mutation to Actionability

Location: S100bc

Interact ID: 10743

Amit M. Oza, MD - Chair

Princess Margaret Cancer Centre, University Health Network

The Role of Targeted Therapy in Gynecologic Cancers

Shannon Neville Westin, MD

The University of Texas MD Anderson Cancer Center

Tumor Sequencing: Who, What, When, and Why to Order Tumor Mutation Analysis

Elise C. Kohn, MD

National Cancer Institute at the National Institutes of Health

Rational Approach to Utilizing Genetic Information

Panel Question and Answer

11:30 AM - 12:45 PM Meet the Professor Session

Primary and Acquired Resistance to Checkpoint Inhibitors - Ticketed Session

Location: E253d

Interact ID: 10903

Charles G. Drake, MD, PhD

Columbia University Herbert Irving Comprehensive Cancer Center

Scott N. Gettinger, MD

Yale Cancer Center, Yale New Haven Hospital

11:30 AM - 12:45 PM Meet the Professor Session

**Treatment Strategies for Locoregionally Advanced Nasopharyngeal Cancer:
Making Sense of Recent Studies - Ticketed Session**

Location: E253c

Interact ID: 10714

Anthony T. C. Chan, MD

State Key Laboratory of Oncology in South China, The Chinese University of Hong Kong

Sue Sun Yom, MD, PhD

University of California, San Francisco

11:30 AM - 1:00 PM Clinical Science Symposium

Innovative Approaches to Oncology Education

Location: S103

Interact ID: 10923

James A. Stewart, MD, FACP, FASCO - Chair

Baystate Medical Center

11:30 AM James A. Stewart, MD, FACP, FASCO

Baystate Medical Center

Introduction

11:35 AM Abstract 11000: Addressing the burden of cancer in East Africa through cascaded training and education by local doctors. *J. Eastin, O. Abrahams, R. Board, G. G. Dark, U. Hofmann, J. Joffe, G. Kogolla, K. K. Maunda, W. O. Mwanda, S. J. Stanway, K. Wakeham*

11:47 AM Abstract 11001: Bridging the gap in global advanced radiation oncology training: Impact of a web-based open-access interactive three-dimensional contouring atlas on radiation oncology practice in Russia. *N. Dengina, S. McClelland III, M. Chernich, E. F. Gillespie, A. Likhacheva, S. Usyckin, A. Pankratov, E. Kharitonova, Y. Egorova, I. Tsimafeyu, S. Tjulandin, C. R. Thomas Jr., T. Mitin*

11:59 AM Abstract 11002: The teaching of multi-disciplinary cancer care: A flipped classroom approach. *H. S. Winter, T. Greenhalgh, N. Warner, A. Segaran, P. Handa*

12:11 PM Abstract 11003: Professional development improves geriatric focused oncology activities in settings across the nation. *D. Economou, P. Burhenn, H. Kim, C. Sun, C. Okamoto, A. Arsenyan, E. Roberts, C. Uranga, V. Katheria, A. Hurria*

12:23 PM Leora Horn, MD (Discussion of Abstract(s) 11000-11003)

Vanderbilt University Medical Center

Innovative Approaches, Evaluation, and Outcomes From a Domestic Perspective

12:35 PM Frank Douglas Ferris, MD (Discussion of Abstract(s) 11000-11003)

OhioHealth

Innovative Approaches, Evaluation, and Outcomes From an International Perspective

12:47 PM Panel Question and Answer

11:30 AM - 1:00 PM Education Session

Collecting and Using Real-World Evidence: Supplementing and Perhaps Replacing Clinical Trials (Includes Presentation of Public Service Award)

Location: S100a

Interact ID: 10696

Monica M. Bertagnolli, MD, FACS, FASCO

Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School
Presentation of the 2018 Public Service Award

Gideon Michael Blumenthal, MD

U.S. Food and Drug Administration

Public Service Award Recipient

Lynne Penberthy, MD - Chair

National Cancer Institute at the National Institutes of Health

NCI-SEER Now and Into the Future As a Partner in Real-World Evidence Generation

Sunday, June 3, 2018

Katherine Elizabeth Reeder-Hayes, MD, MBA, MS

University of North Carolina at Chapel Hill

Yin and Yang: Leveraging Clinical Trials and Real-World Data to Inform Evidence-Based Cancer Care

Sean Khozin, MD, MPH

U.S. Food and Drug Administration

FDA's Informed: Real-World Evidence Comes of Age

Jinani Jayasekera, PhD

Lombardi Cancer Center MedStar Georgetown University Hospital

Simulation Modeling of Cancer Clinical Trials: Drawing New Conclusions From Old Trials

Panel Question and Answer

1:00 PM - 4:00 PM Plenary Session

Plenary Session Including the Science of Oncology Award and Lecture

Location: Hall B1 (Simulcast Location: Hall D1)

Interact ID: 10812

Bruce E. Johnson, MD, FASCO - Chair

Dana-Farber Cancer Institute

Ann H. Partridge, MD, MPH, FASCO - Chair

Dana-Farber Cancer Institute

1:00 PM Bruce E. Johnson, MD, FASCO, and Ann H. Partridge, MD, MPH, FASCO

Dana-Farber Cancer Institute

Welcome and Introduction

1:05 PM Daniel F. Hayes, MD, FACP, FASCO

University of Michigan Comprehensive Cancer Center

Presentation of the 2018 Science of Oncology Award

1:10 PM Douglas R. Lowy, MD

National Institutes of Health

Preventing HPV-Associated Cancers by Vaccination

1:40 PM Bruce E. Johnson, MD, FASCO, and Ann H. Partridge, MD, MPH, FASCO

Dana-Farber Cancer Institute

Introduction to Plenary Session

1:45 PM Abstract LBA1: TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score. *J. A. Sparano, R. J. Gray, W. C. Wood, D. Makower, T. G. Lively, T. J. Saphner, M. M. Keane, H. L. Gomez, P. S. Reddy, T. F. Goggins, I. A. Mayer, D. Toppmeyer, A. Brufsky, M. P. Goetz, D. F. Hayes, E. C. Dees, K. I. Pritchard, C. E. Geyer Jr., J. A. Olson, G. W. Sledge Jr.*

2:00 PM Lisa A. Carey, MD (Discussion of Abstract LBA1)

University of North Carolina

2:15 PM Abstract LBA2: Maintenance low-dose chemotherapy in patients with high-risk (HR) rhabdomyosarcoma (RMS): A report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). *G. Bisogno, G. De Salvo, C. Bergeron, M. Jenney, J. H. Merks, V. Minard-Colin, D. Orbach, H. Glosli, J. Chisholm, M. Casanova, S. Gallego Melcon, A. Ferrari*

2:30 PM Douglas S. Hawkins, MD (Discussion of Abstract LBA2)

Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center

- 2:45 PM Abstract LBA3: CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial.** *A. Mejean, B. Escudier, S. Thezenas, J. Beauval, L. Geoffroy, K. Bensalah, A. Thiery-Vuillemin, L. Cormier, H. Lang, L. Guy, G. Gravis, F. Rolland, C. Linassier, M. Timsit, L. Albiges, C. Beisland, M. Aitchison, S. Colas, T. Leuret, A. Ravaud*
- 3:00 PM Daniel J. George, MD (Discussion of Abstract LBA3)**
Duke University
- 3:15 PM Abstract LBA4: Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) \geq 1%: Open-label, phase 3 KEYNOTE-042 study.** *G. Lopes, Y. Wu, I. Kudaba, D. Kowalski, B. Cho, G. Castro Jr., V. Srimuninnimit, I. Bondarenko, K. Kubota, G. M. Lubiniecki, J. Zhang, D. A. Kush, T. Mok*
- 3:30 PM Leena Gandhi, MD, PhD (Discussion of Abstract LBA4)**
NYU Perlmutter Cancer Center

4:00 PM - 4:30 PM Post-Plenary Session

Post-Plenary Discussion Session I: Breast Cancer

Location: S100a

Interact ID: 10853

Elizabeth A. Mittendorf, MD, PhD - Chair

Dana-Farber/Brigham and Women's Cancer Center

Joseph A. Sparano, MD

Montefiore Medical Center

Panelist

Lisa A. Carey, MD

University of North Carolina

Panelist

Eric P. Winer, MD, FASCO

Dana-Farber Cancer Institute

Panelist

4:30 PM - 5:00 PM Post-Plenary Session

Post-Plenary Discussion Session II: Rhabdomyosarcoma

Location: S100bc

Interact ID: 10854

Richard Aplenc, MD - Chair

Children's Hospital of Philadelphia

Douglas S. Hawkins, MD

Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center

Panelist

Gianni Bisogno, MD

University Hospital of Padova

Panelist

Sunday, June 3, 2018

Robin Lewis Jones, MD, MBBS, MRCP

Royal Marsden Hospital, The Institute of Cancer Research
Panelist

4:45 PM - 6:00 PM Poster Discussion Session

Gastrointestinal (Noncolorectal) Cancer

Location: Hall D2

Interact ID: 10864

Vaibhav Sahai, MBBS, MS - Chair

University of Michigan Comprehensive Cancer Center

Sunil Sharma, MD, FACP - Chair

Translational Genomics Research Institute

4:45 PM Joseph Chao, MD (Discussion of Abstract(s) 4009-4011)

City of Hope

Gastroesophageal Cancers: What Can We Learn From Randomized Trials?

4:57 PM Panel Question and Answer

5:03 PM Daniel Tandel Chang, MD (Discussion of Abstract(s) 4012-4013)

Stanford University School of Medicine

Esophageal Cancer: Is More Really More?

5:15 PM Panel Question and Answer

5:21 PM Rachna T. Shroff, MD (Discussion of Abstract(s) 4014-4016)

University of Arizona

Moving Beyond Gemcitabine Therapy in Pancreatic and Biliary Cancers?

5:33 PM Panel Question and Answer

5:39 PM Jordan Berlin, MD, FASCO (Discussion of Abstract(s) 4017-4020)

Vanderbilt University Ingram Cancer Center

Expanding the Treatment Landscape in Hepatocellular Carcinoma

5:51 PM Panel Question and Answer

Posters discussed in this session are on display in the Gastrointestinal (Noncolorectal) Cancer Poster Session. See page 181 for poster information.

4:45 PM - 6:00 PM Poster Discussion Session

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Location: Arie Crown Theater

Interact ID: 10873

David R. Gandara, MD, FASCO - Chair

University of California, Davis

Kristin Ann Higgins, MD, BS - Chair

Winship Cancer Institute of Emory University

4:45 PM Mark G. Kris, MD, FASCO (Discussion of Abstract(s) 8508-8510)

Memorial Sloan Kettering Cancer Center

What, When, and How? Juggling Sequence and Agent Choices

4:57 PM Panel Question and Answer

- 5:03 PM Alexander V. Louie, MD, PhD, MSc, FRCPC (Discussion of Abstract(s) 8511-8513)**
London Health Sciences Centre
Rethinking Radiation: Is The Stereo(tactic) Too Loud?
- 5:15 PM Panel Question and Answer**
- 5:21 PM Charu Aggarwal, MD, MPH (Discussion of Abstract(s) 8514-8516)**
Abramson Cancer Center
New Targets: Time To Get Excited?
- 5:33 PM Panel Question and Answer**
- 5:39 PM Corey J. Langer, MD (Discussion of Abstract(s) 8517-8519)**
University of Pennsylvania Perelman School of Medicine
PD-L1, CTLA4, Cyclin D, Oh, My!
- 5:51 PM Panel Question and Answer**

Posters discussed in this session are on display in the Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Poster Session. See page 194 for poster information.

4:45 PM - 6:00 PM Education Session

Common Themes in Uncommon Lymphomas: How Biology and Novel Treatments Are Changing the Landscape

Location: E450

Interact ID: 10709

Francine M. Foss, MD - Chair

Yale Cancer Center

Emerging Role of Novel Therapies in Cutaneous T-Cell Lymphoma

Christian Grommes, MD

Memorial Sloan Kettering Cancer Center

Treatment of Primary Central Nervous System Lymphoma: From Chemotherapy to Small Molecules

Thierry Lamy, MD, PhD

Centre Hospitalier Universitaire Pontchaillou

Latest Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia

Panel Question and Answer

4:45 PM - 6:00 PM Education Session

Communicating the Financial Burden of Treatment With Patients

Location: S404

Interact ID: 10690

Ryan David Nipp, MD - Chair

Massachusetts General Hospital

The Clinician's Perspective on Discussing Costs With Patients

Gery Guy, PhD, MPH

Centers for Disease Control and Prevention

Cost in the Era of Targeted Therapies and Immunotherapies for Cancer

Ellen Sonet, MBA, JD

CancerCare

Sunday, June 3, 2018

Assisting Patients With the Cost Burden of Cancer Diagnosis and Treatment: Next-Generation Sequencing Testing, Off-Label Medications, and More

Panel Question and Answer

4:45 PM - 6:00 PM Education Session

Global Myeloma, Health Disparities, and the Cost of Drugs

Location: E451

Interact ID: 10759

Timothy Rebbeck, PhD

Harvard University, T.H. Chan School of Public Health, and Dana-Farber Cancer Institute
Myeloma Outcomes and Disparities in African Americans

Philippe Moreau, MD - Chair

CHU de Nantes-Hôtel Dieu

Global Approaches in Myeloma: Critical Trials That May Change Practice

S. Vincent Rajkumar, MD

Mayo Clinic

Debate: Value and Cost of Myeloma Therapy—We Cannot Afford It

Rafael Fonseca, MD

Mayo Clinic

Debate: Value and Cost of Myeloma Therapy—We Can Afford It

Panel Question and Answer

4:45 PM - 6:00 PM Education Session

Innovative Strategies Targeting Subtypes in Metastatic Breast Cancer

Location: Hall B1

Interact ID: 10769

Matthew P. Goetz, MD

Mayo Clinic

ER+ Metastatic Breast Cancer: Beyond CDK Inhibitors

Stacy L. Moulder, MD, MS - Chair

The University of Texas MD Anderson Cancer Center

Novel Drugable Pathways in Triple-Negative Breast Cancer

Mark D. Pegram, MD

Stanford School of Medicine

Overcoming Resistance in HER2+ Metastatic Breast Cancer

Panel Question and Answer

4:45 PM - 6:00 PM Education Session

Lifestyle Modifications for Primary and Secondary Cancer Prevention: Diet, Exercise, Sun Safety, and Alcohol Reduction

Location: S102

Interact ID: 10907

Noelle K. LoConte, MD - Chair

University of Wisconsin Carbone Cancer Center
Alcohol and Cancer: A Review of the ASCO Position Paper

Jeffrey E. Gershenwald, MD

The University of Texas MD Anderson Cancer Center
Malignant Melanoma Prevention: Lifestyle Changes and Legislation

Cynthia A. Thomson, PhD, RDN

University of Arizona
Diet and Exercise: Role in Primary Cancer Prevention and Cancer Recurrence

Panel Question and Answer

4:45 PM - 6:00 PM Education Session

Novel Approaches in Bone and Soft Tissue Sarcomas: The Emerging Role of Precision Medicine

Location: S103
Interact ID: 10777

Seth Pollack, MD

Fred Hutchinson Cancer Research Center
Is There a Role for Immunotherapy in Sarcomas?

Emanuela Palmerini, MD

Istituto Ortopedico Rizzoli
Precision Medicine in Bone Tumors

Daniela Katz, MD - Chair

Assaf Harofeh Medical Center
Over 50 Subtypes of Soft Tissue Sarcoma: Can We Ever Have a Specific Treatment for Each?

Panel Question and Answer

4:45 PM - 6:00 PM Education Session

Pediatric Clinical Trials: Economics, Cost, and Value of Investment

Location: S504
Interact ID: 10763

Sharon M. Castellino, MD, MSc

Children's Healthcare of Atlanta
Proof-of-Paradigm of Cost-Effectiveness Analysis Within a Therapeutic Clinical Trial

Susan K. Parsons, MD - Chair

Tufts Medical Center
Financial Consideration of Novel Therapeutics Within the Setting of Pediatric Oncology

K. Robin Yabroff, PhD

American Cancer Society
Financial Hardship Associated With Cancer Survivorship

Panel Question and Answer

Sunday, June 3, 2018

4:45 PM - 6:00 PM Education Session

Precision Medicine for a Single Patient: What Does It Really Mean and How Do We Do It?

Location: S406

Interact ID: 10738

Victoria Meucci Villaflor, MD - Chair

Northwestern University

Complexity of Delivering Precision Medicine: Challenges and Opportunities

Matthew Meyerson, MD, PhD

Dana-Farber Cancer Institute

Role of Big Data and Informatics in Precision Medicine

Amy E. McKee, MD

U.S. Food and Drug Administration

Regulatory Science: The Challenges with "SMALL DATA": Small Trials, Off-Label Use, and Single Patient INDs—Are We Doing Enough?

Panel Question and Answer

4:45 PM - 6:00 PM Education Session

The Winds of Change: Optimizing Immunotherapy, Radiopharmaceuticals, and PARP Inhibition in Prostate Cancer

Location: Hall D1

Interact ID: 10913

Martin Pomper, MD

Johns Hopkins University School of Medicine

Radiopharmaceuticals: Emitting the Right Signals in Prostate Cancer

Carmel Jo Pezaro, MBChB

Monash University

Optimal Integration of PARP Inhibitors for Prostate Cancer: Which Test, Which Patient, and Which Therapy?

Ravi Amrit Madan, MD - Chair

National Cancer Institute at the National Institutes of Health

Immunotherapy in Prostate Cancer: The Path Forward

Panel Question and Answer

4:45 PM - 6:00 PM Meet the Professor Session

Addressing Fertility in Young Adult Cancer Survivors - Ticketed Session

Location: E253d

Interact ID: 10798

Karine Chung

USC Fertility

4:45 PM - 6:00 PM Meet the Professor Session

The Peer-Review Process and Writing an Outstanding Manuscript - Ticketed Session

Location: E253c
Interact ID: 10700

Stephen A. Cannistra, MD, FASCO
Beth Israel Deaconess Medical Center

5:00 PM - 5:30 PM Post-Plenary Session

Post-Plenary Discussion Session III: Kidney Cancer

Location: S100a
Interact ID: 10855

Toni K. Choueiri, MD - Chair
Dana-Farber Cancer Institute

Daniel J. George, MD
Duke University
Panelist

Arnaud Mejean, MD, PhD
Hôpital Européen Georges-Pompidou - Paris Descartes University
Panelist

David Chen, MD
Fox Chase Cancer Center
Panelist

5:30 PM - 6:00 PM Post-Plenary Session

Post-Plenary Discussion Session IV: Lung Cancer

Location: S100bc
Interact ID: 10856

Melissa Lynne Johnson, MD - Chair
Sarah Cannon Research Institute

Gilberto Lopes, MD, MBA
Sylvester Comprehensive Cancer Center, University of Miami Health System
Panelist

Leena Gandhi, MD, PhD
NYU Perlmutter Cancer Center
Panelist

Scott Joseph Antonia, MD, PhD
H. Lee Moffitt Cancer Center & Research Institute
Panelist

Notes

Notes

Notes

Notes

Notes

Notes

Notes

7:30 AM - 9:15 AM Highlights of the Day Session

Highlights of the Day Session II

Location: Hall D1

Interact ID: 10815

David C. Smith, MD - Chair

University of Michigan

7:30 AM Harold J. Burstein, MD, PhD, FASCO

Dana-Farber Cancer Institute

Breast Cancer—Metastatic

7:45 AM Elizabeth R. Plimack, MD, MS

Fox Chase Cancer Center

Genitourinary (Nonprostate) Cancer

8:00 AM David G. Pfister, MD, FASCO

Memorial Sloan Kettering Cancer Center

Head and Neck Cancer

8:15 AM Ann S. LaCasce, MD

Dana-Farber Cancer Institute

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

8:30 AM Martin R. Stockler, MBBS, MS, FRACP

NHMRC Clinical Trials Centre, The University of Sydney

Patient and Survivor Care

8:45 AM E. Anders Kolb, MD

Nemours Alfred I. duPont Hospital for Children

Pediatric Oncology

8:00 AM - 9:15 AM Education Session

Cancer Stem Cells: Untangling the Controversies, Rationalizing the Treatments

Location: E451

Interact ID: 10782

Kwok-Kin Wong, MD, PhD - Chair

Dana-Farber Cancer Institute

Cancer Stem Cells: Roots of Therapeutic Resistance?

Christopher Dravis, PhD

Salk Institute

Cancer Self-Replication: An Emergent Property in Lineage-Committed Progenitors?

Yogen Sauntharajah, MD

Cleveland Clinic

Ultimate Precision: Targeting Cancer but Not Normal Self-Replication

Panel Question and Answer

Monday, June 4, 2018

8:00 AM - 9:15 AM Education Session

Genetics and Prevention in Gynecologic Cancer

Location: S100bc

Interact ID: 10744

Christine S. Walsh, MD - Chair

Cedars-Sinai Medical Center

An Overview of Genetic Counseling in Gynecologic Cancers: Who to Test, When to Test, What Panel to Use, and Why

Leslie M. Randall, MD

University of California, Irvine

Gynecologic Cancer Genetics Beyond BRCA

Noah D. Kauff, MD

Memorial Sloan Kettering Cancer Center

Unaffected Obligate Carriers: When to Intervene

Panel Question and Answer

8:00 AM - 9:15 AM Education Session

Hepatocellular Carcinoma: A Global Perspective

Location: S406

Interact ID: 10694

Man-Fung Yuen, MD, PhD

Queen Mary Hospital University of Hong Kong

Global Epidemiology of HCC

Jessica Hwang, MD, MPH - Chair

The University of Texas MD Anderson Cancer Center

HBV and HCV Role in HCC Prevention and Management

Nahum Mendez-Sanchez, MD, PhD

Medica Sur Clinic Mexico City

Global Treatment Pattern Variations in HCC

Panel Question and Answer

8:00 AM - 9:15 AM Education Session

Optimizing Survivorship and Maximizing Survival in Germ Cell Cancer

Location: E450

Interact ID: 10724

Darren R. Feldman, MD - Chair

Memorial Sloan Kettering Cancer Center

State-of-the-Art Management of Germ Cell Cancer

Christian K. Kollmannsberger, MD

British Columbia Cancer Agency - Vancouver Centre

Survivorship and Surveillance in Management of Germ Cell Cancer

Anja Lorch, MD

Heinrich Heine University

Approaches in Management of Refractory Germ Cell Cancer

Panel Question and Answer

8:00 AM - 9:15 AM Education Session

Psychosocial Needs of Cancer Survivors and Best Practices for Distress Screening

Location: S103

Interact ID: 10688

Donald Lee Rosenstein - Chair

University of North Carolina Lineberger Comprehensive Cancer Center

Addressing Distress Across the Cancer Continuum in Different Age Groups

Matthew J. Loscalzo, MSW

City of Hope Comprehensive Cancer Center

Best Practices in Distress Screening

Carole Mayer, PhD

Northeast Cancer Centre, Health Sciences North

Disseminating Psychosocial Services in a Canadian Province

Sophia Kustas Smith, PhD, MSW

Duke University

Novel Approaches to Distress Management

Panel Question and Answer

8:00 AM - 9:15 AM Education Session

Treating Frail Adults With Common Malignancies: Best Evidence to Personalize Therapy

Location: S404

Interact ID: 10789

Ronald John Maggiore, MD - Chair

Wilmot Cancer Institute, University of Rochester Medical Center

How to Personalize Care for Frail Older Adults With Advanced Lung Cancer in the Era of Immunotherapy

Ravindran Kanesvaran, MD

National Cancer Centre Singapore

Treating Older Adults With Advanced Bladder Cancer: Where Evidence and Multimorbidity Collide

Raul Cordoba, MD, PhD, MS

Fundacion Jimenez Diaz University Hospital

Treating for Cure or Palliation: Difficult Decisions for Older Adults With Aggressive Lymphoma

Panel Question and Answer

Monday, June 4, 2018

8:00 AM - 9:15 AM Education Session

When Cancer Hits Close to Home: Treating Colleagues and Loved Ones

Location: S504

Interact ID: 10914

Julia Lee Close, MD - Chair

University of Florida

Will You Be My Doctor? Where Should My Boundaries Be?

Rebecca D. Pentz, PhD

Emory University School of Medicine

Ethical Issues Surrounding the Care of Colleagues and Friends

Stephanie L. Graff, MD

Sarah Cannon Cancer Institutes HCA Midwest Health

How Close Is Too Close: Navigating Difficult Situations

Ranjana Srivastava, MBBS, FRACP

Monash Medical Centre

The Emotional Consequences of Treating Loved Ones: Considerations for the Patient and the Provider

Panel Question and Answer

8:00 AM - 9:15 AM Meet the Professor Session

Precision Active Surveillance in Prostate Cancer: Integrating Molecular Testing and Imaging - Ticketed Session

Location: E253c

Interact ID: 10725

Freddie Hamdy, MD, MBChB, FRCS

University of Oxford

Edward M. Schaeffer, MD, PhD

Northwestern University

8:00 AM - 9:30 AM Clinical Science Symposium

Tumor Testing in Precision Oncology: From Heredity to Counseling to Implementation

Location: S102

Interact ID: 10734

Stephen B. Gruber, MD, PhD - Chair

USC Norris Comprehensive Cancer Center

8:00 AM Abstract LBA1509: Pan-cancer microsatellite instability to predict for presence of Lynch syndrome. A. Latham Schwark, P. Srinivasan, Y. Kemel, J. Shia, C. Bandlamudi, D. Mandelker, M. Dubard-Gault, C. Tran, S. Middha, J. F. Hechtman, A. Penson, A. M. Varghese, L. Zhang, M. E. Robson, D. B. Solit, L. A. Diaz Jr., B. S. Taylor, K. Offit, M. F. Berger, Z. K. Stadler

8:12 AM Sabine Tejpar, MD, PhD (Discussion of Abstract(s) LBA1509)

University Hospital Leuven, KUL

Should All Patients With Cancer Be Tested for Microsatellite Instability?

- 8:24 AM Abstract 1510: Disclosure of secondary germline findings from clinical tumor-normal paired somatic mutation profiling.** *M. S. Daniels, K. H. Lu, B. Arun, M. Routbort, R. Broaddus*
- 8:36 AM Mark E. Robson, MD (Discussion of Abstract(s) 1510)**
Memorial Sloan Kettering Cancer Center
Should Tumor-Normal Genomic Testing Be the Standard of Care in Oncology?
- 8:48 AM Abstract 1511: Genetic counseling (GC) and germline (GL) testing rates after adoption of an integrated clinical cancer genetics (CCG) approach to genomics tumor board (GTB).** *S. Klek, B. Heald, A. Milinovich, Y. Ni, J. Abraham, P. Grivas, H. Mahdi, A. A. Khorana, B. J. Bolwell, D. Sohal, P. Funchain*
- 9:00 AM Daniel P. Silver, MD, PhD (Discussion of Abstract(s) 1511)**
Sidney Kimmel Cancer Center at Thomas Jefferson University
Molecular Tumor Testing: Who Should Be Referred for Inherited Susceptibility Evaluation?
- 9:12 AM Panel Question and Answer**

8:00 AM - 11:00 AM Oral Abstract Session

Breast Cancer—Local/Regional/Adjuvant

Location: Hall D2
Interact ID: 10830

Sherene Loi, MD, PhD - Chair
Peter MacCallum Cancer Centre

Elizabeth A. Mittendorf, MD, PhD - Chair
Dana-Farber/Brigham and Women's Cancer Center

- 8:00 AM Abstract 500: Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.** *M. Gnant, G. Pfeiler, G. G. Steger, D. Egle, R. Greil, F. Fitzal, V. Wette, M. Balic, F. Haslbauer, E. Melbinger-Zeinitzer, V. Bjelic-Radisic, J. C. Bergh, R. Jakesz, C. Marth, P. Sevelada, B. Mlineritsch, R. Exner, C. Fesl, S. Frantal, C. F. Singer*
- 8:12 AM Abstract 501: Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study.** *R. E. Coleman, D. Finkelstein, C. H. Barrios, M. Martin, H. Iwata, J. A. Glaspy, Y. Zhou, D. Jandial, A. Chan*
- 8:24 AM Abstract 502: Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: The ASTRRA study.** *W. Noh, J. Lee, S. Nam, S. Park, S. Im, E. Lee, Y. Jung, J. Yoon, S. Kang, S. Lee, K. Park, J. Jeong, S. Cho, S. Kim, h. Kim, C. Park, S. Han, W. Han, M. Hur*
- 8:36 AM Abstract 503: Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT.** *M. M. Regan, P. A. Francis, O. Pagani, G. F. Fleming, B. Walley, G. Viale, M. Colleoni, I. Lang, H. L. Gomez, C. A. Tondini, G. Pinotti, A. Di Leo, A. S. Coates, A. Goldhirsch, R. D. Gelber*
- 8:48 AM David A. Cameron, MD (Discussion of Abstract(s) 500-503)**
University of Edinburgh, Cancer Research UK Edinburgh Centre
Unlocking the Curative Potential of the Endocrine Axis
- 9:00 AM Panel Question and Answer**

Monday, June 4, 2018

- 9:12 AM Abstract 504: Fifteen-year results of the randomised EORTC trial 22922/10925 investigating internal mammary and medial supraclavicular (IM-MS) lymph node irradiation in stage I-III breast cancer.** *P. Poortmans, S. Collette, H. Struikmans, K. De Winter, E. Van Limbergen, C. Kirkove, V. Budach, K. Peignaux-Casasnovas, E. Vonk, D. Vandenbongard, S. Rivera, D. Zips, G. Van Tienhoven, M. Guckenberger, R. Abdah-Bortnyak, A. Fourquet, H. G. Bartelink*
- 9:24 AM Abstract 505: A gene expression assay for prediction of radiotherapy benefit in breast cancer.** *L. A. Knight, A. McCavigan, C. Steele, S. M. Walker, D. P. Harkin, R. D. Kennedy, N. McCabe*
- 9:36 AM Wendy A. Woodward, MD, PhD (Discussion of Abstract(s) 504-505)**
The University of Texas MD Anderson Cancer Center
Established and New Horizons in Radiotherapy
- 9:48 AM Panel Question and Answer**
- 10:00 AM Abstract 506: PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.** *H. M. Earl, L. Hiller, A. Vallier, S. Loi, D. Howe, H. B. Higgins, K. McAdam, L. Hughes-Davies, A. N. Harnett, M. Ah-See, R. Simcock, D. W. Rea, J. Mansi, J. Abraham, C. Caldas, C. Hulme, D. Miles, A. M. Wardley, D. A. Cameron, J. Dunn*
- 10:12 AM Abstract 507: De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study.** *V. Guarneri, M. Dieci, G. Bisagni, A. Frassoldati, G. V. Bianchi, G. De Salvo, E. Orvieto, M. Curtarello, T. Pascual, L. Pare, M. Ambroggi, C. Giorgi, G. Moretti, G. Griguolo, R. Vicini, A. Prat, P. F. Conte*
- 10:24 AM Abstract 508: Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+).** *J. K. Litton, M. Scoggins, K. R. Hess, B. Adrada, C. H. Barcenas, R. K. Murthy, S. Damodaran, S. M. DeSnyder, A. M. Brewster, A. M. Thompson, G. J. Whitman, N. K. Ibrahim, S. L. Moulder, J. Schwartz-Gomez, E. A. Mittendorf, B. Arun*
- 10:36 AM Martine J. Piccart-Gebhart, MD, PhD, FASCO (Discussion of Abstract(s) 506-508)**
Institut Jules Bordet, Université Libre de Bruxelles
Less Is More: Opportunities to De-escalate Therapy
- 10:48 AM Panel Question and Answer**

8:00 AM - 11:00 AM Oral Abstract Session

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Location: Hall B1
Interact ID: 10845

Robert B. Cameron, MD - Chair
David Geffen School of Medicine at UCLA

Jamie E. Chaft, MD - Chair
Memorial Sloan Kettering Cancer Center

- 8:00 AM Abstract 8500: Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.** *G. A. Durm, S. K. Althouse, A. A. Sadiq, S. I. Jalal, S. Jabbour, R. Zon, G. H. Kloecker, W. B. Fisher, K. L. Reckamp, E. A. Kio, R. M. Langdon Jr., B. Adesunloye, R. D. Gentzler, N. H. Hanna*

- 8:12 AM Abstract LBA8501: Genome-wide sequencing for early stage lung cancer detection from plasma cell-free DNA (cfDNA): The Circulating Cancer Genome Atlas (CCGA) study.** *G. R. Oxnard, T. Maddala, E. Hubbell, A. Aravanis, N. Zhang, O. Venn, A. Valouev, L. Shen, S. Patel, A. Jamshidi, K. Jagadeesh, S. Gross, D. Filippova, J. F. Beausang, M. C. Liu, D. A. Richards, S. Plevritis, R. T. Williams, A. Hartman, C. Swanton*
- 8:24 AM Abstract 8502: Pragmatic study of a lymph node (LN) collection kit for non-small cell lung cancer (NSCLC) resection.** *R. U. Osarogigabon, M. Smeltzer, N. R. Faris, M. Ray, C. Fehnel, C. Houston-Harris, P. Ojeabulu, O. Akinbobola, L. Wiggins, D. Talton, E. Owen, L. Deese, R. Eubanks, B. A. Wolf, T. Robbins*
- 8:36 AM David Harpole, MD (Discussion of Abstract(s) 8500-8502)**
Duke University Medical Center
Non-Small Cell Lung Cancer: Low Tech to High Tech
- 8:48 AM Panel Question and Answer**
- 9:00 AM Abstract 8503: DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma—First results.** *A. K. Nowak, W. J. Lesterhuis, B. G. Hughes, C. Brown, P. Kok, K. J. O'Byrne, T. John, N. Pavlakis, S. C. Kao, S. Yip, D. J. Karikios, W. Lam, A. Langford, M. R. Stockler*
- 9:12 AM Abstract 8504: Inherited predisposition to malignant mesothelioma (MM) due to mutations in DNA repair genes.** *R. Hassan, B. Morrow, T. Walsh, M. K. Lee, J. Gao, I. Mian, J. Khan, M. Raffeld, S. Patel, L. Xi, J. S. Wei, D. Schrupp, M. Hesdorffer, J. Zhang, K. Calzone, E. Padiernos, C. Alewine, S. M. Steinberg, A. Thomas, M. King*
- 9:24 AM Abstract 8505: Impact on health-related quality of life of the addition of bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS phase III trial.** *V. Westeel, G. Eberst, A. Anota, A. Scherpereel, J. Mazieres, J. Margery, L. Greillier, C. Audigier-Valette, D. Moro-Sibilot, O. Molinier, L. Herve, F. Rivière, I. Monnet, V. Gounant, H. Janicot, R. Gervais, C. Locher, F. Morin, G. Zalczman*
- 9:36 AM Thierry Marie Jahan, MD (Discussion of Abstract(s) 8503-8505)**
University of California, San Francisco
Dreams, Genes, and Cream (QOL)
- 9:48 AM Panel Question and Answer**
- 10:00 AM Abstract 8506: Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.** *H. C. Chung, J. A. Lopez-Martin, S. C. Kao, W. H. Miller Jr., W. Ros, B. Gao, A. Marabelle, M. Gottfried, A. Zer, J. Delord, N. Penel, S. I. Jalal, L. Xu, S. Zeigenfuss, S. K. Pruitt, S. A. Piha-Paul*
- 10:12 AM Abstract 8507: Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study.** *D. P. Carbone, D. Morgensztern, S. Le Moulec, R. Santana-Davila, N. Ready, C. L. Hann, B. S. Glisson, A. Dowlati, C. M. Rudin, S. Lally, S. Yalamanchili, J. Wolf, R. Govindan, B. Besse*
- 10:24 AM Apar Kishor Ganti, MD (Discussion of Abstract(s) 8506-8507)**
University of Nebraska Medical Center
Smart Bombs Versus Immuno Assault
- 10:36 AM Panel Question and Answer**

8:00 AM - 11:00 AM Oral Abstract Session

Melanoma/Skin Cancers

Location: Arie Crown Theater
Interact ID: 10847

Antonio C. Buzaid, MD - Chair

Antonio Ermirio de Moraes Oncology Center

Monday, June 4, 2018

Janice M. Mehnert, MD - Chair

Rutgers Cancer Institute of New Jersey

- 8:00 AM Abstract 9500: External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC): Effect of adding EORTC sentinel node (SN) tumor burden criteria on prognostic accuracy in stage III.** *M. F. Madu, V. Franke, B. Van De Wiel, W. M. Klop, K. Józwiak, M. W. Wouters, A. C. Van Akkooi*
- 8:12 AM Abstract 9501: Final analysis of DECOG-SLT trial: Survival outcomes of complete lymph node dissection in melanoma patients with positive sentinel node.** *U. M. Leiter, R. Stadler, C. Mauch, W. Hohenberger, N. Brockmeyer, C. Berking, C. Sunderkötter, M. Kaatz, K. Schatton, P. Lehmann, T. M. Vogt, J. Ulrich, R. Herbst, W. Gehring, J. Simon, U. Keim, P. Martus, C. Garbe*
- 8:24 AM Abstract 9502: Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).** *J. S. Weber, M. Mandalà, M. Del Vecchio, H. Gogas, A. M. Arance, C. L. Cowey, S. Dalle, M. Schenker, V. Chiarion-Sileni, I. Marquez Rodas, J. Grob, M. Butler, M. R. Middleton, M. Maio, V. Atkinson, R. Dummer, V. de Pril, A. H. Qureshi, J. M. Larkin, P. A. Ascierto*
- 8:36 AM April K. S. Salama, MD (Discussion of Abstract(s) 9500-9502)**
Duke University
Re-evaluating Staging and Management of Stage III Melanoma
- 8:48 AM Panel Question and Answer**
- 9:00 AM Abstract 9503: 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.** *G. V. Long, J. Schachter, A. Ribas, A. M. Arance, J. Grob, L. Mortier, A. Daud, M. S. Carlino, C. M. McNeil, M. Lotem, J. M. Larkin, P. Lorigan, B. Neyns, C. U. Blank, T. M. Petrella, O. Hamid, J. Anderson, C. Krepler, N. Ibrahim, C. Robert*
- 9:12 AM Abstract 9504: Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma.** *R. Dummer, P. A. Ascierto, H. Gogas, A. M. Arance, M. Mandalà, G. Liskay, C. Garbe, D. Schadendorf, I. Krajsova, R. Gutzmer, V. Chiarion-Sileni, C. Dutriaux, J. de Groot, N. Yamazaki, C. Loquai, L. A. De Parseval, M. D. Pickard, V. Sandor, C. Robert, K. Flaherty*
- 9:24 AM Douglas Buckner Johnson, MD (Discussion of Abstract(s) 9503-9504)**
Vanderbilt University Medical Center
Updates in Advanced Melanoma Trials
- 9:36 AM Panel Question and Answer**
- 9:48 AM Abstract 9505: Nivolumab (Nivo) as neoadjuvant therapy in patients with resectable merkel cell carcinoma (MCC) in CheckMate 358.** *S. L. Topalian, S. Bhatia, R. R. Kudchadkar, A. Amin, W. H. Sharfman, C. Lebbe, J. Delord, M. M. Shinohara, S. S. Baxi, C. H. Chung, U. M. Martens, R. L. Ferris, J. E. Stein, I. Soumaoro, R. F. Zwirter, T. Chen, Z. Cao, J. M. Taube, P. Nghiem*
- 10:00 AM Abstract 9506: Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy.** *P. Nghiem, S. Bhatia, E. J. Lipson, W. H. Sharfman, R. R. Kudchadkar, P. A. Friedlander, A. S. Brohl, A. Daud, H. M. Kluger, S. A. Reddy, M. A. Burgess, B. A. Hanks, T. Olencki, B. C. Boulmay, L. M. Lundgren, N. Ramchurren, B. Homet Moreno, E. Sharon, M. A. Cheever, S. L. Topalian*
- 10:12 AM Abstract 9507: Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.** *P. Nghiem, S. Bhatia, A. S. Brohl, O. Hamid, J. M. Mehnert, P. Terheyden, K. C. Shih, I. Brownell, C. Lebbé, K. D. Lewis, G. P. Linette, M. Milella, M. Hennessy, M. Bajars, C. Hicking, S. P. D'Angelo*

- 10:24 AM Selma Ugurel, MD (Discussion of Abstract(s) 9505-9507)**
University of Duisburg-Essen
The Changing Landscape of Merkel Cell Carcinoma Treatment
- 10:36 AM Panel Question and Answer**

8:00 AM - 11:00 AM Oral Abstract Session

Sarcoma

Location: S100a
Interact ID: 10851

Juneko E. Grilley-Olson, MD - Chair
University of North Carolina at Chapel Hill

Sam S. Yoon, MD - Chair
Memorial Sloan Kettering Cancer Center

- 8:00 AM Abstract 11500: Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105).** *M. M. Gounder, M. R. Mahoney, B. A. Van Tine, V. Ravi, S. Attia, H. A. Deshpande, A. A. Gupta, M. M. Milhem, R. M. Conry, S. Movva, M. J. Pishvaian, J. Crawford, T. Sabagh, R. G. Maki, W. D. Tap, R. A. Lefkowitz, N. P. Agaram, J. J. Wright, A. C. Dueck, G. K. Schwartz*
- 8:12 AM Abstract 11501: DESMOPAZ pazopanib (PZ) versus IV methotrexate/vinblastine (MV) in adult patients with progressive desmoid tumors (DT) a randomized phase II study from the French Sarcoma Group.** *M. Toulmonde, I. L. Ray-Coquard, M. Pulido, T. Andre, N. Isambert Sr., C. Chevreau, N. Penel, E. Bompas, A. Thyss, F. Bertucci, C. Lebbe, J. Domont, P. Soulie, S. P. Neumann, F. Cecchi, T. A. Hembrough, F. Petitprez, C. A. Bellera, J. Blay, A. Italiano*
- 8:24 AM Abstract 11502: Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).** *W. D. Tap, H. Gelderblom, S. Stacchiotti, E. Palmerini, S. Ferrari, J. Desai, S. Bauer, J. Blay, T. Alcindor, K. N. Ganjoo, J. Martin Broto, C. W. Ryan, D. E. Shuster, L. Zhang, Q. Wang, H. Hsu, P. S. Lin, S. Tong, A. J. Wagner*
- 8:36 AM Rashmi Chugh, MD (Discussion of Abstract(s) 11500-11502)**
University of Michigan
Evolving Role for Systemic Therapy in Locally Aggressive Soft Tissue Tumors
- 8:48 AM Panel Question and Answer**
- 9:00 AM Abstract 11503: Anlotinib for metastasis soft tissue sarcoma: A randomized, double-blind, placebo-controlled and multi-centered clinical trial.** *Y. Chi, Y. Yao, S. Wang, G. Huang, Q. Cai, G. Shang, G. Wang, G. Qu, Q. Wu, Y. Jiang, J. Song, J. Chen, X. Zhu, Z. Cai, C. Bai, Y. Lu, Z. Yu, J. Shen, J. Cai*
- 9:12 AM Abstract 11504: Results of randomized, placebo (PL)-controlled phase II study evaluating efficacy and safety of regorafenib (REG) in patients (pts) with metastatic osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and Unicancer.** *F. Duffaud, J. Blay, O. Mir, P. Boudou-Rouquette, S. Piperno-Neumann, N. Penel, E. Bompas, C. Delcambre, E. Kalbacher, A. Italiano, O. Collard, C. Chevreau, A. Thyss, N. Isambert Sr., J. Delaye, N. De Sousa Carvalho, C. Schiffler, C. Bouvier, V. Vidal, S. Chabaud*
- 9:24 AM Abstract 11505: A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.** *R. F. Riedel, K. V. Ballman, Y. Lu, S. Attia, E. T. Loggers, K. N. Ganjoo, M. B. Livingston, W. A. Chow, J. A. Wright, J. H. Ward, D. A. Rushing, S. H. Okuno, D. R. Reed, D. A. Liebner, V. L. Keedy, L. Mascarenhas, L. E. Davis, C. W. Ryan, D. K. Reinke, R. G. Maki*

Monday, June 4, 2018

- 9:36 AM Silvia Stacchiotti, MD (Discussion of Abstract(s) 11503-11505)**
Fondazione IRCCS Istituto Nazionale dei Tumori
Refining the Role of TKIs in Sarcoma
- 9:48 AM Panel Question and Answer**
- 10:00 AM Abstract 11506: Randomized comparison of pazopanib (PAZ) and doxorubicin (DOX) in the first line treatment of metastatic soft tissue sarcoma (STS) in elderly patients (pts): Results of a phase II study (EPAZ).**
V. Gruenwald, A. Kunitz, M. K. Schuler, P. Schoffski, H. Kopp, S. Bauer, B. Kasper, L. H. Lindner, J. Chemnitz, M. M. Crysandt, A. Stein, B. Steffen, G. Egerer, S. Zimmermann, A. Karch
- 10:12 AM Abstract 11507: Randomized phase II trial of trofosfamide vs. adriamycin in elderly patients with previously untreated metastatic soft tissue sarcoma.**
J. T. Hartmann, H. Kopp, V. Gruenwald, S. Piperno-Neumann, A. Kunitz, R. Hofheinz, L. Mueller, M. Geissler, M. Horger, P. Fix, J. Chemnitz, R. Eckert, C. Hann von Weyhern, S. Bauer, F. Mayer
- 10:24 AM Abstract 11508: Results of a prospective randomized phase III T-SAR trial comparing trabectedin (T) vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS): A French Sarcoma Group (FSG) trial.** A. Le Cesne, J. Blay, D. Cupissol, A. Italiano, C. Delcambre, N. Penel, N. Isambert Sr., C. Chevreau, E. Bompas, F. Bertucci, L. Chaigneau, S. Piperno-Neumann, S. Salas, M. Rios, C. Guillemet, J. Bay, I. L. Ray-Coquard, L. Haddag, O. Mir, S. Foulon
- 10:36 AM Vicki Leigh Keedy, MD (Discussion of Abstract(s) 11506-11508)**
Vanderbilt University Medical Center
Systemic Therapy in Elderly Patients With Sarcoma
- 10:48 AM Panel Question and Answer**

8:00 AM - 11:30 AM Poster Session

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Location: Hall A

Abstracts on Boards 335-346 will be discussed during the Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics Poster Discussion Session.

Posters by Topic

Antibodies: Boards 347-351

Chemotherapy: Boards 345, 352-357

Conduct of Clinical Research: Boards 338, 358-371

Immunoconjugates: Board 372

Other Novel Agents: Boards 335, 337, 342, 344, 346, 373-388

Pharmacology: Boards 343, 389-402

Small Molecules: Boards 336, 339-341, 403-421

Trials in Progress: Boards 422a-434b

- Board 335 Abstract 2509: Preliminary results of a first-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP- α in patients with advanced liver cancer.** D. Sarker, E. R. Plummer, B. Basu, T. Meyer, K. Huang, T. Evans, D. Spalding, Y. Ma, D. H. Palmer, C. E. Chee, N. A. Habib
- Board 336 Abstract 2510: Results of the first-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain (BD) and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (R/R) solid tumors.** S. A. Piha-Paul, J. C. Sachdev, M. A. Barve, P. LoRusso, R. Z. Szmulewitz, S. P. Patel, M. D. McKee, J. E. Wolff, B. Hu, A. Sood, X. Chen, S. C. Wilson, B. H. O'Neil

- Board 337 Abstract 2511: Ph 1 study of MRG-106, an inhibitor of miR-155, in CTCL.** *F. M. Foss, C. Querfeld, Y. H. Kim, L. C. Pinter-Brown, B. M. William, P. Porcu, T. Pacheco, B. Haverkos, J. DeSimone, J. Guitart, A. S. Halwani, H. A. Eradat, A. Huen, A. G. Seto, L. A. Pestano, G. S. Gordon, D. Escolar, P. Rubin, W. S. Marshall, J. Williams*
- Board 338 Abstract 2512: Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in breast cancer patients: Phase 1 dose escalation study.** *T. Kogawa, K. Yonemori, N. Masuda, S. Takahashi, M. Takahashi, H. Iwase, T. Nakayama, T. Saeki, T. Toyama, T. Takano, H. Onuma, H. Ogawa, Y. Tanaka, Y. Igari, M. Sugihara, M. Vigliotti, C. Yu, M. S. Olivo, S. Ueno, H. Iwata*
- Board 339 Abstract 2513: A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1).** *A. E. Drilon, S. I. Ou, B. Cho, D. Kim, J. Lee, J. J. Lin, V. W. Zhu, H. Kim, T. Kim, M. Ahn, D. R. Camidge, J. K. Lim, S. Stopatschinskaja, J. J. Cui, D. M. Hyman, R. C. Doebele, A. T. Shaw*
- Board 340 Abstract 2514: First-in-human study of DS-6051b in patients (pts) with advanced solid tumors (AST) conducted in the US.** *K. P. Papadopoulos, L. Gandhi, P. A. Janne, S. I. Ou, A. Shaw, T. R. Goldberg, J. Greenberg, X. Gu, M. Tachibana, G. Senaldi, R. Shiga, H. Zahir, K. Nakamaru, E. Borazanci*
- Board 341 Abstract 2515: A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors.** *A. B. El-Khoueiry, J. Desai, S. P. Iyer, S. M. Gadgeel, S. S. Ramalingam, L. Horn, P. LoRusso, G. Bajaj, G. Kollia, Z. Qi, S. Basak, B. S. Fischer, M. Davis, P. L. Bedard*
- Board 342 Abstract 2516: Phase I trial of z-endoxifen with estrogen receptor imaging in adults with advanced hormone receptor-positive solid tumors including desmoid and gynecologic tumors.** *N. Takebe, G. H. O'Sullivan Coyne, S. Kummar, J. M. Reid, R. Piekarz, L. Harris, L. Juwara, M. F. Quinn, N. Moore, P. L. Choyke, E. Mena, L. Lindenberg, F. Lin, M. P. Goetz, R. M. McGovern, H. Streicher, J. M. Covey, J. M. Collins, J. H. Doroshow, A. P. Chen*
- Board 343 Abstract 2517: First-in-human, first-in-class phase 1a study of BXQ-350 for solid tumors and gliomas.** *O. Rixe, J. C. Morris, V. K. Puduvalli, J. L. Villano, T. M. Wise-Draper, C. Muller, A. N. Johnson, R. Wesolowski, X. Qi*
- Board 344 Abstract 2518: A phase Ia/Ib trial of the DNA-PK inhibitor M3814 in combination with radiotherapy (RT) in patients (pts) with advanced solid tumors: Dose-escalation results.** *B. Van Triest, L. Damstrup, J. Falkenius, V. Budach, E. Troost, M. Samuels, J. Debus, M. M. Sørensen, K. Berghoff, R. Strotman, M. van Bussel, S. Goel, P. F. Geertsen*
- Board 345 Abstract 2519: First-in-human phase I study of JPH203, L-type amino acids transporter 1 inhibitor, in patients with advanced solid tumors.** *N. Okano, K. Kawai, T. Kobayashi, F. Nagashima, H. Endou, J. Furuse*
- Board 346 Abstract 2520: First-in-class phase I study evaluating MP0250, a VEGF and HGF neutralizing DARPIN molecule, in patients with advanced solid tumors.** *A. Azaro, J. Rodon, M. R. Middleton, R. D. Baird, R. Herrmann, U. Fiedler, J. Haunschild, M. Häuptle, F. J. Hermann, S. Schreiner, A. Harstrick, K. M. Dawson, A. G. Omlin*
- Board 347 Abstract 2521: Can VEGFA and ICAM1 polymorphisms predict response to bevacizumab? A.** *Papachristos, T. Katsila, E. Panoilia, E. Mendrinou, A. John, B. R. Ali, C. P. Kalofonos, G. Patrinos, G. Sivolapenko*
- Board 348 Abstract 2522: A phase I dose escalation study of hPV19, a novel humanized monoclonal antibody against vascular endothelial growth factor (VEGF), in patients with advanced solid tumors refractory to standard therapy.** *D. Ji, W. Shen, H. Li, Y. Xia, Y. Wang, S. Luo, Q. Zhou, Y. Xu, J. Cao*
- Board 349 Abstract 2523: PK/PD properties of BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking Nanobody, in patients (pts) with advanced/metastatic solid tumors.** *C. Le Tourneau, J. Tabernero, R. Claus, R. M. Fritsch, F. Ricci, E. Elez, B. Hackanson, U. Kunz, T. Arnhold, H. Niessen, S. Keller, R. Graeser, N. Isambert Sr.*

Monday, June 4, 2018

- Board 350 **Abstract 2524: Evaluation of fixed-dose regimens of seribantumab in patients with solid tumors.** *B. Adiwijaya, W. Kamoun, S. Ghassemifar, S. Santillana, L. V. Sequist, P. A. Kaufman, J. Ettl, J. F. Liu, M. J. Higgins, J. M. Pipas*
- Board 351 **Abstract 2525: Pharmacokinetics of Hu5F9-G4, a first-in-class anti-CD47 antibody, in patients with solid tumors and lymphomas.** *B. Agoram, B. Wang, B. I. Sikic, N. J. Lakhani, A. Patnaik, J. Liu, R. Secreto, M. Chao, C. H. Takimoto*
- Board 352 **Abstract 2526: A phase I study to evaluate safety, tolerability, pharmacokinetics and activity of oraxol in patients (pts) with advanced malignancies.** *W. Ma, N. S. Azad, E. T. Lam, J. R. Diamond, G. K. Dy, M. Opyrchal, D. Gallagher, C. Brennen, D. Cutler, D. Kramer, W. K. Chan, R. Kwan, G. J. Fetterly, A. A. Adjei, A. Jimeno*
- Board 353 **Abstract 2527: A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without systemic bevacizumab, for patients with advanced cancer and liver involvement.** *E. Fountzilas, E. Krishnan, F. Janku, S. Fu, D. D. Karp, A. Naing, V. Subbiah, D. S. Hong, S. A. Piha-Paul, D. J. Vining, A. M. Tsimberidou*
- Board 354 **Abstract 2528: Plinabulin (Plin), a small molecule with anti-cancer activity and a novel mechanism of action (MoA) in docetaxel (Tax)-induced neutropenia: Phase (p) 2 results from a head-to-head comparison with Pegfilgrastim (Peg).** *D. W. Blayney, Y. Shi, I. Bondarenko, Q. Zhang, N. V. Kovalenko, J. Feng, I. Vynnychenko, M. V. Kopp, S. Ogenstad, L. Du, L. Huang, R. W. Mohanlal*
- Board 355 **Abstract 2529: Phase 1/2a study of BAL101553, a novel tumor checkpoint controller (TCC), administered as 48-hour infusion in adult patients with advanced solid tumors.** *M. Joerger, I. Metaxas, A. Stathis, D. Hess, M. T. Mark, F. Hutter, N. Levy, S. Stuedeli, S. Berardi, M. Landau-Salzberg, M. F. Engelhardt, P. Larger, T. Kaindl, P. Hafner, P. McKernan, H. A. Lane, R. A. Von Moos, C. Sessa*
- Board 356 **Abstract 2530: Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with advanced solid tumors.** *J. S. Lopez, E. R. Plummer, M. Devlin, R. Rulach, A. H. Ingles Garces, N. R. Haris, R. Miller, D. Crawford, M. D'Arcangelo, C. Aversa, A. L. Hannah, S. Anderson, M. F. Engelhardt, T. Kaindl, P. Larger, F. Bachmann, H. A. Lane, P. McKernan, T. Evans, R. S. Kristeleit*
- Board 357 **Abstract 2531: Investigation of profile-related evidence determining individualized cancer therapy (I-PREDICT) in heavily pre-treated patients: A role for combinatorial precision cancer therapy.** *J. K. Sicklick, S. Kato, M. C. Schwaederle, R. Okamura, M. Hahn, C. B. Williams, P. De, A. K. Krie, D. E. Piccioni, V. A. Miller, J. S. Ross, A. Benson, J. Webster, P. J. Stephens, J. Lee, P. T. Fanta, B. Leyland-Jones, R. Kurzrock*
- Board 358 **Abstract 2532: Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.** *T. Al Baghdadi, S. Halabi, E. Garrett-Mayer, P. K. Mangat, E. R. Ahn, V. Sahai, R. H. Alvarez, E. S. Kim, K. J. Yost, K. Guo, A. L. Rygiel, K. R. Antonelli, N. L. Butler, S. S. Bruinooge, R. L. Schilsky*
- Board 359 **Abstract 2533: Enrolling patients in clinical trials: Advice from close family and friends.** *F. Eisinger, T. De La Motte Rouge, J. Viguier, M. Roupret, C. Touboul, C. Lhomel, L. Greillier, J. F. Morere, S. Couraud*
- Board 360 **Abstract 2534: AUCtox: A new method to evaluate the safety of anticancer drugs.** *V. Launay-Vacher, C. Helissey, B. Laguerre, D. Spaeth, T. Lloret, J. Stevens, P. Bossi, F. Scotte*
- Board 361 **Abstract 2535: Trends in oncology trials termination due to toxicity over a period of 16 years.** *L. Vidal, K. K. Curtis, L. Vidal-Fisher, G. Kos, K. R. Moss*
- Board 362 **Abstract 2536: Systematic review of pediatric oncology phase I trials: Toxicity and outcomes in the era of targeted therapies.** *J. W. Cohen, S. Akshintala, E. Kane, S. M. Steinberg, B. C. Widemann, N. N. Shah*

- Board 363 Abstract 2537: A randomized Bayesian phase 1 design combining an MPS-1 inhibitor with paclitaxel: A strategy to improve determination of the incremental toxicity of a novel compound over a known backbone therapy.** *F. Atrafi, O. Boix, P. Rajagopalan, A. W. Tolcher, P. LoRusso, J. P. Eder, K. K. Sankhala, S. P. Chawla, V. Subbiah, J. R. Diamond, M. Gutierrez, R. H. Mathijssen, J. Mei, J. Verweij, I. Bruns, M. P. Lolkema*
- Board 364 Abstract 2538: Successes and challenges faced by tissue collection during trials by oncology translational sciences.** *M. P. Roudier, V. Rocher Ros, C. Hirst, M. Nikolaou, G. N. Jones, S. E. Willis, W. J. Howat, E. Harrington*
- Board 365 Abstract 2539: Prospective assessment of tumor biopsies as part of clinical trials: Patients' (pts) perspectives.** *S. L. Cyriac, M. K. Wilson, V. L. Bowering, W. Hunt, D. Gutierrez, Y. Lee, I. Colombo, L. Bonilla, V. Speers, S. Ghai, N. C. Dhani, M. O. Butler, A. M. Oza, S. Lheureux*
- Board 366 Abstract 2540: Accelerated vs. regular approval: Lessons learned from U.S. FDA oncology approvals.** *I. Carneiro Leao, G. M. Blumenthal, G. H. Reaman, R. Pazdur, K. Liu*
- Board 367 Abstract 2541: A phase I molecular adaptive clinical study to evaluate safety and tolerability of BPM31510-IV in advanced solid tumors: Final study results.** *N. R. Narain, V. Subbiah, D. S. Hong, D. Lucius, V. R. Akmaev, M. A. Kiebish, G. M. Miller, E. Milliman, L. O. Rodrigues, L. Zhang, R. Sarangarajan*
- Board 368 Abstract 2542: Adverse events (AEs) in early phase cancer clinical trials.** *G. Mishkin, A. Denicoff, S. P. Ivy, R. Piekarz, S. Finnigan, J. C. Foster, L. M. Minasian*
- Board 369 Abstract 2543: Violations of the proportional hazards assumption in randomized phase III oncology clinical trials.** *R. Rahman, G. Fell, L. Trippa, B. M. Alexander*
- Board 370 Abstract 2544: FACTS: Factors affecting combination trial success.** *C. J. Paller, E. Huang, T. Luechtefeld, H. A. Massett, C. Williams, J. Zhao, A. Gravell, S. A. Reeves, G. L. Rosner, M. A. Carducci, L. Rubinstein, S. P. Ivy*
- Board 371 Abstract 2545: The rate of tumor growth during treatment accurately predicts the FDA gold standard of overall survival [OS] in a broad range of malignancies.** *J. Wilkerson, K. B. Blagoev, W. D. Stein, E. Hecht, J. A. Chabot, E. Espinal Dominguez, M. Blanco-Codesido, M. J. Murphy, A. T. Fojo, S. E. Bates*
- Board 372 Abstract 2546: Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors.** *E. P. Hamilton, M. A. Barve, A. Bardia, M. Beeram, J. C. Bendell, R. Mosher, E. Hailman, D. A. Bergstrom, H. A. Burris III, H. H. Soliman*
- Board 373 Abstract 2547: A phase 1b study of the safety, pharmacokinetics, and preliminary antitumor activity of citarinostat (ACY-241) in combination with paclitaxel (Pac) in patients (pts) with advanced solid tumors (AST).** *M. S. Gordon, G. Shapiro, J. Sarantopoulos, D. Juric, B. Lu, P. Chen, J. Connarn, Y. Le Bruchec, R. Harvey*
- Board 374 Abstract 2548: NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors.** *A. A. Turk, T. A. Leal, N. Chan, R. Wesolowski, R. O'Regan, M. E. Burkard, A. Tevaarwerk, L. Rice, T. C. Campbell, J. Y. Bruce, J. Malhotra, L. M. Barroilhet, J. M. Mehnert, J. C. Eickhoff, G. Liu, K. B. Wisinski*
- Board 375 Abstract 2549: Phase I trial of the triplet M6620 (formerly VX970) + veliparib + cisplatin in patients with advanced solid tumors.** *G. H. O'Sullivan Coyne, K. T. Do, S. Kummar, N. Takebe, M. F. Quinn, S. A. Piha-Paul, A. Bruns, L. Juwara, E. Sharon, R. Piekarz, H. Streicher, L. Rubinstein, D. Wilsker, R. J. Kinders, R. E. Parchment, E. B. Levy, A. Doyle, J. H. Doroshow, A. P. Chen*
- Board 376 Abstract 2550: Phase Ib/2a study of PLX51107, a small molecule BET inhibitor, in subjects with advanced hematological malignancies and solid tumors.** *A. Patnaik, R. D. Carvajal, K. M. Komatsubara, C. D. Britten, R. Wesolowski, G. Michelson, O. Alcantar, C. Zhang, B. Powell, P. Severson, E. Martin, M. M. Orloff*

Monday, June 4, 2018

- Board 377 **Abstract 2551: Phase I trial of lurbinectedin (PM1183) in Japanese patients with advanced tumors: Results of the dose escalation part.** *S. Takahashi, T. Shimizu, T. Doi, J. A. Lopez-Vilariño, R. Nuñez, C. M. Kahatt, C. Fernandez, K. Zaragoza, H. Sasamoto, A. Soto-Matos*
- Board 378 **Abstract 2552: Abrogation of resistance against bevacizumab (Bev) by mitochondrial inhibition: A phase 0 randomized trial of Bev plus ME344 or placebo in early HER2-negative breast cancer (HERNEBC).** *M. Quintela-Fandino, J. V. Apala, A. C. Salgado, S. A. Mouron, J. A. Guerra, M. G. Cortes, M. Morente, L. Manso*
- Board 379 **Abstract LBA2553: Precision medicine: Clinical outcomes including long-term survival according to the pathway targeted and treatment period: The IMPACT study.** *A. M. Tsimberidou, D. S. Hong, J. J. Wheler, G. S. Falchook, A. Naing, S. Fu, S. A. Piha-Paul, F. Janku, C. Cartwright, R. Broaddus, G. M. Nogueras-Gonzalez, P. Hwu, R. Kurzrock*
- Board 380 **Abstract 2554: A phase 1/2 study of relacorilant + nab-paclitaxel (nab-pac) in patients (pts) with solid tumors: The dose-finding phase.** *P. N. Munster, J. C. Sachdev, G. F. Fleming, T. S. Block, S. P. Shepherd*
- Board 381 **Abstract 2555: Real world results of liquid biopsy in stage 3/4 solid tumors and potential “clinical actionability.”** *R. C. Arend, A. Londono, A. Martínez, A. Ford, C. Brown, C. Yeh, N. Javadi, G. J. Weiss*
- Board 382 **Abstract 2556: A phase Ib study of ADI-PEG 20 plus pembrolizumab in advanced solid cancers.** *K. Chang, N. Chiang, C. Yen, S. Wu, S. Chen, A. Johnston, J. S. Bomalaski, B. Wu, L. Chen*
- Board 383 **Abstract 2557: Phase 1 study of ANDES-1537: A novel antisense oligonucleotide against non-coding mitochondrial DNA in advanced solid tumors.** *M. S. Dhawan, R. R. Aggarwal, E. Boyd, K. Comerford, J. Zhang, B. Méndez, P. Valenzuela, J. Grabowsky, S. Thomas, P. N. Munster*
- Board 384 **Abstract 2558: Characterization of KEAP1-NRF2 genomic alterations across diverse tumor types: Co-occurring alterations, survival outcomes, and implications for targeting cancer metabolism.** *S. Sen, K. R. Hess, J. Roszik, K. R. Shaw, J. Heymach, L. Huang, G. K. Schwartz, F. Meric-Bernstam, V. Subbiah*
- Board 385 **Abstract 2559: Identification of predictive and pharmacodynamic biomarkers associated with the first-in-class selective axl inhibitor bemcentinib across multiple phase II clinical trials.** *R. J. Holt, D. Micklem, A. Brown, M. Yule, S. Loges, J. Lorens*
- Board 386 **Abstract 2560: Interim results from a phase 1 trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumors.** *J. S. Wang, M. A. Barve, E. G. Chiorean, P. LoRusso, K. D. Courtney, D. Qi, A. Olguin, J. Bullington, M. Sardone, V. Dunn, S. Shemesh, J. Chen, C. Brooks, T. M. Bauer*
- Board 387 **Abstract 2561: Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.** *A. Wang-Gillam, A. C. Lockhart, B. R. Tan Jr., R. Suresh, K. Lim, L. Ratner, D. G. DeNardo*
- Board 388 **Abstract 2562: Phase I clinical trial of the glutaminase inhibitor CB-839 plus capecitabine in patients with advanced solid tumors.** *J. R. Eads, S. S. Krishnamurthi, J. N. Saltzman, D. L. Bajor, S. Vinayak, J. Barnholtz-Sloan, N. J. Meropol, S. D. Markowitz, Z. Wang*
- Board 389 **Abstract 2563: The utility of genomics and functional imaging to predict Sunitinib PK and PD: The Predict SU study.** *M. Michael, D. W. Pook, V. Ganju, E. Link, G. C. Toner, R. J. Hicks, A. Matera, M. Thompson, C. Cullinane, I. Campbell, M. Burge, C. S. Karapetis*
- Board 390 **Abstract 2564: Pharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC).** *W. P. Kirschbrown, B. Wang, I. Nijem, A. Ohtsu, P. M. Hoff, M. A. Shah, L. Shen, Y. Kang, J. Tabernero, S. Girish, A. Garg*

- Board 391 Abstract 2565: Validation of a new model for estimating glomerular filtration rate in patients with cancer.** *E. Williams*, R. S. Geisler, I. Beh, G. Bertelli, R. Cathomas, M. J. Dooley, H. M. Earl, M. Fehr, D. Giglio, P. D. Lewis, P. Mark, J. Ocen, S. G. Poole, S. T. Shepherd, A. Quinton, J. Weaver, J. D. White, S. Tavaré, D. I. Jodrell, T. Janowitz
- Board 392 Abstract 2566: Selection of the recommended phase 2 dose (RP2D) for M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF- β and PD-L1.** *Y. Vugmeyster*, J. Wilkins, E. Harrison-Moench, W. Geng, A. Koenig, L. Cao, J. L. Gulley, I. Dussault, A. Khandelwal
- Board 393 Abstract 2567: TAK-659 in combination with NKTR-214 and anti-PD-1 therapy leads to complete and sustained tumor regression and immune memory in pre-clinical syngeneic models.** *J. Yu*, J. H. Sappal, M. Zhang, K. Kannan, J. Zalevsky
- Board 394 Abstract 2568: Unexpected pharmacokinetics of evofosfamide observed in phase III MAESTRO study.** *J. P. Higgins*, N. Sarapa, J. Kim, E. Poma
- Board 395 Abstract 2569: An open-label, randomized cross-over bioavailability and extension study of oral paclitaxel and HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumours.** *C. G. Jackson*, S. Deva, K. F. Bayston, K. Eden, B. R. McLaren, P. Barlow, N. A. Hung, K. Clarke, D. Cutler, G. Fetterly, M. R. Kwan, D. Kramer, W. Chan, T. Hung
- Board 396 Abstract 2570: Gene expression and cytokine modulation in a first in human (FIH) study of a pan BET inhibitor ABBV-075 in solid tumors.** *B. H. O'Neil*, D. Modi, P. LoRusso, S. Wong, M. Motwani, J. C. Sachdev, J. E. Wolff, S. P. Patel, B. Hu, R. Z. Szmulewitz, A. Sood, M. A. Barve, M. D. McKee, S. A. Piha-Paul
- Board 397 Abstract 2571: Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKI) in routine practice in an oncology service. preliminary results.** *M. Sureda*, V. Dominguez, V. Escudero, A. Brugarolas
- Board 398 Abstract 2572: Impact of curcumin with and without (+/-) piperine on tamoxifen exposure.** *G. Hussaarts*, D. Hurkmans, E. O. De Hoop, L. J. van Harten, S. Berghuis, R. J. van Alphen, L. E. Spierings, Q. C. van Rossum, M. B. Vastbinder, R. H. van Schaik, T. van Gelder, A. Jager, R. W. van Leeuwen, R. H. Mathijssen
- Board 399 Abstract 2573: The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy: A case-control study in a Northern Italy Cancer Centre.** *F. Iachetta*, C. Bonelli, A. Romagnani, R. Zamponi, L. Tofani, E. Farnetti, D. Nicoli, A. Damato, M. Banzi, B. Casali, C. Pinto
- Board 400 Abstract 2574: Clinical pharmacology assessment of PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in adult patients (pts) with advanced solid tumors.** *D. Xuan*, X. Xin, B. Gibson, T. Joh, H. Yin, P. D. Garzone, J. C. Sachdev, M. L. Maitland, M. Sharma, V. Moreno, E. Calvo, S. Kummar, E. M. Stringer-Reasor, N. J. Lakhani, A. W. Tolcher, D. M. Beaupre
- Board 401 Abstract 2575: The NantOmics Pharmacogenomics Test: An integrative panomic approach to pharmacogenomics screening.** *C. Schwartz*, J. Little, C. J. Vaske, S. C. Benz, P. Soon-Shiong, S. Rabizadeh, J. Sanborn
- Board 402 Abstract 2576: Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among pts with 5-FU/capecitabine (CAP)-related adverse events (AEs): Experience of 2 decades.** *N. S. Siddiqui*, S. Purvey, R. Hamal, L. Zhang, R. B. Diasio, W. M. Saif
- Board 403 Abstract 2577: Pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with IDH1-mutant advanced solid tumors from a phase 1 study.** *B. Fan*, I. K. Mellinshoff, P. Y. Wen, S. S. Pandya, L. Jiang, G. Liu, T. Nimkar, H. Yang, D. Dai
- Board 404 Abstract 2578: A multicenter study of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib plus durvalumab in patients with relapsed/refractory (R/R) solid tumors.** *D. S. Hong*, D. W. Rasco, M. H. Veeder, J. J. Luke, J. Chandler, A. S. Balmanoukian, T. J. George Jr., P. Munster, J. Berlin, M. Gutierrez, A. C. Mita, H. A. Wakelee, S. Samakoglu, S. Guan, I. W. Dimery, E. Borazanci

Monday, June 4, 2018

- Board 405 **Abstract 2579: A phase 1b dose-escalation study of prexasertib, a checkpoint kinase 1 (CHK1) inhibitor, in combination with cisplatin in patients with advanced cancer.** *M. R. Patel, D. S. Hong, J. C. Bendell, S. F. Jones, E. P. Hamilton, V. Subbiah, D. D. Karp, J. S. Wang, R. Aljumaily, S. Hynes, R. Decker, M. Niland, X. A. Wang, A. K. Lin, K. N. Moore*
- Board 406 **Abstract 2580: Vorolanib (CM082) in Chinese patients with advanced solid tumor: A phase 1, open-label, dose escalation study.** *Y. Song, J. Wang, A. Zhou, W. Zhang, C. Liang, L. Yang*
- Board 407 **Abstract 2581: Clinical pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies from a phase 1 study.** *D. Dai, C. D. Dinardo, E. Stein, S. de Botton, E. C. Attar, H. Liu, G. Liu, I. Lemieux, S. V. Agresta, H. Yang, B. Fan*
- Board 408 **Abstract 2582: BAX-BAK heterodimer as a pharmacodynamic biomarker of on-target drug action of Mcl-1 inhibitors to evaluate in-vivo effectiveness.** *A. K. Srivastava, J. P. Govindharajulu, M. G. Hollingshead, W. J. Moore, F. Tomaino, K. Banfield, T. Lee, E. T. Olejniczak, J. Sensintaffar, M. D. Millin, R. E. Parchment, J. H. Doroshow, S. Fesik*
- Board 409 **Abstract 2583: Phase 1/2 precision medicine study of the next-generation BRAF inhibitor PLX8394.** *F. Janku, U. N. Vaishampayan, V. Khemka, M. Bhatt, E. J. Sherman, J. Tao, J. R. Whisenant, D. S. Hong, N. Bui, S. Kummar, L. G. Feun, A. R. Parikh, C. Zhang, G. Michelson, E. Martin, R. Shellooe, P. Severson, M. Pelayo, D. A. Karlin, S. Sharma*
- Board 410 **Abstract 2584: Precision oncology: Results of a phase I study of M2698, a p70S6K/AKT targeted agent in patients with advanced cancer and tumor PI3K/AKT/mTOR (PAM) pathway abnormalities.** *A. M. Tsimberidou, C. F. Verschraegen, A. M. Weise, J. Sarantopoulos, G. Lopes, J. J. Nemunaitis, C. Hicking, J. Shaw, R. Kaleta, R. Kurzrock*
- Board 411 **Abstract 2585: A phase 1 study of NOX66 in combination with carboplatin in patients with end stage solid tumours.** *P. L. de Souza, M. Messina, I. Minns, M. Shavdia, N. Chikhladze, G. Kelly*
- Board 412 **Abstract 2586: A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.** *F. Janku, G. Iyer, A. Spreafico, N. Yamamoto, Y. Bang, E. Elez, M. J. De Jonge, H. J. Groen, F. Marmé, K. Gollmer, A. St-Pierre, M. Melendez, A. Mais, H. Nauwelaerts, U. M. Stammberger, R. Dummer*
- Board 413 **Abstract 2587: Safety, tolerability, and antitumor activity of once-daily Wee-1 inhibitor AZD1775.** *N. Takebe, G. H. O'Sullivan Coyne, S. Kummar, K. T. Do, A. Bruns, L. Juwara, M. F. Quinn, L. Harris, R. Piekarz, S. A. Prindiville, E. Sharon, H. Streicher, G. Mugundu, J. J. Ji, D. Wilsker, R. J. Kinders, L. Rubinstein, J. H. Doroshow, A. P. Chen*
- Board 414 **Abstract 2588: Dose finding study of varlitinib ± trastuzumab with carboplatin/paclitaxel in advanced solid tumors.** *M. Lee, A. L. Wong, S. G. Ow, R. Sundar, L. Wang, D. S. Tan, R. A. Soo, C. E. Chee, V. Heong, Y. Chen, J. S. Lim, W. Yong, S. E. Lim, B. C. Goh, S. Lee*
- Board 415 **Abstract 2589: Phase 1 study of pegargiminase combined with cisplatin and pemetrexed in patients with ASS1-deficient uveal melanoma.** *P. Chan, M. M. Phillips, R. Khadeir, S. Ellis, J. Thomson, A. Johnston, X. Feng, B. Wu, J. S. Bomalaski, M. Sheaff, P. W. Szlosarek*
- Board 416 **Abstract 2590: Outcomes of patients with gene fusion driven cancers treated on early phase clinical trials.** *R. Groisberg, K. R. Hess, D. S. Hong, J. Heymach, A. Naing, S. A. Piha-Paul, F. Janku, M. M. Javle, M. I. Hu, A. P. Conley, F. Meric-Bernstam, V. Subbiah*
- Board 417 **Abstract 2591: Phase1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors.** *R. K. Paluri, P. Li, B. S. Jones, A. Madan, M. Jerome, D. Miley, J. Keef, F. Robert*

- Board 418 Abstract 2592: A phase I, open-label, multicenter dose escalation study to assess the safety, tolerability, and pharmacokinetics of AZD2811 nanoparticle in patients with advanced solid tumors.** *M. L. Johnson, J. S. Wang, G. S. Falchook, J. Charlton, A. MacDonald, D. Strickland, S. F. Jones, E. J. Pease, W. Brugger, H. A. Burris III*
- Board 419 Abstract 2593: A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors.** *R. Xu, Y. Li, J. Ji, M. Qiu, Y. Zhang, W. Liu, X. Tian, S. Li, H. Wang, F. Wang, D. Zhang, Z. Wang, H. Luo, B. Zou, D. s. Wang, C. Ren, Y. Jin, Y. Zhai, D. Yang*
- Board 420 Abstract 2594: A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor.** *N. J. Lakhani, D. W. Rasco, A. W. Tolcher, Y. Huang, J. Ji, H. Wang, Q. Dong, L. Men, T. J. O'Rourke, S. R. Chandana, A. Amaya, Y. Cole, B. Kaiser, T. A. Mays, A. Patnaik, K. P. Papadopoulos, D. Yang, Y. Zhai*
- Board 421 Abstract 2595: Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.** *M. N. Stein, J. Malhotra, U. Malhotra, A. W. Silk, N. Chan, L. Rodriguez-Rodriguez, J. Aisner, R. Aiken, J. Newman, E. Sadimin, T. Saunders, M. Frankel, A. Kareddula, W. S. El-Deiry, R. Tarapore, J. E. Allen, J. R. Bertino, S. K. Libutti, J. M. Mehnert, A. Zloza*
- Board 422a Abstract TPS2596: The GATTO study: A phase I of the anti-MUC1 Gatipotuzumab (GAT) in combination with the anti-EGFR Tomuzotuximab (TO) in patients with EGFR positive solid tumors.** *S. Ochsenreither, U. Keilholz, K. F. Klinghammer, C. Dicke, M. Kebenko, E. Garralda, J. Tabernero, I. Matos, D. Lorusso, F. Raspagliesi, L. Gianni, G. Del Conte, B. Habel, H. Baumeister, R. Belli, A. Zurlo, W. M. Fiedler*
- Board 422b Abstract TPS2597: AMC 095 (AIDS Malignancy Consortium): A phase I study of ipilimumab (IPI) and nivolumab (NIVO) in advanced HIV associated solid tumors (ST) with expansion cohorts in HIV associated solid tumors and classical Hodgkin lymphoma (cHL).** *L. Rajdev, E. Y. Chiao, S. Lensing, R. F. Little, D. Dittmer, M. H. Einstein, M. Haigentz Jr., J. A. Sparano, R. T. Mitsuyasu*
- Board 423a Abstract TPS2598: MASTER KEY project: A basket/umbrella trial for rare cancers in Japan.** *H. S. Okuma, K. Yonemori, T. Shimizu, Y. Goto, Y. Honma, C. Morizane, E. Noguchi, K. Sudo, W. Munakata, K. Sunami, N. Hiraoka, T. Kohno, A. Hirakawa, T. Shibata, T. Sukigara, A. Kawai, N. Yamamoto, K. Nakamura, T. Nishida, Y. Fujiwara*
- Board 423b Abstract TPS2599: A phase 1 dose escalation (DE) and cohort expansion (CE) study of ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors.** *Y. Ogita, D. Weiss, N. Sugaya, M. Nakamura, H. Ito, T. Ishiguro, S. Shimada, M. Ueda, J. Matsushima, A. Gianella-Borradori*
- Board 424a Abstract TPS2600: Trial design of a first-in-human phase 1 evaluation of SY-1365, a first-in-class selective CDK7 inhibitor, with initial expansions in ovarian and breast cancer.** *G. Shapiro, K. P. Papadopoulos, K. T. Do, D. Juric, R. Jeseslsohn, P. A. Konstantinopoulos, U. A. Matulonis, G. Hodgson, E. DiTomaso, K. Stephens, D. A. Roth, A. W. Tolcher*
- Board 424b Abstract TPS2601: A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors.** *S. Shankar, A. I. Spira, J. Strauss, L. Liu, R. La Motte-Mohs, T. Wu, S. Johnson, E. Bonvini, P. A. Moore, J. M. Wigginton, J. Vasselli*
- Board 425a Abstract TPS2602: A phase 1 study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors.** *D. M. Hyman, I. Brana, A. Spreafico, A. M. Schram, N. B. Pandya, K. Hoffman, R. Hallet, P. Giblin, J. Anido, I. H. Ruano, R. Wasserman, J. Magram, L. L. Siu, J. Tabernero, J. Seoane, J. Baselga*

Monday, June 4, 2018

- Board 425b **Abstract TPS2603: A phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI7247 in patients with select relapsed/refractory hematologic malignancies.** *A. T. Fathi, W. B. Donnellan, R. M. Lyons, M. B. Maris, T. Kim, W. Kim, G. J. Schiller, C. N. Abboud, M. L. Arellano, E. H. Cull, K. W. Yee, D. M. Townsley, F. Wang, J. G. Bothos, N. Yao, G. A. Salles*
- Board 426a **Abstract TPS2604: A phase 1 study evaluating the safety, pharmacology and preliminary activity of MM-310 in patients with solid tumors.** *M. S. Ernstoff, W. Ma, F. Y. Tsai, P. N. Munster, T. Zhang, W. Kamoun, J. M. Pipas, S. Chen, S. Santillana, V. Askoxyllakis*
- Board 426b **Abstract TPS2605: First-in-human phase 1 study of DS-1062a in patients (pts) with advanced solid tumors (AST).** *J. M. Sands, T. Shimizu, E. B. Garon, J. Greenberg, R. S. Heist, F. Kobayashi, Y. Noguchi, D. Okajima, A. I. Spira, N. Yamamoto, T. Yamashita, A. E. Lisberg*
- Board 427a **Abstract TPS2606: CD205-Shuttle study: A first-in-human trial of MEN1309/OBT076 an ADC targeting CD205 in solid tumor and NHL.** *E. Garralda, J. Taberner, V. Moreno Garcia, M. De Miguel, E. R. Plummer, G. H. Jerusalem, M. Spina, C. Rohlf, A. Fandi, S. Buontempo, M. Matera, M. Cioce, D. Paola, M. Binaschi, G. Merlino, P. Mazzei, C. Rossi, G. Tonini, C. Simonelli, A. U. Pellacani*
- Board 427b **Abstract TPS2607: Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies.** *A. A. Adjei, T. S. Bekaii-Saab, J. Berlin, P. A. Philip, T. M. Mercade, A. Walter, L. Cupit, R. Liu, S. Z. Fields, A. Holynskiy*
- Board 428a **Abstract TPS2608: A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (guadecitabine), in children and adults with wild type GIST, pheochromocytoma and paraganglioma associated with succinate dehydrogenase deficiency and HLRCC-associated kidney cancer.** *J. Del Rivero, F. I. Arnaldez, R. Srinivasan, M. Spencer, S. M. Steinberg, K. Pacak, K. Killian, L. J. Helman, P. S. Meltzer, W. M. Linehan, B. C. Widemann, J. Glod*
- Board 428b **Abstract TPS2609: Phase 1/2 trial evaluating intratumoral administration of INT230-6 alone and in combination with an anti-PD1 antibody for advanced malignancies.** *Y. Kanjanapan, N. S. Azad, L. L. Siu, A. J. Olszanski, I. B. Walters, L. Kamen, L. H. Bender, A. B. El-Khoueiry*
- Board 429a **Abstract TPS2610: A Cancer Research UK phase I/IIa trial of BT1718 (a first in class Bicycle Drug Conjugate) given intravenously in patients with advanced solid tumours.** *U. Banerji, N. Cook, T. Evans, I. Moreno Candilejo, P. Roxburgh, C. L. Kelly, N. Sabaratnam, R. Passi, S. Leslie, S. Katugampola, L. Godfrey, N. Tremayne, G. Bennett, M. Koehler, G. Langford, S. N. Symeonides, M. Pittman*
- Board 429b **Abstract TPS2611: Phase I study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplification, HER2 mutation/amplification or HER3/4 mutation.** *S. A. Piha-Paul, S. Fu, D. S. Hong, F. Janku, D. D. Karp, A. Naing, S. Pant, J. Rodon Ahnert, V. Subbiah, A. M. Tsimberidou, T. A. Yap, F. Meric-Bernstam*
- Board 430a **Abstract TPS2612: A phase 1a / 1b first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-0903, a potent inhibitor of AXL kinase, administered daily for 21 days to patients with advanced solid tumors.** *J. Sarantopoulos, M. S. Beg, G. Fotopoulos, J. A. Taverna, S. P. Anthony, S. D. Weitman, S. L. Warner, L. Mouritsen, D. Bearss, S. Smith, H. Beaver, V. Khemka*
- Board 430b **Abstract TPS2613: Toca 6: A phase 1b study of Toca 511 and Toca FC in patients with advanced solid tumors or lymphoma.** *J. R. Merchan, J. Rodon Ahnert, G. Falchook, D. Ostertag, D. Tejera, H. E. Gruber, D. J. Jolly, J. Shorr*

- Board 431a Abstract TPS2614: A modular, multi-arm, multi-part, first time in patient study to evaluate the safety and tolerability of the dual MET kinase/OCT2 inhibitor, OMO-1, alone and in combination with anti-cancer treatments, in patients with locally advanced, unresectable or metastatic solid malignancies.** *E. R. Plummer, M. P. Lolkema, J. G. Aerts, F. Y. De Vos, M. Forster, E. ANGEVIN, R. S. Kristeleit, T. Perera, G. Clack, A. Meulemans, M. Libouban, P. Hari Dass, Y. Drew, N. Tinsley, S. Balaratnam, S. P. Blagden, M. Krebs*
- Board 431b Abstract TPS2615: An explorative phase 2 study of afatinib for advanced cancers carrying an EGFR, a HER2 or a HER3 mutation: A Precision trial of the Belgian Society of Medical Oncology.** *L. Decoster, N. Cappoen, P. G. Aftimos, G. Raicevic, C. D. Rolfo, S. Rottey, F. P. Duhoux, J. Collignon, A. Hebrant, M. Vandenbulcke, J. De Greve*
- Board 432a Abstract TPS2616: A phase 2, open-label study of the combination of spartalizumab (PDR001) and LAG525 for patients with advanced solid tumors and hematologic malignancies.** *S. A. Piha-Paul, A. Amin, C. Kovacs, A. Magley, D. D. Purkayastha, Y. Zhuo*
- Board 432b Abstract TPS2617: A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule ROR γ agonist to treat select solid tumors.** *K. Kelly, M. L. Johnson, D. Mahalingam, S. V. Liu, H. E. Uronis, C. Wu, L. Carter, X. Hu, G. A. Weems, H. Wilkins, L. R. Duska*
- Board 433a Abstract TPS2618: Safety, dose tolerance, pharmacokinetics and pharmacodynamics study of CPX-POM in patients with advanced solid tumors.** *S. J. Weir, R. Wood, T. Ham, R. Challenger, P. Ramamoorthy, G. Reed, M. J. Baltezor, R. A. Jensen, J. A. Taylor III, S. Anant, M. Dalton, M. J. McKenna, V. Zhukova-Harrill, W. McCulloch, H. A. Burris III*
- Board 433b Abstract TPS2619: First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies.** *J. Perez Garcia, J. Cortés, A. Stathis, R. Mous, E. López-Miranda, A. Azaro, S. Genta, P. Nuciforo, A. Vivancos, R. Ferrarotto, F. Bertoni, D. Rossi, N. Spardy Burr, O. Schönborn-Kellenberger, K. Jorga, L. Beni, R. Lehal, M. Bauer, D. Weber, E. Garralda*
- Board 434a Abstract TPS2620: Phase 1 study of an oxidative phosphorylation inhibitor IM156 in patients with advanced solid tumors.** *S. Y. Rha, S. Beom, M. Jung, Y. Shin, J. Cheong, H. Kim, G. Kim, J. Chang, Y. Lee, Y. Chong, S. Yoo, V. O'Neil, F. Janku*
- Board 434b Abstract TPS2621: Phase I study of procaspase activating compound-1 (PAC-1) for treatment of advanced malignancies.** *O. C. Danciu, M. K. Nicholas, M. Holdhoff, R. A. Peterson, T. M. Tarasow, P. J. Hergenrother, A. Z. Dudek*

8:00 AM - 11:30 AM Poster Session

Developmental Therapeutics—Immunotherapy

Location: Hall A

Abstracts on Boards 223-234 will be discussed during the Developmental Therapeutics—Immunotherapy Poster Discussion Session.

Posters by Topic

Biomarkers and Correlative Studies from Immunotherapy Trials: Boards 230, 234-252

Cellular Immunotherapy: Boards 233, 253-270

Immune Checkpoint Inhibitors: Boards 223-226, 228-229, 231, 271-301

Inflammatory Signatures: Boards 302-304

Other: Boards 227, 305-310

Vaccines: Boards 232, 312-314

Trials in Progress: Boards 315a-332b

Monday, June 4, 2018

- Board 223 **Abstract 3009: Cardiovascular adverse events in immune checkpoint inhibitor clinical trials: A U.S. Food and Drug Administration pooled analysis.** *L. Amiri-Kordestani, J. Moslehi, J. Cheng, S. Tang, R. Schroeder, R. Sridhara, K. Karg, J. Connolly, J. A. Beaver, G. M. Blumenthal, R. Pazdur*
- Board 224 **Abstract 3010: Cumulative antibiotic use and efficacy of immune checkpoint inhibitors in patients with advanced cancer.** *N. Tinsley, C. Zhou, S. Villa, G. Tan, P. Lorigan, F. H. Blackhall, T. Elliott, M. Krebs, L. Carter, F. Thistlethwaite, A. Hughes, N. Cook*
- Board 225 **Abstract 3011: Association of gut microbiome with immune status and clinical response in solid tumor patients who received on anti-PD-1 therapies.** *S. Fukuoka, M. Daisuke, Y. Togashi, E. Sugiyama, H. Udagawa, K. Kirita, T. Kamada, A. Kawazoe, K. Goto, T. Doi, K. Shitara, S. Nakamura, H. Nishikawa*
- Board 226 **Abstract 3012: Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.** *D. S. Hong, P. Schoffski, A. Calvo, J. Sarantopoulos, M. Ochoa De Olza, R. D. Carvajal, A. Prawira, C. Kyi, T. Esaki, W. L. Akerley, F. G. De Braud, R. Hui, T. Zhang, R. A. Soo, M. Maur, A. J. Weickhardt, N. Roy Chowdhury, C. Sabatos-Peyton, E. L. Kwak, D. S. Tan*
- Board 227 **Abstract 3013: Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.** *R. J. Sullivan, D. S. Hong, A. W. Tolcher, A. Patnaik, G. Shapiro, B. Chmielowski, A. Ribas, L. H. Brail, J. Roberts, L. Lee, B. O'Connell, J. L. Kutok, S. Mahabhashyam, C. Danský Ullmann, M. A. Postow, J. D. Wolchok*
- Board 228 **Abstract 3014: Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors.** *A. Calvo, H. Joensuu, M. Sebastian, A. Naing, Y. Bang, M. Martin, D. Roda, F. S. Hodi, A. Veloso, J. Mataraza, G. Baneyx, N. Guerreiro, S. Liao, B. Rabault, M. Fjaellskog, A. Cervantes*
- Board 229 **Abstract 3015: Predicting outcomes of advanced non-small cell lung cancer patients treated with PD-1/PDL-1 inhibitors: Independent international validation of the iSEND model.** *W. Park, L. Mezquita, N. Okabe, D. Kwon, D. Saravia, Y. Chae, A. Desai, D. Planchard, C. Caramella, R. Mudaz, M. Jahanzeb, H. Suzuki, B. Besse, G. Lopes*
- Board 230 **Abstract 3016: Medical image computing to assess tumor infiltrating CD8 T cells, tumor immune phenotype and response to anti-PD-1/PD-L1 immunotherapy in prospective phase 1 trials.** *R. Sun, E. Limkin, M. Vakalopoulou, L. Dercle, S. Champiat, S. Han, L. Verlingue, D. Brandao, S. Ammari, L. Mahjoubi, A. Hollebecque, J. Scoazec, A. Marabelle, C. Massard, J. Soria, C. Robert, N. Parajos, E. Deutsch, C. Ferte*
- Board 231 **Abstract 3017: Correlation of survival outcomes with progression heterogeneity in patients (pts) treated with pembrolizumab (pembro).** *L. H. Schwartz, S. Robey, D. C. Turner, Y. Zhang, E. Kim, D. de Alwis, R. Mogg, A. M. Perrone, G. R. Oxnard*
- Board 232 **Abstract 3018: VANCE: First-in-human phase I study of a novel ChAdOx1-MVA 5T4 vaccine in low and intermediate risk prostate cancer.** *I. Redchenko, F. Cappuccini, E. Pollock, R. J. Bryant, L. Carter, C. Verrill, J. Hollidge, L. Goodwin, R. Harrop, P. J. Romero, S. Vigano, T. Evans, J. Catto, F. Hamdy, A. V. Hill*
- Board 233 **Abstract 3019: Genetically engineered t-cell therapy for HPV-associated epithelial cancers: A first in human, phase I/II clinical trial.** *S. L. Doran, S. Stevanovic, S. Adhikary, J. J. Gartner, L. Jia, M. M. Kwong, W. C. Faquin, S. Feldman, R. Somerville, R. M. Sherry, J. C. Yang, S. A. Rosenberg, C. S. Hinrichs*
- Board 234 **Abstract 3020: Pharmacodynamics (PD) and genomic profiling of pts treated with cabiralizumab (cabira) + nivolumab (NIVO) provide evidence of on-target tumor immune modulations and support future clinical applications.** *M. Carleton, J. Powers, P. Phillips, M. S. Beg, J. J. Lee, O. E. Rahma, S. A. Piha-Paul, E. Lee, K. Hestir, K. Xu, D. Pandya, S. P. Inamdar, S. K. Perna, S. A. Huang, Z. A. Wainberg*

- Board 235 Abstract 3021: CD8 and PD-L1 determination in lung tumor tissue as prognostic biomarker and a predictive marker of anti PD-1 efficacy.** *J. Fumet, C. Richard, F. Ledys, Q. Klopfenstein, C. Truntzer, B. P. Coudert, L. Arnould, L. Favier, A. Lagrange, S. Ladoire, P. Saintigny, S. Ortiz-Cuaran, M. Perol, P. Foucher, P. Hofman, M. Ilie, S. Chevrier, R. Boidot, V. Derangere, F. Ghiringhelli*
- Board 236 Abstract 3022: Mismatch repair deficiency testing for immune checkpoint therapy: Immunohistochemistry vs microsatellite instability.** *S. Sudarsanam, F. Blocker, S. Agersborg, V. A. Funari, S. Jiang, W. Chen, J. Ragheb, V. Chizhevsky, M. Albitar*
- Board 237 Abstract 3023: Relationship between checkpoint molecule B7-H3 and refractoriness to anti-PD-1 therapy in non-small cell lung cancer.** *K. Yonesaka, K. Kudo, S. Takamura, H. Sakai, R. Kato, K. Haratani, T. Takahama, K. Tanaka, H. Hayashi, H. Kaneda, M. Takeda, O. Maenishi, M. Yamato, M. Miyazawa, K. Nishio, K. Nakagawa*
- Board 238 Abstract 3024: Co-mutations of DNA damage response system as predictive biomarker for immune checkpoint blockades.** *Z. Wang, J. Zhao, G. Wang, F. Zhang, Y. Zhang, H. Dong, X. Zhao, J. Duan, H. Bai, Y. Tian, R. Wan, L. Xiong, S. Cai, T. Mok, J. Wang*
- Board 239 Abstract 3025: Serum interleukin 8 (IL-8) may serve as a biomarker of response to immune-oncology (I-O) therapy.** *M. Carleton, M. Zhou, O. De Henau, P. Phillips, T. Chen, Y. Feng, S. Huang, A. Walsh, T. P. Reilly, I. Melero Bermejo*
- Board 240 Abstract 3026: Human leukocyte antigen (HLA) B44 supertype and immunotherapy outcomes in non-small cell lung cancer (NSCLC).** *H. Lu, A. L. Cummings, J. W. Goldman, A. E. Lisberg, S. Hu-Lieskovan, T. Grogan, J. Gukasyan, J. Madrigal, J. M. Carroll, K. Bornazyan, B. Jones, Z. S. Noor, J. M. Zaretsky, D. Elashoff, D. J. Slamon, S. M. Dubinett, E. B. Garon*
- Board 242 Abstract 3028: Somatic *STK11/LKB1* mutations to confer resistance to immune checkpoint inhibitors as monotherapy or in combination in advanced NSCLC.** *M. Jure-Kunkel, S. Wu, F. Xiao, S. E. Abdullah, G. Gao, J. M. Englert, H. Hsieh, P. Mukhopadhyay, A. K. Gupta, P. A. Dennis, B. W. Higgs, K. Ranade*
- Board 243 Abstract 3029: First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors.** *R. Geva, M. Voskoboynik, A. M. Beebe, J. Gwo, K. Dobrenkov, E. Chartash, G. V. Long*
- Board 244 Abstract 3030: Underlying host immune dysregulation in cancer patients developing immune-related adverse events.** *D. E. Gerber, S. Khan, X. Luo, S. A. Khan, F. Fattah, J. Saltarski, Y. Gloria-McCutchen, J. Park, Y. Xie, Q. Li, E. Wakeland*
- Board 245 Abstract 3031: Association of TGF- β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF- β receptor type I (TGFBR1) inhibitor in patients with advanced solid tumors.** *V. L. Keedy, T. M. Bauer, J. M. Clarke, H. Hurwitz, I. Baek, I. Ha, C. Ock, S. Nam, M. Kim, N. Park, J. Kim, S. Kim*
- Board 246 Abstract 3032: Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials.** *I. Matos, J. Martin-Liberal, C. Hierro, M. Ochoa De Olza, C. Viaplana, M. Costa, E. Felipe-Falg s, G. Mur-Bonet, M. Vieito, I. Brana, A. Azaro, C. Perez-Gago, V. Rodriguez-Freixinos, G. Argiles, M. Oliveira, E. Felipe, E. Muñoz-Couselo, J. Taberner, R. Dienstmann, E. Garralda*
- Board 247 Abstract 3033: Pilot trial of an indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multi-peptide melanoma vaccine in patients with advanced melanoma.** *C. L. Slingluff, S. Fling, I. S. Mauldin, M. S. Ernstoff, B. A. Hanks, K. A. Delman, D. H. Lawson, B. Gastman, J. C. Kaiser, M. A. Cheever*
- Board 248 Abstract 3034: Germinal immunogenetics as a predictor of anti-PD1/PD-L1 treatment outcome.** *G. A. Milano, S. Refae, N. Ebran, J. Gal, J. Otto, D. Drubay, E. Chamorey, J. Ciccolini, E. Saada*

Monday, June 4, 2018

- Board 249 **Abstract 3035: Exploration of baseline derived neutrophil to lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) treated with immune checkpoint inhibitors (ICI) or cytotoxic chemotherapy (CCT).** *D. G. Kazandjian, Y. Gong, H. Kazandjian, R. Pazdur, G. M. Blumenthal*
- Board 250 **Abstract 3036: Genomic correlates of response to immune checkpoint blockade in microsatellite stable solid tumors.** *N. Vokes, D. Miao, C. Margolis, D. Liu, S. Wankowicz, B. Schilling, L. M. Sholl, G. Getz, P. A. Janne, R. I. Haddad, T. K. Choueiri, D. A. Barbie, R. Haq, M. M. Awad, D. Schadendorf, F. S. Hodi, J. Bellmunt, K. Wong, P. S. Hammerman, E. M. Van Allen*
- Board 252 **Abstract 3038: Demonstration of anti-tumor immunity via intratumoral regulated platform ad-RTS-hIL-12 in advanced breast cancer and recurrent glioblastoma patients.** *F. M. Lebel, J. A. Barrett, H. L. McArthur, J. Y. Buck, N. Demars, R. Mackenna, L. J. Cooper, E. Chiocca*
- Board 253 **Abstract 3039: Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large b cell lymphoma.** *F. L. Locke, A. Ghobadi, L. J. Lekakis, D. B. Miklos, C. A. Jacobson, E. D. Jacobsen, I. Braunschweig, O. O. Oluwole, T. Siddiqi, Y. Lin, P. M. Reagan, U. Farooq, A. Deol, A. Bot, J. M. Rossi, Y. Jiang, A. Xue, W. Y. Go, S. S. Neelapu*
- Board 254 **Abstract 3040: First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, in patients (pts) with advanced solid tumors.** *T. A. Yap, S. Sahebjam, D. S. Hong, V. K. Chiu, E. Yilmaz, S. Efuni, D. O. Grebennik, A. Collaku, E. Ogunmefun, Y. Liu, T. Tayama, R. R. Latek, O. Rixe*
- Board 255 **Abstract 3041: Which is better in CD19 CAR-T treatment of r/r B-ALL, CD28 or 4-1BB? A parallel trial under the same manufacturing process.** *P. Lu, X. Lu, X. Zhang, M. Xiong, J. Zhang, X. Zhou, F. Qi, J. Yang, T. He*
- Board 256 **Abstract 3042: Ex vivo expanded multi-antigen specific lymphocytes for the treatment of solid tumors.** *A. Houghtelin, C. Cruz, R. Ulrey, B. O'Brien, M. Stanojevic, S. Albiaini, D. Saunders, F. Hoq, M. F. Fortiz, H. Lang, P. Hanley, C. Bollard, H. J. Meany*
- Board 257 **Abstract 3043: Regression of epithelial cancers in humans following t-cell receptor gene therapy targeting human papillomavirus-16 E7.** *N. Nagarsheth, S. Norberg, S. L. Doran, J. A. Kanakry, S. Adhikary, C. Schweitzer, S. H. Astrow, W. C. Faquin, N. Gkitsas, S. Highfill, D. Stroncek, C. Hinrichs*
- Board 258 **Abstract 3044: Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) b-cell acute lymphoblastic leukemia (B-ALL) and diffuse large b-cell lymphoma (DLBCL) patients.** *K. T. Mueller, S. A. Grupp, S. L. Maude, J. E. Levine, M. Pulsipher, M. W. Boyer, K. J. August, G. D. Myers, R. Awasthi, E. K. Waldron, L. Bubuteishvili-Pacaud, T. Taran, M. Cota, C. S. Tam, U. Jäger, R. Foley, P. Borchmann, S. J. Schuster, E. K. Waller, T. W. Laetsch*
- Board 259 **Abstract 3045: Durable clinical responses observed from non-Hodgkin lymphoma patients treated with autologous CAR-T cells targeting CD19.** *Y. Liu, B. Zhu, Q. Jia, F. He, H. Fang, J. Chen, Z. Shi, T. Jin, B. Wei, R. Xie, Q. Li, P. Wang*
- Board 260 **Abstract 3046: A phase I trial of T4 CAR T-cell immunotherapy in head and neck squamous cancer (HNSCC).** *S. Papa, A. Adami, M. Metoudi, D. Achkova, M. van Schalkwyk, A. Parente Pereira, L. Bosshard-Carter, L. Whilding, S. van der Stegen, D. Davies, F. Farzaneh, T. Guerrero Urbano, J. Jeannon, J. F. Spicer, J. Maher*
- Board 261 **Abstract 3047: Acquired resistance to T cell adoptive transfer by inflammation-induced melanoma dedifferentiation.** *A. Mehta, Y. Kim, L. Robert, B. Comin-Anduix, B. Berent-Maoz, A. Cochran, J. S. Economou, P. Tumeq, A. Ribas*

- Board 262 Abstract 3048: Screening of neoantigen-specific T cells and establishment of T-cell receptor-engineered T cells: Implications for head and neck squamous carcinoma.** *L. Ren, T. Matsuda, B. Deng, K. Kiyotani, T. Kato, J. Park, T. Y. Seiwert, E. E. Vokes, N. Agrawal, Y. Nakamura*
- Board 263 Abstract 3049: ET190L1-ARTEMIS T cell therapy to induce complete remission of relapsed and refractory (r/r) B-cell lymphoma with no cytokine release syndrome in the first-in-human clinical study.** *Z. Ying, L. Long, H. Liu, M. Zhang, P. He, D. Rizzieri, Y. Song, B. Nejadnik, J. Zhu, C. Liu*
- Board 264 Abstract 3050: A phase I trial of PD-1 deficient engineered T cells with CRISPR/Cas9 in patients with advanced non-small cell lung cancer.** *Y. Lu, J. Xue, T. Deng, X. Zhou, K. Yu, M. Huang, M. Liang, L. Deng, J. Huang, Z. Ding, Y. Gong, J. Zhu, Y. Wang, R. Tong, L. Li, Y. Li, B. Zou, M. Yu, Y. Wei, W. Li*
- Board 265 Abstract 3051: Correlation of pre-CAR CD19 expression with responses and relapses after CART cell therapy.** *V. Pillai, J. Rosenthal, K. Muralidharan, G. B. Wertheim, M. Paessler, S. L. Maude, S. R. Rheingold, S. A. Grupp*
- Board 266 Abstract 3052: Clinical anti-lymphoma activity and toxicity of t cells expressing a novel anti-CD19 chimeric antigen receptor with fully-human variable regions.** *J. N. Brudno, S. D. Hartman, S. Pittaluga, D. Stroncek, N. Lam, J. A. Kanakry, S. Z. Pavletic, L. Mikkilineni, M. Bagheri, M. J. Roschewski, R. M. Dean, J. J. Rose, R. Patel, B. G. Hansen, R. Gress, J. Kochenderfer*
- Board 267 Abstract 3053: Impact of the influenza vaccination on cancer patients undergoing therapy with immune checkpoint inhibitors (ICI).** *R. Gopalakrishnan, D. B. Johnson, S. York, M. N. Neuss, T. J. Osterman, D. D. Chism, K. K. Ancell, I. A. Mayer, V. G. Abramson, M. A. Levy, K. Wyman, J. Gilbert, N. Reddy, D. S. Morgan, K. Rathmell, L. Horn*
- Board 268 Abstract 3054: Safety and activity of programmed cell death-1 gene knockout engineered t cells in patients with previously treated advanced esophageal squamous cell carcinoma: An open-label, single-arm phase I study.** *Z. Jing, N. Zhang, L. Ding, X. Wang, Y. Hua, M. Jiang, S. Wu*
- Board 269 Abstract 3055: Adoptive cellular immunotherapy with APN401, autologous cbl-b silenced peripheral blood mononuclear cells: Data from a phase I study in patients with solid tumors.** *H. Loibner, G. Lametschwandtner, K. Westritschnig, O. Mutschlechner, A. Dohnal, M. O. Salzberg, P. L. Triozzi*
- Board 270 Abstract 3056: Initial safety assessment of MAGE-A10^{e796}TCR T-cells in two clinical trials.** *V. K. Lam, D. S. Hong, J. Heymach, G. R. Blumenschein Jr., B. C. Creelan, P. A. Bradbury, M. O. Butler, J. F. Gainor, R. Govindan, M. L. Johnson, R. Mudad, R. J. Sullivan, F. Brophy, N. Hyland, K. Chagin, T. Holdich, E. Norry, R. G. Amado*
- Board 271 Abstract 3057: Association of efficacy and adverse events of special interest of avelumab in the JAVELIN solid tumor and JAVELIN Merkel 200 trials.** *K. Kelly, J. Manitz, M. R. Patel, A. H. Loos, A. Allignol, V. K. Chand, V. Kasturi, K. M. Chin, J. Warth, H. Zhang, A. von Heydebreck, J. L. Gulley*
- Board 272 Abstract 3058: Circulating miRNA and extracellular vesicle containing miRNA as response biomarkers of anti PD-1/PD-L1 therapy in non-small-cell lung cancer.** *T. Shukuya, J. Amann, V. Ghai, K. Wang, D. P. Carbone*
- Board 273 Abstract 3059: Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy.** *R. S. Herbst, I. Chau, D. P. Petrylak, H. Arkenau, J. C. Bendell, R. Santana-Davila, E. Calvo, N. Penel, J. Martin-Liberal, A. O. Soriano, P. A. Cassier, M. Krebs, N. Isambert Sr., R. Widau, G. Mi, J. Jin, D. R. Ferry, C. S. Fuchs, L. G. Paz-Ares*
- Board 274 Abstract 3060: Cost of inpatient admissions for immune-related adverse effects from immune checkpoint inhibitor therapy: A single center experience.** *J. N. Chu, J. G. Choi, S. Ostvar, J. V. Cohen, I. M. Allen, M. L. Dougan, A. C. Villani, M. Thomas, M. Nasrallah, A. Guidon, S. T. Chen, S. Schoenfeld, M. Sise, R. Leaf, T. G. Neilan, A. Faje, R. J. Sullivan, A. Bardia, C. Hur, K. L. Reynolds*

Monday, June 4, 2018

- Board 275 **Abstract 3061: Veliparib in combination with nivolumab and platinum doublet chemotherapy (CT) in metastatic/advanced NSCLC.** *J. M. Clarke, J. D. Patel, F. Robert, E. A. Kio, E. Thara, B. Garofalo, M. Barnes, T. Tian, Q. Q. Qin, M. Dunbar, S. Nuthalapati, G. Selvaggi, M. D. McKee, M. Dinh, D. R. Camidge*
- Board 276 **Abstract 3062: A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation.** *M. Lala, M. Li, V. Sinha, D. de Alwis, E. Chartash, L. Jain*
- Board 277 **Abstract 3063: Hyperprogressive disease (HPD) in early-phase immunotherapy (IO) trials.** *Y. Kanjanapan, D. Day, L. Wang, A. R. Hansen, A. R. Abdul Razak, A. Spreafico, N. B. Leighl, A. M. Joshua, M. O. Butler, D. Hogg, L. L. Siu, P. L. Bedard*
- Board 278 **Abstract 3064: Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs).** *M. Riudavets, A. Barba, P. Maroto, I. G. Sullivan, G. Anguera, D. Pérez, L. del Carpio, A. Callejo, C. Gonzalez Blanco, E. Garcia Planellas, D. Castillo, C. Facundo, I. Genua, C. Martin Lorente, A. Virgili, A. Sebio, O. Gallego, A. Lopez-Pousa, A. Barnadas, M. Majem*
- Board 279 **Abstract 3065: A meta-analysis to indirectly compare the safety and efficacy of PD-1 and PD-L1 antibodies across solid tumors using a Bayesian hierarchical model.** *M. Koneru, A. Patnaik, J. Liu, S. Nanda, Z. M. Thomas, J. Lin*
- Board 280 **Abstract 3066: Clinical and pharmacological parameters associated with nivolumab toxicity.** *L. Hirsch, A. Bellesoeur, M. Allard, P. Boudou-Rouquette, A. Jouinot, J. Arrondeau, M. Vidal, A. Thomas, J. Chapon, F. Giraud, O. Huillard, M. Alifano, J. Alexandre, B. Blanchet, F. Goldwasser*
- Board 281 **Abstract 3067: Intestinal microbiota to predict lung cancer patients at risk of immune-related diarrhea.** *T. Liu, Q. Xiong, Y. Hu*
- Board 282 **Abstract 3068: A phase 1 study of ALX148, a CD47 blocker, alone and in combination with established anticancer antibodies in patients with advanced malignancy and non-Hodgkin lymphoma.** *N. J. Lakhani, P. LoRusso, N. Hafez, A. Krishnamurthy, T. J. O'Rourke, M. K. Kamdar, P. Fanning, Y. Zhao, F. Jin, H. Wan, J. Pons, S. Randolph, W. A. Messersmith*
- Board 283 **Abstract 3069: Can body composition (BC) be predictive for outcomes and severe toxicities (ST) in metastatic solid tumors patients (pts) treated with checkpoint inhibitor (CPI)? An analysis of 145 patients.** *S. Cousin, A. Crombe, A. Giraud, S. Le Moulec, M. Toulmonde, M. Kind, A. Italiano*
- Board 284 **Abstract 3070: Comparative analysis of durable responders on immune checkpoint inhibitors (ICI) versus other systemic therapies: A meta-analysis of phase III trials.** *E. Pons-Tostivint, A. Latouche, P. Vaflard, F. Ricci, D. Loirat, M. Sablin, R. Rouzier, M. Kamal, C. Morel, C. Lecerf, V. Servois, C. Le Tourneau*
- Board 285 **Abstract 3071: Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors.** *K. A. Autio, H. Arkenau, B. H. O'Neil, J. C. Bendell, A. El-Khoueiry, J. Strauss, A. Weise, N. V. Uboha, N. A. Rizvi, B. Zheng, L. Desnoyers, M. Stroh, L. Carman, R. W. Humphrey, M. Will, V. Boni, A. I. Spira, A. Naing*
- Board 286 **Abstract 3072: Preliminary interim results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic (Pb-Tx) CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors.** *R. E. Sanborn, C. W. Menke, K. A. Autio, H. Arkenau, J. G. Corbacho, P. LoRusso, E. R. Plummer, N. V. Uboha, M. L. Freeman, J. Wydmanski, V. Huels, B. Zheng, M. Will, R. W. Humphrey, F. Thistlethwaite, E. G. de Vries, A. B. El-Khoueiry*
- Board 287 **Abstract 3073: Quality of life in patients with advanced renal cell carcinoma in the randomized, open-label CheckMate 214 trial.** *D. Cella, V. GrÅ¼nwald, B. Escudier, H. J. Hammers, S. George, P. Nathan, M. Grimm, B. I. Rini, J. Doan, C. Ivanescu, J. Paty, S. Mekan, R. J. Motzer*

- Board 288 Abstract 3074: Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockade.** *B. Izar, L. Jerby-Arnon, A. Rotem, P. Shah, D. Liu, G. Zhang, B. Schilling, O. Rozenblatt-Rosen, G. M. Boland, F. S. Hodi, K. Flaherty, E. M. Van Allen, B. E. Johnson, D. Schadendorf, C. Yoon, L. A. Garraway, A. Regev*
- Board 289 Abstract 3075: Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade.** *B. A. Wilky, P. Kumthekar, R. Wesolowski, J. J. Hwang, S. I. Park, I. Proscurshim, G. Yuan, C. D. Dupont, O. Shebanova, J. Cuillerot, E. Dow, J. J. Raizer, C. Gentry, A. Ross, E. Drouin, N. Wilson, J. M. Goldberg, J. Buell, R. B. Stein*
- Board 290 Abstract 3076: Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancers.** *L. Pare, T. Pascual, E. Seguí, M. González-Cao, C. Teixidó, A. Rodriguez, B. González-Farre, M. Cuatrecasas, E. Pineda, G. Crespo, S. Martin-Algarra, E. Perez Ruiz, B. Mellado, J. Maurel, J. Garcia Corbacho, M. A. Molina-Vila, J. M. Llovet, N. Reguart, A. M. Arance, A. Prat*
- Board 291 Abstract 3077: Impact of immune checkpoint inhibitor dose on toxicity, response rate, and survival: A pooled analysis of dose escalation phase 1 trials.** *S. Sen, K. R. Hess, D. S. Hong, A. Naing, L. Huang, F. Meric-Bernstam, V. Subbiah*
- Board 292 Abstract 3078: Phase II open-label, multi-centre study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC.** *J. Lorens, C. E. Arce-Lara, E. Arriola, P. Brunsvig, E. Carcereny Costa, M. Domine, K. H. Dragnev, E. Felip, R. G. Campelo, M. Krebs, S. Ponce Aix, J. F. Spicer, J. Trigo Perez, N. Vinolas, R. J. Holt, A. Brown, M. J. Chisamore*
- Board 293 Abstract 3079: Autoimmune genetic variants as germline biomarkers of response in melanoma immunotherapy treatment.** *V. Chat, R. Ferguson, D. Simpson, E. Kazlow, R. Lax, U. Moran, M. Wilson, A. C. Pavlick, R. J. Sullivan, K. Flaherty, I. Osman, J. S. Weber, T. Kirchhoff*
- Board 294 Abstract 3080: Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial).** *A. Varga, C. Baldini, P. Martin-Romano, B. Besse, D. Planchard, S. Champiat, E. ANGEVIN, A. Hollebecque, R. Bahleda, A. Gazzah, J. Armand, X. Paoletti, C. Massard, J. Soria, A. Marabelle*
- Board 295 Abstract 3081: Role of melanoma cell-intrinsic RIG-I and STING signaling for checkpoint inhibitor-mediated anticancer immunity.** *S. Heidegger, A. Wintges, S. Bek, M. Schmickl, J. Fischer, P. Koenig, T. Haas, H. Poeck*
- Board 296 Abstract 3082: Allo-immunity and graft rejection after checkpoint inhibitor therapy (CPI) in solid organ transplant (SOT) recipients.** *N. Abdel-Wahab, A. Abudayyeh, M. Shah, D. H. Johnson, V. Trinh, M. Abdelrahim, A. Gaber, M. E. Suarez-Almazor, A. Diab*
- Board 298 Abstract 3084: Neurologic immune related adverse events (irAEs) in patients treated with immune checkpoint blockade.** *B. Santomasso, A. Haggiagi, R. Malani, C. A. Maher, J. N. Holder, Y. Shames, J. Wilcox, J. Flynn, S. Briggs, K. Panageas, M. K. Callahan*
- Board 299 Abstract 3085: Efficacy and immune modulation by BXCL701 a dipeptidyl peptidase inhibitor, NKTR-214 a CD122-biased immune agonist with PD1 blockade in murine pancreatic tumors.** *L. Rastelli, S. Gupta, Z. Jagga, D. H. Charych, J. Zalevsky*
- Board 300 Abstract 3086: Phase 1/2 open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation.** *K. N. Moore, C. Dresher, J. Liu, D. M. O'Malley, E. W. Wang, J. S. Wang, V. Subbiah, B. A. Wilky, G. Yuan, C. D. Dupont, A. M. Gonzalez, D. Savitsky, S. Coulter, O. Shebanova, E. Dow, I. Proscurshim, J. Buell, R. B. Stein, H. Youssoufian*

Monday, June 4, 2018

- Board 301 **Abstract 3087: Characterization of immune related hepatitis (irH) from immune checkpoint inhibitors (ICIs).** *J. V. Cohen, J. Misdradj, M. Dougan, R. Fadden, K. M. Rubin, A. Lawless, K. L. Reynolds, D. P. Lawrence, M. Mooradian, K. Flaherty, R. J. Sullivan*
- Board 302 **Abstract 3088: Identifying new biomarkers and targeted molecules for immunotherapy using targeted RNA next generation sequencing.** *W. Ma, I. De Dios, V. A. Funari, M. Sheikholeslami, N. Stavrou, F. Blocker, B. Shahbaba, M. Albitar, S. Sudarsanam*
- Board 303 **Abstract 3089: Pelareorep to promote the expression of a IFN-gamma-related gene signature that predicts response to checkpoint blockade therapy.** *G. A. Wilkinson, A. Piar, C. Resnyk, M. Humphrey, K. Glendinning, H. Tran, R. Chakrabarty, A. Gutierrez, M. C. Coffey*
- Board 304 **Abstract 3090: Analysis of inflammatory signatures of cancer spheroids in blood and their role in metastasis.** *P. Geck, V. Denes, B. Tegze, L. Graf, G. Barna, A. Naphegyi, A. Makarovskiy*
- Board 305 **Abstract 3091: Phase I trial of BMS-986253, an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.** *J. M. Collins, C. R. Heery, R. N. Donahue, C. Palena, R. A. Madan, J. Strauss, M. E. Gatti-Mays, J. Schlom, J. L. Gulley, M. Bilusic*
- Board 306 **Abstract 3092: Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity.** *A. Anthoney, A. Samson, E. West, S. J. Turnbull, K. Scott, E. Tidswell, J. Kingston, M. Johnpulle, S. Noutch, K. Bendjama, M. Homerin, N. Stojkowitz, G. Toogood, C. Twelves, C. Ralph, A. Melcher, F. J. Collinson*
- Board 307 **Abstract 3093: SEA-CD40, a non-fucosylated CD40 agonist: Interim results from a phase 1 study in advanced solid tumors.** *J. E. Grilley-Olson, B. D. Curti, D. C. Smith, S. Goel, T. Gajewski, S. Markovic, O. Rixe, D. L. Bajor, M. Gutierrez, T. Kuzel, A. N. Mehta, B. Amore, A. Guerrero, Z. Wang, A. L. Coveler*
- Board 308 **Abstract 3094: A phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates *de novo* T-cell responses and clinical benefit in patients with advanced solid tumors.** *J. F. Spicer, A. Marabelle, J. Baurain, A. Awada, R. S. Kristeleit, D. Jossang, N. Jebesen, D. Loirat, A. C. Armstrong, G. Curigliano, B. Nicolaisen, O. Rekdal, B. Sveinbjornsson, V. S. Gjerstad, P. Brunsvig*
- Board 309 **Abstract 3095: Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies.** *M. M. Mita, A. C. Mita, B. Chmielowski, E. P. Hamilton, S. Pant, R. J. Waltzman, E. K. Rowinsky, M. Szarek, F. Gonsalves, I. Kurth, C. Andreu, R. Busby, D. M. Darst, S. S. Tavazoie, M. Tavazoie, M. A. Postow*
- Board 310 **Abstract 3096: Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: Temporal trends and clinical significance.** *K. L. Reynolds, J. V. Cohen, D. P. Ryan, E. P. Hochberg, M. Dougan, M. Thomas, A. Guidon, C. Channick, S. T. Chen, S. Schoenfeld, M. Sise, R. Leaf, T. G. Neilan, J. N. Chu, C. Hur, Y. Murciano-Goroff, A. C. Villani, M. Nasrallah, R. J. Sullivan, A. Bardia*
- Board 312 **Abstract 3098: First-in-man study of Ad-sig-hMUC1/ecdCD40L vaccine for immunotherapy of MUC1 overexpressing epithelial cancers.** *T. J. Tan, J. W. Chia, H. Chong, X. Li, S. Tan, R. Hopkins, W. Wang, H. Toh*
- Board 313 **Abstract 3099: Cervical microbiome role in outcomes of therapeutic HPV vaccination for cervical intraepithelial neoplasia.** *R. Ravilla, H. Coleman, L. Chan, C. Chow, B. Fuhrman, W. Greenfield, M. S. Robeson, K. Iverson, H. J. Spencer, M. Nakagawa*

- Board 314 Abstract 3100: Utility of comprehensive genomic profiling (CGP) for personal cancer vaccine development via neoantigen analysis.** *D. Vuzman, S. Pei, A. Pantazi, J. E. Ring, M. Russell, D. Weeraratne, M. Lvova, S. Lyle, J. Y. Tse*
- Board 315a Abstract TPS3101: Phase 1, open-label, adaptive biomarker trial that informs the evolution of combination immuno-oncology (IO) therapies (ADVISE), a precision IO approach to personalized medicine.** *J. J. Luke, N. S. Azad, R. Edwards, S. A. Huang, A. Comprelli, M. Monga, T. P. Reilly, F. S. Hodi*
- Board 315b Abstract TPS3102: ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma.** *M. Wang, F. L. Locke, J. Munoz, A. Goy, H. E. Holmes, T. Siddiqi, I. Flinn, P. A. McSweeney, P. M. Reagan, B. T. Hill, C. A. Jacobson, D. A. Rizzieri, L. T. Heffner, S. M. Jaglowski, D. B. Miklos, P. Shaughnessy, S. Unabia, J. M. Rossi, Y. Jiang, R. K. Jain*
- Board 316a Abstract TPS3103: A phase 1 multicenter study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.** *R. F. Cornell, F. L. Locke, M. R. Bishop, R. Z. Orlowski, S. M. Larson, I. Borrello, S. Giralt, S. Kumar, A. K. Nooka, N. S. Raje, J. M. Rossi, L. Thomrongsith, A. Xue, Z. Roberts*
- Board 316b Abstract TPS3104: A phase 1 multicenter study evaluating the safety and efficacy of MHC class II-restricted MAGE-A3/A6 T-cell receptor engineered T cells (KITE-718) in patients with advanced cancers.** *P. Kebriaei, C. A. Klebanoff, B. C. Creelan, D. S. Hong, G. R. Blumenschein Jr., A. Drakaki, A. Tewari, L. Thomrongsith, Y. Jiang, R. K. Jain*
- Board 317a Abstract TPS3105: A phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro) (MASTERKEY-318).** *J. R. Hecht, A. Prat, M. Pless, A. Cubillo, A. Calvo, S. Raman, J. A. Chesney, C. Liu, E. Chan*
- Board 317b Abstract TPS3106: Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers.** *A. M. Tsimberidou, B. Andersson, C. Stewart, H. Ma, O. Schoor, D. Maurer, C. Wagner, A. Satelli, J. Fritsche, G. L. Stephens, A. Mohamed, Z. Coughlin, A. M. Stungis, K. M. Gharpure, P. Hwu, C. Yee, T. Weinschenk, C. Reinhardt, S. Walter, H. Singh*
- Board 318a Abstract TPS3107: A phase 2 study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (TIL, LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab in patients with locally advanced or metastatic NSCLC.** *S. M. Lee, M. Haigentz Jr., L. C. Villaruz, I. Gorbachevsky, S. Suzuki, S. Tanamly, N. L. Samberg, M. Fardis*
- Board 318b Abstract TPS3108: Evaluating immune checkpoint inhibition in solid tumor patients with homologous recombination repair deficiency.** *F. M. Vargas Madueno, W. Duan, Z. Diaz, J. P. Diaz, F. Albrecht, S. Venkatappa, E. D. Schroeder, S. Aparo, V. Yanek, G. Walker, M. Villalona*
- Board 319a Abstract TPS3109: Phase 1b/2 study of nivolumab in combination with an anti-IL-8 monoclonal antibody, BMS-986253, in a biomarker-enriched population of patients with advanced cancer.** *I. Melero Bermejo, E. M. Jaffee, D. Davar, J. Cardarelli, D. Williams, P. Phillips, M. Carleton, M. Zhou, O. De Henau, M. Monga, C. G. Drake*
- Board 319b Abstract TPS3110: A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.** *S. Qin, R. S. Finn, M. Kudo, T. Meyer, A. Vogel, M. Ducreux, T. M. Mercade, G. Tomasello, F. Boissarie, J. Hou, C. Li, J. Song, A. X. Zhu*
- Board 320a Abstract TPS3111: A phase 3, randomized, open-label study to compare the efficacy of tislelizumab (BGB-A317) versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).** *L. Shen, J. A. Ajani, S. Kim, E. Van Cutsem, B. Guo, J. Song, V. Paton, K. Kato*

Monday, June 4, 2018

- Board 320b **Abstract TPS3112: A phase 3, open-label, multicenter, randomized study to investigate the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus docetaxel in patients with non-small cell lung cancer who have progressed on a prior platinum-containing regimen.** *D. Huang, Z. Wang, X. Yu, Y. Cheng, J. Wang, Y. Fan, Z. Ma, J. Shi, Y. Yu, Y. Hu, J. Song, F. Xia, Z. Shen, Y. Zhang, Y. Xu, C. Condon, F. Shi, Y. Zhou, A. Pirzkall, C. Zhou*
- Board 321a **Abstract TPS3113: Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors.** *J. Desai, M. Voskoboynik, B. Markman, J. Hou, D. Zeng, T. Meniawy*
- Board 321b **Abstract TPS3114: A phase 3, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy.** *F. Ciardiello, Y. Bang, J. C. Bendell, A. Cervantes, R. K. Brachmann, Y. Zhang, M. Raponi, H. Farin, L. Shen*
- Board 322a **Abstract TPS3115: PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors.** *D. A. Vaena, J. Chaves, N. J. Vogelzang, M. R. Matrana, A. E. Gabayan, M. J. Riese, D. C. Cho, M. A. Tagliaferri, J. Zalevsky, S. Xie, U. Hoch, A. N. RIZWAN, S. Aung, M. Imperiale, J. K. Schwarz*
- Board 322b **Abstract TPS3116: A phase Ib study evaluating the safety and tolerability of durvalumab in combination with eribulin in patients with HER2-negative metastatic breast cancer and recurrent ovarian cancer.** *C. A. Landry, J. M. Guziel, M. Ru, C. L. Shapiro, J. Fasano, A. S. Bhardwaj, H. Irie, N. Bhardwaj, A. Tiersten*
- Board 323a **Abstract TPS3117: An open label phase I study to evaluate the safety and efficacy of OBP-301 with pembrolizumab in patients with advanced solid tumors.** *T. Kojima, T. Fujiwara, Y. Shirakawa, H. Ono, M. Nakamoto, H. Hasegawa, N. Hirano, M. Wakabayashi, S. Nomura, Y. Togashi, H. Nishikawa, A. Sato, A. Ohtsu, T. Doi*
- Board 323b **Abstract TPS3118: A phase I/II Trial of CRISPR-Cas9-mediated PD-1 knockout Epstein-Barr virus cytotoxic lymphocytes (EBV-CTLs) for advanced stage EBV associated malignancies.** *J. Wei, J. Yan, S. Su, J. Shao, Y. Zhao, Q. Xu, Y. Yang, Z. Zou, X. Huang, B. Liu*
- Board 324a **Abstract TPS3119: Phase Ib trial of nivolumab combined with metformin for refractory/recurrent solid tumors.** *T. Kubo, K. Hotta, T. Ninomiya, H. Kato, S. Horiguchi, A. Takamoto, T. Kozuki, N. Nogami, H. Ishii, T. Nishina, D. Harada, S. Toyooka, H. Okada, T. Fujiwara, H. Uono, K. Kiura*
- Board 324b **Abstract TPS3120: An open-label, multidrug, biomarker-directed, multicentre phase II umbrella study in patients with non-small cell lung cancer, who progressed on an anti-PD-1/PD-L1 containing therapy (HUDSON).** *J. Heymach, M. Thomas, B. Besse, P. M. Forde, M. M. Awad, G. D. Goss, K. Park, N. A. Rizvi, S. Lao-Sirieix, S. I. Patel, P. G. Mortimer, H. Ambrose, P. J. Jewsbury, K. Sachsenmeier, L. Khoja, W. Brugger*
- Board 325a **Abstract TPS3121: Trial in progress: Platform phase 1 study investigating the safety of stereotactic body radiotherapy with immuno-oncology agents for the treatment of multiple metastases in advanced solid tumors.** *C. C. Foster, G. Kauffmann, S. J. Chmura, J. J. Luke*
- Board 325b **Abstract TPS3122: Expansion cohort of partially irradiated tumors on a phase 1 trial of pembrolizumab and ablative radiotherapy.** *S. R. BHave, J. J. Luke, J. M. Lemons, L. A. Janisch, R. D. Hseu, S. J. Chmura*
- Board 326a **Abstract TPS3123: A multicenter phase 2 study of nivolumab combined with ipilimumab in patients with pediatric solid tumors in adulthood (GETH021).** *X. Mielgo, R. Diaz Beveridge, E. Pineda, J. M. Sepúlveda, R. López Castro, M. Lecumberri-Biurrun, M. A. Vaz Salgado, R. De Las Penas, C. López-López, N. Rodríguez Salas, J. virizuela, R. Lopez, J. Medina, C. Valverde, C. Beato, N. Lainez, C. Rodríguez-Antona, P. Berraondo, A. Herrador, J. GarcÁa-Donas*

- Board 326b Abstract TPS3124: Regorafenib and nivolumab combination therapy for advanced and metastatic solid tumors: Phase I clinical trial (EPOC1603).** S. Fukuoka, H. Hara, S. Shimizu, H. Takahashi, M. Ikeda, H. Tamura, Y. Mikamoto, M. Fukutani, M. Wakabayashi, S. Nomura, A. Sato, K. Shitara
- Board 327a Abstract TPS3125: A phase I/II study of regorafenib (R) plus avelumab (A) in digestive tumors.** S. Cousin, M. Toulmonde, S. Albert, C. A. Bellera, B. Lortal, S. Mathoulin-Pélissier, A. Italiano
- Board 327b Abstract TPS3126: An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (mCRPC; CheckMate 9KD).** K. Fizazi, C. G. Drake, D. R. Shaffer, R. Pachynski, F. Saad, M. Ciprotti, G. Kong, C. J. Ryan, D. P. Petrylak
- Board 328a Abstract TPS3127: A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody, in advanced cancers.** K. P. Papadopoulos, N. J. Lakhani, M. L. Johnson, H. Park, D. Wang, T. A. Yap, K. N. Moore, T. N. Sims, C. Emeremni, M. Karasarides, G. S. Kroog
- Board 328b Abstract TPS3128: Phase I study of recombinant interleukin-15 in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers.** G. H. O'Sullivan Coyne, K. Conlon, N. Takebe, H. Streicher, M. F. Quinn, A. Bruns, T. Navas, R. E. Parchment, L. Rubinstein, E. Sharon, J. H. Doroshow, T. A. Waldmann, A. P. Chen
- Board 329a Abstract TPS3129: The "INSIGHT" trial: An explorative, open-labeled phase I study to evaluate the feasibility and safety of intra-tumoral, intra-peritoneal, and subcutaneous injections with IMP321 (LAG-3Ig fusion protein) for advanced stage solid tumor entities.** D. W. Mueller, T. O. Goetze, R. Eickhoff, A. Reichart, S. Al-Batran
- Board 329b Abstract TPS3130: A sequential cohort study of combination immunotherapy with BN-brachyury vaccine, M7824, ALT-803 and epacadostat in metastatic castration-resistant prostate cancer (mCRPC) (QuEST1).** J. M. Redman, S. M. Steinberg, J. L. Gulley
- Board 330a Abstract TPS3131: A phase 1/2 study with birinapant in combination with pembrolizumab.** R. J. Schilder, M. Albertella, J. Strauss, M. Sydvander, S. M. Nair, K. Urakpo, S. Norin, J. Öhd
- Board 333b Abstract TPS3132: Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma.** J. R. Richter, C. O. Landgren, J. S. Kauh, J. Back, Y. Salhi, V. Reddy, E. Bayever, J. G. Berdeja
- Board 331a Abstract TPS3133: Phase I/II dose escalation and expansion cohort safety and efficacy study of image guided intratumoral CD40 agonistic monoclonal antibody APX005M in combination with systemic pembrolizumab for treatment naive metastatic melanoma.** D. H. Johnson, S. E. Bentebibel, S. Lecagoonporn, C. Bernatchez, C. L. Haymaker, R. Murthy, A. Tam, C. Yee, R. N. Amaria, S. P. Patel, H. A. Tawbi, I. C. Glitza, M. A. Davies, W. Hwu, P. Hwu, W. W. Overwijk, A. Diab
- Board 331b Abstract TPS3134: An open-label, phase 1b study of NEO-PV-01 with pembrolizumab plus chemotherapy in patients with advanced or metastatic nonsquamous non-small cell lung cancer.** R. Govindan, M. M. Awad, L. D. Cleary, M. A. Moles, R. Gaynor, M. J. Goldstein, D. R. Spigel
- Board 332a Abstract TPS3135: HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients.** L. Buonaguro, A. Mayer-Mokler, R. Accolla, Y. Ma, R. Heidenreich, A. Avallone, E. Simeone, A. Koenigsrainer, M. Loeffler, C. Gouttefangeas, C. Flohr, J. Ludwig, H. Rammensee, M. Iñarrairaegui, S. Francque, T. Chaumette, T. Weinschenk, C. Reinhardt, S. U. Gnad-Vogt, H. Singh

Monday, June 4, 2018

Board 332b **Abstract TPS3136: Phase I/II study of BSK01, an artificial intelligence-driven, peptide-pulsed, mature DC immunotherapy for solid and hematological malignancies.** *L. Mirandola, Z. Timsah, D. T. Nguyen, R. Bresalier, N. G. Daver, M. Chiriva-Internati*

8:00 AM - 11:30 AM Poster Session

Education Research

Location: Hall A

Posters by Topic

Education Research: Boards 1-16

Trials in Progress: Boards 17a-17b

- Board 1 Abstract 11004: Quantitative assessment of learning behaviors for oncology providers.** *M. Wood, T. J. George Jr., R. Manochakian, M. Polansky, A. Baer, A. Grupe, Y. Shyr, C. Wang, L. Horn*
- Board 3 Abstract 11006: Development and implementation of an instrument for assessing the proficiency of oncology fellows in the delivery of bad news.** *M. A. Hoffman, D. Cannone, M. L. Barilla-Labarca, M. Kline*
- Board 4 Abstract 11007: Creation of a high-fidelity simulation tool to teach competency in radiation oncology treatment plan evaluation.** *J. Adleman, J. Winter, T. Purdie, A. McNiven, J. M. Croke*
- Board 5 Abstract 11008: Implementation of a model for training and career development in the emerging academic field of global oncology.** *R. Deboer, D. N. Bhatta, G. Buckle, M. J. Xu, S. Kennell-Heiling, M. M. Mwachiro, A. Paciorek, L. Zhang, K. Van Loon*
- Board 6 Abstract 11009: Global oncology fellowship electives: The impact on cancer care and international collaborations.** *J. Butonzi, C. Shyirambere, F. Lansigan, C. Rusangwa, T. H. Davis, A. Hill, K. Rose, R. J. DeBoer, D. Ruhangaza, M. D. Chamberlin*
- Board 7 Abstract 11010: Ten years of ASCO/ESMO global curriculum for training in medical oncology implementation at Instituto Oncologico Nacional in Panama City, Panama.** *O. O. Castillo Fernandez, R. I. Lopez, J. C. Alcedo, J. Lasso De La Vega, M. Lim, A. Villa-Real*
- Board 8 Abstract 11011: Use of medical simulation for cancer education in Nigeria.** *K. N. Eguzo, C. Okwuosa, U. S. Ekanem, C. D. Akwaowo, E. D. Mkpang*
- Board 9 Abstract 11012: Assessing trainee's need and readiness for e-cancer education and training in Africa.** *O. C. Irabor, A. Berger, V. Mbarika, N. Hammad, F. Odedina, W. Ngwa*
- Board 10 Abstract 11013: Impact of closed Facebook group participation on women hematology/oncology physicians.** *J. L. Close, S. M. Cole, R. N. Beg, S. L. Graff, L. B. Matt-Amaral, M. J. Markham*
- Board 11 Abstract 11014: Oncology education for family medicine (FM) residents and family physicians (FPs): A needs assessment survey.** *S. Yip, D. E. Meyers, J. J. Sisler, K. Wycliffe-Jones, E. Kucharski, C. Elser, C. Temple-Oberle, S. Spadafora, P. A. Gfeller-Ingledew, G. Meredith, S. Kuruvilla, N. Sumar, V. C. Tam*
- Board 12 Abstract 11015: Utilization of a web-based supportive oncology training curriculum for healthcare professionals (HCPs).** *S. S. Lo, B. Roggenkamp, K. Hasson, J. R. Trosman, C. A. Rosenberg, T. Lillis, E. Knightly, M. Pasquinelli, L. A. Wiebe, J. Gerhart, F. J. Penedo, J. Martin, P. A. Robinson, A. Scheu, R. Berardi, C. B. Weldon*
- Board 13 Abstract 11016: Gender differences in faculty rank amongst radiation oncologists in United States: A cross-sectional study.** *I. Riaz, U. Zahid, N. Khalid, F. Ali, R. M. Farooqi, S. Yadav, A. Raina, S. Bhattacharjee, F. Khosa*

- Board 14 Abstract 11017: Opportunities for provider education in the use and interpretation of liquid biopsy.** *C. E. Lee, A. M. Wells, N. Sheehy, R. J. Nagy, R. B. Lanman*
- Board 15 Abstract 11018: Prospective study of the perceptions of oncology residents about learning from tumor boards.** *R. Venkitaraman*
- Board 16 Abstract 11019: The MD CaREs initiative: Tailoring oncology education to ethnically and culturally diverse students.** *Z. Diaz, C. Lupi, F. M. Vargas Madueno, B. A. Roller, C. Brewster, A. Wells, J. Ordonez, D. Suarez, M. Paez, J. Boyd, C. D. Runowicz, M. A. Villalona-Calero*
- Board 17a Abstract TPS11020: A feasibility study to examine the role of a mindfulness-based wellness curriculum for early clinical trainees.** *M. S. Chatwal, M. McDowell, C. Vinci, R. R. Reich, A. Reagan, J. E. Gray*
- Board 17b Abstract TPS11021: Establishment of a medical student elective on the oncology consult service using the seven principles of teaching.** *H. A. Deshpande, S. Stein*

8:00 AM - 11:30 AM Poster Session

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft

Location: Hall A

Abstracts on Boards 72-83 will be discussed during the Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft Poster Discussion Session.

Posters by Topic

Acute Leukemia: Boards 72-77, 79-115

Allogeneic Stem Cell Transplantation: Boards 116-119

Chronic Leukemia—CML and Hairy Cell: Boards 120-123

Myelodysplastic Syndromes (MDS): Boards 78, 124-129

Myeloproliferative Syndromes (MPD): Boards 130-132

Trials in Progress: Boards 133a-138b

- Board 72 Abstract 7012: Relationship of minimal residual disease (MRD) in acute lymphocytic leukemia (ALL) and putative leukemia stem cells (LSCs).** *J. M. Gerber, E. Jandrisevits, L. Druhan, A. Lance, A. Price, V. Thurston, J. Ai, T. G. Knight, B. K. Ragon, M. Turner, E. H. Lipford, E. A. Copelan, M. R. Grunwald, B. R. Avalos, D. Foureau*
- Board 73 Abstract 7013: Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.** *E. Jabbour, N. Gökbüget, A. S. Advani, M. Stelljes, W. Stock, M. Liedtke, G. Martinelli, S. M. O'Brien, T. Wang, D. Laird, E. Vandendries, A. Neuhof, D. J. DeAngelo, H. M. Kantarjian*
- Board 74 Abstract 7014: Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.** *T. M. Kadia, J. E. Cortes, A. Ghorab, F. Ravandi, E. Jabbour, N. G. Daver, Y. Alvarado, M. Ohanian, M. Konopleva, H. M. Kantarjian*
- Board 75 Abstract 7015: Profiling the immune checkpoint pathway in acute myeloid leukemia.** *P. Dama, M. Tang, N. Fulton, J. P. Kline, H. Liu*
- Board 76 Abstract 7016: Treg infiltration and the expression of immune checkpoints associated with T cell exhaustion in AML.** *P. Williams, S. Basu, G. Garcia-Manero, J. E. Cortes, F. Ravandi, E. Jabbour, Z. Al-Hamal, M. Konopleva, J. Ning, L. Xiao, J. H. Lopez, S. Kornblau, M. Andreeff, C. E. Bueso-Ramos, J. M. Blando, G. Alatrash, J. P. Allison, H. M. Kantarjian, P. Sharma, N. G. Daver*

Monday, June 4, 2018

- Board 77 **Abstract 7017: Post hoc exploratory analysis of two phase 2 trials of quizartinib monotherapy in patients (pts) with FLT3-ITD-mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment.** *M. J. Levis, C. C. Smith, K. Ishizuka, K. Kobayashi, M. Arunachalam, Y. Wang, D. Lazzaretto, J. E. Cortes*
- Board 78 **Abstract 7018: Erythropoietic cellular analyses in luspatercept-treated lower-risk myelodysplastic syndromes (MDS): Phase 2 PACE-MDS study.** *U. Platzbecker, A. Giagounidis, P. M. Kiewe, U. Germing, K. S. Gotze, K. Mayer, M. Radsak, T. Wolff, J. Chromik, J. Reynolds, C. Barron, C. Rovaldi, R. N. Suragani, X. Zhang, A. Laadem, P. G. Linde, M. L. Sherman, U. Oelschlägel*
- Board 79 **Abstract 7019: First-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (RR) acute myeloid leukemia (AML): Preliminary data.** *G. Borthakur, J. E. Wolff, I. Aldoss, B. Hu, M. Dinh, A. Torres, X. Chen, D. Rizzieri, A. Sood, O. Odenike, B. A. Jonas*
- Board 80 **Abstract 7020: Analysis of anti-leukemic activity, predictive biomarker candidates, immune activation and pharmacodynamics in R/R AML and MDS in response to treatment with bemcentinib (BGB324), a first-in class selective AXL inhibitor, in a phase II open-label, multi-centre study.** *B. T. Gjertsen, M. Hellesøy, H. Reikvam, A. O. Kittang, D. Micklem, A. Brown, J. Lorens, M. Kebenko, M. Janning, M. Binder, W. M. Fiedler, J. E. Cortes, M. Heuser, J. Chromik, P. Paschka, C. E. Vigil, S. Loges*
- Board 81 **Abstract 7021: Is there a benefit of re-induction therapy in adult patients with AML with <20% blasts?** *K. K. Kannan, P. Vellanki, S. Isom, B. Tawfik, A. M. Winter, H. D. Klepin, L. R. Ellis, R. R. Bhave, D. Howard, M. Manuel, S. Dralle, S. Lyerly, B. L. Powell, T. S. Pardee*
- Board 82 **Abstract 7022: Clonal evolution in acute myeloid leukemia (AML): Relapse after a long remission period.** *M. Yilmaz, F. Wang, S. Loghavi, C. E. Bueso-Ramos, C. Gumbs, L. Little, X. Song, J. Zhang, T. M. Kadia, G. Borthakur, E. Jabbour, G. Garcia-Manero, Z. Estrov, H. M. Kantarjian, P. A. Futreal, K. Takahashi, F. Ravandi, N. J. Short*
- Board 83 **Abstract 7023: Impact of numerical variation, allele burden and mutation length on outcomes in acute myeloid leukemia with fms-like tyrosine kinase receptor-3 internal tandem duplication (FLT3-ITD) mutation.** *A. Ghorab, K. Patel, J. E. Cortes, D. Chihara, A. Price, T. M. Kadia, F. Ravandi, N. Pemmaraju, N. G. Daver, C. D. Dinardo, H. M. Kantarjian, G. Borthakur*
- Board 84 **Abstract 7024: iCare 1: A prospective clinical trial to predict treatment response based on genomics-informed computational biology in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).** *L. Drusbosky, K. E. Hawkins, M. Turcotte, G. G. Anderson, S. Vali, T. Abbasi, F. Zou, N. Farhadfar, H. S. Murthy, B. Horn, H. Leather, P. Castillo, R. Brown, M. Norkin, J. W. Hiemenz, J. R. Wingard, J. W. Hsu, C. R. Cogle*
- Board 85 **Abstract 7025: Determining the sensitivity of primary acute myeloid leukemia (AML) samples with FLT3-ITD or FLT3-D835 mutations to FLT3 inhibitors using an ex vivo drug sensitivity screen.** *M. Rosenberg, G. Fan, K. Watanabe-Smith, C. Tognon, B. J. Druker, J. Tyner, M. Loriaux*
- Board 86 **Abstract 7026: Initial report of a phase I study of LY2510924 with idarubicin and cytarabine (IA) in relapsed/refractory (R/R) AML.** *P. Boddur, G. Borthakur, K. Naqvi, W. G. Wierda, P. Bose, E. Jabbour, Z. Estrov, J. A. Burger, Y. Alvarado, A. Deshmukh, A. Patel, A. Cavazos, L. Han, H. M. Kantarjian, M. Andreeff, M. Konopleva*
- Board 87 **Abstract 7027: CX-01, an inhibitor of CXCL12/CXCR4 axis and of platelet factor 4 (PF4), with azacitidine (AZA) in patients with hypomethylating agent (HMA) refractory AML and MDS.** *E. Huseilton, A. F. Cashen, M. Jacoby, I. Pusic, R. Romee, G. L. Uy, J. F. DiPersio, P. Westervelt*

- Board 88 Abstract 7028: Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): Analysis from INO-VATE by bone marrow blast percentage (BMB%).** *A. S. Advani, D. J. DeAngelo, D. I. Marks, M. Stelljes, M. Liedtke, W. Stock, N. Gökbüget, S. M. O'Brien, E. Jabbour, A. A. Merchant, T. Wang, E. Vandendries, A. Neuhof, H. M. Kantarjian*
- Board 89 Abstract 7029: Extensive safety profile of inotuzumab ozogamicin (InO) in relapsed/refractory acute lymphoblastic leukemia (ALL) patients enrolled in the phase 3 INO-VATE trial.** *R. D. Cassaday, D. J. DeAngelo, G. Martinelli, W. Stock, M. Stelljes, N. Gökbüget, A. S. Advani, S. M. O'Brien, M. Liedtke, A. A. Merchant, T. Wang, E. Vandendries, D. I. Marks, E. Jabbour, H. M. Kantarjian*
- Board 90 Abstract 7030: Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome–positive (Ph+) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).** *W. Stock, G. Martinelli, M. Stelljes, D. J. DeAngelo, N. Gökbüget, A. S. Advani, S. M. O'Brien, M. Liedtke, A. A. Merchant, R. D. Cassaday, T. Wang, E. Vandendries, D. I. Marks, H. M. Kantarjian*
- Board 91 Abstract 7031: Phase 1 trial of Pegzilarginase in patients (pts) with relapsed/refractory (R/R) AML or MDS refractory to hypomethylating agents (HMAs).** *G. L. Uy, M. R. Savona, B. K. Tomlinson, H. Carraway, D. L. Bixby, S. E. Assouline, J. M. Brandwein, M. Y. Levy, R. Collins, H. Lara-Guerra, S. Alters, S. Eckert, S. Rowlinson, J. Wooldridge, A. D. Schimmer*
- Board 92 Abstract 7032: A retrospective study of comorbidities and complications in elderly acute myeloid leukemia (AML) patients in the U.S.** *N. Dhopeshwarkar, X. Wang, S. Iqbal, M. Salas*
- Board 93 Abstract 7033: Hypomethylating agent (HMA) treatment as a bridge to allogeneic hematopoietic cell transplantation (HCT) for relapsed/refractory acute myeloid leukemia (RR-AML).** *M. R. Grunwald, D. Boselli, L. M. Bohannon, M. K. Zimmerman, J. Ai, T. G. Knight, B. K. Ragon, D. Plesca, J. S. Trivedi, B. R. Avalos, E. A. Copelan, J. T. Symanowski, J. M. Gerber*
- Board 94 Abstract 7034: Treatment of relapsed/refractory (R/R) b-cell malignancies by chimeric antigen receptor t cells cultured from 50-100 mL peripheral blood in 7-10 days.** *L. Han, J. Zhou, K. Zhou, L. Zhao, X. Zhu, Q. Yin, Q. Gao, Y. Song*
- Board 95 Abstract 7035: Quality of life and psychological distress in patients with acute myeloid leukemia (AML).** *J. Carp, L. Waldman, S. Nicholson, L. Traeger, G. A. Abel, J. Greer, A. T. Fathi, D. P. Steensma, T. W. LeBlanc, D. J. DeAngelo, M. Wadleigh, G. Hobbs, A. M. Brunner, P. C. Amrein, R. M. Stone, J. S. Temel, A. El-Jawahri*
- Board 96 Abstract 7036: In acute myeloid leukemia patients CpG-methylation changes associate with resistance to induction chemotherapy.** *C. D. Niederwieser, C. Rohde, H. Serve, W. E. Berdel, G. Ehninger, S. Göllner, S. Schwind, L. P. Müller, C. Müller-Tidow*
- Board 97 Abstract 7037: Factors influencing first-line therapy of acute myeloid leukemia (AML) patients (pts) in the Connect MDS/AML Disease Registry.** *C. R. Cogle, D. A. Pollyea, M. Abedi, M. A. Thompson, G. J. Roboz, C. U. Louis, E. Flick, M. Nifenecker, P. Kiselev, A. S. Swern, H. P. Erba*
- Board 98 Abstract 7038: Low-toxic myeloablative conditioning regimen in haploidentical hematopoietic stem cell transplantation for elderly patients with acute myeloid leukemia.** *C. Aristei, V. Lancellotta, A. Carotti, C. Zucchetti, A. Pierini, S. Saldi, L. Ruggeri, L. Amico, M. Iacco, A. Velardi, M. Martelli*
- Board 99 Abstract 7039: Characteristics and outcomes of acute myeloid leukemia (AML) with extramedullary disease (EMD).** *F. F. Yalniz, J. E. Cortes, G. Borthakur, G. Garcia-Manero, T. M. Kadia, M. Konopleva, C. D. Dinardo, N. G. Daver, W. G. Wierda, S. Verstovsek, N. Pemmaraju, Z. Estrov, F. Ravandi, H. M. Kantarjian*

Monday, June 4, 2018

- Board 100 **Abstract 7040: Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML).** *T. L. Lin, B. C. Medeiros, G. L. Uy, L. F. Newell, E. K. Ritchie, R. K. Stuart, S. A. Strickland, D. Hogge, S. R. Solomon, R. M. Stone, D. L. Bixby, J. E. Koltitz, G. J. Schiller, M. J. Wieduwilt, D. H. Ryan, R. J. Ryan, M. Chiarella, A. C. Louie, J. E. Lancet, J. E. Cortes*
- Board 101 **Abstract 7041: A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results.** *A. Bazarbachi, M. Yilmaz, F. Ravandi, D. A. Thomas, M. Khouri, G. Garcia-Manero, R. S. Garris, J. E. Cortes, N. J. Short, K. Sasaki, G. C. Issa, P. B. Koller, T. M. Kadia, S. Verstovsek, N. G. Daver, N. Jain, M. Konopleva, S. M. O'Brien, E. Jabbour, H. M. Kantarjian*
- Board 102 **Abstract 7042: Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML).** *C. D. Dinardo, A. S. Stein, E. M. Stein, A. T. Fathi, A. C. Schuh, P. Montesinos Fernández, O. Odenike, H. M. Kantarjian, R. M. Stone, R. Collins, G. Martinelli, M. Arnan, B. Wu, D. O. Koralek, J. Van Oostendorp, J. Gong, K. J. MacBeth, P. Vyas*
- Board 103 **Abstract 7043: A randomized open label exploratory controlled trial of CLT-008 myeloid progenitor cells (MPC) to decrease infections during induction for AML.** *C. N. Abboud, L. P. Akard, C. Andreadis, P. M. Desai, J. M. Foran, O. Frankfurt, S. Gill, J. W. Hsu, J. Lister, J. M. Pagel, G. J. Schiller, M. M. Solh, C. Ustun, M. J. Wieduwilt, B. Janice, A. Wong, L. Kellerman, R. Van Syoc, R. Mamelok, F. Ravandi*
- Board 104 **Abstract 7044: Long-term survival of adults with B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) after treatment with blinatumomab and subsequent allogeneic hematopoietic stem cell transplantation (HSCT).** *M. Topp, A. S. Stein, G. Zugmaier, H. Dombret, M. Brueggemann, M. Bonifacio, X. Dong, H. M. Kantarjian, R. C. Bargou, N. Göckbuget*
- Board 105 **Abstract 7045: Feasibility of HSCT vs consolidation therapy for AML patients aged 60-75 in CR1: A randomized phase III, multicentre EBMT study.** *D. Niederwieser, B. Lowenberg, W. E. Berdel, R. Brand, Y. Chalandon, C. Junghanss, D. Hasenclever, M. Haenel, G. Maschmeyer, M. Mende, M. Mohty, G. Ten Ossenkuppele, J. Passweg, H. Sayer, J. Schetelig, H. C. Schouten, S. Schwind, M. Stelljes, V. Vucinic, J. Cornelissen*
- Board 106 **Abstract 7046: Impact of variant allele frequency of mutant *PTPN11* in AML: Single institution experience of 122 patients.** *M. Alfayez, K. Patel, J. E. Cortes, T. M. Kadia, F. Ravandi, C. D. Dinardo, N. G. Daver, N. Pemmaraju, H. M. Kantarjian, G. Borthakur*
- Board 107 **Abstract 7047: Molecular testing during AML treatment for early prediction of clinical response.** *H. Wong, A. D. Sung, K. E. Lindblad, S. Sheela, G. W. Roloff, K. Romero, M. Goswami, M. P. Mulé, C. B. Destefano, D. Rizzieri, L. W. Dillon, C. Lai, C. S. Hourigan*
- Board 108 **Abstract 7048: Phase 1 study of selinexor plus mitoxantrone, etoposide, and cytarabine in acute myeloid leukemia.** *B. Bhatnagar, A. R. Walker, A. S. Mims, S. Vasu, R. B. Klisovic, G. Behbehani, J. S. Blachly, K. T. Larkin, M. Long, Q. Zhao, P. Ranganathan, J. C. Byrd, W. G. Blum, R. Garzon*
- Board 109 **Abstract 7049: Pharmacodynamic characterization of eryaspase (L-asparaginase encapsulated in red blood cells) in combination with chemotherapy in a phase 2/3 trial in patients with relapsed acute lymphoblastic leukemia (NCT01518517).** *I. El-Hairry, K. Aguera, F. Hoke, K. Swart, A. Hamm, R. Kay, P. Lorenzi*
- Board 110 **Abstract 7050: Relapse prevention with second generation tyrosine kinase inhibitors for ph+ve acute leukemia after allogeneic stem cell transplantation.** *F. Anwer, Z. Warraich, A. Sohail, T. Thai, A. Latif, V. Kapoor, K. R. Maher, F. H. Warraich, S. Warraich, Z. Baig, A. Mushtaq, P. Tennesi, A. McBride*

- Board 111 Abstract 7051: Comparison of somatic mutations profiles from next-generation sequencing (NGS) of cell-free DNA (cfDNA) versus bone marrow (BM) in acute myeloid leukemia (AML).** *R. E. Assi, M. Albitar, W. Ma, K. Patel, K. Takahashi, M. Yilmaz, N. J. Short, E. Jabbour, G. Garcia-Manero, H. M. Kantarjian, Z. Estrov, F. Ravandi*
- Board 112 Abstract 7052: Comparison of blast clearance in peripheral blood and day 14 bone marrow biopsy for evaluation of disease response after 7+3 induction in acute myeloid leukemia (AML).** *F. Covut, D. Gupta, R. Pinto, N. Dambrosio, N. H. El Jurdi, M. Ueda, L. L. Metheny, B. W. Cooper, P. F. Caimi, E. Malek, F. Otegbeye, M. J. De Lima, B. K. Tomlinson*
- Board 113 Abstract 7053: Validation of the ELN-2017 risk classification in younger adult patients (pts) with AML.** *P. Boddu, T. M. Kadia, G. Garcia-Manero, J. E. Cortes, G. Borthakur, M. Konopleva, E. Jabbour, N. G. Daver, C. D. Dinardo, K. Naqvi, M. Yilmaz, N. J. Short, G. M. Nogueras-Gonzalez, S. Pierce, H. M. Kantarjian, F. Ravandi*
- Board 114 Abstract 7054: Outcomes of patients with nucleoplasm 1 (NPM1) mutated acute myeloid leukemia (AML) treated with hypomethylating agents (HMAs).** *M. Swaminathan, E. Jabbour, F. Ravandi, T. M. Kadia, G. Borthakur, M. Konopleva, C. D. Dinardo, S. Pierce, Y. Alvarado, R. E. Assi, I. A. Abou Dalle, E. Tallis, H. M. Kantarjian, G. Garcia-Manero*
- Board 115 Abstract 7055: Timed sequential therapy with high-dose cytarabine and mitoxantrone as an effective and safe induction regimen for acute myeloid leukemia.** *M. L. Larson, S. Burhani, K. Gallas, D. A. Katz, M. Hoyt, P. Venugopal*
- Board 116 Abstract 7056: Post-transplant cyclophosphamide (PT-Cy) based haploidentical transplantation (haploHCT) versus matched sibling (MSD) or matched unrelated donor (MUD) reduced intensity conditioning (RIC) HCT for diffuse large b-cell lymphoma (DLBCL): A CIBMTR and EBMT analysis.** *M. Hamadani, K. W. Ahn, C. Litovich, F. Herve, S. M. Smith, T. S. Fenske, A. Boumendil, S. Dietrich, S. Robinson, S. Montoto, P. Dreger, A. M. Sureda*
- Board 117 Abstract 7057: Development and validation of a risk assessment tool for symptomatic BKV infection.** *A. Abudayyeh, M. Abdelrahim, H. Y. Lin, V. D. Page, G. Rondon, B. Andersson, C. Martinez, J. Tarrand, D. P. Kontoyiannis, D. Marin, A. Gaber, B. Oran, R. Chemaly, A. L. Olson, R. B. Jones, U. R. Popat, E. J. Shpall, K. Rezvani*
- Board 118 Abstract 7058: Cyclophosphamide (Cy) pharmacogenetics (PGx) in allogeneic stem cell transplant (SCT) patients (pts) receiving Cy, fludarabine, total body irradiation and post-transplant Cy (FluCyTBI-postCy).** *J. N. Patel, Q. Zhang, I. Hamadeh, N. Steuerwald, A. Hamilton, J. M. Gerber, M. R. Grunwald, L. Druhan, J. He, B. R. Avalos, E. A. Copelan*
- Board 119 Abstract 7059: Effect of donor type in patients with AML or MDS undergoing reduced intensity hematopoietic cell transplant.** *N. Rashid, R. Romee*
- Board 120 Abstract 7060: Efficacy and safety of moxetumomab pasudotox (moxe) in adult patients (pts) with relapsed/refractory hairy cell leukemia (HCL) in relation to drug exposure, baseline disease burden, and immunogenicity.** *D. Kuruvilla, Y. Chia, L. Santiago, K. Balic, N. Yao, R. J. Kreitman, I. Pastan, X. Li, M. Liang, C. Tseng, R. Faggioni, L. Roskos*
- Board 121 Abstract 7061: Pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of moxetumomab pasudotox (Moxe), an immunotoxin targeting CD22, in adult patients (Pts) with relapsed or refractory hairy cell leukemia (HCL).** *K. Balic, N. Standifer, L. Santiago, D. Kuruvilla, N. Yao, R. J. Kreitman, I. Pastan, X. Li, M. Liang, I. Vainshtein, C. Tseng, R. Faggioni, L. Roskos*
- Board 122 Abstract 7062: Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemia: Phase 1/2 study update.** *C. Gambacorti-Passerini, J. H. Lipton, A. Hochhaus, V. K. Kota, M. Baccarani, S. Durrant, S. E. Assouline, D. Kim, T. H. Brümmendorf, E. Leip, F. An, J. Aguiar, J. E. Cortes*

Monday, June 4, 2018

- Board 123 **Abstract 7063: Long-term treatment-free remission (TFR) following frontline (1L) nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom 144-wk results.** *J. P. Radich*, T. Masszi, M. Gómez Casares, A. Hellmann, J. Stentoft, E. Conneally, V. García Gutierrez, N. Gattermann, P. D. Le Coutre, B. Martino, S. Saussele, F. J. Giles, D. M. Ross, G. Saglio, M. Sondhi, S. Acharyya, S. Chaturvedi, V. Bédoucha, A. Hochhaus
- Board 124 **Abstract 7064: Intensive chemotherapy (IC) versus hypomethylating agents (HMA) for the treatment of younger patients with myelodysplastic syndrome (MDS) and elevated bone marrow blasts.** *P. Strati*, G. Garcia-Manero, T. M. Kadia, G. Borthakur, M. Konopleva, N. G. Daver, C. D. Dinardo, N. J. Short, M. Yilmaz, K. Naqvi, S. Pierce, J. E. Cortes, H. M. Kantarjian, F. Ravandi
- Board 125 **Abstract 7065: PU.1 and JDP2 expression in myelodysplastic syndromes to predict treatment response and leukemia transformation.** *K. Boasman*, M. Simmonds, Y. Saunthararajah, C. R. Rinaldi
- Board 126 **Abstract 7066: Omacetaxine mepesuccinate for patients with higher-risk MDS and CMML after failure of hypomethylating agents: A phase II clinical trial.** *G. Sanchez-Petitto*, G. Garcia-Manero, N. J. Short, K. Naqvi, M. Andreeff, K. Takahashi, S. Kornblau, P. Bose, Z. Estrov, M. Konopleva, A. Patel, R. Islam, Y. Alvarado, C. D. Dinardo, H. M. Kantarjian, E. Jabbour
- Board 127 **Abstract 7067: A pilot trial of anti-KIR antibody with or without 5-azacitidine for myelodysplastic syndrome.** *F. F. Yalniz*, N. G. Daver, S. M. Kornblau, M. Ohanian, G. Borthakur, C. D. Dinardo, M. Konopleva, J. A. Burger, Y. Gasior, S. Pierce, H. M. Kantarjian, G. Garcia-Manero
- Board 128 **Abstract 7068: The impact of clonal size on the revised international prognostic scoring system (R-IPSS) in myelodysplastic syndromes (MDS) with a single cytogenetic abnormality.** *O. Alkharabsheh*, S. S. Saadeh, M. M. Patnaik, H. Alkhateeb, N. Gangat, K. Begna, W. J. Hogan, P. T. Greipp, R. He, P. L. Nguyen, M. R. Litzow, A. Al-Kali
- Board 129 **Abstract 7069: Characteristics and outcomes of myelodysplastic syndrome (MDS) with chromosome (chr)3q abnormalities.** *M. Alfayez*, R. E. Assi, H. M. Kantarjian, E. Jabbour, F. Ravandi, C. D. Dinardo, G. Borthakur, K. Takahashi, J. E. Cortes, G. Garcia-Manero, T. M. Kadia
- Board 130 **Abstract 7070: Effect of enforced expression of *cxcl8* by hematopoietic stem and progenitor cells on niche interactions and hematopoietic progenitor cells in adult zebrafish.** *B. W. Blaser*, S. Avagyan, L. Zon
- Board 131 **Abstract 7071: Impact of ruxolitinib in myelofibrosis post allogeneic stem cell transplant: A pilot study.** *J. Poulouse*, J. J. Pu, J. Malysz, M. Bayerl, J. Fanburg-Smith, R. J. Hohl, S. Mineishi, J. Zhu
- Board 132 **Abstract 7072: The effect of pre-transplant JAK 1/2 inhibitors on outcomes of myelofibrosis patients who receive allogeneic stem cell transplant.** *K. Miller*, G. Hobbs, V. T. Ho, S. Li, Y. A. Chen
- Board 133a **Abstract TPS7073: Phase 3, randomized, placebo-controlled trials evaluating glasdegib in combination with intensive or nonintensive chemotherapy in patients with untreated acute myeloid leukemia.** *J. E. Cortes*, H. Dombret, A. A. Merchant, T. Tauchi, C. DiRienzo, M. Zeremski, B. Sleight, X. Zhang, M. N. Shaik, T. Bell, G. Chan, M. A. Sekeres
- Board 133b **Abstract TPS7074: AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute myeloid leukemia with an IDH1 mutation.** *E. Stein*, C. D. Dinardo, J. Jang, Y. Miyazaki, R. Ovilla Martinez, J. Auer, V. Zhang, D. O. Koralek, B. Wu
- Board 134a **Abstract TPS7075: A phase 3, trial of gilteritinib, as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with *FLT3-ITD*⁺ AML.** *M. J. Levis*, M. Hamadani, B. Logan, M. Rosales, A. E. Perl, S. M. Devine, E. Bahceci, Y. A. Chen

- Board 134b Abstract TPS7076: An open-label, first-in-human, dose escalation study of a novel CD3-CD123 bispecific T-cell engager administered as a single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high risk myelodysplastic syndrome.** *N. Boissel, S. de Botton, X. G. Thomas, E. Rao, H. Bonnevaux, C. Rubin-Carrez, S. Guerif, E. Beys, A. Gosselin, A. Bauchet, V. Novikov, E. Fernandes, D. Wiederschain, E. A. Palatinsky, K. Hsu, P. G. Fraenkel*
- Board 135a Abstract TPS7077: Phase 3 study of first line pevonedistat (PEV) + azacitidine (AZA) versus single-agent AZA in patients with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (AML).** *M. A. Sekeres, R. J. Fram, Z. Hua, L. Ades*
- Board 135b Abstract TPS7078: A phase 3, randomized study of pracinostat (PRAN) in combination with azacitidine (AZA) versus placebo in patients ≥ 18 years with newly diagnosed acute myeloid leukemia (AML) unfit for standard induction chemotherapy (IC).** *G. Garcia-Manero, C. Y. Fong, A. Venditti, S. Mappa, R. Spezia, L. Ades*
- Board 136a Abstract TPS7079: Trial in progress: An open-label, multicenter, phase 3b study to assess the safety and efficacy of midostaurin in patients (pts) aged ≥ 18 y with newly diagnosed (ND) *FLT3*-mutated acute myeloid leukemia (AML) who are eligible for 7+3 or 5+2 chemotherapy (chemo).** *A. Fuentes, M. Ben Ali, J. Maier, Y. Deniau, A. Ruault, L. Cuenot, V. Campello-Iddison*
- Board 137a Abstract TPS7081: Clinical development of asciminib (ABL001) in chronic myeloid leukemia (CML): A randomized phase 3 study vs. bosutinib.** *M. J. Mauro, F. Lang, D. Kim, J. E. Cortes, T. P. Hughes, A. Hochhaus, H. Minami, C. Boquimpani, Y. Minami, D. J. DeAngelo, M. Breccia, M. Talpaz, Y. Goh, O. Ottmann, M. Sondhi, S. Hois, V. Bédoucha, S. H. Schmitz, D. Rea*
- Board 137b Abstract TPS7082: Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes.** *C. Y. Fong, A. H. Wei, M. G. Frattini, M. Jacoby, U. Borate, K. S. Gotze, J. S. Garcia, D. A. Pollyea, L. Holes, Y. Zhou, K. M. Fakouhi, J. Levenson, J. G. Harb, S. K. Agarwal, F. Attarchi, M. H. Mabry, W. Hong, T. M. Jahn, P. Fenaux, G. Garcia-Manero*
- Board 138a Abstract TPS7083: A phase 2, multicenter, open-label study of the safety and efficacy of luspatercept in subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia with or without RBC transfusion dependence.** *R. A. Mesa, G. Barosi, C. N. Harrison, J. Kiladjan, R. P. Gale, A. Laadem, T. Gerike, P. G. Linde, M. L. Sherman, J. Pariseau, S. Verstovsek*
- Board 138b Abstract TPS7084: Clinical activity, safety and tolerability of ASN002, a dual JAK/SYK inhibitor, in patients with non-Hodgkin lymphoma (NHL), myelofibrosis (MF), chronic lymphocytic leukemia (CLL) and solid tumors.** *S. K. Barta, D. W. Rasco, A. I. Chen, S. Elkins, M. Wang, L. J. Denis, S. Toker, H. Usansky, S. Reddy, N. S. Rao*

8:00 AM - 11:30 AM Poster Session

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Location: Hall A

Abstracts on Boards 146-157 will be discussed during the Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Poster Discussion Session.

Posters by Topic

Chronic Lymphocytic Leukemia (CLL): Boards 149-151, 154, 158-170

Hodgkin Lymphoma: Boards 171-180

Non-Hodgkin Lymphoma: Boards 146-148, 152-153, 155-157, 181-217

Trials in Progress: Boards 218a-222b

Monday, June 4, 2018

- Board 146 **Abstract 7509: Romidepsin activity in T follicular helper(TFH)-phenotype PTCL versus non TFH treated on the same clinical trials.** *P. Ghione, N. Ozkaya, P. Faruque, N. Mehta-Shah, M. A. Lunning, J. Ruan, N. Galasso, A. J. Moskowitz, A. Dogan, S. M. Horwitz*
- Board 147 **Abstract 7510: Tenisib, a dual PI3K δ/γ inhibitor: Safety and efficacy results from an on-going phase I/II study in relapsed/refractory T-cell lymphoma.** *Y. Oki, B. Haverkos, J. M. Zain, M. Lechowicz, S. Devata, N. J. Korman, R. Ramchandren, L. C. Pinter-Brown, P. J. Barde, A. Nair, A. Huen*
- Board 148 **Abstract 7511: The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory b- and t-cell non-Hodgkin lymphoma (NHL).** *P. A. Hamlin, B. D. Cheson, C. M. Farber, T. Feldman, T. S. Fenske, B. T. Hess, J. L. Khatcheressian, C. B. Miller, J. Munoz, M. R. Patel, S. M. Smith, S. D. Smith, D. A. Stevens, J. C. Ye, A. Steele, A. Pandey, M. Birrell, J. Leeds, G. Coffey, J. T. Curnutte*
- Board 149 **Abstract 7512: Durability of response to venetoclax (VEN) in patients with CLL relapsed/refractory to ibrutinib and/or idelalisib.** *J. C. Byrd, W. G. Wierda, M. S. Davids, M. Y. Choi, R. R. Furman, A. R. Mato, L. Zhou, M. E. Verdugo, J. Potluri, S. Coutre*
- Board 150 **Abstract 7513: Comparison of different phase II studies using sequential combinations of targeted agents for treating chronic lymphocytic leukemia.** *V. Julia, P. Cramer, J. Bahlo, S. Robrecht, O. Al-Sawaf, P. Langerbeins, M. F. A. ¼rstenau, A. Engelke, A. Fink, K. Fischer, K. A. Kreuzer, M. Ritgen, S. Boettcher, C. M. Wendtner, S. Stilgenbauer, B. Eichhorst, M. J. Hallek*
- Board 151 **Abstract 7514: Depth of response and progression free survival in CLL patients on ibrutinib.** *A. Sigmund, Y. Huang, A. S. Ruppert, F. Ny, M. Lucas, W. Chase, K. J. Maddocks, K. A. Rogers, S. M. Jaglowski, L. A. Andritsos, F. T. Awan, M. R. Grever, J. C. Byrd, J. A. Woyach*
- Board 152 **Abstract 7515: Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): Results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial).** *M. J. Rummel, M. Koenigsmann, K. Chow, W. Knauf, C. A. Lerchenmuller, C. Losem, M. Goerner, B. Hertenstein, T. Decker, A. Ganser, T. Gaska, M. Heike, E. Lange, R. Weide, W. Willenbacher, A. Burchardt, F. Kauff, J. Barth, A. Hinke, R. Greil*
- Board 153 **Abstract 7516: Response rate to lenalidomide plus rituximab (R²) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R² followed by maintenance in relapsed/refractory indolent NHL.** *D. Andorsky, M. Coleman, A. Yacoub, J. M. Melear, H. D. Brooks, S. R. Fanning, K. S. Kolibaba, F. Lansigan, C. Reynolds, J. Li, D. Liu, M. Llorente, J. L. Ricker, J. P. Sharman*
- Board 154 **Abstract 7517: Role of Ofatumumab (OFA) maintenance treatment in relapsed chronic lymphocytic leukemia (CLL): Final analysis of PROLONG study.** *M. Van Oers, L. Smolej, M. Petrini, F. Offner, S. Grosicki, M. Levin, J. Davis, T. Stefanelli, H. Banerjee, P. Hoever, C. Geisler*
- Board 155 **Abstract 7518: Acalabrutinib combined with PI3K δ inhibitor ACP-319 in patients (pts) with relapsed/refractory (R/R) B-cell malignancies.** *P. M. Barr, S. D. Smith, M. J. Roschewski, S. M. O'Brien, J. P. Sharman, J. M. Melear, A. M. Hamdy, R. Izumi, J. G. Slatter, N. Chernyukhin, E. Bibikova, M. Yin, T. Chen, S. E. Spurgeon*
- Board 156 **Abstract 7519: Initial results of a dose escalation study of a selective and structurally differentiated PI3K δ inhibitor, ME-401, in relapsed/refractory (R/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).** *J. D. Soumerai, J. M. Pagel, D. Jagadeesh, H. S. Salman, V. P. Kenkre, A. S. Asch, A. Stathis, N. M. Reddy, A. Iasonos, R. Ghali, A. D. Zelenetz*

- Board 157 Abstract 7520: Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.** *C. L. Batlevi*, S. De Frank, C. Stewart, P. A. Hamlin, M. J. Matasar, J. F. Gerecitano, A. J. Moskowitz, A. M. Hamilton, A. D. Zelenetz, P. Drullinsky, D. J. Straus, A. Kumar, C. H. Moskowitz, J. Dicostanzo, D. Callan, D. Tsui, J. Rademaker, H. Schöder, A. Ni, A. Younes
- Board 158 Abstract 7521: Prognostic role of beta-2 microglobulin (B2M) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) treated with ibrutinib (ibr).** *W. G. Wierda*, J. R. Brown, S. Stilgenbauer, S. Coutre, J. C. Byrd, A. R. Mato, C. Tam, J. C. Barrientos, U. Jäger, S. Devereux, F. Cymbalista, P. M. Barr, C. Dearden, M. Montillo, C. Moreno, E. Y. Liu, A. Szoke, J. P. Dean, S. M. O'Brien
- Board 159 Abstract 7522: Achievement of complete remission (CR) as an endpoint for patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib.** *P. Strati*, M. Sivina, E. Kim, M. J. Keating, W. G. Wierda, A. Ferrajoli, H. M. Kantarjian, Z. Estrov, N. Jain, P. A. Thompson, J. A. Burger
- Board 160 Abstract 7523: Association of ATM mutation and unmutated IGHV status with shorter time to first treatment (TTFT): An analysis of multigene mutation profiling and standard prognostic clinical markers in 384 treatment-naive (TN) chronic lymphocytic leukemia (CLL).** *B. Hu*, K. Patel, H. Chen, X. Wang, R. Luthra, M. Routbort, R. Kanagal-Shamanna, L. Medeiros, C. C. Yin, Z. Zuo, C. Ok, S. Loghavi, P. A. Thompson, M. J. Keating, J. A. Burger, N. Jain, A. Ferrajoli, P. Bose, Z. Estrov, W. G. Wierda
- Board 161 Abstract 7524: Distinct immune signatures in chronic lymphocytic leukemia (CLL) and Richter's syndrome (RS).** *Y. Wang*, S. Sinha, H. Dong, C. Secreto, T. Call, S. A. Parikh, J. F. Leis, K. Rech, A. L. Feldman, S. Kenderian, N. E. Kay, S. M. Ansell, R. He, W. Ding
- Board 162 Abstract 7525: Rapid progression of disease following ibrutinib discontinuation in patients with chronic lymphocytic leukemia.** *P. J. Hampel*, K. G. Chaffee, W. Ding, T. Call, S. Kenderian, E. Mughtar, J. F. Leis, A. A. Chanan-Khan, D. Bowen, A. L. Fonder, S. M. Schwager, S. L. Slager, T. D. Shanafelt, N. E. Kay, S. A. Parikh
- Board 163 Abstract 7526: Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL.** *M. S. Davids*, J. F. Seymour, A. W. Roberts, B. Eichhorst, T. J. Kipps, A. R. Mato, S. Stilgenbauer, M. Mobasher, M. B. Desai, J. Potluri, G. E. Pena, M. E. Verdugo, J. Nielsen, A. Cyr, L. Lash Fleming, M. J. Hallek
- Board 164 Abstract 7527: Economic evaluation for the US of venetoclax (VEN) versus ibrutinib (IBR) versus allogeneic hematopoietic stem-cell transplantation (HSCT) for patients (pts) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) with 17p deletion (del 17p).** *N. Alsaid*, A. McBride, D. O. Persky, F. Anwer, L. A. Andritsos, A. Kumar, S. Yun, H. M. Babiker, I. Abraham
- Board 165 Abstract 7528: Change in tumor lysis syndrome risk after lead-in treatment in a phase 1b/2 study of obinutuzumab, ibrutinib, and venetoclax for chronic lymphocytic leukemia.** *K. A. Rogers*, Y. Huang, A. S. Ruppert, T. Civils, S. Das, C. Fedor, W. Whitlow, F. T. Awan, K. J. Maddocks, J. A. Woyach, J. A. Jones, J. C. Byrd
- Board 166 Abstract 7529: Management and outcomes of 222 CLL patients (pts) treated with venetoclax (VEN) in the real world.** *C. Nabhan*, A. Klink, J. Samp, J. M. Pauff, J. Nielsen, B. Meissner, H. Keim, K. Kennard, A. R. Mato
- Board 167 Abstract 7530: A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3K δ inhibitor therapy.** *A. R. Mato*, S. J. Schuster, N. Lamanna, I. Flinn, J. C. Barrientos, S. Kambhampati, B. D. Cheson, P. M. Barr, J. M. Pagel, J. A. Reeves, F. Lansigan, J. J. Pu, A. P. Skarbnik, G. A. Fonseca, C. Dorsey, E. Luning Prak, D. Paskalis, P. Sportelli, H. P. Miskin, D. M. Brander

Monday, June 4, 2018

- Board 168 **Abstract 7531: B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide.** *M. Fuerstenau, A. Fink, C. Herling, C. Maurer, N. Kutsch, J. De La Serna, M. Coscia, M. Crespo, F. Bosch, T. Noesslinger, P. Ghia, A. P. Kater, M. Ritgen, A. Schilhabel, S. Stilgenbauer, E. Tausch, K. Fischer, M. J. Hallek, B. Eichhorst*
- Board 169 **Abstract 7532: A U.S.-based survey: The experiences of 1147 chronic lymphocytic leukemia (CLL) patients (pts).** *B. Koffman, B. Dennison, K. Kennard, J. C. Byrd, J. M. Pagel, M. S. Davids, C. Nabhan, N. E. Kay, T. Siddiqi, D. M. Brander, D. M. Stephens, B. T. Hill, J. Pinilla-Ibarz, B. D. Cheson, S. T. Rosen, F. T. Awan, M. Y. Choi, A. R. Mato*
- Board 170 **Abstract 7533: The efficacy of duvelisib monotherapy following disease progression on ofatumumab monotherapy in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study.** *B. J. Kuss, M. S. Davids, P. Hillmen, J. H. Essell, C. Moreno, N. Lamanna, Z. Nagy, C. S. Tam, S. Stilgenbauer, U. Jäger, P. Ghia, J. Delgado, N. T. Le, B. Jeglinski, M. Montillo*
- Board 171 **Abstract 7534: Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma.** *D. J. Straus, G. P. Collins, J. A. Walewski, P. L. Zinzani, A. Grigg, A. M. Sureda, Á. Illés, T. Kim, S. Alekseev, L. Specht, V. Buccheri, A. Younes, J. M. Connors, A. Gautam, I. Purevjal, K. Fenton, G. Engley, A. Gallamini*
- Board 172 **Abstract 7535: Limited stage nodular lymphocyte predominant Hodgkin lymphoma (NLPHL): A subgroup analysis of the HD.6 clinical trial.** *B. Monteith, E. C. DiMaria, M. Crump, J. B. Ames, J. N. Winter, M. Djurfeldt, L. E. Shepherd, R. M. Meyer, B. E. Chen, A. E. Hay*
- Board 173 **Abstract 7536: Sintilimab (IBI308) in relapsed/refractory classical Hodgkin lymphoma: A multicenter, single-arm phase 2 trial in China (ORIENT-1 study).** *Y. Shi, H. Su, Y. Song, W. Jiang, X. Sun, W. Qian, W. Zhang, Y. Gao, Z. Jin, J. Zhou, C. Jin, L. Zou, L. Qiu, W. Li, J. Yang, M. Hou, S. Zeng, P. Liu, H. Zhou, X. Li*
- Board 174 **Abstract 7537: Safety and efficacy of decitabine-primed anti-PD-1 (SHR-1210) treatment in patients with relapsed/refractory classical Hodgkin lymphoma.** *C. Wang, Y. Liu, J. Nie, L. Shen, Q. Yang, W. Han*
- Board 175 **Abstract 7538: Immune toxicity in post autologous transplant patients treated with brentuximab vedotin in combination with immune checkpoint blockade.** *C. S. Magid Diefenbach, F. Hong, R. F. Ambinder, J. B. Cohen, K. A. David, R. H. Advani, M. J. Robertson, T. S. Fenske, S. K. Barta, N. Palmisano, J. Svoboda, D. S. Morgan, R. Karmali, B. Kahl, S. M. Ansell*
- Board 176 **Abstract 7539: Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).** *R. W. Chen, S. M. Ansell, A. Gallamini, J. M. Connors, K. J. Savage, G. P. Collins, A. Grigg, A. M. Sureda, N. Ghosh, T. Feldman, A. Fossà, E. Ozdemir, F. Offner, G. Engley, K. Fenton, S. Lee, H. Jolin, A. Gautam, M. Hutchings*
- Board 177 **Abstract 7540: Prognostication of older Hodgkin lymphoma (HL) patients (pts): Findings from a multicenter phase II study.** *A. M. Evens, R. H. Advani, M. A. Fanale, S. M. Smith, I. B. Helenowski, G. Bociek, A. K. Klein, J. N. Winter, L. I. Gordon, P. A. Hamlin*
- Board 178 **Abstract 7541: Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results.** *R. Ramchandren, R. H. Advani, S. M. Ansell, N. L. Bartlett, R. W. Chen, T. Feldman, A. Forero-Torres, J. W. Friedberg, A. K. Gopal, L. I. Gordon, J. Kuruvilla, K. J. Savage, D. J. Straus, A. Younes, K. Fenton, T. J. Manley, G. Engley, J. M. Connors*
- Board 179 **Abstract 7542: Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.** *J. W. Friedberg, A. Forero-Torres, B. Holkova, J. H. Goldschmidt, R. V. Boccia, R. Bordoni, V. M. Cline, D. Patel-Donnelly, P. J. Flynn, G. A. Olsen, R. W. Chen, F. Galderisi, Y. Wang, J. P. Sharman, C. A. Yasenchak*

- Board 180 **Abstract 7543: Survival by age in children and adolescents with Hodgkin lymphoma: A pooled analysis of Children's Oncology Group (COG) trials.** *J. M. Kahn, K. M. Kelly, Q. Pei, D. L. Friedman, F. G. Keller, R. Bush, S. Bhatia, T. O. Henderson, C. L. Schwartz, S. M. Castellino*
- Board 181 **Abstract 7544: Radiation therapy in primary testicular lymphoma (PTL): Does practice match the standard of care?** *T. Ollila, A. J. Olszewski*
- Board 182 **Abstract 7545: Overall survival (OS) and transplantation (ASCT) utilization in real-world patients with relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL).** *C. Nabhan, A. Klink, C. H. Lee, J. R. Laney, Y. Yang, A. G. Purdum*
- Board 183 **Abstract 7546: A basal gene expression signature to predict for synergy of combined EZH2 and HDAC inhibition in EZH2 dysregulated lymphomas.** *J. K. Lue, S. A. Prabhu, Y. Liu, Y. Gonzalez, A. Verma, N. Abshiru, E. Chen, C. Qiao, R. Nandakumar, S. Cremers, N. Kelleher, O. Elemento, J. E. Amengual*
- Board 184 **Abstract 7547: Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).** *M. J. Dyer, S. De Vos, J. Ruan, C. Flowers, K. J. Maddocks, S. Rule, A. M. Hamdy, R. Izumi, J. G. Slatter, J. Cheung, M. M. Frigault, H. Wei, S. Mourya, N. N. Hunder, N. H. Fowler*
- Board 185 **Abstract 7548: Results of real-time cell-of-origin subtype identification by gene expression profiling in patients with ABC-type diffuse large B-cell lymphoma in the phase III trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP (ROBUST).** *G. S. Nowakowski, A. Chiappella, T. E. Witzig, D. W. Scott, M. Spina, R. D. Gascoyne, L. Zhang, J. Russo, J. Kang, J. Zhang, Y. Xu, U. Vitolo*
- Board 186 **Abstract 7549: Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL).** *N. H. Fowler, M. Coleman, D. A. Stevens, S. M. Smith, P. Venugopal, P. Martin, T. J. Phillips, R. Agajanian, D. M. Stephens, R. Izumi, J. Cheung, J. G. Slatter, M. Yin, M. Hiremath, N. N. Hunder, B. Christian*
- Board 187 **Abstract 7550: 90 yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: Updated results after a median follow-up of 8.5 years from the GOTEI trial.** *M. Provencio-Pulla, F. Franco, J. Gómez-Codina, C. Quero, M. Llanos, F. R. Garcia Arroyo, L. De la Cruz-Merino, J. Guma, J. Delgado, R. Alvarez, J. Chacon, A. Royuela, A. Rueda*
- Board 188 **Abstract 7551: Multi-center retrospective study evaluating outcomes of grade 3A follicular lymphoma (FL).** *K. Greene, T. J. Phillips, A. V. Danilov, M. T. Byrne, J. B. Cohen, M. K. Kamdar, A. Peres-da-Silva, M. Churnetski, Z. Pan, N. C. Danielson, A. Kittai, D. M. Stephens*
- Board 189 **Abstract 7552: A proposal for a new staging system for extranodal natural killer T-cell lymphoma, nasal type, to predict the treatment strategy: A multicentre study from the Chinese Southwest Oncology Group and Asia Lymphoma Study Group.** *T. Lin, H. Hong, Y. Li, S. Lim, C. Liang, H. Huang, P. Yi, T. Wu, X. Du, M. Zhang, J. Wang, J. Zhu, G. Wu, Y. Zhu, Z. Peng, J. Wu, Q. Liu, W. Kim*
- Board 190 **Abstract 7553: Lenalidomide with R-IMED (rituximab, ifosfamide, methotrexate, etoposide and dexamethasone) in refractory or relapsed non-GCB diffuse large B-cell lymphoma: A phase II clinical trial.** *T. Lin, F. Sha, H. Huang, Z. Wang, S. Lin, X. Li, H. Hong, X. Fang, F. Li, C. Peng, Q. Ren, L. Zhang, Q. Liu*
- Board 191 **Abstract 7554: Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The French Lymphoma Study Association (LYSA) registry data.** *C. Haioun, C. Laurent, F. Le Bras, T. Dao, E. Itti, C. Malhaire, J. Chopier, R. Sinna, Y. Kirova, E. Bachy, B. Slama, J. Schiano, M. Bannier, A. Traverse-Glehen, R. Bosc, L. Xerri, F. Reyat, H. Tilly, P. Gaulard*
- Board 192 **Abstract 7555: Primary testicular lymphoma: Treatment patterns and survival of 1740 men from the National Cancer Database.** *F. Caumont, J. Burns, S. Akapame, J. Xie, C. R. Porter, J. P. Flores*

Monday, June 4, 2018

- Board 193 **Abstract 7556: Safety and efficacy of GVD and anti-PD-1 (SHR-1210) regimen with or without low-dose decitabine priming for refractory bulky and aggressive primary mediastinal large B-cell lymphoma.** *W. Zhang, Y. Liu, Q. Mei, L. Shen, Q. Yang, W. Han*
- Board 194 **Abstract 7557: Relationship between MRD and PET responses and PFS in previously untreated follicular lymphoma in the GALLIUM trial.** *J. Trotman, A. Davies, W. Hiddemann, E. Hoster, R. Marcus, C. Schmidt, C. Harbron, K. Mundt, T. Nielsen, C. Pott*
- Board 195 **Abstract 7558: Outcomes in newly diagnosed diffuse large b cell lymphoma presenting with hepatic and/ or renal dysfunction.** *S. Sanikommu, H. Bei, M. M. Robinson, J. S. Trivedi, T. Brown, S. I. Park, R. Jacobs, A. Belinda, E. A. Copelan, N. Ghosh*
- Board 196 **Abstract 7559: Outcomes in patients with marginal zone lymphomas undergoing transformation to high-grade lymphomas.** *J. P. Alderuccio, A. Desai, N. Gallastegui Crestani, J. Ramdial, E. L. Kimble, M. I. De La Fuente, J. Chapman, F. Vega, W. Zhao, I. M. Reis, I. S. Lossos*
- Board 197 **Abstract 7560: Randomized, open-label, phase II trial of everolimus versus thalidomide in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma.** *H. Huang, X. Y. Li, H. M. Hong, Z. Wang, X. Fang, F. Li, C. Peng, Q. Ren, F. Sha, L. Zhang, S. Lin, Q. Liu, T. Lin*
- Board 198 **Abstract 7561: Dose-adjusted (DA)-EPOCH-R with high-dose methotrexate (HD-MTX) for newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL): Primary analysis of PEARL5 study.** *K. Miyazaki, N. Asano, T. Yamada, K. Miyawaki, H. Takasaki, T. Igarashi, M. Nishikori, K. Ohata, K. Sunami, I. Yoshida, Y. Nishimura, S. Tamaru, M. Nishikawa, K. Izutsu, T. Kinoshita, J. Suzumiya, K. Ohshima, K. Kato, N. Katayama, M. Yamaguchi*
- Board 199 **Abstract 7562: Long term follow-up (FU) of lenalidomide plus R-CHOP therapy in patients with newly diagnosed diffuse large b-cell lymphoma (DLBCL): Combined analysis from two phase 2 trials.** *A. Castellino, B. LaPlant, L. Pederson, A. Chiappella, G. Gaidano, W. R. Macon, A. Tucci, R. L. King, A. G. Congiu, T. E. Witzig, U. Vitolo, G. S. Nowakowski*
- Board 200 **Abstract 7563: DEVEC metronomic schedule for aggressive B and T-cell lymphomas.** *M. COX, R. Battistini, S. Pelliccia, A. Arcari, P. Anticoli Borza, I. Casaroli, V. Zoli, F. Di Landro, F. Fabbri, G. Galassi, A. Leporace, M. Piedimonte, M. Di Girolamo, D. Prospero, A. Campagna, A. Di Napoli, A. Tafuri, G. Bocci, G. Musuraca*
- Board 201 **Abstract 7564: A phase II trial of bevacizumab-GemAOD regimen for newly diagnosed extranodal NK/T cell lymphoma.** *Z. Li, Y. Wang, J. J. Huang, T. Gao, K. Wu, F. Feng, P. Sun, P. Liu, X. Bi, Y. Xia, H. Rao, S. Lin, H. Wang, W. Jiang*
- Board 202 **Abstract 7565: DLBCL outcomes in Malawi: Effect of HIV and derivation of a simplified prognostic score.** *M. Painschab, E. Kasonkanji, T. Zuze, B. Kaimila, T. Tomoka, B. Dhungel, M. Mulenga, M. Chikasema, B. Tewete, A. Mtangwanika, S. Chiyoyola, W. Mhango, F. Chimzimu, C. Kampani, R. Krysiak, T. C. Shea, N. Montgomery, Y. Fedoriw, S. Gopal*
- Board 203 **Abstract 7566: Pd-11 gene alterations to identify a subset of diffuse large B cell lymphoma that harbor a T cell inflamed phenotype.** *J. K. Godfrey, S. M. Smith, S. Tumuluru, J. P. Kline, J. McElherne, G. Venkataraman, R. Bao*
- Board 204 **Abstract 7567: Factors associated with duration of response after CD19-specific CAR-T cell therapy for refractory/relapsed B-cell non-Hodgkin lymphoma.** *J. Gauthier, A. V. Hirayama, K. A. Hay, D. Li, A. Sheih, V. Wu, J. M. Voutsinas, S. Cherian, X. Chen, B. S. Pender, R. M. Hawkins, A. Vakil, T. Phi, R. N. Steinmetz, S. R. Riddell, D. G. Maloney, C. Turtle*
- Board 205 **Abstract 7568: Phase II study of the PD1-inhibitor pembrolizumab for the treatment of relapsed or refractory mature t-cell lymphoma.** *S. K. Barta, J. M. Zain, S. M. Smith, J. Ruan, H. C. Fung, C. R. Tan, Y. Yang, R. K. Alpaugh, E. A. Ross, K. S. Campbell, N. Khan, R. I. Fisher, Y. Oki*

- Board 207 Abstract 7570: Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses of diabetic patients from the phase II CHRONOS-1 study.** *M. H. Dreyling, S. Leppa, T. Comeau, M. Kosinova, G. Lenz, A. Nagler, D. S. Heo, S. Oh, L. Huang, O. Wirtz, A. Miriyala, J. E. Garcia-Vargas, B. H. Childs, P. L. Zinzani*
- Board 208 Abstract 7571: Predictors of disease progression in smoldering Waldenström macroglobulinemia.** *S. Zanwar, J. P. Abeykoon, S. M. Ansell, S. Kumar, A. Dispenzieri, T. E. Witzig, M. Lacy, G. S. Nowakowski, F. Buadi, D. Dingli, N. Leung, S. V. Rajkumar, R. S. Go, T. M. Habermann, Y. Lin, T. Kourelis, R. A. Kyle, M. A. Gertz, P. Kapoor*
- Board 209 Abstract 7572: Early detection of post-transplant lymphoproliferative disorder using circulating tumor DNA.** *J. Soo, J. Schroers-Martin, A. Garofalo, D. M. Kurtz, N. D'Emilio, D. R. Grimm, H. Luikart, M. Van De Rijn, M. Diehn, K. K. Khush, A. A. Alizadeh*
- Board 210 Abstract 7573: AMC075: A randomized phase II trial of vorinostat with R-EPOCH in aggressive HIV-related NHL.** *J. Ramos, J. A. Sparano, P. C. Moore, E. Cesarman, E. G. Reid, P. G. Rubinstein, R. D. Harrington, R. A. Baiocchi, D. M. Aboulafia, L. Ratner, K. Lawrence, C. Durand, R. Ambinder, J. Y. Lee, R. T. Mitsuyasu, A. Noy*
- Board 211 Abstract 7574: Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA.** *M. Pfreundschuh, N. Murawski, M. Ziepert, B. Altmann, M. H. Dreyling, P. Borchmann, S. Luminari, M. Witzens-Harig, J. Dierlamm, M. Haenel, L. Truemper, B. Metzner, E. Lengfelder, U. B. Keller, C. Ruebe, C. Berdel, N. Schmitz, G. Held, V. Poeschel*
- Board 212 Abstract 7575: R-CHOP preceded by blood-brain barrier permeabilization (BBBp) by NGR-tumor necrosis factor (NGR-hTNF) in patients with relapsed or refractory primary CNS lymphoma (rrPCNSL): First results of the "INGRID" phase II trial.** *A. J. Ferreri, T. Calimeri, G. Conte, P. Lopodote Sr., M. Foppoli, S. Girlanda, A. Corti, D. Cattaneo, F. Fallanca, A. Nonis, M. Ponzoni, G. Citterio, L. Politi, M. Sassone, S. Perrone, C. Cecchetti, F. Ciceri, C. Bordignon, N. Anzalone*
- Board 213 Abstract 7576: Circulating tumor DNA to predict timing of relapse in mantle cell lymphoma.** *M. J. Roschewski, C. J. Melani, S. Pittaluga, K. Dunleavy, N. S. Saba, C. Grant, J. Aaron, A. Jacob, E. Yusko, S. M. Steinberg, E. S. Jaffe, A. Wiestner, W. H. Wilson*
- Board 214 Abstract 7577: Quality of life in cutaneous t-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial.** *P. Porcu, S. Hudgens, P. Quaglino, R. Cowan, L. Floden, M. Leoni, S. Dale, M. Duvic*
- Board 215 Abstract 7578: Efficacy of up-front hematopoietic cell transplantation in peripheral t-cell lymphoma, not otherwise specified (PTCL-NOS): A National Cancer Database analysis.** *B. R. Dholaria, A. Kumar, E. Ayala, M. Jain, L. Sokol, J. C. Chavez, M. Hussaini, M. A. Kharfan-Dabaja, T. Nishihori*
- Board 216 Abstract 7579: The effect of duvelisib, a dual inhibitor of PI3K- δ,γ , on components of the tumor microenvironment in previously untreated follicular lymphoma.** *C. Casulo, A. Goy, K. Van Eygen, J. Sancho, M. Santiago, R. Johnson, K. Bouabdallah, K. Sprott, N. T. Le, J. A. Pachter, D. T. Weaver*
- Board 217 Abstract 7580: Safety and efficacy of anti-CD20 immunotoxin MT-3724 in relapsed/refractory (R/R) b-cell non-Hodgkin lymphoma (NHL) in a phase I study.** *M. A. Fanale, P. A. Hamlin, S. I. Park, D. O. Persky, J. P. Higgins, C. Burnett, K. Dabovic, E. Poma, N. Sarapa, A. Younes*

Monday, June 4, 2018

- Board 218a **Abstract TPS7581: Phase 3 zanubrutinib (BGB-3111) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).** *P. Hillmen, J. R. Brown, B. S. Kahl, P. Ghia, T. Robak, C. Marimpietri, A. Cohen, J. Huang, C. S. Tam*
- Board 218b **Abstract TPS7582: The GAIA (CLL13) trial: An international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL).** *V. Julia, N. Carsten, A. P. Kater, J. Bahlo, M. Fuerstenau, A. Fink, M. Gregor, P. Thornton, T. Tadmor, K. Fischer, M. Ritgen, K. A. Kreuzer, E. Eldering, S. Stilgenbauer, M. Van Oers, C. Geisler, M. J. Hallek, B. Eichhorst*
- Board 219a **Abstract TPS7583: KEYNOTE-667: Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy.** *C. Mauz-Koerholz, K. M. Kelly, F. G. Keller, L. Giulino-Roth, A. Nahar, A. Balakumaran*
- Board 219b **Abstract TPS7584: Phase I/II study to evaluate the safety and efficacy of tenalisib, a novel PI3K δ/γ dual inhibitor in combination with pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma.** *R. Ramchandren, R. Lynch, P. J. Barde, A. Nair*
- Board 220a **Abstract TPS7585: ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large b cell lymphoma (R/R DLBCL).** *O. O. Oluwole, M. R. Bishop, C. Gisselbrecht, L. I. Gordon, M. J. Kersten, D. G. Maloney, N. Schmitz, M. Caballero Barrigon, J. Kuruvilla, K. W. Song, C. A. Jacobson, L. J. Nastoupil, P. Riedell, Y. Jiang, J. M. Rossi, L. Lee, P. C. Cheng, F. L. Locke*
- Board 220b **Abstract TPS7586: A phase 1 open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies.** *A. Y. Krishnan, N. Shah, A. I. Spira, J. L. Kaufman, R. Niesvizky, N. N. Shah, J. M. Burke, L. Popplewell, T. G. Martin, J. Cheung, S. L. Matheny, J. P. Leonard, A. Molina*
- Board 221a **Abstract TPS7587: ILYAD (Indolent Lymphoma and Vitamin D): A phase III double blind, prospective randomized trial to evaluate the supplemental effect of vitamin D on progression-free survival in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy.** *M. Brady, M. S. Strawderman, C. Flowers, B. S. Kahl, J. P. Leonard, L. J. Nastoupil, T. E. Witzig, D. R. Peterson, J. W. Friedberg*
- Board 221a **Abstract TPS7588: A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.** *S. Rule, A. P. Kater, T. H. Brümmendorf, C. Fegan, M. Kaiser, J. A. Radford, S. Stilgenbauer, S. Kayser, M. J. Dyer, P. Brossart, J. Cidado, L. Drew, J. Birkett, A. Davies, W. Shao, W. Brugger*
- Board 222a **Abstract TPS7589: A phase 3 study comparing polatuzumab vedotin plus R-CHP versus R-CHOP in patients with DLBCL (POLARIX).** *H. Tilly, C. Flowers, J. W. Friedberg, C. Herbaux, F. Morschhauser, L. H. Sehn, J. P. Sharman, M. Trněný, L. Wang, C. Lee, G. A. Salles*
- Board 222b **Abstract TPS7590: The PRIMO study: A phase 2 study of duvelisib efficacy and safety in patients with relapsed or refractory peripheral t-cell lymphoma (PTCL).** *S. M. Horwitz, J. Soto, H. Youssoufian, D. Lloyd, N. T. Le*

8:00 AM - 11:30 AM Poster Session**Hematologic Malignancies—Plasma Cell Dyscrasia**

Location: Hall A

Abstracts on Boards 18-29 will be discussed during the Hematologic Malignancies—Plasma Cell Dyscrasia Poster Discussion Session.

Posters by Topic

Autologous Stem Cell Transplantation for Multiple Myeloma or Plasma Cell Disorders: Board 25

Multiple Myeloma: Boards 18-19, 21-24, 26-60

Plasma Cell Disorders: Boards 20, 62-63

Trials in Progress: Boards 64a-68b

- Board 18 Abstract 8009: Updated efficacy data and MRD analysis according to risk status in newly diagnosed myeloma patients treated with carfilzomib + lenalidomide or cyclophosphamide (FORTE trial).** *F. Gay, R. Foà, P. Musto, C. Cerrato, B. Gamberi, E. Zamagni, A. D. Palmas, A. Spadano, P. Omedè, T. Caravita, N. Giuliani, S. Ballanti, F. Patriarca, R. Troia, M. Gentile, G. Desabbata, L. Canepa, A. Palumbo, M. Cavo, M. Boccadoro*
- Board 19 Abstract 8010: A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naïve multiple myeloma (MM): KEYNOTE-185.** *S. Z. Usmani, F. Schjesvold, A. O. Rocafiguera, L. Karlin, R. M. Rifkin, H. A. Yimer, R. LeBlanc, N. Takezako, R. D. McCroskey, K. Suzuki, M. Cavo, T. Facon, S. Jagannath, S. Lonial, R. Ghori, M. Z. Farooqui, J. Liao, P. Marinello, J. San-Miguel*
- Board 20 Abstract 8011: Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: Safety run-in results of andromeda.** *R. Comenzo, E. Kastiris, M. Maurer, J. A. Zonder, M. Minnema, S. Schönland, A. Wechalekar, G. Palladini, X. Qin, S. Y. Vasey, I. Khan, J. M. Schechter, G. Merlini*
- Board 21 Abstract 8012: A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.** *A. J. Yee, J. Laubach, E. L. Campagnaro, B. Lipe, O. Nadeem, C. Cole, E. O'Donnell, R. L. Schlossman, G. Bianchi, A. R. Branagan, S. J. Shapiro, C. C. Harrington, J. N. Burke, M. T. Gammon, K. J. Lively, C. A. Thorburn, M. L. Mann, J. G. Lohr, P. G. Richardson, N. S. Raju*
- Board 22 Abstract 8013: Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).** *A. Chari, S. Z. Usmani, M. Mateos, N. Van De Donk, J. L. Kaufman, P. Moreau, A. O. Rocafiguera, T. Plesner, L. Benboubker, K. Liu, P. Hellemsans, T. J. Masterson, P. L. Clemens, A. Farnsworth, H. Nahi, J. San-Miguel*
- Board 23 Abstract 8014: Phase I-b study of isatuximab + carfilzomib in relapsed and refractory multiple myeloma (RRMM).** *A. Chari, J. R. Richter, N. Shah, S. W. Wong, S. Jagannath, H. J. Cho, N. Biran, J. Wolf, S. S. Parekh, P. N. Munster, D. Madduri, F. Campana, T. G. Martin*
- Board 24 Abstract 8015: Low vs high dose carfilzomib (Cfz) with dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Results of SWOG S1304.** *S. Ailawadhi, R. Sexton, S. Lentzsch, M. H. Abidi, P. M. Voorhees, A. D. Cohen, E. Rohren, S. Heitner, K. Kelly, N. J. Mackler, D. M. Baer, A. Hoering, B. G. Durie, R. Z. Orlowski*
- Board 25 Abstract 8016: Maintenance therapy (MT) with 25 versus 5 mg lenalidomide (Len) after prolonged Len consolidation therapy (CT) in newly-diagnosed, transplant-eligible patients (pts) with multiple myeloma (MM).** *R. Fenk, A. Giagounidis, H. Goldschmidt, M. Heinsch, M. J. Rummel, N. Kröger, A. Boquoi, D. Lopez, K. Hauck, C. Gerrlich, J. Baier, S. Liesenjohann, E. Boelke, E. Mai, C. Aul, J. Strapatsas, A. Dienst, M. Kondakci, R. Haas, G. Kobbe*

Monday, June 4, 2018

- Board 26 **Abstract 8017: Carfilzomib weekly 20/56mg/m², lenalidomide and dexamethasone for early relapsed refractory multiple myeloma.** *V. Richez, S. Guidez, I. Azais, G. Durand, V. Javaugue, A. Brigaud, A. Machet, N. Moya, C. Gruchet, A. Bobin, A. Levy, F. Sabirou, C. Dieval, E. Fleck, I. Princet, D. Bauwens, G. Fouquet, F. Bridoux, H. Avet-Loiseau, X. Leleu*
- Board 27 **Abstract 8018: Overall survival (OS) results of randomized phase III study (ADMYRE trial) of plitidepsin and dexamethasone (DXM) vs. DXM alone in patients with relapsed/refractory multiple myeloma (RRMM): Evaluation of the crossover impact.** *J. Gomez, S. Extremera, A. Nieto*
- Board 28 **Abstract 8019: Carfilzomib, bendamustine, and dexamethasone (KBd) in advanced multiple myeloma: The EMN09-trial.** *M. Gramatzki, A. Guenther, M. Offidani, M. M. Engelhardt, V. Montefusco, F. Patriarca, E. Angelucci, M. Salvini, W. Pönisch, S. Spada, S. Gentili, R. Wäscher, N. Schub, P. Corradini, H. Einsele, P. Sonneveld, M. Boccadoro, F. Gay*
- Board 29 **Abstract 8020: Remission observed from a phase 1 clinical study of CAR-T therapy with safety switch targeting BCMA for patients with relapsed/refractory multiple myeloma.** *Y. Liu, Z. Chen, R. Wei, L. Shi, F. He, Z. Shi, T. Jin, R. Xie, B. Wei, J. Chen, H. Fang, B. Zhu, Q. Li, P. Wang*
- Board 30 **Abstract 8021: A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183.** *M. Mateos, H. Blacklock, F. Schjesvold, A. O. Rocafiguera, D. Simpson, A. George, H. Goldschmidt, A. Larocca, D. W. Sherbenou, I. Avivi, S. Iida, M. Matsumoto, S. Z. Usmani, S. Jagannath, P. Rodriguez-Otero, U. Kher, M. Z. Farooqui, J. Liao, P. Marinello, S. Lonial*
- Board 31 **Abstract 8022: Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.** *N. Biran, D. S. Siegel, J. G. Berdeja, N. S. Raje, R. F. Cornell, M. Alsina, T. Kovacsics, B. Fang, A. Kimball, C. O. Landgren*
- Board 32 **Abstract 8023: Utility and prognostic value of ¹⁸F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma.** *M. A. Aljama, M. Sidiqi, S. Kumar, T. Kourelis, M. A. Gertz, S. V. Rajkumar, W. I. Gonsalves, M. Lacy, F. Buadi, P. Kapoor, A. Dispenzieri, D. Dingli, N. Leung, J. A. Lust, S. R. Hayman, R. S. Go, L. Hwa, R. A. Kyle, R. M. Warsame*
- Board 33 **Abstract 8024: Early MRD negativity to predict deepening myeloma response in relapsed/refractory multiple myeloma (RRMM) patients treated with bb2121 anti-BCMA CART cells.** *N. C. Munshi, J. G. Berdeja, Y. Lin, J. Kochenderfer, N. S. Raje, M. Liedtke, S. Jagannath, D. Madduri, J. Rosenblatt, M. V. Maus, A. Turka, L. P. Lam, K. Hege, T. B. Campbell, M. Massaro, F. Petrocca, D. S. Siegel*
- Board 34 **Abstract 8025: Autologous stem cell transplantation in multiple myeloma patients over age 75.** *N. Dong, P. McKiernan, D. S. Siegel, D. H. Vesole, S. D. Rowley, T. Andrews, A. Ortega, A. P. Skarbnik, N. Biran, J. R. Richter, A. Pecora, A. Goy, R. Panchal, N. Aleksidze, M. Donato*
- Board 35 **Abstract 8026: Single cell analysis of multiple myeloma.** *G. Ledergor, A. Weiner, M. Zada, Y. C. Cohen, M. E. Gatt, N. Snir, H. Magen, M. Koren-Michowitz, H. Keren-Shaul, V. Yellapantula, B. Paiva, A. Nagler, J. San-Miguel, D. Ben-Yehuda, E. Papaemmanuil, I. Avivi, G. I. Barbash, A. Tanay, I. Amit*
- Board 36 **Abstract 8027: Pomalidomide (POM) + low-dose dexamethasone (LoDEX) + daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure.** *D. S. Siegel, G. J. Schiller, C. J. Samaras, M. Sebag, J. G. Berdeja, S. Ganguly, J. Matous, K. W. Song, C. Seet, G. Talamo, S. Srinivas, M. Acosta-Rivera, M. Bar, D. Quick, B. M. Anz, G. Fonseca, D. E. Reece, F. Zafar, W. Chung, N. J. Bahlis*
- Board 37 **Abstract 8028: Graft-versus-host disease (GVHD) risk with daratumumab (Dara) therapy post allogeneic transplantation (alloHCT) for multiple myeloma (MM).** *L. Nikolaenko, S. Chhabra, P. Hari, A. Y. Krishnan, J. R. Richter*

- Board 38 Abstract 8029: A phase 1/2 study of carfilzomib, bendamustine, and dexamethasone (CBD) in newly diagnosed multiple myeloma patients.**
S. Leng, A. Wei, A. Assal, D. Bhutani, G. Baliko, J. Gould, R. J. Shelton, S. Kelly, D. Otap, M. Y. Mapara, S. Lentzsch
- Board 39 Abstract 8030: Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.**
M. Tschautscher, S. V. Rajkumar, F. Buadi, M. A. Gertz, M. Lacy, A. Dispenzieri, S. R. Hayman, Y. L. Hwa, A. L. Fonder, M. A. Hobbs, S. R. Zeldenrust, J. A. Lust, N. Leung, P. Kapoor, T. Kourelis, R. M. Warsame, R. S. Go, W. I. Gonsalves, R. A. Kyle, S. Kumar
- Board 40 Abstract 8031: Daratumumab plus bortezomib-melphalan-prednisone (VMP) in elderly (≥ 75 y) patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE).** M. Cavo, S. Iida, J. Blade, M. Mateos, J. Lee, M. Garg, V. Hungria, M. Beksac, I. Spicka, S. Knop, L. Pour, P. Campbell, A. J. Jakubowiak, J. Wang, S. Wroblewski, R. Kobos, M. Qi, J. San-Miguel
- Board 41 Abstract 8032: Carfilzomib and dexamethasone (Kd56) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Updated overall survival (OS), safety, and subgroup analysis of ENDEAVOR.**
R. Z. Orlowski, P. Moreau, H. Ludwig, A. O. Rocafiguera, W. Chng, H. Goldschmidt, Z. Yang, A. Kimball, M. A. Dimopoulos
- Board 42 Abstract 8033: Lack of racial disparity in outcome of African American (AA) and Caucasian patients with symptomatic multiple myeloma (MM) at the Veterans Affairs (VA) hospitals.** N. Fillmore, S. Yellapragada, P. S. White, C. Ifeorah, M. Gaballa, G. Rivero, S. Pyarajan, N. Do, M. T. Brophy, N. C. Munshi
- Board 43 Abstract 8034: Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma.** B. Buelow, P. Choudry, S. Clarke, K. Dang, L. Davison, S. Force Aldred, K. Harris, P. Pratap, D. Pham, U. Rangaswamy, U. Schellenberger, N. Shah, N. Trinklein, H. Ugamraj, A. Wiita, W. Van Schooten
- Board 45 Abstract 8036: Molecular underpinnings of clinical disparity patterns in African American (AA) versus Caucasian American (CA) multiple myeloma (MM) patients.** E. M. Hill, M. Kwok, V. Yellapantula, M. Hultcrantz, N. Korde, S. Mailankody, E. Papaemmanuil, I. Maric, D. G. Kazandjian, O. Landgren
- Board 46 Abstract 8037: Predictors of long-term survival in newly diagnosed multiple myeloma (NDMM) patients (pts) enrolled in the Connect MM registry.**
C. Gasparetto, R. M. Rifkin, H. R. Terebelo, K. Toomey, B. G. Durie, J. W. Hardin, S. Jagannath, L. I. Wagner, M. Narang, S. Ailawadhi, E. Flick, S. Kotey, S. Srinivasan, A. Kitali, A. Agarwal, R. Abonour
- Board 47 Abstract 8038: Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).** J. Mikhael, P. G. Richardson, S. Z. Usmani, N. S. Raje, W. Bensinger, F. Dubin, Q. Liu, O. Vitse, K. C. Anderson
- Board 48 Abstract 8039: Lenalidomide (LEN) pharmacokinetics (PKs) in multiple myeloma (MM) patients (pts) with various renal functions.** Y. Cao, E. X. Chen, L. W. Le, O. Levina, H. Paul, S. Kakar, A. Lau, H. Chen, C. Chen
- Board 49 Abstract 8040: Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELD) vs Ld in relapsed/refractory multiple myeloma (RRMM).** S. Lonial, M. A. Dimopoulos, K. Weisel, D. White, P. Moreau, M. Mateos, J. San-Miguel, K. C. Anderson, O. Shpilberg, S. Grosicki, I. Spicka, A. Walter-Croneck, H. Magen, A. Belch, D. E. Reece, M. Beksac, S. Shelat, O. Sy, A. K. Singhal, P. G. Richardson
- Board 50 Abstract 8041: Treatment (tx) journeys in newly diagnosed multiple myeloma (NDMM) patients (pts): Results from the Connect MM Registry.** S. Jagannath, R. M. Rifkin, C. Gasparetto, K. Toomey, B. G. Durie, J. W. Hardin, H. R. Terebelo, L. I. Wagner, M. Narang, S. Ailawadhi, S. Srinivasan, A. YoussefAgha, B. Ung, A. Kitali, E. Flick, A. Agarwal, R. Abonour

Monday, June 4, 2018

- Board 51 **Abstract 8042: Health-related quality of life in patients with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation: Results from the ALCYONE trial.** *K. Gries, J. Fastenau, Y. Chen, J. Wang, K. Ho, S. Wroblewski, M. Mateos, J. San-Miguel, M. Cavo, M. Qi*
- Board 52 **Abstract 8043: Real-world evidence of cardiac hospitalizations in carfilzomib- and non-carfilzomib-treated multiple myeloma patients in the United States.** *J. Mikhael, K. Mezzi, K. Iskander, K. Wang, C. Kim, S. Zhu, M. Braunlin, W. A. Werther, A. Chari*
- Board 53 **Abstract 8044: The MD Anderson modified cyclophosphamide, bortezomib, doxorubicin, and dexamethasone (mCBAD) for the treatment of newly diagnosed (NDMM) and relapsed/refractory multiple myeloma (RRMM).** *S. Tabchi, R. Nair, K. K. Patel, H. C. Lee, S. K. Thomas, B. Amini, S. Ahmed, R. S. Mehta, Q. Bashir, M. H. Qazilbash, D. M. Weber, R. Z. Orlowski, R. Alexanian, L. Feng, E. E. Manasanch*
- Board 54 **Abstract 8045: Duration of complete response (DurCR) impacts overall survival (OS) in multiple myeloma (MM).** *S. Sidana, N. Tandon, A. Dispenzieri, M. A. Gertz, F. Buadi, M. Lacy, D. Dingli, A. L. Fonder, S. R. Hayman, M. A. Hobbs, W. I. Gonsalves, R. M. Warsame, T. Kourelis, Y. L. Hwa, P. Kapoor, R. A. Kyle, N. Leung, R. S. Go, S. V. Rajkumar, S. Kumar*
- Board 55 **Abstract 8046: Impact of obesity on response in 751 myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVd) induction.** *R. D. Harvey, J. L. Kaufman, L. T. Heffner, C. C. Hofmeister, M. V. Dhodapkar, S. Lonial, A. K. Nooka*
- Board 56 **Abstract 8047: Relationship of acquired resistance of myeloma cells to bortezomib with Lyn and Src induced inhibition of PP2A and effect of treatment with the tyrosine kinase inhibitor dasatinib.** *B. Paul, D. Feinberg, P. Sundaramoorthy, J. B. Weinberg, Y. Kang*
- Board 58 **Abstract 8049: Quality of life and cancer worry in a follow-up cohort of patients with asymptomatic monoclonal gammopathies.** *M. A. Hildebrandt, R. A. Callender, A. A. Belachew, C. Classen, H. C. Lee, K. K. Patel, T. A. Richards, S. K. Thomas, D. M. Weber, R. Z. Orlowski, E. E. Manasanch*
- Board 59 **Abstract 8050: Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM).** *S. Ailawadhi, P. L. McCarthy, S. A. Holstein, G. Larkins, W. Chung, S. Srinivasan, A. Agarwal, S. Lonial*
- Board 60 **Abstract 8051: Association of venous thromboembolism with increased mortality in patients with multiple myeloma.** *M. W. Schoen, S. Luo, B. Gage, K. R. Carson, K. M. Sanfilippo*
- Board 62 **Abstract 8053: Daratumumab-based therapies in patients with AL amyloidosis.** *J. P. Abeykoon, S. Zanwar, S. Kumar, A. Dispenzieri, S. V. Rajkumar, M. Lacy, D. Dingli, N. Leung, E. Muchtart, W. I. Gonsalves, T. Kourelis, F. Buadi, R. A. Kyle, M. A. Gertz, P. Kapoor*
- Board 63 **Abstract 8054: Characteristics and outcomes of primary plasma cell leukemia in the era of novel agents: Single center experience.** *I. Aboudalle, M. Khan, L. Feng, S. K. Thomas, E. E. Manasanch, K. K. Patel, L. Medeiros, R. Mehta, Q. Bashir, M. H. Qazilbash, R. Z. Orlowski, D. M. Weber, S. Hu, H. C. Lee*
- Board 64a **Abstract TPS8055: Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM).** *R. Z. Orlowski, H. Goldschmidt, M. Cavo, T. G. Martin, G. Paux, C. Oprea, T. Facon*
- Board 64b **Abstract TPS8056: A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM).** *S. Delimpasi, L. Pour, H. W. Auner, M. A. Dimopoulos, A. Rappaport, L. Fortin, J. J. Shah, S. Shacham, M. G. Kauffman, N. J. Bahlis*

- Board 65a Abstract TPS8057: Randomized, open-label, phase 2/3 study of daratumumab (DARA) with or without JNJ-63723283, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM).** *J. Van Droogenbroeck, P. Vlummens, N. Lavi, K. Wu, J. Fu, H. Feng, R. L. Carson, W. Crist, J. Schecter, Y. Cohen*
- Board 65b Abstract TPS8058: Randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients with relapsed or refractory multiple myeloma (RRMM): COLUMBA.** *S. Z. Usmani, M. Mateos, N. J. Bahlis, S. Grosicki, A. Spencer, R. Bandekar, T. J. Masterson, P. L. Clemens, C. J. Heuck, M. Qi, H. Nahi*
- Board 66a Abstract TPS8059: Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).** *P. Sonneveld, E. Terpos, M. A. Dimopoulos, J. Uktropec, E. Smith, N. Houkes, J. M. Schecter, E. Kastritis*
- Board 66b Abstract TPS8060: Phase III (IKEMA) study design: Isatuximab plus carfilzomib and dexamethasone (Kd) vs Kd in patients with relapsed/refractory multiple myeloma (RRMM).** *T. G. Martin, M. A. Dimopoulos, K. Yong, J. Mikhael, M. Risse, G. Assset, P. Moreau*
- Board 67a Abstract TPS8061: A phase 1/2, multicenter, dose-escalation and expansion study of combination therapy with venetoclax, daratumumab, and dexamethasone (with and without bortezomib) in subjects with relapsed or refractory multiple myeloma.** *O. Bueno, R. Slimp, M. Jacobson, J. C. Pesko, H. Li, J. A. Ross, K. Freise, P. C. Maciag*
- Board 68b Abstract TPS8062: Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA.** *S. Rajkumar, P. M. Voorhees, H. Goldschmidt, R. I. Baker, R. Bandekar, S. Kuppens, T. Neff, M. Qi, M. A. Dimopoulos*

9:45 AM - 11:00 AM Award Lecture

ASCO/American Cancer Society Award and Lecture

Location: S102

Interact ID: 10932

Daniel F. Hayes, MD, FACP, FASCO

University of Michigan Comprehensive Cancer Center

Presentation of the 2018 ASCO/American Cancer Society Award

Karen H. Lu, MD

The University of Texas MD Anderson Cancer Center

Hereditary Cancer Genetic Testing and Risk Reduction: Evolving Strategies

9:45 AM - 11:00 AM Education Session

Cancer Care for Displaced Populations: Conflict and Natural Disasters

Location: S504

Interact ID: 10802

Nagi S. El Saghir, MD, FACP - Chair

American University of Beirut

Cancer Care for Patients Displaced by Conflict: The Experience at the American University of Beirut and the Middle East

Monday, June 4, 2018

Richard Sullivan, PhD, MBBS, FFPM

King's Health Partners Cancer Centre

What Is the Role of UN Organizations, NGOs, and Universities?

Enrique Soto Perez De Celis, MD

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Cancer Care in the Face of Devastation: Meaningful Response to Natural Disasters

Panel Question and Answer

9:45 AM - 11:00 AM Education Session

Care After Chemotherapy: Treating the Body and Mind

Location: S100bc

Interact ID: 10822

Deanna Gek Koon Teoh, MD - Chair

University of Minnesota

Mindfulness in Patients With Gynecologic Cancer

Thomas J. Smith, MD, FASCO, FAAHPM

Johns Hopkins University School of Medicine

You're Done With Chemotherapy but Now You Can't Feel Your Feet: Treating Neuropathy in Patients With Gynecologic Cancer

Nicola M. Spirtos, MD

Women's Cancer Center

Through the Cloud: Demystifying Medical Marijuana

Panel Question and Answer

9:45 AM - 11:00 AM Education Session

Monoclonal Antibodies and Immunotherapy: The Real Deal for Acute Lymphoblastic Leukemia?

Location: E450

Interact ID: 10766

Hagop M. Kantarjian, MD, FASCO

The University of Texas MD Anderson Cancer Center

The Role of Blinatumumab and Inotuzumab in the Therapy of Acute Lymphoblastic Leukemia

Stephan A. Grupp, MD, PhD - Chair

Pediatric Oncology, The Children's Hospital of Philadelphia

CAR T Cells: How and How Well They Work in Acute Lymphoblastic Leukemia

David G. Maloney, MD, PhD

Fred Hutchinson Cancer Research Center

Stem Cell Transplant and Immunotherapy in Acute Lymphoblastic Leukemia: Foes or Friends?

Panel Question and Answer

9:45 AM - 11:00 AM Education Session

Users Guide to Implementing and Acting on Geriatric Assessment to Improve Care for Older Adults

Location: S404

Interact ID: 10905

Armin Shahrokni, MD, MPH - Chair

Memorial Sloan Kettering Cancer Center

Preventing Treatment-Related Functional Decline: Strategies to Maximize Resilience

Tanya Marya Wildes, MD

Washington University School of Medicine in St. Louis

Utilizing Geriatric Assessment to Decrease Treatment-Associated Toxicity in Clinical Practice

Martine Puts, RN, PhD

University of Toronto

Team-Based Approaches to Personalize Care for Older Adults: It Takes a Village

Panel Question and Answer

9:45 AM - 11:00 AM Meet the Professor Session

Debate: Adjuvant Therapy in Colon Cancer - Ticketed Session

Location: E253c

Interact ID: 10748

Daniel G. Haller, MD, FASCO

Abramson Cancer Center

Al Bowen Benson, MD, FASCO

Northwestern Medicine

9:45 AM - 11:00 AM Meet the Professor Session

Histiocytosis and Rare Pediatric Tumors - Ticketed Session

Location: E253d

Interact ID: 10762

Susan N. Chi, MD

Dana-Farber Cancer Institute

Carl E. Allen, MD, PhD

Baylor College of Medicine Texas Children's Cancer Center

9:45 AM - 11:15 AM Clinical Science Symposium

Innovative Immune and Genomic Biomarkers for Solid Tumors

Location: E451

Interact ID: 10735

Pamela Jean Goodwin, MD - Chair

Lunenfeld-Tanenbaum Research Institute, Sinai Health System

Monday, June 4, 2018

Vamsidhar Velcheti, MD - Chair

Taussig Cancer Institute, Cleveland Clinic

- 9:45 AM Abstract 12009: Characterisation of the TCR repertoire in NSCLC to reveal the relationship between TCR heterogeneity and genetic heterogeneity that is influenced by mutational load and is associated with disease recurrence.** *K. Joshi, M. Ismail, J. Reading, M. Robert De Massy, I. Uddin, M. Jamal-Hanjani, S. Veeriah, T. Oakes, Y. Wong, A. J. Furness, E. Ghorani, A. Georgiou, C. Beastall, N. Mangal, A. Ben Aissa, M. Werner Sunderland, K. Peggs, C. Swanton, B. Chain, S. A. Quezada*
- 9:57 AM Patrick C. Ma, MD (Discussion of Abstract(s) 12009)**
WVU Cancer Institute, West Virginia University
Linking Immune and Genomic Heterogeneity: Clinical and Biologic Implications
- 10:09 AM Abstract 12010: NRG Oncology/NSABP B-31: Stromal tumor infiltrating lymphocytes (sTILs) and outcomes in early-stage HER2-positive breast cancer (BC).** *R. S. Kim, N. Song, P. G. Gavin, R. Salgado, H. Bandos, Z. Kos, G. Floris, G. G. Van den Eynden, S. S. Badve, P. Rastogi, L. Fehrenbacher, E. P. Mamounas, S. M. Swain, D. L. Wickerham, P. C. Lucas, J. P. Costantino, C. E. Geyer Jr., N. Wolmark, S. Paik, K. L. Pogue-Geile*
- 10:21 AM Kurt A. Schalper, MD, PhD (Discussion of Abstract(s) 12010)**
Yale School of Medicine
Strategies and Clinical Relevance of Scoring TILs in Solid Tumors
- 10:33 AM Abstract 12011: WINTHER: An international WIN Consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies.** *J. Rodon, J. Soria, R. Berger, W. H. Miller Jr., V. Lazar, E. Rubin, A. M. Tsimberidou, P. Saintigny, A. Ackerstein, I. Brana, Y. Loriot, M. Afshar, V. A. Miller, F. Wunder, C. Bresson, J. Martini, J. Mendelsohn, R. L. Schilsky, J. Lee, R. Kurzrock*
- 10:45 AM Eddy Shih-Hsin Yang, MD, PhD (Discussion of Abstract(s) 12011)**
University of Alabama at Birmingham
Incorporating Transcriptomics to Guide Precision Therapeutics
- 10:57 AM Panel Question and Answer**

9:45 AM - 11:15 AM Clinical Science Symposium

The Arrival of Biosimilars

Location: Hall D1

Interact ID: 10828

Colin D. Weekes, MD, PhD - Chair

Massachusetts General Hospital

- 9:45 AM R. Donald Harvey, PharmD, BCOP, FCCP**
Winship Cancer Institute
The Science and Process for Biosimilars
- 9:57 AM Abstract 111: Comparison of efficacy and safety of biosimilar filgrastim in a RCT (PIONEER) and real-world practice (MONITOR-GCSF).** *N. Harbeck, L. Yau, N. Mathieson, A. Krendyukov*
- 10:09 AM Abstract 112: Treatment approach for non-Hodgkin lymphoma patients since first biosimilars of rituximab approved in EU5.** *A. Franceschetti, R. Caldeira*
- 10:21 AM Abstract 109: A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer.** *M. A. Socinski, J. Von Pawel, K. Kasahara, I. Bondarenko, K. Syrigos, V. I. Vladimirov, M. Bryl, M. Zereu, F. Hilton, K. F. Liau, R. S. Herbst*

10:33 AM Abstract 110: Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Toxicity, efficacy, and immunogenicity from the phase 3 Heritage trial. A. Manikhas, E. J. Pennella, I. Bondarenko, G. Mukhametshina, M. L. Abesamis-Tiambeng, C. Akewanlop, I. Vynnychenko, V. Sriuranpong, S. Ray, C. F. Waller, M. Hernandez Bronchud, J. Herson, S. Loganathan, A. Barve, H. S. Rugo

10:45 AM Michael A. Thompson, MD, PhD (Discussion of Abstract(s) 109-112)
Aurora Advanced Healthcare
Incorporating Biosimilars Into Cancer Care

10:57 AM Panel Question and Answer

9:45 AM - 11:15 AM Education Session

**ASCO/American Association for Cancer Research (AACR) Joint Session:
GENIE and CancerLinQ—Two Models for Real-World Data Curation and
Integration**

Location: S406

Interact ID: 10806

Bruce E. Johnson, MD, FASCO - Chair
Dana-Farber Cancer Institute

Michael Caligiuri, MD - Chair
City of Hope National Medical Center

Charles L. Sawyers, MD
Memorial Sloan Kettering Cancer Center
GENIE: Lessons Learned and Challenges With Data Curation

Deborah Schrag, MD, MPH, FASCO
Dana-Farber/Harvard Cancer
GENIE: Real-World Application

Robert S. Miller, MD, FACP, FASCO
American Society of Clinical Oncology
CancerLinQ: Lessons Learned and Challenges With Data Curation

Jeffrey J. Kirshner, MD
Hematology-Oncology Associates of Central New York
CancerLinQ: Real-World Application

Panel Question and Answer

11:30 AM - 12:45 PM Poster Discussion Session

Developmental Therapeutics—Immunotherapy

Location: Hall B1

Interact ID: 10862

Marijo Bilusic, MD, PhD - Chair
National Cancer Institute

Sumit Kumar Subudhi, MD - Chair
The University of Texas MD Anderson Cancer Center

11:30 AM Stephen Lawrence Shiao, MD, PhD (Discussion of Abstract(s) 3009-3011)
Cedars-Sinai Medical Center
Factors Affecting Outcomes to Immune Checkpoint Therapy

Monday, June 4, 2018

11:42 AM *Panel Question and Answer*

11:48 AM **Charlotte Eielson Ariyan, MD, PhD (Discussion of Abstract(s) 3012-3014)**
Memorial Sloan Kettering Cancer Center
Novel Combination Immune Checkpoint Therapies

12:00 PM *Panel Question and Answer*

12:06 PM **Thomas Gajewski, MD, PhD (Discussion of Abstract(s) 3015-3017)**
University of Chicago Medical Center
Evaluation of Imaging Techniques in Immune Checkpoint Therapy

12:18 PM *Panel Question and Answer*

12:24 PM **Sherene Loi, MD, PhD (Discussion of Abstract(s) 3018-3020)**
Peter MacCallum Cancer Centre
Novel Immunotherapeutic Agents

12:36 PM *Panel Question and Answer*

Posters discussed in this session are on display in the Developmental Therapeutics—Immunotherapy Poster Session. See page 251 for poster information.

11:30 AM - 12:45 PM Poster Discussion Session

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft

Location: E450

Interact ID: 10870

Anjali S. Advani, MD - Chair

Taussig Cancer Institute, Cleveland Clinic

Eric Padron, MD - Chair

Moffitt Cancer Center

11:30 AM **Jae Hong Park, MD (Discussion of Abstract(s) 7012-7013)**

Memorial Sloan-Kettering Cancer Center
CAR-T Cell Therapy and Stem Cells in Acute Lymphoblastic Leukemia

11:42 AM *Panel Question and Answer*

11:48 AM **Jacalyn Rosenblatt, MD (Discussion of Abstract(s) 7014-7016)**

Beth Israel Deaconess Medical Center
Immune Checkpoints in Myeloid Malignancies

12:00 PM *Panel Question and Answer*

12:06 PM **Alice S. Mims, MD (Discussion of Abstract(s) 7017-7020)**

Ohio State University Wexner Medical Center
New Agents in Myeloid Malignancies

12:18 PM *Panel Question and Answer*

12:24 PM **Sami N. Malek, MD (Discussion of Abstract(s) 7021-7023)**

University of Michigan Comprehensive Cancer Center
Impact of Disease Burden in Acute Myeloid Leukemia

12:36 PM *Panel Question and Answer*

Posters discussed in this session are on display in the Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft Poster Session. See page 263 for poster information.

11:30 AM - 12:45 PM Education Session

Advances in Immunotherapy for Solid Tumors in Pediatric Oncology

Location: S504

Interact ID: 10760

Terry Fry, MD - Chair

Children's Hospital Colorado

The Role of Biomarkers in Guiding Immunotherapeutic Clinical Decisions

Stephen Gottschalk, MD

St. Jude Children's Research Hospital

The Landscape of CART Beyond ALL

Dean Anthony Lee, MD, PhD

Nationwide Children's Hospital

Emerging Immunotherapeutic Approaches and Practical Strategies in Pediatric Oncology

Panel Question and Answer

11:30 AM - 12:45 PM Education Session

Cardio-Oncology: Novel Cardiac Toxicities in the Era of Precision Medicine

Location: S100bc

Interact ID: 10918

Anne Hudson Blaes, MD - Chair

University of Minnesota

Cardiotoxicity of Anticancer Agents: Past, Present, and Emerging

Javid Moslehi, MD

Vanderbilt University Medical Center

New Emerging Therapies and Associated Cardiotoxicity

Paaladinesh Thavendiranathan, MD

Toronto General Hospital Research Institute

Imaging and Cardiac Biomarkers and Prevention in the Era of Precision Medicine

Panel Question and Answer

11:30 AM - 12:45 PM Education Session

Helping Our Patients Understand Molecular Testing and Its Implications

Location: S100a

Interact ID: 10786

Ben Ho Park, MD, PhD - Chair

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

Getting Down to the Basics: Explaining Molecular Testing to Your Patients

Michael P. Mullane, MD

Aurora Cancer Care

Discussing Test Results: Understanding Actionable and Nonactionable Mutations

Monday, June 4, 2018

Aaron Scott Mansfield, MD

Mayo Clinic

Identifying Appropriate Trials for Our Patients and Considering Compassionate Use Programs

Panel Question and Answer

11:30 AM - 12:45 PM Education Session

Implications of New Staging and ER/PR and HER2 Testing on Treatment Decisions in Early-Stage Breast Cancer

Location: Hall D2

Interact ID: 10772

Elizabeth A. Mittendorf, MD, PhD - Chair

Dana-Farber/Brigham and Women's Cancer Center

How Will New AJCC Staging Affect You?

John Bartlett, MD

Ontario Institute for Cancer Research

Making Sense of New Receptor Testing

Sarat Chandarlapaty, MD, PhD

Memorial Sloan Kettering Cancer Center

Liquid Biopsies: Are They Ready for Prime Time in Breast Cancer?

Panel Question and Answer

11:30 AM - 12:45 PM Education Session

Is There a Precise Adjuvant Therapy for Esophagogastric Junction and Gastric Cancer?

Location: S406

Interact ID: 10729

Peter C. Enzinger, MD

Dana-Farber Cancer Institute

Pre/Post-Op Chemotherapy

Theodore S. Hong, MD

NRG Oncology and Massachusetts General Hospital

Pre/Post-Operative Chemo-Radiation

Ian Chau, MD - Chair

Royal Marsden Hospital

Upcoming Biomarkers and Precise Novel Therapies

Panel Question and Answer

11:30 AM - 12:45 PM Education Session

Molecular Oncology Tumor Board: Synchronous Primary Lung Cancers

Location: E451

Interact ID: 10930

A. John Iafrate, MD, PhD - Chair

Massachusetts General Hospital

Sai-Hong Ignatius Ou, MD, PhD

University of California Irvine School of Medicine
Medical Oncologist's Perspective

Frank C. Detterbeck, MD

Yale School of Medicine
Surgeon's Perspective

David H. Hwang, MD

Brigham and Women's Hospital
Pathologist's Perspective

Panel Question and Answer

11:30 AM - 12:45 PM Education Session

On-the-Ground Experience: Implementing Cancer Control in Low- and Middle-Income Countries

Location: S404

Interact ID: 10801

Verna D. Vanderpuye, MD

Center for Radiotherapy

National Cancer Control Plans: What They Are and How to Keep Them From Being Forgotten

Alex Mutombo Baleka, MD

Kinshasa University Hospital

Challenges in Implementing Cancer Screening and Clinical Trials in Low-Resource Settings

Julie Gralow, MD, FASCO - Chair

Seattle Cancer Care Alliance

What Is Implementation Science and the Breast Cancer Initiative 2.5

Lawrence N. Shulman, MD, FASCO

Abramson Cancer Center

Cancer Center of Excellence in a Low-Income Country: The Experience in Butaro, Rwanda

Panel Question and Answer

11:30 AM - 12:45 PM Education Session

Role of Precision Therapy in the Treatment of Advanced Urothelial Cancer

Location: Hall D1

Interact ID: 10720

Evan Y. Yu, MD - Chair

Seattle Cancer Care Alliance

Targeted Therapies in Advanced Urothelial Cancer

Sandy Srinivas, MD

Stanford University

Immunotherapy-Based Approaches for Advanced Urothelial Cancer

Monday, June 4, 2018

Arlene O. Siefker-Radtke, MD

The University of Texas MD Anderson Cancer Center

Tailoring of Chemotherapy to Fit Patients With Metastatic Urothelial Cancer

Panel Question and Answer

11:30 AM - 12:45 PM Meet the Professor Session

Germline Testing for Hematologic Malignancies: Unique Considerations and Strategies - Ticketed Session

Location: E253c

Interact ID: 10733

Sarah A. Bannon, MS, CGC

The University of Texas MD Anderson Cancer Center

Jane E. Churpek, MD

University of Chicago Medical Center

11:30 AM - 12:45 PM Meet the Professor Session

Point/Counterpoint: Is Genome-Directed Oncology Ready for Prime Time? - Ticketed Session

Location: E253d

Interact ID: 10909

Jeremy Warner, MD, MS

Vanderbilt University Ingram Cancer Center

Yes, and We Have the Technology to Bring Context-Specific Recommendations to the Point of Care

Vinay Prasad, MD, MPH

Oregon Health & Science University

No, Show Me the (Randomized) Data!

Richard Schilsky, MD, FACP, FASCO, FSCT

American Society of Clinical Oncology

Panel Discussion Moderator

12:00 PM - 1:00 PM Annual Business Meeting

ASCO Annual Business Meeting (ASCO Members Only)

Location: S103

1:15 PM - 2:30 PM Poster Discussion Session

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Location: E450

Interact ID: 10871

Jacqueline Barrientos, MD - Chair
Hofstra Northwell School of Medicine

Danielle M. Brander, MD - Chair
Duke University School of Medicine

- 1:15 PM Eric D. Jacobsen, MD (Discussion of Abstract(s) 7509-7511)**
Dana-Farber Cancer Institute
Raising the Bar in T-Cell Lymphomas
- 1:27 PM Panel Question and Answer**
- 1:33 PM Alexey V. Danilov, MD, PhD (Discussion of Abstract(s) 7512-7514)**
Knight Cancer Institute, Oregon Health and Science University
Digging Deeper in Chronic Lymphocytic Leukemia
- 1:45 PM Panel Question and Answer**
- 1:57 PM Franck Morschhauser, MD, PhD (Discussion of Abstract(s) 7515-7517)**
CHU Lille - Hopital Claude Huriez
Lymphoid Malignancies: High-Maintenance Diseases
- 2:03 PM Panel Question and Answer**
- 2:09 PM Loretta J. Nastoupil, MD (Discussion of Abstract(s) 7518-7520)**
The University of Texas MD Anderson Cancer Center
PI3Ks: The Next Generation
- 2:21 PM Panel Question and Answer**

Posters discussed in this session are on display in the Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Poster Session. See page 269 for poster information.

1:15 PM - 2:30 PM Award Lecture

Pediatric Oncology Award and Lecture and Presentation of the Partners in Progress Award

Location: S504
Interact ID: 10933

Daniel F. Hayes, MD, FACP, FASCO
University of Michigan Comprehensive Cancer Center
Presentation of the 2018 Partners in Progress Award and the Pediatric Oncology Award

Danielle Leach, MPA
St. Baldrick's Foundation
Partners in Progress Award Recipient

Gregory H. Reaman, MD, FASCO
U.S. Food and Drug Administration
Facilitating Precision Oncology for Children: Implementing New Legislative Provisions for the Therapeutic Orphans

1:15 PM - 2:30 PM Education Session

Advances in Fertility Preservation for Young Women With Cancer

Location: E451
Interact ID: 10912

Karen L. Smith, MD - Chair
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Integrating Fertility Preservation Into Care of the Newly Diagnosed Young Female Patient With Cancer

Monday, June 4, 2018

Clarisa Gracia, MD, MSCE

Hospital of the University of Pennsylvania

New Developments in Reproductive Endocrinology Techniques for Fertility Preservation in Young Women With Cancer

Halle C. F. Moore, MD

Cleveland Clinic

GnRH Analogs for Fertility Preservation: What Are the Data?

Panel Question and Answer

1:15 PM - 2:30 PM Education Session

Beyond the Knife: The Evolving Management of Oligometastatic Colorectal Cancer

Location: Hall D2

Interact ID: 10747

Sharlene Gill, MD, MPH, MBA - Chair

BC Cancer Agency

Systemic Therapy for Potentially Resectable Metastatic Colorectal Cancer: What Is the Goal?

David M. Liu, MD

University of British Columbia

Nonsurgical Locoregional Strategies to Improve Resectability

Ricky A. Sharma, MD

University College London

External and Internal Radiotherapy Approaches for Oligometastatic Colorectal Cancer

Panel Question and Answer

1:15 PM - 2:30 PM Education Session

How Much Time Do I Have, Doc? Communicating Prognosis in the Era of Exceptional Responders

Location: S100bc

Interact ID: 10698

Thomas William LeBlanc, MD, MA, MHS, FAAHPM - Chair

Duke University Medical Center

Prognostic Understanding in Cancer Care: How Well Do Patients Understand Their Illness?

Jennifer S. Temel, MD

Massachusetts General Hospital

Exceptional Responders, Hope, and Prognostication: Making a Tough Problem Even Tougher

Paul R. Helft, MD

Indiana University Melvin and Bren Simon Cancer Center

Necessary Collusion: Prognostic Communication With Patients With Advanced Cancer

Panel Question and Answer

1:15 PM - 2:30 PM Education Session

Immunotherapy Beyond the Checkpoints: CARs, Trucks, and More

Location: Arie Crown Theater

Interact ID: 10736

David S. Schrupp, MD

National Cancer Institute at the National Institutes of Health

Immunoepigenetics: Therapeutic Implications of Cancer Immunoediting

Vamsidhar Velcheti, MD - Chair

Taussig Cancer Institute, Cleveland Clinic

Cytokines in Cancer Immunotherapy: Recent Updates

Carl H. June, MD

University of Pennsylvania

Genetically Modified Cell Therapy

Panel Question and Answer

1:15 PM - 2:30 PM Education Session

Immunotherapy in Lung Cancer: When, How Long, and What to Do About “-itis”?

Location: Hall B1

Interact ID: 10791

Solange Peters, MD, PhD

Centre Hospitalier Universitaire Vaudois

Biomarkers, Sequence, and Duration of Immunotherapy in Non-Small Cell Lung Cancer

Taofeek Kunle Owonikoko, MD, PhD, MS

Emory University

Role of Immunotherapy in Small Cell Lung Cancer

Shirish M. Gadgeel, MD - Chair

University of Michigan

Management of Immunotherapy Toxicities in Patients With Lung Cancer

Panel Question and Answer

1:15 PM - 2:30 PM Education Session

Metastatic Prostate Cancer Tumor Board: Optimizing Patient Selection and Treatment

Location: Hall D1

Interact ID: 10824

Neeraj Agarwal, MD - Chair

Huntsman Cancer Institute, University of Utah

Treatment of Metastatic Hormone-Sensitive Prostate Cancer and Implications for Subsequent Management

Celestia S. Higano, MD, FACP

University of Washington and Fred Hutchinson Cancer Research Center

Balancing Toxicities, and Therapeutics Perspective

Monday, June 4, 2018

Mary-Ellen Taplin, MD

Dana-Farber Cancer Institute

Optimizing Androgen Receptor Targeting Strategies Perspective

Charles J. Ryan, MD

University of Minnesota

Optimal Patient Selection/Stratification Perspective

Panel Question and Answer

1:15 PM - 2:30 PM Education Session

The Emergence of Cancer Biosimilars in the United States: A Clinician's Guide

Location: S406

Interact ID: 10920

R. Donald Harvey, PharmD, BCOP, FCCP - Chair

Winship Cancer Institute

Preclinical and Clinical Development of Oncology Biosimilars

Leah Christl, PhD

U.S. Food and Drug Administration

Overview of the Regulatory Decision-Making Process

Gary H. Lyman, MD, MPH, FASCO, FRCP

Fred Hutchinson Cancer Research Center

Paving the Way Forward: The Role of Post-Market Evidence Development, Education, and Guidance

Panel Question and Answer

1:15 PM - 2:30 PM Meet the Professor Session

Optimizing Therapy for ER-Positive Metastatic Breast Cancer - Ticketed Session

Location: E253c

Interact ID: 10785

Sara A. Hurvitz, MD

UCLA David Geffen School of Medicine

Janice Maria Walshe, MD

CCRT

1:15 PM - 2:30 PM Meet the Professor Session

Perioperative Systemic Therapy for Localized Renal Cell Carcinoma: To Treat or Not to Treat - Ticketed Session

Location: E253d

Interact ID: 10723

Brian I. Rini, MD

Cleveland Clinic Taussig Cancer Institute

Hyung Lae Kim, MD
Cedars-Sinai Medical Center

1:15 PM - 2:45 PM Clinical Science Symposium

Personalizing Care for Older Adults With Cancer: From Decision-Making to Care Delivery

Location: S404
Interact ID: 10788

Gretchen Genevieve Kimmick, MD, MS - Chair
Duke University Medical Center

Stuart M. Lichtman, MD - Chair
Memorial Sloan Kettering Cancer Center

- 1:15 PM Abstract 10009: Patient-defined goals and preferences among older adults with cancer starting chemotherapy (CT).** *E. Soto Perez De Celis, D. Li, C. Sun, H. Kim, P. Twardowski, M. Fakih, V. M. Chung, M. C. Cristea, D. Lim, Y. Yuan, W. Dale, L. Chien, K. Charles, H. Tan, E. Roberts, J. Moreno, D. Rivera, V. Katheria, A. Hurria*
- 1:27 PM Abstract 10010: Quality of life (QoL) in older patients (pts) with cancer and prognostic factors for QoL decline.** *L. Decoster, C. Quinten, C. Kenis, J. Flamaing, P. R. Debruyne, I. DeGroof, C. N. Focan, F. Cornelis, V. Verschaeve, C. Bachmann, D. Bron, S. Luce, G. Debugne, H. Van Den Bulck, J. Goeminne, D. L. Schrijvers, J. Lobelle, M. Lycke, K. Miliisen, H. Wildiers*
- 1:39 PM Aminah Jatoi, MD (Discussion of Abstract(s) 10009-10010)**
Mayo Clinic
Expanding the Scope of Precision Medicine: Integration of Patient Preference and Experience
- 1:51 PM Abstract 10011: Relationship between preoperative geriatric frailty and need for postoperative intensive care unit admission and subsequent short- and long-term mortality.** *A. Shahrokni, S. Sarraf, K. Alexander, S. W. Sun, S. Kim, S. McMillan, H. Yulico, R. J. Downey, B. Korc-Grodzicki*
- 2:03 PM Abstract 10012: Randomized trial of a pharmacy intervention for older adults with cancer.** *M. Ruddy, A. El-Jawahri, D. Lage, M. Zangardi, C. Chio, E. Kim, B. Li, Y. Long, G. C. Blouin, J. S. Temel, R. D. Nipp*
- 2:15 PM Martine Extermann, MD (Discussion of Abstract(s) 10011-10012)**
H. Lee Moffitt Cancer Center and Research Institute
Moving Geriatric Principles Into Practice: Strategies to Individualize Management at the Point of Care
- 2:27 PM Panel Question and Answer**

1:15 PM - 4:45 PM Poster Session

Gynecologic Cancer

Location: Hall A

Abstracts on Boards 241-251 will be discussed during the Gynecologic Cancer Poster Discussion Session.

Posters by Topic

Cervical Cancer: Boards 249-250, 252-263
Other Cancer: Boards 322-326
Ovarian Cancer: Boards 241-248, 251, 264-312
Uterine Cancer: Boards 313-321
Trials in Progress: Boards 327a-334b

Monday, June 4, 2018

- Board 241 **Abstract 5514: QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥ 3 prior chemotherapy regimens.** *K. N. Moore, A. A. Secord, M. A. Geller, D. S. Miller, N. G. Cloven, G. F. Fleming, A. E. Wahner Hendrickson, M. Azodi, P. DiSilvestro, A. M. Oza, M. C. Cristea, J. S. Berek, J. K. Chan, Y. Li, R. Clark, U. A. Matulonis, B. J. Monk*
- Board 242 **Abstract 5515: Apatinib, a novel VEGFR inhibitor, combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer: A single-arm, open-label, phase 2 study.** *C. Lan, Y. Wang, Y. Xiong, J. Li, Y. Li, Y. Zhang, M. Zheng, Y. Feng, H. Huang, X. Huang*
- Board 243 **Abstract 5516: Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial).** *A. Fagotti, G. Vizzielli, G. Ferrandina, F. Fanfani, V. Gallotta, V. Chiantera, B. Costantini, P. Margariti, S. Gueli Alletti, F. Cosentino, L. Tortorella, G. Scambia*
- Board 244 **Abstract 5517: Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: A NRG oncology/Gynecologic Oncology Group (GOG) study.** *R. A. Burger, D. Enserro, K. S. Tewari, M. F. Brady, M. A. Bookman, G. F. Fleming, H. Q. Huang, H. D. Homesley, J. Fowler, M. Boente, L. M. Randall, J. K. Chan, J. S. Ferris, P. J. DiSaia, L. J. Copeland, R. S. Mannel, M. J. Birrer, B. J. Monk*
- Board 245 **Abstract 5518: AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer—Overall survival (OS) results.** *I. Vergote, L. C. Hanker, A. Floquet, J. Rau, J. Kim, E. Ortega Izquierdo, M. Friedlander, S. Pignata, K. Fujiwara, N. Colombo, M. R. Mirza, B. J. Monk, M. Mörtl, P. Calvert, T. J. Herzog, C. Jackisch, J. Meunier, J. Lee, A. K. Belau, A. Du Bois*
- Board 246 **Abstract 5519: A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).** *J. F. Liu, W. T. Barry, R. M. Wenham, A. E. Wahner Hendrickson, D. K. Armstrong, N. Chan, D. E. Cohn, J. Lee, R. T. Penson, M. C. Cristea, J. L. Abbruzzese, K. MATSUO, A. Olawaiye, S. Farooq, E. M. Swisher, E. M. Van Allen, G. Shapiro, E. C. Kohn, S. P. Ivy, U. A. Matulonis*
- Board 247 **Abstract 5520: Significant overall survival improvement in proliferative subtype ovarian cancer patients receiving bevacizumab.** *S. Kommoss, F. Heitz, B. J. Winterhoff, C. Wang, J. Sehouli, C. Aliferis, R. Kimmig, J. Wang, S. Ma, N. de Gregorio, S. Mahner, A. Du Bois, R. Tourani, T. Park-Simon, K. Baumann, F. A. Taran, F. Kommoss, W. Schroeder, S. C. Dowdy, J. Pfisterer*
- Board 248 **Abstract 5521: Genomic mutation profiles of paired ovarian cancers (OC) across time.** *J. Fehniger, A. A. Berger, L. Juckett, L. M. Gay, J. A. Elvin, D. A. Levine, D. A. Zajchowski*
- Board 249 **Abstract 5522: Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study.** *H. C. Chung, J. H. Schellens, J. Delord, R. Perets, A. Italiano, R. Shapira-Frommer, L. Manzuk, S. A. Piha-Paul, J. Wang, S. Zeigenfuss, S. K. Pruitt, A. Marabelle*
- Board 250 **Abstract 5523: Neoadjuvant chemotherapy with cisplatin and gemcitabine followed by chemoradiation with cisplatin in locally advanced cervical cancer: A phase II, prospective, randomized, trial.** *S. Silva, R. R. Colombo Bonadio, F. Gabrielli, A. s. Aranha, M. Genta, V. C. Miranda, D. Freitas, E. A. Filho, P. A. Ferreira, K. Kalil, M. Scaranti, M. D. Estevez-Diz*
- Board 251 **Abstract 5524: PARAGON: A phase 2 study of anastrozole (An) in patients with estrogen receptor(ER) and / progesterone receptor (PR) positive recurrent/metastatic granulosa cell tumors/sex-cord stromal tumors (GCT) of the ovary.** *S. N. Banerjee, M. Tang, R. O'Connell, A. R. Clamp, R. Lord, V. M. Mullassery, M. Hall, C. Gourley, T. Bonaventura, J. C. Goh, P. Sykes, P. T. Grant, O. McNally, R. J. Edmondson, M. Friedlander*

- Board 252 Abstract 5525: A phase 1/2A trial of synthetic DNA vaccine immunotherapy targeting HPV-16 and -18 after chemoradiation for cervical cancer.** *Y. Hasan, M. T. Spiotto, L. V. Furtado, A. I. Tergas, N. K. Lee, R. A. Brooks, A. R. McCall, D. W. Golden, S. Jolly, G. F. Fleming, M. P. Morrow, J. Skolnik, M. Esser, R. Kumar, R. R. Weichselbaum*
- Board 253 Abstract 5526: Phase II clinical trial of eribulin (E) in advanced/recurrent cervical cancer.** *J. Garcia, Y. G. Lin, S. Louie, P. Fauceglia, D. D. Tsao-Wei, E. Yoo, M. Ciccone, C. Adams, L. L. Brunette, K. MATSUO, H. Q. Pham, A. A. Yessaian, S. G. Groshen, G. Facio, K. Watkins, L. I. Muderspach, A. A. Garcia, L. D. Roman*
- Board 254 Abstract 5527: Propensity score-matched analysis of systemic chemotherapy versus hysterectomy for patients with residual cervical disease after definitive radiotherapy/concurrent chemoradiotherapy.** *M. Takekuma, F. Takahashi, S. Mabuchi, W. Kudaka, K. Horie, M. Ikeda, A. Shikama, A. Mitsunashi, S. Nagao, S. Suzuki, M. Mizuno, S. Nishio, H. Tokunaga, Y. Ota, T. Kasamatsu, R. Kitagawa, T. Toita, H. Kobayashi, M. Ishikawa, N. Yaegashi*
- Board 255 Abstract 5528: Preliminary results from CECILIA, an open-label global safety study of bevacizumab (BEV), carboplatin (C) and paclitaxel (P) therapy for metastatic, recurrent or persistent cervical cancer (CC).** *A. Redondo, N. Colombo, L. M. Dreosti, M. McCormack, A. N. Rodrigues, M. Donica, L. Morales, A. González-Martín*
- Board 256 Abstract 5529: Comparison of different adjuvant therapy after radical surgery in early stage cervical carcinoma: A 3-arm randomized control study.** *H. Huang, L. Yang, Y. Zuo, L. Ma, Y. Chen, S. Yao, L. Li, H. Zhang, M. Zheng, Y. Zhang, X. Huang, J. Li, Y. Li, X. Cao, J. Liu*
- Board 257 Abstract 5530: Association between pap abnormalities and HPV infection in participants in HPV vaccine clinical trials.** *E. Meyers, A. Luxembourg, A. Saah, C. Velicer*
- Board 258 Abstract 5531: The clinical utility of prospective molecular characterization in advanced cervical and vulvovaginal cancer.** *C. F. Friedman, M. Donoghue, M. Vivek, C. Aghajanian, N. Abu-Rustum, K. A. Cadoo, R. N. Grisham, M. L. Hensley, J. A. Konner, C. Kyi, M. M. Leitao, V. Makker, R. E. O’Cearbhaill, W. P. Tew, B. Weigelt, D. Zamarin, K. J. Park, B. S. Taylor, D. M. Hyman*
- Board 259 Abstract 5532: Unexpected lymphatic drainage pathways of cervical cancer: Insights of the sentinel lymph node biopsy.** *V. Balaya, P. Mathevet, L. Magaud, D. Querleu, E. Leblanc, P. Morice, E. Darai, A. Bats, C. Huchon, F. Lecuru*
- Board 260 Abstract 5533: AMPATH Oncology: Baseline HPV detection in Kenyan women enrolled in a longitudinal study of modifiable factors predicting cervical dysplasia.** *D. R. Brown, T. Maina, P. Tonui, J. M. Ong’echa, A. Ermel, K. Muthoka, S. Kiptoo, Y. Tong, Y. Wong, A. Moormann, A. Mwangi, J. Hogan, P. J. Loehrer Sr., E. Omenge*
- Board 261 Abstract 5534: Dose dense neoadjuvant chemotherapy (NACT) with carboplatin-paclitaxel in locally advanced cervical cancer.** *D. Lorusso, I. Sabatucci, G. Maltese, S. Lepori, E. Tripodi, G. Bogani, U. Leone Roberti Maggiore, A. Ditto, F. Martinelli, D. Rossetti, F. Raspagliesi*
- Board 262 Abstract 5535: Evaluation of capecitabine in patients with platinum-pretreated advanced or recurrent cervical carcinoma: A retrospective study of the IRCCS National Cancer Institute of Milan.** *D. Lorusso, S. Lepori, I. Sabatucci, E. Tripodi, G. Maltese, G. Bogani, U. Leone Roberti Maggiore, A. Ditto, F. Martinelli, D. Rossetti, F. Raspagliesi*
- Board 263 Abstract 5536: A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer.** *A. Santin, W. Deng, M. M. Frumovitz, W. K. Huh, S. Khleif, H. A. Lankes, E. Ratner, R. O’Cearbhaill, A. A. Jazaeri, M. Birrer*

Monday, June 4, 2018

- Board 264 **Abstract 5537: Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study.** *C. Aghajanian, R. L. Coleman, A. M. Oza, D. Lorusso, A. Oaknin, A. P. Dean, N. Colombo, J. I. Weberpals, A. R. Clamp, G. Scambia, A. Leary, R. W. Holloway, P. C. Fong, J. C. Goh, D. M. O'Malley, S. N. Banerjee, K. Wride, T. Cameron, J. A. Ledermann*
- Board 265 **Abstract 5538: 53BP1 as a predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.** *R. M. Hurley, A. E. Wahner Hendrickson, D. W. Visscher, P. J. Ansell, M. I. Harrell, J. M. Wagner, V. Negron, K. M. Goergen, M. J. Maurer, A. L. Oberg, M. J. De Jonge, C. M. Van Herpen, J. A. Gietema, R. H. Koornstra, A. Jager, M. W. den Hollander, M. W. Dudley, S. P. Shepherd, E. M. Swisher, S. H. Kaufmann*
- Board 266 **Abstract 5539: The impact of health related quality of life (HRQoL) on short term survival of recurrent ovarian cancer patients: Analysis of pooled data from the North-Eastern German Society of Gynecological Oncology (NOGGO) meta data base.** *J. Sehouli, R. Chekerov, M. Keller, G. Oskay-Oezcelik, E. I. Braicu, R. Richter*
- Board 267 **Abstract 5540: Methylated circulating tumor DNA as a potential marker of PARP inhibitor efficiency in BRCA mutated ovarian cancer patients.** *K. D. Steffensen, R. F. Andersen, A. K. Jakobsen*
- Board 268 **Abstract 5541: Potential impact of dietary intervention/counseling on survival in ovarian cancer patients: Results from an observational study.** *J. Michalak, M. Hernandez, A. Laws, L. Jones, D. C. Bodurka, R. Hajek*
- Board 269 **Abstract 5542: A first-in-human study of monoclonal antibody GM102 in patients with anti-Mullerian-hormone-receptor II (AMHRII) positive gynecological cancers.** *A. Leary, P. G. Aftimos, J. Delord, C. Le Tourneau, I. L. Ray-Coquard, C. Jungels, A. I. Varga, F. Ricci, C. A. Gomez-Roca, G. Bataillon, N. Van Acker, G. Noël, O. Lantz, L. Cassard, A. Coste, B. Jean, I. M. Tabah-Fisch, A. V. Salomon, J. Prost, A. Awada*
- Board 270 **Abstract 5543: Role of primary surgery for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer.** *P. Harter, H. Plett, S. Prader, B. Ataseven, F. Heitz, M. Bommert, S. Schneider, P. Alesina, A. Traut, A. Du Bois*
- Board 271 **Abstract 5544: Identification of outcome-correlated serum cytokine and chemokine clusters in ovarian clear cell carcinoma.** *A. Yabuno, H. Matsushita, D. Shintani, T. Hamano, N. Fujieda, S. Sato, T. Nishikawa, K. Fujiwara, K. Kakimi, K. Hasegawa*
- Board 272 **Abstract 5545: Exploratory analysis of percentage of genomic loss of heterozygosity (LOH) in patients with platinum-sensitive recurrent ovarian carcinoma (rOC) in ARIEL3.** *A. Oaknin, J. A. Ledermann, A. M. Oza, D. Lorusso, C. Aghajanian, A. P. Dean, N. Colombo, J. I. Weberpals, A. R. Clamp, G. Scambia, A. Leary, R. W. Holloway, D. M. O'Malley, I. A. McNeish, E. M. Swisher, T. Cameron, S. Goble, J. Sun, K. K. Lin, R. L. Coleman*
- Board 273 **Abstract 5546: Effect of hypertension (HTN) on progression-free survival (PFS) in patients (pts) receiving front-line bevacizumab (BEV) for primary advanced ovarian cancer (OC) in the NOGGO single-arm OTILIA study: A post hoc analysis in 808 pts.** *R. Armbrust, P. Wimberger, A. Mustea, G. Oskay-Özcelik, M. Keller, R. Richter, J. Harde, M. Zortel, A. Wegenaer, O. Tome, J. Sehouli*
- Board 274 **Abstract 5547: Tumor regression grading after neoadjuvant chemotherapy predicts long-term outcome of stage IIIC epithelial ovarian cancer.** *M. Zhou, L. Li, X. Wang, C. Wang, D. Wang*
- Board 275 **Abstract 5548: Incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients (pts) with a germline (g) BRCA mutation (m) and platinum-sensitive relapsed ovarian cancer (PSR OC) receiving maintenance olaparib in SOLO2: Impact of prior lines of platinum therapy.** *J. Korach, S. Turner, T. Milenkova, I. Alecu, E. McMurtry, R. Bloomfield, E. Pujade-Lauraine*

- Board 276 Abstract 5549: Mirvetuximab soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Maturing safety and activity profile from the FORWARD II phase 1b study.** *D. M. O'Malley, L. P. Martin, L. Gilbert, I. Vergote, U. A. Matulonis, M. J. Birrer, C. M. Castro, K. S. Malek, A. González-Martín, K. N. Moore*
- Board 277 Abstract 5550: Prediction of post-operative residual disease in advanced-stage ovarian cancer (AOC) using whole transcriptome expression: An exploratory analysis of the AGO-OVAR 11 (ICON7) trial.** *F. Heitz, S. Kommos, B. J. Winterhoff, C. Aliferis, A. Burges, C. Wang, U. Canzler, J. Wang, A. K. Belau, L. C. Hanker, S. Ma, F. Hilpert, J. Sehouli, R. Tourani, R. Kimmig, C. Kurzeder, B. Schmalfeldt, S. C. Dowdy, A. Du Bois, J. Pfisterer*
- Board 278 Abstract 5551: METRO-BIBF: Phase II, randomised, placebo controlled, multicentre, trial of low dose (metronomic) cyclophosphamide (MCy) with or without nintedanib in relapsed ovarian cancer (ROC).** *M. Hall, H. Debhi, S. Nicum, R. Lord, S. N. Banerjee, A. R. Clamp, R. Lilleywhite, R. M. Glasspool, A. Feeney, A. Hackshaw, J. A. Ledermann*
- Board 279 Abstract 5552: Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: Uptake of genetic assessment and testing and impact on patient-reported stress, anxiety and depression.** *S. S. Lee, M. K. Frey, D. Gerber, Z. Schwartz, J. Martineau, K. Lutz, E. Reese, E. Dalton, A. Olsen, B. Pothuri, L. R. Boyd, J. P. Curtin, S. V. Blank*
- Board 280 Abstract 5553: A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission.** *R. E. O'Cearbhaill, S. Gnjatic, C. Aghajanian, A. Iasonos, J. A. Konner, N. Losada, D. Sarason, T. Rasalan, W. P. Tew, D. Zamarin, P. Wong, P. Sabbatini*
- Board 281 Abstract 5554: A phase I dose-escalation of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) carboplatin for the frontline treatment of advanced ovarian cancer.** *L. M. Randall, D. Gillen, L. S. Krill, F. W. Liu, K. Pfaendler, R. N. Eskander, K. S. Tewari, R. Bristow, W. Chen*
- Board 282 Abstract 5555: Inter and intra-observer variability with the assessment of RECIST in ovarian cancer.** *M. K. Wilson, T. Chawla, L. Wang, M. Friedlander, A. M. Oza, S. Lheureux*
- Board 283 Abstract 5556: Characterization and predictors of long term (≥ 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients.** *M. Friedlander, J. K. Chan, J. Java, D. K. Armstrong, M. Markman, T. J. Herzog, B. J. Monk, F. J. Backes, A. A. Secord, A. J. Bonebrake, P. G. Rose, K. S. Tewari, R. S. Mannel, S. S. Lentz, M. A. Geller, L. J. Copeland*
- Board 285 Abstract 5558: Predictive factors for prolonged response to olaparib as maintenance therapy in ovarian cancer patients with BRCA mutations.** *S. Labidi-Galy, T. De La Motte Rouge, O. Derbel, E. Kalbacher, A. Wolfer, T. Olivier, K. Hu, O. Tredan, H. Guevara, F. Bazan, V. De Castelbajac, J. Combes, P. Vafflard, L. Crivelli, V. Bonadona, V. Viassolo, L. Golmard, A. Buisson, M. Rodrigues, I. L. Ray-Coquard*
- Board 286 Abstract 5559: Cost-effectiveness of niraparib versus routine surveillance, olaparib, and rucaparib for the maintenance treatment of adult patients with ovarian cancer in the United States.** *M. Fisher, H. Guy, L. Walder*
- Board 287 Abstract 5560: Nanoparticle micellar formulation of paclitaxel in combination with carboplatin for women with recurrent platinum sensitive ovarian cancer (OAS07-OVA): Overall survival results of a phase 3 randomized trial.** *N. Heldring, H. Bjeremo, A. Brize, A. S. Lisyanskaya, I. Vergote*

Monday, June 4, 2018

- Board 288 **Abstract 5561: Tumor molecular profiling to differentiate extreme responses to first-line platinum-based chemotherapy in suboptimally debulked serous ovarian cancer patients.** *J. I. Weberpals, T. Pugh, G. D. Goss, B. Lo, N. Andrews Wright, L. Bernard, D. Torti, J. Torchia, P. Rath, A. Leon, K. Marsh, D. R. Hodgson, G. N. Jones, M. Duciaume, W. J. Howat, P. Marco-Casanova, M. P. Roudier, D. Whelan, H. S. Sekhon*
- Board 289 **Abstract 5562: Integrated molecular analysis of Asian ovarian cancer: Gene expression and whole exome sequencing analyses from the iPocc Translational Research study (TriPocc).** *R. Huang, T. Tan, J. Ye, C. Kuschal, Z. Mok, S. E. Goh, S. Tan, J. Tay, M. Mohd Omar, S. Sato, A. D. Jeyasekharan, D. Lim, R. C. Soong, K. Fujiwara, K. Hasegawa, D. S. Tan*
- Board 290 **Abstract 5563: Locus-specific loss of heterozygosity (LOH) in BRCA1/2 mutated (mBRCA) ovarian tumors from the SOLO2 (NCT01874353) and Study 19 (NCT00753545) clinical trials.** *K. Timms, J. S. Brown, D. R. Hodgson, T. Milenkova, J. A. Ledermann, C. Gourley, E. Pujade-Lauraine, M. Perry, A. Gutin, V. Abkevich, J. S. Lanchbury*
- Board 291 **Abstract 5564: Assessing delay and barriers to risk-reducing surgery in women with BRCA mutations.** *A. Olsen, D. Gerber, O. R. Khouri, J. Lee, J. Fehniger, B. Pothuri*
- Board 292 **Abstract 5565: PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: Results of a phase I dose escalation and expansion study.** *J. C. Sachdev, M. L. Maitland, M. Sharma, V. Moreno, V. Boni, S. Kummar, E. M. Stringer-Reasor, A. Forero-Torres, N. J. Lakhani, B. Gibson, D. Xuan, T. Joh, E. L. Powell, A. Jackson-Fisher, X. Xin, A. W. Tolcher, E. Calvo*
- Board 293 **Abstract 5566: Inhibition of the Wnt/ β -catenin pathway to promote T-cell immunity and survival in a syngeneic mouse model of ovarian cancer.** *D. W. Doo, A. Londono, S. Meza-Perez, A. A. Katre, S. J. Cooper, J. M. Straughn Jr., D. J. Buchsbaum, L. Norian, T. Randall, R. C. Arend*
- Board 294 **Abstract 5567: Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.** *N. Concin, I. Braicu, P. Combe, I. L. Ray-Coquard, F. Joly, P. Harter, P. Wimberger, J. Lotz, A. Ignatov, B. Schmalfeldt, E. van Nieuwenhuysen, S. Darb-Esfahani, M. Riedmann, A. G. Zeimet, S. Mahner, E. Pujade-Lauraine, C. Marth, R. Berger, J. Sehouli, I. Vergote*
- Board 295 **Abstract 5568: Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with three-weekly versus dose dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort.** *T. Sivakumaran, L. R. Mileshekin, P. T. Grant, M. Friedlander, P. M. Webb, G. Au-Yeung*
- Board 296 **Abstract 5569: Gene expression profiling using Nanostring technology to predict surgical outcome in advanced primary high grade serous ovarian cancer (HGSOC) patients (pts). Study of the Tumor Bank Ovarian Cancer (TOC).** *E. I. Braicu, H. Kulbe, F. Dreher, S. Darb-Esfahani, E. T. Taube, R. Chakerov, T. Kessler, M. Muallem, C. Wierling, C. Denkert, H. Lammert, M. Hummel, J. Sehouli*
- Board 297 **Abstract 5570: Differences in survival between Caucasians and Asians.** *J. K. Chan, A. Mann, K. M. Darcy, D. S. Kapp*
- Board 298 **Abstract 5571: Phase Ib study of anti-mesothelin antibody drug conjugate anetumab ravtansine in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.** *I. Bulat, K. N. Moore, A. Haceatran, J. W. Chung, P. Rajagopalan, C. Xia, D. Laurent, B. H. Childs, A. Santin*

- Board 299 Abstract 5572: Toxicity profile of patients with gynecological cancers (Gyne) enrolled in phase I trials.** *Y. Lee, L. Wang, E. C. Kohn, L. Rubinstein, S. P. Ivy, P. Harris, S. Lheureux*
- Board 300 Abstract 5573: Determinants of severe chronic fatigue among epithelial ovarian cancer survivors: A GINECO VIVROVAIRE study.** *F. Joly, E. Kalbacher, D. Berton-Rigaud, O. Tredan, M. Fabbro, N. Heutte, A. Savoye, J. Kurtz, J. Alexandre, P. Follana, V. Delecroix, N. Dohollou, C. Roemer-Becuwe, G. De Rauglaudre, A. Lortholary, K. Prulhiere, A. Gompel, C. Lhommé, D. Ahmed-Lecheheb, A. Floquet*
- Board 301 Abstract 5574: First results of a prospective national controlled study: Prophylactic Radical Fimbriectomy (NCT01608074), in women with a hereditary familial risk of breast/ovarian cancer—Tolerance and pathological findings.** *E. Leblanc, F. Narducci, D. Hudry, L. Bresson, J. Charvolin, G. Ferron, F. Guyon, V. Fourchette, E. Lambaudie, M. Baron, Y. Fouche, S. Gouy, P. Collinet, F. Caquant, C. Pomel, F. Golfier, V. Vaini-Cowen, A. Lemaire, E. Tresch-Bruneel, P. Vuagnat*
- Board 302 Abstract 5575: LION-PAW: Lymphadenectomy in ovarian neoplasm-pleasure ability of women—Prospective substudy of the randomized multicenter LION study.** *A. Hasenburg, J. Sehouli, B. Lampe, A. Reuss, B. Schmalfeldt, A. K. Belau, M. Bossart, S. Mahner, P. Hillemanns, K. Petry, A. Du Bois, U. Herwig, F. Hilpert, M. Gropp-Meier, V. Hanf, W. Janni, E. Greimel, U. A. Wagner, P. Harter*
- Board 303 Abstract 5576: Progression free survival (PFS) as a surrogate endpoint for overall survival (OS) in first-line advanced ovarian cancer (AOC) therapy: A Gynecologic Cancer InterGroup individual (GCIG) patient-level (IPD) analysis of multiple randomized trials.** *X. Paoletti, L. Lewsley, G. Daniele, A. D. Cook, N. Yanaihara, A. Tinker, G. Kristensen, P. B. Ottevanger, G. Aravantinos, I. A. Boere, R. Fruscio, A. K. Reyners, E. Pujade-Lauraine, A. Harkin, S. Pignata, T. Kagimura, S. Welch, K. Eleni, R. M. Glasspool*
- Board 304 Abstract 5577: Phase 1b study of oncolytic vaccinia virus GL-ONC1 in recurrent ovarian cancer (ROC).** *R. W. Holloway, J. E. Kendrick, A. Stephens, J. Kennard, J. Burt, J. LeBlanc, K. Sellers, J. Smith, S. Coakley*
- Board 305 Abstract 5578: Platinum based chemotherapy selects for PDGFR α dependent angiogenesis.** *N. McCabe, A. El-Helali, C. Steele, L. D. Perez, C. O'neill, A. McCavigan, R. Medina, L. A. Knight, S. McQuaid, J. James, C. O. Michie, C. Gourley, W. G. McCluggage, D. P. Harkin, R. H. Wilson, A. Stitt, R. D. Kennedy*
- Board 306 Abstract 5579: Paired somatic and germline genetic testing for ovarian cancer patients: Observations, benefits and implications for treatment.** *D. Chen, P. Reineke, N. Ghahramani, A. Deckman, E. Wellington, M. Umali Salvador, L. Guidugli, M. Pronold, H. LaDuca, M. Jackson*
- Board 307 Abstract 5580: Phase I study of carboplatin (C), pegylated liposomal doxorubicin (PLD) and everolimus (E) in platinum-sensitive epithelial ovarian, Fallopian tube or primary peritoneal cancer in first relapse (NCT01281514).** *L. P. Martin, A. Jain, C. Chu, G. Mantia-Smaldone, S. C. Rubin, E. A. Ross, R. J. Schilder*
- Board 308 Abstract 5581: Clear cell ovarian cancer (CCOC): 115 patient (pt) series showing access to experimental therapy may improve response rates in recurrent disease.** *M. Devlin, D. Chandrasekaran, N. Singh, J. A. Ledermann, M. Lockley, M. McCormack, N. Wilkinson, R. Miller, R. S. Kristeleit*
- Board 309 Abstract 5582: Efficacy and immune modulation of the tumor microenvironment with the combination of the PARP inhibitor rucaparib and CD122-biased agonist NKTR-214.** *A. Simmons, L. Robillard, M. Nguyen, T. C. Harding, D. H. Charych*
- Board 310 Abstract 5583: A gene expression prognostic signature for overall survival in patients with high-grade serous ovarian cancer.** *J. Millstein, T. Budden, M. Anglesio, A. Talhouk, A. Beeghly-Fadiel, A. Berchuck, G. Chenevix-Trench, A. deFazio, P. A. Fasching, S. Gayther, M. Garcia, E. L. Goode, M. Henderson, G. E. Konecny, S. Orsulic, D. Huntsman, D. Bowtell, J. Doherty, P. Pharoah, S. J. Ramus*

Monday, June 4, 2018

- Board 311 **Abstract 5584: Phase III randomized trial of maintenance pegylated liposomal doxorubicin (PLD) / carboplatin versus without in patients with advanced ovarian cancer: An Asian Gynecologic Oncology Group study.** *C. Lai, E. Vallikad, H. Lin, L. Yang, Y. Ou, H. Chou, C. Lin, H. Huang, K. Huang, J. Qiu, Y. Hung, T. Wu*
- Board 312 **Abstract 5585: Histone deacetylase inhibition alters tumor phenotype and stimulates a productive anti-tumor immune response in preclinical models of ovarian cancer.** *T. McCaw, T. Turner, H. M. Smith, D. J. Buchsbaum, T. Randall, R. C. Arend*
- Board 313 **Abstract 5586: Genomic profiling of lymph node metastases in endometrial cancer and association with volume of metastasis.** *S. Sullivan, A. Sripad, N. Desravines, D. R. Roque, D. N. Hayes, V. L. Bae-Jump, E. C. Rossi*
- Board 314 **Abstract 5587: Adjuvant therapy may decrease disparities in outcomes for black endometrial cancer patients.** *F. Zhu, A. R. Howard, M. Giurcanu, C. H. Son, Y. Hasan*
- Board 315 **Abstract 5588: Differences in survival outcomes in advanced endometrial cancer due to variation in adjuvant therapy and histology.** *E. M. Ko, C. Brensinger, D. J. Aviles, A. F. Haggerty, R. L. Giuntoli II, N. A. Latif, M. A. Morgan, L. L. Lin*
- Board 316 **Abstract 5589: Analysis of patient-reported outcomes (PROs) for GOG-258, a randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel (Cis-RT+CP) vs. carboplatin and paclitaxel (CP) for optimally debulked, locally advanced endometrial carcinoma: A Gynecologic Oncology Group/NRG study.** *U. A. Matulonis, V. L. Filiaci, H. Q. Huang, M. Randall, B. Kim, P. DiSilvestro, K. M. Moxley, D. M. O'Malley, M. A. Powell, N. M. Spirtos, K. S. Tewari, W. Richards, J. Nakayama, M. Steinhoff, D. G. Mutch, D. S. Miller, L. B. Wenzel, D. Matei*
- Board 317 **Abstract 5590: Assessment of activating estrogen receptor 1 (ESR1) mutations in gynecologic malignancies.** *S. Gaillard, L. M. Gay, M. Steiner, K. Andreano, B. A. Davidson, L. J. Havrilesky, A. A. Secord, F. A. Valea, G. Colon-Otero, D. A. Zajchowski, C. Chang, D. P. McDonnell, A. Berchuck, J. A. Elvin*
- Board 318 **Abstract 5591: A 12 multigene NGS panel to characterize molecular biotypes in endometrial cancer.** *I. Romero, R. L. Reig, A. Fernandez-Serra, Z. Garcia-Casado, C. Zorrero, C. Illueca, A. Poveda, J. A. Lopez-Guerrero*
- Board 319 **Abstract 5592: Patterns of care and survival outcomes of stage IIIA endometrial cancer: An analysis of the National Cancer Database.** *S. Yan, S. Wu, L. R. Boyd, G. Salame, P. B. Schiff, S. C. Lymberis*
- Board 320 **Abstract 5593: Quality of life (QoL) in a phase III trial of pelvic external beam radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk, early stage endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group study.** *V. Vongruenigen, H. Q. Huang, D. Cella, M. Randall, R. S. Mannel, B. Kim, R. Salani, J. J. Burke II, T. J. Rutherford, N. Spirtos, K. Robison, L. B. Wenzel*
- Board 321 **Abstract 5594: Efficacy and safety of nivolumab (Nivo) in patients (pts) with advanced or recurrent uterine cervical or corpus cancers.** *K. Hasegawa, K. Tamura, N. Katsumata, K. Matsumoto, S. Takahashi, H. Mukai, H. Nomura, H. Minami*
- Board 322 **Abstract 5595: Immune profile and outcomes of patients (pts) with gynecological malignancies (GYN) enrolled in early phases immunotherapy (IO) trials.** *V. Rodriguez Freixinos, A. Garcia, R. Fasani, J. Castellvi, F. Ruiz-Pace, C. Viaplana, L. Fariñas-Madrid, C. Casal, I. Matos, J. Martin-Liberal, I. Braña, C. Hierro, J. Jimenez, E. Garralda, P. Nuciforo, R. Dienstmann, A. Oaknin*
- Board 323 **Abstract 5596: Lenvatinib + pembrolizumab in patients with advanced endometrial cancer: Updated results.** *V. Makker, D. W. Rasco, N. J. Vogelzang, M. Messing, M. S. Brose, A. L. Cohn, C. Aghajanian, D. E. Stepan, C. E. Dutcus, E. V. Schmidt, M. Guo, P. Sachdev, R. C. Shumaker, M. H. Taylor*

- Board 324 Abstract 5597: Biomarker results and preclinical rationale for combination lenvatinib and pembrolizumab in advanced endometrial carcinoma.** *V. Makker, A. L. Cohn, M. H. Taylor, Y. Minoshima, Y. Kato, R. Dairiki, M. Kanekiyo, A. Yachie, K. Kodama, P. Sachdev, J. Matsui, Y. Funahashi, D. W. Rasco*
- Board 325 Abstract 5598: Preoperative olaparib in early-stage endometrial cancer (EC): A phase 0, window of opportunity trial to evaluate the PARP inhibition effect, targeting cell cycle-related proteins (POLEN study).** *I. Romero, M. Rubio, M. Medina, R. Serrano, E. Guerra, A. C. Salgado, B. Pérez, L. Minig, A. Casado, P. Coronado, J. F. Cueva, A. Vilar, A. Torné, J. Ordi, S. Cros, G. Salinas, M. Santacana, J. Schoenenberger-Arnaiz, A. Llombart-Cussac, A. Poveda*
- Board 326 Abstract 5599: Variability in Medicare utilization and payment among gynecologic oncologists.** *S. Lim, A. Puechl, G. Broadwater, J. Ehrisman, A. Lorenzo, J. Foote, B. A. Davidson, J. P. Chino, L. J. Havrilesky*
- Board 327a Abstract TPS5600: GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ 2 line recurrent or metastatic cervical cancer.** *K. S. Tewari, I. Vergote, A. Oaknin, E. Alvarez, D. M. Chase, S. Gaillard, S. Lheureux, D. Rischin, A. Santin, M. Feng, M. Mathias, M. G. Fury, I. Lowy, B. J. Monk*
- Board 327b Abstract TPS5601: A single arm, phase 2, multicenter, international trial of tisotumab vedotin (HuMax-TF-ADC) in previously treated, recurrent or metastatic cervical cancer.** *R. L. Coleman, N. Concin, T. J. Herzog, L. L. Woelber, M. R. Mirza, B. J. Monk, D. Cibula, D. Lorusso, A. González-Martín, K. Windfeld, J. Lammerts van Bueren, S. Vindeloev, R. A. Rangwala, I. Vergote*
- Board 328a Abstract TPS5602: SENTICOL III: International validation study of sentinel node biopsy in early cervical cancer: A GINECO, ENGOT and GCIG study.** *F. Lecuru, M. McCormack, P. Hillemanns, A. Anota, M. M. Leitao, P. Mathevet, R. P. Zweemer, K. Fujiwara, V. Zanagnolo, A. Zahl Eriksson, E. Hudson, G. Ferron, M. Plante*
- Board 328b Abstract TPS5603: A randomized phase II/III trial of conventional paclitaxel and carboplatin (cTC) versus dose-dense paclitaxel and carboplatin (ddTC), with or without bevacizumab (Bmab), for stage IVb, recurrent, or persistent cervical cancer (CC): Japan Clinical Oncology Group study (JCOG1311).** *R. Kitagawa, M. Ishikawa, T. Shibata, K. Miyamoto, H. Kobayashi, T. ONDA, M. Takekuma, F. Takahashi, H. Yokota, M. Tanikawa, M. Mizuno, T. Oishi, Y. Aoki, S. Nishio, T. Iwata, N. Yaegashi*
- Board 329a Abstract TPS5604: A phase 2, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma.** *A. A. Jazaeri, R. P. Edwards, R. M. Wenham, K. MATSUO, G. F. Fleming, D. M. O'Malley, B. M. Slomovitz, B. J. Monk, R. J. Brown, S. Suzuki, I. Gorbachevsky, M. Fardis, E. Zsiros*
- Board 329b Abstract TPS5605: EDMOND: A feasibility study of elemental diet as an alternative to parenteral nutrition for ovarian cancer patients with inoperable malignant bowel obstruction.** *A. Michael, E. Smith, A. Hugg, T. Kilpatrick*
- Board 330a Abstract TPS5606: OVARIO: The phase 2, single-arm, open-label study of maintenance therapy with niraparib + bevacizumab in patients with advanced ovarian cancer following response on frontline platinum-based chemotherapy.** *J. M. Hope, J. Chen, M. Wainszelbaum, D. Gupta*
- Board 330b Abstract TPS5607: ATALANTE (ENGOT-ov29): A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab.** *J. Kurtz, C. Marth, A. Oaknin, B. Asselain, K. H. Baumann, D. Cibula, I. Vergote, T. Levy, E. Pujade-Lauraine*

Monday, June 4, 2018

- Board 331a **Abstract TPS5608: An open-label phase 1 trial of the safety and efficacy of daily subcutaneous SPL-108 injections when used in combination with paclitaxel in patients with platinum-resistant, CD44+, advanced ovarian epithelial cancer.** *E. Girda, A. Buckley de Meritens, M. Finlayson, A. Leiser, D. Nelson, M. H. Silverman, R. Stephenson, L. Rodriguez-Rodriguez*
- Board 331b **Abstract TPS5609: Clinical trial in progress: A study of VB-111 combined with paclitaxel vs. paclitaxel for treatment of recurrent platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).** *R. T. Penson, K. N. Moore, T. J. Herzog, R. A. Burger, L. S. Freedman, N. Lowenton-Spier, D. Harats, N. Sher, Y. C. Cohen, B. J. Monk*
- Board 332a **Abstract TPS5610: A multicentric single-arm phase II clinical trial to evaluate safety and efficacy of the combination of olaparib and PLD for platinum resistant ovarian primary peritoneal carcinoma and fallopian tube cancer patients: The GEICO-1601 ROLANDO trial—A trial in resistant ovarian cancer with olaparib and pegylated liposomal doxorubicin.** *J. A. Perez-Fidalgo, U. Bohn, E. Calvo, Y. Garcia Garcia, E. Guerra, M. Iglesias, L. Manso, A. Santaballa, A. González-Martín*
- Board 332b **Abstract TPS5611: A phase Ib trial of pembrolizumab (Pembro) following adoptive cell therapy (ACT) in patients with platinum-resistant ovarian cancer; The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) trial.** *J. Ethier, L. Bonilla, S. Boross-Harmer, G. Bouchard-Fortier, J. Cipollone, B. A. Clarke, N. C. Dhani, A. M. Easson, N. Franke, D. P. Goldstein, S. Lheureux, H. Majeed, T. May, M. Reedijk, M. Rouzbahman, S. Saibil, P. A. Shaw, P. S. Ohashi, L. T. Nguyen, M. O. Butler*
- Board 333a **Abstract TPS5612: PRO-105, a phase II open-label study of NUC-1031 in patients with platinum-resistant ovarian cancer.** *C. Gourley, H. J. Dalton, S. N. Banerjee, J. Buscema, M. Lockley, J. Krell, B. J. Monk*
- Board 333b **Abstract TPS5613: Phase II study of neoadjuvant IGFBP-2 vaccination with neoadjuvant carboplatin and paclitaxel in advanced ovarian cancer.** *W. R. Gwin, J. Childs, D. Higgins, H. Shakalia, J. B. Liao, M. L. Disis*
- Board 334a **Abstract TPS5614: INNOVATE-3: Phase 3 randomized, international study of tumor treating fields (200 kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer.** *E. D. Kirson, M. Giladi, Z. Bomzon, U. Weinberg, O. Farber*
- Board 334b **Abstract TPS5615: STATEC: A randomised trial of non-selective versus selective adjuvant therapy in high risk apparent stage 1 endometrial cancer.** *T. Mould, A. Brand, H. Nijman, J. A. Ledermann, R. J. Edmondson, J. Twigg, E. Hudson, C. L. Creutzberg, N. Singh, R. Ganesan, A. Feeney, L. Farrelly, L. Hughes, A. Hackshaw, A. Sharp, P. Kok, H. C. Kitchener*

1:15 PM - 4:45 PM Poster Session

Melanoma/Skin Cancers

Location: Hall A

Abstracts on Boards 335-346 will be discussed during the Melanoma/Skin Cancers Poster Discussion Session.

Posters by Topic

Advanced Disease: Boards 337-344, 346-400

Biomarkers/Epidemiology/Outcomes: Boards 345, 401-415

Local-Regional: Boards 335, 336, 416-421

Trials in Progress: Boards 422a-428b

- Board 335 Abstract 9508: Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL).** *R. I. Andtbacka, R. Dummer, D. E. Gyorki, A. C. Berger, R. M. Conry, L. V. Demidov, E. Chan, S. Treichel, M. B. Faries, M. I. Ross*
- Board 336 Abstract 9509: Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study).** *L. Mortier, N. Bertrand, N. Basset-Seguin, P. Saiag, A. Dupuy, S. Dalac-Rat, B. Guillot, C. Templier, E. Desmedt, A. Duhamel, P. Guerreschi*
- Board 337 Abstract 9510: Neoadjuvant (neo) immune checkpoint blockade (ICB) in patients (Pts) with high-risk resectable metastatic melanoma (MM).** *R. N. Amaria, S. M. Reddy, H. A. Tawbi, M. A. Davies, M. I. Ross, I. C. Glitza, J. N. Cormier, C. M. Lewis, W. Hwu, E. Y. Hanna, A. Diab, M. K. Wong, R. E. Royal, N. D. Gross, R. S. Weber, S. Y. Lai, R. A. Ehlers Jr., E. M. Burton, M. T. Tetzlaff, J. A. Wargo*
- Board 338 Abstract 9511: Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study.** *A. Daud, M. N. Saleh, J. Hu, J. S. Bleeker, M. J. Riese, R. Meier, L. Zhou, G. Serbest, K. D. Lewis*
- Board 339 Abstract 9512: Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.** *Y. Zakharia, O. Rixe, J. H. Ward, J. J. Drabick, M. F. Shaheen, M. M. Milhem, D. Munn, E. P. Kennedy, N. N. Vahanian, C. J. Link, R. R. McWilliams*
- Board 340 Abstract 9513: Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.** *A. Ribas, M. M. Milhem, C. J. Hoimes, A. Amin, I. Mehmi, C. D. Lao, R. M. Conry, M. F. Shaheen, S. Jang, A. K. Salama, S. Deva, T. M. Medina, E. V. Schmidt, A. C. Leung, B. Xing, R. Janssen, G. V. Long*
- Board 341 Abstract 9514: Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel).** *D. Olson, J. J. Luke, S. Hallmeyer, M. Bajaj, T. Carll, T. Krausz, Y. Zha, T. Karrison, B. Brockstein, V. K. Sondak, Z. Eroglu, T. Gajewski, N. I. Khushalani*
- Board 342 Abstract 9515: A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma.** *A. Diab, S. Rahimian, C. L. Haymaker, C. Bernatchez, R. I. Andtbacka, M. James, D. B. Johnson, J. Markowitz, R. Murthy, I. Puzanov, M. F. Shaheen, S. Swann*
- Board 343 Abstract 9516: 5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.** *O. Hamid, C. Robert, A. Daud, F. S. Hodi, W. Hwu, R. Kefford, J. D. Wolchok, P. Hersey, R. W. Joseph, J. S. Weber, R. S. Dronca, T. C. Mitchell, A. Patnaik, H. M. Zarour, A. M. Joshua, E. Jensen, N. Ibrahim, S. Ahsan, A. Ribas*
- Board 344 Abstract 9517: Utility of 1-year FDG-PET (PET) to determine outcomes from anti-PD-1 (PD1) based therapy in patients (pts) with metastatic melanoma (MM).** *A. C. Tan, L. Emmett, S. Lo, V. Liu, A. D. Guminski, G. V. Long, A. M. Menzies*
- Board 345 Abstract 9518: Transcriptomic and immunophenotypic profiles of melanoma tissue from patients (pts) treated with anti-PD-1 +/- ipilimumab to define mechanisms of response and resistance.** *T. N. Gide, C. Quek, A. M. Menzies, J. Madore, R. Velickovic, M. Wongchenko, Y. Yan, M. S. Carlino, A. D. Guminski, R. Saw, I. Silva, U. Palendira, J. F. Thompson, R. A. Scolyer, G. V. Long, J. S. Wilmott*
- Board 346 Abstract 9519: Primary analysis of phase 2 results for cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC).** *D. Rischin, M. R. Migden, A. Chang, C. H. Chung, L. Dunn, A. Guminski, A. Hauschild, L. Hernandez-Aya, B. G. Hughes, K. D. Lewis, A. M. Lim, B. Modi, D. Schadendorf, C. Schmults, J. Booth, S. Li, K. K. Mohan, E. Stankevich, I. Lowy, M. G. Fury*

Monday, June 4, 2018

- Board 347 **Abstract 9520: Ipilimumab combined with stereotactic radiosurgery in melanoma patients with brain metastases: A multicenter, open label, phase 2 trial.** *L. Mortier, P. Jamme, J. P. Lacour, C. Robert, T. Lesimple, L. Thomas, L. Machet, P. Saiag, C. Lebbe, C. Dutriaux, J. Grob, A. Duhamel, E. Desmedt, C. Templier, X. Mirabel, N. Reyens, E. Le Rhun*
- Board 348 **Abstract 9521: Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: Overall survival findings.** *T. Sato, P. D. Nathan, L. Hernandez-Aya, J. J. Sacco, M. M. Orloff, J. Visich, N. Little, A. Hulstine, C. M. Coughlin, R. D. Carvajal*
- Board 349 **Abstract 9522: Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAF^{V600} mutation-positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study.** *B. Dreno, P. A. Ascierto, G. A. McArthur, V. Atkinson, G. Liskay, A. M. Di Giacomo, M. Mandalà, L. V. Demidov, D. Stroyakovskiy, L. Thomas, L. De la Cruz-Merino, C. Dutriaux, C. Garbe, I. A. Rooney, J. J. Hsu, E. Park, A. Ribas, J. M. Larkin*
- Board 350 **Abstract 9523: Comprehensive genomic profiling of advanced Merkel cell carcinoma to reveal insights into immunotherapy response.** *T. C. Knepper, J. S. Russell, M. Montesion, E. Sokol, G. M. Frampton, P. Stephens, L. A. Albacker, M. J. Schell, J. A. DeCaprio, K. Y. Tsai, A. S. Brohl*
- Board 351 **Abstract 9524: Association between hospital volume and overall survival (OS) of stage 3 and 4 cutaneous malignant melanoma (MMel).** *A. Kommalapati, S. Tella, A. Ganti, A. S. Marr*
- Board 352 **Abstract 9525: Interim analysis of a prospective, randomized, double blind, placebo controlled, phase IIb trial of the TLPLDC vaccine to prevent recurrence in resected stage III or IV melanoma patients.** *J. W. Myers, G. T. Clifton, D. F. Hale, T. A. Brown II, T. J. Vreeland, R. I. Andtbacka, A. C. Berger, J. W. Jakub, J. J. Sussman, A. M. Terando, M. B. Faries, G. E. Peoples*
- Board 354 **Abstract 9527: Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study.** *J. C. Becker, J. C. Hassel, C. Menzer, K. C. Kähler, T. K. Eigentler, F. E. Meier, C. Berking, R. Gutzmer, P. Mohr, F. Kiecker, M. Kaatz, C. Windemuth-Kieselbach, C. Lorenz-Schlüter, L. Zimmer, S. Ugurel, D. Schadendorf*
- Board 355 **Abstract 9528: A phase Ib study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) combination with axitinib in patients with metastatic mucosal melanoma.** *J. Guo, X. Sheng, L. Si, Y. Kong, Z. Chi, C. Cui, B. Tang, X. Yan, L. L. Mao, B. Lian, X. Wang, S. Li, L. Zhou, X. Bai, J. Dai*
- Board 356 **Abstract 9529: Prediction of response and toxicity to immune checkpoint inhibitor therapies (ICI) in melanoma using deep neural networks machine learning.** *Z. Dawood, N. Coudray, R. H. Kim, S. Nomikou, U. Moran, J. S. Weber, A. C. Pavlick, M. Wilson, A. Tsirigos, I. Osman*
- Board 357 **Abstract 9530: Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma progressing on or after a PD-1/L1 blocking antibody.** *S. S. Agarwala, S. J. Moschos, M. L. Johnson, M. Opyrchal, D. Gabrilovich, P. Danaher, F. Wang, S. Brouwer, P. Ordentlich, S. Sankoh, E. V. Schmidt, M. L. Meyers, R. J. Sullivan*
- Board 358 **Abstract 9531: Treatment-free survival (TFS), a novel outcome applied to immuno-oncology (IO) agents in advanced melanoma (AM).** *M. M. Regan, L. Werner, A. A. Tarhini, S. Rao, K. Gupte-Singh, C. Ritchings, M. B. Atkins, D. F. McDermott*
- Board 359 **Abstract 9532: Activity of targeted therapy after failure of first-line immunotherapy in BRAF-mutant metastatic melanoma.** *C. Y. Xia, D. Y. Wang, R. Mason, J. L. Smith, M. A. McKean, S. Lo, A. D. Guminski, G. V. Long, M. S. Carlino, V. Atkinson, M. Millward, J. L. McQuade, R. N. Amaria, D. B. Johnson, A. M. Menzies*

- Board 361 Abstract 9534: Pembrolizumab as first line therapy in patients with unresectable squamous cell carcinoma of the skin: Interim results of the phase 2 CARSKIN trial.** *E. Maubec, M. Boubaya Sr., P. Petrow, N. Basset-Seguin, J. Grob, B. Dreno, I. Scheer-Senyarich Sr., S. Helfen Sr., J. De Quatrebarbes, E. Poirier, L. Deschamps, C. Alloux, I. Lope, S. Cherbal, M. T. Leccia, M. Beylot-Barry, F. Grange, O. Schischmanoff, A. Tibi, V. Levy*
- Board 362 Abstract 9535: Radioembolization for treatment of uveal melanoma hepatic metastasis: Results of a phase II, single institution, prospective trial.** *C. F. Gonsalves, D. J. Eschelman, R. D. Adamo, P. R. Anne, M. M. Orloff, T. Sato*
- Board 363 Abstract 9536: Relapse after cessation of PD-1 based therapy for complete responders in metastatic melanoma.** *K. Nguyen, R. Mason, R. Ladwa, L. Warburton, M. Millward, A. M. Haydon, M. S. Carlino, J. L. Smith, V. Atkinson*
- Board 364 Abstract 9537: Second-line avelumab treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from a global expanded access program (EAP).** *J. Walker, V. Kasturi, C. Lebbe, S. K. Sandhu, G. Grignani, M. G. Hennessy, S. Hildemann, J. Reed, S. Hariharan*
- Board 365 Abstract 9538: Clinical and economic outcomes associated with sequential treatment in BRAF mutant advanced melanoma patients.** *A. A. Tarhini, D. F. McDermott, A. Ambavane, K. Gupte-Singh, C. Ritchings, V. Aponte-Ribero, A. Benedict, S. Rao, M. M. Regan, M. B. Atkins*
- Board 366 Abstract 9539: A phase II study of JS001, a humanized PD-1 mAb, in patients with advanced melanoma in China.** *Z. Chi, B. Tang, X. Sheng, L. Si, C. Cui, Y. Kong, Y. Chen, S. Qin, J. Chen, D. Wu, X. Song, X. Yan, J. Yu, J. Guo*
- Board 367 Abstract 9540: Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who have received PD-1 based therapy.** *K. Saab, M. Mooradian, D. Y. Wang, J. Chon, C. Y. Xia, A. Bialczak, K. Abbate, A. M. Menzies, D. B. Johnson, R. J. Sullivan, A. N. Shoushtari*
- Board 368 Abstract 9541: Efficacy and genetic analysis for a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic immunotherapy, and ipilimumab combination treatment in patients with stage IIIb-IV unresectable or metastatic melanoma.** *R. I. Andtbacka, M. I. Ross, S. S. Agarwala, M. H. Taylor, J. T. Vetto, R. I. Neves, A. Daud, H. T. Khong, R. S. Ungerleider, M. Tanaka*
- Board 369 Abstract 9542: BRAF/MEK inhibition in melanoma patients with rare BRAF mutations.** *J. C. Hassel, C. Menzer, A. M. Menzies, M. S. Carlino, G. V. Long, R. Kefford, T. K. Eigentler, D. B. Johnson, M. Schlaak, F. Meiss, B. Schilling, R. Gutzmer, C. Pföhler, F. E. Meier, L. Zimmer, T. Haalck, K. Thoms, A. Kopp-Schneider, A. Enk*
- Board 370 Abstract 9543: Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma (cSCC).** *R. R. Kudchadkar, M. L. Yushak, D. H. Lawson, K. A. Delman, M. C. Lowe, M. Goings, S. McBrien, M. Mckellar, K. Sieja, N. Maynard, M. Ford, B. P. Pollack*
- Board 372 Abstract 9545: Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy.** *H. C. Dearden, L. Au, D. Y. Wang, L. Zimmer, Z. Eroglu, J. L. Smith, M. Curvietto, C. Khoo, V. Atkinson, S. Lo, A. Guminski, G. V. Long, S. K. Sandhu, P. A. Ascierto, M. S. Carlino, D. B. Johnson, J. M. Larkin, A. M. Menzies*
- Board 373 Abstract 9546: Ipilimumab and radiation in patients with unresectable melanoma brain metastases: A multicenter, open label, phase-2, Spanish Melanoma Group (GEM) study (NCT-2013-001132-22).** *J. A. Lopez-Martin, A. M. Arance, L. De La Cruz-Merino, A. Illescas, I. Valduvico, A. Berrocal, J. López Torrecilla, I. Marquez Rodas, M. Curiel Garcia, V. Soriano, A. Alvarez, M. Chust Vicente, D. Rodriguez-Abreu, M. Peñas Sanchez, E. Muñoz-Couselo, J. Aristu, A. Gomez Caamaño, S. Martin-Algarra*
- Board 374 Abstract 9547: Sex differences in tolerability to Anti-PD1 therapy: Are we all equal?** *N. Duma, J. Paludo, E. A. Enninga, S. Yadav, J. Vera-Aguilera, L. A. Kottschade, H. Dong, A. A. Adjei, R. S. Dronca*

Monday, June 4, 2018

- Board 375 **Abstract 9548: A randomized phase Ib/II study of the selective small molecule axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma.** *O. Straume, C. Schuster, G. Gausdal, J. Lorens, B. T. Gjertsen*
- Board 376 **Abstract 9549: Outcomes of metastatic melanoma (MM) patients (pts) after discontinuation of anti-Programmed-Death 1 (PD1) therapy without disease progression.** *G. Schvartsman, J. Ma, R. L. Bassett Jr., L. E. Haydu, R. N. Amaria, P. Hwu, W. Hwu, A. Diab, S. P. Patel, M. K. Wong, S. E. Woodman, M. A. Davies, I. C. Glitza, H. A. Tawbi*
- Board 377 **Abstract 9550: Phase 1 study to evaluate safety and efficacy of nivolumab (nivo) + ipilimumab (ipi) + external beam radiotherapy (RT) in patients with metastatic melanoma.** *M. A. Postow, S. J. Knox, D. Goldman, K. Panageas, D. Halpenny, D. McCabe, M. J. Macri, P. Schwarzenberger, T. Ricciardi, A. Ryan, R. R. Venhaus, C. A. Barker*
- Board 378 **Abstract 9551: 42-month follow-up of sonidegib efficacy and safety in advanced basal cell carcinoma: Final analysis from BOLT.** *M. R. Migden, K. D. Lewis*
- Board 379 **Abstract 9552: Characterization of complete responders to combination nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with advanced, unresectable melanoma.** *A. Betof Warner, A. N. Shoushtari, S. Houghton, K. Panageas, P. B. Chapman, J. D. Wolchok, M. A. Postow*
- Board 380 **Abstract 9553: Distinct patterns of response and toxicity (tox) by sites of metastases (mets) in patients (pts) treated with ipilimumab combined with PD-1 antibodies (ipi+PD1).** *I. E. Pires Da Silva, S. Lo, M. Gonzalez, A. Guminski, G. V. Long, A. M. Menzies*
- Board 381 **Abstract 9554: Off treatment survival (OTS) in patients (pts) with advanced melanoma after anti-PD1 therapy.** *S. A. Christiansen, D. Swoboda, K. Gardner, S. Rapisuwon, M. B. Atkins, G. T. Gibney*
- Board 382 **Abstract 9555: Impact of simultaneous radiotherapy in melanoma patients treated with pembrolizumab in the French early access program.** *P. Saiag, L. Mortier, C. Dutriaux, L. Benmahammed, O. Morsli, A. Tadmouri, C. Hunault, M. T. Leccia, N. Meyer*
- Board 383 **Abstract 9556: Survivorship experience for patients (pts) with metastatic melanoma (MM) on long-term targeted therapy (TT).** *C. C. Khoo, J. E. Lai-Kwon, S. Lo, D. Milne, M. Mohamed, J. Raleigh, K. M. Smith, M. Jefford, S. K. Sandhu*
- Board 384 **Abstract 9557: Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data.** *T. K. Owonikoko, K. P. Papadopoulos, M. L. Johnson, M. Gil Martin, V. Moreno, A. K. Salama, E. Calvo, N. S. Yee, H. Safran, A. González-Martín, R. Aljumaily, D. Mahadevan, J. Niu, K. K. Mohan, J. Li, E. Stankevich, I. Lowy, M. G. Fury, H. M. Babiker*
- Board 385 **Abstract 9558: Chemoimmunotherapy combination after PD-1 inhibitor failure to improve clinical outcomes in metastatic melanoma patients.** *J. Vera Aguilera, J. Paludo, A. Bangalore, J. Failing, R. R. McWilliams, L. A. Kottschade, M. S. Block, S. Markovic, R. S. Dronca, Y. Yan*
- Board 386 **Abstract 9559: Analysis of the kinetics and effects of vemurafenib (V) + cobimetinib (C) on intratumoral and host immunity in patients (pts) with BRAFV600 mutant melanoma (BRAFM): Implications for combination with immunotherapy.** *S. Rapisuwon, C. L. Slingsluff Jr., J. A. Wargo, R. J. Sullivan, B. Izar, I. S. Maudlin, G. T. Gibney, W. B. Al-Refaie, B. Haley, M. B. Atkins*
- Board 387 **Abstract 9560: Safety and preliminary activity data from a single center phase II study of triplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [trident] in patients (Pts) with BRAF-mutated metastatic melanoma (MM).** *H. A. Tawbi, R. N. Amaria, I. C. Glitza, D. Milton, W. Hwu, S. P. Patel, M. K. Wong, C. Yee, S. E. Woodman, J. L. McQuade, P. Hwu, K. Perdon, M. Shephard, E. M. Burton, J. A. Wargo, M. A. Davies*

- Board 388 Abstract 9561: Tumor mutational burden, clinical features, and outcomes to PD-1 mono- and combination therapy in patients with cutaneous and unknown primary melanoma.** *A. N. Shoushtari, J. Armenia, A. Arora, J. Rojas-Zamalloa, A. Betof Warner, M. Derr, M. A. Postow, M. K. Callahan, P. Momtaz, D. G. Coit, M. S. Brady, C. E. Ariyan, S. Nair, K. J. Busam, P. B. Chapman, N. Schultz, J. D. Wolchok*
- Board 389 Abstract 9562: Association of body mass index (BMI) with overall survival (OS) in metastatic melanoma (MM) patients (pts) treated with combined anti-CTLA4 + anti-PD1.** *J. L. McQuade, A. Betof Warner, M. Li, J. Chon, L. E. Haydu, C. Daniel-MacDougall, K. R. Hess, D. B. Johnson, A. M. Menzies, M. A. Davies, A. N. Shoushtari*
- Board 390 Abstract 9563: HORIZON: A French descriptive cohort of 663 patients treated for melanoma with pembrolizumab with a focus on the mucosal subgroup (n=59).** *C. Dutriaux, N. Meyer, P. Saiag, E. Boos, C. Hunault, L. Benmahammed, L. Mortier*
- Board 391 Abstract 9564: Immune checkpoint inhibition (ICI) in advanced cutaneous squamous cell carcinoma (cSCC): Clinical response and correlative biomarker analysis.** *J. Park, L. J. Wirth, K. Flaherty, D. P. Lawrence, S. Demehri, S. Kraft, R. Foreman, J. R. Clark, J. V. Cohen, Y. Kim, G. M. Boland, D. T. Frederick, R. J. Sullivan*
- Board 393 Abstract 9566: Treatment of metastatic uveal melanoma (mUM) directed by a comprehensive molecular tumour analysis program (CMTA).** *S. Leyvraz, T. Kessler, M. Schütte, M. Lamping, S. Burock, S. Ochsenreither, V. Amstislavskiy, C. Wierling, K. Jöhrens, F. Klauschen, C. Peuker, F. Kiecker, R. Schäfer, B. Lange, H. Lehrach, A. Joussem, D. T. Rieke, K. F. Klinghammer, U. Keilholz, M. Yaspo*
- Board 394 Abstract 9567: Adverse events of special interest in the phase 3 COLUMBUS study.** *H. Gogas, R. Dummer, P. A. Ascierto, A. M. Arance, M. Mandalà, G. Liszkay, C. Garbe, D. Schadendorf, I. Krajsova, R. Gutzmer, V. Chiarion-Sileni, C. Dutriaux, J. de Groot, N. Yamazaki, C. Loquai, L. A. De Parseval, M. D. Pickard, A. Gollerkeri, C. Robert, K. Flaherty*
- Board 395 Abstract 9568: Multi-spatial whole-lesion molecular heterogeneity of an immunotherapy-resistant metastatic melanoma.** *A. Mitra, W. Roh, A. Reuben, M. Macedo, F. C. Carapeto, C. Gumbs, J. Zhang, S. E. Woodman, P. Hwu, W. Hwu, A. J. Lazar, J. A. Wargo, P. A. Futreal*
- Board 396 Abstract 9569: Immune checkpoint inhibitor (ICI) treatment in advanced melanoma (aMel) patients (pts) with renal or hepatic dysfunction (dysf): Real-world patient characteristics and outcomes.** *S. Spillane, A. P. Abernethy, N. R. Brown, A. N. Freedman, D. Lenis, K. Maignan, A. Mariotto, R. A. Micksad, A. Z. Torres, E. Sharon*
- Board 397 Abstract 9570: Characterization and spatial localization of the tumor immune microenvironment in metastatic uveal melanoma.** *K. M. Komatsubara, R. D. Gartrell, C. Bayan, J. S. Pradhan, S. Hasan, T. D. Hart, M. Borgardus, Y. Lu, D. K. Marks, J. Yang, A. Lopez, C. Chiuzan, B. Horst, B. Taback, L. J. Geskin, B. P. Marr, G. K. Schwartz, Y. M. Saenger, R. D. Carvajal*
- Board 398 Abstract 9571: Factors predicting the use of immunotherapy for patients with advanced melanoma.** *R. W. Joseph, A. Shillington, C. Macahilig, S. J. Diede, V. Dave, Q. Harshaw, F. Liu*
- Board 399 Abstract 9572: Perilesional edema and blood vessel characteristics in brain metastases and implications for treatment with immune therapy.** *T. Tran, L. Jilaveanu, A. Mahajan, S. B. Goldberg, D. Nguyen, V. Chiang, H. M. Kluger*
- Board 400 Abstract 9573: Effects of sonidegib dose reduction or delay in locally advanced basal cell carcinoma: 42-month data from BOLT.** *K. D. Lewis, M. R. Migden*

Monday, June 4, 2018

- Board 401 **Abstract 9574: Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial.** *R. Dummer, A. Hauschild, M. Santinami, V. Atkinson, M. Mandalà, V. Chiarion-Sileni, J. M. Larkin, M. Nyakas, C. Dutriaux, A. M. Haydon, C. Robert, D. Schadendorf, P. Aimone, B. Mookerjee, C. D. Campbell, J. Garrett, J. Brase, R. Kefford, J. M. Kirkwood, G. V. Long*
- Board 402 **Abstract 9575: Gut microbiome and immunotherapy response in melanoma patients.** *B. Peters, M. Wilson, U. Moran, A. C. Pavlick, A. Izsak, T. Wechter, J. S. Weber, I. Osman, J. Ahn*
- Board 403 **Abstract 9576: Validation of a prognostic 53-immune-gene panel in stage II/III melanoma.** *M. Borgardus, R. D. Gartrell, D. K. Marks, C. L. Esancy, S. Pabla, M. S. Ernstoff, J. M. Kirkwood, R. R. Chang, B. Taback, S. J. Lee, J. Krolewski, C. Morrison, Y. M. Saenger*
- Board 404 **Abstract 9577: A multi-gene risk signature for improved identification of cutaneous squamous cell carcinoma (cSCC) patients with a high risk of recurrence.** *C. Schmults, S. T. Arron, A. Wysong, K. R. Covington, R. W. Cook, J. Newman*
- Board 405 **Abstract 9578: Time to treatment failure (TTF) as a potential clinical endpoint in real-world evidence (RWE) studies of melanoma.** *R. Sridhara, J. Zhou, M. R. Theoret, P. S. Mishra-Kalyani*
- Board 406 **Abstract 9579: Blood-based multiplex kinase activity profiling as a predictive marker for clinical response to checkpoint blockade in advanced melanoma.** *D. Hurkmans, E. M. Verdegaal, S. A. Schindler, E. A. Basak, D. M. van den Heuvel, R. de Wijn, R. Ruijtenbeek, J. P. Groten, R. Dummer, S. L. Koolen, M. J. Welters, R. H. Mathijssen, E. Kapiteijn, J. G. Aerts, M. P. Levesque, S. H. van der Burg*
- Board 407 **Abstract 9580: Quantitative multiplex immunofluorescence (qmIF) and genomic evaluation of tumor microenvironment (TME) to identify candidate biomarkers in stage II/III melanoma.** *R. D. Gartrell, D. K. Marks, T. D. Hart, Y. Lu, C. L. Esancy, Z. Blake, B. Taback, B. Horst, Y. M. Saenger*
- Board 408 **Abstract 9581: Phylogenetic analysis of longitudinal melanoma samples to reveal convergent evolution and markers of immunotherapy resistance.** *D. Liu, G. Zhang, A. Shi, B. Izar, A. Heyde, G. G. Kasumova, D. T. Frederick, T. Moll, A. Sahu, E. Ruppin, M. Nowak, M. Kellis, M. Herlyn, D. P. Lawrence, K. Flaherty, E. M. Van Allen, R. J. Sullivan, G. M. Boland*
- Board 409 **Abstract 9582: Impact of a gene expression profiling risk score and web-based melanoma outcome calculator on the precision of AJCC-based prognostic assessment.** *G. Brunner, J. Schmitz, M. Borowski*
- Board 410 **Abstract 9583: Performance of a 31-gene expression profile melanoma test in clinically relevant clinicopathologic subgroups.** *B. Gastman, S. Kurley, K. R. Covington, R. W. Cook*
- Board 411 **Abstract 9584: Mutation burden in conjunction with MAPK-pathway mutation status as a prognostic biomarker of overall melanoma survival.** *J. Cadley, D. Simpson, R. Ferguson, A. Pandya, T. Hekal, T. Richards, K. Ibrahim, J. S. Weber, I. Osman, T. Kirchoff*
- Board 412 **Abstract 9585: Immune gene profiling of pretreatment tumor samples in “real-world” advanced melanoma patients treated with anti-PD-1 and/or anti-CTLA-4.** *E. A. Rozeman, M. H. Geukes Foppen, S. Ong, R. Lacroix, P. Danaher, A. Broeks, A. Cesano, S. Wilgenhof, J. V. Van Thienen, J. B. Haanen, S. Warren, C. U. Blank*
- Board 413 **Abstract 9586: Surveillance for melanoma (MEL): Results of a database study of stage I-III MEL.** *C. Rearick, F. Ding, Y. Lin, A. Rose, C. Sander, M. Davis, P. V. Benos, H. A. Tawbi, A. A. Tarhini, J. M. Kirkwood, D. Davar*
- Board 414 **Abstract 9587: Comprehensive genomic profiling of metastatic cutaneous adnexal carcinomas to reveal multiple routes to targeted and immunotherapies.** *N. Girard, L. M. Gay, J. A. Elvin, J. Vergilio, J. Suh, S. Ramkissoon, S. Daniel, E. A. Severson, K. Killian, S. M. Ali, A. B. Schrock, J. Chung, J. A. Carlson, D. Jones, V. A. Miller, M. C. Mihm Jr., J. S. Ross*

- Board 415 Abstract 9588: Genetic aberrations in the CDK4 pathway and association with innate resistance to PD-1 blockade in acral melanoma.** *J. Yu, Y. Kong, Z. Chi, B. Tang, X. Sheng, L. Si, C. Cui, L. L. Mao, S. Li, B. Lian, X. Wang, X. Bai, J. Guo*
- Board 416 Abstract 9589: Phase III randomized, multicenter trial comparing high-dose IFN- α 2b with temozolomide plus cisplatin as adjuvant therapy for resected mucosal melanoma.** *B. Lian, C. Cui, X. Song, X. Zhang, D. Wu, L. Si, Z. Chi, X. Sheng, Y. Kong, L. L. Mao, L. Zhou, X. Wang, B. Tang, X. Yan, S. Li, D. Li, J. Dai, X. Bai, C. Li, J. Guo*
- Board 417 Abstract 9590: Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma.** *D. Schadendorf, A. Hauschild, M. Santinami, V. Atkinson, M. Mandalà, V. Chiarion-Sileni, J. M. Larkin, M. Nyakas, C. Dutriaux, A. Haydon, L. Mortier, C. Robert, J. Schachter, R. Ji, P. Aimone, S. Manson, R. Kefford, R. Dummer, J. M. Kirkwood, G. V. Long*
- Board 418 Abstract 9591: Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected BRAF-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification.** *J. M. Larkin, A. Hauschild, M. Santinami, V. Atkinson, M. Mandalà, V. Chiarion-Sileni, M. Nyakas, C. Dutriaux, A. Haydon, L. Mortier, C. Robert, J. Schachter, D. Schadendorf, R. Ji, P. Aimone, B. Mookerjee, R. Kefford, R. Dummer, J. M. Kirkwood, G. V. Long*
- Board 419 Abstract 9592: Liver-directed treatment for patients with uveal melanoma hepatic metastasis: A retrospective analysis of overall survival.** *R. S. Seedor, D. J. Eschelmann, C. F. Gonsalves, R. D. Adamo, M. M. Orloff, A. Amjad, E. Sharpe-Mills, R. M. Weight, A. Gradone, C. L. Shields, J. A. Shields, M. J. Mastrangelo, T. Sato*
- Board 420 Abstract 9593: Indirect treatment comparison of nivolumab versus placebo as an adjuvant therapy for resected melanoma.** *A. N. Shoushtari, M. L. Freeman, K. A. Betts, K. Gupte-Singh, E. X. Du, C. Ritchings, S. Rao*
- Board 421 Abstract 9594: Assessing the value of nivolumab (NIVO) versus placebo (PBO) and ipilimumab (IPI) as adjuvant therapy for resected melanoma.** *M. L. Freeman, A. N. Shoushtari, K. A. Betts, K. Gupte-Singh, E. X. Du, C. Ritchings, S. Rao*
- Board 422a Abstract TPS9595: A phase 2, multicenter study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of patients with metastatic melanoma.** *A. Sarnaik, B. D. Curti, D. Davar, J. M. Kirkwood, O. Hamid, J. Lutzky, M. Wilson, H. M. Kluger, E. D. Whitman, G. Q. Phan, S. S. Thomas, K. D. Lewis, H. Arkenau, J. A. Chesney, B. Larsen, I. Gorbachevsky, S. Suzuki, N. L. Samberg, M. Fardis*
- Board 422b Abstract TPS9596: Phase I/II study of the PI3K β inhibitor GSK2636771 in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss.** *H. A. Tawbi, W. Peng, D. Milton, R. N. Amaria, I. C. Glitza, W. Hwu, S. P. Patel, M. K. Wong, S. E. Woodman, C. Yee, J. L. McQuade, M. T. Tetzlaff, A. J. Lazar, S. Cain, E. M. Burton, J. H. Beumer, P. Hwu, M. A. Davies*
- Board 423a Abstract TPS9597: Combining ipilimumab (ipi) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616).** *A. M. Vanderwalde, M. Latkovic-Taber, S. Hu-Lieskovan, K. F. Grossmann, J. A. Sosman, D. Campos, M. Wu, A. Ribas*
- Board 423b Abstract TPS9598: A phase II study of study of bevacizumab (BEV) in combination with atezolizumab (ATEZO) in pts (pts) with untreated melanoma brain metastases (BEAT-MBM).** *G. Schvartsman, I. C. Glitza, D. Milton, R. N. Amaria, P. Hwu, W. Hwu, A. Diab, M. K. Wong, S. P. Patel, J. S. Wefel, E. M. Burton, C. Brown, S. E. Woodman, I. M. Beusch, C. Chung, M. A. Davies, H. A. Tawbi*

Monday, June 4, 2018

- Board 424a **Abstract TPS9599: A randomized phase II study of anti-PD1 antibody [MK-3475 (Pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced merkel cell carcinoma (Alliance A091605).** *J. J. Luke, S. J. Chmura, J. B. Allred, J. K. Salama, H. A. Al-Hallaq, C. Hsu, S. S. Yom, M. Kozloff, P. N. Munster, G. K. Schwartz*
- Board 424b **Abstract TPS9600: A randomized phase III study of duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP): Canadian Clinical Trials Group study (CCTG) ME.13.** *T. D. Baetz, X. Song, D. S. Ernst, E. McWhirter, T. M. Petrella, K. J. Savage, M. Smylie, R. Wong, C. W. Lee, N. Look Hong, D. Logan, M. S. Raza, T. Abbas, D. Nomikos, R. Leung, B. E. Chen, J. Dancey*
- Board 425a **Abstract TPS9601: Trial in progress: A phase 2 study of intratumor pil-12 plus electroporation in combination with intravenous pembrolizumab in patients with stage III/IV melanoma progressing on either pembrolizumab or nivolumab treatment (PISCES).** *R. I. Andtbacka, T. Van Hagen, P. Parente, V. Atkinson, I. Puzanov, G. A. Daniels, S. S. Thomas, A. P. Long, A. M. Haydon, A. Z. Dudek, S. E. Gargosky, C. Twitty, J. M. Kirkwood*
- Board 425b **Abstract TPS9602: Multicenter phase I/IIa study using T cell receptor gene therapy in metastatic melanoma.** *M. W. Rohaan, J. van den Berg, R. Gomez-Eerland, M. van Zon, R. de Boer, E. A. Bakker, L. M. Pronk, B. Van De Wiel, B. Nuijen, M. G. Foppen, J. V. Van Thienen, C. U. Blank, J. B. Haanen*
- Board 426a **Abstract TPS9603: Reversing resistance to PD-1 blockade by combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607 (NCT#02965716).** *S. Hu-Lieskovan, J. Moon, D. Campos, K. F. Grossmann, J. A. Sosman, C. W. Ryan, M. Wu, A. Ribas*
- Board 426b **Abstract TPS9604: Determining optimal sequencing of anti-PD-1 and BRAF-targeted therapy: A phase II randomised study of neoadjuvant pembrolizumab with/without dabrafenib and trametinib (D+T) in BRAF V600 mutant resectable stage IIIb/c/d melanoma (NeoTrio trial).** *M. Gonzalez, A. M. Menzies, R. Saw, A. J. Spillane, O. E. Nieweg, K. F. Shannon, J. F. Thompson, J. R. Howle, S. Ch'ng, J. Stretch, M. Osorio, L. Emmett, H. Rizos, A. D. Guminski, M. S. Carlino, R. A. Scolyer, G. V. Long*
- Board 427a **Abstract TPS9605: ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372.** *S. Bhatia, A. S. Brohl, I. Brownell, S. Chandra, S. Dakhil, M. S. Ernstoff, L. A. Fecher, T. Gooley, G. J. Hanna, R. Hibbert, C. M. Kelly, S. M. Kiriluk, P. Nghiem, V. Nguyen, N. Pelz, A. A. Poisson, K. A. Price, V. K. Sondak, J. A. Thompson, S. S. Tykodi*
- Board 427b **Abstract TPS9606: Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).** *E. A. Rozeman, A. C. Van Akkooi, A. M. Menzies, M. Smith, R. A. Scolyer, L. M. Pronk, M. Gonzales, C. Hoeller, J. Hansson, J. M. Larkin, G. V. Long, C. U. Blank*
- Board 428a **Abstract TPS9607: Confirmatory trial of non-amputative digit preservation surgery in subungual melanoma: JCOG1602 (J-NAIL study).** *Y. Nakamura, K. Tanaka, T. Shibata, J. Mizusawa, T. Mizutani, H. Fukuda, A. Tsutsumida, K. Namikawa, A. Takahashi, Y. Fujisawa, S. Yoshikawa, S. Matsushita, N. Yamazaki*
- Board 428b **Abstract TPS9608: SWOG S1512: A phase II and pilot trial of Pembrolizumab in patients with resectable or unresectable desmoplastic melanoma (DM).** *K. L. Kendra, J. Moon, S. Hu-Lieskovan, W. E. Carson III, D. Campos, A. Cochran, M. Wu, A. Ribas*

1:15 PM - 4:45 PM Poster Session

Patient and Survivor Care

Location: Hall A

Abstracts on Boards 1-12 will be discussed during the Patient and Survivor Care Poster Discussion Session.

Posters by Topic

End-of-Life Care: Boards 10, 12-17

Geriatric Oncology: Boards 18-37

Health Promotion: Boards 38-40

Late and Long-Term Effects: Boards 1-3, 41-67

Palliative Care and Symptom Management: Boards 4-9, 11, 77-112

Psychosocial and Communication Research: Boards 68-75

Trials in Progress: Boards 113a-116b

- Board 1** **Abstract 10013: Impact of cancer on employment and finances in young adult (YA) survivors.** *T. G. Ketterl, J. N. Casillas, P. A. Ganz, L. A. Jacobs, M. S. McCabe, S. C. Palmer, A. H. Partridge, E. Rajotte, B. C. Risendal, D. Rosenstein, K. L. Syrjala, K. S. Baker*
- Board 2** **Abstract 10014: Predictors of long-term follow-up care (LTFU) among survivors of adolescent and young adult (AYA) cancers: A population-based study in the IMPACT cohort.** *D. Kagramanov, R. Sutradhar, Z. Yao, S. Gupta, N. N. Baxter, P. C. Nathan*
- Board 3** **Abstract 10015: Risk of chronic comorbidities in survivors of adolescent and young adult cancer (AYA).** *C. Chao, L. Xu, K. L. Cannavale, F. L. Wong, P. S. Huang, R. M. Cooper, S. Bhatia, S. Armenian*
- Board 4** **Abstract 10016: Scrambler therapy for established chemotherapy-induced neuropathy: A randomized phase II trial.** *C. L. Loprinzi, J. Le-Rademacher, N. Majithia, R. McMurray, M. Bendel, A. S. Beutler, D. H. Lachance, A. L. Chevillie, D. Strick, J. C. Tilburt, T. J. Smith*
- Board 5** **Abstract 10017: Randomized, double-blind, phase III trial of monosialotetrahexosylganglioside versus placebo in GI cancer patients with oxaliplatin induced peripheral neurotoxicity (TJMUCH-GI-001).** *Z. Likun, Y. Ba, R. Liu, D. Huang, H. Li, T. Ning Sr., L. Zhang, S. Ge, M. Bai, X. Wang, R. Han, Y. Yang, Z. Gao, X. Chen, K. Niu, L. Luo, T. Deng, Y. Li*
- Board 6** **Abstract 10018: Pretreatment physical activity to predict short- and long-term chemotherapy-induced peripheral neuropathy (CIPN) in a nationwide longitudinal study of paclitaxel for breast cancer.** *I. Kleckner, E. Culakova, J. S. Gewandter, C. Fung, R. F. Dunne, L. J. Peppone, J. E. Inglis, K. Loh, L. J. Feldman, S. R. Dakhil, J. O. Hopkins, K. M. Mustian, M. C. Janelisn*
- Board 7** **Abstract 10019: Efficacy and safety of additional olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting: A randomized, double-blind, placebo-controlled, crossover study.** *V. Vimolchalao, S. Sakdejayont, P. Wongchanapai, S. Sukprakun, S. Uttamapinan, N. Sintawichai, N. Poovorawan, S. Luangdilok, N. Parinyanitikul, C. Vinayanuwattikun, V. Sriuranpong, S. Tanasanvimon*
- Board 8** **Abstract 10020: Treating anorexia in people with advanced cancer. a randomised, double blind, controlled trial of megestrol acetate, dexamethasone or placebo.** *D. C. Currey, P. A. Glare, G. Watts, S. Louw, P. Martin, K. Clark, B. Fazekas, M. Agar*
- Board 9** **Abstract 10021: Retrospective cohort study comparing hydration protocols with or without mannitol in patients treated with cisplatin (HYDRA study).** *N. LeTarte, E. Lavallée, A. Bégin, M. Monfette, É. Boudrias-Dalle, V. Samouelian, D. Soulières, J. Adam, M. Fournier*

Monday, June 4, 2018

- Board 10 **Abstract 10022: Survival of advanced cancer patients (ACP) receiving early inpatient palliative care (PC) compared to standard oncologic care (SOC) without palliative care.** *F. J. Hlubocky, J. Johnson, S. K. Levine, K. Wroblewski, B. Lane, W. Dale, M. Malec, C. Daugherty*
- Board 11 **Abstract 10023: Association between phase angle and survival in patients with advanced cancer admitted to an acute palliative care unit (APCU).** *D. Hui, J. A. Moore, M. Park, D. D. Liu, E. Bruera*
- Board 12 **Abstract 10024: Comprehensive evaluation of place of death for patients with hematological malignancies, 1999-2015.** *F. L. Chino, A. Kamal, J. P. Chino, T. W. LeBlanc*
- Board 13 **Abstract 10025: Hospice use among Medicare fee-for-service (FFS) or managed-care organization (MCO) enrollees with leukemia and myeloma.** *A. J. Olszewski, P. Egan, T. W. LeBlanc*
- Board 14 **Abstract 10026: Aligning goals of care with aggressiveness at end of life (EOL).** *S. L. Douglas, B. J. Daly, N. J. Meropol, A. R. Lipson*
- Board 15 **Abstract 10027: Impact of palliative care consults on racial disparity in do-not resuscitation (DNR) orders at an urban safety net hospital.** *N. Bhulani, A. Gupta, M. E. Paulk, K. Donnell, V. Harvey, J. Cox, J. V. Cox, U. N. Verma, A. Sanjeevaiah, N. Cheedella, L. Khosama, Y. E. Arriaga, S. K. Syed, S. M. Kazmi, M. S. Beg*
- Board 16 **Abstract 10028: End of life care in gynaecological cancer patients: A population-based study of cancer deaths from the Swedish Register of Palliative Care.** *K. Lindemann, L. Martinsson, D. Lindquist*
- Board 17 **Abstract 10029: Multicenter randomized controlled trial for advanced cancer patients receiving parenteral nutrition (PN) versus oral feeding (OF): Results of AlimK study.** *C. Bouleuc, A. Anota, C. Cornet, G. Grodard, A. Thiery Vuillemin, L. Pazart, R. Aubry*
- Board 18 **Abstract 10030: Impact of patient reported functional limitation on overall survival in older adults undergoing autologous hematopoietic cell transplant (AutoHCT).** *M. T. Nawas, C. Andreadis, T. G. Martin, J. L. Wolf, W. Z. Ai, L. D. Kaplan, G. N. Mannis, A. Logan, L. E. Damon, C. Huang, R. L. Olin*
- Board 19 **Abstract 10031: Randomized clinical trial of telephoned-based physical activity intervention in onco-geriatric patients.** *H. Arrieta, C. Astrugue, S. Regueme, J. Durrieu, A. Maillard, Y. Becouarn, E. Terrebbonne, C. Laurent, B. Maget, V. Servent, S. Lavau-Denès, J. Dauba, M. Fonck, R. Thiébaud, I. Bourdel-Marchasson*
- Board 20 **Abstract 10032: The value of inflammatory markers in predicting overall survival in older adults with cancer.** *T. F. Nishijima, A. M. Deal, J. L. Lund, K. A. Nyrop, H. B. Muss, H. K. Sanoff*
- Board 21 **Abstract 10033: Patient-reported psychosocial needs and psychological distress: the influence on survival in geriatric oncology patients.** *B. Leung, A. Shokoohi, A. Bates, C. Ho*
- Board 22 **Abstract 10034: Is there a role for older-patient-specific cancer clinical trials? A pooled analysis of 2277 older patients in adjuvant breast cancer trials (Alliance A151715).** *D. Dao, T. Zemla, A. Jatoi, R. A. Freedman, A. Hurria, H. Muss, H. J. Cohen, L. N. Shulman, M. L. Citron, D. Budman, R. McMurray, A. Partridge, L. A. Carey, J. M. Lafky, J. Le-Rademacher*
- Board 23 **Abstract 10035: Geriatric comanagement and surgical outcomes of older cancer patients.** *A. Shahrokni, S. Sarraf, K. Alexander, S. W. Sun, S. Kim, H. Yulico, S. McMillan, R. J. Downey, B. Korc-Grodzicki*
- Board 24 **Abstract 10036: Geriatric assessment to predict hospitalization frequency and long-term care utilization in older adult cancer survivors.** *G. R. Williams, L. Dunham, Y. Chang, A. M. Deal, M. Pergolotti, J. L. Lund, E. J. Guerard, K. Kenzik, H. B. Muss, H. K. Sanoff*

- Board 25 Abstract 10037: Phase 2 randomized study of a walking intervention for radiation-related fatigue among older breast cancer patients receiving radiation.** *N. A. VanderWalde, M. Y. Martin, M. Kocak, C. Morningstar, A. M. Deal, K. A. Nyrop, M. Farmer, M. T. Ballo, D. L. Schwartz, H. B. Muss*
- Board 26 Abstract 10038: Anti-PD1 antibodies in late elderly advanced melanoma patients: A retrospective multicentre study.** *F. De Rosa, L. Ridolfi, E. T. Tanda, E. Marra, J. Pigozzo, R. Marconcini, M. Guida, G. Gallizzi, M. Ocelli, L. Pala, E. Gambale, M. Bersanelli, R. Conca, A. Cortellini, F. Morgese, F. Zoratto, L. Stucci, S. Strippoli, E. Petracchi, M. Guidoboni*
- Board 27 Abstract 10039: Examining progression free survival (PFS), overall survival (OS), and toxicities of palbociclib in a geriatric population.** *K. Clifton, J. Kimmel, J. K. Litton, D. Tripathy, M. S. Karuturi*
- Board 28 Abstract 10040: Impact of age on outcomes with PD-(L)1 blockade in patients (Pts) with non-small cell lung cancer (NSCLC).** *M. Lichtenstein, R. D. Nipp, K. Goodwin, D. Anderson, R. Newcomb, J. F. Gainor*
- Board 29 Abstract 10041: Predicting chemotherapy toxicity and death in older adults with colon cancer: Results of MOST (Massilia Oncologic Senior Tests) study.** *F. Retornaz, O. Guillem, D. Gholam, J. Codoul, C. Brativesic, F. Morvan, Y. Rinaldi, N. Barriere, S. Nahon, C. Butaud, O. Guerin, R. Boulahssass, M. Grino, F. Rousseau*
- Board 30 Abstract 10042: Prevalence and clinical correlates of vulnerable status using the Vulnerable Elders Survey 13 (VES-13) in newly diagnosed adult non-Hodgkin lymphoma (NHL) patients: A LEO cross-sectional analysis.** *A. Fama, P. Martin, C. Casulo, L. J. Nastoupil, C. A. Thompson, B. K. Link, I. S. Lossos, B. Kahl, M. Maurer, C. Allmer, D. L. Jaye, A. L. Feldman, S. L. Slager, J. W. Friedberg, T. M. Habermann, C. Flowers, J. R. Cerhan*
- Board 31 Abstract 10043: Utilizing a practical tablet-based modified geriatric assessment in clinic for older adults with multiple myeloma (MM).** *N. Nathwani, A. Hurria, S. E. Kurtin, B. Lipe, S. G. Mohile, D. Catamero, D. Wujcik, A. Davis, K. Birchard, C. T. Stricker, T. M. Wildes*
- Board 32 Abstract 10044: Association between participation in religious activities and depression and anxiety in older patients with cancer.** *Y. Cao, D. Li, K. Charles, E. Soto Perez De Celis, C. Sun, L. Chien, E. Roberts, D. Rivera, J. Moreno, W. Dale, M. Koczywas, V. M. Chung, M. Fakh, J. Chao, M. C. Cristea, D. Lim, S. K. Pal, V. Katheria, H. Tan, A. Hurria*
- Board 33 Abstract 10045: Prognostic benefit of taking statin and/or metformin in elderly patients with advanced non-small cell lung cancer: A nationwide population-based epidemiologic study.** *Y. Lee, J. Lee, J. Jang, J. Kim*
- Board 34 Abstract 10046: The effect of a geriatric oncology (GO) evaluation on treatment (Tx) decisions for older patients (pts) with cancer in Mexico.** *H. C. Verduzco-Aguirre, A. Navarrete Reyes, N. Reyes Martinez, J. Ruiz Lopez, O. Vazquez Valdez, J. Cuadros Moreno, J. Garcia Lara, Y. Chavarri Guerra, E. Leon Rodriguez, J. Avila Funes, E. Soto Perez De Celis*
- Board 35 Abstract 10047: Inflamm-aging and the need to consider age in cytokine-patient-reported outcome (PRO) relationships: The case of acute myeloid leukemia (AML).** *S. M. Alibhai, H. Breunis, J. Matelski, N. Timilshina, A. Kundra, C. Lee, M. Li*
- Board 36 Abstract 10048: The impact of a positive cognitive impairment screen on conversations between patients, caregivers, and oncologists: A UR NCORP randomized study.** *A. Magnuson, L. Lei, M. C. Janelsins, E. Culakova, F. V. Lin, M. Gilles, A. Hurria, W. Dale, P. Duberstein, M. Wittink, M. Wells, N. Gilmore, L. M. Hamel, M. A. O'Rourke, A. A. Onitilo, T. P. Bradley, M. I. Whitehead, S. G. Mohile*
- Board 37 Abstract 10049: Development and temporal validation of a practical prognostic scoring system (ONCOGERIATRIC INDEX -OGI) based on the comprehensive geriatric assessment to predict early death in elderly cancer patients: A 892 patients cohort study.** *J. Telles O Lima, M. R. Bezerra, M. G. Mello, J. Figueiroa, A. Bergmann, Z. Cavalcanti, R. Viana, L. t. Sales, L. C. Thuler*

Monday, June 4, 2018

- Board 38 **Abstract 10050: Diagnosing deficits in quality of life and providing tailored therapeutic options: Results of a randomized trial including 220 patients with colorectal cancer.** *M. Klinkhammer-Schalke, B. Steinger, M. Koller, A. Fürst, P. Piso, M. Kästel, J. Gump, R. Obermaier, F. Hofstaedter, P. Lindberg*
- Board 39 **Abstract 10051: Patient and provider preferences for physician roles in breast cancer survivorship care.** *A. Radhakrishnan, S. J. Katz, S. T. Hawley, L. P. Wallner*
- Board 40 **Abstract 10052: E-cigarette use among patients of smoking-related cancers in the United States.** *O. Akinboro, R. Elias, S. M. Nwabudike, O. Balasire, J. S. Ostroff*
- Board 41 **Abstract 10053: Efficacy of haloperidol versus olanzapine for control of chemotherapy induced nausea and vomiting.** *S. Dulal, B. D. Paudel, A. Shah*
- Board 42 **Abstract 10054: Pilot trial of epidermal growth factor (EGF) ointment for the patients with epidermal growth factor receptor (EGFR) inhibitor related skin side effects.** *S. Oh, S. Lee, J. Kang, S. Kim, C. Kim, J. Jang, I. Hwang, Y. Kim, H. Ahn, L. Park, J. Ji, J. Lee*
- Board 43 **Abstract 10055: Effect of comorbidities on outcomes in colorectal cancer (CRC) survivors.** *C. A. Cuthbert, B. R. Hemmelgarn, W. Y. Cheung*
- Board 44 **Abstract 10056: Cardiometabolic risk in childhood cancer survivors: A Children's Oncology Group study.** *E. Lipshultz, E. J. Chow, D. Doody, L. M. Kopp, S. Aggarwal, S. Armenian, B. Asselin, K. S. Baker, S. Bhatia, L. S. Constone, D. R. Freyer, C. Laverdiere, C. L. Schwartz, S. E. Lipshultz, L. M. Vrooman*
- Board 45 **Abstract 10057: Patient characteristics and long-term outcomes beyond the first 6 months after a diagnosis of cancer-associated thrombosis.** *R. A. Schmidt, A. Alzaki, N. Desilet, N. Ratnaweera, E. A. Peterson, A. Y. Lee*
- Board 46 **Abstract 10058: Pharmacokinetic (PK) modeling of serum platinum to reveal extent of long-term exposure and associated comorbidities after cisplatin treatment.** *O. El Charif, Z. Mu, E. R. Gamazon, P. C. Dinh Jr., S. Ardeshirrouhanifard, P. O. Monahan, D. R. Feldman, L. H. Einhorn, R. J. Hamilton, D. J. Vaughn, N. E. Martin, C. Fung, S. D. Fossa, L. B. Travis, M. Dolan*
- Board 47 **Abstract 10059: Risk factors for the development of atrial fibrillation on ibrutinib treatment.** *R. W. Lentz, S. Ma, N. Akhter*
- Board 49 **Abstract 10061: A longitudinal assessment to evaluate the impact of higher body mass index on cancer-related fatigue in breast cancer patients receiving chemotherapy.** *J. E. Inglis, M. C. Janelinsins, E. Culakova, J. Bautista, K. M. Mustian, P. Lin, I. Kleckner, L. J. Peppone*
- Board 50 **Abstract 10062: Getting the most out of follow-up: A prospective study using the Measure of Ovarian Symptoms and Treatment concerns (MOST) symptom index to evaluate and track adverse effects (AEs) and detect symptoms of recurrence in patients with ovarian cancer (OC) following first line chemotherapy (1LT).** *M. Friedlander, M. King, C. Nagle, A. Obermair, P. T. Grant, A. deFazio, P. M. Webb*
- Board 51 **Abstract 10063: Outcomes of immune-checkpoint inhibitor induced organ toxicities.** *H. Abu Sbeih, T. Tang, D. H. Johnson, A. Diab, Y. Wang*
- Board 52 **Abstract 10064: Vaginal laser to improve symptomatic vulvovaginal atrophy and sexual function in breast cancer patients: Report from LAAVA pilot study.** *A. Pearson, A. Booker, M. Tio, G. M. Marx*
- Board 53 **Abstract 10065: Pregnancies during and following trastuzumab (T) and/or lapatinib (L) in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.** *M. Lambertini, S. Martel, C. Campbell, S. Guillaume, F. Hilbers, U. Schuehly, L. Korde, H. A. Azim Jr., S. Di Cosimo, R. C. Tenglin, J. B. Huober, J. Baselga, A. Moreno-Aspitia, M. J. Piccart-Gebhart, R. D. Gelber, E. De Azambuja, M. Ignatiadis*

- Board 54 **Abstract 10066: Meta-analysis of the cardiac events in the adjuvant trastuzumab trials.** *E. De Azambuja, N. F. Ponde, M. J. Procter, P. Rastogi, R. S. Cecchini, K. V. Ballman, A. Moreno-Aspitia, D. Zardavas, L. Roca, R. D. Gelber, M. Piccart, T. M. Suter*
- Board 55 **Abstract 10067: Impact of body mass index (BMI) and weight change after treatment in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Secondary analysis of the ALTO BIG 2-06 trial.** *S. Martel, M. Lambertini, D. Agbor-Tarh, N. Falbel Ponde, A. Gombos, V. Paterson, F. Hilbers, L. Korde, A. Manukyants, A. C. Dueck, C. Maurer, M. J. Piccart-Gebhart, A. Moreno-Aspitia, C. Desmedt, S. Di Cosimo, E. De Azambuja*
- Board 56 **Abstract 10068: An individual patient level data pooled analysis of T-DM1 cardiac safety in HER2-positive (HER2+) metastatic breast cancer (MBC) patients.** *N. F. Ponde, L. Ameye, M. Lambertini, M. Paesmans, E. De Azambuja*
- Board 57 **Abstract 10069: Risk of solid cancer after treatment for testicular germ cell cancer in the platinum era.** *M. Schaapveld, H. Groot, S. Lubberts, R. De Wit, A. Witjes, J. M. Kerst, I. de Jong, G. Groenewegen, A. J. van den Eertwegh, P. Poortmans, H. Klumpen, H. Berg, van de, T. J. Smilde, B. Vanneste, M. J. Aarts, L. Incrocci, A. C. Van Den Bergh, S. Horenblas, J. A. Gietema, F. Van Leeuwen*
- Board 58 **Abstract 10070: Independent prognostic value of the EORTC QLQ-C30 summary score on all-cause mortality: Results from the population-based PROFILES registry.** *O. Husson, B. H. de Rooij, J. M. Kieffer, S. Oerlemans, F. Mols, N. K. Aaronson, W. Van Der Graaf, L. van de Poll-Franse*
- Board 59 **Abstract 10071: Prevalence and predictors of decreased cardiorespiratory fitness among cancer patients.** *J. P. Caron, D. Payne, B. Coumbe, A. Partridge, A. Nohria, J. Groarke*
- Board 60 **Abstract 10072: Cardioprotective effect and safety of dexrazoxane in all breast cancer stages in patients treated with anthracyclines with or without trastuzumab: A systematic review and meta-analysis.** *A. Macedo, A. N. Rodrigues, R. B. Costa, A. L. Ribeiro*
- Board 61 **Abstract 10073: Symptom burden and employment status in breast cancer (BC) survivors.** *I. V. Luis, A. M. O'Neill, K. Sepucha, K. D. Miller, C. T. Dang, D. W. Northfelt, E. P. Winer, G. W. Sledge Jr., B. P. Schneider, A. Partridge*
- Board 62 **Abstract 10074: Ultra-low doses of TX-004HR to improve symptoms of vulvar and vaginal atrophy (VVA) while maintaining serum levels of estradiol within the normal postmenopausal range.** *S. B. Goldfarb, J. Carter, B. Bernick, S. Mirkin*
- Board 63 **Abstract 10075: Cancer survivorship, financial wellbeing and food insecurity in the U.S.** *Z. Zheng, A. Jemal, X. Han, A. J. Davidoff, M. P. Banegas, J. Zhao*
- Board 64 **Abstract 10076: Oncology patients referred for cognitive training in a military treatment facility: Demographics, symptom reporting and cognitive functioning for CNS and non CNS cancers.** *K. Sullivan, M. A. Knoll, W. A. Law, T. Ranade, B. J. Theeler, C. A. Hamilton, Y. Casablanca, L. M. French*
- Board 65 **Abstract 10077: Self-reported functional assessment by patients receiving different prostate cancer strategies: Five-year results from the VICAN large prospective cohort.** *G. Pignot, R. Touzani, A. D. Bouhnik, P. Marino, J. Walz, S. Rybikowski, N. Salem, S. Dermeche, G. Gravis, M. K. Bendiane*
- Board 66 **Abstract 10078: Cumulative burden of severe chronic health conditions (CHC) and health related quality of life (HRQoL) among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort study (SJLIFE).** *N. Bhakta, T. M. Brinkman, M. J. Ehrhardt, Q. Liu, K. K. Ness, K. R. Krull, D. K. Srivastava, J. L. Klosky, P. A. Ganz, M. M. Hudson, Y. Yasui, L. L. Robison, I. Huang*
- Board 67 **Abstract 10079: Hypogonadism and effects on quality of life in previously treated germ cell tumor survivors: A single-centre, non-randomized, prospective observational study.** *N. Khanal, M. Kalra, S. S. Ahmed, T. J. Miller, N. H. Hanna, P. O. Monahan, T. E. Stump, V. Champion, M. J. Brames, S. Case-Eads, K. M. Lazzara, L. H. Einhorn*

Monday, June 4, 2018

- Board 68 **Abstract 10080: Unmet need for clinician engagement about financial toxicity after diagnosis of breast cancer.** *R. Jagsi, K. C. Ward, P. Abrahamse, L. P. Wallner, A. W. Kurian, A. S. Hamilton, S. J. Katz, S. T. Hawley*
- Board 69 **Abstract 10081: The hidden burden of anxiety and depression in ovarian cancer: A prospective longitudinal study from diagnosis.** *P. M. Webb, V. Beesley, A. deFazio, A. Obermair, P. T. Grant, C. M. Nagle, M. Friedlander*
- Board 70 **Abstract 10082: Sustained long-term benefits of a psycho-educational intervention targeting fear of cancer recurrence in people at high risk of developing another melanoma: A randomised controlled trial.** *M. Dieng, R. L. Morton, D. S. Costa, P. Butow, S. Menzies, S. Lo, G. J. Mann, A. E. Cust, N. Kasparian*
- Board 71 **Abstract 10083: PCPs knowledge and self-efficacy for caring for breast and colon cancer survivors.** *N. Dixit, N. Burke, G. Rodriguez, U. Sarkar, J. Quan, J. Devore, B. Cicerelli, A. Napoles*
- Board 72 **Abstract 10084: Cannabis use in hematopoietic transplantation survivors.** *E. T. Loggers, B. Storer, S. Pergam, R. Urban, H. Greenlee, J. R. Fann, S. Lee*
- Board 73 **Abstract 10085: Randomized trial of a text messaging intervention for symptom distress in BCa patients undergoing chemotherapy.** *K. Wen, L. J. Goldstein, S. M. Miller, E. Obeid, M. B. Daly*
- Board 74 **Abstract 10086: Trust in doctors and non-doctor sources for health and medical information.** *L. Chen, G. Vasudev, A. Szeto, W. Y. Cheung*
- Board 75 **Abstract 10087: Gender differences and trends in suicide risk among cancer survivors.** *N. Osazuwa-Peters, E. Adjei Boakye, M. C. Simpson, L. Zhao, K. A. Mohammed, T. M. Loux, M. A. Varvares, M. Schootman*
- Board 77 **Abstract 10089: Exercise counseling in integrative oncology: Patient characteristics and effects on self-reported symptoms.** *G. Lopez, C. A. Eddy, Y. Li, M. Chen, L. Cohen*
- Board 78 **Abstract 10090: Randomized controlled trial of percutaneous transesophageal gastrostomy for symptom palliation in patients with malignant gastrointestinal obstruction.** *M. Sone, T. Aramaki, Y. Arai, S. Sugawara, S. Morita, H. Ishii, D. Okamoto, Y. Takeuchi, M. Moriguchi, E. Bekku, R. Sato*
- Board 79 **Abstract 10091: PG2 injection, a novel botanical drug approved for improving cancer-related fatigue among advanced cancer patients under standard palliative care: A double blind, multi-center, randomized phase IV study.** *C. Wang, Y. Lai, C. Lin, J. Chen, C. Ho, K. Rau, J. Tsai, C. Chang, S. Yeh*
- Board 80 **Abstract 10092: Prophylactic treatment for acneiform rash caused by EGFR inhibitors: Prospective randomized double-blind trial comparing daily topical chloramphenicol 3% plus prednisolone 0.5% vs chloramphenicol 3% vs aqua cream.** *S. M. Stemmer, H. Prag-Naveh, A. Ollech, A. Popovitzer, O. Purim, D. Flex, Y. Leshem, B. Davidovici, O. Ulitsky, B. Brenner, I. Ben-Aharon, N. Peled, M. David, I. Amitay Laish*
- Board 81 **Abstract 10093: Adapalene gel 0.1% vs. placebo as prophylaxis for anti-EGFR-induced acne-like rash: A randomized left-right comparative evaluation (APPEARANCE).** *M. Tachihara, N. Chayahara, Y. Fujishima, A. Fukunaga, K. Washio, M. Yamamoto, K. Nakata, K. Kobayashi, K. Takenaka, M. Toyoda, N. Kiyota, K. Tobimatsu, H. Doi, N. Mizuta, N. Marugami, A. Kawaguchi, C. Nishigori, Y. Nishimura, T. Mukohara, H. Minami*
- Board 82 **Abstract 10094: Patient reported outcomes (PRO) results for prophylactic effect of dexamethasone on regorafenib-related fatigue and/or malaise: a randomized, placebo-controlled, double-blind clinical study in patients with unresectable metastatic colorectal cancer: KSCC1402/HGCSG1402.** *M. Shimokawa, E. Oki, T. Yamaguchi, H. Tanioka, Y. Miyamoto, A. Tsuji, M. Asayama, T. Shirایشi, S. Yuki, M. Kotaka, A. Makiyama, T. Shimose, S. Masuda, Y. Komatsu, H. Saeki, Y. Emi, H. Baba, Y. Maehara*

- Board 83 Abstract 10095: Cryocompression for enhanced limb hypothermia in preventing paclitaxel-induced peripheral neuropathy.** *R. Sundar, A. Bandla, S. Tan, N. B. Kumarakulasinghe, Y. Huang, S. Ang, Z. Hairom, J. S. Lim, A. S. Wong, G. H. Chan, N. Ngoi, E. Ang, A. Chan, S. Lee, N. Thakor, E. Wilder-Smith*
- Board 84 Abstract 10096: Effects of mindfulness meditation on quality of life in adults with advanced cancer and family caregivers: A randomized pilot.** *S. A. Johns, K. A. Beck-Coon, L. F. Brown, P. V. Stutz, J. K. Daggy, Q. Tang, J. A. Pell, E. V. Newton, P. R. Helft*
- Board 85 Abstract 10097: REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal (IP) bevacizumab (bev) for recurrent ascites in advanced, chemotherapy-resistant, epithelial ovarian cancer (CR-EOC).** *K. M. Sjoquist, L. R. Mileschkin, S. Ananda, C. M. Shannon, D. Bowtell, S. Yip, D. Espinoza, J. C. Goh, M. L. Harrison, M. Plebanski, V. Gebiski, M. R. Stockler, K. Livingstone, M. Tang, M. Friedlander*
- Board 86 Abstract 10098: Celiac plexus radiosurgery: A new palliative modality for upper gastrointestinal malignancies—Final results of a proof-of-concept clinical trial.** *Y. R. Lawrence, L. Hammer, O. Morag, M. Ben-Ailan, D. Alezra, O. Margalit, N. Halpern, B. Boursi, E. Shmueli, G. Jacobson, U. Amit, T. Katzman, K. Shefer, I. Weiss, I. Yanovsky, A. Dicker, T. Golan, D. Hausner, Z. Symon*
- Board 87 Abstract 10099: Relationships between immune cell profiles and frailty in patients with breast cancer from pre- to post- chemotherapy: A University of Rochester NCI community oncology research program prospective, longitudinal study.** *N. Gilmore, M. R. Mohamed, L. Lei, A. Magnuson, R. J. Maggiore, S. G. Mohile, B. Esparaz, J. K. Giguere, J. G. Misleh, M. C. Janelins*
- Board 88 Abstract 10100: Effect of pre-treatment sleep disturbance on radiation therapy (RT)-induced pain in 676 women with breast cancer.** *A. R. Peoples, W. R. Pigeon, D. Li, J. A. Roscoe, S. N. Garland, M. L. Perlis, V. Vinciguerra, T. Anderson, L. S. Evans, J. L. Wade III, D. J. Ossip, G. R. Morrow, J. Ryan-Wolf*
- Board 89 Abstract 10101: Risk stratification using patient-reported outcomes (PROs) in patients (pts) with advanced cancer.** *S. B. Patel, B. Haaland, D. Ose, T. Haydell, J. Martineau, W. A. Dunson Jr., A. W. Chalmers, L. Cannon, B. Kissell, N. J. Meropol, W. L. Akerley*
- Board 90 Abstract 10102: A multi-center, randomized, double-blinded, placebo-controlled trial of additive effect of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: JORTC- PAL08 (DIRECT study).** *E. Satomi, H. Matsuoka, S. Iwase, T. Miyaji, T. Kawaguchi, K. Ariyoshi, S. Oyamada, H. Hasuo, A. Tokoro, T. Shinomiya, H. Tsukuura, Y. Otake, M. Otsuka, Y. Hasegawa, Y. Matsumoto, Y. Kataoka, H. Otani, Y. Kidera, M. Aoyama, T. Yamaguchi*
- Board 91 Abstract 10103: Evaluation of a mobile application to prepare and engage cancer patients prior to a palliative care (PC) visit: Results of a randomized, controlled trial.** *A. Kamal, F. Friedman, J. Nicolla, D. M. Davis*
- Board 92 Abstract 10104: Racial disparities in palliative and hospice care beliefs of lung cancer patients.** *A. V. Shreenivas, J. Morillo, D. Seiden, C. B. Smith*
- Board 93 Abstract 10105: Patterns and determinants of pain and emotional distress in older adults with cancer: A population based study.** *A. J. Davidoff, M. Canavan, S. Wang, C. J. Presley, S. Feder, J. Kapo, E. Sheinfeld, E. Kent*
- Board 94 Abstract 10106: Impact of oncologist outpatient productivity on prevalence of goals of care discussions.** *S. Pintova, C. B. Smith, K. B. Adelson, J. P. Gonsky, N. Egorova, R. Franco, N. A. Bickell*
- Board 95 Abstract 10107: Length of time to conduct goals of care visits.** *S. Pintova, C. B. Smith, K. B. Adelson, J. P. Gonsky, N. Egorova, R. Franco, N. A. Bickell*
- Board 96 Abstract 10108: Community-based palliative care utilization in elderly pancreatic cancer patients.** *Z. Lu, C. M. Ganduglia Cazaban, L. G. LeonNovelo, S. Yennu, S. H. Conway, L. D. Highfield, S. H. Giordano, H. Zhao*

Monday, June 4, 2018

- Board 97 **Abstract 10109: Patterns of palliative care utilization in stage IV non-small cell lung cancer in the National Cancer Database.** *U. Durani, N. Duma, R. D. Frank, G. Goyal, S. Yadav, A. S. Mansfield, J. R. Molina, S. Ailawadhi, T. J. Moynihan, R. S. Go*
- Board 98 **Abstract 10110: Comparisons of palliative care utilization in metastatic cancer patients between multi-payer non-universal health care and single-payer universal health care systems.** *R. N. Kuo, C. Tsai*
- Board 99 **Abstract 10111: Patient-reported outcomes in light of supportive medications in treatment-naïve lung cancer patients.** *J. Hoang, N. Upadhyay, D. N. Dike, J. Lee, C. S. Cleeland, H. Chen, T. R. Mendoza, M. Trivedi*
- Board 100 **Abstract 10112: The impact of pain in recurrent ovarian cancer patients: An individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) of 1226 patients.** *H. Woopen, R. Richter, S. Alavi, G. Inci, R. Chekerov, J. Sehouli*
- Board 101 **Abstract 10113: Prospective phase II pilot study to evaluate the use of intravenous iron in the treatment of anemia in cancer patients.** *Y. Kim, J. Jang, S. Park, J. Lee, S. Lim*
- Board 102 **Abstract 10114: Does cytotoxic chemotherapy (CT) have a role in palliative treatment of hepatocellular carcinoma (HCC)?** *G. Nader Marta, L. G. Fonseca, M. F. Braghiroli, P. M. Hoff, J. Sabbaga*
- Board 103 **Abstract 10115: Incorporating geriatric patient reported outcomes into novel screening tool of distress and supportive care concerns.** *C. B. Weldon, J. Martin, A. Scheu, P. Khosla, B. Roggenkamp, R. Berardi, S. L. Chow, J. R. Trosman, M. Pasquinelli, L. E. Feldman, W. Dale, S. O'Mahony, J. Gerhart, P. B. Mumby, A. Gordon, L. A. Wiebe, C. Deamant*
- Board 104 **Abstract 10116: Barriers to palliative care (PC) utilization in hematopoietic stem cell transplantation (HCT).** *A. El-Jawahri, T. W. LeBlanc, L. J. Burns, E. M. Denzen, C. Meyer, L. Mau, E. Roeland, W. A. Wood, E. W. Petersdorf*
- Board 105 **Abstract 10117: Quality of life (QoL) outcomes including neuropathy associated scale (FACT-T) from a phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) versus paclitaxel plus gemcitabine (PG) as first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC): Korean Cancer Study Group trial (KCSG BR13-11).** *J. Kim, S. Park, S. Im, S. Kim, J. Sohn, K. Lee, Y. Im, T. Kim, J. Ahn, G. Kim, I. Park, Y. Chae, S. Lee, H. Han, K. Jung, Y. Park*
- Board 106 **Abstract 10118: Efficacy of omega-3 (ω3) supplementation versus omega-6 (ω6) supplementation for reducing pain among breast cancer survivors: A URCC NCORP RCT.** *L. J. Peppone, J. E. Inglis, K. M. Mustian, K. Loh, E. Culaikova, I. Kleckner, C. S. Kamen, G. D. Padula, S. G. Mohile, P. Lin, S. Cole, M. C. Janelins*
- Board 107 **Abstract 10119: Longitudinal patient-reported symptom severity and symptom interference with activity-related and mood-related functioning and survival in patients with advanced cancer on early-phase clinical trials of immunotherapeutic or targeted agents.** *G. George, T. R. Mendoza, E. C. Iwuanyanwu, Q. Shi, S. A. Piha-Paul, L. A. Williams, D. D. Karp, A. Naing, F. Janku, R. H. Bokhari, X. S. Wang, D. S. Hong, C. S. Cleeland*
- Board 108 **Abstract 10120: Determinants of quality of life and survival in ambulatory oncology patients receiving chemotherapy.** *D. G. Power, L. Daly, E. Ni Bhuachalla, S. Cushen, P. Mceneaney, D. L. Dahly, A. M. Ryan*
- Board 109 **Abstract 10121: Intensive 4-weeks' mindfulness therapy in the treatment of chronic pain in patients with cancer: Pilot study.** *A. Kieszowska-Grudny, K. Pratkancka, J. Jarosz, D. Jasinska*
- Board 110 **Abstract 10122: The association of serum ghrelin, GIP, insulin, and leptin levels with sleep quality and cancer-related fatigue in cancer survivors.** *P. Lin, E. Culaikova, C. E. Heckler, M. C. Janelins, L. J. Peppone, J. E. Inglis, I. Kleckner, J. O. Hopkins, A. Curtis, B. Esparaz, K. M. Mustian*

- Board 111 Abstract 10123: Incidence of dermatological toxicities and fatigue in patients with cancer treated with regorafenib: A systematic review and meta-analysis of randomized controlled trials.** *M. Quirch, K. Z. Thein, M. S. Khan, A. Sultan, S. Swarup, L. A. Tijani, F. L. Hardwicke, C. Jones*
- Board 112 Abstract 10124: Opioid use in rural breast cancer patients.** *E. P. Araujo-Mino, A. Bulbul, A. Bautista, L. Lentkowski, M. Khorsand-Sahbaie*
- Board 113a Abstract TPS10125: iMETx (Individualized Metabolic Rx): Pilot study of an environmental intervention to increase energy expenditure among breast cancer survivors.** *T. J. Ballinger, E. Nelson, T. Olsen, K. Miller, J. Sledge*
- Board 113b Abstract TPS10126: Circuit aerobic and resistance exercise to target metabolic dysregulation in breast and prostate cancer survivors: The CARE trial study design.** *C. M. Dieli-Conwright, K. Lee, C. Chow, K. Zapanta, I. Kang, J. K. Pinski, T. B. Dorff*
- Board 114a Abstract TPS10127: Early nutrition support therapy to improve the nutrition status of head and neck cancer patients accepted concurrent chemoradiotherapy (NSTIP): Interim analysis from a prospective randomized controlled clinical study.** *P. Zhang, K. Xie, X. Huang, R. C. Li, Y. Song, B. Li, W. Liao, S. Zhang, J. Lang*
- Board 114b Abstract TPS10128: Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV).** *A. Mersiades, A. Tognela, P. Haber, M. R. Stockler, N. Lintzeris, I. McGregor, I. Oliver, D. J. Allsop, C. Gedye, A. Kirby, R. L. Morton, A. T. Tran, K. P. Briscoe, P. Fox, S. J. Clarke, M. Aghmesheh, N. Wong, A. Walsh, C. Hahn, P. S. Grimison*
- Board 115a Abstract TPS10129: Effect of nutritional support with highly purified, whey proteins for malnutrition and sarcopenia in patients affected with stage II-III colorectal or breast cancer: A blind, placebo controlled, randomized clinical trial.** *F. Mazzuca, M. Roberto, A. Botticelli, L. Marchetti, E. Sarfati, E. Crimini, F. Schipilliti, M. Di Girolamo, M. Muscaritoli, P. Marchetti*
- Board 116a Abstract TPS10131: A randomized phase II study of the nutritional and exercise treatment for the elderly patients with advanced non-small cell lung or pancreatic cancer: The NEXTAC-TWO study.** *S. Miura, T. Naito, S. Mitsunaga, K. Omae, K. Mori, T. Inano, T. Yamaguchi, N. Mori, N. Tatematsu, T. Okayama, A. Morikawa, T. Mouri, T. Tsuji, H. Aragane, A. Inui, T. Higashiguchi, K. Takayama*
- Board 116b Abstract TPS10132: A randomized phase II clinical trial of a fasting-mimic diet prior to chemotherapy to evaluate the impact on toxicity and efficacy.** *T. B. Dorff, M. Shelechi, I. Kang, T. E. Morgan, S. G. Groshen, S. Yennu, A. A. Garcia, D. I. Quinn, V. Longo*

1:15 PM - 4:45 PM Poster Session

Tumor Biology

Location: Hall A

Abstracts on Boards 125-136 will be discussed during the Tumor Biology Poster Discussion Session.

Posters by Topic

Cancer Angiogenesis and Metastases: Board 137

Circulating Biomarkers: Boards 132, 134-135, 138-161

Immunobiology: Boards 125-128, 162-174

Molecular Diagnostics and Imaging: Boards 130, 175-190

New Targets and New Technologies: Boards 133, 191-201

Other: Boards 131, 136, 232-238

Tumor-Based Biomarkers: Boards 129, 202-231

Trials in Progress: Boards 239a-239b

Monday, June 4, 2018

- Board 125 **Abstract 12012: Association of loss of adaptive PD-L1 expression with upregulation of PBRM1 chromatin regulator in melanoma.** *D. S. Shin, C. Cheng, N. Truong, M. Onyshchenko, G. Abril-Rodriguez, C. Grasso, B. Comin-Anduix, S. Kurdistani, A. Ribas*
- Board 126 **Abstract 12013: Role of CD4 cells in the complete anti-tumor response to PD1 blockade in a syngeneic murine melanoma model with activated WNT signaling.** *S. Hu-Lieskovan, D. Y. Torrejon, J. M. Zaretsky, J. Tsoi, G. Cheung-Lau, A. Vega-Crespo, K. Meeth, R. M. Prins, T. Graeber, M. Besenberg, C. Grasso, B. Comin-Anduix, A. Ribas*
- Board 127 **Abstract 12014: Facile single cell profiling and clonotype analysis of NSCLC immune microenvironments.** *A. A. Salahudeen, J. Zhu, J. Ju, V. Giangarra, L. Montesclaros, J. Sapida, O. Sharifi, J. Lee, D. Wagh, J. Collier, J. W. Neal, S. K. Padda, H. A. Wakelee, C. Sabatti, C. J. Kuo*
- Board 128 **Abstract 12015: Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC).** *I. Datar, F. Villarreal-Espindola, B. S. Henick, K. N. Syrigos, M. Toki, D. L. Rimm, S. Ferrone, R. S. Herbst, K. A. Schalper*
- Board 129 **Abstract 12016: Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i).** *S. A. Wander, O. Cohen, G. N. Johnson, D. Kim, F. Luo, P. Mao, U. Nayyar, K. Helvie, L. Marini, S. Freeman, G. Getz, L. A. Garraway, E. P. Winer, N. U. Lin, N. Wagle*
- Board 130 **Abstract 12017: Analysis of tumor samples from SOLO2: Concordance of BRCA mutation (BRCAm) detection in tumor vs. blood and frequency of BRCA-specific loss of heterozygosity (LOH) and loss of function somatic mutations.** *D. R. Hodgson, S. P. Dearden, J. S. Brown, T. Milenkova, J. S. Lanchbury, M. Perry, A. Gutin, V. Abkevich, K. Timms, E. Harrington, Z. Lai, B. A. Dougherty, E. Pujade-Lauraine*
- Board 131 **Abstract 12018: Mass spectrometry biomolecular omics profiling and imaging to dissect the initial emergence of molecular drug resistance in ALK-positive (ALK+) lung cancer.** *X. Wu, Z. Lim, S. Komo, C. Walsh, H. Yang, L. Zhu, K. Rhodes, B. Jones, E. Pugacheva, M. Smolkin, E. Seeley, P. C. Ma*
- Board 132 **Abstract 12019: Development of diagnostic method for bone and soft tissue sarcomas of various histological subtypes using serum microRNA profiles.** *N. Asano, J. Matsuzaki, J. Kawachi, S. Takizawa, E. Kobayashi, R. Nakayama, M. Matsumoto, M. Nakamura, T. Kondo, K. Kato, N. Tsuchiya, A. Kawai, T. Ochiya*
- Board 133 **Abstract 12020: PRC-2 epigenetic chromatin reprogramming in ALK-positive (ALK+) lung cancer initial emergence of precision drug resistance.** *P. C. Ma, X. Wu, S. Komo, Z. Lim, H. Yang, K. Rhodes, B. Jones, D. J. Lindner, F. Almeida, V. Neumeister, V. Velcheti, E. Pugacheva, I. Martinez, L. Yin, S. Wen, Z. Zhang*
- Board 134 **Abstract 12021: Development of a comprehensive cell-free DNA (cfDNA) assay for early detection of multiple tumor types: The Circulating Cell-free Genome Atlas (CCGA) study.** *E. A. Klein, E. Hubbell, T. Maddala, A. Aravanis, J. F. Beausang, D. Filippova, S. Gross, A. Jamshidi, K. Kurtzman, L. Shen, A. Valouev, O. Venn, N. Zhang, D. A. Smith, T. J. Yeatman, R. Tibshirani, R. T. Williams, A. Hartman, M. Seiden, M. C. Liu*
- Board 135 **Abstract 12022: Cell-free circulating tumor DNA somatic alteration burden and its impact on survival in metastatic cancer.** *S. S. Pairawan, K. R. Hess, F. Janku, N. S. Sanchez, C. Eng, S. Damodaran, M. M. Javle, A. O. Kaseb, D. S. Hong, V. Subbiah, S. Fu, D. R. Fogelman, V. M. Raymond, R. B. Lanman, F. Meric-Bernstam*
- Board 136 **Abstract 12023: Assessment of the genomic stability and molecular landscape of patient-derived xenograft (PDX) models from NCI's Patient-Derived Models Repository (PDMR).** *B. Das, Y. A. Evrard, L. Chen, R. Patidar, C. Camalier, V. Datta, P. Fliiss, M. M. Gottholm-Ahalt, E. Cantu, G. Rivera, S. Borgel, J. Carter, M. R. Defreytas, M. Morris, D. Newton, M. Radzyminski, M. G. Hollingshead, C. A. Karlovich, P. M. Williams, J. H. Doroshov*

- Board 137 **Abstract 12024: First-in-human phase I trial of BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking nanobody, given every 3 weeks (q3w) in patients (pts) with advanced/metastatic solid tumors.** *C. Le Tourneau, R. Claus, F. Ricci, B. Hackanson, C. Rummelt, O. Fietz, T. Arnhold, D. Roy, Z. Oum'Hamed, R. M. Fritsch*
- Board 138 **Abstract 12025: Monitoring microsatellite instability (MSI) in circulating tumor DNA by next-generation DNA-seq.** *A. Deng, J. Yang, J. Lang, Z. Jiang, W. Wang, D. Yuan, X. Wang, G. Tian*
- Board 139 **Abstract 12026: The prognostic and predictive value of AR-V7 quantification in mCRPC.** *A. Sharp, J. Welti, M. B. Lambros, D. Dolling, C. Aversa, L. Pope, D. Nava Rodrigues, I. Figueiredo, P. Rescigno, M. P. Kolinsky, R. Riisnaes, P. Flohr, D. Bianchini, R. Chandler, J. Mateo, N. Tunariu, S. R. Plymate, J. Luo, J. S. De Bono*
- Board 141 **Abstract 12028: Re-visiting EGFR amplification as a target for anti-EGFR therapy: Analysis of cell-free circulating tumor DNA in patients with diverse cancers.** *S. Kato, R. Okamura, M. Mareboina, S. Lee, A. Goodman, S. P. Patel, P. T. Fanta, R. B. Schwab, J. K. Sicklick, V. M. Raymond, R. B. Lanman, R. Kurzrock*
- Board 142 **Abstract 12029: Correlation between natural killer cell activity and treatment effect in patients with disseminated cancer.** *T. Hansen, L. Nederby, A. H. Zedan, I. Mejlholm, J. Henriksen, K. D. Steffensen, C. B. Thomsen, L. Raunkilde, L. Jensen, A. K. Jakobsen*
- Board 143 **Abstract 12030: Extracellular matrix (ECM) circulating peptide biomarkers as potential predictors of survival in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (mPDA) receiving pegvorhialuronidase alfa (PEGPH20), nab-paclitaxel (A), and gemcitabine (G).** *S. Wang, N. Willumsen, C. Bager, M. A. Karsdal, D. Chondros, D. Taverna*
- Board 144 **Abstract 12031: Role of serum thymidine kinase-1 (TK1) activity in patients (pts) with hormone receptor positive (HR+) advanced breast cancer (ABC) treated with endocrine therapy (ET) in the EFECT trial.** *L. Malorni, C. Biagioni, A. McCartney, G. Schiavon, M. Bergqvist, M. Benelli, I. Migliaccio, L. Biganzoli, M. Bonechi, G. Boccalini, M. Pestrin, F. Galardi, F. De Luca, M. J. Piccart-Gebhart, W. J. Gradishar, S. K. Chia, A. Di Leo*
- Board 145 **Abstract 12032: Combining circulating tumor cells and circulating cancer associated macrophage-like cells for accurately predicting responsiveness of new line therapies in late stage cancers.** *D. Adams, R. C. Bergan, R. K. Alpaugh, S. S. Martin, M. J. Edelman, R. G. Lapidus, S. Chumsri, M. Cristofanilli, C. Tang, S. H. Lin*
- Board 146 **Abstract 12033: Dynamic change of PD-L1 expression on circulating tumor cells in advanced gastrointestinal tumor patients undergoing PD-1 blockade therapy.** *C. Yue, Y. Jiang, P. Li, Y. Wang, D. Li, Y. Yang, Z. Hu, J. Xu*
- Board 147 **Abstract 12034: Theoretical model and clinical validation of blood tumor mutation burden (bTMB) detection for cancer immunotherapy.** *J. Duan, Z. Wang, J. Lu, H. Bai, R. Wan, S. Wang, J. Xu, X. Cao, H. Dong, T. Xu, S. Cai, F. Li, J. Wang*
- Board 148 **Abstract 12035: Correlation of peripheral T cell receptor repertoire with response to neoadjuvant chemotherapy plus trastuzumab in early-stage HER2-positive breast cancer.** *W. Wang, F. Ma, W. Chen, Y. Fan, Z. Yi, D. Xiong, Y. Wang, Y. Guan, X. Guan, X. Xia, L. Yang, X. Yi, B. Xu*
- Board 149 **Abstract 12036: Circulating tumor DNA as a potential indicator of tumor load during interventional therapy of unresectable hepatocellular carcinoma.** *Y. Li, X. Chen, M. Zhan, L. Qiu, W. Zhang, Y. Xin, X. He, Q. Li, J. Bai, L. Chang, A. Wu, R. Chen, Y. Guan, X. Yi, L. Lu*
- Board 150 **Abstract 12037: Correlation of expression of TK1 in plasma-derived exosomes with clinical response to CDK4/6 inhibitors in breast cancer.** *M. Del Re, A. Fontana, S. Crucitta, I. Bertolini, E. Rofi, C. De Angelis, L. Diodati, D. Cavallero, B. Salvadori, A. Falcone, R. Morganti, R. Danesi*

Monday, June 4, 2018

- Board 151 **Abstract 12038: Analysis of single circulating tumor cells (CTCs) to identify resistance mutations to ALK-inhibitors in both ALK-gene and bypass oncogenic pathways.** *E. Paillet, L. Mezquita, V. Faugeroux, M. Oulhen, P. Queffelec, J. Remon, A. Honore, M. Laporte, C. Forcato, Y. Lecluse, L. Lacroix, V. Marty, M. Ngocamus, C. Nicotra, D. Planchard, J. Soria, N. Manaresi, F. Farace, B. Besse*
- Board 152 **Abstract 12039: Integration of lymphocyte ratios (LRs) and circulating tumor cells (CTCs) characterization: The interplay between immunity and metastatic breast cancer (MBC).** *L. Gerratana, M. Bulfoni, D. Basile, G. Pelizzari, M. Bonotto, A. P. Beltrami, Q. Zhang, A. M. Minisini, C. Di Loreto, G. Fasola, M. Cristofanilli, D. Cesselli, F. Puglisi*
- Board 153 **Abstract 12040: Circulating tumor cells enumeration (CTCs) and circulating tumor DNA (ctDNA): Clinical and molecular features of “rapidly progressing” stage IV disease (Stage IV_{prog}).** *L. Gerratana, Q. Zhang, A. A. Davis, Y. Zhang, G. Rossi, K. Strickland, Z. Mu, L. E. Flaum, C. A. Santa-Maria, H. Yang, W. J. Gradishar, L. C. Plataniias, M. Cristofanilli*
- Board 154 **Abstract 12041: Landscape of kinase rearrangements (kRE) detected in circulating tumor DNA (ctDNA).** *B. C. Creelan, D. S. Lieber, A. B. Schrock, R. Madison, J. S. Ross, J. White, V. A. Miller, S. J. Klemptner, S. K. Pal, S. I. Ou, D. Lipson, J. Chung, A. W. Welsh, S. M. Ali*
- Board 155 **Abstract 12042: Circulating tumor DNA as biomarker in mutant malignant melanoma.** *J. Braune, D. von Bubnoff, M. Follo, U. Philipp, E. Graf, D. Pfeifer, J. Duyster, F. Meiss, N. Von Bubnoff*
- Board 156 **Abstract 12043: Predictive tools for bevacizumab therapy in patients with aggressive HER 2-negative metastatic breast cancer: 2-years results from an observational study.** *E. González Flores, I. Alvarez, L. Manso, J. Alonso Romero, J. J. Cruz-Hernández, V. Carañana, I. Gallegos, M. Quindós Varela, J. J. Illarramendi, E. Vicente, A. Ballesteros Garcia, A. Perello, A. Llombart-Cussac, A. Rodriguez, J. Vidal-Martinez*
- Board 157 **Abstract 12044: A priori filtering of post-operative (post-op) circulating tumor DNA (ctDNA) to predict recurrence in post-metastasectomy colorectal cancer patients (CRC pts) without knowledge of tumor genotype.** *M. J. Overman, A. Jaimovich, D. Kennedy, M. Tan, D. Gavino, S. Mortimer, D. Chudova, A. Talasz, J. Odegaard, S. Kopetz*
- Board 158 **Abstract 12045: Mutation count, a potential surrogate for tumor mutation load, of circulating tumor DNA (ctDNA) using targeted panel sequencing correlates with clinical outcomes in late stage lung adenocarcinoma and small cell lung cancer.** *S. Yaung, L. Xi, C. Woestmann, S. McNamara, B. Hinzmann, S. Fröhler, N. Tikoo, C. Ju, A. Balasubramanyam, P. Vitazka, A. Pati, A. F. Lovejoy, D. M. Klass, H. Adams, M. Thomas, F. Herth, T. Muley, B. Wehnl, J. F. Palma, X. M. Ma*
- Board 159 **Abstract 12046: Use of cell-free DNA for management of breast and lung cancer by academic and community providers.** *R. A. Thomas, N. Klar, B. Diergaarde, L. A. Kiedrowski, R. J. Nagy, A. V. Lee, A. Brufsky*
- Board 160 **Abstract 12047: Liquid biopsies (LB) across treatment of 29 metastatic colorectal cancer (mCRC) patients (pts) to reveal driver mutations and tumor evolution with anti-EGFR therapy: Experience in a GI oncology clinic at Fox Chase Cancer Center.** *P. Ghatalia, A. Winer, C. Smith, J. Gou, L. A. Kiedrowski, P. D. Saltzberg, N. Bubes, F. Anari, V. Kasireddy, A. Varshavsky, E. A. Ross, W. S. El-Deiry*
- Board 161 **Abstract 12048: Duvelisib inhibition of chemokines in patients with CLL (DUO study) and iNHL (DYNAMO study).** *D. T. Weaver, K. Sprott, J. Pachter, N. T. Le, M. S. Davids, M. Montillo, Á. Illés, G. Etienne, J. Delgado, B. J. Kuss, C. Tam, F. Offner, S. D. Lunin, F. Bosch, P. Hillmen, N. Lamanna, S. Stilgenbauer, P. L. Zinzani, I. Flinn, J. R. Brown*

- Board 162 Abstract 12049: Immunoprofiling in intrahepatic cholangiocarcinoma (IHCC).** *R. Carmagnani Pestana, L. Solis, X. Wang, R. Abdel-Wahab, H. Chen, W. C. Foo, L. Kwong, M. M. Javle, I. I. Wistuba, R. T. Shroff*
- Board 163 Abstract 12050: Immunologic and clinical implications of CD73 expression in non-small cell lung cancer (NSCLC).** *L. Park, K. Rhee, W. Kim, A. Cho, J. Song, J. F. Anker, M. Oh, P. Bais, S. Namburi, J. Chuang, Y. Chae*
- Board 165 Abstract 12052: TP53 mutations and programmed cell death ligand-1 expression in solid tumors: Associations with clinical factors and outcomes.** *E. Kheder, K. R. Hess, Y. Xing, M. A. Cortez, V. Subbiah, F. Janku, S. Fu, A. Naing, D. D. Karp, S. A. Piha-Paul, T. A. Yap, S. Pant, J. Rodon Ahnert, H. A. Tawbi, J. W. Welsh, F. Meric-Bernstam, D. S. Hong*
- Board 166 Abstract 12053: GBR1302: Effect of CD3-HER2, a bispecific T cell engager antibody, in trastuzumab-resistant cancers.** *J. Back, M. Wermke, J. Maccoin, A. Croset, J. S. Kauh, V. Reddy*
- Board 167 Abstract 12054: Isolation of CD4⁺ T cells specific for neoantigens created by recurrent driver mutations in non-small cell lung cancer (NSCLC) and melanoma.** *J. Veatch, B. Jesernig, S. M. Lee, M. Fitzgibbon, A. M. Houghton, S. R. Riddell*
- Board 168 Abstract 12055: Synergy of TLR4 agonist GSK1795091, an innate immune activator, with agonistic antibody against co-stimulatory immune checkpoint molecule OX40 in cancer immunotherapy.** *H. Gao, S. Bhattacharya, C. J. Matheny, N. Yanamandra, S. Zhang, H. Emerich, Y. Li, P. Bojczuk, H. Shi, W. Wang, C. Hopson, T. Fu, J. P. Allison, P. Sharma, J. F. Smothers, R. Srinivasan, A. Hoos*
- Board 169 Abstract 12056: Dependency of radiotherapy and combinatorial radio-immunotherapy responses on the systemic t cell immune response.** *K. L. Chua, X. Lin, E. Yeo, W. A. Shihabuddeen, P. Chu, K. Low, D. Poon, E. Ong, J. Wee, M. Fehlings, A. Nardin, K. Soo, E. Newell, M. Chua*
- Board 170 Abstract 12057: Association of Akt inhibition with change in immunophenotype of tumor microenvironment (TME) in breast cancer (BC).** *D. K. Marks, R. D. Gartrell, M. E. Asmar, S. Boboila, T. D. Hart, C. L. Esancy, Y. Lu, H. Hibshoosh, E. Connolly, K. Kalinsky, Y. M. Saenger*
- Board 171 Abstract 12058: Tumor PD-L1 heterogeneity in non-small cell lung cancer: Does biopsy size and volume matter?** *M. Khunger, J. Bordeaux, N. Dakappagari, C. Vaupel, A. Khunger, B. Hu, K. A. Schalper, D. L. Rimm, V. Velcheti*
- Board 172 Abstract 12059: PD-1/PD-L1 interaction and CD25/FOXP3⁺ t cells to predict survival benefit from adjuvant chemotherapy in early stage non-small-cell lung cancer (ES-NSCLC).** *J. Bordeaux, N. Dakappagari, N. A. Pennell, J. Stevenson, M. Khunger, C. Vaupel, K. A. Schalper, D. L. Rimm, V. Velcheti*
- Board 173 Abstract 12060: Exploring effects of MEK inhibition in tumor microenvironment in non-small cell lung cancer (NSCLC) pre-clinical models.** *T. Silk, H. Choi, J. Deng, S. Pourpe, K. Wong, T. Merghoub, J. D. Wolchok*
- Board 174 Abstract 12061: Computer extracted features of cancer nuclei from H&E stained tissues of tumor predicts response to nivolumab in non-small cell lung cancer.** *X. Wang, C. Barrera, P. Velu, K. Bera, P. Prasanna, M. Khunger, A. Khunger, V. Velcheti, A. Madabhushi*
- Board 175 Abstract 12062: Upfront next generation sequencing in NSCLC: A publicly funded perspective.** *K. Perdrizet, T. Stockley, M. S. Tsao, J. Morganstein, S. Kamel-Reid, L. Ranich, F. A. Shepherd, G. Liu, P. A. Bradbury, D. Hwang, P. Pal, J. Schwock, S. L. Boerner, J. H. Law, N. B. Leighl*
- Board 176 Abstract 12063: The role of dynamic susceptibility contrast perfusion-weighted MRI in the estimation of IDH mutation in gliomas.** *S. Bisdas, E. Sanverdi, C. Sudre, D. Roettger, S. Brandner, V. Katsaros*
- Board 177 Abstract 12064: Resolving diagnostic uncertainty in bone-predominant metastases in cancer of unknown primary (CUP) using the 92-gene assay.** *K. P. Raghav, G. M. Poage, C. A. Schnabel, G. R. Varadhachary*

Monday, June 4, 2018

- Board 178 **Abstract 12065: Whole genome sequencing in metastatic breast cancer: Lessons learned from the BC Cancer personalized oncogenomics program.**
N. LeVasseur, Y. Shen, E. Y. Zhao, S. Sun, J. J. Laskin, K. A. Gelmon, M. A. Marra, S. K. Chia
- Board 179 **Abstract 12066: Clinical significance of enterocyte-specific gene polymorphisms as candidate marker of oxaliplatin-based treatment for metastatic colorectal cancer.**
M. Suenaga, M. Schirripa, F. Loupakis, S. Cao, W. Zhang, C. Cremolini, S. Lonardi, S. Okazaki, M. D. Berger, Y. Miyamoto, S. Soni, A. Barzi, T. Yamaguchi, A. Falcone, H. Lenz
- Board 180 **Abstract 12067: Poly-ligand profiling (PLP) to differentiate pancreatic cancer patients who benefit from gemcitabine+evofosfamide versus gemcitabine+placebo treatment.**
V. Domyenyuk, D. Magee, Z. Gatalica, A. Stark, P. Kennedy, A. Barker, D. A. Berry, G. H. Poste, D. D. Halbert, C. P. Hart, M. Famulok, G. Mayer, M. Korn, M. R. Miglarese, D. Spetzler
- Board 181 **Abstract 12068: Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired commercial next-generation sequencing assays.**
C. C. Coombs, N. Gillis, K. L. Bolton, J. S. Berg, X. Tan, M. C. Hayward, N. M. Patel, M. Ball, M. Balasis, T. MESA, N. Montgomery, K. L. Richards, W. Y. Kim, D. N. Hayes, S. Earp, J. S. Parker, R. L. Levine, E. Papaemmanuil, A. Zehir, E. Padron
- Board 182 **Abstract 12069: Molecular subtypes of triple-negative breast cancer (TNBC) tumor samples obtained before and after neoadjuvant systemic therapy (NST) and relationship between immunomodulatory (IM) gene signature and intensity of tumor-infiltrating lymphocytes (TILs).**
H. Masuda, K. Harano, S. Miura, Y. Wang, Y. Hirota, O. Harada, Y. Matsunaga, B. Lim, A. L. Wood, A. Lucci, N. Parinyanitikul, H. Lee, G. Gong, A. Rao, R. Seitz, D. R. Hout, S. W. Morris, S. Nakamura, S. Krishnamurthy, N. T. Ueno
- Board 183 **Abstract 12070: Novel platform for monitoring bladder cancer recurrence using expression analysis of small non-coding RNAs.**
I. Aleksic, W. Wang, T. Conklin, I. Sorokin, H. A. Fisher, R. P. Kaufman Jr., B. Mian, B. Kogan, B. McNeil, A. Winer, R. Gupta, A. DiRienzo, M. Tenniswood
- Board 184 **Abstract 12071: Survival of patients treated by a Precision Oncology approach is determined by performance status and lines of therapy.**
B. Gordon, J. Cotta, J. C. Trent II
- Board 185 **Abstract 12072: A cell cycle-related RNA expression signature of neoantigen burden in lung adenocarcinoma.**
M. F. Sharpnack, T. Johnson, G. A. Otterson, D. P. Carbone, K. Huang, K. He
- Board 186 **Abstract 12073: Plasma sequencing of ctDNA in early stage breast cancer as part of the screening process.**
B. Jimenez Rodriguez, G. Diaz Córdoba, A. Garrido Aranda, L. Vicioso, M. C. Parrado, V. de Luque, M. Lozano, M. Moreno Ros, E. Bellagarza, C. Hernando, B. Bermejo, A. Lluch Hernandez, M. Álvarez, F. Jones, A. Nocon, M. Ryder, J. Fredebohm, D. Mehnert, F. Holtrup, E. Alba
- Board 187 **Abstract 12074: Comparison of the prognostic performance between OncoMasTR and OncotypeDX multigene signatures in hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.**
C. M. Kelly, J. Crown, N. Russell, S. Barron, S. Lynch, A. O'Grady, K. Sheehan, J. Fay, V. Amberger-Murphy, A. Saha, T. Loughman, P. Dynoodt, B. Fender, C. Lopez Ruiz, C. Wang, D. O'Leary, D. O'Connor, W. M. Gallagher
- Board 188 **Abstract 12075: Computer-extracted stromal features of African-Americans versus Caucasians from H&E slides and impact on prognosis of biochemical recurrence.**
H. K. Bhargava, P. Leo, R. Elliott, A. Janowczyk, J. Whitney, S. Gupta, K. Yamoah, T. Rebbeck, M. D. Feldman, P. Lal, A. Madabhushi
- Board 189 **Abstract 12076: Comprehensive detection of targetable fusions in lung adenocarcinomas by complementary targeted DNaseq and RNAseq assays.**
R. Benayed, M. D. Offin, K. A. Mullaney, P. Sukhadia, K. M. Rios, P. Desmeules, J. C. Chang, D. M. Hyman, M. F. Berger, A. Zehir, M. E. Arcila, M. G. Kris, A. E. Drilon, M. Ladanyi

- Board 190 Abstract 12077: Longitudinal ctDNA analysis to enable early assessment of prognosis in lung adenocarcinoma in the absence of matched tissue biopsy.** X. M. Ma, N. Tikoo, C. Ju, A. Balasubramanyam, L. Xi, S. Young, D. Klass, A. F. Lovejoy, A. Pati, O. Solberg, Y. Jiang, H. Adams, M. Thomas, F. Lasitschka, M. Meister, M. Schneider, F. Herth, T. Muley, B. Wehnl, J. F. Palma
- Board 191 Abstract 12078: Cancer genomics-based screening of new therapeutic targets and biomarkers for lung cancer.** Y. Daigo, A. Takano, Y. Nakamura
- Board 192 Abstract 12079: Chimeric antigen receptor t cells targeting the lambda light chain of human immunoglobulin as a viable target for b cell non-Hodgkin lymphoma.** R. Ranganathan
- Board 193 Abstract 12080: Successful generation of patient derived xenografts and patient derived 3D cultures as preclinical models for breast cancer.** V. I. Kiver, G. Gambaro, K. Fuchs, B. Brzezicha, C. Schweiger, P. Jurmeister, O. Gorea, S. Burock, C. Liedtke, M. M. Karsten, N. Bangemann, J. U. Blohmer, C. Denkert, C. R. Regenbrecht, J. Hoffmann, U. Keilholz
- Board 194 Abstract 12081: Role of PD-L1 expression in triple-negative breast cancer stem cells.** M. A. Di Nicola, L. Castagnoli, V. Cancila, S. Romero, S. Faraci, C. Chiodoni, G. Talarico, G. Fucà, T. Volpari, M. P. Colombo, M. V. Iorio, E. Tagliabue, C. Tripodo, S. Sangaletti, F. G. De Braud, S. Pupa
- Board 195 Abstract 12082: Local drug activation technology to make cytotoxics safer for localized solid tumors.** S. Srinivasan, N. Yee, F. Dela Cruz, A. Kung, E. Gavia, E. Miller, M. Royzen, J. M. Mejia Oneto
- Board 196 Abstract 12083: Clinicopathologic characteristics and molecular features of BRG1-deficient non-small cell lung cancer (NSCLC).** I. Dagogo-Jack, A. B. Schrock, M. Kem, N. Jessop, J. S. Ross, V. A. Miller, S. M. Ali, A. T. Shaw, M. Mino-Kenudson
- Board 197 Abstract 12084: Incidence of *Neuregulin1 (NRG1)* gene fusions across tumor types.** S. V. Liu, R. Feldman, H. Borghaei, S. M. Gadgeel, P. C. Ma, J. J. Nieva, A. I. Spira, A. M. Vanderwalde, A. J. Wozniak, S. Jonna, E. S. Kim
- Board 198 Abstract 12085: Effect of anti-PD-1 and anti-Id-1 combo on tumor response and survival in lung cancer.** I. Baraibar, M. Roman, I. Lopez, D. Ajona, A. Calvo, E. Guruceaga, J. Corral, J. J. Lasarte, S. Vicent, I. Gil-Bazo
- Board 199 Abstract 12086: Novel ex vivo patient-derived 3D model as a powerful tool to apply precision medicine.** K. Simeone, R. Guay-Lord, M. Lateef, B. Péant, E. Carmona, J. Kendall-Dupont, A. Orimoto, T. Gervais, A. Mes-Masson, F. Saad
- Board 200 Abstract 12087: Genetic and chemical screens in 2-D vs. 3-D generate distinct leads for target and drug discovery.** P. Gupta, D. X. Jin, Y. Feng, E. Sokol, D. H. Miller
- Board 201 Abstract 12088: Early assessment of treatment effect in advanced lung adenocarcinoma via longitudinal ctDNA analysis.** X. M. Ma, L. Xi, S. Young, N. Tikoo, A. Balasubramanyam, C. Ju, D. Klass, A. F. Lovejoy, A. Pati, O. Solberg, Y. Jiang, H. Adams, B. Wehnl, M. Thomas, F. Lasitschka, M. Meister, M. Schneider, F. Herth, J. F. Palma, T. Muley
- Board 202 Abstract 12089: Quantitative measurement of total erbB2 (H2T), p110 t-erbB2, and erbB2:erbB3 (H23D) heterodimer expression and p110 t-erbB2 in malignant progression from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC).** Y. Zong, K. Shen, J. Sperinde, G. Wallweber, W. Huang, J. W. Winslow, W. Liang, M. D. Pegram
- Board 203 Abstract 12090: Towards a molecular algorithm predicting glioma treatment response and resistance: A biomarker analysis and path to real time profiling in N²M².** T. Kessler, F. Sahm, G. Balasubramanian, E. Pfaff, D. T. Jones, A. Wick, J. Debus, A. Unterberg, A. Berberich, C. Herold-Mende, S. Pfister, B. Brors, S. Dettmer, I. Karapanagiotou-Schenkel, F. Winkler, M. Bendszus, A. von Deimling, M. Platten, W. Wick

Monday, June 4, 2018

- Board 204 **Abstract 12091: *PBRM1* mutation and immunotherapy efficacy: A comprehensive genomic profiling (CGP) assessment.** *G. Bratslavsky, L. M. Gay, E. Sokol, J. A. Elvin, J. Vergilio, J. Suh, S. H. Ramkissoon, S. Daniel, E. A. Severson, J. K. Killian, S. M. Ali, J. Chung, A. B. Schrock, G. M. Frampton, D. Fabrizio, V. A. Miller, M. Naqvi, M. Mollapour, R. J. Corona, J. S. Ross*
- Board 205 **Abstract 12092: *PD-L1* genomic alterations (GA) in solid tumors and hematologic malignancies: A comprehensive genomic profiling (CGP) study.** *L. M. Gay, D. Fabrizio, G. M. Frampton, L. A. Albacker, E. Sokol, J. A. Elvin, J. Vergilio, J. Suh, S. H. Ramkissoon, E. A. Severson, S. Daniel, S. M. Ali, J. Chung, A. B. Schrock, V. A. Miller, J. J. Pu, R. J. Corona, G. Bratslavsky, J. S. Ross*
- Board 206 **Abstract 12093: Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM).** *M. Dankner, M. Lajoie, D. Moldoveanu, S. Rajkumar, T. Nguyen, P. Savage, M. Guiot, X. Huang, A. Protopopov, M. Lvova, D. Vuzman, M. Park, K. Petrecca, D. Hogg, M. O. Butler, A. Spreafico, C. L. Mihalciou, I. Watson, P. Siegel, A. A. Rose*
- Board 207 **Abstract 12094: Large-scale analyses of tumor mutation burdens (TMBs) across various advanced gastrointestinal (GI) malignancies in the nationwide cancer genome screening project, SCRUM-Japan GI-SCREEN.** *Y. Nakamura, W. Okamoto, K. Shitara, T. Kojima, C. Morizane, Y. Naito, S. Yuki, Y. Kagawa, Y. Narita, Y. Nakashima, H. Takahashi, M. Ueno, K. Kato, Y. Komatsu, A. Ohtsu, K. Akagi, T. Yoshino*
- Board 208 **Abstract 12095: Preselection of lung cancer cases using FGFR1 mRNA and gene copy number for treatment with ponatinib.** *T. L. Ng, H. Yu, D. Smith, T. A. Boyle, E. R. York, S. Leedy, D. Gao, L. Heasley, F. R. Hirsch, D. R. Camidge*
- Board 209 **Abstract 12096: *RAS* alterations: Next-generation sequencing of 1,526 patients with diverse malignancies reveals prognostic and therapeutic correlates.** *S. Kato, R. Okamura, G. A. Daniels, A. Goodman, S. Lee, N. Khalid, R. Collier, M. Mareboina, P. Riviere, T. J. Whitchurch, P. T. Fanta, J. K. Sicklick, R. Kurzrock*
- Board 210 **Abstract 12097: Landscape of *BRCA1* and *BRCA2* germline, somatic, and reversion alterations detectable by cell-free DNA testing among patients with metastatic breast, ovarian, pancreatic, or prostate cancer.** *A. Bardia, T. A. Rich, V. M. Raymond, S. R. Fairclough, A. O. Sartor, M. B. Lilly, M. Nezami, S. P. Patel, B. A. Carneiro, A. C. Fan, A. Brufsky, B. A. Parker, B. B. Bridges, N. Agarwal, B. L. Maughan, R. B. Lanman, M. Cristofanilli*
- Board 211 **Abstract 12098: Genetic variants within the glucocorticoids related genes to predict outcome in patients with metastatic colorectal cancer (mCRC).** *A. Puccini, F. Loupakis, S. Cao, R. Tokunaga, M. Naseem, F. Battaglin, M. D. Berger, M. McSkane, S. Soni, W. Zhang, J. Millstein, C. Mancao, C. Cremolini, A. Falcone, H. Lenz*
- Board 212 **Abstract 12099: Phosphorylation of AKT kinase substrates to predict response to the AKT inhibitor MK2206 in the I-SPY 2 trial in both HER2- and HER2+ patients.** *J. D. Wulfkuhle, D. M. Wolf, C. Yau, R. I. Gallagher, L. Brown Swigart, G. L. Hirst, L. Esserman, D. A. Berry, L. van 't Veer, E. Petricoin III*
- Board 213 **Abstract 12100: Non-V600 BRAF mutations in advanced malignancies: Prevalence and survival impact.** *E. Kheder, Y. Xing, K. R. Hess, F. Janku, K. R. Shaw, L. Huang, K. Patel, F. Meric-Bernstam, V. Subbiah*
- Board 214 **Abstract 12101: Exploring the association between somatic molecular features and tumor mutation burden in 513 non-small-cell lung cancer.** *C. Zhu, J. Zhao, Q. Xie, P. Dai, L. Miao, S. Yang, R. Guo, Y. Zhang, G. Lin, J. Liu, H. Yang, Y. Guan, L. Yang, X. Yi, X. Xia*
- Board 215 **Abstract 12102: Impact of tumor-infiltrating lymphocytes on response to neoadjuvant chemotherapy in triple-negative early breast cancer: Translational subproject of the WSG-ADAPT TN trial.** *C. Liedtke, F. Feuerhake, M. Garke, M. Christgen, R. E. Kates, E. Grischke, H. Forstbauer, M. W. Braun, M. R. Warm, C. Hackmann, C. Uleer, B. Aktas, C. Schumacher, S. Kummel, R. Wuerstlein, U. Nitz, H. H. Kreipe, O. Gluz, N. Harbeck*

- Board 216 **Abstract 12103: Association of activation levels of TIE2 with response to the angiogenesis inhibitor trebananib in HER2+ patients in the I-SPY 2 trial.** *R. I. Gallagher, J. D. Wulfkuhle, C. Yau, D. M. Wolf, L. Brown Swigart, G. L. Hirst, L. Esserman, D. A. Berry, L. van 't Veer, E. Petricoin III*
- Board 217 **Abstract 12104: Single-cell profiling of NSCLC tumor treated with Durvalumab and in combination with Tremelimumab.** *Y. Shrestha, Q. Zhang, L. Cheng, R. Halpin, B. W. Higgs, R. Raja, K. Streicher*
- Board 218 **Abstract 12105: A gene expression signature of FOXM1-AURKB-CDKN1A to recapitulate molecular characteristics of standardized uptake value of ¹⁸F-FDG-PET in breast cancer.** *S. Ahn, S. Kim, S. Bae, C. Yoon, J. Jeong, I. Chu*
- Board 219 **Abstract 12106: Circadian clock gene PER1 mutations in colorectal cancer (CRC).** *F. Battaglin, J. Xiu, M. Winerip, R. M. Goldberg, P. A. Philip, A. Seeber, A. Puccini, R. Tokunaga, M. Naseem, S. Soni, M. McSkane, M. D. Berger, A. Barzi, W. Zhang, J. J. Hwang, A. F. Shields, J. Marshall, W. M. Korn, H. Lenz*
- Board 220 **Abstract 12107: Genetic variations in the β 2M/HLA-E immunomodulatory complex to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line FOLFIRI/Cetuximab: Data from the phase III FIRE-3 trial.** *M. Naseem, S. Stintzing, S. Cao, A. Puccini, R. Tokunaga, F. Battaglin, A. Barzi, M. D. Berger, S. Soni, M. McSkane, W. Zhang, J. Millstein, V. Heinemann, H. Lenz*
- Board 221 **Abstract 12108: Landscape of osimertinib resistant mutations between the two common subtypes of EGFR 19del or L858R in NSCLC.** *Y. Zhang, J. Zhao, R. Guo, G. Lin, L. Liu, C. Zhu, N. Liang, H. Yang, W. Wang, P. Dai, Y. Guan, L. Yang, X. Yi, X. Xia*
- Board 222 **Abstract 12109: Comparison of annotation services for the VA Precision Oncology Program.** *E. Katsoulakis, J. Duffy, B. J. Hintze, N. L. Spector, M. J. Kelley*
- Board 223 **Abstract 12110: Identification of actionable genomic alterations utilizing cfDNA.** *N. S. Sanchez, A. M. Bailey, C. Wathoo, K. Balaji, M. Demirhan, D. Yang, M. Kahle, A. O. Kaseb, M. M. Javle, C. Eng, V. Subbiah, F. Janku, V. M. Raymond, R. B. Lanman, K. R. Shaw, F. Meric-Bernstam*
- Board 224 **Abstract 12111: Pan-cancer mesenchymal assay to predict response to MEK inhibitors.** *N. McCabe, L. A. Knight, L. D. Perez, B. Price, A. McCavigan, A. El-Helali, S. Eddie, C. Gourley, D. P. Harkin, R. D. Kennedy*
- Board 225 **Abstract 12112: Association of mucosal Fusobacterium with clinical stage and immune gene signatures of rectal adenocarcinoma.** *M. S. Lee, C. A. Carlson, B. F. Calvo, B. H. O'Neil, N. A. McCoy, D. S. Bortone, B. G. Vincent, T. O. Keku*
- Board 226 **Abstract 12113: Co-expression patterns of immune checkpoint molecules in relation to PD-L1 expression.** *S. K. Pal, A. M. Vanderwalde, C. Szeto, S. C. Benz, J. Z. Sanborn, C. J. Vaske, S. K. Reddy, O. Hamid*
- Board 227 **Abstract 12114: Genomic landscape of diverse rare tumors: Next-generation sequencing of paired DNA and RNA analysis.** *R. Okamura, S. Kato, R. Parulkar, C. Szeto, S. Reddy, R. Kurzrock*
- Board 228 **Abstract 12115: Computer-extracted features relating to spatial arrangement of tumor infiltrating lymphocytes to predict response to nivolumab in non-small cell lung cancer (NSCLC).** *C. Barrera, P. Velu, K. Bera, X. Wang, P. Prasanna, M. Khunger, A. Khunger, V. Velcheti, E. Romero, A. Madabhushi*
- Board 229 **Abstract 12116: Detection of germline homologous recombination deficiency (HRD) in patients with metastatic esophagogastric (EG) cancer using clinical next generation sequencing (NGS).** *Y. Y. Janjigian, P. Jonsson, Y. Kemel, V. Joseph, Y. Tuvy, Z. Shameer, V. Ravichandran, L. Zhang, D. Mandelker, G. Y. Ku, J. F. Hechtman, D. P. Kelsen, D. H. Ilson, K. Offit, M. F. Berger, N. Schultz, M. E. Robson, D. B. Solit, B. S. Taylor, Z. K. Stadler*
- Board 230 **Abstract 12117: Three-fold overestimation of tumor mutation burden using 248 gene panel versus whole exome.** *A. Nguyen, C. Garner, S. K. Reddy, J. Z. Sanborn, S. C. Benz, T. E. Seery, S. Rabizadeh*

Monday, June 4, 2018

- Board 231 **Abstract 12118: Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.** *R. Kurzrock, R. Parulkar, T. J. Yeatman, W. S. El-Deiry, T. J. Pluard, C. Garner, S. K. Reddy*
- Board 232 **Abstract 12119: FDG-uptake and expression levels of TILs and PD-L1 in primary breast cancer.** *T. Hirakata*
- Board 233 **Abstract 12120: Survival outcome of breast cancer (BC) patients presenting with recurrent and de novo isolated contralateral lymph node metastases (CLNM).** *A. Al-Awadhi, X. Lei, R. A. Sanford, V. Valero, S. H. Giordano, M. Chavez-MacGregor*
- Board 234 **Abstract 12121: Early mortality with immune checkpoint inhibitors (IOs) in solid tumors: An inconvenient truth?** *E. Winquist, S. Kuruvilla, A. C. Nichols, J. G. Lenehan, S. Macneil, D. A. Palma*
- Board 235 **Abstract 12122: Acquired BRAF fusions as a mechanism of resistance to EGFR therapy.** *M. Vojnic, C. Kurzatkowski, D. Kubota, K. Suzawa, Z. Liu, M. Mattar, I. Khodos, J. T. Poirier, E. de Stanchina, C. M. Rudin, G. J. Riely, H. A. Yu, M. E. Arcila, M. Ladanyi, R. Somwar*
- Board 236 **Abstract 12123: A comprehensive genomic analysis of squamous cell carcinomas of the lung, esophagus, and head and neck.** *L. A. Kujtan, P. Case, R. Imperial, O. M. Toor, A. Khaliq, V. Muthukumar, K. F. Kennedy, R. M. Mohammad, A. Hussain, T. J. Pluard, J. Case, J. Subramanian, A. Masood*
- Board 237 **Abstract 12124: Molecular comparison of interval and screen-detected breast cancers.** *D. A. Cheasley*
- Board 238 **Abstract 12125: Are racial differences in obesity and insulin resistance related to aggressive breast cancer?** *E. Gallagher, D. Leroith, S. M. Feldman, E. R. Port, N. Friedman, S. K. Boolbol, B. K. Killelea, L. Choi, K. Fei, R. Franco, D. Cruz, N. A. Bickell*
- Board 239a **Abstract TPS12126: A phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors.** *J. Rodon Ahnert, M. H. Taylor, E. M. O'Reilly, J. Zhang, R. C. Doebele, Y. Ben, L. L. Sharp, W. J. Boyle, C. Chang, G. Frey, W. Chen, M. Melnick, J. M. Short, H. A. Burris III*
- Board 239b **Abstract TPS12127: Canadian profiling and targeted agent utilization trial (CAPTUR/PM.1): A phase II basket precision medicine trial.** *T. Skamene, L. L. Siu, D. J. Renouf, J. J. Laskin, P. L. Bedard, S. J. Jones, C. Ferrario, J. Whitlock, J. Petrie, P. Sullivan, E. R. Malone, D. Nomikos, B. E. Chen, J. Dancey*

3:00 PM - 4:15 PM Poster Discussion Session

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Location: S406

Interact ID: 10861

William Douglas Figg, PharmD - Chair

National Institutes of Health

John Frederick Hilton, MD, FRCPC - Chair

The Ottawa Hospital

3:00 PM Anastasios Stathis, MD (Discussion of Abstract(s) 2509-2511)

IOSI - Oncology Institute of Southern Switzerland

Inhibition of Transcriptional and Epigenetics Targets

3:12 PM Panel Question and Answer

- 3:18 PM** **Valentina Boni, MD, PhD (Discussion of Abstract(s) 2512-2514)**
START Madrid CIOCC Hospital Universitario Sanchinarro
Disrupting Signal Transduction in Enriched Patient Populations
- 3:30 PM** *Panel Question and Answer*
- 3:36 PM** **Sandra P. D'Angelo, MD (Discussion of Abstract(s) 2515-2516)**
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College
Desmoid Tumors Biology: Exploiting Estrogen and Notch Signaling
- 3:48 PM** *Panel Question and Answer*
- 3:54 PM** **Brian Andrew Van Tine, MD, PhD (Discussion of Abstract(s) 2517-2520)**
Washington University in St. Louis
Emerging Agents: Metabolism, DNA Repair, and Hypoxia
- 4:06 PM** *Panel Question and Answer*

Posters discussed in this session are on display in the Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics Poster Session. See page 242 for poster information.

3:00 PM - 4:15 PM Poster Discussion Session

Hematologic Malignancies—Plasma Cell Dyscrasia

Location: E450

Interact ID: 10872

Alfred L. Garfall, MD - Chair

Abramson Cancer Center

Adriana C. Rossi, MD - Chair

NewYork-Presbyterian Weill Cornell Medical Center

- 3:00 PM** **Ashraf Z. Badros, MD (Discussion of Abstract(s) 8009-8011)**
University of Maryland
Novel Approaches to Newly Diagnosed Plasma Cell Dyscrasias
- 3:12 PM** *Panel Question and Answer*
- 3:18 PM** **Rachid C. Baz, MD (Discussion of Abstract(s) 8012-8014)**
Moffitt Cancer Center
Novel Antibody Strategies in Relapsed/Refractory Myeloma
- 3:30 PM** *Panel Question and Answer*
- 3:36 PM** **Elizabeth O'Donnell, MD (Discussion of Abstract(s) 8015-8017)**
Massachusetts General Hospital Cancer Center
Does Dose Matter in Myeloma?
- 3:48 PM** *Panel Question and Answer*
- 3:54 PM** **Xavier Leleu, MD, PhD (Discussion of Abstract(s) 8018-8020)**
CHU de Poitiers
Managing Refractory Myeloma: When All Else Fails
- 4:06 PM** *Panel Question and Answer*

Posters discussed in this session are on display in the Hematologic Malignancies—Plasma Cell Dyscrasia Poster Session. See page 277 for poster information.

Monday, June 4, 2018

3:00 PM - 4:15 PM Award Lecture

B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology

Location: S404

Interact ID: 10934

Daniel F. Hayes, MD, FACP, FASCO

University of Michigan Comprehensive Cancer Center

Presentation of the 2018 B. J. Kennedy Award for Scientific Excellence in Geriatric Oncology

Supriya Gupta Mohile, MD, MS

University of Rochester Medical Center

Honoring the Preferences of Older Patients With Cancer and Caregivers Through Improved Communication

3:00 PM - 4:15 PM Education Session

Cultivating Primary Resilience: Burnout Prevention on a Larger Scale

Location: S102

Interact ID: 10780

Susana N. Banerjee, PhD, MA, MBBS, MRCP - Chair

The Royal Marsden NHS Foundation Trust

A Perspective From Across the Pond: Physician Burnout in Europe

Vicky Makker, MD

Memorial Sloan Kettering Cancer Center

Implementing a Burnout Prevention Program Among Medical Oncology Fellows: Challenges, Successes, and Opportunities

James W. Lynch, MD

University of Florida

Wellness on a Larger Scale: Institutional Programs for Burnout Prevention

Panel Question and Answer

3:00 PM - 4:15 PM Education Session

Developing and Optimizing Molecular Oncology Tumor Boards in Pediatric Oncology

Location: S504

Interact ID: 10761

Rajen Mody, MD - Chair

University of Michigan Medical Center

Where Are We Now?

Elaine R. Mardis, PhD

Ohio State University Comprehensive Cancer Center

Where Are We Going?

Donald Williams Parsons, MD, PhD

Texas Children's Cancer Center Baylor College of Medicine

NCI/COG Pediatric Match Trial

Panel Question and Answer

3:00 PM - 4:15 PM Education Session

Patient–Clinician Communication Is a Two-Way Street: Driving in Parallel Toward Well-Being

Location: S103

Interact ID: 10685

Timothy D. Gilligan, MD, FASCO - Chair

Cleveland Clinic Taussig Cancer Institute

Patient-Clinician Communication: Implementing the New ASCO Consensus Guideline

Andrea Catherine Enzinger, MD

Dana-Farber Cancer Institute

Addressing Spirituality Within the Care of Patients

Liz Salmi

The Liz Army

The Patient Is the Center: Anchoring the Conversation

Panel Question and Answer

3:00 PM - 4:15 PM Meet the Professor Session

Targeting Tumor Metabolism in Gynecologic Cancer - Ticketed Session

Location: E253c

Interact ID: 10745

Ernst Lengyel, MD, PhD

The University of Chicago

Victoria Lin Bae-Jump, MD, PhD

University of North Carolina at Chapel Hill

3:00 PM - 4:15 PM Meet the Professor Session

Tools for Advancing Precision Oncology - Ticketed Session

Location: E253d

Interact ID: 10683

Ravi Salgia, MD, PhD

City of Hope

3:00 PM - 4:30 PM Clinical Science Symposium

Breast Cancer Immunotherapy: Can We Crack the Code?

Location: Hall D2

Interact ID: 10773

Rebecca Alexandra Dent, MD - Chair

National Cancer Centre Singapore

Heather L. McArthur, MD, MPH - Chair

Cedars-Sinai Medical Center

Monday, June 4, 2018

- 3:00 PM Abstract 1009: The integrated genomic and immune landscapes of lethal metastatic breast cancer (MBC).** *L. De Mattos-Arruda, S. Sammut, E. M. Ross, R. Bashford-Rogers, E. Greenstein, S. Morganello, O. M. Rueda, E. Martinez-Saez, V. Peg, J. Cortés, S. Nik-Zainal, M. Murtaza, N. Friedman, F. Markowetz, J. Seoane, C. Caldas*
- 3:12 PM Abstract 1010: Determinants of high tumor mutational burden (TMB) and mutational signatures in breast cancer.** *R. Barroso-Sousa, E. Jain, D. Kim, A. H. Partridge, O. Cohen, N. Wagle*
- 3:24 PM Heather L. McArthur, MD, MPH (Discussion of Abstract(s) 1009-1010)**
Cedars-Sinai Medical Center
Translating Immunobiology Into Effective Therapeutic Strategies
- 3:36 PM Abstract 1011: TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.**
S. Vinayak, S. M. Tolaney, L. S. Schwartzberg, M. M. Mita, G. A. McCann, A. R. Tan, A. E. Wahner Hendrickson, A. Forero-Torres, C. K. Anders, G. M. Wulf, P. M. Dillon, F. Lynce, C. Zarwan, J. K. Erban, B. J. Dezube, Y. Zhou, N. Buerstatte, S. Arora, H. Achour, M. L. Telli
- 3:48 PM Abstract 1012: Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): Final response data stage I and first translational data.** *M. Kok, L. Voorwerk, H. Horlings, K. Sikorska, K. van der Vijver, M. Slagter, S. Warren, S. Ong, T. Wiersma, N. Russell, F. Lalezari, M. de Maaker, I. Kemper, I. A. Mandjes, M. Chalabi, G. S. Sonke, R. Salgado, S. C. Linn, T. Schumacher, C. U. Blank*
- 4:00 PM Rita Nanda, MD (Discussion of Abstract(s) 1011-1012)**
The University of Chicago
Enhancing Checkpoint Inhibitors in Triple-Negative Breast Cancer
- 4:12 PM Panel Question and Answer**

3:00 PM - 6:00 PM Oral Abstract Session

Gastrointestinal (Noncolorectal) Cancer

Location: Arie Crown Theater

Interact ID: 10836

E. Gabriela Chiorean, MD - Chair

Fred Hutchinson Cancer Research Center

Keith Robert Unger, MD - Chair

Georgetown University

- 3:00 PM Abstract 4000: FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).** *L. Dahan, J. Phelip, K. Le Malicot, N. Williet, J. Desrame, J. Volet, C. Petorin, D. Malka, C. Rebischung, T. Aparicio, C. Lecaille, Y. Rinaldi, A. Turpin, A. Bignon, J. Bachelot, J. Seitz, C. Lepage, E. Francois*
- 3:12 PM Abstract LBA4001: Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.** *T. Conroy, P. Hammel, M. Hebban, M. Ben Abdelghani, A. C. Wei, J. Raoul, L. Chone, E. Francois, P. Artru, J. J. Biagi, T. Lecomte, E. Assenat, R. Faroux, M. Ychou, J. Volet, A. Sauvanet, C. Jouffroy-Zeller, P. RAT, F. Castan, J. Bachelot*

- 3:24 PM Abstract LBA4002: Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial.** *G. Van Tienhoven, E. Versteijne, M. Suker, K. B. Groothuis, O. R. Busch, B. A. Bonsing, I. H. de Hingh, S. Festen, G. A. Patijn, J. de Vos-Geelen, A. H. Zwinderman, C. J. Punt, C. H. van Eijck*
- 3:36 PM Colin D. Weekes, MD, PhD (Discussion of Abstract(s) 4000-LBA4002)**
Massachusetts General Hospital
Combination Chemotherapy for Pancreas Cancer: Leaping Forward
- 3:48 PM Panel Question and Answer**
- 4:00 PM Abstract 4003: REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.** *A. X. Zhu, Y. Kang, C. Yen, R. S. Finn, P. Galle, J. M. Llovet, E. Assenat, G. Brandi, H. Lim, M. Pracht, K. Rau, P. Merle, K. Motomura, I. Ohno, B. Daniele, D. Shin, G. Gerken, P. Abada, Y. Hsu, M. Kudo*
- 4:12 PM Abstract 4004: A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).** *P. L. Kunz, P. J. Catalano, H. Nimeiri, G. A. Fisher Jr., T. A. Longacre, C. J. Suarez, J. C. Yao, M. H. Kulke, A. E. Hendifar, J. C. Shanks, M. H. Shah, M. Zalupski, E. L. Schmulbach, D. L. Reidy, J. R. Strosberg, P. J. O'Dwyer, A. B. Benson III*
- 4:24 PM Abstract 4005: Azedra (iobenguane I 131) in patients with malignant, recurrent and/or unresectable pheochromocytoma or paraganglioma (PPGL): Updated efficacy and safety results from a multi-center, open-label, pivotal phase 2 study.** *D. Pryma, B. Chin, R. Noto, J. Dillon, L. Solnes, T. White, N. Stambler, T. Lin, V. A. DiPippo, J. D. Jensen, S. Mahmood, V. Wong, C. Jimenez*
- 4:36 PM Emily K. Bergsland, MD (Discussion of Abstract(s) 4003-4005)**
University of California, San Francisco
Potpourri: Hepatocellular Carcinoma, Neuroendocrine, and More
- 4:48 PM Panel Question and Answer**
- 5:00 PM Abstract 4007: A randomized phase III study comparing S-1 plus docetaxel with S-1 alone as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer (JACCRO GC-07 trial).** *Y. Koda, K. Yoshida, M. Kochi, W. Ichikawa, Y. Kakeji, T. Sano, N. Nagao, M. Takahashi, A. Takagane, M. Nakamura, M. Kaji, H. Okitsu, T. Nomura, T. Matsui, T. Yoshikawa, J. Matsuyama, M. Yamada, Y. Ito, M. Takeuchi, M. Fujii*
- 5:12 PM Abstract LBA4008: Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: Efficacy and safety in the phase III randomized factorial ASPECT trial.** *J. Jankowski, J. de Caestecker, S. Love, G. Reilly, Y. Ang, K. Ragunath, A. Tucker, I. Penman, C. Rodgers, E. Roffe, C. E. Brooks, S. Attwood, D. Morris, R. Harrison, P. Bhandari, P. Watson, S. Sanders, H. Barr, P. Moayyedi, J. Neale*
- 5:24 PM Abstract 4062: Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.** *C. S. Fuchs, M. Ozguroglu, Y. Bang, M. Di Bartolomeo, M. Mandala, M. Ryu, L. Fornaro, T. Olesiński, C. Caglevic, H. C. Chung, K. Muro, E. Goekkurt, W. Mansoor, R. S. McDermott, E. Shacham-Shmueli, X. Chen, S. Kang, C. A. Mayo, A. Ohtsu, K. Shitara*
- 5:36 PM Zev A. Wainberg, MD (Discussion of Abstract(s) 4007, LBA4008, 4062)**
University of California Los Angeles School of Medicine
Gastroesophageal Cancers: Progress Across the Spectrum
- 5:48 PM Panel Question and Answer**

3:00 PM - 6:00 PM Oral Abstract Session

Genitourinary (Prostate) Cancer

Location: Hall D1

Interact ID: 10838

Atish Dipankar Choudhury, MD, PhD - Chair

Dana-Farber Cancer Institute

Martha P. Mims, MD, PhD - Chair

Baylor College of Medicine

- 3:00 PM Abstract 5000: A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13 trial.** *P. I. Kellokumpu-Lehtinen, M. Hjal̄m-Eriksson, L. Astrom, T. Marttila, C. Thellenberg-Karlsson, S. Nilsson, W. Anders, T. Huttunen, C. Ginman*
- 3:12 PM Abstract 5001: Accuracy of ⁶⁸Ga-PSMA11 PET/CT on recurrent prostate cancer: Preliminary results from a phase 2/3 prospective trial.** *W. Fendler, J. Calais, J. Gartmann, N. G. Nickols, R. E. Reiter, M. Rettig, T. A. Hope, R. Slavik, P. Gupta, A. Quon, M. Allen-Auerbach, K. Herrmann, J. Czernin, M. Eiber*
- 3:24 PM Abstract 5002: A randomized study of finite abiraterone acetate (AA) plus leuprolide (LHRHa) versus LHRHa in biochemically recurrent non metastatic hormone naïve prostate cancer (M0HNPC).** *E. Efsthliou, X. Wang, A. J. Zurita, S. Tu, A. Aparicio, J. Wang, P. G. Corn, S. K. Subudhi, J. C. Araujo, L. K. Reece, L. Pruitt, M. L. Vanalstine, C. Logothetis*
- 3:36 PM Felix Feng, MD (Discussion of Abstract(s) 5000-5002)**
University of California, San Francisco
Judicious Use of Therapeutics and Imaging in Early-Stage Prostate Cancer
- 3:48 PM Panel Question and Answer**
- 4:00 PM Abstract 5003: Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.** *N. Clarke, P. J. Wiechno, B. Alekseev, N. Sala, R. Jones, I. Kocak, V. E. Chiuri, J. Jassem, A. Flechon, C. Redfern, C. D. Goessl, J. Burgents, R. Kozarski, D. R. Hodgson, F. Saad*
- 4:12 PM Abstract 5004: The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E).** *A. J. Armstrong, S. Halabi, J. Luo, D. M. Nanus, P. Giannakakou, R. Z. Szmulewitz, D. C. Danila, P. Healy, M. Anand, C. Rothwell, J. Silberstein, G. Galletti, J. Somarelli, S. Gupta, S. Gregory, H. I. Scher, R. Dittamore, S. T. Tagawa, E. S. Antonarakis, D. J. George*
- 4:24 PM Abstract LBA5005: Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC).** *S. Halabi, S. Dutta, C. M. Tangen, M. Rosenthal, D. P. Petrylak, I. M. Thompson Jr., K. N. Chi, J. S. De Bono, A. Fandi, J. C. Araujo, M. A. Eisenberger, C. Logothetis, D. I. Quinn, K. Fizazi, C. S. Higano, D. J. George, M. J. Morris, E. J. Small, I. Tannock, W. K. Kelly*
- 4:36 PM Anthony M. Joshua, MBBS, FRACP, PhD (Discussion of Abstract(s) 5003-LBA5005)**
The Kinghorn Cancer Centre, St. Vincent's Hospital
Genes, Race, and Outcomes in Prostate Cancer
- 4:48 PM Panel Question and Answer**

- 5:00 PM Abstract 5006: Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer.** *J. L. Gulley, M. Borre, N. J. Vogelzang, S. Ng, N. Agarwal, C. C. Parker, D. W. Pook, P. Rathenborg, T. W. Flaig, J. Carles, N. D. Shore, L. Chen, C. R. Heery, W. R. Gerritsen, F. Priou, P. W. Kantoff*
- 5:12 PM Abstract 5007: KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).** *J. S. De Bono, J. C. Goh, K. Ojamaa, J. Piulats Rodriguez, C. G. Drake, C. J. Hoimes, H. Wu, C. H. Poehlein, E. S. Antonarakis*
- 5:24 PM Abstract 5008: A randomized phase 2 study investigating 3 dosing regimens of radium-223 dichloride (Ra-223) in bone metastatic castration-resistant prostate cancer (mCRPC).** *C. N. Sternberg, F. Saad, J. N. Graff, A. Peer, U. N. Vaishampayan, E. Leung, E. Rosenbaum, H. Gurney, R. Epstein, I. D. Davis, B. Wu, L. Trandafir, V. J. Wagner, M. Hussain*
- 5:36 PM Douglas G. McNeel, MD (Discussion of Abstract(s) 5006-5008)**
University of Wisconsin
On the Frontier: Immunotherapy and Radiopharmaceutical Therapy in Prostate Cancer
- 5:48 PM Panel Question and Answer**

3:00 PM - 6:00 PM Oral Abstract Session

Lung Cancer—Non-Small Cell Metastatic

Location: Hall B1
Interact ID: 10846

Melissa Lynne Johnson, MD - Chair
Sarah Cannon Research Institute

Viola Weijia Zhu, MD, PhD - Chair
University of California, Irvine School of Medicine

- 3:00 PM Abstract LBA9000: IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.** *R. M. Jotte, F. Cappuzzo, I. Vynnychenko, D. Stroyakovskiy, D. Rodriguez Abreu, M. A. Hussein, R. A. Soo, H. J. Conter, T. Kozuki, C. Silva, V. Graupner, S. Sun, R. S. Lin, C. Kelsch, M. Kowanetz, T. Hoang, A. Sandler, M. A. Socinski*
- 3:12 PM Abstract 9001: Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227.** *H. Borghaei, M. D. Hellmann, L. G. Paz-Ares, S. S. Ramalingam, M. Reck, K. J. O'Byrne, P. Bhagavatheeswaran, F. E. Nathan, J. R. Brahmer*
- 3:24 PM Tom Stinchcombe, MD (Discussion of Abstract(s) LBA9000-9001)**
Duke University Cancer Center
First-Line Immunotherapy Strategies: What's Best?
- 3:36 PM Panel Question and Answer**
- 3:45 PM Abstract 9002: Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.** *M. A. Socinski, R. M. Jotte, F. Cappuzzo, F. J. Orlandi, D. Stroyakovskiy, N. Nogami, D. Rodriguez-Abreu, D. Moro-Sibilot, C. A. Thomas, F. Barlesi, G. G. Finley, C. Kelsch, A. Lee, S. Coleman, Y. Shen, M. Kowanetz, A. Lopez-Chavez, A. Sandler, M. Reck*

Monday, June 4, 2018

- 3:57 PM Abstract 9003: Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC.** *K. C. Arbour, L. Mezquita, N. Long, H. Rizvi, E. Auclin, A. Ni, G. Martinez Bernal, J. E. Chaft, R. Ferrara, W. V. Lai, L. Hendriks, J. K. Sabari, C. Caramella, A. J. Plodkowski, D. Halpenny, D. Planchard, G. J. Riely, B. Besse, M. D. Hellmann*
- 4:09 PM Marina Chiara Garassino, MD (Discussion of Abstract(s) 9002-9003)**
Fondazione IRCCS Istituto Nazionale dei Tumori
Choosing Immunotherapy Partners Wisely: What to Add and What to Leave Out
- 4:21 PM Panel Question and Answer**
- 4:30 PM Abstract 9004: Dacomitinib (daco) versus gefitinib (gef) for first-line treatment of advanced NSCLC (ARCHER 1050): Final overall survival (OS) analysis.** *T. Mok, Y. Cheng, X. Zhou, K. Lee, K. Nakagawa, S. Niho, M. Y. Lee, R. G. Linke, R. Rosell, J. Corral Jaime, M. Migliorino, A. Pluzanski, E. I. Sbar, T. Wang, J. Liang White, Y. Wu*
- 4:42 PM Abstract 9005: Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009).** *A. Nakamura, A. Inoue, S. Morita, Y. Hosomi, T. Kato, T. Fukuhara, A. Gemma, K. Takahashi, Y. Fujita, T. Harada, K. Minato, K. Takamura, K. Kobayashi, T. Nukiwa*
- 4:54 PM Daniel Shao-Weng Tan, MBBS, PhD (Discussion of Abstract(s) 9004-9005)**
National Cancer Center Singapore
Shifting Sands: Improving on First-Generation EGFR TKIs
- 5:06 PM Panel Question and Answer**
- 5:15 PM Abstract 9006: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026.** *N. Furuya, T. Fukuhara, H. Saito, K. Watanabe, S. Sugawara, S. Iwasawa, Y. Tsunozuka, O. Yamaguchi, M. Okada, K. Yoshimori, I. Nakachi, A. Gemma, K. Azuma, K. Hagiwara, T. Nukiwa, S. Morita, K. Kobayashi, M. Maemondo*
- 5:27 PM Abstract 9007: Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): Survival follow-up results of JO25567.** *N. Yamamoto, T. Seto, M. Nishio, K. Goto, I. Okamoto, T. Yamanaka, M. Tanaka, K. Takahashi, M. Fukuoka*
- 5:39 PM Lecia V. Sequist, MD, MPH (Discussion of Abstract(s) 9006-9007)**
Massachusetts General Hospital Cancer Center and Harvard Medical School
Angiogenesis Plus EGFR TKI: Is Progression-Free Survival Enough?
- 5:51 PM Panel Question and Answer**

4:30 PM - 6:00 PM Clinical Science Symposium

Targeted Therapy in Leukemia

Location: E450

Interact ID: 10764

Tara L. Lin, MD - Chair

University of Kansas Medical Center

Bayard L. Powell, MD - Chair

Wake Forest School of Medicine

- 4:30 PM Abstract 7009: A phase 1 dose escalation study of the *IDH1m* inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).** *J. M. Watts, M. R. Baer, S. Lee, J. Yang, S. N. Dinner, T. Prebet, G. J. Schiller, K. Seiter, P. B. Ferrell, P. F. Kelly, P. Li, J. Sweeney, C. Watson, H. Mohamed, J. E. Cortes*

- 4:48 PM Uma Borate, MD, MS (Discussion of Abstract(s) 7009)**
Oregon Health & Science University
IDH Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
- 5:06 PM Abstract 7010: Durable response with venetoclax in combination with decitabine or azacitadine in elderly patients with acute myeloid leukemia (AML).** *C. D. Dinardo, K. W. Pratz, J. Potluri, V. A. Pullarkat, B. A. Jonas, A. H. Wei, P. S. Becker, O. Frankfurt, T. Xu, W. Hong, B. Chyla, D. A. Pollyea, A. G. Letai*
- 5:24 PM Prapti Arvind Patel, MD (Discussion of Abstract(s) 7010)**
The University of Texas Southwestern Medical Center
BCL-2 Inhibition in Acute Myeloid Leukemia
- 5:42 PM Panel Question and Answer**

4:45 PM - 6:00 PM Poster Discussion Session

Gynecologic Cancer

Location: S100bc
Interact ID: 10867

Deborah Kay Armstrong, MD - Chair

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

Linda R. Duska, MD, MPH - Chair

University of Virginia School of Medicine

- 4:45 PM Carol Aghajanian, MD (Discussion of Abstract(s) 5514-5515)**
Memorial Sloan Kettering Cancer Center
Targeted Agents: Finding the Mark
- 4:57 PM Panel Question and Answer**
- 5:03 PM Stephanie Gaillard, MD, PhD (Discussion of Abstract(s) 5516-5518)**
Johns Hopkins School of Medicine
The Journey of Upfront Therapy in Ovarian Cancer
- 5:15 PM Panel Question and Answer**
- 5:21 PM Sarah Madhu Temkin, MD (Discussion of Abstract(s) 5519-5521)**
Virginia Commonwealth University
Refining the Language of Ovarian Cancer
- 5:33 PM Panel Question and Answer**
- 5:39 PM Don S. Dizon, MD, FACP, FASCO (Discussion of Abstract(s) 5522-5524)**
Lifespan Cancer Center
New Approaches for Less Studied Tumors
- 5:51 PM Panel Question and Answer**

Posters discussed in this session are on display in the Gynecologic Cancer Poster Session.
See page 295 for poster information.

4:45 PM - 6:00 PM Poster Discussion Session

Melanoma/Skin Cancers

Location: E451
Interact ID: 10875

Ragini Reiney Kudchadkar, MD - Chair

Winship Cancer Institute

Monday, June 4, 2018

Alexander Christopher Jonathan Van Akkooi, MD, PhD - Chair

Netherlands Cancer Institute

- 4:45 PM Joshua Matthew Varghise Mammen, MD (Discussion of Abstract(s) 9508-9510)**
University of Kansas
Neoadjuvant Treatment of Skin Malignancies
- 4:57 PM Panel Question and Answer**
- 5:03 PM Alexander M. Menzies, MBBS, FRACP, PhD (Discussion of Abstract(s) 9511-9513)**
Melanoma Institute Australia
Combination Treatment for Advanced Melanoma
- 5:15 PM Panel Question and Answer**
- 5:21 PM Michael A. Postow, MD (Discussion of Abstract(s) 9514-9515)**
Memorial Sloan Kettering Cancer Center
Treatment of Advanced Melanoma After Progression on PD-1 Blockade
- 5:33 PM Panel Question and Answer**
- 5:39 PM Harriet M. Kluger, MD (Discussion of Abstract(s) 9516-9519)**
Yale Cancer Center
Updated Efficacy Studies of Anti-PD-1 Therapy and Associated Biomarkers
- 5:51 PM Panel Question and Answer**

Posters discussed in this session are on display in the Melanoma/Skin Cancers Poster Session. See page 304 for poster information.

4:45 PM - 6:00 PM Poster Discussion Session

Patient and Survivor Care

Location: S404

Interact ID: 10876

Patricia A. Robinson, MD - Chair

Loyola University Medical Center

Shoshana M. Rosenberg, ScD - Chair

Dana-Farber Cancer Institute

- 4:45 PM Tara O. Henderson, MD, MPH (Discussion of Abstract(s) 10013-10015)**
University of Chicago
Living Well Beyond Cancer: #AYA survivorship
- 4:57 PM Panel Question and Answer**
- 5:03 PM Judith A. Paice, PhD, RN (Discussion of Abstract(s) 10016-10018)**
Northwestern University
Novel Interventions in Peripheral Neuropathy: A Burning Issue
- 5:15 PM Panel Question and Answer**
- 5:21 PM Kathryn Jean Ruddy, MD, MPH (Discussion of Abstract(s) 10019-10021)**
Mayo Clinic
Minimizing Collateral Damage From Cancer Treatment
- 5:33 PM Panel Question and Answer**
- 5:39 PM Areej El-Jawahri, MD (Discussion of Abstract(s) 10022-10024)**
Massachusetts General Hospital
Palliative Care: When and Where?
- 5:51 PM Panel Question and Answer**

Posters discussed in this session are on display in the Patient and Survivor Care Poster Session. See page 313 for poster information.

4:45 PM - 6:00 PM Poster Discussion Session

Tumor Biology

Location: S406

Interact ID: 10879

Kurt A. Schalper, MD, PhD - Chair

Yale School of Medicine

Eddy Shih-Hsin Yang, MD, PhD - Chair

University of Alabama at Birmingham

4:45 PM Vamsidhar Velcheti, MD (Discussion of Abstract(s) 12012-12015)

Taussig Cancer Institute, Cleveland Clinic

Overcoming Resistance to Immune Checkpoint Blockade

4:57 PM Panel Question and Answer

5:03 PM Pamela Jean Goodwin, MD (Discussion of Abstract(s) 12016-12017)

Lunenfeld-Tanenbaum Research Institute, Sinai Health System

Novel Applications of Genomics in Women's Cancer

5:15 PM Panel Question and Answer

5:21 PM Trever Grant Bivona, MD, PhD (Discussion of Abstract(s) 12018-12020)

University of California, San Francisco

Novel Molecular Analysis to Interrogate Tumor Phenotypes: Epigenetics, miRNA, and Beyond

5:33 PM Panel Question and Answer

5:39 PM Wafik S. El-Deiry, MD, PhD, FACP (Discussion of Abstract(s) 12021-12023)

Fox Chase Cancer Center

Resources and Tools for Precision Oncology: cfDNA Genome Atlas and PDX Models

5:51 PM Panel Question and Answer

Posters discussed in this session are on display in the Tumor Biology Poster Session. See page 321 for poster information.

4:45 PM - 6:00 PM Award Lecture

Gianni Bonadonna Breast Cancer Award and Lecture

Location: Hall D2

Interact ID: 10931

Daniel F. Hayes, MD, FACP, FASCO

University of Michigan Comprehensive Cancer Center

Presentation of the 2018 Gianni Bonadonna Breast Cancer Award

Gabriel N. Hortobagyi, MD, FACP, FASCO

The University of Texas MD Anderson Cancer Center

Mentoring, Empowering, Opening Doors

Monday, June 4, 2018

4:45 PM - 6:00 PM Education Session

Challenges Facing Family Caregivers and Emerging Novel Interventions

Location: S504

Interact ID: 10796

Sung Won Choi, MD, MS - Chair

University of Michigan

Family Caregiving Throughout the Illness Trajectory: Diagnosis, Treatment, Survivorship

Robert Noll, PhD

University of Pittsburgh

Psychosocial Support and Coping Skills in Family Caregiving

Tammy I. Kang, MD, MSCE

Texas Children's Hospital

Family Caregiving in the Palliative Care and End-of-Life Setting

Kathi Mooney, PhD, RN

University of Utah

Novel Technology Interventions in Family Caregiving: Lessons Learned From the Clinical Setting

Panel Question and Answer

4:45 PM - 6:00 PM Education Session

Next-Generation Platform Trials: Innovations in Trial Design

Location: S100a

Interact ID: 10718

Mary Weber Redman, PhD - Chair

Fred Hutchinson Cancer Research Center

Statistical Innovations for Molecularly Driven Trials

Paul M. Williams, PhD

Frederick National Laboratory for Cancer Research

Optimal Source for Molecular Characterization

Alexander E. Drilon, MD

Memorial Sloan Kettering Cancer Center

Tumor-Agnostic Drug Development

Panel Question and Answer

4:45 PM - 6:00 PM Education Session

No Decision Is Final: Making a Career Transition

Location: S102

Interact ID: 10779

Brian C. Boulmay, MD - Chair

Louisiana State University

Preparing Trainees for the Real World: Exploring Options Within Oncology

Marcelo Blaya, MD

Memorial Healthcare System

Moving From Academic Medicine to Private Practice: Lessons and Perspectives

Maria Catherine Pietanza, MD

Merck & Co., Inc.

Transitioning From Academic Medicine to a Career in the Pharmaceutical Industry

Tatiana Michelle Prowell, MD

U.S. Food and Drug Administration

Seeking New Opportunities: What to Look for and How to Prepare for Them

Panel Question and Answer

4:45 PM - 6:00 PM Education Session

Tele-Oncology: Beyond the Basics

Location: S103

Interact ID: 10695

Ana Maria Lopez, MD, MPH - Chair

University of Utah

Setting up a Tele-Oncology Service: Technology, Training, and Reimbursement

Sahussapont Joseph Sirintrapun, MD

Memorial Sloan Kettering Cancer Center

Tele-Pathology to Support Tele-Oncology Care

Joseph Greer, PhD

Massachusetts General Hospital

Apps and Mobile Tools for Cancer Care

Karen Edison, MD

University of Missouri Health System

Critical Policy Issues in Telecare

Panel Question and Answer

4:45 PM - 6:00 PM Meet the Professor Session

The Role of Minimal Residual Disease of Myeloma in Clinical Practice - Ticketed Session

Location: E253c

Interact ID: 10756

Jesus San-Miguel, MD

Clinica Universidad de Navarra

Carl Ola Landgren, MD, PhD

Notes

7:30 AM - 9:15 AM Highlights of the Day Session

Highlights of the Day Session III

Location: Hall D1

Interact ID: 10816

Suzanne George, MD - Chair

Dana-Farber Cancer Institute/Harvard Medical School

7:30 AM Ruth O'Regan, MD

University of Wisconsin Carbone Cancer Center
Breast Cancer—Local/Regional/Adjuvant

7:45 AM E. Gabriela Chiorean, MD

Fred Hutchinson Cancer Research Center
Gastrointestinal (Noncolorectal) Cancer

8:00 AM Rahul Raj Aggarwal, MD

UCSF Helen Diller Family Comprehensive Cancer Center
Genitourinary (Prostate) Cancer

8:15 AM Karen Kelly, MD, FASCO

University of California Davis Comprehensive Cancer Center
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Thoracic Cancers

8:30 AM Gregory J. Riely, MD, PhD

Memorial Sloan Kettering Cancer Center
Lung Cancer—Non-Small Cell Metastatic

8:45 AM Leslie Anne Fecher, MD

Abramson Cancer Center of the University of Pennsylvania
Melanoma/Skin Cancers

9:00 AM Victor Manuel Villalobos, MD, PhD

University of Colorado
Sarcoma

8:00 AM - 9:15 AM Education Session

Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options

Location: E451

Interact ID: 10708

Susan Mary O'Brien, MD - Chair

University of California, Irvine

Is There Still a Role for Chemo-Immunotherapy in the Treatment of Chronic Lymphocytic Leukemia?

Anthony R. Mato, MD, MSCE

Memorial Sloan Kettering Cancer Center

Sequencing of New Molecules in the Treatment of Chronic Lymphocytic Leukemia

Alessandra Ferrajoli, MD

The University of Texas MD Anderson Cancer Center

The Challenge of Chronic Lymphocytic Leukemia in the Elderly Population

Panel Question and Answer

Tuesday, June 5, 2018

8:00 AM - 9:15 AM Education Session

Emerging Therapeutics in Gynecologic Cancer

Location: S100a

Interact ID: 10904

Charles Kunos, MD, PhD - Chair

National Cancer Institute

Coming Soon? New Treatments in Ovarian Cancer

Brad Nelson

BC Cancer Agency

Immunotherapy in Gynecologic Cancers: Just the Facts, No Hype

Ramez Nassef Eskander, MD

University of California Irvine Medical Center

Epigenetic Modifiers As a Therapeutic Approach in Gynecologic Cancers

Panel Question and Answer

8:00 AM - 9:15 AM Education Session

Gaining Confidence in the Management of Immune-Related Toxicities in the Era of Checkpoint Blockade

Location: S100bc

Interact ID: 10916

Patrick Alexander Ott, MD, PhD - Chair

Dana-Farber Cancer Institute

Overview of Immune-Related Toxicities

Julie R. Brahmer, MD, FASCO

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

General Management of Immune-Related Toxicities Incorporating Guidelines Into Practice

Jeffrey S. Weber, MD, PhD

New York University Perlmutter Cancer Center

Challenging Cases of Immune-Related Toxicities

Panel Question and Answer

8:00 AM - 9:15 AM Education Session

Managing Cognitive Changes in Cancer Survivors

Location: S504

Interact ID: 10687

Michelle Christine Janelins, PhD, MPH - Chair

University of Rochester Medical Center

Trajectory and Risk Factors for Cognitive Changes in Patients With Cancer

Kevin R. Krull, PhD

St. Jude Children's Research Hospital

Addressing the Unique Cognitive Needs of Pediatric and AYA Cancer Survivors

Jeffrey Scott Wefel, PhD

The University of Texas MD Anderson Cancer Center

Assessment and Clinical Implications of Cognitive Change in Adult Cancer Survivors

Panel Question and Answer

8:00 AM - 9:15 AM Education Session

The Landscape of Basket Trials in Advanced Colorectal Cancer

Location: E450

Interact ID: 10705

Tim Maughan, MD

CRUK/MRC Oxford Institute for Radiation Oncology

Integrating Germline Genetic Testing Into Oncologic Practice for Colorectal Cancer

Josep Tabernero, MD, PhD

Vall d'Hebron University Hospital

Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer

Peter J. O'Dwyer, MD - Chair

University of Pennsylvania Abramson Cancer Center

Basket Trials in Colorectal Cancer

Panel Question and Answer

8:00 AM - 11:00 AM Oral Abstract Session

Tumor Biology

Location: S406

Interact ID: 10852

Wafik S. El-Deiry, MD, PhD, FACP - Chair

Fox Chase Cancer Center

Patrick C. Ma, MD - Chair

WVU Cancer Institute, West Virginia University

- 8:00 AM Abstract 12000: Association of high tissue TMB and atezolizumab efficacy across multiple tumor types.** *F. A. Legrand, D. R. Gandara, S. Mariathasan, T. Powles, X. He, W. Zhang, S. Jhunjhunwala, D. Nickles, R. Bourgon, E. Schleifman, S. M. Paul, E. E. Kadel III, M. Kowanetz, C. Cummings, Y. Li, D. Fabrizio, E. Peters, P. S. Hegde, L. Amler, D. S. Shames*
- 8:12 AM Abstract 12001: Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results.** *V. Velcheti, E. S. Kim, T. Mekhail, C. Dakhil, P. J. Stella, X. Shen, S. Hu, S. M. Paul, D. S. Shames, C. Yun, S. Phan, M. A. Socinski*
- 8:24 AM Abstract 12002: Multiplexed analysis of myeloid cell (MC) markers to characterize the innate immune composition and clinical features of human non-small cell lung carcinomas (NSCLC).** *B. S. Henick, I. Datar, F. Villarroel-Espindola, M. F. Sanmamed, J. Yu, R. Tuktamyshev, A. C. Li, M. Toki, K. N. Syrigos, D. L. Rimm, L. Chen, R. S. Herbst, K. A. Schalper*
- 8:36 AM Hossein Borghaei, DO, MS (Discussion of Abstract(s) 12000-12002)**
Fox Chase Cancer Center
Circulating Biomarkers for Immunotherapy: Are They Ready for Your Clinic?

Tuesday, June 5, 2018

8:48 AM *Panel Question and Answer*

9:00 AM **Abstract 12003: Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: Exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study.** *C. Swanton, O. Venn, A. Aravanis, E. Hubbell, T. Maddala, J. F. Beausang, D. Filippova, S. Gross, A. Jamshidi, L. Shen, A. Valouev, N. Zhang, K. L. Bolton, T. J. Yeatman, M. Seiden, G. R. Oxnard, M. C. Liu, R. T. Williams, A. Hartman, J. Baselga*

9:12 AM **Abstract 12004: Confounding effects of clonal hematopoiesis in clinical genomic profiling of solid tumors.** *A. Zehir, R. Ptashkin, D. Mandelker, C. C. Coombs, K. L. Bolton, Z. Yelskaya, D. M. Hyman, D. B. Solit, J. Baselga, L. Zhang, M. E. Arcila, M. Ladanyi, R. L. Levine, M. F. Berger*

9:24 AM **Kenna R. Shaw, PhD (Discussion of Abstract(s) 12003-12004)**
The University of Texas MD Anderson Cancer Center
Strengths and Pitfalls in Noninvasive Tumor Mutation Testing: Is Clonal Hematopoeisis a Problem?

9:36 AM *Panel Question and Answer*

9:48 AM **Abstract 12005: Whole exome sequencing (WES) to define the genomic landscape of young lung cancer patients (pts).** *X. Wu, Y. Chen, L. Zhu, E. Stylianou, J. Barnholtz-Sloan, Z. Zhang, P. C. Ma*

10:00 AM **Abstract 12006: Application of a real world endpoint to identify and characterize genetic profiles of patients (pts) with poor prognosis in advanced non-small-cell lung cancer (aNSCLC).** *G. Crane, K. Trunzer, S. Whipple, K. Cuenco, J. Tolson, B. Kathuria, A. Das-Gupta*

10:12 AM **Abstract 12007: Liquid biopsy to predict benefit from rechallenge with cetuximab (cet) + irinotecan (iri) in RAS/BRAF wild-type metastatic colorectal cancer patients (pts) with acquired resistance to first-line cet+iri: Final results and translational analyses of the CRICKET study by GONO.** *D. Rossini, C. Cremolini, E. Conca, M. Del Re, A. Busico, F. Pietrantonio, F. Bergamo, R. Danesi, M. Casagrande, E. Tamburini, E. Dell'Aquila, A. Strippoli, G. Masi, G. Tonini, F. Negri, D. C. Corsi, P. Ermacora, R. Intini, A. Falcone, D. Santini*

10:24 AM **Abstract 12008: Evolution of genomic instability in metastatic cancer.** *E. Y. Zhao, E. D. Pleasance, M. R. Jones, Y. Shen, C. R. Reisle, A. J. Mungall, R. Moore, Y. Zhao, D. J. Renouf, J. J. Laskin, M. A. Marra, S. J. Jones*

10:36 AM **David Neil Hayes, MD, MPH (Discussion of Abstract(s) 12005-12008)**
University of Tennessee Health Science Center
Novel Insights From Genomics for Clinical Utility

10:48 AM *Panel Question and Answer*

9:45 AM - 11:00 AM Education Session

Assessing Immunotherapy Response and Progression

Location: S100bc

Interact ID: 10717

Sanjay Goel, MD

Montefiore Medical Center/Albert Einstein College of Medicine

Assessing Response to Therapy: Radiographic Response Criteria Review

Georgina V. Long, MD, PhD, FRACP

Melanoma Institute Australia, The University of Sydney, Mater Hospital, and Royal North Shore Hospital

Treatment Beyond Progression: Current Understanding and Implications

Christophe Le Tourneau, MD, PhD - Chair

Institut Curie

Hyperprogression: Myth or Reality?

Panel Question and Answer

9:45 AM - 11:00 AM Education Session

New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little?

Location: E451

Interact ID: 10710

Ranjana H. Advani, MD

Stanford Cancer Institute

Evolving Treatment Paradigms of Early-Stage Hodgkin Lymphoma

Joseph M. Connors, MD - Chair

British Columbia Cancer Agency Center for Lymphoid Cancer

New Risk-Adapted Treatment Strategies in Advanced-Stage Hodgkin Lymphoma

Catherine S. Magid Diefenbach, MD

Perlmutter Cancer Center at NYU Langone Health

Beyond Transplant: Novel Therapies in Relapsed Hodgkin Lymphoma

Panel Question and Answer

9:45 AM - 11:00 AM Education Session

The Latest on Management Approaches for Adjuvant Endocrine Therapy Toxicity

Location: S504

Interact ID: 10793

Patricia A. Robinson, MD - Chair

Loyola University Medical Center

Metabolic Alterations: The Unintentional Consequence of Cancer Treatment

Ting Bao, MD

Memorial Sloan Kettering Cancer Center

How to Integrate Integrative Therapies

Luke Joseph Peppone, PhD

University of Rochester Medical Center

How to Optimize Bone Health in Extended Survivorship: Not Just a Breast Cancer Issue

Panel Question and Answer

9:45 AM - 12:45 PM Oral Abstract Session

Gastrointestinal (Colorectal) Cancer

Location: Hall D1

Interact ID: 10835

Tuesday, June 5, 2018

Jennifer Rachel Eads, MD - Chair

University Hospitals Seidman Cancer Center, Case Western Reserve University

Hanna Kelly Sanoff, MD, MPH - Chair

The University of North Carolina Lineberger Comprehensive Cancer Center, and Alliance

- 9:45 AM Abstract 3500: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC-6.** *H. Schmoll, K. Haustermans, T. J. Price, B. Nordlinger, R. Hofheinz, J. Daisne, J. Janssens, B. Brenner, P. Schmidt, H. Reinel, S. Hollerbach, K. Caca, F. W. Fauth, C. Hannig, J. R. Zalcberg, N. C. Tebbutt, M. E. Mauer, S. Marreaud, M. P. Lutz, E. Van Cutsem*
- 9:57 AM Abstract 3501: Long-term results of the ADORE trial: Adjuvant oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) versus 5-fluorouracil and leucovorin (FL) after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer.** *Y. Hong, S. Kim, J. Lee, B. Nam, J. Kim, K. Kim, J. Park, Y. Park, J. Baek, T. Kim, K. Lee, J. Ahn, K. Jung*
- 10:09 AM Abstract 3502: Modified FOLFOX6 with or without radiation in neoadjuvant treatment of locally advanced rectal cancer: Final results of the Chinese FOWARC multicenter randomized trial.** *Y. Deng, P. Chi, P. Lan, L. Wang, W. Chen, L. Cui, D. Chen, J. Cao, H. Wei, X. Peng, Z. Huang, G. Cai, R. Zhao, Y. Luo, H. Zhou, Y. Wei, H. Zhang, J. Zheng, J. Wang*
- 10:21 AM Cathy Eng, MD, FACP (Discussion of Abstract(s) 3500-3502)**
The University of Texas MD Anderson Cancer Center
Systemic Therapy in Rectal Cancer: Ox-Aggerating the Benefit?
- 10:33 AM Panel Question and Answer**
- 10:42 AM Abstract LBA3503: A UNICANCER phase III trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7.** *F. Quenet, D. Elias, L. Roca, D. Goere, L. Ghouti, M. Pocard, O. Facy, C. Arvieux, G. Lorimier, D. Pezet, F. Marchal, V. Loi, P. Meeus, H. De Forges, T. Stanbury, J. Paineau, O. Glehen*
- 10:54 AM Larissa K. F. Temple, MD (Discussion of Abstract(s) LBA3503)**
University of Rochester
What Is the Future of HIPEC?
- 11:06 AM Panel Question and Answer**
- 11:15 AM Abstract 3504: Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumab based therapy: Result of E7208.** *H. S. Hochster, P. J. Catalano, P. J. O'Dwyer, E. P. Mitchell, D. J. Cohen, B. A. Faller, J. S. Kortmansky, S. M. Kircher, J. Lacy, H. Lenz, U. N. Verma, A. B. Benson III*
- 11:27 AM Abstract 3505: First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study.** *F. Pietrantonio, F. Morano, S. Corallo, S. Lonardi, C. Cremolini, L. Rimassa, A. Sartore-Bianchi, M. Tampellini, S. Bustreo, M. Clavarezza, R. Murialdo, A. Zaniboni, V. Adamo, G. Tomasello, M. Giordano, F. Petrelli, R. Longarini, V. Zagonel, M. Di Bartolomeo, F. G. De Braud*
- 11:39 AM Fotios Loupakis, MD, PhD (Discussion of Abstract(s) 3504-3505)**
Oncologic Institute of Veneto, IRCCS
EGFR and VEGFR Inhibition: Back to the Future?
- 11:51 AM Panel Question and Answer**
- 12:00 PM Abstract 3506: Plasma HER2 (ERBB2) copy number to predict response to HER2-targeted therapy in metastatic colorectal cancer.** *A. Bardelli, G. Siravegna, A. Sartore-Bianchi, R. J. Nagy, B. Mussolin, A. Cassingena, C. Martino, S. Lonardi, V. Zagonel, F. Leone, A. Amatu, L. Trusolino, J. Odegaard, R. B. Lanman, S. Marsoni, S. Siena*

- 12:12 PM Abstract 3507: Actionable fusions in colorectal cancer using a cell-free circulating tumor DNA (ctDNA) assay.** *K. Clifton, V. M. Raymond, A. Dasari, K. P. Raghav, C. M. Parseghian, A. A. Pereira, J. M. Loree, R. Yaeger, J. H. Strickler, R. B. Corcoran, R. B. Lanman, S. Kopetz, V. K. Morris II*
- 12:24 PM Heinz-Josef Lenz, MD (Discussion of Abstract(s) 3506-3507)**
University of Southern California
True Blood: Are Tumor Biopsies Obsolete?
- 12:36 PM Panel Question and Answer**

9:45 AM - 12:45 PM Oral Abstract Session

Gynecologic Cancer

Location: S100a
Interact ID: 10839

Helen Mackay, MRCP, MD - Chair
Princess Margaret Cancer Centre

Karen McLean, MD, PhD - Chair
University of Michigan

- 9:45 AM Abstract 5500: Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602.** *T. Onda, T. Satoh, T. Saito, T. Kasamatsu, T. Nakanishi, K. Takehara, K. Miyamoto, M. Wakabayashi, A. Okamoto, K. Ushijima, H. Kobayashi, K. Kawana, H. Yokota, M. Takano, K. Omatsu, Y. Watanabe, K. Yamamoto, N. Yaegashi, T. Kamura, H. Yoshikawa*
- 9:57 AM Abstract 5501: A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study.** *R. L. Coleman, D. Enserro, N. Spirtos, T. J. Herzog, P. Sabbatini, D. K. Armstrong, B. Kim, K. Fujiwara, J. L. Walker, P. J. Flynn, A. A. Secord, D. E. Cohn, M. F. Brady, R. S. Mannel*
- 10:09 AM Abstract 5502: Outcomes and costs of open, robotic, and laparoscopic radical hysterectomy for stage IB1 cervical cancer.** *D. J. Margul, J. Yang, B. L. Seagle, M. Kocherginsky, S. Shahabi*
- 10:21 AM Ginger J. Gardner, MD (Discussion of Abstract(s) 5500-5502)**
Memorial Sloan-Kettering Cancer Center
Continuing Surgical Debates in Gynecologic Cancer
- 10:33 AM Panel Question and Answer**
- 10:45 AM Abstract 5503: ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155).** *D. S. Miller, G. Scambia, I. Bondarenko, A. M. Westermann, A. Oaknin, A. M. Oza, A. S. Lisyanskaya, I. Vergote, R. M. Wenham, S. M. Temkin, H. Gabra*
- 10:57 AM Abstract 5504: Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer.** *S. N. Westin, J. K. Litton, R. A. Williams, C. J. Shepherd, W. Brugger, E. J. Pease, P. T. Soliman, M. M. Frumovitz, C. F. Levenback, A. Sood, L. Meyer, S. L. Moulder, V. Valero, S. Saleem, A. Rodriguez, A. Cyriac, L. Engerman, C. Samuel, G. B. Mills, R. L. Coleman*

Tuesday, June 5, 2018

- 11:09 AM Abstract 5505: Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III GOG study.** *M. L. Hensley*, D. Enserro, H. Hatcher, P. B. Ottevanger, A. Krarup-Hansen, J. Blay, C. Fisher, K. M. Moxley, S. B. Lele, J. S. Lea, K. S. Tewari, P. H. Thaker, O. Zivanovic, D. M. O'Malley, K. Robison, D. S. Miller
- 11:21 AM Gini F. Fleming, MD, FASCO (Discussion of Abstract(s) 5503-5505)**
The University of Chicago
Treatment Dilemmas in Uterine Cancer
- 11:33 AM Panel Question and Answer**
- 11:45 AM Abstract 5506: Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.** *S. Pignata*, D. Lorusso, F. Joly, C. Gallo, N. Colombo, C. Sessa, A. Bamias, C. Pisano, F. Selle, E. Zaccarelli, G. Scambia, P. Pautier, M. Nicoletto, U. De Giorgi, C. Dubot, A. Bologna, M. Orditura, I. L. Ray-Coquard, F. Perrone, G. Daniele
- 11:57 AM Abstract 5507: Correlation of imaging and plasma-based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC): A GOG 218 ancillary data analysis.** *M. Buechel*, D. Enserro, R. A. Burger, M. F. Brady, K. Wade, A. A. Secord, A. B. Nixon, S. Mirniaharikandehi, H. Liu, B. Zheng, H. Gray, K. S. Tewari, D. M. O'Malley, R. S. Mannel, K. N. Moore, M. J. Birrer
- 12:09 PM Abstract 5508: Cost-effectiveness of maintenance therapy in advanced ovarian cancer: Paclitaxel, bevacizumab, niraparib, rucaparib, olaparib, and pembrolizumab.** *J. E. Wolford*, J. Bai, L. E. Minion, R. Keller, R. N. Eskander, J. K. Chan, B. J. Monk, K. S. Tewari
- 12:21 PM Charlie Gourley, PhD (Discussion of Abstract(s) 5506-5508)**
University of Edinburgh Cancer Research UK Centre, MRC IGMM
Bevacizumab: The Saga Continues
- 12:33 PM Panel Question and Answer**

11:30 AM - 12:45 PM Education Session

Next-Generation Diagnostics Beyond Tissue

Location: S406

Interact ID: 10737

Patrick C. Ma, MD - Chair

WVU Cancer Institute, West Virginia University

Novel Platforms and Clinical Applications for Noninvasive Molecular Testing

Sai-Hong Ignatius Ou, MD, PhD

University of California Irvine School of Medicine

Liquid Biopsy to Identify Actionable Genomic Alterations

Peter Kuhn, PhD

University of Southern California

Noninvasive Biomarkers for Immunotherapy

Panel Question and Answer



This publication is supported by:



Support for this meeting is funded through

CONQUER CANCER[®]
THE ASCO FOUNDATION